<SEC-DOCUMENT>0000950170-22-003495.txt : 20220314
<SEC-HEADER>0000950170-22-003495.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314061809
ACCESSION NUMBER:		0000950170-22-003495
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIODESIX INC
		CENTRAL INDEX KEY:			0001439725
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				203986492
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39659
		FILM NUMBER:		22735019

	BUSINESS ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-417-0500

	MAIL ADDRESS:	
		STREET 1:		2970 WILDERNESS PLACE
		STREET 2:		SUITE 100
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bdsx-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-14T04:24:27.3083+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:bdsx="http://biodesix.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_e59d62d4-9d9f-4d04-a8c9-59db6bc180ed" name="dei:CurrentFiscalYearEndDate" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227">--12-31</ix:nonNumeric><ix:nonNumeric id="F_ab46d256-df52-4f77-8d90-e3095403b859" name="dei:DocumentFiscalPeriodFocus" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227">FY</ix:nonNumeric><ix:nonFraction id="F_bede26c1-bcbf-4c97-9e63-739d552d824e" name="us-gaap:NumberOfOperatingSegments" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">One</ix:nonFraction><ix:nonNumeric id="F_66ac4874-d4f0-401e-a7bf-7f2f9e7f0fb6" name="dei:AmendmentFlag" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227">false</ix:nonNumeric><ix:nonFraction id="F_e28ee59e-2ec0-403a-86b7-fd43d6ed7b38" name="us-gaap:PreferredStockValue" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_edabff51-0ce4-48c5-96f3-64ef856b5af6" name="us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability</ix:nonNumeric><ix:nonNumeric id="F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric id="F_1bc620bb-3e6b-402e-8838-283423ba32f6" name="dei:EntityCentralIndexKey" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227">0001439725</ix:nonNumeric><ix:nonFraction id="F_830ca1b5-f04d-4413-9871-696b9cc2f4f6" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_639add45-6192-49bc-b32f-a9b5c8b2fcec" name="us-gaap:PreferredStockValue" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_0b6261a9-728a-45c1-9cff-b460d2223b68" name="us-gaap:CommitmentsAndContingencies" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_407518a8-f622-40ce-9fc1-00bcdbe09352" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20" format="ixt-sec:durwordsen">Three years</ix:nonNumeric><ix:nonNumeric id="F_cd5e018e-3c53-41fb-bbd2-697f64fb59f7" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" contextRef="C_c0b9fafd-8fca-406e-9064-e1666d07eb7c" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bdsx-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_a728943e-0005-498d-bf19-caa91ad50029"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5d6b3d47-9c02-4894-9b66-a374b4ec92de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b6cb7b5-b083-4ec5-b29c-9ae0101aa74b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70269112-fe2a-430e-be5e-df5d73c366d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9923eaf7-8b89-4851-b161-00aa62740c91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3f722d28-c570-4810-8fc4-68f71db16286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd80bb2e-8eca-4461-9d92-d498ba929922"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be6ca8b8-4a35-4cad-b184-8b65c4c20b91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec1496fb-b414-4020-84e5-09472bae83a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1355f790-e2f7-4e53-b996-2166830c4202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:LitigationClaimsAndAssessmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-31</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_55faf862-904e-4749-90ab-5601a8d113a1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87d5899a-2fad-4727-bf84-4cd4bb1daada"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69b62320-c88d-472b-b26b-8b37a1a5a0b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_826b69bf-89e7-459f-b550-a6811c484337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98732f46-6752-47d9-bc3f-82fa1ccee5a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1521a2fc-d6fd-463e-a4d0-5ff13f834737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_79ecbe49-ef52-4aab-acc0-1a7416b448df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e272dfed-04df-4966-8eea-8a8670605352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5f9b32d4-40ac-442c-bd25-14dd2c52ccb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03721b15-782d-4e40-bfe2-237a592136a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_624583b0-5d27-4880-a354-cf2da9d3adee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75d6eb43-fbcb-4d67-83f4-dade72088b51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c2b5021-3880-4a79-86df-3e22efd61deb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2d8d257d-2c7e-4c61-95ab-cfad10d07908"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da0bc552-b359-4652-9ba1-d8e29a01881e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_610d8971-4d2b-4f1e-a390-dfe80b599dfb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_75149308-b918-457f-8ee9-7f3492120224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_547a9002-43fc-4570-ad79-1223f9f65e63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79311547-11e0-4926-93f9-d08f788a5f28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a0bd65dc-a53d-46d1-bb23-8dd79665bc2d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4841ec21-e13f-4543-9fc7-01050702bdab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fa48f27-8cf4-4782-b6a4-0cea10e6953e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_367888ff-2937-4bf4-a0e7-2638e425e939"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ca090c1c-03b5-4f4f-bb08-20bb2d2a2b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21dd0a17-272e-43c9-926c-8361d449c139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CollateralAxis">bdsx:CashCollateralizedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7388a94f-fccb-4085-aaf4-6b5e7ca6360d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5e31d38e-c781-4c35-a556-26cdca8b81b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cea9870b-55e4-4464-845c-28e908ce7ebd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d377042-8c80-4077-9d06-ae158bc05d91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d547382-c6f4-454f-8385-5aac59c66fbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_351c91ef-f104-49d7-9d7f-d572749a1c07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e24974c-f120-44e6-86d6-efe03fc47db4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbb42c62-9833-417a-a5af-55f85ae20dd0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8aafb945-b385-4de6-9940-2ec65935d0bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f1ea6781-dd41-46fb-8136-21495568924f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMoneyOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_427d2811-f473-4d72-b6e7-7528519f151a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4d3ebbe2-4eae-4d8f-8107-5bbc08d2d099"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a29723b5-20cb-4e63-a0da-30a2983860b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5852124a-5af9-43ed-b3c2-0ff2fe0b33b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a136b0aa-9769-4cf4-9832-546661048e81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:LitigationClaimsAndAssessmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2af95b4c-4f7e-4e7e-9808-928b36f0a3d9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66cad3c3-9239-41d0-b072-1849ca46dde8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_70caefc6-3ec4-4c3c-872d-2ca7c3a4dd74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_233385c2-cf9b-4c0e-ab38-fbc8fe271a49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62628f3e-204a-4e47-888d-80b800906159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fba42090-b52d-468d-87b6-b763c9054b8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9919b40f-119b-49c1-a2ac-2b76d5a098a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06bff184-ac5d-48a3-b2c8-c2f0e2ca06b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e5ba80b-b01d-424c-b1c0-f4822ff4bb56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b2acc98-6825-4199-91a5-077e16b3afd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_001d92ef-337f-44d0-9202-4f278bb0fa67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10bed5db-cad0-4d81-95a0-1793592b5166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c77d5c42-d4c0-47d9-86be-96adc70e0b54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_98e59e9a-da90-42c6-9029-2c28be33926b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_462729a6-5e59-40a9-995d-eddd6dbf59aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bd35d5ad-8efe-4775-803e-5923630c295d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5bb21277-4d96-4ddb-9ba4-3f3d05e4f337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_894dacc7-f9c8-465f-bb3e-677c3cff01e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_479edcde-8115-401c-b300-335b4e160d8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_83cbaa1a-e64a-4c26-b830-afa34cebed4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cb16d514-420d-4abb-9a34-052d761abec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b727503-f6ad-446e-9456-ccd781d7dcdc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09226d1e-919a-4649-b557-d8d34553ce34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80a34980-9af4-46a5-ab87-825a03cf6961"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_03977998-feb5-4ba1-9a39-98aa6bcd1820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_320c8bd8-4ae2-4caf-892d-f84cf7a846c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e8e4408-1447-42cb-bbca-6204beddc1bb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ffcdd51b-98b2-4868-af53-a0434a4dc1dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2fde2582-8789-4b20-b26a-e76c33d3ce5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_22af9de2-1e40-4b4f-b58e-22e115d6077d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_80994f88-01c2-4120-9cc2-79754d8c1bc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8907904-d558-4f3f-8e7e-17a1beefe665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1b5736c7-1ac5-4a03-9e32-a0ecc2616053"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4423134-5dfd-4ff0-b0de-41bf317abf38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2edad21-1169-40d3-81f2-27f946978341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c75df96-50d6-49ea-8d24-017d2bbea9a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b477c33a-377c-4327-9710-03e518e2ecbe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee59665c-33bf-4b10-9799-81bdb60203c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-11</xbrli:startDate><xbrli:endDate>2022-03-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a21cae4c-4605-4cd5-b0d4-b15582d30357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_848353f5-4aab-4165-b023-6cc47cbe6d8d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1b296b71-3c6b-456d-b731-b251aa4ad227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be505f23-bf3c-4be3-8972-80834ee53690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_21e9a711-1b6a-4991-8e79-b6cc008e7545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d29dc415-dc05-49ca-b2ef-a00ef315776c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-07</xbrli:startDate><xbrli:endDate>2022-03-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_016d7540-660c-40c6-93d0-aeabbf4df993"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d257b176-1b0a-4664-adfe-14f34c0c1a52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d46f5a7-a39a-4c26-9184-61e4e53c8f05"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89b9d305-cd7b-433d-9431-082e759b7f72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_577649de-5c2b-46f6-b8d5-5679a06e7577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd2c7fce-711f-4dae-a54c-036949770fed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f406a25c-1311-429f-acab-1fbc603fcfb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab23c5df-8c6e-46f4-83d5-abf0ca403590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54f8436f-4f07-4679-9f01-6b88613fe77b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b5d3e429-66cd-4136-bc88-3e646c9bc008"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07202086-28e8-435f-adff-fe19436c69b0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93914a7c-1f7d-4779-a324-6676f6a64acb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10d387cc-753c-46a2-9b2a-9b1890b49bdb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_883404a9-e780-4066-b552-a0e49d50d630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-02</xbrli:startDate><xbrli:endDate>2020-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_939cfa52-44fa-40af-9e11-eaed7a69e39b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53c549cf-8442-4882-99fb-2cabbc0b4a81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_01ea5af0-61c2-43e8-83f4-995b808a9869"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_afa76821-90e9-46a2-abff-2d96c1240f4d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6b886bcd-bd24-4350-8fd7-27742802fadf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3926ceff-39bd-4d7e-94cc-3a867487d940"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ff8a944-a271-4148-9c58-ee869ad37333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24b5491d-ac78-49f4-af90-1e06570e8d91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9acde59f-b452-4eee-bf70-79e2b788507e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMoneyOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb0c87cc-2dbf-4d30-9a38-bfb702341b31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_14445421-ccca-421e-9c3f-7d1d23b7cde7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d1d55fa8-853c-4dce-a4aa-f84151407d63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc89134f-48d3-4944-93af-a1d690ce60d2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_706d9a9e-6a0d-4d6c-8f9b-08761cf3807f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a948fe3c-6e1a-4be0-9898-30610de47069"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ce3a578-735a-4075-87ce-b954e21a6041"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8a6364fe-eb05-498f-8396-31e93f9646a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_34f7bf9b-9a78-44bf-9b7d-69e71e140c33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c0b9fafd-8fca-406e-9064-e1666d07eb7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72bbc621-8c29-4345-9567-e3a8ec5494ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_394f3bb1-4c63-47eb-b527-f498fe718a44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c137ab7e-b733-4793-ad80-a153a9ec42f6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dce01a48-8efc-4803-9957-bfa88c6b1299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_78ad82cd-de66-4f58-ab74-efd387f2e192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab45d19d-f12a-40a2-85e6-c11af3ecf535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_030eae36-c23d-4bad-9c99-3d09f8369ed2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_162734b5-e9c9-4193-b4c1-2b7ff33ee96f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_612986b7-0cbc-4490-8560-a7436c79aa80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a45a1ed-39d8-491b-b8f4-7363b3b51b79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_932b3ab0-8853-42c8-a37c-36341f8a9210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d049bfe6-5f3b-4066-8ad9-a9ca88059623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe826522-5651-4f06-9c96-09860263bc0d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c47916fb-71bf-444f-a33a-35da68f40857"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8f3232a-4dcd-431e-b582-72448f737920"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e6943b1f-ff25-4706-9e32-e38b76243a20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_809d867f-6c56-4037-8eba-8f755ea5fa57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88dca331-7477-419b-b234-6230d9c7f1f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-13</xbrli:startDate><xbrli:endDate>2021-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-27</xbrli:startDate><xbrli:endDate>2020-10-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_661f4aa1-a621-4d97-add7-7f08a6309ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f45d621-66e2-469e-81de-170b52163c24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_36978c15-7cae-4bbc-a497-ec47b32704f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e458ef0f-2999-44aa-a713-1bddf0308c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_337f9ff9-e36d-4674-9452-b807a7edb7f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeac8352-9485-4d28-a4b8-6c7dcaf0bab3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be2758e9-5945-4245-bf58-cd5421da5cb6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_928809ae-df57-4571-ac21-764ca2a55ad5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f4a0f9f9-1aed-4b51-a28b-499431427de3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b402d595-7ac8-45f1-be4c-8e6d1bdb6938"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9a21cd39-7714-46bd-8caa-1643fbfd5aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bcbcd9a8-1029-4466-92ef-98684be0f3eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0104f2bd-d332-41e4-b969-1fde8368c3ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8df4046d-0fe5-4898-9781-f03f716cfbc0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_605a1f05-b224-4c9a-a68f-b4ebf4f58a59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65d95f34-c5e6-4335-9e70-651be939c9e0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f88e0dd-ea33-4f83-a540-f014f811689b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc019ec1-5478-4ebc-a4e8-0c7a3e9bf2db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea5e3fdf-996d-4c05-8f7c-0456bb8ec3b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bdsx:LossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02073a80-e7d4-420b-a2a9-04056034b97e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9aed1045-15a0-4022-9dcf-4923b612a501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6eb42b97-11c3-44ad-9689-15a6c7ffc9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_695b6e0d-d079-4a22-b7f4-5eba3c5f5ec8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f0f230b-11a1-485f-b548-212c085d2be9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e65faf54-05c3-4544-989f-b6ba7475a88f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_635f9c56-917e-4e2a-96b7-a3121ec435e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be8dd81f-cfc5-46e4-b488-457166af9cbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cad7d434-2ef5-46b9-aa6d-b243e79c1d26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e357cb78-de71-44ba-be5d-e72858c2520f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e3023eb-44b0-4fc0-a3c5-71c2b1aa3636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_12147dfe-e917-4369-b593-468bf48cc6b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-19</xbrli:startDate><xbrli:endDate>2021-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f68dea5d-5219-4f85-b2dc-32544a35182b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17de90cc-7d15-42d1-b8bb-764245d80c72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001439725</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InterestBearingDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U_Test"><xbrli:measure>bdsx:Test</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>bdsx:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UsdPerSquareFoot"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Installment"><xbrli:measure>bdsx:Installment</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_RenewalOption"><xbrli:measure>bdsx:RenewalOption</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> 	 	</span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5462b55-ea1c-4ea5-bd8f-2222a018bf99" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:18.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88faae8a-c60f-431b-8a8f-696d49b31d5e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a0119293-f68a-49ff-9f94-cf4cea6b14e6" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b29ef097-86ac-42ec-b79f-13b187048af4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6ffe8d9-1b5b-4468-8575-49318405c9ad" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:2.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_45d29eb8-9b27-49c8-b78c-8221563c556b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-39659</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:22.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6caabd6c-073a-400f-a605-2e21b75ba48e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:22.0pt;font-family:Times New Roman;">Biodesix, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Exact name of Registrant as specified in its Charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3bbb5cc3-a906-4fd6-8160-7a046e8ddcdf" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd707062-49ae-4084-9e87-805db5fadbaf" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">20-3986492</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a99fe405-ab72-4c16-b695-3f448d64ae6c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2970 Wilderness Place</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9f48a41-7c4d-4c44-ab72-3e3a19fadc8e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Suite 100</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1984a7eb-55a5-4d2f-be54-201f99dbd6e6" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Boulder</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a61b697d-dec3-4568-b610-dcd80705453f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CO</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0af45ed-5f5e-4150-92f6-ced1f6b459e7" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">80301</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b9e74f90-2e14-4162-95a5-4de6dd930c37" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">303</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f48a5de-cb66-4078-b07d-a208005ea6b5" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">417-0500</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:39.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.0%;"></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_457bfb8b-35db-4c50-a7cd-5f0abeb3f65f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e07ecc0-bc2a-4c4d-8b0d-41400bf1477c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">BDSX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d5a8314b-abd9-402c-8475-7a1cf0d808d7" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NASDAQ Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744; </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3712829c-b4fd-4a15-a66d-c19a6454d0df" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_887ae845-6dec-4bcc-bd34-b88e4a10c405" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28436b64-b787-4df5-8850-309bec6bb130" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0531cd42-4a6b-4a6c-8d0c-718010a9027e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746; </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.306%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:55.348%;"></td>
    <td style="width:1.169%;"></td>
    <td style="width:20.503%;"></td>
    <td style="width:0.724%;"></td>
    <td style="width:2.227%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:0.7pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_04b2971b-9be0-469d-851b-6491bde5d5d4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">  </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e38eddb5-aea3-47e0-94f8-98942d863c1f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:2.15pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:2.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cdcd01f5-fd2a-46a3-bf02-7eba79cff251" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:0.93625;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.6pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8ab46c1-22db-44ed-974f-b4d90b1ca662" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.6pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8f38885d-1ad1-470e-bbf9-d56a2b186a35" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.6pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Yes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_28d4ccc2-8fcc-4331-8179-aabec9374630" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> &#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.6pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">As of June 30, 2021, the aggregate market value of common stock held by non-affiliates of the Registrant was $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b94eea19-fee5-4da0-9f3f-0ce3a26590ff" contextRef="C_fba42090-b52d-468d-87b6-b763c9054b8c" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">196.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> million, based on the closing price of the common stock as reported on the Nasdaq Global Select Market for that date.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.6pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The number of shares of Registrant&#x2019;s Common Stock outstanding as of March 9, 2022 was </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ad500a7-c735-424e-bcf4-bd88f615e8c7" contextRef="C_fe826522-5651-4f06-9c96-09860263bc0d" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">31,307,853</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1b785c3-6cf9-456c-aa88-8d34cc177fd4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Portions of the Company&#x2019;s definitive Proxy Statement for its 2022 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0254166666666664;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.102%;"></td>
    <td style="width:83.0%;"></td>
    <td style="width:6.898%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Calibri;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factor"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#n1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(5,99,193,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Annual Report on Form 10-K, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potentially,&#x201d; &#x201c;predict,&#x201d; &#x201c;should,&#x201d; &#x201c;will&#x201d; or the negative of these terms or other similar expressions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, factors, and assumptions described under the section titled &#x201c;Risk Factors&#x201d; and elsewhere in this annual Report on Form 10-K, regarding, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to achieve or sustain profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attain significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties managing our growth, which could disrupt our operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to retain sales and marketing personnel, and failure to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests to generate revenue growth;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.1020833333333333;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to maintain our current relationships, or enter into new relationships, with biopharmaceutical companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant fluctuation in our operating results, causing our operating results to fall below expectations or any guidance we provide;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the demand for our COVID-19 and antibody testing program and our ability to meet such demand;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product performance and reliability to maintain and grow our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">third-party suppliers, including courier services, contract manufacturers and single source suppliers; making us vulnerable to supply problems and price fluctuations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of a pandemic, epidemic, or outbreak of an infectious disease in the United States (U.S.) or worldwide, including the COVID-19 pandemic on our business;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">natural or man-made disasters and other similar events, including the COVID-19 pandemic, negatively impacting our business, financial condition, and results of operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to offer high-quality support for our diagnostic tests, which may adversely affect our relationships with providers and negatively impact our reputation among patients and providers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to continue to innovate and improve our diagnostic tests and services we offer;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">security or data privacy breaches or other unauthorized or improper access;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant disruptions in our information technology systems;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the incurrence of substantial liabilities and limiting or halting the marketing and sale of our diagnostic tests due to product liability lawsuits;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to compete successfully with competition from many sources, including larger companies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.0589583333333332;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance issues, service interruptions or price increases by our shipping carriers and warehousing providers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-containment efforts of our customers, purchasing groups and integrated delivery networks having a material adverse effect on our sales and profitability;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential effects of litigation and other proceedings;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic and financial market conditions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to attract and retain key personnel;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">current and future debt financing placing restrictions on our operating and financial flexibility;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests, or expand our operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the acquisition of other businesses, which could require significant management attention;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the uncertainty of the insurance coverage and reimbursement status of newly approved diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future healthcare reform measures that could hinder or prevent the commercial success of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with anti-corruption, anti-bribery, anti-money laundering and similar laws;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with healthcare fraud and abuse laws;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to comply with ongoing FDA or other domestic and foreign regulatory authority requirements, or unanticipated problems with our diagnostic tests, causing them to be subject to restrictions or withdrawal from the market;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future product recalls;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">legal proceedings initiated by third parties alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the volatility of the trading price of our common stock;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inaccurate estimates or judgments relating to our critical accounting policies, which could cause our operating results to fall below the expectations of securities analysts and investors; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:6.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks, uncertainties and factors, including those set forth under Risk Factors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These risks are not exhaustive. Other sections of this Annual Report on Form 10-K may include additional factors that could harm our business and financial performance. New risk factors may emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Annual Report on Form 10-K or to conform these statements to actual results or to changes in our expectations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, statements that &#x201c;we believe&#x201d; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should read this Annual Report on Form 10-K and the documents that we reference and have filed as exhibits with the understanding that our actual future results, levels of activity, performance and achievements may be different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">usiness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">mission</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is to improve every patient&#x2019;s lung care by empowering physicians with swift, comprehensive and actionable insights.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">vision</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is to be a trusted business partner that the world relies on for data-driven diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Business Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. (&#x201c;Biodesix&#x201d;, &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our&#x201d; or the &#x201c;Company&#x201d;) is a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a multi-omic approach with a holistic view of the patient&#x2019;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#x2019;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex&#174;, to discover innovative diagnostic tests for clinical use. Because of this approach, we believe we are unique in the diagnostics market as this approach allows for a broader and more holistic understanding of each patient&#x2019;s disease state. Our data-driven and multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, patients, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate in a single segment and derive our revenue from two sources: (i) providing diagnostic testing services associated with (a) blood-based lung tests and (b) Coronavirus Disease 2019 (COVID-19) tests (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services). We derived 90% of our total revenues for fiscal 2021 and 2020 from our diagnostic testing business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. Since our inception, we have performed over 500,000 tests and continue to generate a large and growing body of clinical evidence. We have participated in 27 clinical studies, five of which are ongoing, and have published over 300 peer-reviewed publications and presentations. We have over 150,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development (R&amp;D) initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have commercialized eight diagnostic tests which are currently on market and we perform over 30 assays for research use as part of our laboratory services that have been used by over 50 biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Blood-Based Lung Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have five diagnostic blood-based tests across the lung cancer continuum of care, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which generated $18.7 million and $12.6 million in revenue for fiscal 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively, an annual growth rate of 49%.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnosis</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify XL2&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#174; tests, together marketed as part of our Nodify Lung</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatment &amp; Monitoring</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat ddPCR&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VeriStrat&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tests, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">marketed as part of our new IQLung&#153; testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat NGS&#153; (NGS) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, our 72-hour blood-based NGS test, was launched in November 2021 to a select group of physicians, with broad US launch in January 2022. The GeneStrat NGS test is marketed as part of the new IQLung testing strategy with the GeneStrat ddPCR and VeriStrat tests.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe&#153; testing program. We generated $30.2 million and $28.3 million in revenue from COVID-19 testing during fiscal 2021 and 2020, respectively. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA)-authorized tests, a part of our customizable WorkSafe&#153; program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2020, the U.S. Department of Health and Human Services Secretary declared a public health emergency for COVID-19 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 Droplet Digital&#153; polymerase chain reaction (ddPCR) test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place. Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab tests, we operate and have commercialized the Biodesix WorkSafe testing program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to using the Bio-Rad tests as part of our WorkSafe testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, during the three months ended June 30, 2021, we began partnering with GenScript Biotech Corporation to commercialize </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the blood-based cPass&#153; SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first and only surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or previous SARS-CoV-2 infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. We have announced multiple partnerships for COVID-19 testing, and maintain an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State. Additionally, we have overseen and managed onsite testing and validating testing for the Big Ten Conference athletic competitions through the term of our contract which expired on June 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has disrupted, and we expect will continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#x2019; public health orders and the guidance from the Centers for Disease Control and Prevention (CDC). Employees who can perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. Our sales, marketing and business development efforts have also been constrained by our operational response to the COVID-19 pandemic due to travel restrictions. We expect to continue to adjust our operational norms to help slow the spread of COVID-19 in the coming months, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we saw a decline in business with existing and new biopharmaceutical customers. We began to see recovery during the fourth quarter 2020 as our delivered tests exceeded first quarter 2020 delivered tests and we continued to see the recovery extending through 2021. Further, our clinical studies, such as our ongoing INSIGHT and ALTITUDE studies, as well as our arrangements including contracted clinical trials with our biopharmaceutical customers, are expected</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic. Our biopharmaceutical services revenue grew by approximately 20% during 2021 as compared to 2020; however, we are continuing to experience delays in clinical trials from across the country and world due to COVID-19 restrictions. We expect further improvement in our biopharmaceutical activities during 2022 as compared to 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversely, we experienced a significant increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program, our COVID-19 testing and services, since the onset of the pandemic. COVID-19 diagnostic testing and services contributed approximately $30.2 million and $28.3 million during fiscal years 2021 and 2020, respectively. The first quarter 2021 was our high-water mark for COVID-19 testing revenue. We experienced a steady decline in subsequent quarters as immunizations in the U.S. accelerated. We do not anticipate the need for COVID testing to be commensurate with the peak demand experienced during the first quarter 2021 and instead expect the demand to moderate as new variants and infection occur. The reduction in demand for COVID-19 diagnostic testing will be a key indicator of continued recovery and is taken as a positive sign for both our Lung Diagnostic and Biopharmaceutical Services as we head into 2022. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">here is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to acquiring herd immunity based on previous natural infection, and the availability and rapid distribution of vaccines, the evolution of variant strains that impact diagnostic test performance, or otherwise, the need for COVID-19 testing could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See &#x201c;Risk Factors&#x201d; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Full Year Results for 2021</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, compared to the prior year:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Total Revenue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $54.5 million, an increase of 20%;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lung Diagnostic Revenue of $18.7 million, an increase of 49%</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Services Revenue of $5.6 million, an increase of 20%</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Revenue of $30.2 million, an increase of 7%</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gross Margin </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $24.0 million, an increase of 2%;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses, excluding Direct costs and expenses, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">were $64.9 million, an increase of 40%;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses, excluding Direct costs and expense and non-cash stock compensation expense,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> were $60.0 million, an increase of 40%;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $43.2 million, an increase of 38%;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basic and Diluted Net Loss Per Common Share </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $1.58;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Cash Used by Operating Activities </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $28.2 million, compared to $21.4 million used; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $32.7 million as of December 31, 2021.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Market Opportunity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnostic Testing Market Size and Opportunity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Despite significant advances over the last decade, lung cancer is still the deadliest type of cancer in both men and women in the United States. While diagnostic testing has become routinely used at certain points in the lung cancer continuum of care (diagnosis, treatment and monitoring), we believe there is substantial need for novel, advanced testing to improve on the current standard of care. We estimate that in the United States, the lung cancer continuum of care currently represents over 10 million annual testing opportunities and is over a $27 billion market annually for testing alone.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img33530786_0.jpg" alt="img33530786_0.jpg" style="width:609px;height:178px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their research and development pipelines and increase chances of drug development success. We estimate that biopharmaceutical partnering and research opportunities represents over a $2 billion market annually.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lung Cancer Continuum of Care &#x2013; Clinical Unmet Needs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Standards of care in lung cancer have evolved rapidly over the past decade, along with our understanding of the disease. With the introduction of numerous treatment options, physicians need an ever-increasing amount of information in order to select the best treatment plan for each individual patient. We believe that the lung cancer continuum of care has a variety of clinical unmet needs ranging from initial diagnosis of lung cancer after discovery of a lung nodule to treatment guidance for early and advanced stage disease, and monitoring for disease progression.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Diagnosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We estimate approximately 1.6 million new incidental lung nodules and potentially 4 million lung nodules from the adoption of screening could be identified annually in the United States. Following initial discovery of a nodule, patients are typically evaluated by a pulmonologist for risk of lung cancer before an invasive procedure is carried out to obtain a tissue sample to confirm diagnosis. This risk assessment is based on clinical factors such as the patient&#x2019;s smoking history and age, and radiological features such as the size and location of the nodule, obtained from a computed tomography (CT) scan. On initial assessment, we estimate that approximately 80% of patients are identified as low to moderate risk (5-65%) where guideline recommendations for their care plan are unclear, often</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">resulting in either </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">overtreatment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of patients with benign nodules or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">undertreatment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in patients with cancer. An estimated 17% of patients with malignant nodules are initially sent to watchful waiting, where a follow-up CT scan is scheduled in three to six months, potentially delaying their diagnosis. Conversely, we estimate that 62% of biopsies and 35% of surgeries performed on lung nodules find benign disease, representing a significant overtreatment that incurs both risk and cost to the patient and their providers. We therefore believe that there is a clear clinical need for blood-based diagnostic testing to help improve the initial risk assessment of pulmonary nodules, helping direct patients to the relevant treatment pathway, and ultimately improving patient outcomes and saving costs to the system.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment Guidance &#x2013; Early Stage</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We estimate that there are over 700,000 testing opportunities annually in the United States in early-stage lung cancer to assess a patient&#x2019;s risk of recurrence following curative-intent surgery, and to detect potential target mutations for therapeutics. Depending on a patient&#x2019;s risk of recurrence, they may also receive chemotherapy, radiotherapy or chemoradiation post-surgery. The assessment of risk of recurrence is primarily based on the stage of cancer at diagnosis, with stage I patients typically receiving no additional treatment beyond surgery. However, 20 to 40% of patients with stage I disease do still recur within five years following surgery, representing a sub-group of patients who may have benefitted from more intensive treatment protocol. We believe there is a clear clinical need for blood-based diagnostic testing prior to surgery to identify stage I patients who may benefit from a more intensive treatment protocol and we also believe there is the need for identifying stage II and IIIA patients where low risk patients may benefit from a less intensive treatment protocol. There have also been recent advances in the use of targeted therapies in early-stage lung disease. These therapies </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">typically target specific genomic mutations or alterations found in some tumors. We believe there is therefore an emerging need for testing designed specifically for mutation detection in early-stage disease.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment Guidance &#x2013; Advanced Stage: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimate that there are over 3 million diagnostic testing opportunities annually in the United States to guide advanced stage lung cancer treatment decisions. With nearly 50 FDA-approved systemic treatment regimens listed in national treatment guidelines for non-small cell lung cancer (NSCLC), there is an elevated need for personalized biomarkers to help physicians identify the right patient for the right treatment. Multiple tissue-based diagnostic tests have been approved to identify patients eligible for targeted therapies and immunotherapy; however, about 50% of patients do not have sufficient tissue collected following diagnosis to facilitate testing. To compound the issue, different molecular tests take varying amounts of time (days versus weeks) to report results back to the ordering physician, which often leads to treatment decisions being made on incomplete information. Therefore, we believe there is an imminent need for a blood-based testing solution that measures tumor mutations and the patient&#x2019;s immune profile, to provide physicians with more comprehensive and timely information to assess the overall prognosis of the patient and personalize treatment.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Monitoring</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We estimate that there are over 800,000 testing opportunities in the United States for blood-based tumor and immune profiling to monitor for disease recurrence and progression in NSCLC patients. Unfortunately, advanced stage lung cancer is often terminal, so repeat tissue biopsy to assess the evolution of resistance mutations or to detect disease progression is not feasible from either a cost or risk perspective to the patient, which we believe demonstrates an important need for blood-based testing to help routinely monitor these patients. As a patient progresses through therapies, changes in their immune system occur and blood-based immune profiling could help physicians identify these changes prior to subsequent therapy selection.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Current Limitations in Biomarker Discovery and Companion Diagnostics</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We estimate the biopharmaceutical biomarker testing and companion diagnostic market opportunity represents a $2 billion market annually</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Over the last two decades, the use of biomarker testing in clinical trials has increased, with 55% of oncology trials involving the use of biomarker testing in 2018 versus 15% in 2000. From 2005 to 2015, a study identified that incorporating biomarkers into clinical development programs increased their probability of therapeutic success rate from phase 1 to FDA-approval by 570%, representing an increase from 1.6% without biomarkers to 10.7% with biomarkers. We believe the field of biomarker discovery and companion diagnostic development for biopharmaceutical therapeutics is set to continue growing as biopharmaceutical companies seek to de-risk their product development efforts and increase chances of drug development success. However, we believe as the market continues to advance, inherent limitations of both biomarker discovery and companion diagnostic development have become more apparent.</span></p>
  <p style="margin-left:4.16%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Biomarker Discovery</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are many limitations with biomarker discovery in biopharmaceutical drug development, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biomarkers with clinical utility are difficult to discover and validate in independent datasets. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Classical statistical approaches to biomarker discovery are limited. Single-omic tests fail to see the whole biological picture.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tissue biopsies are limited by the amount of a sample that can be collected: longitudinal testing is difficult and the biology is only from the profile of the tumor (host response is not accounted for).</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials are expensive and take a long period of time. It is often difficult to meet enrollment goals for clinical trials with slow diagnostic testing turnaround times.</span></div></div>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Companion Diagnostics (CDx): </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While developing companion diagnostics is critical to precision medicine, the promise of companion diagnostics has not been fully realized and there are multiple limitations that still need resolution. The path to co-develop a successful companion diagnostic with a corresponding drug has several challenges, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Traditional companion diagnostic agreements may fail to realize the full value of a testing opportunity, leading to difficulty in funding appropriate commercialization.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Drug development is a lengthy, complex and costly process. There can be a financial impact to a pharmaceutical company to have a drug selected by a test.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current diagnostic reimbursement policies may not always support the coverage and payment of new companion diagnostics.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regulatory agencies continue to work on defining the co-development process, but the environment is continually changing.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">The Diagnostic Cortex - Our Proprietary Artificial Intelligence (AI) Platform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cortex, to discover innovative diagnostic tests for clinical use. We focus on developing technologies that are capable of single and multi-omic research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of clinical diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Researchers commonly encounter issues with machine learning-based biological discoveries that cannot be repeated or validated when assessed in additional specimen cohorts. This challenge, commonly referred to as overfitting, occurs when the machine identifies a perfect pattern in an initial training dataset but is unable to identify the same pattern in a new dataset. For over 15 years we have focused on developing our platform to overcome this challenge through proprietary computational techniques to ensure each diagnostic test that is discovered can be further developed to perform consistently in the clinical testing environment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are able to combine blood-based biological information related to the tumor, immune system, and host-status with clinical and radiomic data through our proprietary AI platform, which enables us to interpret the holistic disease state of each patient or clinical dataset we encounter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continuously evolve and improve the Diagnostic Cortex platform. These improvements range from basic code optimization to complex improvements such as the incorporation of novel computational methods for the optimization of multi-omic diagnostic tests. Any AI platform is inherently limited without the highest quality data inputs. Therefore, all of the technologies that we employ have been chosen and developed to provide high-quality data to enable our Diagnostic Cortex platform. We feel that this level of data integrity is crucial for the development of diagnostic tests that require the advanced pattern matching abilities of deep learning algorithms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and learn about biological discoveries that are clinically meaningful. Additionally, we incorporate clinical and molecular profiling data aggregated through our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, into our platform. We have over 150,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external development initiatives. With our data-driven and multi-omic approach as data inputs into the Diagnostic Cortex, we are able to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a diagram outlining our innovative diagnostic test discovery, development and commercialization infrastructure as outlined in the text above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><img src="img33530786_1.jpg" alt="img33530786_1.jpg" style="width:720px;height:315px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We employ multiple technologies, as illustrated below, including genomics, proteomics, transcriptomics, and radiomics, generated by different assay techniques, including ddPCR, NGS, LC-MS, ELISA, and our proprietary DeepMALDI mass spectrometry platform for the blood-based molecular analysis of the tumor, immune system, and host-status of each patient and/or clinical dataset. Through our learning loop, we continuously revisit our technology strategy and roadmap to integrate new technologies into our evolving platform, which ultimately support the addition of new service and product revenue offerings. We focus on developing technologies that are capable of single and multi-omic research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.16%;font-size:10.0pt;margin-top:0.05pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img33530786_2.jpg" alt="img33530786_2.jpg" style="width:709px;height:368px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most diagnostic companies focus their strategy on using a single technology to discover biomarkers for a broad range of clinical questions. We believe that no single technology can interrogate the complexity of the human disease state to help solve all clinical questions. For that reason, we employ a multi-omic approach to solving diagnostic challenges leveraging our proprietary transparent AI platform, the Diagnostic Cortex. Because of this approach, we believe we are unique in the diagnostics market, allowing for a broader and more holistic understanding of each patient&#x2019;s disease state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are experts in many technologies, but we are a true market leader with over 15 years of experience in the field of clinical proteomics. For over 10 years, we have been discovering and developing proteomic-based diagnostic tests and have a deep understanding of how to incorporate technologies that can be applied to blood samples in order to extract important protein-based biological information in the form of diagnostic tests, which can aid clinicians and scientists in understanding the dynamic biology of their system of interest, such as a patient with cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our suite of technologies that assist us in discovery, development and commercialization of novel diagnostic tests includes:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">DeepMALDI Mass Spectrometry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed DeepMALDI, a proprietary high-density matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) mass spectrometry (MS) technology, to produce blood-based proteomic data for disease diagnosis, personalized health care, precision medicine for direct treatment options, and disease screening in lung and other disease states. DeepMALDI overcomes the limitations of conventional MALDI and other mass spectrometry methods to produce highly sensitive, stable, and reproducible data by: (1) utilizing optimized signal-to-noise reduction and signal processing algorithms; and (2) novel batch correction methods and spectral alignment methods. The combination of these improvements yields substantially higher quality data content and is thereby much better suited for the discovery of biomarkers with clinical utility.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current DeepMALDI methods allow us to achieve finer mass resolution, greater sensitivity, and 20-times faster imaging speeds than other instruments. Additionally, we believe recent enhancements to our DeepMALDI methods and MALDI-ToF technology evolution now allows us to measure more than 2,000 proteins, an improvement from the estimated 900 proteins we could measure a year ago. We intend to maintain our leadership role in the discovery of proteomics-based diagnostic tests. We utilize our DeepMALDI and MALDI-ToF technologies in our discovery and development efforts and as part of our collaborations with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquid Chromatography Mass Spectrometry MS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use Multiple Reaction Monitoring (MRM) MS with triple quadrupole mass spectrometers and up-front liquid chromatography (LC) sample injection in the Nodify XL2 test. This mass spectrometry method offers highly sensitive, specific, and cost-effective analysis for simultaneous quantitation of hundreds to several thousands of targeted peptides in a single experiment. We have since included the MRM technologies as part of our services for discovery and development with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enzyme-Linked Immunosorbent Assay</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ELISA is the most widely used ligand binding assay platform within and outside the pharmaceutical industry. Formats include direct, indirect and sandwich assays and are typically run in manually or semi-automated modes. We use a semi-automated implementation of ELISA in clinical testing for the Nodify CDT test and the Platelia SARS-CoV-2 Total Ab test, and the cPASS neutralizing antibody test for COVID-19. The acquisition of Oncimmune USA in 2019 expanded our ability to conduct very high throughput and cost-effective ELISAs in our clinical testing laboratory. We have now included the ELISA technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Droplet Digital Polymerase Chain Reaction Technology (ddPCR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use the ddPCR technology for multiplexed, semi-automated nucleic acid detection. This allows high sensitivity, fast turn-around times, flexibility in our laboratory workflows, rapid scaling from low to moderate analyte complexity, and high-volume scalability. ddPCR is an absolute quantitation method based on the partitioning of circulating nucleic acids into up to 20,000 droplets per reaction and is used for the GeneStrat test and Bio-Rad SARS-CoV-2 ddPCR test for COVID-19. We have included the ddPCR technologies for research and development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Next Generation Sequencing Technology</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use an NGS technology for broad genomic sequencing of clinical specimens. Our strategy with NGS relies on a menu of off-the-shelf and custom research use assays, which we develop and make available as a part of our commercial pipeline and biopharmaceutical test services. The NGS technology integrates automated systems to yield high sensitivity results with a rapid turnaround time. Since adoption of this technology, we have included the NGS technologies for research and product development both internally and externally with our biopharmaceutical customers and academic partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Solutions and Products</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To help address the current limitations with standard of care in lung cancer diagnosis, treatment, and monitoring, we use combinations of tumor, immune and host profiling, radiological imaging, patient clinical profiling, and our proprietary AI platform to provide a holistic view of each patient&#x2019;s dynamic disease state.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have five blood-based diagnostic tests across the lung cancer continuum of care to help address clinical unmet needs by physicians.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Diagnosis</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We believe there is a clinical need to help physicians reclassify risk of malignancy in patients presenting with suspicious lung nodules. We offer the blood-based Nodify Lung Nodule Risk Assessment testing strategy to aid physicians in stratifying patients into distinct nodule management treatment pathways: diagnostic procedure or imaging surveillance. Nodify Lung consists of two blood-based proteomic tests: the Nodify CDT test helps identify patients with lung nodules that are likely malignant and the Nodify XL2 test conversely helps identify those that are likely benign.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment Guidance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We believe there is an imminent need for a blood-based testing solution that measures tumor-specific mutations and the patient&#x2019;s immune profile to provide physicians with more comprehensive information to assess the overall prognosis of the patient and personalize treatment plans. We offer the blood-based IQLung testing strategy, which consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test for patients diagnosed with NSCLC. With a 72-hour turnaround time, we are able to quickly provide critical diagnostic information to physicians to facilitate personalized treatment decisions for their patients.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Monitoring</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: We believe longitudinally monitoring advanced NSCLC patients for the dynamic evolution of their tumor and immune profile while on treatment can provide an earlier indication of treatment resistance and/or disease progression. We offer the IQLung testing strategy as a blood-based monitoring tool for physicians to track their patients&#x2019; disease evolution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:15.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img33530786_3.jpg" alt="img33530786_3.jpg" style="width:720px;height:183px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnosis &#x2013; Nodule Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our blood-based nodule management offering, Nodify Lung Nodule Risk Assessment assists physicians in reclassifying a patient&#x2019;s risk of lung cancer by incorporating their protein biomarker results with radiographic imaging and clinical characteristics. Nodify Lung consists of the Nodify CDT and Nodify XL2 proteomic tests, which can be ordered separately or together from a single blood draw to help reclassify risk of cancer to aid physicians in stratifying patients into distinct nodule management pathways: intervention or surveillance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nodify CDT test is used to help identify lung nodules that are likely malignant and the Nodify XL2 test helps identify lung nodules that are likely benign. Nodify Lung is available for patients 40 years or older, with nodules between 8 and 30mm, and less than 65% pre-test risk of lung cancer. The testing strategy starts with the Nodify CDT test to determine if a nodule is likely malignant or at a higher risk of lung cancer. The Nodify CDT test helps physicians identify cancer more quickly by prioritizing patients with a higher risk of malignancy for a diagnostic procedure, such as biopsy or surgery. If the nodule is not identified as having a high risk of malignancy by the Nodify CDT test, then the Nodify XL2 test is performed to help determine if the patient&#x2019;s nodule is likely benign or has a reduced risk of lung cancer and may be a candidate for CT imaging surveillance. The Nodify Lung testing strategy is represented graphically in the image below starting with the patient&#x2019;s pre-test risk of malignancy and ending with the guideline-recommended diagnostic procedure for each risk category.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.65pt;line-height:1.1979166666666667;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><img src="img33530786_4.jpg" alt="img33530786_4.jpg" style="width:709px;height:303px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We launched the Nodify Lung combined offering of the Nodify CDT and Nodify XL2 tests in March 2020. However, the Nodify XL2 test has been available to all physicians since September 2019 and has been available to a select group of physicians since October 2018. We acquired the Nodify XL2 test from Integrated Diagnostics (Indi) in July 2018 and acquired the Nodify CDT test from Oncimmune USA in October 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify CDT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nodify CDT test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely malignant or at a higher risk of being cancerous. Results allow physicians to identify patients who may be better candidates for timely invasive diagnostic procedures such as bronchoscopy, transthoracic needle biopsy, or surgical resection, with the hope of catching cancer earlier. The Nodify CDT test enhances lung nodule risk assessment to facilitate compliance with clinical treatment guidelines such as those of the American College of Chest Physicians (ACCP). The Nodify CDT test is intended for use in patients who are 40 years or older, have nodules between 8 and 30mm, and pre-test risk of lung cancer of less than 65%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The test measures the levels of seven circulating autoantibodies (P53, NY-ESO-1, CAGE, GBU4-5, SOX2, HuD, and MAGE A4) associated with lung cancer, combined with an algorithm to report out three potential results: High Level, Moderate Level, or No Significant Levels of Antibodies Detected (NSLAD). The seven autoantibodies have shown to be elevated for all types of lung cancer, and from the earliest stage of the disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unlike the tumor antigens themselves, the autoantibody levels can be measured accurately through a blood sample, based upon the signal amplification generated by the immune response to cancer. This mechanism of action likely reflects very early events in a tumor&#x2019;s evolution; as the immune system initiates a response to the cancer, it can also trigger an expansion of self-reactive antibodies that can be measured in circulation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the test result of High Level, Moderate Level, or NSLAD, each test report includes the patient&#x2019;s pre-test risk of malignancy as calculated by the Solitary Pulmonary Nodule (SPN) Risk Assessment calculator, and their post-test risk of cancer incorporating the result of the test. The SPN Risk Assessment calculator was developed by Stephen Swensen, M.D., of the Mayo Clinic and is designed to provide a risk of malignancy for a patient with a newly discovered incidental nodule. The model incorporates six clinical and radiologic factors into the equation: age, nodule size, smoking status, nodule location, spiculation (nodule edge characteristic), and previous history of lung cancer. Incorporating the autoantibody levels with the risk model provides physicians with a more accurate assessment of risk. The test has been studied in 14 peer reviewed published studies and presentations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify XL2</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nodify XL2 test is a blood-based proteomic test that helps identify patients who have a suspicious lung nodule that is likely benign or at a reduced risk of being cancerous. Results allow physicians to identify patients who may be better candidates for routine CT surveillance to monitor for growth or shrinkage of the nodule over time instead of an invasive diagnostic procedure. The Nodify XL2 test is used for patients who are 40 years or older, have nodules between 8 and 30mm, and have a pre-test risk of lung cancer of less than or equal to 50%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nodify XL2 test integrates peptides measured by LC-MS with clinical and radiological characteristics that are combined by an algorithm to report out three potential results: Likely Benign, Reduced Risk, or Indeterminate. Specifically, the Nodify XL2 test measures the relative abundance of two peptides (LG3BP and C163A) in circulation in the patient&#x2019;s blood. The native proteins from which the peptides are derived, have been associated with an inflammatory response to cancer. The clinical factors are patient age and smoking status, and radiological factors are nodule size, location, and edge characteristics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the test result of Likely Benign, Reduced Risk, or Indeterminate, each test report includes the patient&#x2019;s pre-test risk of lung cancer as calculated by the SPN Risk Assessment calculator, and their post-Nodify XL2 risk of malignancy incorporating the result of the test. Incorporating the peptide levels with the risk model provides physicians with a revised assessment of risk incorporating the patient&#x2019;s biology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In summary, the inclusion of the Nodify Lung testing strategy into clinical practice helps physicians reclassify risk of malignancy of low to moderate risk lung nodules by incorporating the patient&#x2019;s own biology into the assessment. The Nodify CDT test helps physicians identify patients with a high-risk lung nodule who may benefit from timely intervention, which can ultimately help identify lung cancer earlier. The Nodify XL2 test helps physicians identify patients with a very low risk lung nodule who may benefit from CT surveillance and could avoid unnecessary invasive procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Blood samples for the Nodify XL2 and Nodify CDT tests can be collected in the physician&#x2019;s office, laboratory, or at home through use of mobile phlebotomy. Mobile phlebotomy options facilitate testing for patients even if they are not seen in person by the physician and instead are seen through telehealth visits. This benefits the patient as scheduling can be conveniently fit to their needs and can keep them away from a physician&#x2019;s office or hospital for safety concerns, especially with the evolving coronavirus pandemic. Additionally, mobile phlebotomy benefits the physician as the logistics around a blood draw or tissue sampling are out of their hands. We have a national network of contracted Nurses and Phlebotomists to support at-home or mobile blood collection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Both tests require a single blood sample shipped at ambient temperature to our certified, high-complexity clinical laboratory in De Soto, Kansas. Nodify CDT testing requires whole blood and Nodify XL2 testing requires either a whole blood tube, or whole blood spotted onto our proprietary Blood Collection Device (BCD). The introduction of the BCD and now the whole blood tube as qualified specimen collection methods for use with the Nodify XL2 test alleviated the need for serum separation processing steps by phlebotomists at blood draw sites such as centrifugation, and cold chain (dry ice) shipments, which has increased the market access to our proteomic-based tests. Results for the Nodify CDT test alone are typically available within one day. If both tests are ordered for the patient and Nodify CDT returns a result of NSLAD, then both test results are typically available within 4 to 5 days. All results are available through a portal, fax, hard copy, or mobile device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatment Guidance and Monitoring</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Profiling the tumor through blood-based testing can help identify mutations in genes that may be driving growth of the tumor and may be targets for therapeutics. However, tumors also suppress intrinsic mechanisms that prevent the patient&#x2019;s immune system from identifying and eliminating the cancer cells. Profiling the immune system can show if the patient&#x2019;s immune system may have been subverted and therefore, is less likely to be responsive to immunotherapies. Our blood-based IQLung testing strategy consists of the GeneStrat ddPCR and GeneStrat NGS tumor profiling tests and the VeriStrat immune profiling test, which can be ordered together or separately for patients with NSCLC. Together, the tests typically have a 72-hour turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img33530786_5.jpg" alt="img33530786_5.jpg" style="width:720px;height:329px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat ddPCR</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GeneStrat test is a blood-based tumor profiling test that detects the guideline recommended, actionable mutations in lung cancer: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EGFR, KRAS, BRAF, EML4-ALK, ROS-1, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">RET. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Physicians can order one or any combination of the gene tests, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat test performance and potential clinical utility have been published in 3 peer reviewed studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GeneStrat test results are typically available within 36 hours from our receipt of the sample in our Boulder, Colorado clinical laboratory. In a study at Eastern Carolina University, it was observed that blood-based testing was up to three weeks faster than tissue-based testing, with tissue-based testing taking a median of 26 days from sample collection. With GeneStrat testing, results are typically available in time for the patients first oncology visit, allowing the patient to start front-line treatment as quickly as possible. In the same study, it was observed that only 4% of patients had tissue-based molecular test results prior to start of front-line treatment. Meanwhile, after integrating Biodesix testing at the institution, 72% of patients had molecular test results available. Testing with the GeneStrat test can help physicians identify driver mutations quickly to help speed up time to treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat NGS Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GeneStrat NGS test is a blood-based 52-gene tumor profiling test panel that detects the guideline recommended, actionable mutations in lung cancer including five gene classes (SNV, INDELS, CNA, fusions, and exon-skipping). Specific variants of relevance to NSCLC include EGFR, KRAS, BRAF, EML4-ALK, ROS-1, RET, MET, NTRK. The GeneStrat NGS test is used for late-stage, metastatic NSCLC and Physicians can order one or any combination of the IQLung tests, whichever they deem medically necessary for the individual patient. The presence of a mutation in one of the genes could indicate the patient is a candidate for the associated guideline-recommended targeted therapy. The GeneStrat NGS test performance and potential clinical utility have been published in two published studies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneStrat NGS test results are typically available within 72 hours from our receipt of the sample in our Boulder, Colorado clinical laboratory.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img33530786_6.jpg" alt="img33530786_6.jpg" style="width:720px;height:291px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that rapid, blood-based tumor profiling with the GeneStrat ddPCR and GeneStrat NGS tests can be complementary to both targeted tissue-based testing (including PD-L1) and tissue-based broad genomic sequencing. Testing with GeneStrat ddPCR and GeneStrat NGS tests at diagnosis can help quickly identify patients who are eligible for targeted therapies. Additionally, blood-based testing upfront can help save valuable tissue for diagnostic evaluation, PD-L1 testing and broad genomic profiling for rare mutations to enroll in clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VeriStrat</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The VeriStrat test is a blood-based proteomic test that provides a personalized view of each patient&#x2019;s immune response to their lung cancer. Results help inform physicians whether their patient has a more aggressive cancer and can help with treatment planning. The VeriStrat test profiles the patient&#x2019;s immune system by measuring eight protein features measured by mass spectrometry and interpreted by a proprietary machine learning-based algorithm to produce either a VeriStrat Good or VeriStrat Poor test result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The presence of a VeriStrat Poor result indicates the presence of chronic inflammation and a chronic acute phase immune response. A chronic acute phase immune response can trigger the immune system to provide growth factors to the tumor to increase blood flow and tumor growth. The test has been studied in over 85 peer-reviewed and published clinical studies across many different types of therapies such as chemotherapy, targeted therapies, immune therapies, and combinations. The results consistently show the test to be predictive of outcomes, independent of other prognostic factors including PD-L1 expression and performance status. Patients who test as VeriStrat Poor, on average, have an overall survival that is less than half of those who test as VeriStrat Good, independent of treatment type, demonstrating that the test is strongly prognostic. Conversely, patients with a VeriStrat Good test result typically respond better to standard of care treatments than those patients that test as VeriStrat Poor. By using the VeriStrat test for immune profiling, physicians can help identify the patients with an immune status associated with generally poor prognosis who should be treated with alternate therapies or in clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GeneStrat ddPCR testing is performed using PCR technology, GeneStrat NGS testing is performed using Next Generation Sequencing technology, and the protein features in VeriStrat are measured using MALDI-ToF mass spectrometry. Results are typically available within 72 hours through a portal, fax, hard copy, or mobile device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GeneStrat ddPCR and GeneStrat NGS tests require whole blood specimen collection tubes, and VeriStrat requires a whole blood sample spotted onto our proprietary BCD. Both sample types are shipped at ambient temperature and testing is performed in our certified, high-complexity clinical laboratory in Boulder, Colorado.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biodesix WorkSafe COVID-19 Testing Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two diagnostic tests for the SARS-CoV-2 virus that causes COVID-19. The first test is the Bio-Rad SARS-CoV-2 ddPCR test, which is a molecular test intended for detecting active SARS-CoV-2 infection. The test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The test was FDA EUA authorized on April 29, 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within a month of initiating our development collaboration with Bio-Rad, we were able to launch two tests for commercial use. We were able to bring these tests to market as fast as possible due to our scientific diagnostic expertise, technologies and existing commercial infrastructure. In addition to our launch agility, we have been able to rapidly scale our laboratory operations for high-volume testing. We remain committed to delivering rapid test results in 24 to 48 hours on average.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab tests, we operate and have commercialized the Biodesix WorkSafe testing program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to using the Bio-Rad tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, during the three months ended June 30, 2021, we began partnering with GenScript Biotech Corporation to commercialize </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the blood-based cPass&#153; SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first and only surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to vaccination or previous SARS-CoV-2 infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity. We have announced multiple partnerships for COVID-19 testing, and maintain an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State. Additionally, we have overseen and managed onsite testing and validating testing for the Big Ten Conference athletic competitions through the term of our contract which expired on June 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bio-Rad SARS-CoV-2 ddPCR test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Bio-Rad SARS-CoV-2 ddPCR test, also known as a molecular or viral test, is intended for the qualitative detection of nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The test targets detection of the nucleic acid from SARS-CoV-2 (not from any other viruses or pathogens) in respiratory specimens to identify and isolate infected individuals. Recent studies have shown that ddPCR-based testing is more sensitive than qPCR for detecting SARS-CoV-2, specifically in the reduction of false negative results. In one study, the ddPCR test demonstrated 95% accuracy vs. 47% for other &#x201c;bulk&#x201d; RT-PCR technologies used in other molecular tests Specimens are shipped at ambient temperature or dry ice depending on the viral transport media (VTM) used, and testing is performed using ddPCR in our certified, high-complexity clinical laboratory in Boulder, Colorado. Results are typically available through fax, hard copy, or encrypted email within 24 to 48 hours on average from receipt of the sample.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platelia SARS-CoV-2 Total Ab Test</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Platelia SARS-CoV-2 Total Ab test (also known as a serology or antibody test) is intended for use as an aid in identifying individuals who have developed an adaptive immune response to the SARS-CoV-2 virus, indicating recent or prior infection. The test uses whole blood to detect circulating antibodies against the virus. The sensitivity is 98% and specificity is 99% eight days after the onset of symptoms. At this time, it is not known how long antibodies persist following infection and if the presence of antibodies confers protective immunity. The test is intended for the qualitative detection of total anti-SARS-CoV-2 nucleocapsid antibodies (IgG, IgM and IgA) in human serum or plasma specimens. The test requires a 3 mL blood draw, and samples are shipped at ambient temperature. Testing is conducted using semi-automated ELISA technology in our certified, high-complexity clinical laboratory in De Soto, Kansas. Results are typically available within 24 to 48 hours from receipt of the sample through fax, hard copy, or encrypted email.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Biopharmaceutical Diagnostic Discovery, Development and Testing Services Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our leadership in clinical proteomics and our multi-omic approach to probe the cancer disease state provides our customers with a clear and distinct advantage over other diagnostic service providers who solely focus on either genomics or proteomics. Similar to our commercial clinical testing business, our biopharmaceutical diagnostic discovery, development and testing services business leverages the Diagnostic Cortex to provide an extensively validated and deep learning approach to discovering new biomarkers, which in turn helps drive the clinical development of therapeutics. We recognize each clinical development program is complex, which is why we offer end-to-end diagnostic solutions, ranging from initial biomarker discovery and feasibility projects to commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To address the increasing complexity of disease biology and new drug mechanisms of action, we employ a range of genomic and proteomic technologies to uncover insights about the tumor biology and patient&#x2019;s immune response to cancer for therapeutics in clinical development. With our broad technology and service offering, including the performance of over 30 assays for research use as part of our laboratory services (see diagram below), we are able to provide the depth and breadth of biomarker tools for our partners for multi-omic analyses across their product development efforts. Although we recognize the importance of a multi-omic, approach in translational research, we are experts in discovering and developing proteomic-based diagnostic tests to help interrogate the immune profile and host disease state of patients on particular therapeutics. Traditionally, oncology biomarkers have been discovered from tumor tissue, but with the increased trend in the number of programs featuring immuno-oncology agents in therapeutic development, we believe there is a clinical unmet need for blood-based tumor markers and host/immune biomarkers to complement information obtained from tissue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><img src="img33530786_7.jpg" alt="img33530786_7.jpg" style="width:720px;height:317px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe we provide benefit to our biopharmaceutical customers as they integrate strategies for increasing the probability of success for pivotal clinical trials. Specifically, our diagnostic testing services may help enable quicker enrollment rates for patients in prospective clinical trials, ranging from phase 1 to phase 3, and could help identify patient populations who may experience the greatest benefit from new therapeutics. Ultimately, our goal is to help biopharmaceutical customers realize greater efficiency in their clinical development programs. Additionally, we have the ability to access and leverage our large sample and data biobank for our partners&#x2019; data mining needs, including new test discovery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While our biopharmaceutical discovery, diagnostic development and testing revenue continues to grow, it is important to note that we benefit greatly from these partnerships in many ways that expand beyond revenue. We are continuously expanding our knowledge and biological understanding of multiple diseases and the rapidly evolving treatment landscape, while our Diagnostic Cortex continues to be powered through these biomarker analyses. Additionally, our sample and data biobank continue to grow and can be further leveraged for internal test development and external partnering. Importantly, we look to supplement our product development efforts with companion diagnostics as they are developed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we have over 50 biopharmaceutical customers and academic partners who have utilized our diagnostic tests and services. The following are a few case studies of early-stage biomarker discovery and development with our biopharmaceutical customers.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AstraZeneca: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We provided services to AstraZeneca to retrospectively analyze samples from the FLAURA clinical trial (NCT02296125). The goal of this analysis was to interpret and establish the clinical utility of blood-based longitudinal monitoring of EGFR sensitizing and resistance mutations by ddPCR in advanced NSCLC patients treated with osimertinib. The data demonstrated that these circulating DNA mutations could be tracked in blood to interpret the patient&#x2019;s prognosis, and could help AstraZeneca to identify disease progression 3 months (median) in advance of standard imaging.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Genentech: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We partnered with Genentech to discover a novel proteomic classifier for advanced NSCLC patients treated with atezolizumab. The test was discovered on a small clinical cohort (n=77) and was independently validated on blinded samples (n=270) from the POPLAR clinical trial (NCT01903993). The validation revealed that the proteomic test was predictive of progression free survival and overall survival for atezolizumab versus the control arm docetaxel. Additionally, an analysis compared the correlation between our proteomic classifier with standard of care biomarkers (PD-L1 expression status and tumor mutation burden), which revealed there was no significant correlation. We published additional work on the Genentech </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">classifier this fall with three posters presented at the society of immunotherapy conference (SITC). This data reinforces that our classifier provides unique and valuable information in the treatment of patients with advanced NSCLC. It is our belief that Genentech could use this strategy to identify patients that could derive a longer progression free survival from atezolizumab.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Merck KGaA &amp; Pfizer: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We announced the initiation of a clinical phase development program for the anti-PD-L1 checkpoint inhibitor, avelumab with Merck KGaA and Pfizer on February 12, 2020. The new proteomic test was developed through retrospective analysis of the circulating proteome combined with our proprietary AI platform. We have completed initial discovery of the test that identifies likely responders to avelumab and efforts are now focusing on transferring the test into our CLIA lab in Boulder, Colorado for clinical phase test validation.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">HiberCell:</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In January 2021, we announced a broad collaboration with HiberCell for companion diagnostic discovery, development and commercialization. The agreement initially focuses on the further development of an ELISA as a companion diagnostic in future registrational trials in breast cancer for Imprime PGG programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Competitive Advantages</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe the following are our key competitive advantages:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our proprietary extensively validated deep learning platform, which is tailored to discover diagnostic tests that address clinical unmet needs. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our platform is an extensively validated deep learning platform optimized for discovery of diagnostic tests. By combining our data-driven and multi-omic approach with deep learning techniques, we believe we have overcome many standard machine learning challenges. This has enabled us to develop commercial tests for clinical unmet needs and collaborate with our biopharmaceutical customers and academic partners.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our data-driven approach to precision medicine combined with our biobank, which enables us to accelerate development of new tests. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have over 150,000 samples and data in our biobank, including tumor profiles and immune profiles, used for both internal and external research and development initiatives. Our biobank, clinical trials, commercial testing and other partnerships provide an ongoing source of new data that further enhances our proprietary AI platform. We are continuously identifying and incorporating new market insights and input from our customers, key opinion leaders, and scientific experts to leverage this data in developing our diagnostic tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our leadership in clinical proteomics, demonstrated research, development, and scientific expertise, combined with our intellectual property portfolio. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our leadership in clinical proteomics and our multi-omic approach, we believe provides us with a distinct advantage over our competitors, who focus on any single technology, such as genomics or proteomics. Our certified, high-complexity laboratories offer significant advantages in development of commercial tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our proprietary technologies and processes are protected by a portfolio of approximately 109 issued patents in the United States and internationally, and 22 uniquely registered United States trademarks. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We take efforts to protect our proprietary position using a variety of methods, such as a pursuit of United States and foreign patent applications related to our proprietary technology, use of trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our demonstrated success commercializing diagnostic tests in lung disease as well as unprecedented turnaround times. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With eight diagnostic tests launched and three currently in development, our commercial portfolio of blood-based solutions currently addresses clinical unmet needs within diagnosis, treatment and monitoring of lung cancer. Our diagnostic tests provide rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#x2019;s care plan. For example, t</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have displayed agility in our R&amp;D and commercial launch efforts and within a month of initiating a development collaboration, launched three diagnostic tests for COVID-19 for commercial use.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our depth and breadth of point of care access to physicians allows us to drive adoption of our diagnostic tests while incorporating real-life feedback to inform new product development. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial team&#x2019;s primary focus is to articulate the scientific and clinical evidence behind our tests, how they impact clinical care and can ultimately help to improve patient outcomes. Our demonstrated scientific expertise, leadership in clinical proteomics and breadth of data, including peer-reviewed publications, presentations and clinical studies, forms the basis of our relationships with major hospitals and physician networks across the United States.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our commercial infrastructure, which includes our extensive knowledge and experience in sales, marketing, reimbursement and operations, provides us with the ability to launch, scale and drive revenue. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe our commitment to commercial excellence helps us to leverage insights, operational excellence and proven approaches to deliver </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">revenue growth and enhance the brand of our company and products. We are able to deploy rapid clinical testing turnaround times and develop commercial tests at scale. Scaling of our test capacity to meet volumes is then achieved by adding instrumentation and qualified personnel to our quality systems.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We strive to provide swift, comprehensive and actionable insights to improve patient outcomes across lung disease and to help answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies. To achieve this, we intend to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Drive increased awareness, adoption, and reimbursement coverage of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continuously educating physicians, key opinion leaders, hospital systems, advocacy groups, patients, payers, academic research organizations, and technology assessment and guideline organizations on the clinical data and benefits of our tests;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">utilizing our pulmonology- and oncology-focused sales force and commercial reach with targeted awareness campaigns to employ highly targeted sales and marketing tactics in pulmonology clinics specializing in the management of lung nodules and the diagnosis of lung cancer;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continuing to invest in the expansion of our sales force and commercial support team;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incorporating our testing services into diagnostic pathways and protocols via a top-down strategy that introduces our diagnostic tests to the largest United States health systems; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">leveraging our clinical data to gain broad coverage from public and private payers for our tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Deepen our relationships with current biopharmaceutical customers and establish new customer opportunities by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">leveraging existing projects and relationships to expand sales with our current biopharmaceutical customers; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">targeting companies developing novel companion diagnostic strategies and drug development projects best suited to our platform for new test discovery, development and commercialization.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Further demonstrate the clinical utility and health economic benefits of our diagnostic tests by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investing in commercial clinical testing, research studies and clinical trials to further demonstrate the clinical utility of our tests;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">providing rapid, actionable, and holistic diagnostic information to help inform physicians on the next steps in a patient&#x2019;s care plan; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">providing timely and actionable clinical information to help improve overall patient outcomes and lower the overall healthcare cost.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Introduce new diagnostic tests in lung disease by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">engaging with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic and therapeutic landscape and to identify additional clinical unmet needs;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">entering strategic partnerships with biopharmaceutical companies, academic research organizations, technology providers, and other diagnostic companies; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developing companion diagnostic tests to support the therapeutics&#x2019; regulatory approval and adoption process for our biopharmaceutical customers.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Enhance our proprietary AI platform and expand our technology portfolio by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continuing to invest in R&amp;D capabilities to foster innovation in test discovery and development;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identifying, acquiring technologies and integrating new data types into our proprietary AI platform;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">entering strategic partnerships across our commercial product portfolio and product development efforts in order to further our development capabilities, accelerate launch of commercial products, or expand our service offering; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achieving &#x201c;Explainable AI&#x201d; by developing and incorporating computational tools that determine how the Diagnostic Cortex makes decisions for patient classification and outcome prediction.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Continue to expand and leverage our biobank by:</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanding and enhancing the robustness of our samples and the data set, including through our collaborations and partnerships;</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pursuing commercial opportunities with companies and researchers who are interested in utilizing our biobank for their own discovery and development efforts; and</span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.0%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.2857295918914%;">o</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monetizing these commercial opportunities.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Diagnostic Tests in Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the goal of finding solutions for clinical unmet needs related to diagnosis, treatment and monitoring in lung disease, our diagnostic tests in development include the following:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Early-Stage NSCLC&#x2014;Risk of Recurrence (ROR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Currently, surgical resection of the tumor without systemic or radiation therapy is standard of care for stage I NSCLC patients. However, 20 to 40% of surgically treated patients will suffer a recurrence within 5 years after surgery. From market research with pulmonologists, thoracic surgeons, and medical oncologists, we identified a significant clinical unmet need for a blood-based test to help identify stage I NSCLC patients who are at a higher risk of recurrence and may benefit from a more aggressive surgical procedure, or from neoadjuvant or adjuvant systemic treatment. Based on this unmet diagnostic need, we discovered the Risk of Recurrence (ROR) test, which is a pre-surgery blood-based proteomic test, designed with the Diagnostic Cortex to predict whether a stage I NSCLC patient has a higher risk of recurrence post-surgical resection. Knowing this information early and before surgery may change the surgical plan and/or support treatment decisions such as neoadjuvant or adjuvant therapy, which have the potential to reduce tumor volume and address micro-metastatic disease as early as possible. Our ROR test validated in an independent sample set, and we are currently working with major academic institutions across the United States to further validate the test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Late-Stage NSCLC&#x2014;Immunotherapy Treatment Guidance (PIR)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2015, the first immunotherapy-based treatment regimen was approved by the FDA for use in lung cancer. Currently, there are 9 immune checkpoint inhibitor (ICI) regimens (single agent or combinations) recommended by the NCCN guidelines for treatment of advanced NSCLC patients. For a portion of patients treated, these drugs can result in significant improvement in overall survival compared with platinum-based chemotherapy options.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The combination ICI regimens see some improvement in performance over single agent ICI, but side effect profiles are worse, and costs are higher than for single agent ICI. In addition, recent data have shown that a subset of patients experience more rapid disease progression on ICI compared with chemotherapy. We utilized the Diagnostic Cortex platform to discover our Primary Immune Response (PIR) test. PIR is a blood-based proteomic test designed to profile a potential to mount an immune response to their cancer and predict those patients likely to respond to ICI monotherapy treatment, ICI + chemotherapy combination treatment, or who would be highly resistant to ICI therapy. Our PIR test has been validated in multiple independent sample sets for advanced stage NSCLC patients treated with single agent ICI, and we are currently working with major academic institutions across the United States to further validate the test in a prospective study called BEACON-Lung.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Monitoring &#x2013; Progression &amp; Resistance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Blood-based monitoring with our ddPCR technology may offer a feasible method to non-invasively evaluate therapeutic mechanism of action, disease progression, and the emergence of resistance mutations in patients treated with targeted therapies. Our internal validation studies have shown the utility of the GeneStrat </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">EGFR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ddPCR test in all three of these indications. The test can identify disease progression up to 3 months (median) in advance of standard imaging. Using ddPCR for longitudinal blood-based monitoring of EGFR cell-free DNA mutations is a cost-effective testing method while patients are being treated with targeted therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are dedicated to continuously publishing and presenting new data on the clinical validation and utility of our diagnostic tests. We have participated in 27 clinical studies, 5 of which are ongoing, and have published over 300 peer-reviewed publications and presentations. The following are our ongoing clinical studies for our diagnostic testing solutions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ORACLE Registry Study (NCT03766958)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ORACLE registry study was designed to develop real-world clinical utility data for Nodify XL2 and is titled &#x201c;An Observational Registry Study to Evaluate the Performance of the Nodify XL2 Test&#x201d;. The study objectives are to show a reduction in invasive procedures on patients with benign nodules compared to a historical control obtained from chart review. The first patient enrolled on October 16, 2018. As of May 1, 2020, 423 patients have been enrolled and are undergoing primary endpoint analysis, with 2-year follow-up estimated to be completed by the first half of 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">ALTITUDE Clinical Utility Study (NCT04171492)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ALTITUDE clinical utility study is designed to evaluate the performance of Nodify Lung (Nodify XL2 and Nodify CDT) in a randomized controlled study (RCT). The study is titled &#x201c;A Multicenter, Randomized Controlled Trial, Prospectively Evaluating the Clinical Utility of the Nodify XL2 Proteomic Test in Incidentally Discovered Low to Moderate Risk Lung Nodules&#x201d;. We received central investigational review board (IRB) approval in December 2019 and have an enrollment goal of 2,000 patients. The study objectives are to evaluate how the addition of the Nodify Lung test result impacts the clinical decision making for patients with new, incidentally identified solid lung nodules assessed as low to moderate risk of lung cancer. The trial has an adaptive study design with a blinded standard of care arm and 2:1 randomization for open-label results for Nodify XL2. The study launched in December of 2020. Phase 1 of the study with only Nodify XL2 is expected to enroll 500 patients. Phase 2 of the adaptive study design will include an open-label arm for Nodify CDT, which is aligned with our commercial testing algorithm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">INSIGHT Observational Study (NCT03289780)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The INSIGHT observational study is designed to evaluate the real-world clinical utility and performance of the IQLung (GeneStrat ddPCR, GeneStrat NGS and VeriStrat) testing strategy. The title is &#x201c;Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)&#x201d; and the first patient enrolled was on May 11, 2016. To date, we have over 3,500 patients enrolled with a target 5,000 enrollment goal. Final analysis with 3-year follow-up is estimated to be completed by 2024. Results of an interim analysis were presented at ASCO 2020. The study rationale is to guide the adoption of VeriStrat and inform medical decision making, including treatment choice, and enable the validation of additional mass spectrometry-based proteomic tests. The primary study objective is to describe the impact of the VeriStrat test results on treatment decisions, including but not limited to the percentage change in treatment decision, differences in chosen treatments between patients classified as VeriStrat Good and those classified as VeriStrat Poor, and the percentage of patients receiving systemic therapy or supportive therapies only.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">BEACON-Lung Clinical Study (Trial in Progress)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In partnership with ALCMI (Addario Lung Cancer Medical Institute), the BEACON-Lung clinical study is intended to evaluate the performance and utility of our proteomic product currently in development, PIR, in advanced stage NSCLC patients who express high PD-L1. The study title is &#x201c;A Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated with An Immune Checkpoint Inhibitor (ICI) With or Without Platinum-Based Chemotherapy.&#x201d; The study design is an observational, multicenter, open-label study to assess biomarkers (serum, microbiome, radiomics and tissue) as predictive of early progression in 390 treatment-naive patients with advanced stage NSCLC and PD-L1 greater than or equal to 50% treated with two standard of care regimens, triplet therapy (platinum-based chemotherapy plus ICI regimen) and ICI monotherapy (single agent ICI). The objectives are to collect biospecimens and evaluate candidate biomarkers, with a focus on PIR, to detect early progression on ICI monotherapy versus triplet therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">DROPLET</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Droplet is an exploratory observational study to assess the utility a novel gene linkage phenomenon as measured by the Bio-Rad SARS-CoV-2 ddPCR test, on the correlative immune response in individuals previously infected with the COVID-19 virus. The primary objective of this study (titled &#x201c;ddPCR Linkage, Viral Load and Immune Response in Individuals Infected with COVID-19&#x201d;) is to evaluate the correlation between linkage, viral load and the immune responses in individuals who have had a natural infection with SARS-CoV-2. Fifty patients will be enrolled and serially tested for viral load and immune responses for up to 12 months. More recently, the focus of the study has shifted to monitoring vaccine antibody durability and T cell responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our lung cancer and nodule management tests, commercial efforts are focused on the promotion of our testing strategies to healthcare professionals actively involved in the diagnosis and treatment of lung cancer. Primarily focusing on pulmonology and oncology, the commercial team, consisting of specialty sales representatives, medical affairs, marketing and customer care representatives, works to educate and inform the entire patient care group consisting of physicians, nurses, office staff, laboratory personnel, and administration as to the appropriate use and value provided by our testing. The team&#x2019;s goal is to drive test adoption through articulating the scientific and clinical evidence behind our tests, how they impact the clinical care of a patient, and how the tests can ultimately help to improve patient outcomes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients with pulmonary nodules are concentrated in the pulmonology sub-specialty, where additional resources such as lung cancer screening and nodule management clinics may exist to provide an increased level of care. We are also engaging large hospital systems in a &#x201c;top-down&#x201d; approach, with a goal of incorporating our tests into system wide pathways and protocols.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After a physician orders our tests, blood is collected either in the physician office or laboratory, third-party &#x201c;store front&#x201d; patient service centers, or it can be collected in the patient&#x2019;s home or workplace. We have contracted with a network of patient service centers and mobile phlebotomy services to be enable collection of blood samples outside of the physician office, at home or work for patients across the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our Biodesix WorkSafe testing program, we have a dedicated outreach team that works with the State of Colorado healthcare providers and hospitals, and employers looking to safely return to work across many industries, including food services, oil and gas, biotechnology and pharmaceuticals, sports teams, universities, and many small businesses. We recognize everyone&#x2019;s COVID-19 situation is unique, which is why we provide end-to-end customized solutions to support testing for our different customers, such as risk assessment tools, physician ordering services, on-site testing, phlebotomy services, shipping logistics, and ongoing client support.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business development team is focused on selling our complete offering of tests and services to biopharmaceutical companies in the United States and internationally. We currently hold a medical device establishment license in accordance with the Health Canada Medical Devices Regulations of the Food and Drugs Act and successfully passed an international Health Canada inspection in October 2021. Our team consists of customer facing business development associates that work with our biopharmaceutical customers to identify projects, draw up statements of work and negotiate service agreements. Alliance managers help to manage the contractual obligations and scope of the project, whereas our operations team assures the project is managed with adequate resources and delivers on time. We take a two-pronged approach generating business in this segment. Primarily, we leverage existing projects and relationships to expand sales in current accounts. We also actively map ongoing drug development projects in biopharmaceutical companies and target programs best suited to our platform for new test development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Coverage and Reimbursement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The primary source of reimbursement for our tests in the United States is from third-party payers including government payers, such as Medicare, and commercial payers, such as insurance companies. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reimbursement for laboratory tests in the United States is determined by various payers, including private third-party payers, managed care organizations, and state and federal health care programs, such as Medicare and Medicaid. In Medicare, coverage of an item or service depends on whether it is &#x201c;reasonable and necessary&#x201d; under the section 1862(a)(1)(A) of the Social Security Act (SSA). For single-source laboratory tests, this determination is typically made by the Medicare Administrative Contractor (MAC) with jurisdiction over the laboratory where the test is performed. Our Boulder, Colorado laboratory is currently under the jurisdiction of Novitas Solutions, Inc. Our De Soto, Kansas laboratory is under the jurisdiction of Wisconsin Physicians Service Insurance Corporation, which participates in the MolDX program (administered by another MAC, Palmetto GBA) to set coverage policy for molecular diagnostic tests.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicare pays for clinical diagnostic laboratory tests (CDLTs), on the Clinical Laboratory Fee Schedule (CLFS). Section 216(a) of the Protecting Access to Medicare Act of 2014 (PAMA), added section 1834A to the SSA, which established the current CLFS rate setting processes and coding provisions for CDLTs, and created a new subcategory of CDLTs called Advanced Diagnostic Laboratory Tests (ADLTs), with separate reporting and payment requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under section 1834A and its implementing regulations, clinical laboratories that receive the majority of their Medicare revenues from payments made under the CLFS and the Physician Fee Schedule report on a triennial basis (or annually for ADLTs), private payer rates and volumes for their tests with specific billing codes based on final payments made during a set data collection period. The payment rate for a test for the ensuing three-year period (or one year for ADLTs) is set at the weighted median of the rates reported under the specific billing code for that test. Newly established codes for CDLTs are priced until the next private payer rate reporting cycle either based on the payment rate of a comparable code on the CLFS, as determined by CMS (&#34;crosswalking&#34;) or at the median of rates submitted by the individual MACs based on statutory and regulatory factors (&#34;gapfilling&#34;). New ADLTs are initially priced at &#x201c;actual list charge&#x201d; for a nine-month period, after which they are priced based on private payer rates, with a recoupment provision if actual list charge is more than 130% of the weighted median of private payer rates reported.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The various payers in the United States also determine their own billing rules. In December 2020, Medicare revised its billing rules for clinical laboratory tests to require cancer-related protein-based Multianalyte Assays with Algorithmic Analyses to be billed directly to Medicare by the performing laboratory in most cases when performed on a specimen collected from a hospital outpatient. Molecular pathology tests and most ADLTs are also generally required to be billed directly to Medicare by the laboratory under these circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For our COVID-19 testing program, the primary source of reimbursement is through contracts with hospitals, companies providing wellness testing for their employees, or direct pay from patients. We believe that our lung cancer tests can both improve patient outcomes and help guide cost-effective treatment choices for patients with and at-risk of lung cancer. Achieving broad coverage and adequate reimbursement for each of our tests is a key component of our financial success and will continue to be important over time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Families First Coronavirus Response Act (FFCRA) and Coronavirus Aid, Relief, and Economic Security Act (CARES), Congress has imposed a broad requirement that Medicare fee-for-service, Medicare Advantage, Medicaid, and commercial payers generally cover clinical diagnostic laboratory tests administered during the Public Health Emergency for the detection of SARS-CoV-2 or the diagnosis of the virus that causes COVID-19. Where applicable, the FFCRA and CARES require payers to cover COVID-19 tests without cost sharing or medical management techniques like prior authorization. Medicare fee-for-service does not require cost sharing or prior authorization for any clinical diagnostic laboratory tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Department of Health &amp; Human Services (HHS) has indicated in guidance that the coverage requirements of the FFCRA and CARES can apply both to infection and serological testing, but that they are only applicable to testing that is &#x201c;diagnostic,&#x201d; which &#x201c;may</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">include testing of individuals with signs or symptoms compatible with COVID-19, as well as asymptomatic individuals with known or suspected recent exposure to SARS-CoV-2.&#x201d; Testing that is &#x201c;not primarily intended for individualized diagnosis or treatment of COVID-19 or another health condition,&#x201d; including &#x201c;testing conducted to screen for general workplace health and safety,&#x201d; is beyond the scope of the statutory coverage requirements. We believe these coverage requirements apply to the Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test when performed for diagnostic purposes. In some cases, we submit claims to insurance payers for the Bio-Rad SARS-CoV-2 ddPCR test and/or the Platelia SARS-CoV-2 Total Ab test. In these cases, insurance payers may have a different position on the scope of mandatory coverage of our tests under the FFCRA and CARES. More commonly, we enter into arrangements with clients under which the client pays us directly for testing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with applicable laws and regulations, as well as internal compliance policies and procedures adds complexity to the billing process. The Centers for Medicare &amp; Medicaid Services (CMS) is responsible for overseeing the establishment of new Healthcare Common Procedure Coding System (HCPCS) codes for billing the Medicare program and other payers. CMS continuously evaluates and implements changes to the Medicare billing, coding, and reimbursement processes. To receive reimbursement from third-party payers, we bill our tests using a variety of HCPCS codes or Current Procedural Terminology (CPT) codes, as defined by the American Medical Association. For some of the tests we conduct, there may not be a specific CPT or HCPCS code, in which case the test may be billed under a miscellaneous code for an unlisted molecular pathology procedure or unlisted multiple analyte test with algorithmic analysis (MAAA) procedure. Because these miscellaneous codes do not describe a specific service, the third-party payer claim may be examined to determine the service provided, whether the service was appropriate and medically necessary and whether payment should be rendered. This process can result in a delay in processing the claim, a lower reimbursement amount, and/or denial of the claim.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competitors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We primarily face competition from lung cancer diagnostic solutions companies in the United States, Europe and Asia seeking to answer clinical questions in the space, all of whom provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnosis&#x2014;Nodule Management</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not aware of any other company that offers two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. We are aware of efforts by Veracyte, Inc. to develop and validate a test that may be competitive to the Nodify XL2 and/or Nodify CDT tests in the future. Additionally, Veracyte currently markets a test that is used post-bronchoscopy that is not competitive with our pre-bronchoscopy nodule risk assessment tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Prognosis, Treatment Guidance and Monitoring&#x2014;NSCLC</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are unaware of any other diagnostic test available, commercially or in development, that will compete with our VeriStrat immune profiling test. There is substantial interest and activity in tumor profiling through liquid biopsy. Our genomic test offerings, the GeneStrat ddPCR and GeneStrat NGS tests, face competition from academic hospital laboratories, and companies such as Guardant Health and Foundation Medicine. We believe that there are several companies and academic research institutions in the process of developing tests for monitoring patients on or following treatment for recurrence or progression of lung cancer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19 Testing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our competitors include university and state laboratories, national reference laboratories such as Lab Corporation and Quest Diagnostics, in-hospital laboratories, and a number of other diagnostic providers. We are aware that a number of other companies have announced development efforts to develop COVID-19 tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Biopharmaceutical Diagnostic Discovery, Development &amp; Testing Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of a number of companies who compete with our diagnostic tests and services, including diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. From the perspective of tumor profiling, we believe Guardant Health and Foundation Medicine are our most significant competitors. Conversely, in the immune profiling market, we believe Adaptive Biotechnologies and Personalis are our most significant competitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Clinical Laboratory Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We perform the VeriStrat, GeneStrat ddPCR, GeneStrat NGS, and COVID-19 ddPCR tests in our Boulder, Colorado high-complexity CLIA certified clinical laboratory. The laboratory is College of American Pathology (CAP) accredited, New York State Department of Health (NYSDOH)&#x2014;permitted and licensed, ISO 13485:2016 Quality Management Systems&#x2014;Requirements for Regulatory Purposes for Medical Devices certified, along with all other states that require licensing: California, Maryland, Pennsylvania, and Rhode Island. All aspects of the testing process from receipt of the test requisition form through to delivery of test results are performed in the Boulder, Colorado facility. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within 3 days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Nodify XL2, Nodify CDT, COVID cPASS and COVID-19 total antibody tests are performed in our De Soto, Kansas high-complexity CLIA certified clinical laboratory. This clinical laboratory is also CAP-accredited, NYSDOH&#x2014;permitted and licensed, ISO 13485:2016 Quality Management Systems&#x2014;Requirements for Regulatory Purposes for Medical Devices certified and licensed by California, Maryland, Pennsylvania, and Rhode Island. Receipt of requisitions and testing is performed in our De Soto, Kansas clinical laboratory. Delivery of the test results is performed by personnel from our Boulder, Colorado headquarters. The proprietary testing methods use semi-automated workflows that facilitate the successful delivery of greater than 90% of our tests within 5 days, and we believe our existing workflows will continue to successfully deliver our tests within this timeframe.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel in both facilities are responsible for quality assurance oversight, licensing, and regulation compliance and maintenance to ensure data integrity and consistent, validated processes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supply Chain</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of components. Bio-Rad, as described below, is the sole source supplier for our GeneStrat test and COVID-19 and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests but there are known secondary suppliers for these materials. We have initiated the second source qualification process for the majority of these critical components.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we purchase supplies through purchase orders without long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we rely on contract manufacturers for the production of our diagnostic tests. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test, but these supplies are able to be supplied by known suppliers. A disruption to this supply would negatively impact our ability to perform the GeneStrat and SARS-CoV-2 tests until alternatives could be validated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis. A disruption to this supply would negatively impact our ability to perform these tests until an alternative supplier could be validated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All materials for our VeriStrat test and Nodify XL2 tests have alternative suppliers readily available, and a disruption in any single supplier would not materially impact our ability to deliver the test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has allowed us to pressure-test our supply chain and logistics processes as we purchased additional manufacturing capacity above our normal run rates to ensure that supply to execute on tests for the foreseeable future was available in-stock and in-house. Our suppliers have been able to allocate sufficient capacity to meet this increased demand with reasonable lead times and therefore we believe sufficient capacity exists for the expected volumes of all tests for the next 12 months.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends, in part, on our ability to obtain and maintain intellectual property and proprietary protection for our products and other know-how, to operate our business without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of others, and to defend and enforce our intellectual property and proprietary rights. We take efforts to protect our proprietary position using a variety of methods, which include pursuit of United States and foreign patent applications related to our proprietary technology, inventions and improvements that we determine are important to our business. We also may rely on trade secrets, trademarks, know-how, continuing technological innovation and potential in-licensing and acquisition opportunities to develop and maintain our proprietary position. For more information regarding risks relating to intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have invested heavily in the protection of our key assets, namely the VeriStrat&#174; and GeneStrat&#174; tests, and we acquired a patent portfolio relating to the Nodify XL2&#174; and Nodify CDT&#174; tests in our acquisitions of Indi in June 2018, and of Oncimmune USA in October 2019 from Oncimmune Limited (Oncimmune). We own patents and patent applications as well as trade secrets relating to our products currently in development, a collection device for whole blood, our business strategy, client lists and business methods. Further, we have expanded our access to key intellectual property through license and co-development agreements, including our Non-Exclusive License Agreement with Bio-Rad (the Bio-Rad License), which allows us to use the Droplet Digital PCR&#153; technology developed by Bio-Rad and which we employ in our GeneStrat test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent strategy has focused on creating and acquiring protection for our VeriStrat and Nodify XL2 proteomic tests, while utilizing trade secret and some methods patent protection for our genomic test (the GeneStrat ddPCR and GeneStrat NGS&#153; tests) and ELISA test (the Nodify CDT test). We have entered into a non-exclusive license agreement with Bio-Rad, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. For more information regarding this license and supply agreement, please see &#x201c;&#x2014;Material Agreements&#x2014;Agreements with Bio-Rad.&#x201d; Bio-Rad owns patents relating to ddPCR and to which we have a non-exclusive license to utilize for the performance of ddPCR in cancer detection testing for third parties as set forth in the Bio- Rad License Agreement. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR test and Platelia SARS-CoV-2 Total Ab test for commercial diagnostic services. For more information regarding the permission granted to us by Bio-Rad with respect to such tests, please see &#x201c;Business&#x2014;Material Agreements&#x2014;Agreements with Bio-Rad.&#x201d; We are unaware of patents owned by Bio-Rad relating to its COVID- 19 antibody test but acknowledge that Bio-Rad has know-how and trade secrets relating to this test. We have patent protection in the United States and other countries around the world for the primary use of the VeriStrat test for profiling of patients with NSCLC, and various other uses of the VeriStrat test, such as breast cancer, prostate cancer, head and neck cancer have received patent protection. We have also received patent protection relating to our core classifier development program, our Diagnostic Cortex&#174; technologies and our approaches to using MALDI-ToF technology (DeepMALDI&#174; techniques). Additionally, our first device patent was issued in 2019 for our internally designed blood collection device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our patent portfolio includes approximately 50 issued United States patents, 59 issued foreign patents, which includes 5 European patents that were nationalized in multiple European countries, and 41 pending applications (including 21 foreign patent applications). With regard to our product development efforts, new applications have been filed around developments relating to ARDS and COVID diagnostics, new analytic methodologies using Shapley values and semi-quantitative spectra analysis in MALDI, and national stage applications are now in active prosecution to protect our pipeline ROR and PIR tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent portfolio can be broken down into 5 major categories:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents and patent applications relating to the VeriStrat and Nodify tests and uses of these tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents and patent applications relating to methods for developing classifiers, including using the Diagnostic Cortex and DeepMALDI technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents and patent applications relating to tests currently in development;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents and patent applications relating to our novel blood collection device; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">5)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issued patents and patent applications relating to tests developed for our third-party partners.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patents relating to the VeriStrat test are scheduled to expire between 2026 and 2032. The patents relating to the Nodify XL2 test are scheduled to expire beginning in 2031 (excluding any patent term extension granted by the United States Patent and Trademark Office (USPTO)), and the patents relating to the Nodify CDT test are scheduled to expire in 2027. The patent related to the blood collection device is scheduled to expire in 2039. Should our current patent applications in prosecution in the United States issue, the resulting patents would be scheduled to have expiration dates between 2036 and 2040 (excluding any patent term extension(s) granted by the USPTO).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have one pending Patent Cooperation Treaty (PCT) application. PCT patent applications are not eligible to become issued patents until, among other things, we file such PCT applications as national stage patent application(s) within 30 months in the countries in which we seek patent protection. If we do not timely file any national stage patent applications, we may lose our priority date with respect to any such PCT patent applications and any patent protection on the inventions disclosed in such PCT patent applications. Provisional patent applications are not eligible to become issued patents but can become the basis of PCT foreign stage and United States non-provisional patent applications, if such applications are filed within 12 months of filing the related provisional patent application. If we do not timely file any non-provisional patent applications, we will lose our priority date and any patent protection on the inventions disclosed in any such provisional patent application.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed, including the United States, the patent term is generally 20 years from the earliest filing date of a non-provisional patent application, assuming the patent has not been terminally disclaimed over a commonly-owned patent or a patent naming a common inventor, or over a patent not commonly owned but that was disqualified as prior art as the result of activities undertaken within the scope of a joint research agreement. The life of a patent, and the protection it affords, is therefore limited and once the patent lives of our issued patents have expired, we may face competition, including from other competing technologies. In the United States, the term of a patent may also be eligible for patent term adjustment for delays within the USPTO. The term of a patent that covers a biological product may also be eligible for patent term extension when FDA approval is granted for a portion of the term effectively lost as a result of the FDA regulatory review period, subject to certain limitations and provided statutory and regulatory requirements are met. Any such patent term extension can be for no more than five years, only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval, and only those claims covering the approved biological product, a method for using it or a method for manufacturing it may be extended. We may not receive an extension if we fail</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to exercise due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. There can be no assurance that we will benefit from any patent term extension or favorable adjustment to the term of any of our patents. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to maintain and solidify our proprietary and intellectual property position will depend on our success in obtaining effective patent claims and maintaining and enforcing claims that are granted. However, our owned and licensed patents could be invalidated or narrowed or otherwise fail to adequately protect our proprietary and intellectual property position and our pending owned and licensed patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because branding is as much a part of any intellectual property strategy as patent or trade secret protection we have a number of registered and pending trademarks relating to our company and products. We have received or filed for trademark protection in the United States for our tradename (Biodesix), the names of five of our commercial tests (namely the VeriStrat, GeneStrat ddPCR, GeneStrat NGS, Nodify XL2 and Nodify CDT tests), and a suite of research tests (ImmunoStrat), as well as having trademark protection for our core development and methodological platforms, such as our Diagnostic Cortex and DeepMALDI technologies. In all, as of December 31, 2021, we have 22 uniquely registered United States trademarks, 11 of which (including Biodesix, VeriStrat, and GeneStrat) have received foreign issuances as well, with 3 additional trademarks pending approving from the USPTO. We will continue to pursue protection in the United States and abroad for our branded assets and will continue to use branding to protect products currently in development, key Biodesix developments and non-trade secret methodologies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also rely on trade secrets, including know how, confidential information, unpatented technologies and other proprietary information, to strengthen or enhance our competitive position, protect and maintain aspects of our business that are not amenable to, or that we do not presently consider appropriate for, patent protection, and prevent competitors from reverse engineering or copying our technologies. We have decided that some technologies, such as our laboratory methodologies (including sample preparation and assay development), and some information (such as client and billing information) are best kept as trade secrets. However, trade secrets and confidential know-how are difficult to protect. To avoid inadvertent and improper disclosure of trade secrets, and to avoid the risks of former employees using these trade secrets to future employment, it is our policy to require employees, consultants and independent contractors to assign all rights to intellectual property they develop in connection with their employment with or services for the Company to the Company. We also protect our existing and developing intellectual property expressly through confidentiality provisions in agreements with third parties. There can be no assurance, however, that these agreements will be self-executing or otherwise provide meaningful protection for our trade secrets or other intellectual property or proprietary information, or adequate remedies in the event of unauthorized use or disclosure of such trade secrets or other intellectual property or proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our trade secrets and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in the measures we take to protect and preserve our trade secrets, such measures can be breached, and we may not have adequate remedies for any such breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to pursue additional intellectual property protection to the extent we believe it would advance our business objectives, which may include objectives within and outside the United States. Despite our efforts to protect our intellectual property rights, and despite the breadth of protection that has issued around our key assets, these rights may not be respected in the future or may be circumvented or challenged (and potentially invalidated) in a legal proceeding in any jurisdiction where we have intellectual property rights. In addition, the laws of various foreign countries where we have received intellectual property protection and where we may eventually distribute our products may not afford the same protections or assurances to the same extent as the laws in the United States. See &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property&#x201d; for additional information regarding these and other risks related to our intellectual property portfolio and their potential effect on us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical laboratory tests like our diagnostic tests are regulated under CLIA and State law. The FDA regulates medical devices pursuant to the FDCA, including many diagnostic test kits, such as in vitro diagnostic tests (IVDs). However, most Laboratory Developed Tests (LDTs) are not currently subject to the FDA&#x2019;s regulation (although reagents, instruments, software or components provided by third parties and used to perform LDTs may be subject to such regulation) because the FDA has historically exercised enforcement discretion over LDTs. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. FDA&#x2019;s authority to regulate LDTs has been contested for many years, and there have been several legislative and administrative proposals regarding LDT regulation seeking to end or limit enforcement discretion and to bring LDTs under new or existing FDA regulatory frameworks:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 9, 2012, Congress passed legislation in the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) requiring the agency to notify the Committee on Health, Education, Labor, and Pensions and the House Committee </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">on Energy and Commerce of its intent to regulate LDTs. This law, though enacted, had a 5-year sunset provision, meaning that FDA is no longer subject to this notification requirement.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2014, the FDA issued two draft guidance documents: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Framework for Regulatory Oversight of Laboratory Developed Tests</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which provided an overview of how the FDA would regulate LDTs through a risk-based approach, and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA Notification and Medical Device Reporting for Laboratory Developed Tests</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, which provided guidance on how the FDA intended to collect information on existing LDTs, including adverse event reports. In the Framework for Regulatory Oversight draft guidance, the FDA asserted that LDT manufacturers would be subject to medical device premarket submission, registration, listing, and adverse event reporting requirements phased in over several years based on which tests posed the highest risk to public health.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 18, 2016, however, the FDA announced that it would not release the final guidance and would instead continue to work with stakeholders, the new administration, and Congress to determine the right approach.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 13, 2017, the FDA released a discussion paper on possible approaches to regulate LDTs in which it described a policy wherein previously marketed LDTs would not be expected to comply with most or all FDA oversight requirements, except for adverse event and malfunction reporting. In addition, certain new and significantly modified LDTs would not be expected to comply with pre-market review unless the agency determines certain tests could lead to patient harm.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2017, the draft Diagnostic Accuracy and Innovation Act (DAIA) was introduced and outlined a risk-based regulatory approach for in vitro clinical tests (IVCT), i.e., all IVDs regardless of whether they are commercially distributed diagnostic kits or LDTs.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2017, the FDA issued a document describing 20 case studies of LDTs that raised concerns about the safety and efficacy of this category of tests.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FDA responded to the DAIA draft with its own proposal for IVCTs, including PMA, provisional approval, and precertification, in addition to authority to revoke approval, request raw data, and take corrective action against test developers to protect public health.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 31, 2018, the FDA issued its Safety Communication entitled &#x201c;The FDA Warns Against the Use of Many Genetic Tests with Unapproved Claims to Predict Patient Response to Specific Medications&#x201d; alleging that the agency was &#x201c;aware&#x201d; of healthcare providers making &#x201c;inappropriate changes to a patient&#x2019;s antidepressant medication based on the results from genetic tests.&#x201d; Following this Safety Alert, the FDA contacted several laboratories that offered tests that made claims regarding drug responses for specific medications. While most laboratories addressed the FDA&#x2019;s concerns by removing specific medication names from their labeling, the FDA issued an enforcement letter against a laboratory for making such claims without first undergoing the FDA premarket review.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2018, a new draft bill which revised the DAIA and incorporated feedback from the FDA was released. The Verifying Accurate, Leading-edge, IVCT Development (VALID) Act creates a risk-based regulatory framework for IVCT regulation. Under the VALID Act framework, premarket review would be required for certain higher risk tests, while lower risk tests would be subject to a precertification pathway.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 4, 2019, the FDA issued a warning letter to Inova Genomics Laboratory for its pharmacogenomics tests, i.e., tests that predict medication response, among other things. In this letter, the FDA rebutted Inova&#x2019;s argument that it believed it was operating within the scope of FDA&#x2019;s LDT exemption and not subject to the FDA&#x2019;s premarket review or labeling requirements by noting that the FDA has not created a legal &#x201c;carve-out&#x201d; or exemption for LDTs and that it ultimately retains discretion to take action when appropriate.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 5, 2020, identical versions of the VALID Act were introduced in both chambers of Congress. The same day, the House bill was referred to the House Committee on Energy and Commerce.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 19, 2020, HHS announced a new policy determining that FDA must engage in notice-and-comment rulemaking before requiring premarket review of LDTs.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 16, 2020, HHS directed FDA to review voluntarily submitted EUAs for LDTs; if FDA&#x2019;s review time exceeds 14 days, the submission would be referred to the National Institute of Health National Cancer Institute and also to other scientific government agencies, or to outside technical contractors if FDA remains unable to conduct the reviews. </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 24, 2021, an updated version of the VALID Act was reintroduced in both chambers of Congress.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On November 15, 2021, HHS formally rescinded its August 19, 2020 policy statement regarding FDA&#x2019;s ability to require premarket review of LDTs absent notice-and-comment rulemaking. That same day, FDA revised its policy with respect to COVID-19 diagnostic tests, announcing that developers of LDTs for SARS-CoV-2 were expected to either submit an EUA request or cease marketing and offering their tests within 60 calendar days. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently market our GeneStrat, VeriStrat, Nodify XL2 and Nodify CDT tests as LDTs in the United States. As a result, we believe our diagnostic services are not currently subject to the FDA&#x2019;s enforcement of its medical device regulations and the applicable FDCA provisions. If the FDA disagrees with the LDT status of any of our tests, the FDA may consider the test to be an unapproved medical device and may subject us to FDA enforcement action, including, without limitation, requiring us to seek clearance, authorization or approval for the laboratory test. If the FDA were to begin enforcement with respect to our LDTs, we could incur substantial costs and delays associated with trying to obtain pre-market clearance or approval and costs associated with complying with post-market requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, the FDA has not engaged in notice-and-comment rulemaking or released broad-sweeping guidance over LDTs, but it could choose to do so in the future and if pre-market review is required, our business could be negatively impacted as a result of commercial delay that may be caused by the new requirements. The cost of conducting clinical trials and otherwise developing data and information to support pre-market applications may be significant. If we are required to submit applications for our currently marketed tests, we may be required to conduct additional studies, which may be time-consuming, costly and could result in our currently-marketed tests being withdrawn from the market. Continued compliance with the FDA&#x2019;s regulations would increase the cost of conducting our business, and subject us to heightened regulation by the FDA including penalties for failure to comply with these requirements. Failure to comply with applicable regulatory requirements could result in an enforcement action by the FDA, such as fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal sanctions. There are other regulatory and legislative proposals that would increase general FDA oversight of clinical laboratories and LDTs. Until the FDA finalizes its regulatory position regarding LDTs, or the VALID Act or other legislation is passed reforming the federal government&#x2019;s regulation of LDTs, it is unknown how the FDA may regulate our tests in the future and what testing and data may be required to support any required clearance or approval. The outcome and ultimate impact of such proposals on the business is difficult to predict at this time and we are monitoring developments and anticipate that our products will be able to comply with requirements that may be imposed by the FDA. In the meantime, we maintain our CLIA accreditation, which permits the use of LDTs for diagnostics purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FDA Emergency Use Authorization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 564 of the FDCA allows the FDA to authorize the shipment of drugs, biological products, or medical devices that either lack required approval, licensure, or clearance (unapproved products), or are approved but are to be used for unapproved ways to diagnose, treat, or prevent serious diseases or conditions in the event of an emergency declaration by the HHS Secretary. 21 U.S.C. &#167; 360bbb-3(a)(1)-(2).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 31, 2020, HHS Secretary Alex M. Azar II declared a public health emergency for COVID-19, under 21 U.S.C. &#167; 360bbb-3(b)(1), justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19. This determination was published in the Federal Register on February 7, 2020. 85 Fed. Reg. 7316 (Feb. 7, 2020). The public health emergency has been extended several times and remains in effect.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While this emergency declaration is effective, the FDA may authorize the use of an unapproved product or an unapproved use of an approved product if it concludes that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an agent referred to in the emergency declaration could cause a serious or life-threatening disease or condition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is reasonable to believe that the authorized product may be effective in diagnosing, treating, or preventing that disease or condition or a serious or life-threatening disease or condition caused by an approved product or a product marketed under an EUA;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the known and potential benefits of the authorized product, when used for that disease or condition, outweigh known and potential risks, taking into consideration the material threat of agents identified in the emergency declaration;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">there is no adequate, approved, and available alternative to the authorized product for diagnosing, preventing, or treating the relevant disease or condition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any other criteria prescribed by the FDA is satisfied. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Id. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#167; 360bbb-3(c).</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Bio-Rad SARS-CoV-2 ddPCR test, the cPASS neutralization antibody test kit, and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. We have completed all required performance verification studies to validate the use of the tests in our laboratories in accordance with the FDA Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency, CAP and New York State Clinical Laboratory Standards of Practice (NYS CLEP) requirements. The FDA Policy for COVID-19 tests is a guidance document that explains the FDA&#x2019;s current thinking on the topic, is subject to change, and does</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">not establish any legally enforceable responsibilities. The FDA does not expect a separate notification or EUA request from high complexity CLIA laboratories that are performing testing for SARS-CoV-2 using only EUA-authorized test kits purchased from commercial manufacturers or their distributors. According to previous versions of the FDA's Policy for COVID-19 tests, a laboratory may make certain modifications to an EUA-authorized test if the modified test is validated using a bridging study without submitting an EUA amendment or formal notification. According to the current FDA Policy for COVID-19 tests (Nov. 15, 2021), a laboratory that modified an EUA authorized test pursuant to the previous policy for use of a new specimen through a bridging study when the new specimen type had been previously authorized for another test of the same technology may continue to offer the modified test without submitting an EUA amendment or formal notification.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Federal and State Laboratory Licensing Requirements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biodesix Boulder, Colorado clinical laboratory is a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, Biodesix&#x2019;s Quality Management System (QMS) holds an ISO 13485:2016 certificate (recently passed recertification audit in December 2021). The Biodesix Boulder, Colorado clinical laboratory has received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers, and Molecular and Cellular Tumor Markers and Virology as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CLIA regulations establish standards for proficiency testing; facility administration; general laboratory systems; pre-analytic, analytic systems, post- analytic systems; personnel qualifications and responsibilities; quality control, quality assessment; and specific provisions for laboratories performing moderate to high complexity tests. Our Boulder, Colorado clinical laboratory is inspected biennially as part of its ongoing certification under CLIA certificate of accreditation by CAP. The Boulder, Colorado clinical laboratory most recently passed its CAP inspection in April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under CLIA, a laboratory is any facility that performs laboratory testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease, or the impairment of or assessment of health. CLIA requires that a laboratory hold a certificate applicable to the type of laboratory examinations it performs and that it complies with, among other things, standards covering operations, personnel, facilities administration, quality systems and proficiency testing, which are intended to ensure, among other things, that clinical laboratory testing services are accurate, reliable and timely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biodesix De Soto, Kansas clinical laboratory is a CAP-accredited clinical laboratory regulated by CMS pursuant to CLIA. CMS has granted CAP deeming authority under CLIA, which allows CAP to inspect laboratories in lieu of CMS. In addition to holding a CLIA Certificate and CAP laboratory accreditation, the De Soto, Kansas clinical laboratory most recently passed its first CAP inspection in June 2021. Biodesix&#x2019;s QMS holds an ISO 13485:2016 certificate (recently passed surveillance audit in December 2021). The De Soto, Kansas clinical laboratory has received approval from the NYSDOH, NYS CLEP in Soluble Tumor Markers and Diagnostic Immunology as well as holding state permits and licenses in California, Maryland, New York, Pennsylvania, and Rhode Island.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The International Organization for Standardization (ISO) is an independent, non-governmental international organization that defines world-class specifications for products, services and systems, to ensure quality, safety and efficiency. ISO 13485:2016 is a harmonized, international regulatory benchmark for quality management systems that addresses most or all of the QMS requirements in markets including the United States, European Union, Australia, Japan and Canada. The ISO 13485:2016 certificate confirms that an organization operates a QMS that conforms to the standards established by ISO. The FDA has proposed a rule to harmonize and modernize its QSR, which would supplant the existing requirements with ISO 13485:2016. Although this rule has been delayed several times since spring 2018, the Office of Management and Budget (OMB) updated its website (January 2022) to indicate that the FDA&#x2019;s proposed rule to harmonize the agency&#x2019;s medical device Quality System Regulation with the ISO 13485 standard has been finished and is now under review by OMB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To renew our CLIA certificate, we are subject to survey and inspection every two years to assess compliance with program standards. Laboratories such as ours, which are performing high complexity testing, are required to meet more stringent CLIA requirements than laboratories performing less complex tests, and therefore our laboratories are also subject to random, unannounced survey and inspection at any time. In addition, a laboratory that is certified as &#x201c;high complexity&#x201d; under CLIA may develop, manufacture, validate and use proprietary LDTs. CLIA requires analytical validation including accuracy, precision, specificity, sensitivity and establishment of a reference range for any LDT used in clinical testing. The regulatory and compliance standards applicable to the testing we perform may change over time and any such changes could have a material effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CLIA provides that a state may adopt laboratory regulations that are more stringent than those under federal law, and a number of states have implemented their own more stringent laboratory regulatory requirements. State laws may require that out-of-state laboratories maintain an in-state laboratory license to perform tests on samples from patients who reside in that state. As a condition of licensure, certain states may require that laboratory personnel meet qualifications, quality control procedures, facility requirements, record maintenance requirements or other state-specific requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because our Boulder, Colorado clinical laboratory is located in the State of Colorado, we do not need a specific State of Colorado laboratory license, however, we maintain licenses to conduct testing in other states where nonresident laboratories are required to obtain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">state laboratory licenses. We maintain licenses for our Boulder, Colorado and De Soto, Kansas laboratories with the NYSDOH. We also hold licenses in other states in which we operate, including California, Maryland, Pennsylvania and Rhode Island, that require licensing of out-of-state laboratories under certain circumstances. Other states may currently have or adopt similar licensure requirements in the future, which may require us to modify, delay or stop its operations in those states until such requirements are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with CLIA certification and state clinical laboratory licensure requirements may result in a range of enforcement actions, including certificate or license suspension, limitation, or revocation, directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions, and revocation of the laboratory&#x2019;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CLIA and state laws and regulations, operating together, sometimes limit the ability of laboratories to offer consumer-initiated testing, also known as direct access testing. We do not offer direct access testing and instead require that our tests be ordered by licensed healthcare providers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Boulder, Colorado and De Soto, Kansas laboratories are certified and adhere to the NYS CLEP, based on New York State Public Health Law, Article 5 Title 5. NYS CLEP is exempt from CLIA and establishes their own method of laboratory certification and test validation approval. To process New York State patient specimens a laboratory must submit a robust analytical and clinical validation package to demonstrate clinical utility of the test and receive approval prior to offering the test in the state of New York. All of our tests have obtained NYS CLEP approval including GeneStrat ddPCR, GeneStrat NGS, VeriStrat, Nodify XL2 and Nodify CDT tests. NYS CLEP requires semi-annual inspections to ensure the laboratory meets all general and specialty standards. Both Biodesix laboratories passed NYS CLEP inspections in May 2019. Due to the pandemic, routine re-inspections have been delayed by NYS CLEP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Regulatory framework for medical devices in the United States</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, which are defined to include, among other things, IVDs. The FDA regulates the research, design, development, pre-clinical and clinical testing, manufacturing, safety, effectiveness, packaging, labeling, storage, recordkeeping, pre-market clearance or approval, adverse event reporting, marketing, promotion, sales, distribution and import and export of medical devices. It is possible that one of our current, or future, tests will be subject to FDA authority and oversight as either an IVD or a CDx pursuant to the FDA&#x2019;s authority to regulate medical devices under the FDCA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medical devices are subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laboratory and clinical testing, labeling, packaging, storage and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">service operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product marketing, promotion and advertising, sales and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">post-market approval studies; and </span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product import and export</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the European Economic Area (EEA), a medical device must meet the Medical Devices Directive&#x2019;s (MDD)/In Vitro Medical Devices Directive&#x2019;s (IVDD) Essential Requirements or, applicable on May 26, 2021, the Medical Devices Regulation&#x2019;s (MDR) / applicable on May 26, 2022, In Vitro Medical Devices Regulation&#x2019;s (IVDR) General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#x2019;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers of medical devices must document in a clinical evaluation report (CER) the evaluation of the clinical data related to the device. The CER is part of the device&#x2019;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk- ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, inter alia, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#x201c;substantially equivalent&#x201d; devices is very restrictive and requires, inter alia, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#x201c;equivalent device&#x201d; is not its own, that the manufacture has in place a contract with the manufacturer of the &#x201c;equivalent device.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Device classification</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the FDCA, medical devices are classified into one of three classes: Class I, Class II or Class III, depending on the degree of risk to patients that is associated with each medical device and the amount of oversight needed to provide reasonable assurances with respect to safety and effectiveness of the medical device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be reasonably assured by adherence to a set of FDA regulations, referred to as the General Controls for Medical Devices, which require compliance with the applicable portions of the FDA&#x2019;s QSR, facility registration and product listing, reporting of adverse events and malfunctions, and appropriate, truthful and non-misleading labeling and promotional materials. Some Class I devices also require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I products are exempt from the premarket notification requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class II devices are subject to the General Controls as well as any special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, patient registries, FDA guidance documents and post-market surveillance. Most Class II devices are subject to premarket review and clearance by the FDA. Premarket review and clearance by the FDA for Class II devices is accomplished through the 510(k) premarket notification process, although some Class II devices are exempt from the 510(k) requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Class III devices include devices deemed by the FDA to pose the greatest risk: such as life-supporting or life-sustaining devices, implantable devices, or those deemed novel and not substantially equivalent to a predicate device following the 510(k) process. CDx tests are regularly considered Class III devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Premarket submission process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless a statutory or regulatory exemption or enforcement discretion policy applies, before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, the manufacturer must obtain the FDA&#x2019;s: (1) permission for commercial distribution under section 510(k) of the FDCA (510(k) clearance); or (2) approval of a PMA; or (3) de novo classification and authorization. These processes can be resource intensive, expensive, and lengthy, and require payment of significant user fees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 510(k)-clearance process, the manufacturer must submit to the FDA a premarket notification, demonstrating that the device is &#x201c;substantially equivalent&#x201d; to a legally marketed predicate device. A predicate device is a legally marketed device that is not subject to a PMA, i.e., a device that was legally marketed prior to May 28, 1976 (pre-amendments device) and therefore a PMA is not required, a device that has been reclassified from Class III to Class II or I, or a device that was previously found substantially equivalent through the 510(k) process. To be &#x201c;substantially equivalent,&#x201d; the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Premarket notifications typically include bench, analytical, and preclinical data. Clinical data is sometimes required to support substantial equivalence. If a manufacturer obtains a 510(k) clearance for its device and then makes a modification that could significantly affect the device&#x2019;s safety or effectiveness or constitutes a major change or modification in the intended use of the device, a new clearance, authorization or approval may be required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By statute, the FDA is required to complete its review of a 510(k) notification within 90 days of receiving the 510(k) notification. As a practical matter, clearance often takes longer, and clearance is never assured. Although many 510(k) premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device is substantially equivalent, it will grant clearance to commercially market the device. If the FDA determines that the device is not &#x201c;substantially equivalent&#x201d; to a predicate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">device, or if the device is automatically classified into Class III, the device sponsor must then fulfill the much more rigorous, costly, and time-consuming PMA approval process or seek reclassification of the device through the de novo process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain a PMA, the applicant must submit data and information demonstrating reasonable assurance of the safety and effectiveness of the device for its intended use to the FDA&#x2019;s satisfaction. Accordingly, a PMA typically includes, but is not limited to, extensive technical information regarding device design and development, pre-clinical and clinical trial data, manufacturing information, labeling, and financial disclosure information for the clinical investigators in device studies. The PMA application must provide valid scientific evidence that demonstrates to the FDA&#x2019;s satisfaction a reasonable assurance of the safety and effectiveness of the device for its intended use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once filed as a PMA, the FDA has 180 days to review the filed PMA application, although the review of an application more often occurs over a significantly longer period of time. During this review period, the FDA may request additional information or clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#x2019;s response to deficiencies communicated by the FDA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to approval of a PMA, the FDA may conduct inspections of any clinical trial data and clinical trial sites, as well as inspections of any manufacturing facility and processes. The FDA can delay, limit or deny approval of a PMA application for many reasons, including (1) the device may not be shown safe or effective to the FDA&#x2019;s satisfaction; (2) the data from pre-clinical studies and/or clinical trials may be found unreliable or insufficient to support approval; (3) the manufacturing process or facilities may not meet applicable requirements; and (4) changes in FDA approval policies or adoption of new regulations may require additional data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device, subject to the conditions of approval and the limitations established in the approval letter. The FDA also may determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when data is available. The PMA process can be expensive, uncertain and lengthy. A number of devices for which the FDA approval has been sought by other companies have never been approved by the FDA for marketing. New PMA applications or PMA supplements are required for any modifications to the manufacturing process, equipment or facility, quality control procedures, sterilization, packaging, expiration date, labeling, device specifications, ingredients, materials or design of a device that has been approved through the PMA process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a condition of PMA application approval, the FDA may also require some form of post-approval study or post-market surveillance, whereby the applicant conducts a follow-up study or follows certain patient groups for a number of years and makes periodic reports to the FDA on the clinical status of those patients when necessary to protect the public health or to provide additional or longer-term safety and effectiveness data for the device. The FDA may also approve a PMA application with other post-approval conditions intended to ensure the safety and effectiveness of the device, such as, among other things, restrictions on labeling, promotion, sale, distribution and use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Alternatively, the FDA also allows the submission of a direct de novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 510(k), de novo or PMA processes can be expensive, lengthy and unpredictable. The FDA&#x2019;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k)-clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Companion Diagnostics and the Premarket Process</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that one of our future product candidates may include a companion diagnostic or complementary diagnostic (collectively CDx). CDx&#x2019;s can identify patients who are most likely to benefit from a particular therapeutic product; identify patients likely to be at increased risk for serious side effects as a result of treatment with a particular therapeutic product; or monitor response to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. The use of the CDx will be stipulated in the labeling of both the CDx and the therapeutic product. The FDA may require an application for the CDx to be separate from the drug approval process, and this could potentially delay the approval of any new drug application or the CDx, or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">complicate the review process. CDx&#x2019;s are generally regulated as Class III medical devices by the FDA and are therefore most often subject to the PMA approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA issued guidance in July 2016 for the co-development of CDx tests with a therapeutic product and issued another draft guidance in December 2018 specific to oncology CDx tests. The FDA finalized this draft guidance in April 2020 in &#x201c;Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products.&#x201d; The guidance is meant to guide the development of CDx products, which are defined as IVDs that provide information that is essential for the safe and effective use of the therapeutic product. A CDx is often developed and approved or cleared contemporaneously with the therapeutic, and the use of the CDx is stipulated in the labeling of both the CDx and the corresponding therapeutic product. While it supports contemporaneous marketing authorizations, if there are any deficiencies in the submissions, the FDA may place a PMA review of a CDx on hold or request additional testing, which could potentially delay the approval of the corresponding new drug application or the marketing authorization of the CDx, or otherwise complicate the review process. Some oncology CDx tests can be developed in a way that results in labeling for a specific group of oncology therapeutic products, rather than a single therapeutic product.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Post-Market FDA Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if regulatory clearance, authorization or approval of a device is granted, the FDA may impose limitations on the uses and indications for which the device may be labeled and promoted, and the device remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared, authorized or approved. After a device, including a device exempt from FDA premarket review, is placed on the market, numerous post-market regulatory requirements apply, and the FDA has broad authority to enforce these requirements. Medical device manufacturers are subject to unannounced inspections by the FDA and other state, local and foreign regulatory authorities to assess compliance with the QSR and other applicable regulations, and these inspections may include the manufacturing facilities of any suppliers. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include sanctions such as: warning letters, fines, injunctions, consent decrees and civil penalties; unanticipated expenditures, including requirements to repair, replace, and/or refund the cost of the devices, recall or seizure of our products; operating restrictions, partial suspension or total shutdown of production; the FDA&#x2019;s refusal of our requests for 510(k) clearance, de novo classification, or PMA of new products, new intended uses or modifications to existing products; the FDA&#x2019;s refusal to issue certificates to foreign governments needed to export products for sale in other countries; and withdrawing 510(k) clearance or PMAs that have already been granted and criminal prosecution. In the event that a supplier fails to maintain compliance with the FDA&#x2019;s or our quality requirements, we may have to qualify a new supplier and could experience manufacturing delays as a result.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Federal and State Fraud and Abuse Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to federal fraud and abuse laws such as the federal Anti-Kickback Statute (AKS), the federal prohibition against physician self- referral (Stark Law), the Eliminating Kickbacks in Recovery Act (EKRA), and the federal False Claims Act (FCA). We are also subject to similar state and foreign fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The AKS (Social Security Act &#167; 1128B(b)) prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce such person to refer an individual, or to purchase, lease, order, arrange for, or recommend purchasing, leasing or ordering, any item or service that may be reimbursable, in whole or in part, under a federal healthcare program, such as Medicare or Medicaid. There are a number of statutory exceptions and regulatory safe harbors to the AKS that provide protection from AKS liability to arrangements that fully satisfy the applicable requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">EKRA (18 USC &#167; 220) prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program. The term &#x201c;health care benefit program&#x201d; is broadly defined such that EKRA extends to referrals reimbursed by both governmental and commercial third-party payers. EKRA includes a number of statutory exceptions that provide protection from EKRA liability if the applicable requirements are met.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Stark Law (Social Security Act &#167; 1877) generally prohibits, among other things, clinical laboratories and other so-called &#x201c;designated health services&#x201d; entities from billing Medicare for any designated health services when the physician ordering the service, or any member of such physician&#x2019;s immediate family, has a financial relationship, such as a direct or indirect investment interest in or compensation arrangement with the billing entity, unless the arrangement meets an exception to the prohibition. The Stark Law also prohibits physicians from making such referrals to a designated health services entity. There are also similar state laws that apply where Medicaid and/or commercial payers are billed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FCA (31 USC &#167; 3729) imposes civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment to the government that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#x201c;qui tam&#x201d; whistleblower to bring actions on behalf of the federal government alleging violations of the FCA and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to share in any monetary recovery. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $11,803 to $23,607 per false claim or statement for penalties assessed after December 13, 2021, with respect to violations occurring after November 2, 2015.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offeror or payer knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular provider, practitioner, or supplier, and contracting with an individual or entity that the person knows or should know is excluded from participation in a federal health care program. In addition, federal criminal statutes created by HIPAA prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to these federal laws, there are often similar state anti-kickback and false claims laws that typically apply to arrangements involving reimbursement by a state-funded Medicaid or other health care program. Often, these laws closely follow the language of their federal law counterparts, although they do not always have the same exceptions or safe harbors. In some states, these anti-kickback laws apply with respect to all payers, including commercial payers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A number of states have enacted laws that require pharmaceutical and medical device companies to monitor and report payments, gifts and other remuneration made to physicians and other healthcare providers, and, in some states, marketing expenditures. In addition, some state statutes impose outright bans on certain manufacturer gifts to physicians or other health care professionals. Some of these laws, referred to as &#x201c;aggregate spend&#x201d; or &#x201c;gift&#x201d; laws, carry substantial fines if they are violated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs and extensive annual trainings for all of our employees and contractors. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with the law, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. If any of the physicians or other healthcare providers or entities with whom we do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Anti-Corruption</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Foreign Corrupt Practices Act of 1977 (FCPA) and similar international bribery laws make it unlawful for persons or entities to make payments to foreign government officials to assist in obtaining and maintaining business. Specifically, the anti-bribery provisions of the FCPA prohibit any offer, payment, promise to pay, or authorizing the payment of money or anything of value to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to a foreign official to do or omit to do an act in violation of his or her duty, or to secure any improper advantage in order to assist in obtaining or retaining business for or with, or directing business, to any person. In addition to the anti-bribery provisions of the FCPA, the statute also contains accounting requirements designed to operate in tandem with the anti-bribery provisions. Covered companies are required to make and keep books and records that accurately and fairly reflect the transactions of the company and devise and maintain an adequate system of internal accounting controls. With our international operations through our third-party partnerships, we could incur significant fines and penalties, as well as criminal liability, if we fail to comply with either the anti-bribery or accounting requirements of the FCPA, or similar international bribery laws. Even an unsuccessful challenge of our compliance with these laws could cause us to incur adverse publicity and significant legal and related costs. We successfully passed our first FCPA compliance review in 2021 with no findings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Privacy and Data Protection Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerous federal and state laws and regulations, including HIPAA, as amended by the HITECH Act, govern the collection, dissemination, security, use and confidentiality of protected health information (PHI) and personal information. In the course of performing our business we obtain personal information, including PHI. Laws and regulations relating to privacy, data protection, and consumer protection are evolving and, in some cases, particularly with regard to newer laws, may be subject to potentially differing interpretations. Under HIPAA and HITECH, the HHS issues regulations that establish uniform standards governing the conduct of certain electronic healthcare transactions and requirements for protecting the privacy and security of PHI, used or disclosed by covered entities (CEs) and their authorized business associates (BAs). Because we are a health care provider that electronically transmits health care information, and we also provide certain services to CEs and receive PHI from them, we are at times either a CE or a BA, as defined</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">by HIPAA. Our subcontractors that create, receive, maintain, transmit or otherwise process PHI on our behalf are HIPAA BAs and must also comply with HIPAA, as applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA and HITECH include the privacy and security rules, breach notification requirements and electronic transaction standards. The privacy rule governs the use and disclosure of PHI, generally prohibits the use or disclosure of PHI except as permitted under the rule, and mandates certain safeguards to protect the privacy of PHI. The privacy rule also sets forth individual rights, such as the right to access or amend certain records containing such individual&#x2019;s PHI, or to request restrictions on the use or disclosure of such individual&#x2019;s PHI. The security rule requires CEs and BAs to safeguard the confidentiality, integrity, and availability of electronically transmitted or stored PHI (also referred to as ePHI) by implementing administrative, physical and technical safeguards. Under HIPPAA&#x2019;s breach notification rule, a CE must notify individuals, the Secretary of HHS, and in some circumstances, the media of certain breaches of unsecured PHI or ePHI, and similar breach notification provisions apply to certain BAs under the HITECH Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Penalties for failure to comply with a requirement of HIPAA and HITECH vary depending on the number and nature of the violations and any history of prior violations, but can be significant and include civil monetary or criminal penalties. HIPAA is enforced by the Department of Health and Human Services, Office for Civil Rights, and HIPAA also authorizes state attorneys general to file suit on behalf of their residents for violations. Courts are able to award damages, costs and attorneys&#x2019; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to file suit in civil court for violations of HIPAA, its standards have been used as the basis for duty of care cases in state civil suits such as those for negligence or recklessness in improper use, access to or disclosure of PHI. In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA CEs, such as us, and their BAs for compliance with the HIPAA privacy and security standards and breach notification rules. It also tasks HHS with establishing a methodology whereby harmed individuals who were the victims of breaches of unsecured PHI may receive a percentage of the civil monetary penalty paid by the violator.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may be subject to state privacy, cybersecurity, and data breach notification laws, which may govern the collection, use, disclosure and protection of health-related and other personal information. California, for example, has enacted the Confidentiality of Medical Information Act, which, in addition to HIPAA and HITECH, sets forth standards with which all California health care providers must abide. Colorado has enacted the Colorado Privacy Act, and Virginia has enacted the Consumer Data Protection Act, both of which also have standards that must be complied with that supplement Federal data protection requirements, State laws may be more stringent, broader in scope or offer greater individual rights with respect to PHI than HIPAA, and state laws may differ from each other in regards to personal information treatment, which may complicate compliance efforts. For instance, the California Consumer Privacy Act (CCPA) became effective on January 1, 2020 and was amended by the passage of the California Privacy Rights Act (CPRA) in November of 2020. The CCPA, among other things, gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA has been amended from time to time, and it remains unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. Although there are certain exemptions for PHI and clinical trial data, the CCPA&#x2019;s implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future and the CCPA may increase our compliance costs and potential liability. Additionally, the CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes and opt outs for certain uses of sensitive data. It would also create a new California data protection agency specifically tasked to enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. Similar laws have been proposed in other states and at the federal level, and if passed, such laws may have potentially conflicting requirements that could continue to make compliance challenging and costly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the Federal Trade Commission (FTC) and state attorneys general enforce consumer protection laws that prohibit unfair and deceptive acts and practices, including Section 5 of the FTC Act, which creates standards for the collection, use, dissemination and security of health-related and other personal information. Claims of unfair or deceptive trade practices regarding privacy and security can lead to significant liabilities and consequences, including regulatory investigations, penalties, fines and orders as well as civil claims, which could impact our data practices and operations or cause reputational damage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to laws and regulations in foreign countries covering data privacy and other protection of health and employee information that may add additional compliance burden and complexity. For example, in the EEA, the collection and use of personal data is governed by the European Union's General Data Protection Regulation (GDPR). In the United Kingdom, the GDPR has been adopted in substantially the same form, however the UK may potentially make revisions in the coming years. The GDPR, together with national legislation, regulations and guidelines of the EU member states and the United Kingdom governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze, store, transfer and otherwise process personal data. European and United Kingdom data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which adds to the complexity of processing personal data in or from the EEA or United Kingdom. Guidance on implementation and compliance practices are often updated or otherwise revised. GDPR applies extra-territorially under certain circumstances and imposes stringent requirements on controllers and processors of personal data, including, for example, requirements to ensure a legal bases to process personal information, provide robust disclosures to individuals, facilitate data subject rights, provide</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">data security breach notifications within 72 hours after discovering a breach in certain circumstances, limit retention of personal information and apply enhanced protections to health data and other categories of sensitive personal information. The GDPR also has requirements around international transfers of personal data. Requirements around transfers to the United States and other jurisdictions have increased since a July 2020 decision by the Court of Justice of the European Union invalidated the Privacy Shield as a basis to transfer personal data from Europe to the United States, and added requirements for reliance on Standard Contractual Clauses. Regulatory guidance on requirements for international transfers, and other GDPR compliance matters, continues to evolve. Failure to comply with the requirements of the GDPR may result in fines of up to &#x20ac;20 million or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. To comply with the GDPR and other applicable international data protection laws and regulations, we may be required to put in place additional mechanisms ensuring compliance, which may result in other substantial expenditures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cybersecurity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business relies on secure and continuous processing of information and the availability of our IT networks and IT resources, as well as critical IT vendors that support our technology, research and other data processing operations. While we take steps to protect our systems and data, security incidents, data breaches, computer malware and computer hacking attacks have become more prevalent across industries, including the life sciences sector, and may occur on our systems or those of our third-party service providers. Unauthorized persons may in the future be able to exploit weaknesses in the security systems of our (or our third-party service providers) IT networks and gain access to PHI and other personal information, or sensitive trade secrets or other proprietary information. Any wrongful use or disclosure of PHI, other personal information, trade secrets or other proprietary information by us or our third-party service providers could subject us to regulatory fines or penalties, third-party claims or otherwise could adversely affect our business and results of operations. Although HIPAA and the regulations promulgated thereunder do not provide for a private right of action, failures to adequately protect PHI or our IT systems could be viewed as violations of the HIPAA security rule or violations of other applicable information security laws, regulations, contractual obligations or industry standards, and could further result in costly data breach notification obligations that negatively impact our reputation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, data security incidents or data breaches, as well as attacks on our IT systems, could result in operational disruptions or data loss or corruption that could adversely impact our business and operations, result in substantial investment of resources to investigate, recover and remediate and subject us to heightened regulatory scrutiny.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">International Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries in which we may offer any of our diagnostic tests in the future have anti-kickback regulations prohibiting providers from offering, paying, soliciting or receiving remuneration, directly or indirectly, in order to induce business that is reimbursable under any national health care program. In situations involving physicians employed by state-funded institutions or national health care agencies, violation of the local anti-kickback law may also constitute a violation of the FCPA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FCPA prohibits any United States individual, business entity or employee of a United States business entity to offer or provide, directly or through a third party, including any potential distributors we may rely on in certain markets, anything of value to a foreign government official with corrupt intent to influence an award or continuation of business or to gain an unfair advantage, whether or not such conduct violates local laws. In addition, it is illegal for a company that reports to the SEC to have false or inaccurate books or records or to fail to maintain a system of internal accounting controls. We will also be required to maintain accurate information and control over sales and distributors&#x2019; activities that may fall within the purview of the FCPA, its books and records provisions and its anti-bribery provisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The standard of intent and knowledge in anti-bribery cases is minimal. Intent and knowledge are usually inferred from that fact that bribery took place. The accounting provisions do not require intent. Violations of the FCPA&#x2019;s anti-bribery provisions for corporations and other business entities are subject to a fine of up to $2 million and officers, directors, stockholders, employees, and agents are subject to a fine of up to $100,000 and imprisonment for up to five years. Other countries, including the United Kingdom and other OECD Anti-Bribery Convention members, have similar anti-corruption regulations, such as the United Kingdom Anti-Bribery Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When marketing our diagnostic tests outside of the United States, we may be subject to foreign regulatory requirements governing human clinical testing, prohibitions on the import of tissue necessary for us to perform our diagnostic tests or restrictions on the export of tissue imposed by countries outside of the United States or the import of tissue into the United States, and marketing approval. These requirements vary by jurisdiction, differ from those in the United States and may in some cases require us to perform additional pre-clinical or clinical testing. In many countries outside of the United States, coverage, pricing and reimbursement approvals are also required.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market access, sales and marketing of medical devices in non-U.S. countries are subject to foreign regulatory requirements that vary widely from country to country. For example, in the EEA, a medical device must meet MDDs/IVDD Essential Requirements or, applicable on May 26, 2021, the MDR applicable on May 26, 2022, IVDR General Safety and Performance Requirements which apply to it, taking into account its intended purpose as defined by the data supplied by the manufacturer on the label, in the instructions for use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">or in promotional or sales materials or statements and as specified by the manufacturer in the clinical evaluation. Before placing a medical device on the EEA market, the manufacturer must draw up a declaration of conformity, certifying that the device complies with the MDD/IVDD/MDR/IVDR, and must then affix the CE mark. For medium and high-risk devices as well as low risk devices that are placed on the market in sterile condition, have a measuring function, or are reusable surgical instruments, the manufacturer must obtain a CE Certificate from a notified body. The notified body typically audits and examines the device&#x2019;s technical documentation, including the clinical evaluation, and the quality system for the manufacture, design and final inspection of the relevant device before issuing a CE Certificate. Following the issuance of this CE Certificate, manufacturers may draw up the declaration of conformity and affix the CE mark to the devices covered by this CE Certificate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers of medical devices must document in a CER the evaluation of the clinical data related to the device. The CER is part of the device&#x2019;s technical file. The evaluation shall document that the applicable Essential Requirements/General Safety and Performance Requirements are met and document the evaluation of the undesirable side-effects and the acceptability of the benefit-risk- ratio. The CER must be updated based on information from the post-market surveillance and vigilance activities related to the device. The CER shall consist, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, of analyzed clinical data collected from a clinical investigation of the device, or the results of other studies on substantially equivalent devices. Reliance on &#x201c;substantially equivalent&#x201d; devices is very restrictive and requires, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter alia</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, that the manufacturer has full access to the technical documentation of the equivalent device on an ongoing basis and, if the &#x201c;equivalent device&#x201d; is not its own, that the manufacture has in place a contract with the manufacturer of the &#x201c;equivalent device.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Similar requirements apply in the UK. For access to the UK market, manufacturers must obtain a UKCA Certificate and affix a UKCA mark to their medical devices. However, the CE mark will be accepted in the UK until July 1, 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Healthcare Reform</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2010, the Patient Protection and Affordable Care Act (ACA) was enacted in the United States. The ACA made a number of substantial changes to the way healthcare is financed both by governmental and private insurers. For example, the ACA requires each medical device manufacturer to pay a sales tax equal to 2.3% of the price for which such manufacturer sells its medical devices. The medical device tax was permanently repealed at the end of 2019. The ACA also contains a number of other provisions, including provisions governing enrollment in federal and state healthcare programs, reimbursement matters, and fraud and abuse, which we expect will impact our industry and our operations in ways that we cannot currently predict.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning in 2017, the Trump administration sought to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. The Trump administration issued three executive orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. For example, on December 20, 2019, President Trump signed appropriations legislation for fiscal year 2020 that repealed certain ACA-mandated fees, including the so-called &#x201c;Cadillac&#x201d; tax on certain high-cost employer-sponsored insurance plans, for tax years beginning after December 31, 2019; the annual fee imposed on certain health insurance providers based on market share, for calendar years beginning December 31, 2020; and the medical device excise tax on non-exempt medical devices, for sales after December 31, 2019. While Congress did not pass comprehensive legislation that would repeal all or part of the ACA, two bills affecting the implementation of certain taxes under the ACA have been signed into law. Specifically, the Tax Cuts and Jobs Act of 2017 (TCJA), among other things, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment, or penalty, imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate.&#x201d; Beginning in 2021, the Biden administration has signaled its intent to pursue policies strengthening the ACA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other things, led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that started in 2013 and, due to subsequent statutory amendments, will remain in effect through 2030 unless additional Congressional action is taken. In 2020, the CARES Act temporarily suspended the 2% cut in Medicare payments from May 1, 2020 through December 31, 2020, and it extended the sequestration reductions through FY 2030 to offset the cost of such temporary suspension. The Consolidated Appropriations Act, 2021 further extended the temporary suspension through March 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 14, 2021, Congress enacted legislation that further extended the suspension through December 31, 2021. On December 10, 2021, further legislation was enacted to extend the suspension through March 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The American Taxpayer Relief Act of 2012 made other changes, including reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve R&amp;D, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop. Additionally, the Biden administration has already indicated a shift in direction from Trump administration policies by issuing orders and other documents rolling back regulations and Executive Orders from the Trump administration, and as noted, indicating that it will pursue policies strengthening the ACA. The recent change in presidential administration could materially impact our business in ways that are difficult to predict.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, in its enactment of the Consolidated Appropriations Act, Congress enacted the No Surprises Act. This law, which took effect January 1, 2022, bars an out-of-network providers from billing patients in excess of the in-network cost sharing for services furnished with respect to a visit at certain in-network health care facilities. The law establishes an independent dispute resolution process between the provider and the payer to determine the appropriate payment rate to the provider. As written, the No Surprises Act may apply to laboratory tests furnished by an independent laboratory with respect to a hospital visit. The law establishes a notice and consent exception that generally does not apply to laboratory tests, although it allows HHS to apply this exception to certain advanced tests. Regulations and subregulatory guidance were issued by HHS, the Department of Labor, and the Department of the Treasury in 2021, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with the first set of regulations was issued as an Interim Final Rule on July 1, 2021, and the second set issued as an Interim Final Rule on September 30, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> These regulations and subregulatory guidance have provided additional information on the applicability of the No Surprises Act, the rules governing the independent dispute resolution process, and specific provider requirements (including the obligation to furnish a &#x201c;good faith estimates&#x201d; of &#x201c;expected charges&#x201d; to uninsured or self-pay patients), as well as areas of temporary enforcement discretion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Environmental, Health and Safety Regulations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to various federal, state, local, and foreign environmental, health and safety laws and regulations and permitting and licensing requirements. Such laws include those governing laboratory practices, the generation, storage, use, manufacture, handling, transportation, treatment, remediation, release and disposal of, and exposure to, hazardous materials and wastes and worker health and safety. Our operations involve the generation, use, storage and disposal of hazardous materials, and the risk of injury, contamination or non-compliance with environmental, health and safety laws and regulations or permitting or licensing requirements cannot be eliminated. In particular, the introduction of our Bio-Rad SARS-CoV-2 ddPCR and Platelia SARS-CoV-2 Total Ab tests requires that we maintain compliance with applicable and evolving federal and state laws and regulations relating to COVID-19, including the generation, use, storage, and disposal of testing materials and agents. Compliance with environmental laws and regulations has not had a material effect on our capital expenditures, earning or competitive position. Most recently, the Boulder, Colorado clinical laboratory passed an on-site inspection from the CDC in June 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated in Delaware in 2005 as Elston Technologies, Inc. Our principal executive offices are located at 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301, and our telephone number is (303) 417-0500. On June 20, 2006, we changed our name to Biodesix, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an &#x201c;emerging growth company&#x201d; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended (the Securities Act), for complying with new or revised accounting standards. In other words, an &#x201c;emerging growth company&#x201d; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our IPO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we are a &#x201c;smaller reporting company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i) the market value of our common stock held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">as of the end of that year&#x2019;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For certain risks related to our status as an emerging growth company, see &#x201c;Risk Factors&#x2014;Risks Related to our Common Stock&#x2014;We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Human Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our culture is underpinned by our cultural beliefs including an unwavering commitment to inclusion and diversity. We are committed to fostering a diverse and inclusive workplace that attracts and retains exceptional talent offering opportunities for our team members to grow and develop in their careers, supported by strong compensation, benefits and health and wellness programs. We regularly engage our team members in monthly all-hands meetings to align and focus on the current state of affairs of our business, our partnerships, new products, clinical trials, and other pertinent information about our business. We engage our team members in programs such as peer recognition, recruitment and our newly introduced Diversity, Equity and Inclusion Council that focus on recognizing outstanding individual contributions to company performance, cultural fit of new team members and acknowledging the diversity of our team to ensure our team members feel valued and can do their best work. We have a national annual community service initiative, &#x201c;Biodesix Gives Back&#x201d; that allows each team member to invest ten hours of paid community service to organizations of their choosing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had approximately 218 full-time and part-time employees, all of which are located in the United States. Of our 218 full-time and part-time team members, the majority of our team member base is located in proximity to our corporate office and testing facilities located in Boulder, Colorado and our laboratory in De Soto, Kansas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diversity, Equity and Inclusion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that a diverse employee population, including cultural background, gender, ethnicity, sexual orientation and lived experiences, is critical to our success. Our employees are encouraged to leverage their personal strengths and experiences to continually innovate and contribute to the development of new ideas and process improvements that drive better experiences for our partners.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Engagement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our company culture emphasizes the satisfaction and well-being of our team members and a diverse, engaged workforce. We solicit the opinion and views of our team members through surveys and peer focus groups. We have an established and valued Peer Recognition Culture. Teammates recognize other teammates publicly for their support and contributions fostering collaboration, engagement and retention. We regularly review feedback we receive on our current cultural beliefs to determine if any modifications are needed. During the year ended December 31, 2021, we updated our cultural beliefs to align with our core values that reflect our current focus on Teamwork, Innovation, Making an Impact and Excel. Additionally, the Company annually celebrates our top sales performers through our President&#x2019;s Club and other top company performers as nominated by fellow team members through our four (4) Performance Excellence Awards that recognize creativity and innovation, an entrepreneurial spirit, a strategic impact on the success of the Company and lastly, embodying the Biodesix cultural beliefs and goes &#x201c;above and beyond&#x201d; daily.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Training and Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We invest in our team members career growth and provide team members with a wide range of development opportunities, including face-to-face, virtual, and self-directed learning, mentoring, coaching, and external development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Health, Safety and Wellness</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The physical health, financial stability, life balance and mental health of each of our team members is vital to our success. We sponsor several cancer awareness activities in our local communities to bring engagement and awareness of health, safety and wellness to positively impact lives. We provide an Employee Assistance Program through our professional employer organization (PEO) to enhance physical, financial, and mental well-being for all our team members. Since the onset of the COVID-19 pandemic, we have successfully transitioned a significant portion of our workforce to a remote working environment and implemented strict safety and social distancing measures in our sites to protect the health and safety of our team members. We also have provided extraordinary safety protocols and standards for all of &#x201c;essential&#x201d; team members who work in our Laboratories and our field sales organization including regularly scheduled serial testing for COVID-19. We also have an active &#x201c;Friends and Family&#x201d; COVID-19 testing program for our team members, their families and close friends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pay Equity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The main objective of our compensation program is to provide a compensation package that will attract, retain, motivate, and reward superior team members who operate in a highly competitive and technologically challenging environment. We emphasize overall Company performance and provide equity incentives for all team members to align their financial interests with the interests of shareholders. In addition, we offer an employee stock purchase plan to all employees in which participants are eligible to purchase shares at a discount to market. We think like customers and act like owners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix seeks fairness in total compensation. We benchmark with external comparisons, internal comparisons and look at the relationship between team member roles within the organization. We also review our compensation practices, both in terms of our overall workforce and individual team members, to ensure our pay is fair and equitable. We currently have no pay disparities based on gender, race, or ethnicity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We file with, or furnish to, the SEC reports including our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended. These reports are available free of charge on our corporate website (www.biodesix.com) as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. Copies of any materials we file with the SEC can be obtained at www.sec.gov. The foregoing website addresses are provided as inactive textual references only. The information provided on our website (or any other website referred to in this report) is not part of this report and is not incorporated by reference as part of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Risk</span><span id="item_1a_risk_factor"></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risk Factors Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a summary of the principal risks that could adversely affect our business, operations and financial results. This summary does not address all of the risk that we face and should be read in conjunction with the entire Risk Factors section below beginning at &#x201c;Risks Related to Our Business and Industry&#x201d; within this Item 1A. Risk Factors.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audited financial statements include a statement that there is a substantial doubt about our ability to continue as a going concern and a continuation of negative financial trends could result in our inability to continue as a going concern.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The commercial success of our current and future diagnostic tests and services depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success and revenue growth are highly dependent on the demand for, and increased adoption of, our diagnostic tests, including our COVID-19 testing program, which are subject to a number of risks and uncertainty.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We need to ensure strong product performance and reliability to maintain and grow our business.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Natural or man-made disasters, pandemics, outbreaks, or other similar events, including a sustained outbreak or second wave of the novel strain of coronavirus disease, COVID-19, could significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our industry is highly competitive and subject to rapid change, which could make our diagnostic tests and services obsolete. If we are unable to continue to innovate and expand and enhance our diagnostic tests and service offerings, we could lose customers or market share.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are disruptions in our information technology systems, including any security or data privacy breaches or other unauthorized or improper access.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, and results of operations and cash flows. All of the risks described below should be carefully considered together with the other information contained and incorporated by reference in this report.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to our Business and Industry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a history of net losses, and we expect to continue to incur losses for the foreseeable future. If we achieve profitability, we may not be able to sustain it.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred losses since our inception and expect to continue to incur losses for the foreseeable future. We reported net losses of $43.2 million and $31.4 million the years ended December 31, 2021 and 2020, respectively. As a result of these losses, as of December 31, 2021, we had an accumulated deficit of approximately $302.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that our sales and marketing, research and development, regulatory and other expenses will continue to increase as we expand our marketing efforts for our diagnostic tests and services, expand existing relationships with our customers, obtain regulatory clearances or approvals or certifications for future enhancements to our existing diagnostic tests and services and conduct further clinical trials. In addition, we expect our general and administrative expenses to increase due to the additional costs associated with scaling our business operations and testing capacity, particularly with respect to our COVID-19 testing capacity, as well as being a public company, including due to legal, accounting, insurance, exchange listing and compliance, investor relations and other expenses. As a result, we expect to continue to incur operating losses and may never achieve profitability. We will need to generate significant additional revenue in order to achieve and sustain profitability. Even if we achieve profitability, we cannot be sure that we will remain profitable for any substantial period of time. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The continuing spread of COVID-19 and the impact to our business may continue to have a material and adverse effect on our ability to generate revenues, maintain compliance with our financial covenants and result in our inability to continue as a going concern. Any such impacts could have a material and adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our financial statements as of and for the period ended December 31, 2021 were prepared on the assumption that we would continue as a going concern. These financial statements did not include any adjustments that might result from the outcome of this uncertainty. As of December 31, 2021, we maintained cash and cash equivalents of $32.7 million and we have $10 million in principal balance remaining on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants. As a result of the items mentioned above, our management has determined that there is a substantial doubt about our ability to continue as a going concern over the next twelve months from the date these financial statements were issued. Although we have taken steps to improve our liquidity through the recent amendments to our 2021 Term Loan to modify certain financial covenants and have taken measures to reduce planned capital expenditures and operating expenses, these actions alone will not be sufficient to mitigate our liquidity concerns in the wake of the material impact to our revenues, operating results and cash flows from the continued spread of COVID-19. In addition, if we are not able to improve our operating results, we may need to limit our operations substantially. We will need to raise additional capital in the form of equity or debt to increase our liquidity but there is no assurance that we will be able to secure any such funding in a sufficient amount or on terms that are acceptable to us. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. Furthermore, the reaction of investors to the inclusion of a going concern statement in this report, and our potential inability to continue as a going concern, could materially adversely affect the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The commercial success of our current and future diagnostic tests and services and our revenue growth depends upon attaining significant market acceptance among payers, providers, clinics, patients, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, on the acceptance of our diagnostic tests and services as being safe and relatively simple for medical personnel to learn and use, clinically flexible, operationally versatile and, with respect to providers and payers, cost effective. We cannot predict how quickly, if at all, payers, providers, clinics and patients will accept future diagnostic tests and services or, if accepted, how frequently they will be used. These constituents must believe that our diagnostic tests offer benefits over other available alternatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of market acceptance of our current and future diagnostic tests and services depends on a number of factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether there is adequate utilization of our tests by clinicians, biopharmaceutical companies and other target groups based on the potential and perceived advantages of our diagnostic tests over those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the convenience and ease of use of our diagnostic tests relative to those currently on the market;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to provide incremental data that show the clinical benefits and cost effectiveness, and operational benefits, of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the coverage and reimbursement acceptance of our products and services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pricing pressure, including from group purchasing organizations (GPOs), seeking to obtain discounts on our diagnostic tests based on the collective bargaining power of the GPO members;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negative publicity regarding our or our competitors&#x2019; diagnostic tests resulting from defects or errors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the accuracy of our tests relative to those of our competitors;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product labeling or product insert requirements by the FDA or other regulatory authorities or conformity assessment bodies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the labeling cleared or approved by the FDA or other regulatory authorities or conformity assessment bodies.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, even if our diagnostic tests achieve widespread market acceptance, they may not maintain that market acceptance over time if competing diagnostic tests or technologies, which are more cost effective or are received more favorably, are introduced. Failure to achieve or maintain market acceptance and/or market share would limit our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is no assurance that our COVID-19 and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operation and profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may encounter difficulties in managing our growth, which could disrupt our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had approximately 218 full and part-time employees. Over the next several years, we expect to increase significantly the number of our employees and the scope of our operations, particularly in the areas of sales, marketing and reimbursement, product development, regulatory affairs and other functional areas, including finance, accounting, quality and legal. Additionally, we expect to expand our testing capacity as we commercialize additional diagnostic tests. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. Any inability to manage growth could delay the execution of our business plans or disrupt our operations and have a material and adverse effect on our prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have experienced multiple cycles of growth and anticipate further growth in our business operations. This future growth could create strain on our organizational, administrative and operational infrastructure, including laboratory operations, quality control, customer service and sales organization management. We expect to continue to increase headcount and to hire more specialized personnel in the future as we grow our business. We will need to continue to hire, train and manage additional qualified scientists, laboratory personnel, client and account services personnel, and sales and marketing staff and improve and maintain our technology to properly manage our growth. If our new hires perform poorly, if we are unsuccessful in hiring, training, managing and integrating these new employees or if we are not successful in retaining our existing employees, our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to maintain the quality or expected turnaround times of our diagnostic tests and services, or satisfy customer demand as it grows. We may not be able to expand our COVID-19 testing capacity rapidly enough to meet the current and anticipated demand. Our ability to manage our growth properly will require us to continue to improve our operational, financial and management controls, as well as our reporting systems and procedures. The time and resources required to implement these new systems and procedures is uncertain, and failure to complete this in a timely and efficient manner could materially adversely affect our operations. Additionally, if we are required to reduce expenses substantially to sustain our operations, we may not have the human resources to maintain growth in our business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to retain sales and marketing personnel and, as we grow, fail to increase our sales and marketing capabilities or develop broad awareness of our diagnostic tests in a cost-effective manner, we may not be able to generate revenue growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have limited experience marketing and selling our diagnostic tests. We currently rely on our direct sales force to sell our diagnostic tests in the United States, and any failure to maintain and grow our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of our diagnostic tests. The members of our United States sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to generate future growth, we plan to continue to expand and leverage our sales and marketing infrastructure. Identifying and recruiting qualified sales and marketing personnel and training them on how to promote our diagnostic tests, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or diagnostic tests that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to expand and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our diagnostic tests. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time, or timely reduce fixed costs, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of our diagnostic tests will depend to a significant extent on our ability to expand our marketing efforts. We plan to dedicate significant resources to our marketing programs. It will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our diagnostic tests in a cost-effective manner is critical to achieving broad acceptance of our diagnostic tests. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad use of our diagnostic tests, which in turn could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we cannot maintain our current relationships, or enter into new relationships, with biopharmaceutical companies, our revenue prospects could be reduced.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We collaborate with biopharmaceutical companies to analyze patient samples for multiple applications primarily to support clinical trials, including patient identification, companion or complementary diagnostics and retrospective testing. For fiscal years 2021 and 2020, revenue from our top biopharmaceutical customer accounted for 2% and 3% of our total revenue, respectively. The revenue attributable to our biopharmaceutical customers may also fluctuate in the future, which could have a material adverse effect on our financial condition and results of operations. In addition, the termination of these relationships could result in a temporary or permanent loss of revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future success depends in part on our ability to maintain these relationships and to establish new relationships. Many factors have the potential to impact such collaborations, including the type of biomarker support required and our ability to deliver it and our biopharmaceutical customers&#x2019; satisfaction with our tests or services and other factors that may be beyond our control. Furthermore, our biopharmaceutical customers may decide to decrease or discontinue their use of our tests due to changes in research and product development plans, failures in their clinical trials, financial constraints, or utilization of internal testing resources or tests performed by other parties, or other circumstances outside of our control. In addition to reducing our revenue, the loss of one or more of these relationships may reduce our exposure to research and clinical trials that facilitate the collection and incorporation of new information into our biobank and proprietary AI platform.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We engage in conversations with biopharmaceutical companies regarding potential commercial opportunities on an ongoing basis. There is no assurance that any of these conversations will result in a commercial agreement, or if an agreement is reached, that the resulting relationship will be successful or that clinical or research studies conducted as part of the engagement will produce successful outcomes. Speculation in the industry about our existing or potential relationships with biopharmaceutical companies can also be a catalyst for adverse speculation about us, our tests and our technology, which can adversely affect our reputation and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our quarterly and annual revenue and operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. Our quarterly and annual operating results may fluctuate as a result of a variety of factors, many of which are outside</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our control and, as a result, may not fully reflect the underlying performance of our business. These fluctuations may occur due to a variety of factors, including, but not limited to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of demand for our diagnostic tests, which may vary significantly;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of manufacturing our diagnostic tests, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers and manufacturers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenditures that we may incur to acquire, develop, or commercialize additional tests and technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated pricing pressures;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rate at which we grow our sales force and the speed at which newly hired salespeople become effective, and the cost and level of investment therein;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the degree of competition in our industry and any change in the competitive landscape of our industry, including consolidation among our competitors or future partners;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">coverage and reimbursement policies with respect to lung cancer treatment equipment, and potential future diagnostic tests that compete with our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and success or failure of clinical trials for our diagnostic tests or any enhancements to such tests we develop or competing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">positive or negative coverage, or public perception, of our diagnostic tests or those of our competitors or broader industry trends;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact, if any, of the spread of COVID-19 and any newly discovered variants, and the resulting effects on the number of patients treated or the demand for our non-COVID-19 tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of, and level of investment in, research, development, licenses, regulatory approval, conformity certification, commercialization activities, acquisitions and other strategic transactions, or other significant events relating to our diagnostic tests, which may change from time to time;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and cost of obtaining regulatory approvals, conformity certifications or clearances for planned or future improvements or enhancements to our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulatory requirements or in the status of regulatory approvals or applications or conformity certifications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pricing, discounts, and incentives for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">future accounting pronouncements or changes in our accounting policies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general market conditions.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we can provide no assurances that the demand for our COVID-19 and antibody testing program will be sustained, and even if it is, the period of time for which it would be sustained. As vaccines for COVID-19 become more available and widespread in the future, we expect the demand for our COVID-19 diagnostic and antibody tests will decrease. As a result, the increase in revenue due to any increase in demand for our COVID-19 and antibody testing program is not indicative of results expected for any future period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual financial results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Further, our historical results are not necessarily indicative of results expected for any future period, and quarterly results are not necessarily indicative of the results to be expected for the full year or any other period, and accordingly should not be relied upon as indicative of future performance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any guidance we may provide, or if the guidance we provide is below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any publicly stated guidance we may provide, and could in turn negatively impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We need to ensure strong product performance and reliability to maintain and grow our business</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We need to maintain and continuously improve the performance and reliability of our diagnostic tests, including our Biodesix WorkSafe testing program, the Nodify XL2 and Nodify CDT tests, and the GeneStrat and VeriStrat tests, to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. Our diagnostic tests may contain errors or defects, and while we have made efforts to test them extensively, we cannot assure that our current diagnostic tests, or those developed in the future,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">will not have performance problems. Performance issues with our diagnostic tests will increase our costs in the near-term and accordingly adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply problems and price fluctuations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on third-party suppliers, including in some instances single source suppliers, to provide us with certain components of our diagnostic tests. The number of suppliers feeding into the production of our diagnostic tests is in excess of 65 worldwide. We consider a select few of these suppliers, located in the United States, Europe and China, as critical single source providers of components. Bio-Rad Laboratories, as described below, is the sole source supplier for our GeneStrat tests and COVID-19 diagnostic and antibody testing program. Oncimmune is also the sole source supplier for our Nodify CDT tests. While we have initiated the second source qualification process for the majority of these critical components, we may not be successful in securing second sourcing for all of them at all or on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may purchase supplies through purchase orders and may not have long-term supply agreements with, or guaranteed commitments from, many of our suppliers, including single source suppliers. Additionally, at present, we rely on contract manufacturers for the production of our supplies for our diagnostic test. Many of our suppliers and contract manufacturers are not obligated to perform services or supply diagnostic testing materials for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We depend on our suppliers and contract manufacturers to provide us and our customers with materials in a timely manner that meet our and their quality, quantity and cost requirements. These suppliers and contract manufacturers may encounter problems during manufacturing for a variety of reasons, any of which could delay or impede their ability to meet our demand. These suppliers and contract manufacturers may cease producing the components we purchase from them or otherwise decide to cease doing business with us. Further, we maintain limited volumes of inventory from most of our suppliers and contract manufacturers. If we inaccurately forecast demand for finished goods, we may be unable to meet customer demand which could harm our competitive position and reputation. In addition, if we fail to effectively manage our relationships with our suppliers and contract manufacturers, we may be required to change suppliers or contract manufacturers. While we believe replacement suppliers exist for all materials, components and services necessary to manufacture our diagnostic tests, establishing additional or replacement suppliers for any of these materials, components or services, if required, could be time-consuming and expensive, may result in interruptions in our operations and product delivery, may affect the performance of our diagnostic tests or could require that we modify their processes. Even if we are able to find replacement suppliers, we will be required to verify that the new supplier maintains facilities, procedures and operations that comply with our quality expectations and applicable regulatory requirements. Any of these events could require that we obtain a new regulatory authority approval before we implement the change, which we may not obtain on a timely basis or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our third-party suppliers fail to deliver the required commercial quantities of materials on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement suppliers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality on a timely basis, the continued commercialization of our diagnostic tests, the supply of our diagnostic tests to customers and the development of any future diagnostic tests will be delayed, limited or prevented, which could have material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We entered into a nonexclusive license and supply agreement with Bio-Rad in August 2019. We rely on Bio-Rad to supply equipment and reagents used to perform ddPCR testing, a service offered by us under a variety of fee for service agreements and the core technology powering the GeneStrat test. Under the terms of this arrangement, we were granted non-exclusive rights to utilize the intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of ddPCR in cancer detection testing for third parties in the United States. We agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad. As further consideration for the non-exclusive license, we agreed to pay a royalty of two and one half percent (2.5%) on net service fees (such fees are defined in the Non-Exclusive License Agreement with Bio-Rad) collected from contracted third parties who receive ddPCR services from us. In addition, we have separately been granted permission by Bio-Rad to use the Bio-Rad SARS-CoV-2 ddPCR test and Platelia SARS-CoV-2 Total Ab test for commercial diagnostic services. On May 24, 2021, we entered into the First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc. which amended the original agreement such that, effective May 1, 2021, we are not required to pay a royalty of two and one half percent (2.5%) on net service fees. For more information regarding this license and supply agreement and the permission granted to us by Bio-Rad with respect to such tests, please see &#x201c;Business&#x2014;Material Agreements&#x2014;Agreements with Bio-Rad&#x201d; previously filed in our Form S-1 on October 23, 2020 and &#x201c;First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021&#x201d; previously filed in our Form 10-Q on August 10, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This relationship may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with Bio-Rad, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to sufficiently reduce costs in the performance, manufacturing and production of our diagnostic tests to achieve sustainable gross margins.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We partner with contract manufacturers in the development and production of supplies for our diagnostic tests. While we are undertaking a number of initiatives designed to reduce the cost of performing our diagnostic tests, including reducing the costs of supplies, there is no guarantee that we will be able to achieve planned cost reductions from our various cost savings initiatives. There may also be unforeseen occurrences that increase our costs, such as increased prices of the components of our diagnostic tests, changes to labor costs or less favorable terms with third-party suppliers or contract manufacturing partners. If we are unable to reduce our costs, or if cost reductions are less significant or less timely than projected, we will not be able to achieve sustainable gross margins, which would adversely affect our ability to invest in and grow our business and adversely impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, including the outbreak of the novel strain of coronavirus disease, COVID-19, and its variants could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide, our business may be adversely affected. COVID-19 has spread throughout the United States and to most countries globally. Numerous U.S. state and local jurisdictions have imposed, and others in the future may impose, &#x201c;shelter-in-place&#x201d; orders, quarantines, executive orders and similar government orders and restrictions for their residents to control the spread of COVID-19. In March 2020, the Governor of Colorado, where our headquarters are located, issued &#x201c;stay at home&#x201d; orders limiting non-essential activities, travel and business operations. Such orders or restrictions have resulted in reduced operations at our headquarters, work stoppages, slowdowns and delays, travel restrictions and cancellation of events. Other disruptions or potential disruptions include the inability of our suppliers to manufacture components and parts and to deliver these to us on a timely basis, or at all; disruptions in our production schedule and ability to assemble diagnostic tests; inventory shortages or obsolescence; delays in actions of regulatory bodies; diversion of or limitations on employee resources that would otherwise be focused on the operations of our business; delays in growing or reductions in our sales organization, including through delays in hiring, lay-offs, furloughs or other losses of sales representatives; business adjustments or disruptions of certain third parties, including suppliers, medical institutions and clinical investigators with whom we conduct business; and additional government requirements or other incremental mitigation efforts that may further impact our or our suppliers&#x2019; capacity to manufacture our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic also has negatively affected our non-COVID-19 testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we have been receiving fewer samples for non-COVID-19 testing on a daily average basis from our clinical and biopharmaceutical customers than before the outbreak of the COVID-19 pandemic. Further, our clinical studies, such as our ongoing INSIGHT study and our recently launched ALTITUDE study, as well as our arrangements with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has also created an opportunity for our diagnostic tests and we have commercialized two diagnostic tests to test for the presence of COVID-19 and antibodies. We are expecting to increase our testing capacity for our COVID-19 diagnostic and antibody testing program in the near term to meet the rising demand for rapid and accurate testing. We expect that the revenue we generate from this expansion will comprise a significant portion of our revenue for the first quarter of 2021. However, there is no assurance that our COVID-19 diagnostic and antibody testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or be accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to the availability of vaccines, or otherwise, the need for a COVID-19 test could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent to which the COVID-19 pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity and spread of COVID-19 and the actions to contain COVID-19 or treat its impact, among others. Furthermore, there is no assurance that our diagnostic tests will continue to be effective against the virus in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While the potential economic impact brought by, and the duration of, any pandemic, epidemic or outbreak of an infectious disease, including COVID-19, may be difficult to assess or predict, the widespread COVID-19 pandemic has resulted in, and may continue to result in, significant disruption of global financial markets and a reduction in our ability to access capital, which could adversely affect our liquidity. In addition, a recession or market correction resulting from the spread of an infectious disease, including COVID-19, could materially affect our business. Such economic recession could have a material adverse effect on our long-term business. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this &#x201c;Risk Factors&#x201d; section.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Natural or man-made disasters and other similar events, including the COVID-19 pandemic, may significantly disrupt our business, and negatively impact our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A significant portion of our employee base, operating facilities and infrastructure are centralized in Boulder, Colorado and we operate a laboratory facility in De Soto, Kansas. Any of our facilities may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, infectious disease outbreaks or pandemic events, including the COVID-19 pandemic, power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business, financial condition and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business, financial condition and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any failure to offer high-quality support for our diagnostic tests and services may adversely affect our relationships with providers and negatively impact our reputation among patients and providers, which may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In implementing and using our diagnostic tests and services, providers depend on our support to resolve issues in a timely manner. We may be unable to respond quickly enough to accommodate short-term increases in demand for customer support. Increased customer demand for support could increase costs and adversely affect our business, financial condition and results of operations. Our sales are highly dependent on our reputation and on positive recommendations from our existing patients, care partners, providers and clinics. Any failure to maintain high-quality customer support, or a market perception that we do not maintain high-quality customer support, could adversely affect our reputation, our ability to sell our diagnostic tests and services, and in turn our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The sizes of the markets for our diagnostic tests and services and any future diagnostic tests and services may be smaller than we estimate and may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our estimates of the annual total addressable market for our diagnostic tests and services are based on a number of internal and third-party estimates and assumptions, including, without limitation, the assumed prices at which we can sell our diagnostic tests and services in the market. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result, our estimates of the annual total addressable market for our diagnostic tests and services in different market segments may prove to be incorrect. If the actual number of patients who would benefit from our diagnostic tests, the price at which we can sell them or the annual total addressable market for them is smaller than we have estimated, it may impair our sales growth and negatively affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our industry is subject to rapid change, which could make our solutions and the diagnostic tests we develop and services we offer, obsolete. If we are unable to continue to innovate and improve our diagnostic tests and services we offer, we could lose customers or market share.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our industry is characterized by rapid changes, including technological and scientific breakthroughs, frequent new product introductions and enhancements and evolving industry standards, all of which could make our current diagnostic tests and others we are developing obsolete. Our future success will depend on our ability to keep pace with the evolving needs of our customers on a timely and cost-effective basis and to pursue new market opportunities that develop as a result of scientific and technological advances. In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. There have also been advances in methods used to analyze very large amounts of molecular information. We must continuously enhance our offerings and develop new and improved diagnostic tests to keep pace with evolving standards of care. If we do not leverage or scale our sample and data biobank to discover new diagnostic tests or applications or update our diagnostic tests to reflect new scientific knowledge, including about lung cancer biology, information about new cancer therapies or relevant clinical trials, our diagnostic tests could become obsolete and sales of our current diagnostic tests and any new tests we develop could decline or fail to grow as expected. This failure to make continuous improvements to our diagnostic tests to keep ahead of those of our competitors could result in the loss of customers or market share that would adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may face additional costs, loss of revenue, significant liabilities, harm to our brand, decreased use of our products or services and business disruption if there are any security or data privacy breaches or other unauthorized or improper access.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with various facets of our business, we collect and use a variety of personal data, such as names, mailing addresses, email addresses, mobile phone numbers, location information, prescription information and other medical information. Any failure to prevent or mitigate security breaches or improper access to, use, disclosure or other misappropriation of our data or consumers&#x2019; personal data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">could result in significant liability under state, (e.g., state breach notification and privacy laws such as the CCPA) federal (e.g., HIPAA), and the HITECH Act and laws in other jurisdictions (e.g., the GDPR). Such an incident may also cause a material loss of revenue from the potential adverse impact to our reputation and brand, affect our ability to retain or attract new users of our diagnostic tests and services and potentially disrupt our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unauthorized disclosure of sensitive or confidential patient or employee data, including personally identifiable information, whether through a breach of computer systems, systems failure, employee negligence, fraud or misappropriation, or otherwise, or unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result in negative publicity, legal liability and damage to our reputation. Unauthorized disclosure of personally identifiable information could also expose us to sanctions for violations of data privacy laws and regulations around the world. To the extent that any disruption or security breach resulted in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. For example, the loss of or damage to clinical trial data, such as from completed or ongoing clinical trials, for any of our product candidates would likely result in delays in our marketing approval efforts and significantly increased costs in an effort to recover or reproduce the data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we become more dependent on information technologies to conduct our operations, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, may increase in frequency and sophistication. These threats pose a risk to the security of our systems and networks, the confidentiality and the availability and integrity of our data and these risks apply both to us, and to third parties on whose systems we rely for the conduct of our business. Because the techniques used to obtain unauthorized access, disable or degrade service or sabotage systems change frequently and often are not recognized until launched against a target, we and our partners may be unable to anticipate these techniques or to implement adequate preventative measures. We have in the past experienced, and may in the future, experience security incidents. While no security incidents in the past have had a material adverse effect on our business, financial condition and results of operations, we cannot predict the impact of any such future events. Further, we do not have any control over the operations of the facilities or technology of our cloud and service providers, including any third-party vendors that collect, process and store personal data on our behalf. Our systems, servers and platforms and those of our service providers may be vulnerable to computer viruses or physical or electronic break-ins that our or their security measures may not detect. Individuals able to circumvent such security measures may misappropriate our confidential or proprietary information, disrupt our operations, damage our computers or otherwise impair our reputation and business. We may need to expend significant resources and make significant capital investments to protect against security breaches or to mitigate the impact of any such breaches. In addition, to the extent that our cloud and other service providers, experience security breaches that result in the unauthorized or improper use of confidential data, employee data or personal data, we may not be indemnified for any losses resulting from such breaches. There can be no assurance that we or our third-party providers will be successful in preventing cyber-attacks or successfully mitigating their effects. Recent cyber-attacks purportedly originated by Russian controlled entities have exacerbated in the wake of Russia&#x2019;s invasion of Ukraine and our systems may be infiltrated by foreign actors. If we are unable to prevent or mitigate the impact of such security breaches, our ability to attract and retain new customers, patients and other partners could be harmed as they may be reluctant to entrust their data to us, and we could be exposed to litigation and governmental investigations, which could lead to a potential disruption to our business or other adverse consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have significant payer concentration, with a limited number of customers accounting for a substantial portion of our revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For year ended December 31, 2021, Medicare reimbursed to us 18% of our diagnostic test revenue and two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">customers accounted for 45% of our total revenue. For the year ended December 31, 2020, Medicare reimbursed to us 17% of our diagnostic test revenue and two customers accounted for 47% of our total revenue. There are risks whenever a large percentage of total revenues are concentrated with a limited number of payers and customers. It is not possible for us to predict the level of demand for our diagnostic tests and services that will be generated by any of these customers in the future. In addition, revenues from these larger customers may fluctuate from time to time based on these customers&#x2019; business needs, the timing of which may be affected by market conditions or other factors outside of our control. These payers and customers could also potentially pressure us to reduce the prices we charge for our diagnostic tests and services, which could have an adverse effect on our margins and financial position and could negatively affect our revenues and results of operations. If any of our largest payers terminates its relationship with us or our tests are no longer reimbursable by such payer, such termination could negatively affect our revenues and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our diagnostic tests and manage our inventory.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our diagnostic tests based on our estimates of future demand for our diagnostic tests. Our ability to accurately forecast demand for them could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our diagnostic tests or for those of our competitors, our failure to accurately forecast customer acceptance of new diagnostic tests, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand for our diagnostic tests, our supply chain, manufacturing partners and/or internal manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">team may not be able to deliver components and diagnostic tests to meet our requirements, and this could result in damage to our reputation, sales growth and customer relationships. In addition, if we experience a significant increase in demand, such as we are currently experiencing with respect to our COVID-19 and antibody testing program, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we experience significant disruptions in our information technology systems, our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We depend on our information technology systems for the efficient functioning of our business, including the performance, distribution and maintenance of our diagnostic tests and services, as well as for accounting, data storage, compliance, purchasing and inventory management. We do not have redundant information technology in all aspects of our systems at this time. Our information technology systems may be subject to computer viruses, ransomware or other malware, attacks by computer hackers, failures during the process of upgrading or replacing software, databases or components thereof, power outages, damage or interruption from fires or other natural disasters, hardware failures, telecommunication failures and user errors, among other malfunctions. We could be subject to an unintentional event that involves a third party gaining unauthorized access to our systems, which could disrupt our operations, corrupt our data or result in release of our confidential information. Technological interruptions would disrupt our operations, including our ability to timely ship and track diagnostic test orders and results, project inventory requirements, manage our supply chain and otherwise adequately service our customers or disrupt our customers&#x2019; ability to use our diagnostic tests. In the event we experience significant disruptions, we may be unable to repair our systems in an efficient and timely manner. Accordingly, such events may disrupt or reduce the efficiency of our entire operation and have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Currently, we carry business interruption coverage to mitigate certain potential losses but this insurance is limited in amount, and we cannot be certain that such potential losses will not exceed our policy limits. The successful assertion of one or more large claims against us that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could have a material adverse effect on our business, financial condition and results of operations. We are increasingly dependent on complex information technology to manage our infrastructure. Our information systems require an ongoing commitment of significant resources to maintain, protect and enhance our existing systems. Failure to maintain or protect our information systems and data integrity effectively could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our diagnostic tests and services. The expense and potential unavailability of insurance coverage for liabilities resulting from issues with our diagnostic tests and services could harm us and negatively impact sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the marketing and sale of our diagnostic tests and services. For example, we may be sued if our diagnostic tests or services cause or are perceived to cause injury or are found to be otherwise unsuitable during manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health of the patient. For example, medical personnel, care partners and patients collect samples for our diagnostic tests. If these medical personnel, care partners or patients are not properly trained, are negligent or use our diagnostic tests incorrectly, the capabilities of such tests may be diminished or the patient may suffer critical injury. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies for our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our diagnostic tests and services. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our diagnostic tests and services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">harm to our reputation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product recalls, withdrawals, or labeling, marketing, or promotional restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse impact on the market price of our common stock; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exhaustion of any available insurance and our capital resources.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our diagnostic tests and services. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face competition from many sources, including larger companies, and we may be unable to compete successfully.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There are a number of lung cancer diagnostic solutions companies in the United States, Europe and Asia. Notable competitors in the United States include Veracyte, Inc., Guardant Health, Inc., and Foundation Medicine, Inc. These competitors all provide cancer-focused diagnostic tests to hospitals, researchers, clinicians, laboratories and other medical facilities. Many of these organizations are significantly larger with greater financial and personnel resources than us, and enjoy significantly greater market share and have greater resources than we do. As a consequence, they may be able to spend more on product development, marketing, sales and other product initiatives than we can. Some of our competitors have:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantially greater name recognition;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">broader, deeper, or longer-term relations with healthcare professionals, customers, and third-party payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">more established distribution networks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">additional lines of diagnostic tests and the ability to offer rebates or bundle them to offer greater discounts or other incentives to gain a competitive advantage;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">greater experience in conducting research and development, manufacturing, clinical trials, marketing and obtaining regulatory clearance or approval or certification for diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">greater financial and human resources for product development, sales and marketing and patent litigation.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our continued success depends on our ability to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">further penetrate the lung disease diagnostic solutions market and increase utilization of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effectively manufacture our diagnostic tests and their component parts as well as drive down the cost of service.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, competitors with greater financial resources than ours could acquire other companies to gain enhanced name recognition and market share, as well as new technologies or diagnostic tests that could effectively compete with our existing diagnostic tests, which may cause our revenue to decline and would harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our competitors also compete with us in recruiting and retaining qualified scientific, management and commercial personnel, as well as in acquiring technologies complementary to, or necessary for, development of our diagnostic tests. Because of the complex and technical nature of diagnostic testing and the dynamic market in which we compete, any failure to attract and retain a sufficient number of qualified employees could materially harm our ability to develop and commercialize our diagnostic tests, which would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As we attain greater commercial success, our competitors are likely to develop diagnostic tests that offer features and functionality similar to our diagnostic tests that are currently on the market. Improvements in existing competitive diagnostic tests or the introduction of new competitive diagnostic tests may make it more difficult for us to compete for sales, particularly if those competitive diagnostic tests demonstrate better reliability, convenience or effectiveness or are offered at lower prices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Performance issues, service interruptions or price increases by our shipping carriers and warehousing providers could adversely affect our business and harm our reputation and ability to provide our services on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expedited, reliable shipping and delivery services and secure warehousing are essential to our operations. We rely heavily on providers of transport services for reliable and secure point-to-point transport of our diagnostic tests to our customers and for tracking of these shipments, and from time to time require warehousing for our diagnostic tests, sample collection kits and supplies. Should a carrier encounter delivery performance issues such as loss, damage or destruction of any systems, it would be costly to replace such systems in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a timely manner and such occurrences may damage our reputation and lead to decreased demand for our diagnostic tests and increased cost and expense to our business. In addition, any significant increase in shipping or warehousing rates could adversely affect our operating margins and results of operations. Similarly, strikes, severe weather, natural disasters, civil unrest and disturbances or other service interruptions affecting delivery or warehousing services we use would adversely affect our ability to process orders for our diagnostic tests on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely on commercial courier delivery services to transport samples to our laboratory facility in a timely and cost-efficient manner and if these delivery services are disrupted, our business will be harmed. Our business depends on our ability to quickly and reliably deliver test results to our customers. Blood samples are typically received within days from the United States and outside the United States for analysis at our Boulder, Colorado and De Soto, Kansas facilities. Disruptions in delivery service, whether due to labor disruptions, bad weather, natural disaster, civil unrest or disturbances, terrorist acts or threats or for other reasons could adversely affect specimen integrity and our ability to process samples in a timely manner and to service our customers, and ultimately our reputation and our business. In addition, if we are unable to continue to obtain expedited delivery services on commercially reasonable terms, our operating results may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cost-containment efforts of our customers, purchasing groups and governmental purchasing organizations could have a material adverse effect on our sales and profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and Integrated Delivery Networks (IDNs). GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors on behalf of their members, which may include hospitals and other providers. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our diagnostic tests, thereby reducing our revenue and margins.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#x2019; notice. Accordingly, the members of such groups may choose to purchase alternative diagnostic tests due to the price or quality offered by other companies, which could result in a decline in our revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pricing and reimbursement of medical devices is not harmonized at European level, but is the exclusive competence of the EU Member States. In Europe, pricing and reimbursement decisions are generally made by regional or centralized bodies based on an assessment of the efficacy and clinical effectiveness of the devices or broad device types or procedures. There is a general trend for EU Member States to adopt cost containment measures to control public spend on medical devices. Due to the competitive nature of product offers and prices, we may not be able to obtain new, or maintain existing, contract positions with the EU Member States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation and other legal proceedings may adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#x2019; confidence and reduce long-term demand for our diagnostic tests and services, even if the regulatory or legal action is unfounded or not material to our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain product and professional liability insurance, but this insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General economic and financial market conditions may exacerbate our business risks.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Global macroeconomic conditions and the world&#x2019;s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result of uncertainties with respect to financial institutions and the global credit markets and other macroeconomic challenges such as inflationary pressures currently or potentially affecting the economy of the United States and other parts of the world, customers and distributors may experience serious cash flow problems and other financial difficulties,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreasing demand for our products. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, events in the United States or foreign markets, such as the United Kingdom&#x2019;s exit from the European Union, the worldwide effects from the spread of COVID-19 and political and social unrest in various countries around the world, can impact the global economy and capital markets. Additionally, if our customers and distributors are not successful in generating sufficient revenue or are precluded from securing financing, their businesses will suffer, which may materially and adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not realize the benefits or costs of our Co-Development and Collaboration Agreement with AVEO Oncology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2014, we entered into a Co-Development and Collaboration Agreement with AVEO Oncology (formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) whereby the two parties agreed to various terms and conditions necessary for the co-development of AVEO&#x2019;s compound ficlatuzumab (the Collaboration Agreement).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were granted a limited legal interest in ficlatuzumab and may not have the right to control the development and exploitation of ficlatuzumab. As consideration for the grant, we agreed to cover the first $15.0 million of ficlatuzumab&#x2019;s clinical development costs, with both parties then sharing all costs equally after the cap was reached.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October of 2016, the Collaboration Agreement was amended to eliminate the requirement that we cover all of the initial costs. Under the amended terms, we agreed to allow AVEO to recapture its cost that it otherwise would not have been responsible for said recapture to occur out of any royalties or revenues eventually derived from the Collaboration Agreement. As part of the Collaboration Agreement, unless we or AVEO exercise our right to opt-out of co-development, we equally share in any income received from licensing rights to ficlatuzumab to any third parties. In September 2020, we exercised our opt-out right for the payment of half of the development and regulatory costs for ficlatuzumab. This opt-out was effective as of December 2, 2020 with remaining obligations estimated to be $0.1 million. Following the effective date, we will be entitled to a 10% royalty of net sales of ficlatuzumab and 25% of license income generated from the licensing of ficlatuzumab. Ficlatuzumab is currently being evaluated in squamous cell carcinoma of the head and neck (SCCHN), metastatic pancreatic ductal cancer (PDAC), and acute myeloid leukemia (AML). For more information regarding this Collaboration Agreement, please see &#x201c;Business &#x2014;Drug Co-Development.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our relationship with AVEO may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of this relationship, we will achieve the revenue or specific net income that justifies our entry into it. Any termination of this relationship, or delays in entering into new strategic partnership agreements with AVEO, could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are exposed to significant future payments and other obligations associated with our acquisitions of Integrated Diagnostics and Oncimmune, U.S.A., and may not realize the advantages we expect from these acquisitions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2018, we purchased select assets and liabilities from Integrated Diagnostics, Inc. and IND Funding, LLC (collectively, the Seller or Indi) which included the CLIA lab in Seattle, Washington, and all rights to the Nodify XL2 test and intellectual property rights related to that test. The purchase was made for total consideration of $27.6 million, consisting of $8.0 million (10,649,604 shares) of our Series G Preferred Stock and contingent consideration with an initial fair market value of $19.6 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The acquisition of Indi included a contingent consideration arrangement that requires additional consideration to be paid by us to the Seller based on the milestone of the attainment of a three consecutive month gross margin target of $2 million within a seven-year period. Under the terms of the original agreement, when the gross margin target was met, the Company was required to issue 2,520,108 shares of common stock. For the six months following the achievement of the milestone, the Indi had the option to require the Company to redeem the common shares for $37.0 million in cash over eight equal installments. If Indi elected not to exercise this option, we had 12 months to repurchase the common stock in two equal quarterly cash installments totaling $37 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company met the gross margin target of $2.0 million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make six quarterly installments of approximately $4.6 million each beginning in January 2022 and a final payment of approximately $9.3 million in July 2023 for a total of $37.0 million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement. The amendment to the original agreement is subject to consent from our lender under the 2021 Term Loan and related amendments. As of December 31, 2021, we have not made any payments in connection with the contingent consideration. We obtained consent and subsequently made the first milestone payment of $4.6 million in January 2022 and we are in discussions with our lender to obtain consents for future payments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, on October 31, 2019 we completed an acquisition of United Kingdom-based Oncimmune, Ltd.&#x2019;s (Oncimmune) United States operations including its CLIA lab in De Soto, Kansas and its incidental pulmonary nodule (IPN) malignancy test, then marketed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in the United States as the EarlyCDT&#174;-Lung. We renamed the test and relaunched the test on February 28, 2020 as the Nodify CDT test and the De Soto, Kansas lab will be the sole United States provider of the Nodify CDT test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the acquisition, we and Oncimmune entered into several agreements to govern the relationship between the parties and to allow us to provide the Nodify CDT test. The overarching umbrella Purchase and Commercialization Agreement (PCA) defines the general relationship between the parties. Included under the PCA was (a) an APA whereby we acquired all of the United States assets associated with the De Soto, Kansas clinical laboratory, as well as the trademarks and patent application associated with the test; (b) an intellectual property license granting us the rights necessary under Oncimmune&#x2019;s background intellectual property rights to perform the Nodify CDT test; (c) a supply agreement for supplying us with the necessary materials and reagents needed to run the Nodify CDT test; and (d) a development agreement where Oncimmune agrees to assist us in further developing the Nodify CDT test. We were also granted an option through December 31, 2020 to acquire the rights to expand the field of use of the Nodify CDT test to include lung cancer screening, which we elected to not exercise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We agreed to a revenue share payment of 8% of recognized revenue for non-screening tests up to an annual minimum volume and 5% thereafter, with an escalating minimum through the first four years of sales. An insignificant amount of royalty payments was paid for the year ended December 31, 2020. In September 2020, we notified Oncimmune that we would not exercise this option for expansion of the field of use.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our acquisitions may require us to incur non-recurring and other charges, increase our near and long-term expenditures, or disrupt our management and business. We cannot be certain that, following the realization of these acquisitions, we will achieve the revenue or specific net income that justifies our entry into them. This could delay our sales and marketing efforts, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our senior management and other key personnel. Our success will depend on our ability to retain senior management and to attract and retain qualified personnel in the future, including sales and marketing professionals, scientists, clinical specialists, and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our research and development programs and laboratory operations depend on our ability to attract and retain highly skilled scientists and technicians.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to attract or retain qualified scientists and technicians in the future due to the competition for qualified personnel among life science businesses, particularly near our headquarters in Boulder, Colorado and our laboratory facility in De Soto, Kansas. We also face competition from universities and public and private research institutions in recruiting and retaining highly qualified scientific personnel. We may have difficulties locating, recruiting, or retaining qualified salespeople. Recruiting and retention difficulties can limit our ability to support our research and development and sales programs. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have issued and may continue to issue equity awards that vest over time. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#x201c;key man&#x201d; insurance policies on the lives of these individuals or the lives of any of our other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our corporate culture has contributed to our success, and if we cannot maintain this culture as we grow, we could lose the innovation, creativity and teamwork fostered by our culture and our business may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our culture has been and will continue to be a critical contributor to our success. We expect to continue to hire aggressively as we expand, and we believe our corporate culture has been crucial in our success and our ability to attract highly skilled personnel. If we do not continue to develop our corporate culture or maintain and preserve our core values as we grow and evolve, we may be unable to foster the innovation, curiosity, creativity, focus on execution, teamwork and the facilitation of critical knowledge transfer and knowledge sharing we believe we need to support our growth. Moreover, liquidity available to our employee securityholders could lead to disparities of wealth among our employees, which could adversely impact relations among employees and our culture in general. Our anticipated headcount growth and our transition from a private company to a public company may result in a change to our corporate culture, which could harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the Code) a corporation that undergoes an ownership change, generally defined as a greater than 50% change by value in its equity ownership by certain shareholders over a three-year period, is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and its research and development credit carryforwards to offset future taxable income. The applicable rules generally operate by focusing on changes in ownership among stockholders considered by the rules as owning, directly or indirectly, 5% or more of the stock of a company, as well as changes in ownership arising from new issuances of stock by the company. We believe that our NOLs are currently not subject to limitation under these rules. However, if we undergo an ownership change now or in the future, our ability to utilize NOLs and research and development credit carryforwards could be limited by Sections 382 and 383 of the Code. Future changes in stock ownership may be beyond our control. In addition, our ability to deduct net interest expense may be limited if we have insufficient taxable income for the year during which the interest is incurred, and any carryovers of such disallowed interest would be subject to the limitation rules similar to those applicable to NOLs and other attributes. For these reasons, in the event we experience a change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The terms of our secured credit agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021 (Effective Date), we entered into an agreement with Silicon Valley Bank, a California corporation (SVB or Lender) to refinance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">long-term debt (2021 Term Loan). The initial amount borrowed under the 2021 Term Loan was $30 million </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provides for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Further, we granted the Lender a security interest in substantially all of our assets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan may be prepaid by us at any time, subject to a prepayment penalty of up to 3% of the outstanding principal amount, depending on the date of prepayment. The 2021 Term Loan contains customary affirmative and negative covenants for a loan, requires us to comply with a minimum liquidity ratio covenant, and has a trailing six month rolling minimum revenue requirement. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with the covenants and loan requirements may result in an event of default.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $4.6 million January 2022 milestone payment under the Indi APA, repay $20 million in outstanding principal on December 31, 2021, waive the $600,000 prepayment fee on the $20 million Term Loan repayment, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement to not less 75% for the three months ended March 31, 2022 and not less than 75% on a trailing six month rolling basis for each quarter thereafter of the Company&#x2019;s projected revenue performed at the end of each reporting period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan also contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. These covenants may restrict our ability to pursue new business opportunities and access additional capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property, which could have a material adverse effect on our business, financial condition, and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will need to raise additional capital to fund our existing operations, develop our platform, commercialize new diagnostic tests or expand our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need to raise additional capital in the future to expand our business, to pursue strategic investments, to take advantage of financing opportunities or for other reasons, including to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increase our sales and marketing efforts to drive market adoption of and address competitive developments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fund development and marketing efforts of our diagnostic tests or any other future diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expand our technologies into other types of cancer management and lung disease detection diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire, license, or invest in technologies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">acquire or invest in complementary businesses or assets; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">finance capital expenditures and general and administrative expenses.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our present and future funding requirements will depend on many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to achieve revenue growth;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our rate of progress in establishing payer coverage and reimbursement arrangements with domestic and international commercial third-party payers and government payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of expanding our laboratory operations and offerings, including our sales and marketing efforts;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our rate of progress in, and cost of the sales and marketing activities associated with, establishing adoption of and reimbursement for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our rate of progress in, and cost of research and development activities associated with, diagnostic tests in research and early development;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effect of competing technological and market developments;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs related to international expansion; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential cost of and delays in product development as a result of any regulatory oversight applicable to our diagnostic tests.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The various ways we could raise additional capital carry potential risks. If we raise funds by issuing equity securities, our stockholders could experience dilution. Any preferred equity securities issued also could provide for rights, preferences or privileges senior to those of holders of our common stock. If we raise funds by issuing debt securities, those debt securities would have rights, preferences and privileges senior to those of holders of our common stock. The terms of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies or diagnostic tests, pay a portion of our royalties, or grant licenses on terms that are not favorable to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may acquire other businesses, which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our business strategy, we may in the future make additional acquisitions or investments in complementary companies, diagnostic tests or technologies that we believe fit within our business model and can address the needs of our customers and potential customers. In the future, we may not be able to acquire and integrate other companies, diagnostic tests or technologies in a successful manner. We may not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all. In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated. If we do complete acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by our customers, investors and industry analysts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable assets acquired. We may have to pay cash, incur debt or issue equity securities to pay for any such acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, acquisitions may require large, onetime charges and can result in increased debt or contingent liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations. We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, the anticipated benefit of any strategic alliance, joint venture or acquisition may not materialize, or such strategic alliance, joint venture or acquisition may be prohibited. For example, our 2021 Term Loan restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to our Governmental Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The insurance coverage and reimbursement status of newly approved diagnostic tests, particularly in a new category of diagnostics and therapeutics, is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for current or future diagnostic tests could limit our ability, and that of our collaborators, to fully commercialize our diagnostic tests and decrease our ability to generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The availability and extent of reimbursement by governmental and private payers is essential for most patients to be able to afford the clinical diagnostic tests and cellular therapeutics that we and our collaborators currently or in the future plan to develop and sell. In addition, because our clinical diagnostics and diagnostic tests represent new approaches to the research, diagnosis, detection and treatment of diseases, we cannot accurately estimate how our diagnostic tests, and those jointly created with our collaborators, would be priced, whether reimbursement could be obtained or any potential revenue generated. Sales of our diagnostic tests will depend substantially, both domestically and internationally, on the extent to which the costs of our diagnostic tests are paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payers. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize some of our diagnostic tests or services. Even if coverage is provided, the available reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our investment in any of our diagnostic tests or services. Changes in the reimbursement landscape may occur, which are outside of our control, and may impact the commercial viability of our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is significant uncertainty related to the insurance coverage and reimbursement of newly launched, cleared, authorized or approved diagnostic tests. In the United States, many significant decisions about reimbursement for new diagnostics and medicines are typically made by the CMS, an agency within the HHS. CMS decides whether and to what extent a new diagnostic or medicine will be covered and reimbursed under Medicare, although it frequently delegates this authority to local Medicare Administrative Contractors (MACs). Private payers tend to follow Medicare to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel diagnostic tests such as ours. Additionally, reimbursement authorities or bodies in Europe may be more conservative than CMS. For example, a number of cancer drugs have been approved for reimbursement in the United States and have not been approved for reimbursement, or have been approved under restricted conditions, in certain European countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outside the United States, the reimbursement process and timelines vary significantly. In Europe, pricing and reimbursement of medical devices is the exclusive competence of the EU Member States. However, the European Commission is facilitating a voluntary corporation between the EU Member States on health technology assessments (HTA) which consists of a network of the EU Member States&#x2019; national authorities and bodies responsible for HTA and a joint action to support cooperation at scientific and technical level between the HTA bodies. We cannot be sure that such prices and reimbursement decisions will be acceptable to us or our collaborators. If the regulatory authorities in these foreign jurisdictions set prices or make reimbursement criteria that are not commercially attractive for us or our collaborators, our revenues and the potential profitability of our products in those countries would be negatively affected. An increasing number of countries are taking initiatives to control the healthcare budget by focusing cost-cutting efforts on medicinal products, and to a lesser extent, medical devices, provided under their state-run healthcare systems. These price control efforts have impacted all regions of the world, but have been most prominent in the EU. Additionally, some countries require approval of the sale price of a product before it can be marketed or mandatory discounts or profit caps may be applied. Further, after the sale price is approved, it remains subject to review during the product lifecycle. In many countries, the pricing review period begins after marketing or product licensing approval is granted or the CE mark is obtained. As a result, we or our collaborators might obtain marketing approval for a product or service in a particular country, but then may experience delays in the reimbursement approval or be subject to price regulations that would delay the commercial launch of our product or service, possibly for lengthy time periods, which could negatively impact the revenues we are able to generate from the sale of that product or service in that particular country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, increasing efforts by governmental and third-party payers, in the United States and abroad, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for newly cleared, authorized, certified or approved devices and medicines and, as a result, they may not cover or provide adequate payment for our clinical diagnostics to be sold by us or our collaborators. For example, in May 2018 the United States government released a &#x201c;blueprint,&#x201d; or plan, to reduce the cost of drugs. This blueprint contains certain measures that HHS has been working to implement, although it is possible that HHS&#x2019;s regulatory priorities may change under the new Biden administration. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, which are, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to experience pricing pressures on our clinical diagnostics sold by us and our collaborators due to the trend toward value-based pricing and coverage, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Measures to reduce healthcare costs may hurt our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The majority of our customers are healthcare providers who depend upon reimbursement by government and commercial insurance payers for lung cancer diagnostic solutions services. With a majority of United States patients with lung cancer covered by Medicare, the Medicare reimbursement rate is an important factor in a customer&#x2019;s decision to use our diagnostic tests and limits the prices we may charge for them. Commercial insurance payers may also exert downward pressure on payment rates for lung cancer treatment services. A reduction in reimbursement rates for lung cancer treatments may adversely affect our customers&#x2019; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, thereby potentially reducing demand for our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare reform measures could hinder or prevent the commercial success of our diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our diagnostic tests. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our diagnostic tests. The effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our diagnostic tests. For example, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the ACA), contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which will impact existing government healthcare programs and will result in the development of new programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been judicial challenges to certain aspects of the ACA, as well as efforts by the Trump administration and Congress to repeal, replace or alter the implementation of certain aspects of the ACA. For example, as part of the Tax Cuts and Jobs Act of 2017 (TCJA), Congress eliminated the tax penalty, starting January 1, 2019, for not complying with the ACA&#x2019;s individual mandate to carry health insurance. The Further Consolidated Appropriations Act of 2020, Pub. L. No. 116-94, signed into law December 20, 2019, fully repealed the ACA&#x2019;s &#x201c;Cadillac Tax&#x201d; on certain high-cost employer-sponsored insurance plans, the annual fee imposed on certain health insurance providers based on market share (repeal effective in 2021), and the medical device excise tax on non-exempt medical devices. On December 14, 2018, a Texas District Court Judge invalidated the ACA in its entirety because he concluded that the individual mandate, which was repealed by Congress as noted above, is unconstitutional and cannot be severed from the remainder of the ACA. The Fifth Circuit Court of Appeals affirmed the district court&#x2019;s ruling that the individual mandate was unconstitutional, but it remanded the case back to the district court for further analysis of whether the mandate could be severed from the ACA; that is, whether the entire ACA was therefore also invalid. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020; the case is expected to be decided by mid-2021. It is unclear how this decision, subsequent appeals, and other efforts to challenge, repeal, or replace, or alter the implementation of the ACA will affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030 unless additional Congressional action is taken, with the exception of a temporary suspension of the 2% cut in Medicare payments from May 1, 2020 through March 31, 2021. Additionally, the American Taxpayer Relief Act of 2012, among other things, reduced CMS payments to several providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biden administration and Congress may continue to pursue significant changes to the current healthcare laws, and the Biden administration has indicated its intent to strengthen the ACA and focus on reducing the cost of healthcare. We face uncertainties that might result from modifications or repeal of any of the provisions of the ACA, including as a result of current and future executive orders and legislative actions. The impact of those changes on us and potential effect on the medical device industry as a whole is currently unknown. Any changes to the ACA are likely to have an impact on our results of operations, and may negatively affect our business, financial condition and results of operations. We cannot predict what other healthcare programs and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to set a price that we believe is fair for our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to generate revenue and achieve or maintain profitability; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of capital.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. Future changes in healthcare policy could increase our costs and subject us to additional regulatory requirements that may interrupt commercialization of our current and future solutions. Future changes in healthcare policy could also decrease our revenue and impact sales of and reimbursement for our current and future diagnostic tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We must comply with anti-corruption, anti-bribery, anti-money laundering and similar laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the FCPA, which generally prohibits companies in the United States from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business and requires companies to maintain accurate books and records and internal controls. We are also subject to requirements under the United States Treasury Department&#x2019;s Office of Foreign Assets Control, United States domestic bribery laws and other anti-corruption, anti-bribery and anti-money laundering laws. While we have policies and procedures in place designed to promote compliance with such laws, our employees or other agents may nonetheless engage in prohibited conduct under these laws for which we or our executives might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, international customers may currently order our diagnostic tests, either directly from us or through a potential joint venture, and we are subject to the FCPA, which prohibits companies and their intermediaries from making payments in violation of law to non-United States government officials for the purpose of obtaining or retaining business or securing any other improper advantage. Our reliance on independent distributors to sell our diagnostic tests internationally demands a high degree of vigilance in maintaining our policy against participation in corrupt activity, because these distributors could be deemed to be our agents and we could be held responsible for their actions. Other United States companies in the medical device and biopharmaceutical field have faced criminal penalties under the FCPA for allowing their agents to deviate from appropriate practices in doing business with these individuals. We are also subject to similar anti-bribery laws in the jurisdictions in which we operate, including laws promulgated by OECD countries in which we operate, such as Israel. These laws are complex and far-reaching in nature, and, as a result, we cannot assure you that we would not be required in the future to alter one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees and could result in a material adverse effect on our business, prospects, financial condition and results of operations. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We must comply with healthcare fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Various federal and state laws, as well as the laws of foreign countries, prohibit payments to induce the referral, purchase, order or use of healthcare products or services and require medical device companies to limit prevent, and/or monitor, and report certain payments to third-party payers, health care professionals, and other individuals. These healthcare fraud and abuse, anti-kickback, public reporting and aggregate spend laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with lung cancer treatment providers, hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. These laws prohibit certain marketing initiatives that are commonplace in other industries. If we were to offer or pay inappropriate inducements for the purchase, order or use of our diagnostic tests or our services, or our arrangements are perceived as inappropriate inducements, we could be subject to claims under various healthcare fraud and abuse laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restrictions under applicable United States federal and state healthcare laws and regulations include the following:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal Anti-Kickback Statute, a criminal law, prohibits, among other things, persons and entities from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, leasing, ordering, or arranging for, referring, or recommending the purchase, lease, order of any good or service for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Eliminating Kickbacks in Recovery Act, which prohibits knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in return for the referral of a patient to, or in exchange for an individual using the services of certain entities, including laboratories, if the services are covered by a health care benefit program;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Beneficiary Inducement Statute, which prohibits any person, organization, or entity from giving anything of value to a federal health care program beneficiary that is likely to induce or influence the beneficiary&#x2019;s choice of provider, practitioner, or supplier for covered services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal civil False Claims Act, which may be enforced through civil whistleblower or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">qui tam </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actions and is often used to enforce the federal Anti-Kickback Statute and other healthcare laws and regulations, imposes civil penalties and potential exclusion from federal healthcare programs, against individuals or entities for, among other things, knowingly presenting, or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">causing to be presented, to the federal government, claims for payment that are false or fraudulent or for making a false record or statement material to an obligation to pay the federal government or for knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal criminal statutes created by HIPAA impose criminal liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program, including private insurance plans, or, in any matter involving a healthcare benefit program, for knowingly and willfully making materially false, fictitious, or fraudulent statements in connection with the delivery of or payment for health care benefits; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other federal and state laws, as well as the laws of foreign countries, generally prohibit individuals or entities from knowingly presenting, or causing to be presented, claims for payments to government or commercial payers that are false or fraudulent, or for items or services that were not provided as claimed. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates and medical devices from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If any physicians or other healthcare providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers can also be held liable under these laws if they are deemed to &#x201c;cause&#x201d; the submission of false or fraudulent claims by providing inaccurate billing or coding information to customers, by providing improper financial inducements, or through certain other activities. We attempt to ensure that any billing and coding information we provide for our diagnostic tests emphasizes the need for physicians and other providers to make independent judgments, use accurate and appropriate billing and coding that complies with all applicable payer policies, and document the medical need for their patients as appropriate. Nevertheless, the government may not regard any billing errors that may be made by our customers as inadvertent and may examine our role in providing information to our customers, physicians and patients concerning the benefits and potential coverage of more frequent therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">FDA regulation of our industry generally or our tests specifically could be disruptive to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations are subject to extensive federal, state, local and foreign laws and regulations, including FDA laws and regulations, all of which are subject to change. These laws and regulations are complex and are subject to interpretation by the courts and by government agencies. We believe that we are in material compliance with all statutory and regulatory requirements applicable to us, but there is a risk that one or more government agencies could take a contrary position, or that a private party could file suit under the qui tam provisions of the federal False Claims Act or a similar state law. Such occurrences, regardless of their outcome, could damage our reputation and adversely affect important business relationships with third parties, including managed care organizations, and other private third-party payers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has recently increased its attention to marketing of pharmacogenetic tests. For example, in late 2018, the FDA issued a safety communication regarding genetic laboratory tests with claims to predict a patient&#x2019;s response to specific medications that have not been reviewed by the FDA and may not be supported by clinical evidence. Among other tests, the FDA notice cited genetic tests that claim results can be used to help physicians identify which antidepressant medication would have increased effectiveness or side effects compared to other antidepressant medications. As explained by the FDA in its update to this safety communication, the FDA sent notices to several firms marketing such pharmacogenetic tests where the FDA believes the relationship between genetic variations and the medication&#x2019;s effects has not been established, including a warning letter sent to a laboratory, in part, for failing to obtain premarket review of its test. HHS recently issued an announcement stating that the FDA cannot require premarket review of any LDT without engaging in formal notice-and-comment rulemaking, as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The HHS announcement was made on the Department&#x2019;s website and we can provide no assurances that the HHS statement will not be rescinded or revised or that it would preclude the FDA from renewing its attention on diagnostic tests, including those that we provide. If this were to happen, it may impact our marketing practices relating to the relevant tests, which in turn may have an adverse impact on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The SARS-CoV-2 tests we perform are currently the subject of EUAs, which permit the use of unapproved medical products or unapproved uses of medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditions when there are no adequate, approved, and available alternatives, as provided under section 564 for the Federal Food, Drug, and Cosmetic Act (FDCA). EUAs are temporary authorizations that are revoked at the end of the public health emergency, when there is an adequate, approved, or available alternative, or when there are performance or safety concerns. These EUAs also set out conditions for laboratories who are authorized to perform the particular test. The HHS statement mentioned above did not affect EUAs for COVID-19 laboratory-developed tests that were already in effect at the time the statement was released. The HHS statement did not affect EUAs issued for commercially developed COVID-19 IVD tests, which apply to test developers and authorized laboratories.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EUA for Bio-Rad&#x2019;s SARS-CoV-2 Droplet Digital PCR&#153; test provides several conditions for authorized laboratories, including that the test result reports will include Fact Sheets that are authorized as part of the EUA, deviations from the authorized procedures, including specimen types, are not permitted, notification of public health authorities of intent to run the test prior to initiating testing, collection and reporting of performance data to the FDA, including false positives, false negatives, and significant deviations from the established performance characteristics, and appropriate training and protective equipment for laboratory staff. This EUA also states that authorized laboratories must maintain records associated with the EUA and be made available to the FDA for inspection upon request. Printed materials, advertising, and promotion related to use of the test must be consistent with the authorized labeling and Fact Sheets, as well as other terms set forth in the EUA and any applicable requirements under the FDCA and its implementing regulations, and conspicuously bear the following statements:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has not been FDA cleared or approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has been authorized by the FDA under an EUA for use by authorized laboratories;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other statements that appear in advertising and promotional materials must not represent or suggest that this test is safe or effective for the detection of SARS-CoV-2.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EUA for Bio-Rad&#x2019;s serological test for the antibodies associated with SARS-CoV-2, also sets out several conditions for authorized laboratories that mirror the conditions for the PCR test described above, except that the printed materials, advertising, and promotion of the test must conspicuously bear the following statements:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has not been FDA cleared or approved;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has been authorized by the FDA under an EUA for use by authorized laboratories;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test has been authorized only for the detection of total antibodies, including IgM/IgG/IgA, against SARS-CoV-2, not for any other viruses or pathogens; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. &#167; 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Failure to comply with federal, state and foreign laboratory licensing requirements and the applicable requirements of the FDA or any other regulatory authority, could cause us to lose the ability to perform our tests, experience disruptions to our business, or become subject to administrative or judicial sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The diagnostic testing industry is subject to extensive laws and regulations, many of which have not been interpreted by the courts, including the application of the FDA&#x2019;s EUA authority. As noted above, the EUAs for the COVID-19 tests that are part of our Biodesix WorkSafe testing program set out certain conditions for authorized laboratories using the tests, which have not received premarket clearance, approval, or a de novo from the FDA. If we fail to meet these conditions, the FDA may take enforcement action, such as issuing a warning letter, seeking an injunction, seizure, fines, or criminal penalties. Pursuant to the August 19, 2020 statement by HHS, the FDA cannot require any LDT to undergo premarket approval until it has engaged in notice-and-comment rulemaking. Laboratory tests that have already received an EUA to detect the COVID-19 virus were &#x201c;unaffected&#x201d; by the announcement. Tests without FDA clearance, approval, or authorization would not be considered covered countermeasures under the Public Readiness and Emergency Preparedness Act (PREP Act). The HHS statement also did not affect EUAs issued for commercially developed COVID-19 IVD tests, which apply to test developers and authorized laboratories.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also subject to CLIA, a federal law that regulates clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. CLIA requires virtually all laboratories to be certified by the federal government and mandates compliance with various operational, personnel, facilities administration, quality and proficiency testing requirements intended to ensure that testing services are accurate, reliable and timely. CLIA certification is also</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prerequisite to be eligible to bill state and federal health care programs, as well as many private third-party payers, for laboratory testing services. As a condition of CLIA certification, each of our laboratories is subject to survey and inspection every other year, in addition to being subject to additional random inspections. The biennial survey is conducted by CMS, a CMS agent (typically a state agency), or, if the laboratory holds a CLIA certificate of accreditation, a CMS-approved accreditation organization.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sanctions for failure to comply with CLIA requirements, including proficiency testing violations, may include suspension, revocation, or limitation of a laboratory&#x2019;s CLIA certificate, which is necessary to conduct our business, as well as the imposition of significant fines or criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing licensure, or our failure to renew a CLIA certificate, a state or foreign license, or accreditation, could have a material adverse effect on our business. If the CLIA certificate of any one of our laboratories is revoked, CMS could seek revocation of the CLIA certificates of our other laboratories based on their common ownership or operation, even though they are separately certified.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we are subject to state laws and regulations governing laboratory licensure. Some states have enacted state licensure laws that are more stringent than CLIA. Although we have obtained licenses from states where we believe we are required to be licensed, we may become aware of other states that require out-of-state laboratories to obtain licensure in order to accept specimens from the state, and it is possible that other states currently have such requirements or will have such requirements in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to regulation in foreign jurisdictions as we seek to expand international utilization of our tests or such jurisdictions adopt new licensure requirements, which may require review of our tests in order to offer them or may have other limitations that may limit our ability to make our tests available outside of the United States. Complying with licensure requirements in new jurisdictions may be expensive, time-consuming and subject us to significant and unanticipated delays. Changes in state or foreign licensure laws that affect our ability to offer and provide diagnostic services across state or foreign country lines could materially and adversely affect our business. In addition, state and foreign requirements for laboratory certification may be costly or difficult to meet and could affect our ability to receive specimens from certain states or foreign countries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with applicable clinical laboratory licensure requirements may result in a range of enforcement actions, including suspension, limitation or revocation of our CLIA certificate and/or state licenses, imposition of a directed plan of action, onsite monitoring, civil monetary penalties, criminal sanctions and revocation of the laboratory&#x2019;s approval to receive Medicare and Medicaid payment for its services, as well as significant adverse publicity. Any sanction imposed under CLIA, its implementing regulations, or state or foreign laws or regulations governing clinical laboratory licensure or our failure to renew our CLIA certificate, a state or foreign license or accreditation, could have a material adverse effect on our business, financial condition and results of operations. Even if we were able to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Boulder, Colorado and De Soto, Kansas laboratories are both CAP-accredited clinical laboratories regulated by CMS pursuant to CLIA. We also have a current CLIA certificate for each facility. To maintain these certificates, we are subject to survey and inspection every two years. Moreover, CLIA inspectors may make random inspections of our laboratory from time to time. Furthermore, our diagnostic tests are categorized as LDTs and are not currently subject to FDA regulation, although certain components provided by third parties and used to create and/or administer the test may be. LDTs are a subset of IVDs that are intended for clinical use and developed, validated, and offered within a single laboratory for use only in that laboratory. The FDA&#x2019;s authority to regulate LDTs has been frequently contested, and HHS recently issued a public statement purporting to rescind the FDA&#x2019;s policies regarding the premarket review of LDTs. According to the HHS statement, the FDA will not require premarket review of LDTs unless it engages in notice-and-comment rulemaking. There is no guarantee, however, that the HHS statement will not be revised or rescinded, that legislation reforming the federal government&#x2019;s regulation of LDTs will not be passed, or that LDTs will otherwise continue to be able to operate without first receiving FDA premarket review. Failure to adhere to any new FDA regulation would result in fines, product suspensions, warning letters, recalls, injunctions and other civil and criminal penalties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in the way that the FDA regulates tests performed by laboratories like ours could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, the FDA has exercised enforcement discretion with respect to most LDTs and has not required laboratories that furnish LDTs to comply with the agency&#x2019;s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA publicly announced its intention to regulate certain LDTs and issued two draft guidance documents that set forth a proposed phased-in risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. However, these guidance documents were withdrawn at the end of the Obama administration and replaced by an informal discussion paper reflecting some of the feedback that the FDA had received on LDT regulation. The FDA acknowledged that the discussion paper in January 2017 does not represent the formal position of the FDA and is not enforceable. Nevertheless, the FDA wanted to share its synthesis of the feedback that it had received in the hope that it might advance public discussion on future LDT oversight. HHS has since issued a statement purporting to rescind FDA&#x2019;s policies regarding the premarket review of LDTs, stating that FDA must engage in notice and comment rulemaking (as opposed to through guidance documents, compliance manuals, website statements, or other informal issuances) prior to requiring premarket review of LDTs. HHS issued this statement on its website and it may be subject to change. Also, it is possible that Congress will pass legislation to reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the federal government&#x2019;s regulation of LDTs or that FDA will engage in notice-and-comment rulemaking to require premarket review of LDTs, which could result in delay or additional expense in offering our tests and tests that we may develop in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our current line of diagnostic tests is covered under CLIA and CMS, although our COVID testing program and select partnerships we may enter may cause us to be subject to additional FDA requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The laws and regulations governing the marketing of diagnostic products are evolving, extremely complex and in many instances, there are no significant regulatory or judicial interpretations of these laws and regulations. Pursuant to its authority under the FDCA, the FDA has jurisdiction over medical devices, including in vitro diagnostics and, therefore, potentially our clinical laboratory tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the FDCA and its implementing regulations, the FDA regulates the research, testing, manufacturing, safety, labeling, storage, recordkeeping, premarket clearance or approval, marketing and promotion, and sales and distribution of medical devices in the United States to ensure that medical products distributed domestically are safe and effective for their intended uses. Although the FDA has asserted that it has authority to regulate the development and use of LDTs, such as our and many other laboratories&#x2019; tests, as medical devices, it has generally exercised enforcement discretion and is not otherwise regulating most tests developed and performed within a single high complexity CLIA-certified laboratory. On August 19, 2020, HHS issued a statement purporting to rescind the FDA&#x2019;s policies regarding the premarket review of LDTs, absent notice-and-comment rulemaking. the FDA&#x2019;s policies to date have been articulated through guidance documents, compliance manuals, website statements, and other informal issuances. The FDA could, at any time, engage in notice-and-comment rulemaking, or Congress could take action to amend the law to change the current regulatory framework for in vitro diagnostics and LDTs. Further, the HHS statement was issued on its website and may be subject to change, particularly given the reasoning that additional flexibility is needed due to the COVID-19 pandemic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our tests, as utilized in our clinical laboratory, are and would be considered LDTs and that as a result, the FDA does not require that we obtain regulatory clearances or approvals for our LDTs or their components pursuant to the FDA&#x2019;s current policies and guidance. Although we believe that our tests and test components are either exempt from FDA medical device regulations or are subject to an enforcement discretion policy, it is possible that the FDA would not agree with our determinations or that the FDA will change its regulations and policies such that our products become regulated as medical devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In contrast with our LDTs, the FDA has regulatory jurisdiction over the two FDA EUA-authorized COVID-19 tests that were developed by Bio-Rad, which we offer as part of our Biodesix WorkSafe testing programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, therefore, are or may become subject to extensive regulation by the FDA in the United States. Government regulations specific to medical devices are wide ranging and govern, among other things:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test design, development, manufacture, and release;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laboratory and clinical testing, labeling, packaging, storage, and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product safety and efficacy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">premarketing clearance or approval;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">service operations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">record keeping;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product marketing, promotion and advertising, sales, and distribution;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">post-market approval studies; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product import and export.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. Class I devices, which have the lowest level of risk associated with them, are subject to general controls. Class II devices are subject to general controls and special controls, including performance standards. Class III devices, which have the highest level of risk associated with them, are subject to general controls and premarket approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before a new medical device or service, or a new intended use for an existing product or service, can be marketed in the United States, a company must first submit and receive either 510(k) clearance, de-novo authorization, or premarket approval (PMA) from the FDA, unless an exemption applies. Most Class I devices and some Class II devices are exempt from these requirements. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is substantially equivalent to a legally-marketed predicate device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (preamendments device), a device that was originally on the United States market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be substantially equivalent, the proposed device must have the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the process of obtaining PMA approval, the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, clinical trial, manufacturing and labeling data. The PMA process is typically required for devices that are deemed to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also allows the submission of a direct de-novo petition. This procedure allows a manufacturer whose novel device is automatically classified into Class III to request down-classification of its medical device into Class I or Class II on the basis that the device presents low or moderate risk, rather than requiring the submission and approval of a PMA application. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 510(k), de-novo or PMA process can be expensive, lengthy and unpredictable. The FDA can delay, limit, or deny clearance or approval of a device for many reasons, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or conformity assessment body that the diagnostic tests are safe or effective for their proposed intended uses;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the disagreement of the FDA with the design or implementation of our clinical trials or the interpretation of data from clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">serious and unexpected adverse device effects experienced by participants in our clinical trials;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data from our clinical trials may be insufficient to support clearance or approval, where required;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the manufacturing process or facilities we use may not meet applicable requirements; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">repair, replacement, refunds, recall or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operating restrictions, partial suspension, or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">denial of our requests for regulatory clearance or premarket approval of new diagnostic tests or services, new intended uses, or modifications to existing diagnostic tests or services;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of regulatory clearance or premarket approvals that have already been granted; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">criminal prosecution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed above, we believe that our current line of diagnostic tests and their components are LDTs, subject to state licensing requirements and federal regulation by CMS under CLIA, although our COVID-19 testing program and select partnerships we may enter may cause us to be subject to additional FDA regulations discussed above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we believe that we are currently in material compliance with applicable laws and regulations, it is possible that the FDA, or other regulatory agencies, would not agree with our determinations. If our products became become subject to 510(k) or other similar FDA regulations, we would need to comply with the applicable regulations or face significant civil and criminal penalties. In addition, IVDs and CDx tests are widely considered to be Class III devices, and it is possible that in the future, we may develop tests that fall into this category. CDx tests in particular may require further administrative procedures in the PMA process. Exposure to these additional regulatory requirements would also affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success depends on our ability to develop, receive regulatory clearance or approval or certification for, and introduce new diagnostic tests or enhancements to existing diagnostic tests that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future diagnostic tests and failure to obtain necessary clearances or approvals for our future diagnostic tests would adversely affect our ability to grow our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">It is important to our business that we build a pipeline of diagnostic test offerings that address limitations of current lung disease diagnostic tests. As such, our success will depend in part on our ability to develop and introduce new diagnostic tests. However, we may not be able to successfully develop and obtain regulatory clearance or approval or certification for enhancements to our existing diagnostic tests, or new diagnostic tests for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these diagnostic tests may not be accepted by physicians or users.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of any new diagnostic test or enhancement to an existing diagnostic test will depend on a number of factors, including our ability to, among others:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify and anticipate physician and patient needs properly;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">develop and introduce new diagnostic tests or enhancements to our existing diagnostic tests in a timely manner;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">avoid infringing upon, misappropriating, or violating the intellectual property rights of third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demonstrate, if required, the safety and efficacy of new diagnostic tests with data from clinical studies;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain the necessary regulatory clearances or approvals or certifications for new diagnostic tests or enhancements to existing diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">comply fully with FDA and foreign regulations on marketing of new diagnostic tests or modified diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">provide adequate training to potential users of our diagnostic tests.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we do not develop new diagnostic tests or enhancements to our existing diagnostic tests in time to meet market demand or if there is insufficient demand for these diagnostic tests or enhancements, or if our competitors introduce new diagnostic tests with functionalities that are superior to ours, our results of operations will suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some of our future diagnostic tests may require FDA clearance of a 510(k) submission. Other diagnostic tests may require the approval of a PMA. In addition, some of our future diagnostic tests may require clinical trials to support regulatory approval and we may not successfully complete these clinical trials. The FDA may not approve or clear these diagnostic tests for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or premarket approval of new diagnostic tests. Failure to receive clearance or approval for our new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Modifications to our marketed tests may require new 510(k) clearances or PMA approvals, or may require us to cease marketing or recall the modified tests until clearances or approvals are obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Modifications to our diagnostic tests may require new regulatory approvals or clearances, including 510(k) clearances or premarket approvals, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer&#x2019;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our diagnostic tests in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our diagnostic tests as modified, which could require us to redesign our diagnostic tests and harm our operating results. In these circumstances, we may be subject to significant enforcement actions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or efficacy, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a premarket approval application. Where we determine that modifications to our diagnostic tests require a new 510(k) clearance or premarket approval application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced diagnostic tests in a timely manner, which in turn would harm our future growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we or our suppliers fail to comply with ongoing FDA or other domestic and foreign regulatory authority or conformity assessment body requirements, or if we experience unanticipated problems with our diagnostic tests, they could be subject to restrictions or withdrawal from the market.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any medical device that we manufacture, including those for which we obtain regulatory clearance or approval or certification, and the manufacturing processes, reporting requirements, post-approval clinical data and promotional activities for such diagnostic test, will be subject to continued regulatory review, oversight, and periodic inspections by the FDA and other domestic and foreign regulatory bodies or conformity assessment bodies. In particular, we and our suppliers may be required to comply with FDA&#x2019;s Quality System Regulations (QSR codified at 21 C.F.R. &#167; 820) for medical devices and ISO regulations for the manufacture of our diagnostic tests and other regulations which cover the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of any diagnostic test for which we obtain clearance or approval. Regulatory bodies, such as the FDA, and conformity assessment bodies enforce the QSR and other regulations through periodic inspections and audits. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies or conformity assessment bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, one or more of the following enforcement actions:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated expenditures to address or defend such actions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">customer notifications for repair, replacement, or refunds;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recall, detention, or seizure of our diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operating restrictions or partial suspension or total shutdown of production;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusing or delaying our requests for 510(k) clearance or premarket approval of new diagnostic tests or modified versions of current diagnostic tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operating restrictions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawing 510(k) clearances on PMA approvals that have already been granted;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">revocation of EUAs that have been authorized previously;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal to grant export approval for our diagnostic tests; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">criminal prosecution.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of these actions were to occur it would harm our reputation and cause our diagnostic test sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our diagnostic tests on a timely basis and in the required quantities, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we are required to conduct surveillance to monitor the safety or effectiveness of our diagnostic tests, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our diagnostic tests. Later discovery of previously unknown problems with our diagnostic tests, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such diagnostic tests or manufacturing processes, withdrawal of the diagnostic tests from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our diagnostic tests and services may in the future be subject to product recalls that could harm our reputation, business and financial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our diagnostic tests and services in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations. Other jurisdictions have similar recall requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval or certification of any future diagnostic tests and to manufacture, market and distribute our diagnostic tests after clearance or approval is obtained.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. For example, the Verifying Accurate, Leading-edge IVCT Development (VALID) Act recently introduced in Congress would codify into law the term &#x201c;in vitro clinical test&#x201d; in order to create a new medical product category separate from medical devices that would include products currently regulated as in vitro diagnostics as well as LDTs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our diagnostic tests. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future diagnostic tests. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any change in the laws or regulations that govern the clearance and approval processes relating to our current, planned and future diagnostic tests could make it more difficult and costly to obtain clearance or approval for new diagnostic tests or to produce, market and distribute existing diagnostic tests. Significant delays in receiving clearance or approval or the failure to receive clearance or approval for any new diagnostic tests would have an adverse effect on our ability to expand our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical trials may be necessary to support future product submissions to FDA. These clinical trials are expensive and will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new diagnostic tests and will adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initiating and completing clinical trials necessary to support any future PMA applications, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and ability to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our diagnostic tests or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our diagnostic tests or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as contractually required or expected, we may not be able to obtain regulatory clearance or approval or certification for or commercialize our diagnostic tests and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have the ability to independently conduct our pre-clinical and clinical trials for our future diagnostic tests and services and we must rely on third parties, such as contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct such trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our diagnostic tests and services on a timely basis, if at all, and our business, operating results and prospects may be adversely affected. Furthermore, our third-party clinical trial investigators may be delayed in conducting our clinical trials for reasons outside of their control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our use, disclosure, and other processing of personally identifiable information, including health information, is subject to HIPAA and other federal, state, and foreign privacy and security regulations, and our failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, a material adverse effect on our business, operating results and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain and process, and our third-party vendors, collaborators, contractors and consultants maintain and process on our behalf, a large quantity of sensitive information, including confidential business, personal and patient health information in connection with our clinical studies and our employees, and are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information. Failure by us or our third-party vendors, collaborators, contractors and consultants to comply with any of these laws and regulations could result in notification obligations or enforcement actions against us, which could result in fines, imprisonment of company officials and public censure, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects. These laws, rules and regulations evolve frequently and their scope may continually change, through new legislation, amendments to existing legislation and changes in enforcement, and may be inconsistent from one jurisdiction to another. The interpretation and application of consumer, health-related and data protection laws, especially with respect to genetic samples and data, in the United States, the European Union (EU) and elsewhere, are often uncertain, contradictory and in flux. As a result, implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state health information privacy laws and federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of our collaborators.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Domestic laws in this area are complex and developing rapidly. Many state legislatures have adopted legislation relating to privacy, data security and data breaches. Laws in all 50 states require businesses to provide notice to customers whose personally identifiable information has been disclosed as a result of a data breach. The laws are not consistent, and compliance in the event of a widespread data breach is costly. States are also frequently amending existing laws, requiring attention to frequently changing regulatory requirements. For example, California recently enacted the CCPA, which became effective on January 1, 2020. The CCPA, among other things, requires new disclosures to California consumers and affords such consumers new abilities to access and delete their personal information, opt-out of certain sales of personal information and receive detailed information about how their personal information is used. The CCPA provides for fines of up to $7,500 per violation, as well as a private right of action for data breaches that is expected to increase the frequency of data breach litigation. While the CCPA has already been amended multiple times, it is unclear how this legislation will be further modified or how it will be interpreted. Interpretations of the CCPA may continue to evolve with regulatory guidance and the CCPA continue to be amended, including through a ballot initiative, the CPRA. That passed in November 2020. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights, including regarding certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to enforce the law, which may likely result in increased regulatory scrutiny of California businesses in the areas of data protection and security. The effects of this legislation potentially are far-reaching, however, and may require us to modify our data processing practices and policies and incur substantial compliance-related costs and expenses. The CCPA and other changes in state and federal laws or regulations relating to privacy, data protection and information security, particularly any new or modified laws or regulations that require enhanced protection of certain types of data or new obligations with regard to data retention, transfer or disclosure, could increase the cost of providing our offerings, require significant changes to our operations or even prevent us from providing certain offerings in jurisdictions in which we currently operate and in which we may operate in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the breadth of these data protection laws and the narrowness of their exceptions and safe harbors, it is possible that our business or data protection policies could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of heightened regulatory focus on data privacy and security issues. Although we endeavor to comply with our published policies and documentation and ensure their compliance with current laws, rules and regulations, we may at times fail to do so or be alleged to have failed to do so. The publication of our privacy policy and other documentation that provide promises and assurances about privacy and security can subject us to potential state and federal action in the United States if they are found to be deceptive, unfair, or misrepresentative of our actual practices. Any failure by us or other parties with whom we do business to comply with this documentation or with federal, state, local or international regulations could result in proceedings against us by governmental entities, private parties or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operations are found to be in violation of any of the data protection laws described above or any other laws that apply to us, we may be subject to penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in government healthcare programs, injunctions, private qui tam actions brought by individual whistleblowers in the name of the government, class action litigation and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corrective action plan or other agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, numerous state and federal laws and regulations govern the collection, dissemination, use, privacy, confidentiality, security, availability, integrity, and other processing of PHI and PII. These laws and regulations include HIPAA. HIPAA establishes a set of national privacy and security standards for the protection of protected health information (as defined in HIPAA, PHI) by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. We are a covered entity under HIPAA when we are conducting our clinical trials. We are a covered entity with regard to our observational studies and clinical trials, and also a business associate under HIPAA for certain other business activities, and we execute business associate agreements with our clients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA requires covered entities and business associates, such as us, to develop and maintain policies with respect to the protection of, use and disclosure of electronic PHI, including the adoption of administrative, physical and technical safeguards to protect such information, and certain notification requirements in the event of a data breach.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA imposes mandatory penalties for certain violations. Penalties for violations of HIPAA and its implementing regulations start at $119 per violation and are subject to a cap of $1,785,651 for violations of the same standard in a single calendar year. However, a single breach incident can result in violations of multiple standards. HIPAA also authorizes state attorneys general to file suit on behalf of their residents. Courts may award damages, costs and attorneys&#x2019; fees related to violations of HIPAA in such cases. While HIPAA does not create a private right of action allowing individuals to sue us in civil court for violations of HIPAA, its standards have been used as the basis for duty of care in state civil suits such as those for negligence or recklessness in the misuse or breach of PHI.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, HIPAA mandates that the Secretary of HHS conduct periodic compliance audits of HIPAA covered entities and business associates. With regard to business associates, those audits assess the business associate&#x2019;s compliance with the HIPAA Privacy and Security Standards. Such audits are conducted randomly and after an entity experiences a breach affecting more than 500 individuals&#x2019; data. Undergoing an audit can be costly, can result in fines or onerous obligations, and can damage a business associate&#x2019;s reputation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to HIPAA, numerous other federal, state, and foreign laws and regulations protect the confidentiality, privacy, availability, integrity and security of PHI and other types of PII. Some of these laws and regulations may be preempted by HIPAA with respect to PHI, or may exclude PHI from their scope but impose obligations with regard to PII that is not PHI, and in some cases, can impose additional obligations with regard to PHI. These laws and regulations are often uncertain, contradictory, and subject to changing or differing interpretations, and we expect new laws, rules and regulations regarding privacy, data protection, and information security to be proposed and enacted in the future. HHS is also proposing amendments to the HIPPA Privacy Rule to modernize certain data sharing provisions and enhance patient access to their information. This complex, dynamic legal landscape regarding privacy, data protection, and information security creates significant compliance issues for us and our clients and potentially exposes us to additional expense, adverse publicity and liability. While we have implemented data privacy and security measures in an effort to comply with applicable laws and regulations relating to privacy and data protection, some PHI and other PII or confidential information is transmitted to us by third parties, who may not implement adequate security and privacy measures, but it is possible that laws, rules and regulations relating to privacy, data protection, or information security may be interpreted and applied in a manner that is inconsistent with our practices or those of third parties who transmit PHI and other PII or confidential information to us. If we or these third parties are found to have violated such laws, rules or regulations, it could result in government-imposed fines, orders requiring that we or these third parties change our or their practices, or criminal charges, which could adversely affect our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices, systems and compliance procedures in a manner adverse to our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may eventually operate in a number of countries outside of the United States whose laws, including data privacy laws, may in some cases be more stringent than the requirements in the United States. For example, EU and UK data privacy laws have specific requirements relating to cross-border transfers of personal data to certain jurisdictions, including to the United States, have strict requirements relating to personal data collection, use or sharing, and have more stringent requirements relating to organizations&#x2019; privacy programs and provide stronger individual rights. Moreover, we may also be subject to evolving international privacy and data security regulations which could result in greater compliance costs and in turn lead to penalties, where such compliance programs are not implemented correctly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our processing activities are subject to the EU General Data Protection Regulation and the UK General Data Protection Regulation (collectively, the &#x201c;GDPR&#x201d;) &#x2013; including, those involving pseudonymised / key-coded data - as the GDPR applies extra-territorially. The GDPR imposes strict requirements on controllers and processors processing personal data, including, for example, requirements to: (i) identify a legal basis for the processing of personal data, (ii) provide robust disclosures to individuals, (iii) respond to requests from individuals to exercise their data subject rights, (iv) provide personal data breach notifications within 72 hours after discovering the breach, (v) limit the collection and retention of personal data, (vi) impose specific contractual obligations on processors engaged to process personal data on the instructions of the controller, and (vii) apply enhanced protections to health data and other special categories of personal data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The EU GDPR also provides that EU Member States may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share such personal data and cause our costs to increase and harm our financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to comply with the requirements of the GDPR may result in fines of up to &#x20ac;20 million (&#163;17.5 million in the case of the UK GDPR) or up to 4% of the total worldwide annual turnover of our preceding fiscal year, whichever is higher, and other administrative penalties. GDPR compliance may require us to put in place additional mechanisms, which may result in compliance costs and other substantial expenditures. This may be onerous and adversely affect our business, financial condition, results of operations and the profitability of our platform of diagnostic tests. Failure to comply with the GDPR and other countries&#x2019; privacy or data security-related laws, rules or regulations could result in material penalties imposed by regulators, affect our compliance with contracts entered into with our collaborators and other third-party payers, and have an adverse effect on our business and financial condition. Currently, the GDPR is only applicable to us as a processor, but as we continue to expand into the European market, the GDPR will have direct applicability to us as a controller.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GDPR also prohibits the transfer of personal data from the EEA/UK to a country outside of the EEA/UK (e.g., the United States) unless made to a country deemed to have adequate data privacy laws by the European Commission (or UK Government in case of the UK GDPR) or a data transfer mechanism has been put in place. Until recently, one such data transfer mechanism was the EU-US Privacy Shield. However, in July 2020 the Court of Justice of the European Union (CJEU) declared the Privacy Shield to be invalid. The CJEU upheld the validity of standard contractual clauses (SCCs) as a legal mechanism to transfer personal data but companies relying on SCCs will need to carry out a transfer privacy impact assessment, which among other things, assesses laws governing access to personal data in the recipient country and considers whether supplementary measures that provide privacy protections additional to those provided under SCCs will need to be implemented to ensure an essentially equivalent level of data protection to that afforded in the EEA. In turn, the findings of the CJEU will have significant implications for cross-border data flows and may lead to increased transaction, compliance, and technological costs to support international data transfers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Organizations operating in Canada and covered by the Personal Information Protection and Electronic Documents Act (PIPEDA), or equivalent Canadian provincial laws, must obtain an individual&#x2019;s consent when they collect, use or disclose that individual&#x2019;s personal information. Individuals have the right to access and challenge the accuracy of their personal information held by an organization, and personal information may only be used for the purposes for which it was collected. If an organization intends to use personal information for another purpose, it must again obtain that individual&#x2019;s consent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We regularly monitor, defend against and respond to attacks to our networks and other information security incidents. Despite our information security efforts, our facilities, systems, and data, as well as those of our third-party service providers, may be vulnerable to privacy and information security incidents such as data breaches, viruses or other malicious code, coordinated attacks, data loss, phishing attacks, ransomware, denial of service attacks, or other security or IT incidents caused by threat actors, technological vulnerabilities or human error. If we, or any of our vendors that support our IT or have access to our data, including any third-party vendors that collect, process and store personal data on our behalf, fail to comply with laws requiring the protection of personal information, or fail to safeguard and defend personal information or other critical data assets or IT systems, we may be subject to regulatory enforcement and fines as well as private civil actions. We may be required to expend significant resources in the response, containment, mitigation of cybersecurity incidents as well as in defense against claims that our information security was unreasonable or otherwise violated applicable laws or contractual obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these employees could include intentional, reckless and/or negligent conduct or unauthorized activity that violates:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA regulations, including those laws requiring the reporting of true, complete, and accurate information to the FDA authorities;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">federal and state healthcare fraud and abuse laws and regulations; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">laws that require the true, complete and accurate reporting of financial information or data.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by the HHS Office of Inspector General (OIG) could result in penalties, a loss of business from third parties, and severe reputational harm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics and compliance policies to govern and deter such behaviors, but it is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ongoing research and development and clinical trial activities are subject to extensive regulation and review by numerous governmental authorities both in the United States and abroad. We are currently conducting pre-and post-market clinical studies of some of our tests. In the future we may conduct clinical trials to support approval of new diagnostic tests and services, or new indications. Clinical studies may need to be conducted in compliance with FDA regulations or the FDA may take enforcement action. The data collected from these clinical studies may ultimately be used to support marketing authorization for these diagnostic tests and services. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our product candidate claims or that the FDA or foreign authorities and conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our tests are safe and effective for the proposed indicated uses, which could cause us to abandon development of our tests and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, may impact our ability to commercialize our tests and generate revenues.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval or certification. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions, and contract research organizations to perform the trials, and would control only certain aspects of their activities. Nevertheless, we would be responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties would not relieve us of our regulatory responsibilities. We and our third-party contractors are required to comply with good clinical practices (GCPs) which are regulations and guidelines enforced by the FDA, and comparable regulations enforced by foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any third-party contractor fails to comply with applicable GCPs, the clinical data generated in clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities or conformity assessment bodies may require us to perform additional clinical trials before clearing or approving our marketing applications. A failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory clearance or approval or certification process. In addition, if these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of these factors could be beyond our control. We may not be able to undertake additional trials, repeat trials or enter into new arrangements with third parties without undue delays or considerable expenditures. If there are delays in testing or clearances or approvals as a result of the failure to perform by third parties, our research and development costs would increase and we may not be able to obtain regulatory clearance or approval or certification for our tests. In addition, we may not be able to establish or maintain relationships with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our tests, or to achieve sustained profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The results of our clinical trials may not support our product candidate claims or may result in the discovery of adverse side effects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that the results of our future clinical trials will support our future product claims or that the FDA or comparable foreign regulatory authorities or conformity assessment bodies will agree with our conclusions regarding them. Success in pre-clinical studies and early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior trials and pre-clinical studies. The clinical trial process may fail to demonstrate that our product candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a product candidate and may delay development of others. Any delay or termination of our clinical trials will delay the filing of our product submissions and, ultimately, our ability to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercialize our product candidates and generate revenues. It is also possible that patients enrolled in clinical trials will experience adverse side effects that are not currently part of the future product&#x2019;s profile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our billing, collections and claims processing activities are complex and time-consuming, and any delay in transmitting and collecting claims or failure to comply with applicable billing requirements, could have an adverse effect on our future revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Billing for our tests is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, such as government payers, insurance companies and patients, all of which may have different billing requirements. We may face increased risk in our collection efforts, including long collection cycles and the risk that we may never collect at all, either of which could adversely affect our business, financial condition and results of operations. Several factors make the billing process complex, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differences between the list price for our tests and the reimbursement rates of payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with complex federal and state regulations related to billing government healthcare programs, including Medicare and Medicaid, to the extent our tests are covered by such programs;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differences in coverage among payers and the effect of patient co-payments or co-insurance;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differences in information and billing requirements among payers;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes to codes and coding instructions governing our tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">incorrect or missing billing information; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the resources required to manage the billing and claims appeals process.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These billing complexities and the related uncertainty in obtaining payment for our tests could negatively affect our revenue and cash flow, our ability to achieve profitability and the consistency and comparability of our results of operations. In addition, if claims for our tests are not submitted to payers on a timely basis, or if we fail to comply with applicable billing requirements, it could have an adverse effect on our revenue and our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payers require us to identify the test for which we are seeking reimbursement using a Current Procedural Terminology (CPT) code. The CPT code set is maintained by the American Medical Association (AMA). In cases where there is not a specific CPT code to describe a test, such as with Nodify CDT and GeneStrat, the test may be billed under an unlisted molecular pathology procedure code or through the use of a combination of single gene CPT codes, depending on the payer. The Protecting Access to Medicare Act of 2014 (PAMA) authorized the adoption of new, temporary billing codes and unique test identifiers for FDA-cleared or approved tests as well as advanced diagnostic laboratory tests. The AMA has created a new section of CPT codes, Proprietary Laboratory Analyses codes to facilitate implementation of this section of PAMA. In addition, CMS may assign unique level II Healthcare Common Procedure Coding System codes to tests that are not already described by a unique CPT code. VeriStrat and Nodify XL2 both have test specific CPT codes, but the GeneStrat and Nodify CDT tests do not at this time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the instance where a code used does not describe a specific test, the insurance claim must be examined to determine what test was provided, whether the test was appropriate and medically necessary, and whether payment should be rendered, which may require a letter of medical necessity from the ordering physician. This process can result in a delay in processing the claim, a lower reimbursement amount or denial of the claim. As a result, obtaining approvals from third-party payers to cover our tests and establishing adequate reimbursement levels is an unpredictable, challenging, time-consuming and costly process and we may never be successful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the generation, use, storage and disposal of hazardous materials. We work with materials, including chemicals, biological agents and compounds and samples that could be hazardous to human health and safety or the environment. Our operations also produce hazardous and biological waste products. Accordingly, we and our third-party manufacturers and suppliers are subject to federal, state, local and foreign environmental, health and safety laws and regulations, and permitting and licensing requirements, including those governing the generation, use, manufacture, storage, handling, transportation, release and disposal of, and exposure to, these materials, and worker health and safety.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot eliminate the risk of contamination or injury resulting from such hazardous materials. We also cannot guarantee that the procedures utilized by our third-party manufacturers for handling and disposing of hazardous materials and wastes comply with all applicable environmental, health and safety laws and regulations. As a result, we may be held liable for any resulting damages, costs or liabilities, including cleanup costs and liabilities, which could be significant, or our commercialization, research and development efforts and business operations may be restricted or interrupted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. Compliance with such laws and regulations is expensive, and current or future environmental, health and safety laws and regulations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">may restrict our operations. If we do not comply with applicable environmental health and safety laws and regulations, and permitting and licensing requirements, we may be subject to fines, penalties, a suspension of our business or other sanctions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our success may be impaired if we are unable to obtain, maintain and protect our intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success will depend in part on our ability to obtain and maintain patent and other intellectual property protection in the United States and other countries with respect to our diagnostic tests, products and services and technology. We rely on patent protection, as well as a combination of copyright, trade secret and trademark laws, to protect our proprietary technology and prevent others from duplicating our suite of diagnostic tests and products. However, these means may afford only limited protection and may not:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevent our competitors from duplicating our diagnostic tests and products, including our COVID-19 testing program and Nodify XL2, Nodify CDT, GeneStrat and VeriStrat tests;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">prevent our competitors from gaining access to our proprietary information and technology, including the Diagnostic Cortex platform, tech platforms such as the DeepMALDI analysis and intellectual property covering technologies that allow us to develop &#x201c;test algorithms&#x201d;; or</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allow us to gain or maintain a competitive advantage.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of our patents, including those we may license, may be challenged, invalidated, rendered unenforceable or circumvented. Consequently, we do not know whether any of our diagnostic tests, products and services will be protectable or remain protected by valid and enforceable patents. We may not prevail if our patents are challenged by competitors or other third parties. The United States federal courts or equivalent national courts or patent offices elsewhere may invalidate our patents, find them unenforceable, or narrow their scope. Furthermore, competitors may be able to design around our patents by developing similar or alternative technologies or products in a non-infringing manner, or obtain patent protection for more effective technologies, designs or methods, including for treating lung cancer. If these developments were to occur, our diagnostic tests and products may become less competitive and sales may decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have filed numerous patent applications seeking protection of diagnostic tests and other inventions originating from our research and development. Our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The scope of a patent may also be reinterpreted and significantly reduced after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us, or otherwise provide us with the protection or competitive advantages we are seeking.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain or maintain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent years. No consistent policy regarding the breadth of claims allowed in biotechnology and pharmaceutical patents has emerged to date in the United States or in many foreign jurisdictions. In addition, the determination of patent rights with respect to pharmaceutical compounds and technologies commonly involves complex legal and factual questions, which has in recent years been the subject of much litigation. Various courts, including the United States Supreme Court have rendered decisions that affect the scope of patentability of certain inventions or discoveries relating to biotechnology. These decisions state, among other things, that a patent claim that recites an abstract idea, natural phenomenon, or law of nature (for example, the relationship between particular genetic variants and cancer) are not themselves patentable. Precisely what constitutes a law of nature or abstract idea is uncertain, and it is possible that certain aspects of our technology could be considered unpatentable under applicable law. As a result, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Depending on decisions by the United States Congress, the federal courts and the United States Patent and Trademark Office (USPTO), the laws and regulations governing patents could change in unpredictable ways that would weaken our and our licensors&#x2019; ability to obtain new patents or to enforce our existing owned or in-licensed patents and patents that we might obtain or in-license in the future. Additionally, our pending and future patent applications may not result in patents being issued which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. The scope of patent protection outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other countries may diminish our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property rights or narrow the scope of our owned and licensed patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our technology, or if the scope of the patent protection obtained is not sufficient, our competitors could develop and commercialize diagnostic tests, products and services similar or superior to ours, and our competitive position may be adversely affected. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our copyrights may be limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patent protection for the patents underlying our diagnostic tests, products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. Trade secrets and know-how can be difficult to protect. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information. Additionally, despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology and the movement of personnel from academic to industry scientific positions. Consequently, we may be unable to prevent our proprietary technology from being exploited in the United States and abroad, which could affect our ability to expand in domestic and international markets or require costly efforts to protect our technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property rights owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions, which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that we or our employees have misappropriated the intellectual property rights of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors, and third parties may claim an ownership interest in intellectual property we regard as our own.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our employees and consultants were previously employed at or engaged by universities or other medical device, diagnostic, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and independent contractors do not use the intellectual property rights, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, used, infringed, misappropriated or otherwise violated the intellectual property rights or disclosed the alleged trade secrets or other proprietary information, of these former employers, competitors or other third parties, or to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">claims that we have improperly used or obtained such trade secrets. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Any litigation or the threat of litigation may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize potential diagnostic tests, products and services, which could harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property rights we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our diagnostic tests or products, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An inability to incorporate technologies or features that are important or essential to our diagnostic tests or products could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our rights to our COVID-19 testing program, either of the Nodify XL2 and Nodify CDT tests, or the VeriStrat and GeneStrat tests.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property rights. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future diagnostic tests, products and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. In 2011, the Leahy-Smith America Invents Act (Leahy-Smith Act) was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications are prosecuted and also may affect patent litigation. These also include provisions that switched the United States from a first-to-invent system to a first-inventor-to-file system, allow third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to attack the validity of a patent by the USPTO administered post grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">review and derivation proceedings. Under a first-inventor-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor was the first to invent the claimed invention. The USPTO recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, only became effective in 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the United States Supreme Court and the United States Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. Recent United States Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by United States and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these trademarks or trade names, which we need to build name recognition among potential partners and customers in our markets of interest. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">dilution claims brought by owners of other trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have not yet registered certain of our trademarks in all of our potential markets, although we have registered several connected to our diagnostic tests, products and services in the United States. If we apply to register these and trademarks in the United States and other countries, our applications may not be allowed for registration in a timely fashion or at all, and our registered trademarks may not be maintained or enforced. During trademark registration proceedings, we may receive rejections. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademark applications and registrations, and our trademarks may not survive such proceedings. If we do not secure registrations for our trademarks, we may encounter more difficulty in enforcing them against third parties than we otherwise would.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our efforts to enforce or protect our rights related to trademarks, trade secrets, domain names or other intellectual property rights may be ineffective, could result in substantial costs and diversion of resources and could adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or other intellectual property rights, which could be expensive, time consuming and unsuccessful.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors or other third parties may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or other intellectual property rights, or we may be required to defend against claims of infringement, misappropriation or other violations. In addition, our patents also may become involved in inventorship, priority or validity disputes. To counter or defend against such claims can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke those parties to assert counterclaims against us alleging that we infringe their patents or other intellectual property. In any such proceeding, a court or other administrative body may decide that a patent or other intellectual property right owned by us is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover such technology. Grounds for a validity challenge could include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, non-enablement or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include reexamination, post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions, including opposition proceedings. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our diagnostic tests, products and services or prevent third parties from competing with our diagnostic tests, products and services. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which the patent examiner and we or our licensing partners were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on our diagnostic tests, products and services. An adverse result in any litigation or other proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, some of our owned and in-licensed patents and patent applications are, and may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing diagnostic tests, products, services or technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if resolved in our favor, litigation or other proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The intellectual property landscape in the field of precision oncology is in flux, and it may remain uncertain for the coming years. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. As we move into new markets and applications for our diagnostic tests, products or services, incumbent participants in such markets may assert their patents and other intellectual property rights against us as a means of slowing our entry into such markets or as a means to extract substantial license and royalty payments from us. Our competitors and others may now and, in the future, have significantly larger and more mature patent portfolios than we currently have. In addition, future litigation may involve patent holding companies or other adverse patent owners who have no relevant product or service revenue and against whom our own patents may provide little or no deterrence or protection. Therefore, our commercial success depends in part on our non-infringement of the patents or other intellectual property rights of third parties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">However, we may in the future be subject to claims that we, or other parties we have agreed to indemnify, infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because patent applications are published sometime after filing, and because applications can take several years to issue, there may be additional currently pending third-party patent applications that are unknown to us, which may later result in issued patents. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We may not have sufficient resources to bring these actions to a successful conclusion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is a substantial amount of litigation and other patent challenges, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology industry, including patent infringement lawsuits, interferences, oppositions and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">review proceedings before the USPTO, and corresponding foreign patent offices. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, including our competitors, exist in the fields in which we are developing diagnostic tests and in which we may develop future diagnostic tests, products and services. As the precision oncology industry expands and more patents are issued, the risk increases that our diagnostic tests may be subject to claims of infringement of the patent rights of third parties. Numerous significant intellectual property issues have been litigated, are being litigated and will likely continue to be litigated, between existing and new participants in our existing and targeted markets, and competitors have and may assert that our diagnostic tests or services infringe their intellectual property rights as part of a business strategy to impede our successful entry into or growth in those markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could incur substantial costs and divert the attention of our management and technical personnel in defending against any of these claims. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the inevitable uncertainty in intellectual property litigation, we could lose a patent infringement or other action asserted against us regardless of our perception of the merits of the case. There is no assurance that a court would find in our favor on questions of infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold that these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize any product candidates we may develop and any other product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such United States patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such United States patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such United States patent.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell diagnostic tests, products or services, and could result in the award of substantial damages against us, including treble damages, attorney&#x2019;s fees, costs, and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties, which could be significant, and obtain one or more licenses from third parties, or be prohibited from selling certain diagnostic tests, products or services. We may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in diagnostic test introductions while we attempt to develop alternative diagnostic tests, products or services to avoid infringing third-party patents or intellectual property rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing diagnostic tests, products or services, and the prohibition of sale of any of our diagnostic tests, products or services could materially affect our business and our ability to gain market acceptance for our diagnostic tests, products and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our agreements with some of our customers, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, operating results or financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the priority or inventorship of our patents and other intellectual property rights.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#x2019; ownership of our owned or in-licensed patents, trade secrets or other intellectual property rights. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property rights that are important to our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or our licensors are unsuccessful in any interference proceeding or other priority or inventorship dispute, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture, and commercialization of one or more of our diagnostic tests, products or services. The loss of exclusivity or the narrowing of our owned and licensed patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations, or prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent protection depends on compliance with various required procedures, document submissions, fee payments and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States at several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-United States patent agencies. We are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property rights. The USPTO and various non-US governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors may be able to enter the market without infringing our patents and this circumstance would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Issued patents covering our diagnostic tests and any other or future diagnostic tests, products or services could be found invalid or unenforceable if challenged.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and some of our patents or patent applications, including licensed patents, may be challenged, in courts or patent offices in the United States and abroad, in opposition, derivation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">inter partes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">review, post-grant review or interference. Additionally, if we and our licensing partners initiate or become involved in legal proceedings against a third party to enforce a patent covering one of our diagnostic tests, products, services or technologies, the defendant could counterclaim that the patent covering our diagnostic tests, products or services is invalid or unenforceable. In patent litigation in the United States, counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution. In addition, the United States now awards patent priority to the first party to file a patent application, and others may submit patent claims covering our inventions prior to us. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unenforceability, we would lose at least part, and perhaps all, of the patent protection on our diagnostic tests or any diagnostic tests, products and services that we may develop.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A successful third-party challenge to our patents could result in the unenforceability or invalidity of such patents, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights, which could have a material adverse impact on our business. Furthermore, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future diagnostic tests, products or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be aware of all third-party intellectual property rights potentially relating to our current or future diagnostic tests, products or services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We, or our current or future license partners or collaborators, might not have been the first to make the inventions covered by each of our pending patent applications and we might not have been the first to file patent applications for these inventions. To determine the priority of these inventions, we may have to participate in interference proceedings, derivation proceedings or other post-grant proceedings declared by the USPTO. The outcome of such proceedings is uncertain, and other patent applications may have priority over our patent applications. Such proceedings could also result in substantial costs to us and divert our management&#x2019;s attention and resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on licenses from third parties in relation to certain diagnostic tests, products and services and if we lose these licenses then we may be subjected to future litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to license agreements that grant us rights to use certain intellectual property rights, including patents and patent applications, typically in certain specified fields of use, in connection with our diagnostic tests, products and services. Some of those licensed rights could provide us with freedom to operate for aspects of our diagnostic tests, products and services. We may need to obtain additional licenses from others to advance our research, development and commercialization activities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The in-licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to in-license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. In addition, we expect that competition for the in-licensing or acquisition of third-party intellectual property rights for product candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to in-license or acquire the third-party intellectual property rights for product candidates on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to suitable product candidates, our business, financial condition, results of operations and prospects for growth could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our existing license agreements impose, and we expect that our future license agreements will impose, various diligence, royalty payment, milestone payment, insurance and other obligations on us. If we fail to comply with these obligations or other obligations in our license agreements, our licensors may have the right to terminate these agreements, in which event we may not be able to develop and market any product or use any technology that is covered by these agreements. If our license agreements terminate, or we experience a reduction or elimination of licensed rights under these agreements, we may have to negotiate new or reinstated licenses with less favorable terms or we may not have sufficient intellectual property rights to operate our business. The occurrence of such events could materially harm our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property rights. Our licensors may not successfully prosecute the patent applications we license. Even if patents issue in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents or may pursue such litigation less aggressively than we would. Without protection for the intellectual property rights we license, other companies might be able to offer substantially identical diagnostic tests for sale, which could adversely affect our competitive business position and harm our business prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, disputes may also arise between us and our current or future licensors regarding intellectual property rights subject to a license agreement, including those relating to:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether, and the extent to which, our diagnostic tests, products, services, technology, and processes infringe on intellectual property rights of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether our licensor or its licensor had the right to grant the license agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether third parties are entitled to compensation or equitable relief, such as an injunction, for our use of the intellectual property rights without their authorization;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our involvement in the prosecution of licensed patents and our licensors&#x2019; overall patent enforcement strategy;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amounts of royalties, milestones, or other payments due under the license agreement;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property rights by our licensors and us and our collaborators; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the priority of invention of patented technology.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we do not prevail in such disputes, we may lose any or all of our rights under such license agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the agreements under which we currently license intellectual property rights or technology from third parties are complex and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property rights or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property rights that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, or are insufficient to provide us the necessary rights to use the intellectual property rights, we may be unable to successfully develop and commercialize any affected diagnostic tests, products or services, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Absent the license agreements, we may infringe patents subject to those agreements, and if the license agreements are terminated, we may be subject to litigation by the licensor. Litigation could result in substantial costs to us and distract our management. If we do not prevail, we may be required to pay damages, including treble damages, attorneys&#x2019; fees, costs and expenses and royalties or be enjoined from selling our diagnostic tests, products or services, which could adversely affect our ability to offer diagnostic tests, products or services, our ability to continue operations and our financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Some intellectual property that we in-license may have been developed through government funded programs and thus may be subject to federal regulations such as &#x201c;march-in&#x201d; rights, certain reporting requirements and a preference for companies based in the United States. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with manufacturers that are not based in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of the intellectual property that we license may have been developed through the use of United States government funding and therefore may be subject to certain federal regulations. As a result, the United States government may have certain rights to intellectual property embodied in our diagnostic tests, products and services pursuant to the Bayh-Dole Act of 1980 (Bayh-Dole Act). These United States government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the United States government has the right to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#x201c;march-in rights&#x201d;). To date, none of our commercialized products are subject to march-in rights. The United States government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the United States government requires that any products of the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for United States manufacturers may limit our ability to contract</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with product manufacturers outside of the United States for products covered by such intellectual property. To the extent any of our current or future owned or licensed intellectual property is generated through the use of United States government funding, the provisions of the Bayh-Dole Act may similarly apply. Any failure by us to comply with federal regulations regarding intellectual property rights that were developed through the use of United States government funding could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our diagnostic tests, products and services for an adequate amount of time.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if patents covering our diagnostic tests, products and services are obtained, once the patent life has expired, we may be open to competition from competitive diagnostic tests, products and services. Given the amount of time required for the development, testing and regulatory review of potential new diagnostic tests, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing diagnostic tests, products or services similar or identical to ours.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third parties may attempt to commercialize competitive diagnostic tests, products or services in foreign countries where we do not have any patents or patent applications and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending patents on our diagnostic tests, products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing diagnostic tests or products made using our inventions in and into the United States or other jurisdictions. Competitors may use our diagnostic tests, products, services and technologies in jurisdictions where we have not obtained patent protection to develop their own diagnostic tests and, further, may export otherwise infringing diagnostic tests or products to territories where we have patent protection but enforcement is not as strong as that in the United States. These diagnostic tests and products may compete with our diagnostic tests, products or services and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing diagnostic tests, products and services in violation of our intellectual property rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries, including India, China, and certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our current or future licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intellectual property rights do not necessarily address all potential threats.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may be able to make diagnostic tests or products that are similar to our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests or the COVID-19 tests that we use in our COVID-19 testing program or utilize similar technology that is not covered by the claims of our patents or that incorporates certain technology in our Nodify XL2, Nodify CDT, GeneStrat or VeriStrat tests or such COVID-19 tests that is in the public domain;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our current or future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own or license now or may own or license in the future;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we, or our current or future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">it is possible that our current or future pending patent applications will not lead to issued patents;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive diagnostic tests, products and services for sale in our major commercial markets;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not develop additional proprietary technologies that are patentable;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patents of others may harm our business; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property rights.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect that the price of our common stock will fluctuate substantially and you may not be able to sell your shares at or above the price you paid for them.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock is likely to be highly volatile and may fluctuate substantially due to many factors, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">volume and customer mix for our COVID-19, Nodify XL2, Nodify CDT, GeneStrat and VeriStrat testing;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the introduction of new diagnostic tests or enhancements to such tests by us or others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes or other developments with respect to our or others&#x2019; intellectual property rights;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to develop, obtain regulatory clearance or approval or certification for, and market new and enhanced diagnostic tests on a timely basis;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product liability claims or other litigation;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">quarterly variations in our results of operations or those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">media exposure of our diagnostic tests or of those of others in our industry;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in governmental regulations or in the status of our regulatory approvals or applications;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in earnings estimates or recommendations by securities analysts; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general market conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In recent years, the stock markets generally have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may significantly affect the market price of our common stock, regardless of our actual operating performance, and you may not realize any return on your investment in us and may lose some or all of your investment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in the past, class action litigation has often been instituted against companies whose securities have experienced periods of volatility in market price. Securities litigation brought against us following volatility in our stock price, regardless of the merit or ultimate results of such litigation, could result in substantial costs, which would hurt our financial condition and operating results and divert management&#x2019;s attention and resources from our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Securities analysts may not publish favorable research or reports about our business or may publish no information at all, which could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a trading market for our common stock develops, the trading market will be influenced to some extent by the research and reports that industry or financial analysts publish about us and our business. We do not control these analysts. As a newly public company, we may be slow to attract research coverage and the analysts who publish information about our common stock will have had relatively little</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience with us, which could affect their ability to accurately forecast our results and could make it more likely that we fail to meet their estimates. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us provide inaccurate or unfavorable research or issue an adverse opinion regarding our stock price, our stock price could decline. If one or more of these analysts cease coverage of us or fail to publish reports covering us regularly, we could lose visibility in the market, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Shares of our common stock may be at risk for delisting from the Nasdaq Global Select Market in the future and delisting may adversely affect the value of your investment in the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares of our common stock may be at risk of delisting from the Nasdaq Global Select Market if the bid price per share of our common stock does not remain above the applicable listing standards in the future. Moreover, there is no assurance that we will be able to take action to meet these listing standards if such bid price falls below the minimum required price. If our common stock were to be delisted, the liquidity of our common stock would be adversely affected and the market price of our common stock could decrease further. Our failure to be listed on NASDAQ or another established securities trading market or quotation system could have a material adverse effect on the value of your investment in the Company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an &#x201c;emerging growth company&#x201d; and a &#x201c;smaller reporting company,&#x201d; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company,&#x201d; as defined in the JOBS Act. We may take advantage of certain exemptions and relief from various public reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley Act). We will be exempt from any rules that could be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotations or a supplement to the auditor&#x2019;s report on financial statements; we will be subject to reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and we will not be required to hold nonbinding advisory votes on executive compensation or stockholder approval of any golden parachute payments not previously approved.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an &#x201c;emerging growth company&#x201d; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an &#x201c;emerging growth company&#x201d; until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) the last day of the fiscal year ending after the fifth anniversary of the completion of our IPO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a &#x201c;smaller reporting company&#x201d; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (2) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by nonaffiliates exceeds $700 million as of the end of that year&#x2019;s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements with other public companies difficult or impossible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investors may find our common stock less attractive to the extent we rely on the exemptions and relief granted by the JOBS Act. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may decline or become more volatile.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our estimates or judgments relating to our critical accounting policies are based on assumptions that change or prove to be incorrect, our operating results could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets, liabilities, equity, revenue and expenses that are not readily apparent from other sources. It is possible that interpretation, industry practice and guidance may evolve over time. If our assumptions change or if actual circumstances differ</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from our assumptions, our operating results may be adversely affected and could fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our directors, officers and principal stockholders have significant voting power and may take actions that may not be in the best interests of our other stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our officers, directors and principal stockholders each holding more than 5% of our common stock collectively control approximately 66.3% of our outstanding common stock as of December 31, 2021. As a result, these stockholders, if they act together, will be able to control the management and affairs of our company and most matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change of control and might adversely affect the market price of our common stock. This concentration of ownership may not be in the best interests of our other stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to incur significant additional costs as a result of being a public company, which may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of our IPO completed in October 2020, we expect to incur costs associated with corporate governance requirements that are applicable to us as a public company, including rules and regulations of the SEC, under the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and the Securities Exchange Act of 1934, as amended (the Exchange Act), as well as the rules of Nasdaq. These rules and regulations are expected to significantly increase our accounting, legal and financial compliance costs and make some activities more time-consuming. We also expect these rules and regulations to make it more expensive for us to maintain directors&#x2019; and officers&#x2019; liability insurance. As a result, it may be more difficult for us to attract and retain qualified persons to serve on our Board of Directors or as executive officers. Accordingly, increases in costs incurred as a result of becoming a publicly traded company may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of becoming a public company, we are required, under Section 404 of the Sarbanes-Oxley Act to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting beginning with our Annual Report on Form 10-K for the year ended December 31, 2021. This assessment includes disclosure of any material weaknesses identified by our management in our internal control over financial reporting. A material weakness is a deficiency or combination of deficiencies in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company&#x2019;s annual and interim financial statements will not be detected or prevented on a timely basis.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are effective. The effectiveness of our controls and procedures may be limited by a variety of factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">faulty human judgment and simple errors, omissions, or mistakes;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fraudulent action of an individual or collusion of two or more people;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inappropriate management override of procedures; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the possibility that any enhancements to controls and procedures may still not be adequate to assure timely and accurate financial control.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When we cease to be an &#x201c;emerging growth company&#x201d; under the federal securities laws, our auditors will be required to express an opinion on the effectiveness of our internal controls. If we are unable to confirm that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence in the accuracy and completeness of our financial reports, which could cause the price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the periodic reporting requirements of the Exchange Act. We have designed our disclosure controls and procedures to provide reasonable assurance that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. Notwithstanding the foregoing, the exclusive forum provision will not apply to any claim to enforce any liability or duty created by the Exchange Act or the Securities Act and for which the federal courts have exclusive jurisdiction. We believe this exclusive forum provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated articles of incorporation provide that we will indemnify our directors and officers to the fullest extent permitted by Section 145 of the Delaware General Corporate Law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, as permitted by the Delaware General Corporate Law, our amended and restated articles of incorporation and our indemnification agreements that we have entered into with our directors and officers provide that:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by applicable law. Such law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#x2019;s conduct was unlawful;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification;</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rights conferred in our amended and restated articles of incorporation are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not retroactively amend our amended and restated articles of incorporation provisions to reduce our indemnification obligations to directors, officers, employees and agents.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="n1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1B. Unresolved S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">taff Comments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">perties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our headquarters is located in Boulder, Colorado, where we lease office and laboratory space, under an operating lease agreement that expires in January 2023, which has recently been amended to extend to January 2024. We also lease office and laboratory space located in De Soto, Kansas, under an operating lease agreement that expires in October 2023. A portion of our employees are located outside of Colorado and Kansas, and others work from home. We believe our existing facilities meet our current needs. We will need additional office space in the future as we continue to build and expand our development, commercial and support teams. We believe we can find suitable additional space in the future on commercially reasonable terms.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.367%;"></td>
    <td style="width:1.744%;"></td>
    <td style="width:31.349%;"></td>
    <td style="width:1.744%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:14.023%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.744%;"></td>
    <td style="width:16.027%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Location</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Square Feet</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expiration</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boulder, Colorado</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office and laboratory</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,722</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 14, 2024</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">De Soto, Kansas</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Office and laboratory</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,066</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2023</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. In September 2021, we reached a settlement agreement with the plaintiffs, which received preliminary approval from the Circuit Court of the City of St. Louis, State of Missouri (the Court) on November 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, regarding a dispute involving the Telephone Consumer Protection Act (TCPA). On January 31, 2022, the Court approved the final settlement payment to third parties of approximately $210,000 which was accrued as a legal contingency during the year ended December 31, 2021. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not presently a party to any other legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">holder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Market Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock is traded on The NASDAQ Global Market under the symbol &#34;BDSX.&#34; The high and low closing prices for our common stock on The NASDAQ Global Market from January 1, 2021 to December 31, 2021 were $31.21 and $4.09, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Holders of our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 9, 2022, there were approximately 204 holders of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Dividend Policy</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid dividends on our common stock and do not expect to pay dividends on our common stock for the foreseeable future. We anticipate that all of our liquidity in the foreseeable future will be used for the operation and growth of our business. Any future determination to declare dividends will be subject to the discretion of our Board of Directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, and any other factors deemed relevant by our Board of Directors. In addition, the terms of our term loan restrict our ability to pay dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will further restrict our ability to declare or pay dividends on our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Use of Proceeds</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 30, 2021, the Company raised approximately $16.3 million in gross proceeds from the sale of 3,756,994 common shares in an at-the-market offering. The Company received net proceeds of $15.7 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. The net proceeds received were used to, among other things, fund the partial repayment of the 2021 Term Loan (see &#x2013; Part II - Item 8, Financial Statements and Supplementary Data).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We registered these shares under the Securities Act on a Registration Statement on Form S-3 (Registration No.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">333-261095), which was filed on November 24, 2021 and declared effective on November 29, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no sales of unregistered securities for the year ended December 31, 2021. From January 1, 2020 through December 31, 2020, we granted stock options under our 2016 and 2006 Stock Plans to purchase 0.8 million shares of our common stock at exercise prices ranging from $0.77 to $6.83 per share, and issued an aggregate of 0.4 million shares of common stock pursuant to the exercise of stock options with aggregate proceeds of approximately $1.3 million. These issuances were undertaken in reliance upon an exemption from registration under Rule 701 of the Securities Act of 1933.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reserved]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The following discussion of our financial condition and results of operations should be read together with our audited financial statements and related notes and other financial information included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, based upon current expectations that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#x201c;Risk Factors&#x201d; under Part II, Item 1A below. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ from those anticipated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and we undertake no obligation to update or revise these statements in light of future developments. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A), is provided to supplement the audited financial statements and the related notes in Part II - Item 8 of this Annual Report on Form10-K. We intend for this discussion to provide you with information that will assist you in understanding our financial statements, the changes in key items in those financial statements from year to year and the primary factors that accounted for those changes. Data for the years ended December 31, 2021 and 2020 has been derived from our audited financial statements included in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology multi-omic approach with a holistic view of the patient&#x2019;s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient&#x2019;s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe helps improve overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI-based Diagnostic Cortex&#174; platform to discover innovative diagnostic tests for clinical use. The Diagnostic Cortex is an extensively validated deep learning platform optimized for the discovery of diagnostic tests, which we believe overcomes standard machine learning challenges faced in life sciences research. Our data-driven and multi-omic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We continuously incorporate new market insights and patient data to enhance our platform through a data-driven learning loop. We regularly engage with our customers, key opinion leaders, and scientific experts to stay ahead of the rapidly evolving diagnostic treatment landscape to identify additional clinical unmet needs where a diagnostic test could help improve patient care. Additionally, we incorporate clinical and molecular profiling data from our commercial clinical testing, research studies, clinical trials, and biopharmaceutical customers or academic partnerships, to continue to advance our platform. We have over 150,000 samples and data in our biobank, including tumor profiles and immune profiles, which are used for both internal and external research and development initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have commercialized eight diagnostic tests which are currently available for use by physicians. Our Nodify XL2 and Nodify CDT tests, marketed as part of the Nodify Lung Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer two commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules. Our GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests, marketed as the IQLung testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat targeted tumor profiling test and the VeriStrat immune profiling test now have a less than 36-hour average turnaround time, down from the previous 72-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions. In response to the COVID-19 pandemic, through our partnership with Bio-Rad, we commercialized the Biodesix WorkSafe&#153; testing program. Our scientific diagnostic expertise, technologies, and existing commercial infrastructure enabled us to rapidly commercialize two FDA EUA authorized tests, a part of our customizable program. Both diagnostic tests are owned and were developed by Bio-Rad and Bio-Rad has granted us permission to utilize both tests for commercial diagnostic services. Then U.S. Health and Human Services Secretary Azar</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">declared a public health emergency for COVID-19 in February 2020 which justified the authorization of emergency use of diagnostic tests for the detection and/or diagnosis of COVID-19. The Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 Total Ab test have been granted FDA EUA pursuant to the current emergency declaration. The Bio-Rad SARS-CoV-2 ddPCR test was FDA EUA authorized on May 1, 2020, authorizing performance of the test in laboratories certified under CLIA to perform high complexity tests. The second test is the Platelia SARS-CoV-2 Total Ab test, which is an antibody test intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection. The Platelia SARS-CoV-2 Total Ab test was FDA EUA authorized on April 29, 2020. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety, and we cannot predict how long the EUAs for the SARS-CoV-2 tests will remain in place. In addition to the seven tests currently available to physicians, the Company launched the GeneStrat NGS&#153; (NGS) test, our 72-hour blood-based NGS test, in November 2021 to a select group of physicians, with broad US launch in the first quarter 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to using the Bio-Rad SARS-CoV-2 tests as part of our testing program, we performed feasibility, verification, and validation studies, including developing software for process automation, sample accessioning, data management and reporting, all required to demonstrate the test operated as claimed by the manufacturer and as required by our certifying regulatory agencies for high complexity laboratory testing. We secured independent reference specimens run with EUA tests to validate these tests as fit for diagnostic use in our laboratories. Post-launch development support for these tests have included improvements in on-boarding new personnel, logistics of sample collection, sample receipt and data reporting, all required to support our testing program. Additional releases of the laboratory data management software are ongoing and planned for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning in the quarter ended June 30, 2021, we began partnering with GenScript Biotech Corporation to commercialize </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the blood-based cPass SARS-CoV-2 Neutralizing Antibody testing as a service. The test is the first surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the RBD in the spike protein of SARS-CoV-2 that are produced in response to vaccination or previous SARS-CoV-2 infection.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies. We have announced multiple partnerships for COVID-19 testing, and maintain an agreement with the State of Colorado to be one of the diagnostic companies to support widespread COVID-19 testing for the State. Additionally, we have overseen and managed onsite testing and validating testing for the Big Ten Conference athletic competitions through the term of our contract which expired on June 30, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the eight diagnostic tests currently on the market, we perform over 30 assays for research use as part of our laboratory services that have been used by over 50 biopharmaceutical companies and academic partners. All of our diagnostic testing is performed at one of our two accredited, high-complexity clinical laboratories in Boulder, Colorado and De Soto, Kansas.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our inception, we have performed over 500,000 tests and continue to generate a large and growing body of clinical evidence consisting of over 300 clinical and scientific peer-reviewed publications, presentations, and abstracts. Through ongoing study of each of our tests, we continue to grow our depth of understanding of disease biology and the broad utility of each of our tests. We believe we are poised for rapid growth by leveraging our scientific development and laboratory operations expertise along with our commercial infrastructure which includes sales, marketing, reimbursement, and regulatory affairs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, we market our tests to clinical customers through our targeted sales organization, which includes sales representatives that are engaged in sales efforts and promotional activities primarily to pulmonologists, oncologists, cancer centers and nodule clinics. We market our tests and services to biopharmaceutical companies globally through our targeted business development team, which promotes the broad utility of our tests and testing capabilities throughout drug development and commercialization which is of value to pharmaceutical companies and their drug-development process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have funded our operations to date principally from net proceeds from the sales of our common stock through both an IPO and issuances from our Form S-3 shelf, the sale of convertible preferred stock, revenue from diagnostic testing and services, and the incurrence of indebtedness. We had cash and cash equivalents of $32.7 million and $62.1 million as of December 31, 2021 and 2020, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Factors Affecting Our Performance</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe there are several important factors that have impacted our operating performance and results of operations, including:</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Testing volume and customer mix. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our revenues and costs are affected by the volume of testing and mix of customers from period to period. We evaluate both the volume of our commercial tests, or the number of tests that we perform for patients on behalf of clinicians, as well as tests for biopharmaceutical companies. Our performance depends on our ability to retain and broaden adoption with existing customers, as well as attract new customers. We believe that the test volume we receive from clinicians and biopharmaceutical companies are indicators of growth in each of these customer verticals. Customer mix for our tests has the potential to significantly impact our results of operations, as the average selling price for biopharmaceutical </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sample testing is currently significantly greater than our average selling price for clinical tests since we are not a contracted provider for, or our tests are not covered by all clinical patients&#x2019; insurance. We evaluate our average selling price for tests that are covered by Medicare, Medicare Advantage and commercial payers to understand the trends in reimbursement and apply those trends to our revenue recognition policies.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Reimbursement for clinical diagnostic testing. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our revenue depends on achieving broad coverage and reimbursement for our tests from third-party payers, including both commercial and government payers. Payment from third-party payers differs depending on whether we have entered into a contract with the payers as a &#x201c;participating provider&#x201d; or do not have a contract and are considered a &#x201c;non-participating provider.&#x201d; Payers will often reimburse non-participating providers, if at all, at a lower rate than participating providers.</span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Historically, we have experienced situations where commercial payers proactively reduced the amounts they were willing to reimburse for our tests, and in other situations, commercial payers have determined that the amounts they previously paid were too high and have sought to recover those perceived excess payments by deducting such amounts from payments otherwise being made. When we contract to serve as a participating provider, reimbursements are made pursuant to a negotiated fee schedule and are limited to only covered indications. Becoming a participating provider generally results in higher reimbursement for covered indications and lack of reimbursement for non-covered indications. As a result, the impact of becoming a participating provider with a specific payer will vary. If we are not able to obtain or maintain coverage and adequate reimbursement from third-party payers, we may not be able to effectively increase our testing volume and revenue as expected. Additionally, retrospective reimbursement adjustments can negatively impact our revenue and cause our financial results to fluctuate.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Investment in clinical studies and product innovation to support growth. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A significant aspect of our business is our investment in research and development, including the development of new products and our investments in clinical utility studies. We have invested heavily in clinical studies for our on market and pipeline products. Our studies focus primarily on the clinical utility of our tests including the ongoing INSIGHT study which seeks to enroll up to 5,000 patients to continue our clinical understanding of the predictive and prognostic value of the VeriStrat test. The ALTITUDE study, launched during the fourth quarter 2020, seeks to further demonstrate the efficacy of the Nodify XL2 and Nodify CDT tests. A secondary focus of our studies is understanding the economic impact of our tests in assisting with decisions related to patient management and the potential impact of our tests in reducing overall healthcare costs.</span></div></div>
  <p style="margin-left:7.867%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical research has resulted in approximately 90 peer-reviewed publications for our tests. In addition to clinical studies, we are collaborating with investigators from multiple academic cancer centers. We believe these studies are critical to gaining physician adoption and driving favorable coverage decisions by payers and expect our investments in research and development to increase. Further we also expect to increase our research and development expenses to fund further innovation and develop new clinically relevant tests.</span></p>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ability to attract new biopharmaceutical customers and maintain and expand relationships with existing customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our business development team promotes the broad utility of our products for biopharmaceutical companies in the United States and internationally. Our revenue, business opportunities and growth depend in part on our ability to attract new biopharmaceutical customers and to maintain and expand relationships with existing biopharmaceutical customers. We expect to increase our sales and marketing expenses in furtherance of this as we continue to develop these relationships, we expect to support a growing number of investigations and clinical trials. If our relationships expand, we believe we may have opportunities to offer our platform for companion diagnostic development, novel target discovery and validation efforts, and to grow into other commercial opportunities. For example, we believe our multi-omic data including genomic and proteomic data, in combination with clinical outcomes or claims data, has revenue-generating potential, including for novel target identification and companion diagnostic discovery and development.</span></div></div>
  <div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Motivating and expanding our field sales force and customer support team</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Our field sales force is the primary point of contact in the clinical setting. These representatives of the company must cover expansive geographic regions which limits their time for interaction and education of our products in the clinical setting. We plan to invest heavily in the field sales force to increase the total number of sales representatives and thereby reduce the geographic footprint each representative must cover. This investment will allow the larger sales force to maximize their education and selling efforts and achieve greater returns. Additionally, we plan to invest in the Boulder-based marketing and customer support teams to continue to provide the field team with the resources to be successful in the field.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While each of these areas present significant opportunities for us, they also pose significant risks and challenges that we must address. See Part II, Item 1A. &#x201c;Risk Factors&#x201d; for more information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Pandemic</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic has disrupted, and we expect will continue to disrupt, our lung diagnostic testing operations. To protect the health and well-being of our workforce, partners, vendors and customers, we provide voluntary COVID-19 testing for employees</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">working on-site, implemented social distance and building entry policies at work, restricted travel and facility visits, and followed the States of Colorado and Kansas&#x2019; public health orders and the guidance from the CDC. Employees who can perform their duties remotely are asked to work from home and those on site are asked to follow our social distance guidelines. Our sales, marketing and business development efforts have also been constrained by our operational response to the COVID-19 pandemic. We expect to continue to adjust our operational norms to help slow the spread of COVID-19 in the coming months, including complying with government directives and guidelines as they are modified and supplemented.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 9, 2021, President Biden signed two new Executive Orders that would require vaccinations for all federal workers and contractors. In addition, it was also announced that the Department of Labor&#x2019;s Occupational Safety and Health Administration (OSHA) and the CMS would each be releasing emergency rules that would respectively require (i) employers with 100 or more employees and (ii) workers in health care setting that receive Medicare and Medicaid reimbursement to implement vaccination and testing protocols. In January 2022, the United States Supreme Court blocked the Biden administration from enforcing its sweeping vaccine-or-test requirements for large private companies, but allowed a vaccine mandate to stand for medical facilities that take Medicare or Medicaid payments. We are currently a party to several federal contracts and in order to remain compliant with President Biden&#x2019;s Executive Orders, all Biodesix teammates were required to have received an effective dose of the COVID-19 vaccine no later than January 4, 2022. Exemptions were requested for qualifying medical reasons or sincerely held religious belief, subject to review and approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and the surge associated with the Delta and Omicron variants have negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies. For example, cancer patients may have more limited access to hospitals, healthcare providers and medical resources as they take steps to control the spread of COVID-19. Our biopharmaceutical customers are facing challenges in recruiting patients and in conducting clinical trials to advance their pipelines, for which our tests could be utilized. As a result of the COVID-19 pandemic, beginning in the latter half of March 2020, we saw a decline in business with existing and new biopharmaceutical customers. We began to see recovery during the fourth quarter 2020 as our delivered tests exceeded first quarter 2020 delivered tests and we expect to continue to see the recovery extending into 2022; however, the rate of growth experienced since we began to see recovery is below our expectations and has been impacted by ongoing surges, such as the surge in the Delta and Omicron variants, which have negatively impacted patients willingness or ability to gain access to healthcare providers and medical resources. Further, our clinical studies, such as our ongoing INSIGHT and ALTITUDE studies, as well as our arrangements including contracted clinical studies with our biopharmaceutical customers, are expected to take longer to complete than what we expected before the outbreak of the COVID-19 pandemic. Our biopharmaceutical services revenue grew by approximately 20% during 2021 as compared to 2020; however, we are continuing to experience delays in clinical trials from across the country and world due to COVID-19 restrictions. We expect further improvement in our biopharmaceutical activities during 2022 as compared to 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversely, we experienced a significant increase in revenues related to an increase in the demand for our Biodesix WorkSafe testing program, our COVID-19 testing program, since the onset of the pandemic. COVID-19 diagnostic services contributed approximately $30.2 million and $28.3 million during fiscal years 2021 and 2020, respectively. The first quarter 2021 was our high-water mark for COVID-19 testing revenue. We experienced a steady decline in subsequent quarters as immunizations in the U.S. accelerated. We do not anticipate the need for COVID testing to be commensurate with the peak demand experienced during the first quarter 2021 and instead expect the demand to moderate as new variants and infection occur. The reduction in demand for COVID-19 diagnostic testing will be a key indicator of continued recovery and is taken as a positive sign for both our Lung Diagnostic and Biopharmaceutical Services as we head into 2022. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">here is no assurance that our COVID-19 testing program will continue to be accepted by the market or that other diagnostic tests will become more accepted, produce quicker results or are more accurate. Further, the longevity and extent of the COVID-19 pandemic is uncertain. If the pandemic were to dissipate, whether due to a significant decrease in new infections, due to acquiring herd immunity based on previous natural infection, and the availability and rapid distribution of vaccines, the evolution of variant strains that impact diagnostic test performance, or otherwise, the need for COVID-19 testing could decrease significantly and this could have an adverse effect on our results of operations and profitability. As a result, the increase in revenue due to any increase in demand for these diagnostic tests may not be indicative of our future revenue. See Part II., Item 1A. &#x201c;Risk Factors&#x201d; for a description of how the COVID-19 pandemic may adversely affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fourth Quarter and Full Year 2021 Financial and Operational Highlights</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generated record revenue in fiscal year 2021 of $54.5 million, representing an increase of 20% as compared to fiscal year 2020. The following were significant developments affecting our business, capital structure and liquidity during the year ended December 31, 2021 as compared to the same period in 2020 unless otherwise noted:</span></p>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue of $7.2 million and $54.5 million for the fourth quarter and fiscal year 2021, respectively, with continued lung diagnostic year over year growth despite COVID-19 variant surges;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Core lung diagnostic revenue of $5.4 million and $18.7 million for the fourth quarter and fiscal year 2021, respectively, an increase of 48% and 49%. Nodify nodule management tests and sales force expansion continue to drive lung diagnostic growth;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biopharmaceutical Services revenue of $1.4 million and $5.6 million for the fourth quarter and fiscal year 2021, respectively, a decrease of 29% and increase 20%;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">COVID-19 testing revenue of $0.4 million and $30.2 million for the fourth quarter and fiscal year 2021, respectively, a decrease of 98% and increase 7%. The decline over the fourth quarter of 2020 is commensurate with the shift away from lab-based testing and towards point-of-care and at-home rapid antigen testing during much of the back half of 2021;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fourth quarter 2021 gross margin of $4.7 million or 65% as a percentage of revenue as compared to 46% primarily driven by the mix shift of sales to higher-margin core lung diagnostics and away from lower-margin COVID-19 testing;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses (excluding direct costs and expenses) of $16.4 million and $64.9 million for the fourth quarter and fiscal year 2021, an increase of 9% and 40% as the Company doubled the size of the lung focused direct and dedicated sales force in 2021;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss of $13.3 million and $43.2 million for the fourth quarter and fiscal year 2021, respectively, an increase of 193% and 38%;</span></div></div>
  <div style="margin-left:2.398%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.065%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.140304501956927%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents of $32.7 million, inclusive of a fourth quarter 2021 equity capital issuance of $15.7 million in net proceeds and the partial prepayment of $20 million of the 2021 Term Loan.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Operating Results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnostic Tests</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenue is generated from delivery of results from our diagnostic tests. In the United States, we performed tests as both an in-network and out-of-network service provider depending on the test performed and the contracted status of the insurer. We provide diagnostic tests in two primary categories: (i) core lung diagnostics testing and (ii) COVID-19 testing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consider diagnostic testing to be completed upon the delivery of test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed, which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering the nature of the payer, the historical amount of time until payment by a payer and historical price concessions granted to groups of customers.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Services</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue is generated from the delivery of our on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer. At times we collaborate with large biopharmaceutical companies in an attempt to discover biomarkers that would be helpful in their drug development or marketing. The performance obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue derived from services is often unpredictable and can cause dramatic swings in our overall net revenue line from quarter to quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Direct costs and expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of diagnostic testing generally consists of cost of materials, direct labor, including bonus, employee benefits, equipment and infrastructure expenses associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties. Costs associated with performing our tests are recorded as the tests are processed regardless of whether revenue was recognized with respect to the tests. Infrastructure expenses include depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs. Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. While we do not believe the technologies underlying these licenses are necessary to permit us to provide our tests, we do believe these technologies are potentially valuable and of possible strategic importance to us or our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">competitors. Under these license agreements, we are obligated to pay aggregate royalties ranging from 1% to 8% of sales in which the patents or know-how are used in the product or service sold, sometimes subject to minimum annual royalties or fees in certain agreements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the aggregate cost of diagnostic testing to increase in line with the increase in the number of tests we perform, but the cost per test to decrease modestly over time due to the efficiencies we may gain as test volume increases, and from automation and other cost reductions. Cost of services includes costs incurred for the performance of development services requested by our customers. Costs of development services will vary depending on the nature, timing and scope of customer projects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist of costs incurred to develop technology and include salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs, contract services, clinical studies, other outside costs and costs to develop our technology capabilities. Research and development expenses account for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with the discovery and development of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External expenses include: (i) payments to third parties in connection with the clinical development of our product candidates, including contract research organizations and consultants; (ii) the cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to contract manufacturing organizations (CMOs) and consultants; (iii) scientific development services, consulting research fees and for sponsored research arrangements with third parties; (iv) laboratory supplies; and (v) allocated facilities, depreciation and other expenses, which include direct or allocated expenses for IT, rent and maintenance of facilities. External expenses are recognized based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers or our estimate of the level of service that has been performed at each reporting date. We track external costs by the stage of program, clinical or preclinical.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Internal expenses include employee-related costs, including salaries and related benefits for employees engaged in research and development functions. We do not track internal costs by product candidate because these costs are deployed across multiple programs and, as such, are not separately classified.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development costs are expensed as incurred. Payments made prior to the receipt of goods or services to be used in research and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Costs to develop our technology capabilities are recorded as research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase as we continue to innovate and develop additional products and expand our data management resources. As our services revenue grows, an increasing portion of research and development dollars are expected to be allocated to cost of goods for biopharmaceutical service contracts. This expense, though expected to increase in dollars, is expected to decrease as a percentage of revenue in the long term, though it may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales, marketing, general and administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our sales and marketing expenses are expensed as incurred and include costs associated with our sales organization, including our direct sales force and sales management, client services, marketing and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, and travel, as well as marketing and educational activities and allocated overhead expenses. We expect our sales and marketing expenses to increase in dollars as we expand our sales force, increase our presence within the United States, and increase our marketing activities to drive further awareness and adoption of our tests and our future products. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage of our revenues from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our general and administrative expenses include costs for our executive, accounting, finance, legal and human resources functions. These expenses consist principally of salaries, bonuses, employee benefits, and travel, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses. We expect that our general and administrative expenses will continue to increase in dollars, primarily due to increased headcount and costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and requirements of the SEC, director and officer insurance premiums and investor relations. These expenses, though expected to increase in dollars, are expected to decrease as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Contingent Consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the purchase transaction of Indi, we recorded contingent consideration pertaining to the amounts potentially payable to Indi shareholder pursuant to the terms of the asset purchase agreement. The fair value of contingent consideration was assessed at each balance sheet date and changes, if any, to the fair value are recognized as operating expenses within the statement of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company met the gross margin target of $2.0 million for three consecutive months during the three months ended June 30, 2021. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. The significant unobservable inputs used in the measurement of fair value included the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from 11% to 13.5%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense and Interest Income</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense consists of cash and non-cash interest from our 2021 Term Loan, the 2018 Notes, Paycheck Protection Program loan, convertible debt and changes in the value of our contingent consideration associated with the passage of time subsequent to the achievement of the contingency in the second quarter 2021. Our convertible debt, along with the related accrued interest, was automatically converted to 1,848,280 shares of our common stock upon completion of our IPO in October 2020. Interest income, which is included in &#x2018;Other income, net&#x2019; in the statements of operations consists of income earned on our cash and cash equivalents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the significant components of our results of operations for the periods presented (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.694%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.352%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.352%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.352%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:8.091%;"></td>
    <td style="width:2.793%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,506</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,557</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,949</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,518</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,998</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,520</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,789</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,818</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,971</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,517</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,857</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,660</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,622</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">818</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">804</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95,446</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,491</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,955</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(40,940</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,934</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(18,006</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(79</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(4,508</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7,604</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(3,096</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,252</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,252</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(100</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on debt extinguishments, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,298</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,298</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">440</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">449</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,219</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,416</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,197</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(74</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(43,159</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(31,350</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(11,809</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(38</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We generate revenue from our diagnostic tests and services that we provide. Our revenues for the periods indicated were as follows (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.954%;"></td>
    <td style="width:1.215%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:9.564%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:1.215%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:9.564%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:1.215%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:9.369%;"></td>
    <td style="width:0.696%;"></td>
    <td style="width:1.215%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:8.117%;"></td>
    <td style="width:2.477%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic revenue</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,937</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,919</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,018</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,569</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,638</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">931</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,506</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,557</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,949</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue increased $8.9 million or 20% for the year ended December 31, 2021 compared to the year ended December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenue increased $8.0 million or 20% for the year ended December 31, 2021 compared to the year ended December 31, 2020. The primary driver of the increase in revenue for diagnostic testing was attributable to the success in our targeted strategy of growth in our core lung diagnostic testing. Lung diagnostic revenue grew by $6.1 million or 49% for the year ended December 31, 2021 compared to the same period in 2020 driven primarily from an increase in Nodify XL2 and Nodify CDT tests delivered. We began to see recovery during the fourth quarter 2020 in lung diagnostic testing as our delivered tests exceeded first quarter 2020 delivered tests as healthcare practitioners, including pulmonologists, increasingly returned to pre-pandemic related care. The increase in Diagnostic test revenue was also attributable to the expansion of the sales organization during fiscal year 2021. However, the Company&#x2019;s sales efforts continued to be impacted by the COVID-19 pandemic and the surge associated with the Delta and Omicron variants which have</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negatively affected, and we expect may continue to negatively affect, the growth rate of our lung diagnostic testing-related revenue and our clinical studies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to lung diagnostic testing revenue, our COVID-19 testing revenue increased by $1.9 million, or 7% from $28.3 million in fiscal year 2020 to $30.2 million in 2021 due primarily to the delivery of our COVID-19 tests that were delivered in the first half of 2021. The first quarter 2021 was our peak for COVID-19 testing revenue but we have experienced a substantial decline in COVID-19 testing revenue subsequently as a result of the expiration of our contract with the Big Ten during the second quarter 2021 and as immunizations in the U.S. accelerated. The longevity and extent of COVID-19 revenue is uncertain and may not be indicative of our future revenue and we expect it to vary based on new variants and rates of infection.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue increased $0.9 million or 20% for the year ended December 31, 2021 compared to the year ended December 31, 2020, due primarily to the recovery in testing volumes from clinical studies and services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Direct costs and expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses related to revenue increased $8.5 million or 39% for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase in direct costs and expenses is primarily driven by the increase in lung diagnostic tests delivered during the year ended December 31, 2021 compared to the same period in 2020 and an increase in cost per COVID-19 test.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses increased $2.0 million or 18% for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase in cost was due primarily to increased employee compensation and benefits costs associated with non-cash stock-based compensation as a result of the transition from a private to a public company and increased headcount of our research and development personnel, partially offset by decreased spending on clinical trials.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our external and internal costs for the years ended December 31, 2021 and 2020 (in thousands, except percentages):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.137%;"></td>
    <td style="width:1.187%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.406%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:1.187%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.406%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:1.187%;"></td>
    <td style="width:1.197%;"></td>
    <td style="width:9.202%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.187%;"></td>
    <td style="width:0.594%;"></td>
    <td style="width:7.95%;"></td>
    <td style="width:2.792%;"></td>
    <td style="width:1.187%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">External expenses:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials and associated costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,061</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,487</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(426</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(17</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other external costs</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,810</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,823</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">987</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total external costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,871</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,310</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">561</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Internal expenses</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,918</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,508</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,410</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,789</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,818</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,971</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales, Marketing, General and Administrative</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative expenses increased $15.7 million or 45% for the year ended December 31, 2021 compared to the year ended December 31, 2020. This increase was driven primarily by increases in employee compensation and benefits associated with expansion of the Company&#x2019;s workforce and increased non-cash share-based compensation expense. This increase is also the result of increases in non-employee costs associated with legal and other fees as a result of the transition from a private to a public company.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Contingent Consideration</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of contingent consideration increased $0.8 million or 98% for the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase is a result of the change in fair value to reflect the passage of time, changes in discount rate, as well as estimates regarding the period in which targets that trigger the payment of contingent consideration will be achieved and subsequently paid. The gross margin target was met during the three months ended June 30, 2021. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense decreased $3.1 million or 41% for the year ended December 31, 2021 compared to the year ended December 31, 2020. This decline was due to a decrease of interest expense related to convertible notes, which were converted to common stock upon the completion of our IPO in October 2020, and a decrease resulting from the refinancing of our term loan, reducing near-term interest costs. Partially offsetting this decline is the increase to contingent consideration recorded as &#x2018;Interest expense&#x2019; resulting from the passage of time and fixed payment schedule during the year ended December 31, 2021 of $2.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Change in Fair Value of Warrant Liability</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2020, we recognized a charge for the change in estimated fair value of our warrant liability related to warrants issued in connection with our Series G preferred stock of $1.3 million. Effective with the closing of our initial public offering in October 2020, the warrants to purchase Series G preferred stock were automatically converted to warrants to acquire common stock and the carrying value of the warrants of $1.6 million were reclassified to additional paid-in capital.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gain on Debt Extinguishment, net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021, we recognized a $2.3 million net gain on debt extinguishment. The Company recorded a gain on debt extinguishment of $3.1 million related to the legal release and forgiveness of the Paycheck Protection Program Loan in full. The gain was partially offset by losses on debt extinguishment of $0.7 million and $0.1 million resulting from the repayment and termination of our 2018 secured promissory note with Innovatus and the write-off of debt issuance costs associated with a $20 million prepayment of our 2021 Term Loan, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other (expense) income, net</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expense, net for the year ended December 31, 2021 is primarily attributable to a loss on disposal of property and equipment. Other income, net for the year ended December 31, 2020 was primarily attributable to sublease income from two subleases that expired in the second and third quarter of 2020 and a gain on disposal of property and equipment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an emerging growth company and, as such, have yet to generate positive cash flows from operations. We have funded our operating activities primarily through financing activities, which include both debt and equity offerings. In October 2020, we completed an IPO, resulting in net proceeds of approximately $63.8 million after deducting offering costs, underwriting discounts and commissions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). As a result of the pandemic, the Company diversified its diagnostic testing beyond lung diagnostic testing to include the critical service of COVID-19 diagnostic testing. Beginning in the third quarter 2020, the Company&#x2019;s COVID-19 testing services began to experience rapid growth with a peak in the first quarter 2021; however, subsequent to this peak, we have experienced a rapid decline in COVID-19 testing revenue primarily as a result of a few significant contracts that have expired as well as the ongoing increase in COVID-19 vaccination rates across the U.S. In addition, the COVID-19 pandemic negatively affected, and we expect may continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies. We began to see recovery beginning in the fourth quarter 2020 as our core lung diagnostics delivered tests exceeded first quarter 2020 delivered tests and have experienced continued recovery during 2021 as lung diagnostic revenue grew 49% during 2021 as compared to 2020. However, given the continuation of the pandemic through COVID-19 variants, including the associated hospitalization surges and the impact on the medical ecosystem, which include clinical studies and pulmonary practices, the demand for our lung diagnostic testing and biopharmaceutical services has not recovered in line with our expectation from the time of our IPO. While the full outcome of the COVID-19 pandemic is unknown, it continues to negatively impact our ability to grow and scale our business in line with our expectations and disclosures at the time of our IPO. As a result, the items identified above have had an adverse effect on our revenue, results of operations and cash flows.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, we completed the closing of our 2021 Term Loan for a principal amount of $30 million and extinguished our prior 2018 term loan for $25.9 million. The 2021 Term Loan contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulation, payment of taxes, insurance coverage, notice of certain events, and reporting requirements. Further, the 2021 Term Loan contains customary negative covenants limiting the ability to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, make certain restricted payments, and sell assets, subject to certain exceptions. The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined in the 2021 Term Loan) of not less than 0.95 to 1.00, and has a trailing six-month rolling revenue requirement of not less than 70% of the Company&#x2019;s projected revenue performed at the end each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the second quarter 2021, the Company determined that it would apply for forgiveness under the SBA&#x2019;s Loan Forgiveness program, a change from its previous intent to repay. Subsequently, in July 2021 the Company applied for loan forgiveness and on August 17, 2021, the Company received legal release and formal notification that the PPP Loan was forgiven in full. As of and for the three</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">months ended September 30, 2021, the Company reduced the &#x2018;Current portion of notes payable&#x2019; and recorded a gain on extinguishment in the statements of operations for the $3.1 million forgiven.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (the 2021 Term Loan Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three month period ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $15 million for the benefit of our lender if the balance of our cash and cash equivalents declines below $40 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 30, 2021, the Company raised approximately $16.3 million in gross proceeds from the sale of 3,756,994 common shares at a public offering price of $4.35 per share in an at-the-market offering. The Company received net proceeds of $15.7 million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $4.6 million January 2022 milestone payment under the Indi APA, repay $20 million in outstanding principal on December 31, 2021, waive the $600,000 prepayment fee on the $20 million Term Loan repayment, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement to not less 75% for the three months ended March 31, 2022 and not less than 75% on a trailing six month rolling basis for each quarter thereafter of the Company&#x2019;s projected revenue performed at the end of each reporting period. The Lender agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially prepay the $20 million in outstanding principal, thereby eliminating the restricted cash collateral account. As of December 31, 2021, the Company was in compliance with all restrictive and financial covenants associated with its borrowings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we maintained cash and cash equivalents of $32.7 million and we have $10 million in principal balance remaining on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration of the outstanding balance. We have taken steps to improve our liquidity through and the actions noted above and have also undertaken several proactive measures to mitigate the financial and operational impacts of COVID-19 through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiations with certain creditors to modify existing terms of arrangements to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. We plan to raise additional funding through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis nor can there be any assurance that the Company will be a beneficiary of the COVID-19 Action Plan. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while we make</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">investments to support our anticipated growth. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes our cash flows for the periods indicated (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.611%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.077%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.077%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash flows (used in) provided by:</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(28,223</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(21,366</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,547</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,927</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,262</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,131</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(29,508</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,838</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cash flows resulted in a net decrease in cash of $29.5 million during the year ended December 31, 2021 compared to a net increase in cash of $56.8 million for the year ended December 31, 2020. For the year ended December 31, 2021, net cash used in operating activities increased by approximately $6.9 million, primarily due to a year-over-year increase in net loss of $11.8 million and decrease in non-cash adjustments to net loss of $4.5 million driven primarily by a decrease in amortization of convertible notes debt discount in 2020 of $4.4 million and an increase in net gain on debt extinguishment in 2021 of $2.3 million. This is partially offset by an increase in stock-based compensation expense of $1.2 million, increase in contingent consideration of $0.8 million, and increase in other non-cash items of $0.2 million. In addition, the Company experienced favorable changes in net working capital of $9.4 million primarily as a result of increased cash collections from customers, partially offset by increased payments to vendors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities during the year ended December 31, 2021 totaled $2.5 million, a decrease of $0.4 million compared to the same period in 2020. The decrease in net cash used in investing activities was primarily due to payments in 2020 to acquire Oncimmune assets that are not present in 2021. This is partially offset by an increase in purchases of property and equipment during 2021 in support of our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities during the year ended December 31, 2021 totaled $1.3 million, a decrease of $79.9 million compared to the same period in 2020. The net cash provided by financing activities for the year ended December 31, 2021 primarily resulted from $15.7 million net proceeds from our at-the-money public offering, net proceeds from our 2021 Term Loan of $29.9 million, and proceeds from the issuance of common stock under the ESPP and exercise of stock options of approximately $1.0 million, primarily offset by the repayment of $25.3 million from our 2018 Term Loan and a $20 million prepayment on our 2021 Term Loan. The net cash provided by financing activities for the year ended December 31, 2020 primarily resulted from $72.0 million gross proceeds from our initial public offering, $13.0 million in proceeds from the issuance of convertible notes payable, $1.3 million proceeds from stock option exercises, and $3.1 from proceeds from our paycheck protection program loan, offset by equity financing and other costs associated with our initial public offering of $8.3 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our non-cancelable contractual obligations and commitments as of December 31, 2021 (in thousands):</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:44.659%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:7.882%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:7.882%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:7.882%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:7.882%;"></td>
    <td style="width:0.946%;"></td>
    <td style="width:1.02%;"></td>
    <td style="width:1.205%;"></td>
    <td style="width:7.956%;"></td>
    <td style="width:0.946%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="18" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Payments due by period</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Less than<br />1 year</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1 to 3<br />years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4 to 5<br />years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">More than<br />5 years</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease obligations </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">937</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">775</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">158</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Borrowings and interest </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(3)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,386</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">532</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,368</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,486</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of contingent consideration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(4)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37,000</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,500</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,500</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52,323</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,807</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,026</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,490</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:9.5pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Royalty payments that we may owe are not included as the amount and timing of such payments is uncertain.</span></div></div>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:9.5pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">We are obligated under non-cancellable operating leases for all of our facilities. Lease terms for our facilities range from less than one to three years and generally require us to pay real estate taxes, certain insurance and operating costs.</span></div></div>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:9.5pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Includes the 2021 Term Loan payments of principal, interest and final payment fee of $2.7 million payment due upon loan maturity.</span></div></div>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:9.5pt;font-family:Times New Roman;transform-origin:top left;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(4)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">The gross margin target associated with the purchase transaction of Indi was achieved in the quarter ending June 30, 2021, giving rise to the previously disclosed contingent obligations of $37.0 million in the aggregate payable through the issuance of Company&#x2019;s shares of common stock subject to a fixed price put option. The Company entered into an amendment in August 2021 to the original agreement in which all parties agreed to forgo the issuance of shares of common stock of the Company that would otherwise be issued to it, and the Company will instead make six quarterly installment payments of $4.6 million beginning in January 2022 and a final payment of approximately $9.3 million in July 2023 for a total of $37.0 million. The aggregate amount of payments owed by the Company under this </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="display:flex;margin-top:2.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);transform:scale(0.67);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:9.5pt;font-family:Times New Roman;transform-origin:top left;visibility:hidden;display:inline-flex;font-size:9.5pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Off-Balance Sheet Arrangements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Significant Judgments and Estimates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with accounting principles generally accepted in the United States, we are required to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Certain of these estimates significantly influence the portrayal of our financial condition and results of operations and require us to make difficult, subjective or complex judgments. Our critical accounting policies primarily relate to our fair value estimates, and are described in greater detail in Note 2 to our financial statements in Part 8 of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize revenue when our customers obtain control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for our goods or services. To determine revenue recognition for our arrangements with our customers, we perform a five-step process, which includes: (i) identifying the contract(s) with a customer; (ii) identifying the performance obligations in the contract; (iii) determining the transaction price; (iv) allocating the transaction price to the performance obligations in the contract; and (v) recognizing revenue when (or as) we satisfy our performance obligations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnostic test revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues are recognized upon completion of our performance obligation to the deliver test results to our customer, either the prescribing physician or third-party to which we contracted for services to be performed. We consider diagnostic testing to be completed upon the delivery of test results to our customer which is considered the performance obligation. The fees for such services are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. We determine the transaction price related to our contracts by considering the nature of the payer, the historical amount of time until payment by a payer and historical price concessions granted to groups of customers. These estimates require significant judgment by management.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Service revenues</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Service revenues are recognized upon completion of our performance obligation to deliver testing results for assay development and testing services. The performance obligations and related revenue for these sales is defined by a written agreement between us and our customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer, which is considered the performance obligation. Customers for these services are typically large pharmaceutical companies where collectability is reasonably assured and therefore revenue is accrued upon completion of the performance obligations. Revenue derived from services is often unpredictable and can cause dramatic swings in our overall net revenue line from quarter to quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-based Compensation and Grant Date Fair Value</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Share-based compensation related to stock options granted to our employees, directors and non-employees is measured at the grant date based on the fair value of the award. For our service-based awards, the fair value of each award is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period of the respective awards. Compensation expense for share-based awards with performance conditions is recognized based upon the probability the performance conditions will be met as defined in the grant. Restricted stock units are measured at their grant date fair value using the closing price of our common stock on the date of grant and recognized to expense on a straight-line basis over the vesting period of each award. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use the Black-Scholes option-pricing model to estimate the fair value of our share-based option awards, which requires assumptions to be made related to expected term of an award, expected volatility, the risk-free rate and expected dividend yield. Following the completion of our initial public offering, our Board of Directors has determined the fair value of our common stock is based on our closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. Changes in these subjective assumptions can materially affect the estimated value of equity grants and the share-based compensation that we record in our financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Pronouncements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. B</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ased on our current analysis expect the adoption to result in the recognition of approximately $1.5 million of right of use assets and associated lease liabilities, inclusive of both lease and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC Topic 326). This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Implications of Being an Emerging Growth Company and Smaller Reporting Company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an &#x201c;emerging growth company&#x201d; within the meaning of the Jumpstart Our Business Startups Act (JOBS Act). As an emerging growth company, we may take advantage of certain exemptions from various public company reporting requirements, including the requirement that our internal control over financial reporting be audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (the &#x201c;Sarbanes-Oxley Act&#x201d;), certain requirements related to the disclosure of executive compensation in our periodic reports and proxy statements, the requirement that we hold a nonbinding advisory vote on executive compensation and any golden parachute payments. We may take advantage of these exemptions until we are no longer an emerging growth company. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act, for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to take advantage of the extended transition period to comply with new or revised accounting standards and to adopt certain of the reduced disclosure requirements available to emerging growth companies. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies, which may make comparison of our financials to those of other public companies more difficult.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will remain an emerging growth company until the earliest to occur of (i) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (ii) the date we qualify as a &#x201c;large accelerated filer,&#x201d; with at least $700 million of equity securities held by non-affiliates; (iii) the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; and (iv) until December 31, 2025 (the year ended December 31st following the fifth anniversary of our initial public offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, we are a &#x201c;smaller reporting company&#x201d; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which: (i) the market value of our common shares held by non-affiliates exceeds $250 million as of the end of that year&#x2019;s second fiscal quarter, or (ii) our annual revenues exceeded $100 million during such completed fiscal year and the market value of our common shares held by non-affiliates exceeds $700 million as of the end of that year&#x2019;s second fiscal quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitati</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ve Disclosures About Market Risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risk in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risk for changes in interest rates related primarily to our cash and cash equivalents, marketable securities and our indebtedness, including </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our outstanding 2021 Term Loan. As of December 31, 2021, we had $10 million outstanding on the 2021 Term Loan subject to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Historically, we have not entered into derivative agreements such as interest rate caps and swaps to manage our floating interest rate exposure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodically throughout the year, we have maintained balances in various operating accounts in excess of federally insured limits. Our cash and cash equivalents are funds held in checking and bank savings accounts, primarily at two U.S. financial institutions. We consider all highly liquid instruments purchased with an original maturity of three months or less to be cash equivalents. We continually monitor our positions with, and the credit quality of, the financial institutions with which we invest.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, a hypothetical 100 basis point increase in interest rates would not have a material impact on our investment portfolio, financial position or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">s and Supplementary Data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial statements and supplementary data are as set forth in the index to the financial statements on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> and Procedures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We maintain &#34;disclosure controls and procedures,&#34; as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, or Exchange Act, that are designed to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognized that disclosure controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the disclosure controls and procedures are met. Our disclosure controls and procedures have been designed to meet reasonable assurance standards. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on their evaluation as of the end of the period covered by this Annual Report on Form 10-K, our Chief Executive Officer and Chief Financial Officer have concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Report on Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as such term is defined in Exchange Act Rules 13a-15(f). Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> based on the criteria established in &#34;Internal Control &#x2013; Integrated Framework&#34; issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), using the 2013 framework. Based on our assessment, our Chief Executive Officer and Chief Financial Officer concluded that, as of </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company's internal control over financial reporting was effective based on the criteria set forth by COSO.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This annual report does not include an attestation report of our registered public accounting firm due to a transition period established by rules of the Securities and Exchange Commission for newly public companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the quarter ended </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were no changes that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Off</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">icers and Corporate Governance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item with respect to directors is incorporated by reference from the information under the captions &#34;Board and Corporate Governance Matters&#x2014;Election of Directors&#34; and &#34;&#x2014;Director Independence&#34; contained in our Proxy Statement to be filed with the Securities and Exchange Commission within 120 days of the fiscal year ended December 31, 2021 in connection with the solicitation of proxies for our 2022 Annual Meeting of Stockholders (the Proxy Statement). Certain information required by this item concerning executive officers is set forth in the Proxy Statement under the caption &#34;Executive Compensation&#x2014;Executive Officers&#34; and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 405 of Regulation S-K calls for disclosure of any known late filing or failure by an insider to file a report required by Section 16(a) of the Exchange Act. This disclosure is contained in the section entitled &#34;Stock Ownership&#x2014;Delinquent Section 16(a) Reports&#34; in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a Code of Business Conduct and Ethics that applies to all of our officers and employees, including our President and Chief Executive Officer, our Chief Financial Officer and other employees who perform financial or accounting functions. The Code of Business Conduct and Ethics sets forth the basic principles that guide the business conduct of our employees. Stockholders may request a free copy of our Code of Business Conduct and Ethics by contacting Biodesix, Inc., Attention: Chief Financial Officer, 2970 Wilderness Place, Suite 100, Boulder, Colorado 80301.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, there have been no waivers under our Code of Business Conduct and Ethics. We intend to disclose future amendments to certain provisions of our Code of Business Conduct and Ethics or waivers of such Codes granted to executive officers and directors on our website at http://www.biodesix.com within four business days following the date of such amendment or waiver.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Board of Directors has appointed an Audit Committee, comprised of Ms. Jean Franchi, as Chairwoman, Mr. Hany Massarany and Dr. Matthew Strobeck. The Board of Directors has determined that Ms. Franchi qualifies as an Audit Committee Financial Expert under the definition outlined by the Securities and Exchange Commission. In addition, each of the members of the Audit Committee qualifies as an &#34;independent director&#34; under the current rules of The NASDAQ Stock Market and Securities and Exchange Commission rules and regulations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference from the information under &#34;Executive Compensation&#34; contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Own</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ers and Management and Related Stockholder Matters.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference from the information under the captions &#34;Stock Ownership&#x2014;Security Ownership of Certain Beneficial Owners and Management&#34; and &#34;Executive Compensation&#x2014;Equity Compensation Plan Information&#34; contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Transactions, and Director Independence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference from the information under the caption &#34;Board and Corporate Governance Matters&#x2014;Certain Relationships and Related Party Transactions&#34; and &#34;&#x2014;Director Independence&#34; contained in the Proxy Statement and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tant Fees and Services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item is incorporated by reference from the information under the caption &#34;Audit Matters&#x2014;Principal Accountant Fees and Services&#34; contained in the Proxy Statement and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement_sch"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits, Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statement Schedules.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(a)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Documents filed as a part of the report. </span></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">1.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span></div></div>
  <p style="margin-left:6.667%;text-indent:-3.704%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reference is made to the Index to Financial Statements of Biodesix, Inc. included in Item 8 of Part II hereof.</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">2.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statement Schedules</span></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All schedules have been omitted because they are not required, not applicable, or the required information is included in the financial statements or notes thereto.</span></p>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">3.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Item 15(b) below. Each management contract or compensating plan or arrangement required to be filed has been identified. </span></div></div>
  <div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">(b)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. Form</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> 10-K Summary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="exhibit_index"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Index</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.33%;"></td>
    <td style="width:1.623%;"></td>
    <td style="width:1.447%;"></td>
    <td style="width:88.599%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex31_716.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of Biodesix, Inc., dated October 30, 2020 (incorporated by reference to Exhibit 3.1 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on December 10, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459020056735/bdsx-ex32_717.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of Biodesix, Inc. (incorporated by reference to Exhibit 3.2 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on October 12, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex41.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Specimen stock certificate evidencing shares of Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Eleventh Amended and Restated Investor Rights Agreement, by and among Biodesix, Inc. and the investors listed on Exhibit A thereto, dated October 10, 2018 (incorporated by reference to Exhibit 4.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex43.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant held by Innovatus Life Sciences Lending Fund I, LP, to Purchase Series G Preferred Stock, dated February 23, 3018 (incorporated by reference to Exhibit 4.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex44.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Secured Promissory Note held by Innovatus Life Sciences Lending Fund I, LP, in Biodesix, Inc., dated February 23, 2018 (incorporated by reference to Exhibit 4.4 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.5**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex45_270.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to Exhibit 4.5 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. Amended and Restated 2006 Employee, Director and Consultant Stock Plan, as amended to date (incorporated by reference to Exhibit 10.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1021.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1022.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Option Agreement under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Notice of Exercise under the Amended and Restated 2006 Employee, Director and Consultant Stock Plan (incorporated by reference to Exhibit 10.2.3 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex103.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. 2016 Equity Incentive Plan, as amended to date (incorporated by reference to Exhibit 10.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1041.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1042.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Option Agreement under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1043.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Notice of Exercise under the 2016 Equity Incentive Plan (incorporated by reference to Exhibit 10.4.3 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex105.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021013512/bdsx-ex1051_388.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Forms of Stock Option Grant Notice, Option Agreement and Notice of Exercise under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.1 to the Company's Form 10-K filed with the SEC on March 16, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.5.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1052_236.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Forms of Restricted Stock Unit Award Grant Notice and Award Agreement under the 2020 Equity Incentive Plan (incorporated by reference to Exhibit 10.5.2 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.401%;"></td>
    <td style="width:88.599%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520275630/d937421dex106.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 26, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1051.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc., First Amended Bonus-to-Options Program, adopted by the Board of Directors on October 15, 2010 (incorporated by reference to Exhibit 10.5.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1052.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc., Second Amended Bonus-to-Options Program, adopted by the Board of Directors on June 21, 2011 (incorporated by reference to Exhibit 10.5.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.7.3+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1053.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc., Third Amended Bonus-to-Options Program, adopted by the Board of Directors on December 31, 2015 (incorporated by reference to Exhibit 10.5.3 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8.1+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1061.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Stock Option Grant Notice under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.8.2+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1062.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Option Agreement under the Biodesix, Inc. Bonus-To-Options Program (incorporated by reference to Exhibit 10.6.2 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.9+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520268763/d937421dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement, by and between Biodesix, Inc. and each of its directors and executive officers (incorporated by reference to Exhibit 10.7 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 14, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10.1&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1091.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 16, 2018 (incorporated by reference to Exhibit 10.9.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.10.2&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1092.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Letter, by and between Biodesix, Inc. and Scott Hutton, dated February 23, 2020 (incorporated by reference to Exhibit 10.9.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11.1&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated March 11, 2011 (incorporated by reference to Exhibit 10.10.1 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.11.2&#134;+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10102.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Employment Letter, by and between Biodesix, Inc. and Robin Harper Cowie, dated February 23, 2020 (incorporated by reference to Exhibit 10.10.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.12+**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consulting Agreement, by and between David Brunel and Biodesix, Inc., dated September 19, 2020 (incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13.1&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1011.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated October 5, 2011 (incorporated by reference to Exhibit 10.11 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.13.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex10_132.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office Lease between Aero-Tech Investments, LLC and Biodesix, Inc., dated January 24, 2022.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.14&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1013.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Assignment of De Soto Facility, dated November 1, 2019 (incorporated by reference to Exhibit 10.13 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15.1&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex10131.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix, Inc., dated February 23, 2018 (incorporated by reference to Exhibit 10.13.1 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.15.2&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex10142.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Limited Consent Agreement and Second Amendment to Loan and Security Agreement, by and among Innovatus Life Sciences Lending Fund I, LP, the Lenders listed therein, and Biodesix, Inc., dated June 30, 2018, as amended to date (incorporated by reference to Exhibit 10.14.2 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.16**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Patent Assignment between Biodesix, Inc., and Integrated Diagnostics, Inc., dated June 30, 2018 (incorporated by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.401%;"></td>
    <td style="width:88.599%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.17&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">IP Assignment Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.15 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.18&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1016.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">IP License Agreement between Oncimmune Limited, and Biodesix, Inc., dated October 31, 2019 (incorporated by reference to Exhibit 10.16 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.19&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1017.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.17 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.20&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1018.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Supply Agreement between Biodesix, Inc., and Oncimmune, dated October 31, 2019 (incorporated by reference to Exhibit 10.18 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.21&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1019.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Supply Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated August 1, 2019 (incorporated by reference to Exhibit 10.19 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.22&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520266992/d937421dex1020.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Co-Development and Collaboration Agreement between AVEO Pharmaceuticals, Inc., and Biodesix, Inc., dated April 9, 2014, as amended October 14, 2016 (incorporated by reference to Exhibit 10.20 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 9, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.23&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1022.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Contingent Value Rights Agreement between Biodesix, Inc. and Holders on Schedule A mentioned within, dated February 22, 2016 (incorporated by reference to Exhibit 10.22 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.24&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1023.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Asset Purchase Agreement among Biodesix, Inc., Integrated Diagnostics, Inc., and the stockholders of Integrated Diagnostics, Inc., listed therein, dated June 30, 2018 (incorporated by reference to Exhibit 10.23 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.25**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1038_489.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 2 to Asset Purchase Agreement and Plan of Reorganization (incorporated by reference to Exhibit 10.38 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.26&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1024.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Asset Purchase Agreement between Oncimmune Limited and Biodesix, Inc., dated June 27, 2019, as amended to date (incorporated by reference to Exhibit 10.24 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.27&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1025.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc., and Centura Health Corporation, dated April 3, 2020 (incorporated by reference to Exhibit 10.25 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.28&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1026.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated April 23, 2020 (incorporated by reference to Exhibit 10.26 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.29&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1027.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated May 27, 2020 (incorporated by reference to Exhibit 10.27 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.30&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1028.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to COVID-19 Testing Laboratory Services Agreement by and between Biodesix, Inc. and Centura Health Corporation, dated August 7, 2020 (incorporated by reference to Exhibit 10.28 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.31&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1029.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Contract Agreement between Biodesix, Inc. and the Colorado Department of Public Health and Environment, dated September 11, 2020 (incorporated by reference to Exhibit 10.29 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.32&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1030.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated March 23, 2020 (incorporated by reference to Exhibit 10.30 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.33&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1031.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc. dated April 3, 2020 (incorporated by reference to Exhibit 10.31 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:11.401%;"></td>
    <td style="width:88.599%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.34&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1032.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Material Transfer Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated April 17, 2020 (incorporated by reference to Exhibit 10.32 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.35&#134;**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520262422/d937421dex1033.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Price Agreement by and between Biodesix, Inc. and Bio-Rad Laboratories, Inc., dated May 12, 2020 (incorporated by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1 filed with the SEC on October 2, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.36**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1033.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter from Bio-Rad Laboratories, Inc. dated August 7, 2020 (incorporated by reference to Exhibit 10.33 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.37**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000119312520273369/d937421dex1034.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Letter from Bio-Rad Laboratories, Inc. dated August 14, 2020 (incorporated by reference to Exhibit 10.34 to the Company&#x2019;s Registration Statement on Form S-1/A filed with the SEC on October 21, 2020).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.38**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021043081/bdsx-ex1037_47.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to the Non-Exclusive License Agreement between Bio-Rad Laboratories, Inc., and Biodesix, Inc., dated May 24, 2021 (incorporated by reference to Exhibit 10.37 to the Company's Form 10-Q filed with the SEC on August 10, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.39**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021014880/bdsx-ex101_29.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loan and Security Agreement, dated March 19, 2021 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 23, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.40**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000156459021056811/bdsx-ex1039_135.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent and First Amendment to Loan and Security Agreement, dated September 30, 2021 (incorporated by reference to Exhibit 10.39 to the Company's Form 10-Q filed with the SEC on November 15, 2021).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.41**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Purchase Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.42**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1439725/000095017022003002/bdsx-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Registration Rights Agreement, dated March 7, 2022, by and between Biodesix, Inc. and Lincoln Park Capital Fund, LLC (incorporated by reference to Exhibit 10.2 to the Company's current report on Form 8-K filed with the SEC on March 7, 2022).</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="#power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Power of Attorney (included on the signature page of this Form 10-K).</span></a><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2*</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><a href="bdsx-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#134; Portions of this exhibit have been omitted as the Registrant has determined that the omitted information (i) is not material and (ii) would likely cause competitive harm to the Registrant if publicly disclosed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">**Previously filed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNAT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">URES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.334%;"></td>
    <td style="width:5.139%;"></td>
    <td style="width:3.182%;"></td>
    <td style="width:46.345%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:  March 14, 2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ RYAN H. SIUREK</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Ryan H. Siurek</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;font-style:italic;">Chief Accounting Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="power_attorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ATTORNEY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each person whose signature appears below constitutes and appoints Scott Hutton and Robin Harper Cowie, and each of them, his or her true and lawful agent, proxy and attorney-in-fact, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to file with the Securities and Exchange Commission this Form 10-K and any and all amendments and exhibits thereto, and all documents in connection therewith, granting unto each such attorney-in-fact and agent full power and authority to do and perform each and every act and thing necessary or appropriate to be done, as fully for all intents and purposes as he or she might or could do in person, hereby approving, ratifying and confirming all that such agent, proxy and attorney-in-fact or any of his or her substitutes may lawfully do or cause to be done by virtue hereof.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.997%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:43.292%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:21.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ SCOTT HUTTON</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer (Principal Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Scott Hutton</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ ROBIN HARPER COWIE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer, Secretary and Treasurer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Robin Harper Cowie</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ JOHN PATIENCE</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chairman and Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">John Patience</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ JEAN FRANCHI</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Jean Franchi</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ JON FAIZ KAYYEM</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Jon Faiz Kayyem, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ HANY MASSARANY</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Hany Massarany</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ JACK SCHULER</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Jack Schuler</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ MATTHEW STROBECK</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Matthew Strobeck, Ph.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ CHARLES WATTS</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Charles Watts, M.D.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statements and Supplementary Data</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:93.0%;"></td>
    <td style="width:7.0%;"></td>
   </tr>
   <tr style="height:9.35pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">&#160;(</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6d30694e-bcd4-4785-a3fd-77d1310227ea" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">KPMG LLP</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a82babb5-5fc1-4e72-840d-1ab6724bc858" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Denver, CO</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">, Auditor Firm ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_47b89904-5eed-46eb-8925-7f420becbab5" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">185</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Operations for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows for the Years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Regist</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Board of Directors and Stockholders of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Opinion on the Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying balance sheets of Biodesix, Inc. (the Company) as of December 31, 2021 and 2020, the related statements of operations, convertible preferred stock and stockholders&#x2019; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Going Concern</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered recurring losses from operations and needs to raise additional equity or debt capital to fund its operations. These matters raise substantial doubt about its ability to continue as a going concern. Management&#x2019;s plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ KPMG LLP</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2016</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denver, Colorado</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 14, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:64.363%;"></td>
    <td style="width:1.707%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:14.192%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.707%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:14.025%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="8" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c97a060c-38e1-4c70-819e-c9c099c2946c" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,712</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa006dbb-1b9d-42cd-863f-b9cc3713c84b" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable, net of allowance for doubtful accounts of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_705efec6-7fe4-498b-8154-f6f942b3c647" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6d056a0-8957-4d6a-9458-807af481982b" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5deee8a-c735-4409-b396-5c61d59ef62f" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,656</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c312136d-9c60-4bf5-9611-777a112395f5" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AccountsReceivableNetCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,304</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2d7924b-23e8-4dec-87dd-e0b289172b28" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_365d0f09-5cfc-4f36-b286-b903bf860966" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bf7ec2d-003a-4693-ade0-d553bcbdd098" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,613</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4c7b19d-0dcd-4c44-a92d-3418ff3f9b10" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,140</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non&#x2011;current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d52b2dca-ed09-4ef5-8fb6-3ddde77e932b" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,179</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3dfd5fbb-94e2-4aa2-b78f-9a30f9fd6163" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8625fa79-f682-45b6-981c-ed6fd4cbe1ed" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,617</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e293c8c1-b1df-402e-93ad-552530a276c9" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c07db3c3-2f98-42bf-92b8-eb0be7b02ba6" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7ba7f49-85df-4b67-9422-a9add0ebeaf6" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,031</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_032ae51e-3dcb-44ad-89c5-c3fb8bd8d0ea" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,657</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2cd5302-0d1d-40e7-ba22-af95513af5ed" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total non&#x2011;current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40e66de6-68f8-41d7-aaef-0c3956e9c3a0" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f60d577-648e-4d1f-b9f8-ee89e3e7399d" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,930</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4cfa0e6-2f8a-49d9-90d9-74812ff538d3" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f5b1e43-834f-4477-999e-6f2646d27b87" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="8" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liabilities and Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f3e0413-2fe4-4be7-b703-6555c5b0a477" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,662</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3fe0f515-de85-4a6a-9caf-c82d05898da7" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c615615b-914f-40f5-8298-a0fc94e96b29" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,665</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a25f82d-a135-4105-8846-beec16859d25" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b910e700-bfa7-4758-9852-3f82b682eaef" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0557bab8-ec6b-4c5a-b485-52194390dfe8" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,532</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35d7ddbe-b52b-4f2c-bfde-73941b9ccd13" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,764</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of notes payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34ab67b0-f402-46e7-9d2b-fda6b4604da5" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f20cebed-1944-4bd8-90e6-8e569f4a4968" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:NotesPayableToBankCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,840</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29f698c8-f5ee-474c-b698-ac718fed6344" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,960</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbc0fc7d-9905-4831-a1a8-d057dc0141d3" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non&#x2011;current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long&#x2011;term notes payable, net of current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1667083a-8f19-45d7-b975-3d80ea99cf11" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23e67a3a-3c8f-4d10-9206-96c4e75931e5" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2662b8d-bff3-4e45-bb4d-8b4046c4cfdd" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,028</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca481b70-4a91-467e-8887-78bac1efeab1" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c220aed6-6c31-44e8-898e-bcf40b63e409" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73bf2955-0027-49b4-b6c2-c6448ec9dca1" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total non&#x2011;current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8aeb57f5-f6fe-400f-94e0-44d90ea5af18" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,410</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6114d46-e89a-400d-9984-fd5504931c00" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:LiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">47,779</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ca4c190-908a-4f71-9521-c65acf1e7e28" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,370</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3da121dc-6f89-4277-8798-cd7e964f10aa" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_830ca1b5-f04d-4413-9871-696b9cc2f4f6;"><span style="-sec-ix-hidden:F_0b6261a9-728a-45c1-9cff-b460d2223b68;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commitments and contingencies</span></span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholders' equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2544811-f089-4a6c-9171-e4b1a8104b51" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_067f41f5-8947-4baf-86da-39dba7af7af6" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d4cc2aa-6b95-41a7-81d1-0669cfaee431" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6842d37d-1e4e-455a-a9d5-a7908ea1ba71" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;authorized; <br />&#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75e835f0-2797-477d-bbda-7e02dd2db677" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_26210952-89ff-4612-834a-2a69ccb80074" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_4b68c146-b3ee-4c16-8118-7f6fadbaecc6" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6f4f3ca0-c526-4f5d-b6fb-a45e3b1fe476" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(2021 and 2020) issued and outstanding</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_639add45-6192-49bc-b32f-a9b5c8b2fcec;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e28ee59e-2ec0-403a-86b7-fd43d6ed7b38;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fae82ac-37d4-412f-b89f-d099a31dc32e" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF"><ix:nonFraction id="F_246ec85f-c335-4e2f-a5eb-09a382b45178" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;par value, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb96377f-9a30-451e-8cdf-937e03942a7a" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_81c66f84-85f5-4ebd-8e34-7061942a058c" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;authorized; <br />&#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c04edd4d-9bdc-4057-881e-06ed7c0917b9" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_5c9aa52c-8fce-4899-864e-62b2485dbe18" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">30,789,649</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(2021) and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b4d9ff3-067c-42da-a57c-da9a47428e4d" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_09e00fa0-cd54-4019-b3a5-fcd9b0d3d623" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,561,504</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;(2020) shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_333306e4-a00c-4c6b-9cd8-feb529c5300d" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_406ea035-c487-450a-b38e-c05bda194998" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional paid&#x2011;in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ddce792-0fe6-4afc-8db0-9f508700971b" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0612c151-ed01-44aa-9ca6-d63d6013d026" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299,953</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87c2e490-652a-4377-a6bd-4ff4d3d7ea93" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">301,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_769834fa-a9ac-4b28-9e94-be321b2df59a" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">258,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stockholders' equity</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dd8ac2e-8b9b-4ba8-aae3-df2fad43e9b6" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_740800a4-0dca-40ec-8421-d153739d5521" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total liabilities and stockholders' equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60f21456-d50f-4791-9f70-dbfdf9b9d506" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,097</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92510354-a913-4fb9-a28b-a5780a9e273e" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">121,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_operations"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.49%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.235%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.059%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_778fe8b9-c1bb-4e60-87ba-dcb8ac52bd88" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,506</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af2460c8-7a2e-440a-a7e8-b815599aa86d" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30e73413-c3a7-4a32-9025-8ff14f3e3e27" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,518</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59e37158-79a7-4c28-8e82-be840b7a90a5" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:DirectCostsAndExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1993b80-353a-4165-bb83-803843044870" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8340d21-11df-4e0e-9b5f-9cdba13cb7a6" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_626976af-8a4e-4c06-a6eb-0d30555235b7" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,517</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2333f51f-a18a-4354-bead-d931a4024db6" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0291282c-e631-45ed-9fc5-f2d977394360" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a977ba4f-d6b7-421f-a7ca-3024ad848b92" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7a0cb64-6ccc-4c62-be32-361a88f16545" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">95,446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b0b6931-e22e-4463-83ab-1ed287af0e1a" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,491</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2d44788-6279-4090-afd4-18016ebe140b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de74d6cf-f4a2-465b-9b36-a833f7de4e68" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,934</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc066dc2-e17c-415c-82d6-6a3512874c48" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d09904ff-8c05-4d8e-a182-c7c356b03bcb" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,604</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec428b01-4e0a-4076-accf-dafde67697fd" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on debt extinguishments, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c93dc31a-5892-4417-8e9d-5951d1c5ca82" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:middle;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other (expense) income, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0371225-bbd4-41b5-aa1e-dc40376a3797" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d18bc84-605f-4431-a679-555f6dc83c63" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:OtherNonoperatingIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">440</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37d2e0ea-575f-4eac-b8ef-60bd9c71a390" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,219</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dd43783-85a2-478c-ac04-4940432ca0d0" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">8,416</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6200d4e-af09-429c-817c-69a328b17e03" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25069897-48ff-47de-9538-fc09cf43159f" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d88e464-eb1e-4cc8-bb5d-5acf08b46add" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.58</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c2bf116-05b3-4f7e-8a29-25cbb7b2e383" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">6.48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3fe6400-9fda-49d5-bd3c-8c30be30dd2a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">27,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_621033b1-8bba-4cf5-9c84-7941e1b27802" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">4,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_convertible_preferred_stock_s"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Convertible Preferred Sto</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ck and Stockholders' Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.247%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:6.771%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:6.362%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:6.9%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:6.483%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:6.502%;"></td>
    <td style="width:0.482%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.965%;"></td>
    <td style="width:6.39%;"></td>
    <td style="width:0.64%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:0.992%;"></td>
    <td style="width:6.576%;"></td>
    <td style="width:0.64%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Convertible Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Additional Paid&#x2011;In</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total Stockholders' Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance &#x2011; January 1, 2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e996c48-ca78-4742-968c-3e6a905269c1" contextRef="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">118,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09601a98-2aa7-4701-bab5-520488bda399" contextRef="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba51245d-b41d-4b0c-8a81-1773aaf30be3" contextRef="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF">255</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_451d1e8f-42ab-4687-924a-52877f26a712" contextRef="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_554afdd8-21e0-4dad-ae81-c6d6404b368b" contextRef="C_07202086-28e8-435f-adff-fe19436c69b0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,324</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a681c0-9278-451c-a1b1-978514e7aee3" contextRef="C_14445421-ccca-421e-9c3f-7d1d23b7cde7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">227,464</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9c444cb-0ec1-4c47-b98a-49ee48c7658c" contextRef="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">225,139</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock in initial public offering, net of discounts and commission of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_881c015e-3e12-4e28-b31a-afe29171b98c" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,040</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;and direct offering costs of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_792d8089-c5d2-4103-9fb4-49282bd5ace0" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CapitalUnitsTotalCostToInvestors" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,203</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be7d56e4-e468-4818-a875-2a38b7ec5ce7" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">4,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c88051c3-ed20-4d05-9ede-5d77758b1183" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3c31bfc-1bbf-49c8-b7f1-10837e5cc16b" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,753</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4eeb78a-2966-4164-a585-9c3264b35879" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of preferred stock into common stock upon initial public offering</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bce0269a-c355-4346-831e-b31b4e8e3234" contextRef="C_80a34980-9af4-46a5-ab87-825a03cf6961" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" sign="-" format="ixt:numdotdecimal">118,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c97da2d7-8337-48e6-8f68-71013f6e7e53" contextRef="C_80a34980-9af4-46a5-ab87-825a03cf6961" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">193,959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81556e0f-92f3-4325-8fab-ea863d142c9b" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">20,091</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf98d3e0-5df7-4252-a8fd-e109c9566e31" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7da11809-5bc8-46e1-bffe-970cce6a8ecd" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,939</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f91fd82-ad0e-4c83-8a56-75d9aaa14cc4" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of convertible debt into common stock upon initial public offering</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c6ddd66-699a-4a79-9935-61cd66ed5d86" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e29ad72-0e57-4ded-a36c-904901115837" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d82ee9d4-b2d1-4919-a663-4cb8c23f52cc" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,614</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_141db9ff-23aa-4006-9a59-b37de8c62491" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0a76af3-cd5b-4833-b820-0a5f05429c5c" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6ffa636-2500-4df6-8810-ab905e96322c" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,274</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e92bb17-e553-424b-bc09-abcf45242b07" contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_151fcd91-3a48-4cd2-8823-33f442bfd2c3" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f975b3b-03ac-42a4-b210-de37e953eae0" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock&#x2011;based compensation</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88b4d96b-496c-43a3-98c8-067b435c831c" contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_055d8f93-0be8-4e91-9a9f-164d776b82fc" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ae9c62b-d123-4415-8a0e-d166974edb0b" contextRef="C_da0bc552-b359-4652-9ba1-d8e29a01881e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2858d8e1-0339-4d39-aa29-4031ffc41ec3" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance &#x2011; December 31, 2020</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aecd0145-ceb2-4182-b3b6-304f2ea1d249" contextRef="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">26,562</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b921fe2-7472-48f2-a8e1-7dde47b9d96d" contextRef="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3">27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23e990b1-c969-4924-b2fa-5044e656369b" contextRef="C_233385c2-cf9b-4c0e-ab38-fbc8fe271a49" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">299,953</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72336864-afb2-47a8-8bac-f9e5ec49d842" contextRef="C_162734b5-e9c9-4193-b4c1-2b7ff33ee96f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">258,814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f218ce8d-fcbd-4c94-afb4-110b86c428b4" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">41,166</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock, net of discounts and commission of $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcf61ca7-b309-4927-820a-d00708538ab6" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1b3daa8-d6cd-4887-8cf1-2d4f48dbd0fa" contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">3,757</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87d5386f-7ebb-454c-a976-7f352daf1d25" contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5629fc2a-86d6-4ad6-813b-4c72df351da0" contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,675</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18b0f66f-5caf-44ec-853b-877cd5276c27" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,679</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5939728-9ff5-4a97-a0fa-1e149e247fa1" contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f67d98b6-4baa-4374-ac70-4267a8ec9404" contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f482c65-df6d-436e-bfa0-ce6e2d1b4d27" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6821b58-ec25-40d1-916f-f97422750fc1" contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cbcf421b-8acf-4dda-b871-be1c4fd08a17" contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3eb6bdd1-fb32-4130-992c-9e4169696f21" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock&#x2011;based compensation</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13a798c6-48b2-4e5d-9fec-ef9e647225f2" contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c2e1df7-1215-4d54-ae8a-bd1f8a330cb8" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68dc4fa1-f3b8-4c0e-acf6-410c74d5dc4f" contextRef="C_24b5491d-ac78-49f4-af90-1e06570e8d91" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94931d21-35d4-40b9-9cd9-234b3ece841b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance - December 31, 2021</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61fb320b-8e23-4539-b6fa-4bf488ff99c9" contextRef="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8" name="us-gaap:SharesOutstanding" unitRef="U_shares" scale="3" decimals="INF" format="ixt:numdotdecimal">30,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69304e0e-e8ea-4cc5-be5e-39d13e5630b3" contextRef="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ee62580-d9ca-45ce-84fa-c1532fb1ebd8" contextRef="C_8a6364fe-eb05-498f-8396-31e93f9646a7" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">321,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6821ae3c-abbd-45b5-acaf-1fc5876237f5" contextRef="C_2af95b4c-4f7e-4e7e-9808-928b36f0a3d9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">301,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b411fe8-8753-4232-a2f4-35b1a3cd3189" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,727</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.639%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.072%;"></td>
    <td style="width:0.798%;"></td>
    <td style="width:1.605%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.072%;"></td>
    <td style="width:0.798%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0bda03a-f312-4515-a145-d0d1a688dc6d" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5443b5d0-5eff-4f39-b8d8-88c3079da98f" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,350</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted<br />&#160;&#160;&#160;cash used in operating activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_512bf02d-4434-4a3f-a2ce-549a6097def0" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,178</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2844d605-a984-4e57-9907-8d96ab0650a9" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization of convertible notes debt discount</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca6d9c6c-67a2-43eb-93f1-3f75ee7ee5fd" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AmortizationOfDebtDiscountPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gain on debt extinguishments, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0edb1c8e-6453-4afe-a604-b10a9365a83c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,298</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock&#x2011;based compensation expense</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f5ce441-b5bc-4831-89eb-b92af7826edf" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1555ba3-868b-44a7-9cd8-d6e7d2ada538" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of warrant liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d147651-cecf-4bcb-87c1-0b79c736c6d7" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,252</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in contingent consideration</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c51cbd86-fde4-44d7-8693-1219310bc782" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_835c29cc-1699-4381-b541-4f68a0dcf3c1" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for doubtful accounts</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2ffa533-cbe7-4af9-964c-449de9e5ac7d" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1dde67f-826f-4331-8be7-13665b12f8da" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProvisionForDoubtfulAccounts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest, amortization of debt issuance costs and other</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75eb1aea-7dcf-4383-ade6-fc7e0525221f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bf35a02-d910-47fe-8650-6679724def24" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,418</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7645b386-5a11-4aff-853e-47cae5639e53" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11,454</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7affd27-2190-47ff-a88a-b35713e3f5f8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,308</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c88a1c6b-96e9-44fe-ac16-b7a2c18a7ae9" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,369</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46a7189b-71a4-4bf7-ad04-85a331ed2e42" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,588</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other long-term assets and liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63df9a6d-622b-4778-add9-2bb76d9b2c36" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">875</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e431f608-81d8-4e41-8d3a-6c266e3fad8d" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,808</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable and other accrued liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b357534c-f7f3-49f9-ae52-31d0c296d9e9" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4c8a214-fb2b-4da8-a5dc-e0e5eef589c8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,654</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9963acf-4ae8-431c-9ab3-eca1d833f1c8" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,682</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3f7a5da-6d72-490e-8ea6-22278e412b86" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash and cash equivalents and restricted cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0aba40dc-2d18-4699-8fda-f124e8a2b144" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c2e56cc-1e8a-4cd9-ad7a-4ed4fef402ed" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">21,366</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe5a8015-61e3-4e7b-b7ba-d6017b122718" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4716bf4a-6921-4d64-bbd3-689f3a031392" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patent costs and intangible asset acquisition, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b622401-7fca-42dd-98e1-c55135f648f2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cf71f07-42d1-4a14-b1f8-e640836e8730" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments to acquire Oncimmune assets</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95ef9cd3-afdf-42b9-a1d4-ccdbb6582cd8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:PaymentsToAcquireOncimmune" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash and cash equivalents and restricted cash used in investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3034a289-4340-4f11-8d67-a13b023b59a3" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,547</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d66d1608-5add-4d8c-a99a-d04b837ffc0b" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from initial public offering</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a68b7f18-a485-49f9-86ef-2f32f26b0d45" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,000</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from the issuance of common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dd4d4efb-a701-404f-8a96-08b083f92be2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,343</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock under employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c86a6f55-8923-4b29-b181-70b5a6428489" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e043977-1be6-4a71-a798-35e12fa67611" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">769</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0afc4431-4097-4f2d-aa26-ad076a4ed816" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,340</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from issuances of convertible notes payable</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08d78d47-95bb-44c9-b76a-c8a93493d676" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Proceeds from term loan and notes payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6163864d-a3a4-4d1f-8d3b-8495d17aac64" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,078</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4cb789ac-b567-41b0-b19b-0d2df6fe1b01" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,085</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Repayment of term loan and notes payable</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b54c090b-bc86-4ad2-a352-bf7021f823c3" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:RepaymentsOfLongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,428</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of debt issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60b237af-17f3-4d23-9df4-8551f7fdbe36" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">164</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity financing costs</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20277a66-1ea6-4364-a0b5-51b9c6f00bef" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc577af9-8a8e-4dd0-9cf5-2d56c03dc167" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,243</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ade2fa23-55c5-442a-acd3-3c4ff4e27351" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash and cash equivalents and restricted cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb4fa72d-2564-486e-9adf-25047abe3679" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,262</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc0471f5-b848-421c-a581-3b59ad08f819" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,131</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase (decrease) in cash and cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_972d2373-d591-411f-8fa7-f71a0c821f7e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a489004-a373-49e6-b950-496768d520ce" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents, and restricted cash &#x2011; beginning of period</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc2d9e89-6fe6-4685-8a28-d1145f723de4" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f70ee8c6-831d-4487-a75e-59a517c3876f" contextRef="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,468</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash, cash equivalents, and restricted cash &#x2011; end of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_023650d6-616b-4063-b435-e66f5cfb4731" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,798</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7352dd4d-39a0-4b10-879e-df51b1cdd626" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Statements of Cash Flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Continued from the previous page)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Supplemental cash flow information</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.648%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.244%;"></td>
    <td style="width:0.603%;"></td>
    <td style="width:1.614%;"></td>
    <td style="width:1.206%;"></td>
    <td style="width:13.263%;"></td>
    <td style="width:0.603%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5be56280-4dfb-4a67-a3c7-5bbd44ffd4b8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ConversionOfPreferredStockIntoCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">193,959</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Conversion of convertible notes and accrued interest into common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d32af77d-d320-4a2e-8909-fa6894987a60" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of put option liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b74113d7-e903-47ba-a149-3621362f08a5" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Value of put option recorded at issuance of convertible debt payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bceeb9a9-3af3-4316-9092-cb52eb975d21" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,389</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash paid for interest</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d53cfc78-27f5-41d6-a6cc-7056271af848" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,676</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3c74a15-77dc-4df8-91b3-7677fcbce212" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:InterestPaidNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,844</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbdac08f-b3e8-43b1-a74e-fd2c38750eb3" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-cash debt issuance costs included in Accrued liabilities</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_948e00c3-679d-4933-bc79-bb8eb5388958" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying Notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">BIODESIX, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Financ</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3494f61-0d4a-43ac-a7d4-53d58fb60535" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 1 &#x2013; Organization and Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) granted Emergency Use Authorization (EUA) of the Bio-Rad SARS-CoV-2 Droplet Digital&#153; polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Blood-Based Lung Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company offers </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1c4e9ff-d2d5-4d0a-af7f-9db23edc0381" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:NumberOfCancerTest" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnosis</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify XL2&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#174; tests, together marketed as part of our Nodify Lung</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d900339-1cea-4dae-8cee-80141f30c7ec" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:NumberOfCommercialBloodBasedTest" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat ddPCR&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VeriStrat&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tests, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">marketed as part of our new IQLung&#153; testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat NGS&#153; (NGS) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, our 72-hour blood-based NGS test, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner. The GeneStrat NGS test is marketed as part of the new IQ Lung testing strategy with the GeneStrat ddPCR and VeriStrat tests.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate and have commercialized the Biodesix WorkSafe&#153; testing program, under which the Company offers </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e9123bb-9c76-4349-9182-65ab2d6d729d" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:NumberOfSARSCoV2Test" unitRef="U_Test" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> SARS-CoV-2 tests:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, which is authorized by the FDA to be performed by Clinical Laboratory Improvement Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platelia SARS-CoV-2 Total Ab </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">cPass&#153; SARS-CoV-2 Neutralization Antibody </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or a previous SARS-CoV-2 infection. This test was commercially introduced during the second quarter 2021 in partnership with GenScript Biotech Corporation.</span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#x2019;s testing services are made available through its clinical laboratories.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3909a406-516e-442a-bd16-344eff5bb9be" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:InitialPublicOfferingIPOPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2020, the Company completed its initial public offering (IPO), in which it issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5edc8b80-c110-42bf-85b7-0dc7c6b6219e" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3e22da9-2695-4a3c-a613-d02ac4df2700" contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc6264ff-aadc-4bba-926a-65556663d67d" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5">63.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the IPO, all shares of the Company&#x2019;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e903810-8ace-4e5a-b997-bb5543b1e782" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">21,939,025</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, and all then outstanding warrants to purchase the Company&#x2019;s Series G convertible preferred stock were automatically converted into warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca8fe066-bb91-4697-b1bd-3335bf99e3e1" contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock.</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">At-the-Money Offering</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 30, 2021, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3246f5f3-16f3-4d9b-bc3e-f84dbcebc96f" contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8459429b-7bba-49a3-9584-1f73eaf47386" contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,756,994</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> common shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3555ee6-205e-4162-8ec6-304dda965a7a" contextRef="C_f1ea6781-dd41-46fb-8136-21495568924f" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">4.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share in an at-the-market offering. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65df139e-b143-40e7-8544-d434113e54c8" contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The net proceeds received were used to, among other things, fund the partial repayment of the 2021 Term Loan (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e464f26c-c023-467d-b0ee-c80c97c38b79" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 2 &#x2013; Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef5d774f-8139-495a-9d87-97b86b83b728" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we maintained cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a040874-0bfe-4ded-aeab-14db25d4268d" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and we have $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c261a83d-a52b-4fe2-bbcb-f909c2667bcf" contextRef="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd" name="us-gaap:DebtInstrumentAnnualPrincipalPayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in principal balance outstanding on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan (see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Note 8 &#x2013; Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balance. We have taken steps to improve our liquidity through raising debt and equity capital during 2021, amendments to our 2021 Term Loan and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiation with certain creditors to modify existing terms of arrangement to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_597119b2-dcaa-4fcc-8633-338799426b0b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bede26c1-bcbf-4c97-9e63-739d552d824e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c82bcb7c-5397-4876-aebf-786956c85abf" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 11 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf4c07c1-0f70-47ad-9b43-bb0da37a9798" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:DirectCostsAndExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_764261b5-2c6d-45ae-a945-d38d46302403" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1b86b40-61cb-48d2-b0b3-4bbcfa3a7047" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These expenses consist principally of salaries, bonuses, employee benefits, travel, stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a2fccb52-2dfb-4c65-9600-c44f102c2d95" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af43aeef-a14d-4a02-a536-f656e6e360f1" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5b72a1d-ca59-45a0-a12d-95ac0164056a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ce19e79-5c54-4c48-88b2-d9027e374ecc" contextRef="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d56923e-c6c8-4d64-8c70-ad8c4ca6c392" contextRef="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f" name="us-gaap:RestrictedCash" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million restricted cash, respectively, which was included in &#x2018;Other current assets&#x2019; in the accompanying balance sheets.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_054b9adb-08ca-4ab1-b9e2-3832e7c168e8" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab8cae4e-a76a-48e7-b63b-494acba9f9de" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:InventorySuppliesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expenses'. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f121317-8137-4109-8d16-5097b130f429" contextRef="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e56ccb39-1744-45b9-84d1-38a074cb108f" contextRef="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f" name="us-gaap:OtherInventorySupplies" unitRef="U_USD" scale="6" decimals="-5">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95e38aed-b1ba-4af8-b3ca-fa17c5c10d51" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_407518a8-f622-40ce-9fc1-00bcdbe09352;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fc2f600-9db0-4359-9915-b0459d2b1444" contextRef="C_479edcde-8115-401c-b300-335b4e160d8a" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_473b7666-d11a-4a37-916e-4a1b7cbc2a59" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_b3dcef61-3731-4d5f-bbbf-1d6449d4f1a8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1f83732d-655a-4549-9cd3-909570756af6" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07d09f7f-c7ab-4f6e-860b-6527b9524112" contextRef="C_ca090c1c-03b5-4f4f-bb08-20bb2d2a2b74" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d290808d-c2ac-4571-9d06-d87c31de6f21" contextRef="C_cb16d514-420d-4abb-9a34-052d761abec3" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88cb62a8-9cc6-42b2-a27f-7b4218dc5590" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_13c80031-0fe8-4c84-aae3-d2d12e7500f6" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="6" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f25f727-de30-41f6-a972-d64bf0b84532" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1155c48e-c344-48fd-9594-28412bedea7a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accumulated impairment losses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ad8740b-03f5-4f44-b5a8-85a61f99d3a0" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.823%;"></td>
        <td style="width:2.083%;"></td>
        <td style="width:86.094%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 4 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for further discussion related to estimated fair value measurements.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c4246295-9c70-4661-bf3b-ddfea2f62c90" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:ContingentConsiderationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7145a749-ae3b-4174-b4fa-4a43c0f35323" contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b80ede5a-90b6-49f6-a8de-ea069996f3c0" contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_652dd579-95ce-44c3-99eb-5db2706d60c8" contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">11</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_086a9913-801e-4173-b708-7fb2ce4c4bd7" contextRef="C_479edcde-8115-401c-b300-335b4e160d8a" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">13.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3810fc8-648a-464a-890b-e902d73b7546" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:WarrantLiabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the completion of the Company&#x2019;s IPO in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#x2019;s IPO in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e183da4d-26da-4c81-8dae-ca31db06893b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:PutOptionLiabilityPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Put Option Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020 and 2019, the Company issued convertible debt with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an IPO. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate. The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our IPO, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5db77ff2-4f98-441e-a0e4-cbc16d4b9b1a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share&#x2011;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service-condition RSUs. As a result of our IPO, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 12 &#x2014; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information related to share-based compensation.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaacec93-07b2-4330-892b-df0387d26a34" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until the Company&#x2019;s IPO in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#x2019;s losses. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_63ed0ba9-a815-451e-8f43-46d9b11cc989" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 3 &#x2013; Recent Accounting Pronouncements</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cb64db38-b758-4d45-9193-582754162a0c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current analysis we expect the adoption to result in the recognition of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_edabff51-0ce4-48c5-96f3-64ef856b5af6;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34ceab9a-033d-4714-8e55-a25b2036ef92" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_c2f421b0-9815-4d0f-82f3-8fb130ccb067" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">right of use assets</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and associated lease liabilities, inclusive of both lease and non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_34a57628-9596-4a92-8e77-d84395666e4d" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 4 - Fair Value</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recurring Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. </span><span><ix:nonNumeric id="F_3dc7e661-76c0-4aa4-bb97-825e96cd10ef" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" escape="true" continuedAt="F_3dc7e661-76c0-4aa4-bb97-825e96cd10ef_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, based on interest rates currently available for similar borrowings and were (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_3dc7e661-76c0-4aa4-bb97-825e96cd10ef_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.854%;"></td>
        <td style="width:1.187%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.611%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.187%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.331%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.187%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.331%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.187%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.925%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed4c7655-c163-48c9-96a6-a886131cb7dc" contextRef="C_be8dd81f-cfc5-46e4-b488-457166af9cbd" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74897a41-612d-4cc2-8231-f0b356fffb13" contextRef="C_9923eaf7-8b89-4851-b161-00aa62740c91" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd12b3e0-8f54-40e9-8f7d-768072cfbaf2" contextRef="C_bcbcd9a8-1029-4466-92ef-98684be0f3eb" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dff430fd-cbd8-41db-8ea7-998646ba9934" contextRef="C_394f3bb1-4c63-47eb-b527-f498fe718a44" name="us-gaap:LongTermDebtFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our IPO in October 2020, the warrant liability, put option liability and contingent value rights granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a94c1b53-bf1f-4dfe-aa02-9271f5b6e33b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_a94c1b53-bf1f-4dfe-aa02-9271f5b6e33b_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_a94c1b53-bf1f-4dfe-aa02-9271f5b6e33b_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.364%;"></td>
        <td style="width:13.765%;"></td>
        <td style="width:0.677%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.364%;"></td>
        <td style="width:12.708%;"></td>
        <td style="width:0.677%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_393deaab-fc10-4b92-a41f-292c5150fdcd" contextRef="C_8ff8a944-a271-4148-9c58-ee869ad37333" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,764</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49611ea0-5b29-4961-8b2b-2c566b0fbb99" contextRef="C_2f88e0dd-ea33-4f83-a540-f014f811689b" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,028</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c12f2d10-19d0-460d-8bf1-094fcf53d017" contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca0f581f-972f-4939-b3c0-3c3ef4c6dc05" contextRef="C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9ac31d1-fc8b-4aa7-b2a9-8d93818ade3a" contextRef="C_5f9b32d4-40ac-442c-bd25-14dd2c52ccb2" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fd406883-6f91-4a22-9159-b2df1b827f82" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in contingent consideration for the year ended December 31, 2021 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.082%;"></td>
        <td style="width:1.892%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:16.837%;"></td>
        <td style="width:0.983%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbd60dea-464a-4d4d-a396-1b97d46ec6e1" contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e312cd7-57bd-49cf-8222-5a06da88eb7c" contextRef="C_2e24974c-f120-44e6-86d6-efe03fc47db4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,622</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6db431e3-e2f6-4543-9405-db2f9058b130" contextRef="C_2e24974c-f120-44e6-86d6-efe03fc47db4" name="bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,238</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54fdd0b7-cabd-436a-b1f7-d9219acc5817" contextRef="C_2f88e0dd-ea33-4f83-a540-f014f811689b" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:10.338%;"></td>
        <td style="width:0.909%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:8.975%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:8.975%;"></td>
        <td style="width:0.918%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:1.205%;"></td>
        <td style="width:9.356%;"></td>
        <td style="width:0.918%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the Year Ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br />Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Put<br />Option<br />Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrant<br />Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br />Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f772dc9-1ce7-4572-b255-6c5bf4fea735" contextRef="C_695b6e0d-d079-4a22-b7f4-5eba3c5f5ec8" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,114</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e527da77-a9ba-4263-9262-6ad1720a3916" contextRef="C_34f7bf9b-9a78-44bf-9b7d-69e71e140c33" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffaf5b7c-de7a-4f5f-8428-180d1b897a59" contextRef="C_351c91ef-f104-49d7-9d7f-d572749a1c07" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3">372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7f41c13-7a54-488c-b0dd-b5ac2c9f4bf6" contextRef="C_9919b40f-119b-49c1-a2ac-2b76d5a098a0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3">60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36b83262-a801-4da0-b96c-7ff7b636d0f2" contextRef="C_87d5899a-2fad-4727-bf84-4cd4bb1daada" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abb2c160-f024-4eda-b7ee-62dfc4cea2f0" contextRef="C_f8907904-d558-4f3f-8e7e-17a1beefe665" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3">818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_304aecfc-6560-4d88-8788-29866d444354" contextRef="C_635f9c56-917e-4e2a-96b7-a3121ec435e4" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de431a39-786d-463e-b525-641c6494297f" contextRef="C_ffcdd51b-98b2-4868-af53-a0434a4dc1dd" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" sign="-">60</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassified to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e61814b-34a1-4fb7-aa0f-0c9901a9b020" contextRef="C_87d5899a-2fad-4727-bf84-4cd4bb1daada" name="bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28f0264d-4868-4a4c-adcf-a05ad95349dd" contextRef="C_635f9c56-917e-4e2a-96b7-a3121ec435e4" name="bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,624</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2861e4c-287d-4bd9-9276-1417ea0d7d79" contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,932</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (Indi APA). The contingent consideration arrangement </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_821fef07-221b-418d-abb2-505cff61a5ba" contextRef="C_6d377042-8c80-4077-9d06-ae158bc05d91" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74905c39-d10e-4cd6-871e-d157ebcdedc8" contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa816f01-0388-4d3f-89eb-f1623d97cb62" contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. Under the terms of the agreement, when the gross margin target was met the Company was required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e3a69e0-7033-4a87-92a8-df8ec3aba72e" contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2" name="bdsx:BusinessCombinationContingentConsiderationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. For the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e3a9818-09cb-4b91-87e1-b083be5915dd" contextRef="C_b402d595-7ac8-45f1-be4c-8e6d1bdb6938" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">six</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abe666cc-9730-48d7-828a-c3c261f7df39" contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash over </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_660ee890-c963-44df-9e66-ef8b88b59396" contextRef="C_8d547382-c6f4-454f-8385-5aac59c66fbb" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal quarterly installments. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24858df4-8b10-41a4-ade1-93f3daf8b4ea" contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5" name="us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3993bfb1-e7d3-4b4c-b141-a089565dceca" contextRef="C_3926ceff-39bd-4d7e-94cc-3a867487d940" name="bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8b2ae33-5ff5-4003-b710-7e8b5d8b23f3" contextRef="C_427d2811-f473-4d72-b6e7-7528519f151a" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" unitRef="U_USD" scale="6" decimals="-5">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company met the gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f247fe6-1f1f-4730-8c4b-747e62bdff6c" contextRef="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make six quarterly installments of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6e4baee-aca5-4778-b3e6-57b5af23f548" contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5" name="bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" unitRef="U_USD" scale="6" decimals="-5">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e824bea-afef-4115-adda-2e56170079d1" contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5">9.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in July 2023 for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8df7a778-d050-4c27-9e32-d5ec1db43b1b" contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5" name="bdsx:BusinessCombinationContingentConsiderationFinalPayment" unitRef="U_USD" scale="6" decimals="-5">37.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to make these payments are subject to consent from our lender under the 2021 Term Loan and related amendments (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). We obtained consent and subsequently made the first milestone payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f9ba6d6-1b32-4250-bda3-2ea47aadebed" contextRef="C_69b62320-c88d-472b-b26b-8b37a1a5a0b7" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in January 2022 and we are in discussions with our lender to obtain consents for future payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07c971a9-2258-4fda-a03a-121d160c6851" contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="INF">11</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f20b59b-d390-48a1-a44f-314b3ba6f683" contextRef="C_479edcde-8115-401c-b300-335b4e160d8a" name="bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" unitRef="U_pure" scale="-2" decimals="INF">13.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#x2018;Current portion of contingent consideration&#x2019; while the remaining amount to be paid is recorded as &#x2018;Contingent consideration&#x2019; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. The net change to contingent consideration recorded as operating expenses during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was a loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14924d83-3f88-4074-81aa-bdfd3b31a652" contextRef="C_ea5e3fdf-996d-4c05-8f7c-0456bb8ec3b7" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8a83e04-46ae-485e-87e5-ac7992da6d22" contextRef="C_0e3023eb-44b0-4fc0-a3c5-71c2b1aa3636" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="6" decimals="-5">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The amount recorded as &#x2018;Interest expense&#x2019; during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_248d90a4-790e-4952-9bfe-ab50bfc4e995" contextRef="C_5bb21277-4d96-4ddb-9ba4-3f3d05e4f337" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Put Option Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#x2019;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ebc50e5-3634-49ae-b674-3f3f210bc70f" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="bdsx:PutOptionLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#x2019;s IPO in October 2020 and reclassified to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrant Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99c412d2-afab-4aff-bab1-cf4b58064234" contextRef="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">613,333</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0adeb0c-7fa9-48ad-b1c5-3c2ee89d9bd8" contextRef="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.75</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1373e188-51fa-4287-a338-85d5c1757b17" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 23, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The estimated fair value of the warrant on the issuance date of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a00a8aa6-fb28-4325-ab85-5a2f1ddba7b1" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#x2019;s IPO, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#x2019;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d616768e-7d1e-426e-b56b-6a0d2f2e9f7a" contextRef="C_78ad82cd-de66-4f58-ab74-efd387f2e192" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80715f30-5dbc-43ed-ad03-889b5259be0c" contextRef="C_78ad82cd-de66-4f58-ab74-efd387f2e192" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.46</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and were also transferred to additional paid-in capital. During 2020, the Company recorded an increase in the value of the warrant liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_923cee1f-e051-4122-b0a7-7b1c78edd181" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="6" decimals="-5">1.3</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Value Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#x2011;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5553525-e45d-40d5-bc56-59fd1e0036b3" contextRef="C_cea9870b-55e4-4464-845c-28e908ce7ebd" name="bdsx:ContingentValueRightsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CVRs originally valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fbfe204-185d-433e-adbf-5f8b18231335" contextRef="C_cea9870b-55e4-4464-845c-28e908ce7ebd" name="bdsx:ContingentValueRights" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. One CVR represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6819c12-1723-4f64-8799-431e7f200d8c" contextRef="C_e458ef0f-2999-44aa-a713-1bddf0308c7f" name="bdsx:ContingentValueRightsPercentage" unitRef="U_pure" scale="-2" decimals="INF">0.00375</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#x2019;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a63b2c7-e8e6-4074-9782-0f714f51ea0f" contextRef="C_e458ef0f-2999-44aa-a713-1bddf0308c7f" name="bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders" unitRef="U_pure" scale="-2" decimals="2">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8ddf0c5-4a0d-48c4-b5e2-bd8b7ab47d77" contextRef="C_5d6b3d47-9c02-4894-9b66-a374b4ec92de" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 15 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments and Contingencies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for a discussion of the Co-Development Agreement with AVEO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Financial Assets and Liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_681f3860-e0e6-4356-bc17-d0929a4a7b47" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 5 &#x2013; Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61bda6a8-3706-4b10-9386-a7958e94a114" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.837%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.837%;"></td>
        <td style="width:0.983%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a8cfcc2-8f9e-450f-937f-dca216bb5d34" contextRef="C_54f8436f-4f07-4679-9f01-6b88613fe77b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,784</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3946f441-320b-4631-9666-8b8543c47470" contextRef="C_9f0f230b-11a1-485f-b548-212c085d2be9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,730</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d157f1bd-5824-4d5c-b27c-6d614dbc5bc3" contextRef="C_f4a0f9f9-1aed-4b51-a28b-499431427de3" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,339</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce7a3bce-6309-43c8-a135-87e619ed5873" contextRef="C_4d3ebbe2-4eae-4d8f-8107-5bbc08d2d099" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f60f8958-2f84-458d-8b25-e2e1afc05941" contextRef="C_547a9002-43fc-4570-ad79-1223f9f65e63" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db0b1d88-3c32-418c-9bd4-7389fd1b4f85" contextRef="C_afa76821-90e9-46a2-abff-2d96c1240f4d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">871</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_062d01f5-ef8b-4527-a574-8fa4e6a86af4" contextRef="C_a948fe3c-6e1a-4be0-9898-30610de47069" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">391</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1b81f2e-3d43-4ec9-8956-f0ee07506a75" contextRef="C_610d8971-4d2b-4f1e-a390-dfe80b599dfb" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">424</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80a1b4ac-4ed6-4e37-b0c7-ed29ac87178c" contextRef="C_70269112-fe2a-430e-be5e-df5d73c366d7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f2431fb-32c1-4f23-a1e4-09de355b69fb" contextRef="C_939cfa52-44fa-40af-9e11-eaed7a69e39b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vehicles</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd1fcd84-dfab-40bd-9bc4-bfa2da86fcc9" contextRef="C_d257b176-1b0a-4664-adfe-14f34c0c1a52" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f0522c9-3616-4364-81f8-43dcadd8d8c0" contextRef="C_dc019ec1-5478-4ebc-a4e8-0c7a3e9bf2db" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a159355-f9e4-4afe-ba4a-37608f9b517a" contextRef="C_1b5736c7-1ac5-4a03-9e32-a0ecc2616053" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">381</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a623e27-c595-451b-9f17-d4bd46525656" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,928</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_740c8357-9951-461e-bca8-07f75600cf16" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,902</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b7afb4b-fb5c-4c00-8681-76fe3acfac90" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,749</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b473cbf-a1f9-4a5b-93f0-87bc3c18ad6e" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,724</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7541899-acb5-4382-a2c3-a910a5307805" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,179</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_086471a3-fc11-403c-919a-f99f9711feef" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d3670c6-85cc-43c4-aa1a-c1f44ce9b2e4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.781%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.839%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.829%;"></td>
        <td style="width:0.974%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0f4e8fa-1527-4982-9fff-170962c6e898" contextRef="C_016d7540-660c-40c6-93d0-aeabbf4df993" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a1ccc2c-bfaa-4367-ad00-3b1d137f37f4" contextRef="C_5852124a-5af9-43ed-b3c2-0ff2fe0b33b7" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ab5916a-8d88-4104-982b-0b3eea9c7ff4" contextRef="C_a2edad21-1169-40d3-81f2-27f946978341" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8042d53-cd0b-4be8-9f9c-e2a38190aa94" contextRef="C_cd2c7fce-711f-4dae-a54c-036949770fed" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">478</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cee0a9cd-a2cc-4b08-848e-982b0c01dc83" contextRef="C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_199d610e-47b0-42fc-b471-7705c9759b68" contextRef="C_72bbc621-8c29-4345-9567-e3a8ec5494ab" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3">839</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8efb30bf-4cca-4661-91f0-5d1d5f91308b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 6 &#x2013; Goodwill and Intangible Assets</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7624079-170b-4deb-ba9b-9205eb1ee354" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.774%;"></td>
        <td style="width:1.039%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:5.936%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:1.234%;"></td>
        <td style="width:9.47%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:0.835%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:6.382%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:5.936%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:0.733%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:9.591%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:0.714%;"></td>
        <td style="width:1.197%;"></td>
        <td style="width:6.382%;"></td>
        <td style="width:0.733%;"></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br />Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br />Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7d8d682-4bff-4669-b9b1-99b43d5f442f" contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea46fe23-488b-4924-a41a-1c52bae44bdc" contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b42add44-f2a6-4790-910a-d45d3175ba58" contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,189</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f8895f30-96e9-4818-b404-477b72819343" contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_276a66fa-e5d9-4007-aa6b-267d7bb40e02" contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3eaa5896-e10a-4225-9e65-390dbe416f3b" contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2306df8-7da0-4267-bc14-6982ee5944a8" contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8c916df-f661-433d-a19b-204a7c5645fe" contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f66249f1-2b01-4114-8c8c-0767197f1697" contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0de07b3d-9c3d-4194-bff4-35c6a0abd617" contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501" name="us-gaap:FiniteLivedIntangibleAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73d40dd2-726e-4114-a8d5-a3c1529cbde6" contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,694</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2db07255-481d-4f78-b790-8c55bb81d761" contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets not subject to<br />&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6a82f76-394e-4d3e-9bd8-79b31329f200" contextRef="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17357625-5163-497d-9232-2f1a9fc5957a" contextRef="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39966ac4-2f40-4524-8c04-7a32e7610258" contextRef="C_001d92ef-337f-44d0-9202-4f278bb0fa67" name="bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec7c671e-7c1d-4e20-bb13-323c59d97048" contextRef="C_001d92ef-337f-44d0-9202-4f278bb0fa67" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6941ad82-78e2-49c9-9c6c-90f46df8fea0" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,755</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_325f97c4-0e6f-43b7-ac99-9a49ac548109" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fd45fef-7ad9-4fff-8991-81793ace6df1" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,617</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc412614-ccc2-4f3b-a42a-4d7e0f8fbd72" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,448</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6257eb31-e518-4ef7-89cd-d93e3116cf91" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,188</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_04252324-cb21-402a-afec-b9ba5776a8bc" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4f7e75bf-1853-442d-a229-9b640b7e704e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.583%;"></td>
        <td style="width:2.152%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:11.457%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.832%;"></td>
        <td style="width:0.974%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4fe4e5b-8e11-4755-87ad-5e17eeaa5882" contextRef="C_0ce3a578-735a-4075-87ce-b954e21a6041" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e16335e-7c56-4698-9dcb-ce4c3a44634a" contextRef="C_883404a9-e780-4066-b552-a0e49d50d630" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec8d3f0c-7b45-4b30-95a1-011306fc1630" contextRef="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_543973e9-a989-4329-af20-2a78c8c6ff2f" contextRef="C_661f4aa1-a621-4d97-add7-7f08a6309ae0" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,051</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bf09a32-9e55-4c94-8a67-29e6e203a789" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8de7efbb-82a3-438f-906a-f335332b1315" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,064</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future estimated amortization expense of intangible assets is (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:77.393%;"></td>
      <td style="width:1.874%;"></td>
      <td style="width:1.206%;"></td>
      <td style="width:18.924%;"></td>
      <td style="width:0.603%;"></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of <br />December 31, 2021</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b60b418-ea68-4acd-a22d-2665ac2c70e8" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f684200-e432-4daf-be28-1b639950b3bf" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,969</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e584bacf-7bf5-4ca8-b246-3ad1388684ea" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,959</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff2f91af-0440-4c98-9b0c-ab1e11f977e4" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,954</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ffd7c99b-6d5d-49fe-afbd-5265760554d4" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,941</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e5274ef-a33a-4a66-84ce-6238c570be57" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,719</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f87bd7a2-aa97-47e7-877b-8ce09e5b3121" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:FiniteLivedIntangibleAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,517</ix:nonFraction></span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
    </table></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0729588-aacb-43d1-889b-effb5643b50e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 7 &#x2013; Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_651a9aab-ba66-426c-ba5d-5c10bf5a533c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.784%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.832%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:1.596%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.832%;"></td>
        <td style="width:0.974%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_131635cb-225f-4ea0-9b42-801831bbfee3" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,029</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c85fbf07-2d86-4eed-a011-a2223c357145" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,975</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc36a362-0115-4b17-b36b-6853b2678902" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">870</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9c908e4-4960-4260-87d1-d7021b9bd434" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="bdsx:AccruedClinicalTrialExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0eef5e28-273a-4a0e-ba01-c14ddc64b5e3" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46f254cc-a0b9-40e7-b7f8-aeb6b44cc54c" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,099</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e94883c-c385-40b3-9791-538c73761c44" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,665</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28697c34-4d2c-4e72-96c0-ec6b14286993" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,789</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_73259ccc-640e-42f2-aa1e-dc1a3c9f2afb" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 8 &#x2013; Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our long-term debt consists of notes payable associated with our 2021 Term Loan, 2018 Notes and Paycheck Protection Program, each of which is described in further detail below. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffd8bb15-6901-4b9d-82d2-e3db1f3a6fc5" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" escape="true" continuedAt="F_ffd8bb15-6901-4b9d-82d2-e3db1f3a6fc5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_ffd8bb15-6901-4b9d-82d2-e3db1f3a6fc5_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.308%;"></td>
        <td style="width:1.577%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.386%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.577%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.755%;"></td>
        <td style="width:1.002%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a463a212-b4bb-4146-b1a3-134eb20ff9eb" contextRef="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 Notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a6fd8e1-2d43-4d54-a7c7-f467a3027005" contextRef="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24,972</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Paycheck Protection Program</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_514cc4c9-9d70-4a03-a6af-66a6010043ea" contextRef="C_e272dfed-04df-4966-8eea-8a8670605352" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,107</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_974cfa85-bc2f-475d-9fd7-f6cef71826f5" contextRef="C_f68dea5d-5219-4f85-b2dc-32544a35182b" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83c2a474-c0df-46ab-89fd-86b128394719" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85d29684-e990-4a0d-a23d-b511d8e3df7e" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94442431-c467-4da6-844e-78322e1d08ba" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,012</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82bd5617-03d9-4368-b4af-6f2803b7292d" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:NotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee76aeed-ea98-470e-95c8-b4873e7062ef" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91735e5a-70be-4f8a-9c30-d5731b1fb277" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:NotesPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,840</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c971170c-6729-444f-a525-c1c7eb91ab04" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,993</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08fee7e6-fc3b-4530-baaa-24483be256ed" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:LongTermNotesPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,926</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Term Loan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9506b9a4-025e-45d1-ac3f-9d195aa246e8" contextRef="C_dce01a48-8efc-4803-9957-bfa88c6b1299" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_046f3317-1f65-4c58-af42-f77c56c930ea" contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8" name="us-gaap:DebtInstrumentDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan provides for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_87580cdc-eb4a-46a7-8b5e-f0c3936c66d1" contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6" name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monthly</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a83cc44-cb57-4cc8-b33c-42269a67ea7d" contextRef="C_02073a80-e7d4-420b-a2a9-04056034b97e" name="bdsx:RevenueMilestone" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">65</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.</span></ix:nonNumeric></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s final payment, due at maturity on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5194cad8-037f-429c-9f90-1e40a65eb8cd" contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6" name="us-gaap:DebtInstrumentMaturityDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, shall include all outstanding principal and accrued and unpaid interest, lender fees and expenses, of which the majority will include a final payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_339ba870-99f3-4e74-adea-73667a6b1ea9" contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and all other sums, if any, that shall have become due and payable hereunder with respect to the 2021 Term Loan. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_727f342c-a435-4135-9f8f-3e93508a786a" contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final payment will be amortized as interest expense over the term of the 2021 Term Loan. The Company has the option to prepay, prior to maturity, the total outstanding principal amount plus accrued and unpaid interest, subject to a prepayment penalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_859ae49e-d51a-43a9-a380-f07533ef5d1e" contextRef="C_4841ec21-e13f-4543-9fc7-01050702bdab" name="bdsx:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid prior to the first anniversary of the Effective Date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2d4002c-872e-4293-bf7b-290984db9576" contextRef="C_3e8e4408-1447-42cb-bbca-6204beddc1bb" name="bdsx:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid on or after the first anniversary but prior to the second anniversary of the Effective Date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb682cdb-7eca-40ba-9324-5c4d542b6582" contextRef="C_be6ca8b8-4a35-4cad-b184-8b65c4c20b91" name="bdsx:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid on or after the second anniversary but prior to October 19, 2025, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0852ee3-e682-4048-9525-45e95d4d06df" contextRef="C_605a1f05-b224-4c9a-a68f-b4ebf4f58a59" name="bdsx:DebtInstrumentPrepaymentPenaltyPercentage" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% thereafter.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company granted the Lender a security interest in substantially all of the Company&#x2019;s assets. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d7e7edb-8dee-49be-b029-6ef31fb2c26e" contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8" name="us-gaap:DebtInstrumentCovenantDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02f5aabc-5fe0-4f43-b879-6bc9cec95c2a" contextRef="C_12147dfe-e917-4369-b593-468bf48cc6b6" name="bdsx:MinimumLiquidityRatioCovenant" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">0.95</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9d4c00d-dbd9-4833-9aa8-abc7ed7f705c" contextRef="C_12147dfe-e917-4369-b593-468bf48cc6b6" name="bdsx:PercentageOfMinimumRevenueRequirement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s projected revenue performed at the end of each reporting p</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eriod.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (First Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three month period ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87bcc55b-9b96-43d5-b6b9-c2258e4e9fe5" contextRef="C_70caefc6-3ec4-4c3c-872d-2ca7c3a4dd74" name="us-gaap:CashCollateralForBorrowedSecurities" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the benefit of our lender if the balance of our cash and cash equivalents declines below $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64419dce-d17d-4f57-b80f-7df78268e9bd" contextRef="C_848353f5-4aab-4165-b023-6cc47cbe6d8d" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca47098b-9626-407f-a84d-1913c352fb66" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="bdsx:MilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million January 2022 milestone payment under the Indi APA, repay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b8fcd0b-5586-403a-9e3f-7ddbd9bb3a78" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in outstanding principal on December 31, 2021, waive the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_882e4c37-4727-4154-b7bc-6373346c9454" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="bdsx:PrepaymentFeeWaivedAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">600,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prepayment fee on the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e4fa26d-2a33-4cff-9c49-085cac29a695" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million Term Loan repayment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement to not less </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e437c5e-2376-4db7-9d46-f6dd1cf837a6" contextRef="C_9a21cd39-7714-46bd-8caa-1643fbfd5aa9" name="bdsx:PercentageOfMinimumRevenueRequirement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the three months ended March 31, 2022 and not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f00b7ca-b6d7-4c13-a9be-959ec9bf21a2" contextRef="C_93914a7c-1f7d-4779-a324-6676f6a64acb" name="bdsx:PercentageOfMinimumRevenueRequirement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on a trailing six month rolling basis for each quarter thereafter of the Company&#x2019;s projected revenue performed at the end of each reporting period</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Lender agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially prepay the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_403c2f7f-5b73-4b65-855c-955ead573da8" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="bdsx:PartialRepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in outstanding principal, thereby eliminating the restricted cash collateral account. The Company recorded a loss on extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f444c63-484d-480e-addd-a9f719a9ea10" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million resulting from the write-off of debt issuance costs associated with the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_998fa2af-2784-424f-a1ca-a3d4dc6da3fc" contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million repayment of our 2021 Term Loan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. Failure to comply with the covenants and loan requirements may result in an event of default. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2034726a-ce2d-4fe3-8c78-efd22ffc7359" contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8" name="us-gaap:DebtInstrumentCovenantCompliance"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company was in compliance with all restrictive and financial covenants associated with its borrowings.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property without charge.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Notes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2018, the Company issued long-term debt of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42ab7e99-67d7-406c-8bea-7ce14e783a07" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">23.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes). Innovatus is also a holder of the Company&#x2019;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the time of issuance, the Company paid a facility fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3d23391-1d02-4704-b717-6b54717153b9" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="us-gaap:DebtInstrumentFeeAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued a warrant to Innovatus, with an initial estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eff85a36-cf30-4347-a63e-362880312847" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, for the purchase of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_232ac950-59b8-40d5-84d8-0908c41d0616" contextRef="C_d049bfe6-5f3b-4066-8ad9-a9ca88059623" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">613,333</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes. The 2018 Notes bore annual interest at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f5d46ff-4eac-4372-859b-0e76e48e7fdd" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_499ec967-7dc9-4c5a-9c13-2d3fac0759fb" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% was payable in cash, with the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6adb858e-fd44-4008-8f93-cab69e410b32" contextRef="C_a728943e-0005-498d-bf19-caa91ad50029" name="bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% added to principal through December 31, 2020. Total interest added to principal was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ff372c8-92bf-4748-8067-e450ce68ac76" contextRef="C_8f45d621-66e2-469e-81de-170b52163c24" name="bdsx:DebtInstrumentInterestAddedToPrincipalValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_27ce5d56-c9a1-439d-af34-4cadb13703b2" contextRef="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff" name="bdsx:DebtInstrumentInterestAddedToPrincipalValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of March 31, 2021 and December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, in connection with entering into the 2021 Term Loan agreement with SVB, the Company repaid all outstanding principal, accrued and unpaid interest, and prepayment fees in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fe4b790-d841-4a68-ace6-e1b570e8ded2" contextRef="C_98e59e9a-da90-42c6-9029-2c28be33926b" name="us-gaap:RepaymentsOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due under the 2018 Notes and contemporaneously terminated the related Loan and Security Agreement, dated as of February 23, 2018, as amended, between Innovatus and the Company. As a result of the extinguishment of the 2018 Notes, the Company recognized a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53534fe5-e097-438c-b00e-b9d3858ef1e0" contextRef="C_cad7d434-2ef5-46b9-aa6d-b243e79c1d26" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the three months ended March 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Paycheck Protection Program Note Payable</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0353a6a2-607e-4c90-965f-3377ec032f55" contextRef="C_dc89134f-48d3-4944-93af-a1d690ce60d2" name="us-gaap:DebtInstrumentCarryingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2130ff27-ebab-41bc-8da7-550f5bdbb8a4" contextRef="C_0c2b5021-3880-4a79-86df-3e22efd61deb" name="us-gaap:DebtInstrumentDescription" continuedAt="F_2130ff27-ebab-41bc-8da7-550f5bdbb8a4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PPP Loan had a maturity date on the two-year anniversary of the funding date, April 2022, and included a fixed rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f0881c9-b7d9-4e27-bc8b-4e9503c5a108" contextRef="C_17de90cc-7d15-42d1-b8bb-764245d80c72" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">1.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), were scheduled to commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_2130ff27-ebab-41bc-8da7-550f5bdbb8a4_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pay any facility charge to obtain the PPP Loan.</span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Note and Agreement contained customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All or a portion of the PPP Loan may be forgiven by the SBA upon application by the Company. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfa707fc-e789-4849-b775-e5124be0b348" contextRef="C_2d8d257d-2c7e-4c61-95ab-cfad10d07908" name="bdsx:PayrollCostsExcludesCompensationOfEmployee" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, prorated annually. Not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_657ec7be-ab4b-4792-8bb7-0cf49099e981" contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6" name="bdsx:PercentageForNonPayrollCosts" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6d7596d-d766-46a5-a160-805ea2beabe9" contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6" name="bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less annually are reduced by more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e1beb2e-216b-4094-a2a8-d073ace61020" contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6" name="bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. During the second quarter of 2021, the Company determined that it would apply for forgiveness under the SBA&#x2019;s Loan Forgiveness program, a change from its previous intent to repay. Subsequently, in July 2021 the Company applied for loan forgiveness and on August 17, 2021, the Company received legal release and formal notification that the PPP Loan was forgiven in full. During the three months ended September 30, 2021, the Company reduced the &#x2018;Current portion of notes payable&#x2019; and recorded a gain on extinguishment in the statements of operations for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e391fa58-07d0-4a9b-906f-4ea72954f435" contextRef="C_462729a6-5e59-40a9-995d-eddd6dbf59aa" name="us-gaap:ConvertibleNotesPayableCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_30a15258-3e8a-462b-8dab-e1d6fdf78f5c" contextRef="C_f406a25c-1311-429f-acab-1fbc603fcfb9" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.1</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million forgiven.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae1d0aa4-d7bd-4e22-85c6-2ca14bb2f846" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.397%;"></td>
        <td style="width:1.911%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:16.883%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of<br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6aa77d44-ee00-4175-8f1d-50177781aeef" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c68e9aa-ed15-46f8-b9d4-58b8ff604514" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf1f313c-4887-48f3-9e90-bdc79d09511f" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e10be224-8d83-4f9e-ac49-573fd966aa4c" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,818</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86e7b3e9-3e14-47b6-92f6-5473f16c818e" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,206</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b53d2cb7-eff6-4e32-b0b1-bd838e4fd7ba" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="bdsx:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c7e33c68-c876-484f-9ba9-d72561febd96" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:LongTermDebt" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,075</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85af869a-e843-4386-be04-721e2bf2e2a7" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:WarrantsForConvertiblePreferredStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 9 &#x2013; Warrants to Pur</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">chase Convertible Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. Through the closing of the Company&#x2019;s IPO, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_650747cf-66a1-4c06-ab12-c62dcd3d72c1" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true" continuedAt="F_650747cf-66a1-4c06-ab12-c62dcd3d72c1_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.005%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:9.144%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.163%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.144%;"></td>
        <td style="width:0.983%;"></td>
        <td style="width:1.215%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:9.19%;"></td>
        <td style="width:1.002%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series E</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series G </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#x2011; January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81454514-eb1b-40e9-b388-c419fb029a30" contextRef="C_22af9de2-1e40-4b4f-b58e-22e115d6077d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3">925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93fe64a5-68d5-4f2d-a897-0edbc0348e10" contextRef="C_22af9de2-1e40-4b4f-b58e-22e115d6077d" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aae7fe6c-ca09-468c-a9b2-ffc9eb802181" contextRef="C_01ea5af0-61c2-43e8-83f4-995b808a9869" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3">613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e92813b-a8db-485e-a66a-985f7ac1f80f" contextRef="C_01ea5af0-61c2-43e8-83f4-995b808a9869" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8997f25-fd8f-4c8f-b010-86a2667592ed" contextRef="C_6b886bcd-bd24-4350-8fd7-27742802fadf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" unitRef="U_shares" scale="3" decimals="-3">925</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5978ed7-05ce-41ba-a077-c70910ea60d8" contextRef="C_6b886bcd-bd24-4350-8fd7-27742802fadf" name="bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe7c9cc2-fe1d-476a-928a-9b98150ac940" contextRef="C_79ecbe49-ef52-4aab-acc0-1a7416b448df" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" unitRef="U_shares" scale="3" decimals="-3">613</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c19fdf97-5fe9-42db-aac8-be15e585bfb7" contextRef="C_79ecbe49-ef52-4aab-acc0-1a7416b448df" name="bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">0.75</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#x2011; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrants to purchase Series E convertible preferred stock were not exercised and expired during the three months ended June 2020.</span></p><div style="font-size:6.7pt;font-family:Times New Roman;"><ix:continuation id="F_650747cf-66a1-4c06-ab12-c62dcd3d72c1_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our IPO, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e94d3bc-b964-4ceb-a375-8586fe676416" contextRef="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">103,326</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants to purchase common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f873ec34-df61-4d21-b174-6977ef9320f0" contextRef="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">4.46</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which have an expiration date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f39bc261-6fcd-41e3-9672-47ea0d9befda" contextRef="C_c47916fb-71bf-444f-a33a-35da68f40857" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 23, 2028</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All common stock warrants remain outstanding as of December 31, 2021.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_39e03c4c-4d8d-400e-aa80-1599e4f33205" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 10 &#x2013; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3166d777-7ec1-470b-b442-6834581f8060" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac741efd-1edc-4237-9d17-95958b692a2d" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71bcac94-ea87-4e2d-9738-1ea6ece509e5" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:CommonStockVotingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holder of each share of common stock is entitled to one vote per share.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c0fba96-4e2a-4431-9f51-b026898d4aad" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49b832a1-9905-4744-bfe4-41e3f9e913c4" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in a registered IPO at a price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_326a62cb-976d-48bd-b056-3266c2538560" contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">18.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The net proceeds to the Company were </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8867cf9-b81f-4260-857b-3ea97bb26ae8" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" unitRef="U_USD" scale="6" decimals="-5">63.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32a6ab47-3d72-4185-a05b-a6305c95b6e0" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" unitRef="U_USD" scale="6" decimals="-5">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and direct offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fcb07529-4df4-4f4d-8703-cdb191a99c48" contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162" name="bdsx:DirectOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 30, 2021, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_617c4516-efcf-4dad-bb92-bc924bfd1246" contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">16.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20384f65-feac-4e1e-b3ab-a0a2bb1843a5" contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,756,994</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> common shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e32b16d2-e0c0-42aa-9f26-a50d24091d57" contextRef="C_89b9d305-cd7b-433d-9431-082e759b7f72" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">4.35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per share in an at-the-market offering. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ed0940c-1522-4837-af2b-73abb1327eb0" contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f" name="bdsx:ProceedsFromIssuanceOfCommonStockNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7041410d-a33e-459f-8347-bfe7cb94ff43" contextRef="C_89b9d305-cd7b-433d-9431-082e759b7f72" name="bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d5ab358-7c65-47cd-9ebc-09bd59b50c00" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93ce613a-cc53-4b7d-aef3-a8b2a4a55350" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" decimals="INF">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76d61d23-cca3-4969-b2e8-f85145cef475" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_3f787c3e-ef10-4765-878b-354070f3a680" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_5647cd01-22a0-4778-a85f-cc22fb472d5e" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_13f7f390-4ecb-4665-bf8a-5545685e6f03" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were issued or outstanding.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cab09024-92bc-4ed1-b7af-0992c14a15bc" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:RevenueFromContractWithCustomerTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 11 &#x2013; Revenue and Accounts Receivable Credit Concentration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_404125b2-8754-44b0-8ad1-a7468af4343e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:PrimarySourcesOfRevenueDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, historical price concessions granted to groups of customers, and its historical collection experience using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5941f7a1-cffc-43b4-b716-c62fb3832030" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DisaggregationOfRevenueTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.364%;"></td>
        <td style="width:13.765%;"></td>
        <td style="width:0.677%;"></td>
        <td style="width:1.605%;"></td>
        <td style="width:1.364%;"></td>
        <td style="width:12.708%;"></td>
        <td style="width:0.677%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c4bafe5-e438-45bf-9d80-8a8232f036d0" contextRef="C_3f722d28-c570-4810-8fc4-68f71db16286" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c153983-d07d-472f-83a2-225a8e653fff" contextRef="C_0104f2bd-d332-41e4-b969-1fde8368c3ec" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e385779d-fdad-4e4c-83b5-af44b1305836" contextRef="C_a0bd65dc-a53d-46d1-bb23-8dd79665bc2d" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,569</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4782bf6-3d65-4a40-8c9f-cc68a230b365" contextRef="C_612986b7-0cbc-4490-8560-a7436c79aa80" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9217db37-5422-4388-8015-1c2bf603afd2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd80a2ea-0ba7-40cf-985d-db8af7649419" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">45,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Revenue</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#x2018;Revenues&#x2019; in the statements of operations. Of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_212187a1-25aa-403e-b4e9-1f4d0ede98ea" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in &#x2018;Deferred Revenue&#x2019; recorded in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b61d79f-0036-42c8-995d-447c856df8ad" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recognized in revenues. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a7cbe27-d5e0-4429-a357-6751815dab63" contextRef="C_cd80bb2e-8eca-4461-9d92-d498ba929922" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was added to 'Deferred revenue' for up-front cash payments received for which revenue recognition criteria have not been met. The 'Deferred revenue' of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1603fa8-8369-46f4-b18d-60076fe8601d" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million recorded in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78d45b34-6c99-47b6-a314-f71ced934b26" contextRef="C_3fa48f27-8cf4-4782-b6a4-0cea10e6953e" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e815fdd6-9ddf-4a6c-86a2-44aa4b0ba1b9" contextRef="C_36978c15-7cae-4bbc-a497-ec47b32704f2" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in non-current deferred revenue, respectively, recorded within &#x2018;Other long-term liabilities&#x2019; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_13095e9a-2665-417c-b159-f973f2f24a83" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" escape="true" continuedAt="F_13095e9a-2665-417c-b159-f973f2f24a83_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.832%;"></td>
        <td style="width:1.586%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:13.43%;"></td>
        <td style="width:2.003%;"></td>
        <td style="width:1.586%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:12.354%;"></td>
        <td style="width:2.003%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32f412b2-6e32-4d7a-8832-1fc08bcfba5b" contextRef="C_d1d55fa8-853c-4dce-a4aa-f84151407d63" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d7491a-af0a-410e-a15a-9c7d602159f6" contextRef="C_cbb42c62-9833-417a-a5af-55f85ae20dd0" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da1da65f-c16f-4988-8997-fbc1daf6381d" contextRef="C_06bff184-ac5d-48a3-b2c8-c2f0e2ca06b8" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ecf95bf-7b58-40f2-b846-4c6c896c42a3" contextRef="C_ab23c5df-8c6e-46f4-83d5-abf0ca403590" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06b29edc-6034-4dab-9d4c-37ff0879d54e" contextRef="C_1b2acc98-6825-4199-91a5-077e16b3afd5" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">18</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3721b856-472e-4566-996a-a9c68b1a8670" contextRef="C_2a45a1ed-39d8-491b-b8f4-7363b3b51b79" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2">17</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s total revenue for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. The Company is subject to credit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_13095e9a-2665-417c-b159-f973f2f24a83_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.844%;"></td>
        <td style="width:1.586%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:13.423%;"></td>
        <td style="width:2.004%;"></td>
        <td style="width:1.586%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:12.347%;"></td>
        <td style="width:2.004%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f10f695-713f-462f-b876-7028ac51c1dc" contextRef="C_1521a2fc-d6fd-463e-a4d0-5ff13f834737" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de0ccd21-1fee-41ff-a64e-1ea695a1bedb" contextRef="C_706d9a9e-6a0d-4d6c-8f9b-08761cf3807f" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec73a432-8907-4f99-aac7-c8a9b12be7b2" contextRef="C_320c8bd8-4ae2-4caf-892d-f84cf7a846c3" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aca676c5-f4e2-4b8b-b1c4-b34816f3702a" contextRef="C_80994f88-01c2-4120-9cc2-79754d8c1bc6" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e8d158b-1ec3-4889-8742-f1e61a012f3e" contextRef="C_fb0c87cc-2dbf-4d30-9a38-bfb702341b31" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1175ba5-bafe-49bc-8765-33b300b347ab" contextRef="C_2b6cb7b5-b083-4ec5-b29c-9ae0101aa74b" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2a739c0-437e-4dc0-bdf2-fca919a9857e" contextRef="C_03977998-feb5-4ba1-9a39-98aa6bcd1820" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13e31fa6-db87-4386-a464-e19acd3f9e18" contextRef="C_2fde2582-8789-4b20-b26a-e76c33d3ce5a" name="us-gaap:ConcentrationRiskPercentage1" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4bb5ae99-05d7-4147-bfff-c681cfbee58f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 12 &#x2013; Share Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bcc26043-89b6-4280-aead-6aeaaace1da4" contextRef="C_d29dc415-dc05-49ca-b2ef-a00ef315776c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional awards may be granted under the 2006 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f94d81a1-91e4-4f5e-a666-e51de2a8726c" contextRef="C_826b69bf-89e7-459f-b550-a6811c484337" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional awards may be granted under the 2016 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of our IPO, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares reserved for issuance under the 20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_036588fe-972e-44f7-b90a-aae326ade434" contextRef="C_e65faf54-05c3-4544-989f-b6ba7475a88f" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,893,395</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_42f5d6af-c8b6-49c6-8183-283b25e0ff23" contextRef="C_577649de-5c2b-46f6-b8d5-5679a06e7577" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors. Up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8314ca1-984a-4416-83cd-5adb3fe3f4ea" contextRef="C_2b727503-f6ad-446e-9456-ccd781d7dcdc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,893,395</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sh</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a89a81dc-dc30-47f4-80dd-f59c4d3f8838" contextRef="C_0e5ba80b-b01d-424c-b1c0-f4822ff4bb56" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">630,685</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective with our IPO in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (ESPP). A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0bbc8ed-781c-40c3-8bb1-d5a7fe0b520e" contextRef="C_75149308-b918-457f-8ee9-7f3492120224" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">338,106</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68fb3023-ded5-4148-86fa-23f5e4a00201" contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="INF">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cf712d1-c83d-462b-b6ac-c6788f6952c4" contextRef="C_8df4046d-0fe5-4898-9781-f03f716cfbc0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" unitRef="U_pure" scale="-2" decimals="INF">15</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33192717-327c-44b6-8ff4-5daf7a795f6b" contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" unitRef="U_pure" scale="-2" decimals="INF">85</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of the fair market value of the Company&#x2019;s common stock on the first or last day of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">offering </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">period, whichever is lower. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72481a48-1591-4839-875a-2d9866e67905" contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d" name="bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5f92b92-acea-4368-9c0d-1e986a2a8b90" contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d" name="bdsx:DescriptionOfOfferingPeriodUnderPlan"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03b87f3f-b7b7-4b89-96b9-fdbc866759f4" contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">42,855</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the ESPP leaving </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dca7ac85-e75d-43a9-8974-354be1d89683" contextRef="C_8df4046d-0fe5-4898-9781-f03f716cfbc0" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">295,251</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remaining for future issuance.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Awards Granted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_352d5769-2566-4573-bb80-7ab884cd3d4a" contextRef="C_c8f3232a-4dcd-431e-b582-72448f737920" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-statutory stock options, which may be issued to employees, non-employees and directors, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da66cc35-f664-43c8-8ba9-38cdddbb13ff" contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance-based options vest in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4288b980-f64a-4656-999c-7c5802741355" contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee" name="bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting" unitRef="U_Installment" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal annual installments beginning one year after the grant date</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. On January 1, 2019, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d308581-fc39-4728-8143-4bf6feaeb6a5" contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">168,466</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance-condition options, with an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2949a6ab-087b-4084-b8c6-69d4d8a061aa" contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">0.77</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef943d77-b482-42ba-afbf-caa38ebecd07" contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2021 and 2020, the performance-conditions w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ere met and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41166e0a-d082-4ea9-9919-912385baf637" contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">56,156</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> opti</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ons and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4957c9a3-ca24-4c11-8f4f-79aef916954f" contextRef="C_62628f3e-204a-4e47-888d-80b800906159" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">56,155</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options, respectively, vested. During the year ended December 31, 2019, the performance-conditions were not met and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49fa3046-8204-4449-be74-eb0211ff243a" contextRef="C_be2758e9-5945-4245-bf58-cd5421da5cb6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">56,155</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options were forfeited.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> holders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company has granted service-condition RSUs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bonus-To-Options Program</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also has a Bonus-to-Options Program (the &#x201c;Bonus Option Program&#x201d;), is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;. Bonus Options issued must be exercised within a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef495dc2-5bbb-45f0-9a17-59c9b0250a79" contextRef="C_bd35d5ad-8efe-4775-803e-5923630c295d" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b5a09821-7bd3-4b85-bddb-d9a1e594a625" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.344%;"></td>
        <td style="width:1.122%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:14.376%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.679%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:13.856%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.679%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:14.431%;"></td>
        <td style="width:0.594%;"></td>
        <td style="width:1.679%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:10.666%;"></td>
        <td style="width:0.594%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Contractual<br />Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#x2011; January 1, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_109ee011-3955-4684-a302-6122398795d8" contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4208f1b-0822-4e55-a1c3-c38475c4fdee" contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">11.11</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81831752-bbde-462e-830a-a6bac53ff2d5" contextRef="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_440c30ab-4652-4b80-bb3a-4c7e76daaf05" contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,723</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdd547b2-c78a-460f-b515-ed863105e7c2" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_176b99a6-acc1-4b92-8c6c-a6296233fc5d" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.67</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41c40cdf-f63d-4e21-9d7e-dff638553eb1" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ed04cea-ef3d-4a94-922b-f33489147e5d" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.03</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f34221a-afb2-48cb-acc3-e9f243138ac3" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">20</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c091fd0-bc79-48cf-868e-912f4e910e24" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.69</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#x2011; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0ff4d44-c7f0-4ca5-abc2-23f59ba61f2d" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b2f25cc-f7d8-4b73-9588-74bce2ee7c4a" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41445e30-7d13-4b0d-94f3-a33d79de7c42" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9e77969-8cfa-40b3-b765-909a9729b887" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#x2011; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87caafc7-3676-486e-a445-01dee1063771" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">373</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9c12ec8-b779-4a97-8b0c-a459cb9ae77d" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1666cc5c-5d6f-419a-a940-53ae97ee58e0" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de16ee81-0bc0-43db-8277-0288a1fc6205" contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85f3e6aa-190a-4dfc-a118-36ac915f2216" contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c6cddbe-02c6-4b92-bdab-975cd0a4b91a" contextRef="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5">3.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022 and 2021 by the Compensation Committee of the Board of Directors. In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_621f72f0-3de2-48d6-a531-d3f49bcf8403" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-tax share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.362%;"></td>
        <td style="width:1.614%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:20.603%;"></td>
        <td style="width:0.974%;"></td>
        <td style="width:2.44%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:20.603%;"></td>
        <td style="width:0.993%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13bc2db3-54e2-46a0-94d4-0ee11ee67cb9" contextRef="C_0ce3a578-735a-4075-87ce-b954e21a6041" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c7d45c1-d656-4d1e-846b-e185a0fafd0d" contextRef="C_b5d3e429-66cd-4136-bc88-3e646c9bc008" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">572</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac9116dd-8510-4d6c-9ef4-0fd763176911" contextRef="C_10bed5db-cad0-4d81-95a0-1793592b5166" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f44dc272-7c79-4ecb-9ff1-0d92475c4b55" contextRef="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,323</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89993d4e-f855-444c-944c-6275dd70d5af" contextRef="C_661f4aa1-a621-4d97-add7-7f08a6309ae0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,120</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e312f6d-8884-4d44-a2b7-54e53de965d3" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,944</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64b18c36-e4ce-49cc-a121-d54dd77b2a02" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,709</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unrecognized remaining share-based compensation expense for options and RSUs was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_434d3855-008a-41fe-8c5a-e63a3a921ac6" contextRef="C_88dca331-7477-419b-b234-6230d9c7f1f8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and is expected to be amortized to expense over the next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0df67da-180e-45b1-84f2-cf8ae529464a" contextRef="C_3c75df96-50d6-49ea-8d24-017d2bbea9a8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11cd6d0a-7a93-472e-8a95-3733c6dd8d23" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.57%;"></td>
        <td style="width:1.113%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:13.542%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.651%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.552%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:1.651%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:13.57%;"></td>
        <td style="width:0.992%;"></td>
        <td style="width:1.651%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:10.314%;"></td>
        <td style="width:0.992%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Contractual<br />Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99d9442f-9433-4220-91b3-fa55a518362b" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,321</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58973a74-a386-45bc-9eec-20c6a94c36a3" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.82</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e027aec9-7c2c-4e4a-a8eb-f5b1916eb907" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60f536e5-cd75-4406-a141-b7d66d3a067c" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dcbdc32-d575-416c-a4aa-4a9239569721" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c52527f0-1af0-4809-adec-9638f539051a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">17.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_427fd403-7beb-47ba-b958-6696b353de09" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">225</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b77e388a-a33b-410f-86df-21365f7462b0" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.22</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6f9a21e-6068-434f-b995-f94da3449855" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">408</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61e69b68-83c1-43fa-8bbd-aafa2fc206c7" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">1.51</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#x2011; December 31, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6999750-b2fc-45d4-943d-5fff18f8a095" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,878</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d287f169-25dc-4868-897d-de3f89823582" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_faf7bdf1-79d1-4b17-9450-dc7bbaa68483" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ad0bbb9-2ae4-4271-9d32-f6cc4e153fae" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,288</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#x2011; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbe7d857-baa2-4173-bcce-51119d1f399e" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87148521-c26d-44cf-9ba2-0ecafe816157" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.02</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ed24b12-45f6-4271-96b1-6dfc380106eb" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f42b397b-4958-4927-a0f3-234cc0933a91" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,849</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef543adc-28f6-4fd5-9871-e5f80143a3ec" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_f5584c44-5cb0-4eec-bbf7-2362d5946c1e" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:DividendsCommonStock" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_b709d95b-7118-47b5-97c3-c2f8ccf1e935" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"></td>
        <td style="width:1.623%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:20.254%;"></td>
        <td style="width:2.003%;"></td>
        <td style="width:2.467%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:20.254%;"></td>
        <td style="width:2.003%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b43d9300-c727-4996-977e-ff2c3178ad48" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a5704efe-38b8-46e0-81ca-1a11bdd91fdc" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.73</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74fd29be-5820-495d-9015-aa9f65b57509" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">68.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7adc7778-c44a-4301-8b22-0c33e7803c3a" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk&#x2011;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d740904f-fb77-4b51-8af4-a67fb1e027a1" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2e135db-2e4d-45b8-bfdc-b4a228a242db" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.34</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e378b568-fdec-40a2-8b4d-a3ec191344de" contextRef="C_55faf862-904e-4749-90ab-5601a8d113a1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">71,707</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> service-condition RSUs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d43dfaee-4b19-4fce-8b7a-93dfc4d53b40" contextRef="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">150,811</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs outstanding, with a weighted average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4e14394-8514-4ed7-a675-144e222a5442" contextRef="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">5.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_1516a025-ecb3-4999-a8ef-93a949a859a4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 13 &#x2013; Net Loss per Common Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the Company&#x2019;s stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f7b051b-76f9-4577-834e-4c2aa0dbb224" contextRef="C_6d377042-8c80-4077-9d06-ae158bc05d91" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeca0c44-cf3f-4eb8-a0f7-d633c8703a0e" contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2" name="bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. If the gross margin target was met, the Company was required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e477f12b-0924-4b1f-95ad-512aeb6ede48" contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2" name="bdsx:BusinessCombinationContingentConsiderationShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Company met the gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70a6591a-abbc-483d-801b-560fad6ea5c2" contextRef="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for three consecutive months during the three months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which all parties agreed to forgo the issuance of common stock. As a result of the achievement of the gross margin target, the Company included the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71e6f1c1-1a9b-4c7c-80a4-c35d11da2dbe" contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,520,108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share from the date the gross margin target was met until the amendment was executed. These shares are not included in the statements of convertible preferred stock and stockholders' equity (deficit) or shares issued and outstanding in the accompanying balance sheets.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2f8306ea-df48-4c27-9297-27d7c0a70822" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.306%;"></td>
        <td style="width:1.466%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:14.702%;"></td>
        <td style="width:0.946%;"></td>
        <td style="width:1.466%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:14.739%;"></td>
        <td style="width:0.965%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dbb539b-8d5b-4b1d-abd7-a19dcdc0eb8c" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">43,159</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b36839fe-6a50-438d-aac8-2e3fcde7e6e8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used<br />&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a310717-09a5-4310-ab41-4dbede3686d9" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">27,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3286821c-2133-4e52-8ae9-2b4f65cd6ad9" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">4,838</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58f7618a-6b11-46ee-be74-105a4d630da1" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">1.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9f62c9c-6b57-481e-ab28-29e78b2b2742" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-">6.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The potentially dilutive securities as of December 31, 2021 and 2020 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan and would be subject to the treasury stock method when dilutive the terms of which are described in further detail in Note 12 &#x2013; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cd1e1372-924a-4354-9b26-d6d1ae01ce0e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_cd1e1372-924a-4354-9b26-d6d1ae01ce0e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_cd1e1372-924a-4354-9b26-d6d1ae01ce0e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.154%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:15.686%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:1.531%;"></td>
        <td style="width:0.603%;"></td>
        <td style="width:15.686%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_26065f2f-d6bd-4b71-ba20-47f4b31b9a24" contextRef="C_894dacc7-f9c8-465f-bb3e-677c3cff01e9" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">3,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f058f1a5-d4ba-4995-b60f-2455515f53ee" contextRef="C_337f9ff9-e36d-4674-9452-b807a7edb7f4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0fa7332-99e9-4ae4-9849-8063b606bab7" contextRef="C_367888ff-2937-4bf4-a0e7-2638e425e939" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49b25dec-77b5-4c69-a12d-2facb4d08610" contextRef="C_7d46f5a7-a39a-4c26-9184-61e4e53c8f05" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_938b946c-929d-4b75-a156-786ef8ad5a60" contextRef="C_ab45d19d-f12a-40a2-85e6-c11af3ecf535" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">103</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a78c5df1-775f-41b8-a65f-7a7c37d0694c" contextRef="C_6eb42b97-11c3-44ad-9689-15a6c7ffc9fc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">151</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfb1c8b7-0fe0-43f6-8f25-7d84060d22a6" contextRef="C_53c549cf-8442-4882-99fb-2cabbc0b4a81" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">79</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3b123f7-72ca-478b-a736-6de71ca8b0f2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">3,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa6eb4b4-1b65-482e-ba47-7aab851054ab" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" scale="3" decimals="-3" format="ixt:numdotdecimal">2,677</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_ab4b3245-5fb3-4d25-be40-3f3a835b1b4b" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 14 - Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3200757-4594-433e-9ab8-e891109f95b3" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> current provision for income taxes has been recorded. </span><span><ix:nonNumeric id="F_6d0cd5e0-e749-4776-afee-5d7ef8f38a50" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true" continuedAt="F_6d0cd5e0-e749-4776-afee-5d7ef8f38a50_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_6d0cd5e0-e749-4776-afee-5d7ef8f38a50_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.411%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:0.816%;"></td>
        <td style="width:13.75%;"></td>
        <td style="width:1.995%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:0.816%;"></td>
        <td style="width:12.414%;"></td>
        <td style="width:1.995%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_104c5004-a81f-4e92-99d7-7702b3674356" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06ea8f46-f0d5-4a02-ae1e-5f18ff4e62e4" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">21</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b45fc76-473f-4c51-a9bd-8ea652dcab65" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c581a5b7-8fcb-418c-8308-83be6e0cef26" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb22459b-0d8b-4323-8497-36874ea5155f" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_034ad6bd-c2aa-4fcc-a72c-2eb97cecf8c7" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_084c73b6-623d-41ca-8e7b-d5e5012b9e37" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b56d67eb-7f25-42f3-9c7b-5ddf4ef358f8" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d6b246ee-7524-46cc-b3e2-b511ec79968e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d891242d-c27d-4ca8-9eed-ef74801973fb" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="2" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><div style="font-size:11.0pt;font-family:Calibri;"><ix:nonNumeric id="F_77e2b204-e3fd-4927-b50f-c9e82ce353d2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.721%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:14.209%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.595%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.873%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf7b9ada-904d-4969-8c18-9543475c826a" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,874</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b27a644f-1627-44dc-8153-5c70474e7282" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ac3fa4a6-424d-427c-a2be-53ce6d30fa85" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,372</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60651b9f-fdbf-476a-9069-f6ae5edc2079" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,860</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8043f75c-4387-42d7-bee2-15528d965080" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetInterestCarryforward" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">554</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7ff450c-2914-4327-8416-5bd1eaf07402" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">215</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96beb281-c012-432d-9180-0aecad2f4c76" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">279</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9b8b3a5-75db-4110-958f-b835e6bc94b6" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c50829cf-3dbd-4e39-86b8-8cefe774e876" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">865</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_405e06a8-747c-47de-84b0-b8d996953a80" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c521fd6-1455-4a31-990e-e6f87527924f" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,406</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_924c2398-ea14-4fa4-9209-a9bb12743870" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2781f81-6a99-471e-a1af-0445ede09132" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,538</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b0b6535-b987-4d4e-8cbb-8e51e06fc3f7" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,457</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b9a4cde6-7bb1-4c5d-9a9c-f85ae6c1a506" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,083</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54ccb579-3b5a-4de0-bffd-eca2e6cc73af" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae6ec16f-1668-4717-bbed-59b01afe7671" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a48144ad-1c57-427e-a23f-8eab2efd3ecc" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81f6a985-98d4-4b49-a9c3-9db910b3a55e" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f026914-2333-4421-a9b3-6bc72fbebf48" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,153</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_311c9dae-af9d-4c0e-91e5-8b55837939f6" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:DeferredIncomeTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,455</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1afc761-e877-4e58-9a4a-c845a922d5db" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5">267.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0508813-48aa-42bb-84e2-6c5691e3d6db" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_319634d6-2dd7-4c48-8a33-10c7c0ddc4e9" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:TaxCreditCarryforwardDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expire beginning in 2026</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9cb08973-d2c0-4cfb-b36a-f295cf732326" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a73ad311-2575-42d5-96f6-7839ebf1a9c6" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" unitRef="U_pure" scale="-2" decimals="INF">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of net deferred tax assets.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5996a28-df13-43ef-b0bb-de1e589e24e2" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86da0c8c-be2b-40f8-9d28-4e6e8e38eb92" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2020.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2021, the Company determined that it now has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7843014-4b4c-4168-b90d-cf4d7031cada" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ad31a2f1-831a-42ad-9f19-b8a93d523339" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c500205f-de75-4265-b348-b00c75d81f3e" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true" continuedAt="F_c500205f-de75-4265-b348-b00c75d81f3e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:11.0pt;font-family:Calibri;"><ix:continuation id="F_c500205f-de75-4265-b348-b00c75d81f3e_1">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"></td>
        <td style="width:2.681%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:13.793%;"></td>
        <td style="width:0.798%;"></td>
        <td style="width:1.391%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:12.448%;"></td>
        <td style="width:0.798%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48188f59-740d-47a0-89aa-55a9b73fe333" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57ef72da-66d6-4af9-8898-f2965dd9bdf4" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41480ca7-c625-403a-9351-90f7e1597b30" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">106</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_358ab6ca-b42d-4c99-b5cc-7a82f178cefc" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">609</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55a199de-e8b5-4513-a987-0dccd6d5e101" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">843</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f6bf76e-0d94-4820-9208-f9aed31d2692" contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s federal and state returns for all years remain open to examination by tax authorities.</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6e9209db-89a1-429c-87c3-1ecf01011a30" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 15 &#x2013; Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases facilities under non&#x2011;cancelable operating leases. Rent expense </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb798a55-de2e-4726-ad2c-43e5c1e45c2a" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e33b5ed-297c-4bfe-bcb2-a62aebb8f335" contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc" name="us-gaap:OperatingLeasesRentExpenseNet" unitRef="U_USD" scale="6" decimals="-5">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c19413a3-5ac9-407f-a68e-e5fd41d0c0f0" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"></td>
        <td style="width:1.892%;"></td>
        <td style="width:1.206%;"></td>
        <td style="width:18.302%;"></td>
        <td style="width:0.603%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of <br />December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce5f89b7-2a58-4bc4-9c91-2f1b86108113" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2be389aa-7606-4302-8028-d727f338c66c" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">149</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dad2c922-38f2-43f6-9c26-fd817c3cffbb" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_568c5153-d8ba-4f37-8a64-631c327a92c9" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5450b329-e9be-4370-a810-102e7f7b742e" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf8c3ef6-3547-4229-a979-7bcb772b4d24" contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">937</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Co&#x2011;Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#x2011;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#x2011;of&#x2011;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ba5ef3b-daf3-4784-811e-1bcc79214770" contextRef="C_c77d5c42-d4c0-47d9-86be-96adc70e0b54" name="bdsx:PercentageOfDevelopmentAndRegulatoryCosts" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_892b91cc-339c-4cc3-9c5f-4ab741260810" contextRef="C_a29723b5-20cb-4e63-a0da-30a2983860b7" name="bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" unitRef="U_pure" scale="-2" decimals="2">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47a41bbb-37b9-4a04-ba20-029798616fa3" contextRef="C_b477c33a-377c-4327-9710-03e518e2ecbe" name="bdsx:RemainingEstimatedObligation" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in remaining obligations related to the AVEO agreement as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Following the Effective Date, the Company is entitled to a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63ca21fc-fb93-4fcc-8abf-16192f6ecd9a" contextRef="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210" name="bdsx:PercentageOfRoyaltyPaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6efed886-5116-4769-a578-ce5d5d92cb75" contextRef="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210" name="bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23a715be-241c-400d-b588-b869f86ff17d" contextRef="C_b477c33a-377c-4327-9710-03e518e2ecbe" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expenses related to this agreement for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Expenses related to this agreement for the year ended December 31, 2020 were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c721cf37-e3dd-434e-9dde-71be916ef3ba" contextRef="C_10d387cc-753c-46a2-9b2a-9b1890b49bdb" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc5b46a0-da75-4b95-b560-5252a5406a70" contextRef="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ae2618c-865f-45b0-b369-c4881bb739d3" contextRef="C_7388a94f-fccb-4085-aaf4-6b5e7ca6360d" name="bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" unitRef="U_pure" scale="-2" decimals="3">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c1d135fa-6bad-4c27-a837-77ffa74e5b68" contextRef="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac" name="bdsx:LicenseAgreementExpiryDate" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2024</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. Royalty expense under the Bio-Rad License was not significant for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21d5411a-3e25-4707-a5e9-ac4e7a3ed612" contextRef="C_03721b15-782d-4e40-bfe2-237a592136a5" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly Caprion Biosciences, Inc.) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97a6761d-6790-4ad5-80d3-9c221c1711e2" contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea" name="bdsx:PercentageOfFeePaymentsOnNetSales" unitRef="U_pure" scale="-2" decimals="2">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59c65876-0cf5-463b-92f7-e178f28ad3e9" contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea" name="bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue" unitRef="U_pure" scale="-2" decimals="5">0.675</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9e732b28-3c0a-4c65-b5c3-f3486b89aa49" contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea" name="bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the first commercial sale, ending in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65a32eba-7b44-4677-976b-24cd9cd204c7" contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea" name="bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Royalty expense under the CellCarta License for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eacdbf66-35d8-43b9-9211-641f5640214e" contextRef="C_98732f46-6752-47d9-bc3f-82fa1ccee5a9" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_219e6750-fcb9-422e-9e82-d79669f5a76b" contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210" name="bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" unitRef="U_pure" scale="-2" decimals="2">8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of recognized revenue for non-screen tests up to an annual minimum volume and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_754e3f30-7bad-4689-bd9e-7018ad5920a1" contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210" name="bdsx:MinimumAnnualVolumePercentageThereafter" unitRef="U_pure" scale="-2" decimals="INF">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% thereafter, with an escalating minimum </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_70bcaf0d-ea43-458b-8df1-b15f92c50e52" contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210" name="bdsx:PeriodOfEscalationsOfSales"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">through the first four years of sales</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Royalty expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9cd5ef6-8da0-4d0b-bc8e-cf4c75793335" contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1928d5eb-f33d-418c-bd38-a01c9593e8b2" contextRef="C_a21cae4c-4605-4cd5-b0d4-b15582d30357" name="us-gaap:RoyaltyExpense" unitRef="U_USD" scale="6" decimals="-5">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were incurred for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation, Claims and Assessments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. In September 2021, we reached a settlement agreement with the plaintiffs, which received preliminary approval from the Circuit Court of the City of St. Louis, State of Missouri (the Court) on November 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, regarding a dispute involving the Telephone Consumer Protection Act (TCPA). On January 31, 2022, the Court approved the final settlement payment to third parties of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e309f22f-473e-4d8b-8008-5b2e784a847c" contextRef="C_1355f790-e2f7-4e53-b996-2166830c4202" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_3b3f356b-3895-4a40-b563-748958fadaf5" contextRef="C_a136b0aa-9769-4cf4-9832-546661048e81" name="us-gaap:LossContingencyAccrualAtCarryingValue" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">210,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which was accrued as a legal contingency during the year ended December 31, 2021. We are not presently a party to any other legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a6ba7e91-b6e6-405a-87b0-2209328e19ee" contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 16 &#x2013; Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 7, 2022 (the Effective Date), the Company entered into a purchase agreement, dated as of March 7, 2022 with Lincoln Park Capital Fund, LLC, an Illinois limited liability company (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87dd8bee-2f40-49bb-b880-b304cb4f2519" contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd2e1070-f6ec-4965-90cd-1724f906047e" contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5" name="bdsx:StockIssuableDuringPeriodValueCommittedShares" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#x2019;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#x2019;s sole discretion, over the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ca4ec026-b196-453e-b269-eb8e4f33a921" contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1" name="bdsx:PurchaseAgreementTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36-month</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period commencing on the Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8bb8fbf-4235-4898-9969-825c81676355" contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">50,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, but that amount may be increased up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9dadd16-42d8-4dcb-95b7-0133a1a8d017" contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5" name="bdsx:SaleOfStockStockIssuablePerDayShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">100,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, depending upon the market price of the Company&#x2019;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_abf288fe-a781-4968-a795-fbedd8160bc7" contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5" name="bdsx:SaleOfStockStockIssuablePerDayValue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#x2019;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeee6542-0954-4e9c-95ce-527c97d7eee7" contextRef="C_83cbaa1a-e64a-4c26-b830-afa34cebed4f" name="bdsx:SharesIssuedOrIssuableThresholdLimitDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasda</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">q rules.</span></ix:nonNumeric></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8526e5c0-c1eb-48fd-84ca-dab928e4601a" contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1" name="bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.99</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the Effective Date, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a6a87f-ac98-4e09-9cfc-a079a93f9537" contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1" name="bdsx:SaleOfStockSharesIssuedAsCommitmentFee" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">184,275</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to Lincoln Park as a commitment fee and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c9ca431-428b-4107-afa9-2c518ed5caf0" contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5" name="bdsx:SharesIssuedAsCommitmentFeeValue" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the Company will be required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea808ddb-61f6-4da1-8bb2-cdff96738ade" contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1" name="bdsx:CommitmentSharesIssuableOnConditionalBasis" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,426</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares (collectively, the Commitment Shares).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Centennial Valley Properties I, LLC Lease Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space located at 919 West Dillion Road; Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#x2019;s current leased premises at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2970 Wilderness Place, Suite 100 in Boulder, Colorado</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the Company intends to move its corporate headquarters to the Leased Premises by mid-2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d09cc180-b37d-4949-9a6c-dbebedf51400" contextRef="C_75d6eb43-fbcb-4d67-83f4-dade72088b51" name="us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he initial term of the Lease wi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ll extend </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8cefd16f-a53e-43f3-8bf9-d96dfb63de93" contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b568f062-9170-4b42-9e6e-4b0142fcd8fa" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:LeaseCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 1, 2023</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d781f0b-1705-4495-b732-b2484875c8db" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:LeaseAgreementNumberOfOptionsToExtend" unitRef="U_RenewalOption" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> renewal </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bf396c44-b7af-4527-bc05-4b9510cec56e" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" format="ixt:booleantrue"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">options to extend</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the term of the Lease for an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cd5e018e-3c53-41fb-bbd2-697f64fb59f7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c9621bf-fb5b-4a61-aeb2-b8b5a6a364b9" contextRef="C_09226d1e-919a-4649-b557-d8d34553ce34" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> terms for each renewal.</span></ix:nonNumeric></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lease, the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f8788d2-2d65-4158-9251-12b4ac3792ac" contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac" name="bdsx:LeasedPropertyBuildingCapacity" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">79,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_890bfdc0-99cd-407a-b46d-bc7d083abae5" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:BaseRentPerMonthFromCommencementDate" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">227,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month and escalating, based on fixed escalation provisions, to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08efaded-5c4e-4776-9013-5ff674da88be" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:RentAfterFixedEscalationProvisions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">326,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c348d5c-7127-4ff3-bbfa-c42ce5b65315" contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac" name="bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">19,980</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48c49038-81bb-4d3d-aed8-5569f3143cc9" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">18.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million toward the cost of construction and improvements for the Leased Premises </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the Company exercised its option for an additional tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1a52e59-a3ad-4376-aa1f-25c32cb5a383" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:AdditionalTenantImprovementAllowancePerRentableSquareFeet" unitRef="U_UsdPerSquareFoot" scale="0" decimals="2" format="ixt:numdotdecimal">25.00</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per rentable square foot (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_023af0d9-e444-49a5-a960-6de29682f5aa" contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5" name="bdsx:InterestRateOnExtraAllowanceAmount" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">6</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per year over the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial Term</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature, including maintaining a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0eedc99-2b40-47fe-b34f-d304599a7e98" contextRef="C_eeac8352-9485-4d28-a4b8-6c7dcaf0bab3" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#x2019;s obligations under the Lease. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bc3ef3f-283e-41ba-b5c1-69673b120ec0" contextRef="C_21dd0a17-272e-43c9-926c-8361d449c139" name="us-gaap:LineOfCredit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit has to be cash collateralized by the Company through a restricted cash account for the benefit of the Landlord.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.132
<SEQUENCE>2
<FILENAME>bdsx-ex10_132.htm
<DESCRIPTION>EX-10.132
<TEXT>
<html>
 <head>
  <title>EX-10.132</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 10.13.2</font></p>
  <p style="margin-left:25.48%;text-indent:0.0%;font-size:10.0pt;margin-top:4.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.657%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">THIRD AMENDMENT TO OFFICE LEASE</font></p>
  <p style="margin-left:0.92%;text-indent:6.787%;font-size:10.0pt;margin-top:0.45pt;line-height:1.1931249999999998;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.046%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">This Third Amendment to Office Lease (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Third Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) is dated as of January 24, 2022, by and between Aero-Tech Investments, LLC, a Colorado limited liability company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Landlord</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), and Biodesix, Inc., a Delaware corporation (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Tenant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.45pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:31.28%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:31.435%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Recitals</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.259%;display:flex;margin-top:0.0pt;line-height:1.1931249999999998;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.046%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4812671687155974%;">A.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Landlord and Tenant entered into that certain Office Lease dated as of October 5, 2011, as amended by that certain First Amendment to Office Lease dated as of May 31, 2016 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">First Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;), that certain Second Amendment to Office Lease dated as of August 29, 2017, and the Letter Agreement dated June 30, 2021 (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Lease</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) pursuant to which Tenant leased certain space as further described in the Lease of the building having a street address of 2970 Wilderness Place, Colorado 80301 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Building</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) and containing approximately 34,595 rentable square feet of space.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.259%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.046%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4812671687155974%;">B.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">The Term of the Lease is scheduled to expire on January 14, 2023, and Tenant desires to extend the Term for an additional twelve (12) months with the option to accelerate Expiration Date at any time on not less than ninety (90) days&#x2019; notice to Landlord.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:4.259%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.093%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.4812671687155974%;">C.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Landlord and Tenant desire to amend the Lease on the terms and conditions set forth in this Third Amendment.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.1pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:25.48%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:25.611%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Amendment</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:6.792%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1835416666666665;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.12%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the foregoing and the promises and conditions of this Third Amendment, the parties agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.25pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Capitalized Terms</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. All capitalized terms not otherwise defined in this Third Amendment shall have the same meanings as defined in the Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.046%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Extension of Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. The Term is hereby extended such that the Expiration Date, as set forth in the Summary of Basic Lease Information comprising a portion of the Lease, is hereby amended, and restated to be January 14, 2024. The period from January 15, 2023, through and including January 14, 2024, is referred to herein as the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Extended Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.917%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.343%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.373939020820928%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Additional Amendments to Lease:</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.583%;display:flex;margin-top:0.0pt;line-height:12.6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.343%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.617299847430667%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">During the Extended Term, the Annual Base Rent shall be $28.00/Square Foot/Year.</font></div></div>
  <div style="margin-left:7.593%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.056%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6068696094451727%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">In the event Tenant subleases the Premises or any portion thereof prior to the expiration of the Lease, Landlord will receive 100% of any net profits above the Rent payable by Tenant under the Lease.</font></div></div>
  <div style="margin-left:7.593%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.028%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6068696094451727%;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Addendum One to the Lease (which was previously amended and restated in its entirely pursuant to the First Amendment) is hereby deleted in its entirety and is of no further force or effect.</font></div></div>
  <div style="margin-left:7.593%;display:flex;margin-top:0.1pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.037%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6068696094451727%;">3.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">Tenant shall have the right (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Early Termination Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;) to accelerate the Expiration Date with respect to the entire Premises only, from the scheduled Expiration Date to the last day of any calendar month during the Term, as extended by this Amendment, on not less than ninety (90) days&#x2019; prior written notice to Landlord. If Tenant validly exercises the Early Termination Option, then (i) notwithstanding any contrary provision of the Lease, but subject </font></div></div>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.06708333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:7.593%;display:flex;margin-top:0.1pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.037%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.6068696094451727%;"></font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to the terms of this section, the Term of the Lease shall expire, with respect to the entire Premises, on such accelerated Expiration Date with the same force and effect as if such term were, by the provisions of the Lease, fixed to expire on such accelerated Expiration Date; and (ii) without limiting the foregoing, (A) Tenant shall surrender the Premises to Landlord in accordance with the terms of the Lease on or before such accelerated Expiration Date, (B) Tenant shall remain liable for all Rent and other amounts payable under the Lease for the period up to and to and including such accelerated Expiration Date, even though billings for such amounts may occur after such accelerated Expiration Date, (C) Tenant&#x2019;s restoration obligations in respect of the Premises shall be as set forth in the Lease, (D) if Tenant fails to surrender all or any portion of the Premises on or before such accelerated Expiration Date, Tenant&#x2019;s tenancy shall be subject to Article 23 (Holdover) of the Lease, and (E) any other rights or obligations of Landlord or Tenant under the Lease which, in the absence of the early termination of the Term, would have survived the scheduled Expiration Date shall survive such accelerated Expiration Date. Notwithstanding any contrary provision of the Lease, from and after the date Tenant duly exercises the Early Termination Option, Tenant shall not assign the Lease or sublease all or any portion of the Premises for any period following such accelerated Expiration Date.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.083%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Counterparts; Facsimile, PDF</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. This Third Amendment may be executed in any number of identical counterparts, all of which, when taken together, shall constitute the same instrument. A facsimile or .pdf copy of this Third Amendment shall be deemed an original for all relevant purposes. Time is of the essence with respect to all rights and obligations of the parties under this Third Amendment.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.074%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Ratification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Except as modified by this Third Amendment, the Lease shall remain otherwise unmodified and in full force and effect and the parties ratify and confirm the terms of the Lease as modified by this Third Amendment. The Lease (as amended hereby) contains the entire agreement between Landlord and Tenant as to the Premises, and there are no other agreements, oral or written, between Landlord and Tenant relating to the Premises.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.05pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Conflict</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Except as modified hereby, the Lease shall be and remain in full force and effect. In the event of any conflict between the terms of the Lease and the terms of this Third Amendment, the terms of this Third Amendment shall control.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.2pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.5pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:0.926%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;margin-right:1.065%;min-width:3.333%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.3641520479641485%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. Tenant covenants, warrants and represents to Landlord that no broker or other similar agent represented Tenant in the negotiation of this Amendment other than Cushman &amp; Wakefield (Steve Billigmeier and Rob Bain) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Tenant&#x2019;s Broker</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">&#x201d;). Landlord covenants, warrants and represents to Tenant that no broker or other similar agent represented Landlord in the negotiation of this Amendment. Each party agrees to and hereby does defend, indemnify and hold the other harmless against and from any brokerage commissions or finder&#x2019;s fees or claims therefore by a party other than Tenant&#x2019;s Broker claiming to have dealt with the indemnifying party and all costs, expenses and liabilities in connection therewith, including, without limitation, reasonable attorneys&#x2019; fees and expenses, for any breach of the foregoing. The foregoing indemnification shall survive the termination or earlier expiration of the Lease.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:31.28%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:31.444%;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">[Signatures on Following Page]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:4.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.25%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, Landlord and Tenant have executed this Third Amendment as of the day and year first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.4pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">LANDLORD:	AERO-TECH INVESTMENTS, LLC, a Colorado limited liability company</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.653%;text-indent:-7.897%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ AARON CLAMAN	</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:-7.486%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">                 Aaron Claman, its Manager</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.05pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">TENANT:	BIODESIX, INC. a Delaware corporation</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.55pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.653%;text-indent:-7.897%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">By:  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:Times New Roman;">/s/ ROBIN HARPER COWIE</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:-7.486%;padding-left:6.68%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:4.083%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">                 Robin Harper Cowie, its CFO</font></p>
  <p style="margin-left:0.56%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>bdsx-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:20.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Board of Directors<br>Biodesix, Inc.:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the registration statements (No. 333-249805) on Form S-8 and (No. 333-261905) on Form S-3 of our report dated March 14, 2022, with respect to the financial statements of Biodesix, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ KPMG LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denver, Colorado<br>March 14, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>bdsx-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Scott Hutton, certify that:</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:43.002%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:3.996%;"></td>
    <td style="width:51.998%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 14, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>bdsx-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Robin Harper Cowie, certify that:</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K of Biodesix, Inc.;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.0%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.519%;"></td>
    <td style="width:49.476%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 14, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>bdsx-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:3.835%;"></td>
    <td style="width:44.882%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 14, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ SCOTT HUTTON</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scott Hutton</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Executive Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>bdsx-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report of Biodesix, Inc. (the &#x201c;Company&#x201d;) on Form 10-K for the year ending December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</font></p>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:6.667%;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:7.14323979728499%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:1.282%;"></td>
    <td style="width:3.835%;"></td>
    <td style="width:44.882%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 14, 2022</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ ROBIN HARPER COWIE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robin Harper Cowie</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img33530786_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+!#4# 2(  A$! Q$!_\0
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MF*\CI/\ A9>K8_X];;\S2?\ "R]7_P"?6V_,US7]C:E_SXS_ /?!I/[&U/\
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M6/\ H&W'_?!KN]E1[')[2J=5_P +8UO_ )]+7\S1_P +8UO_ )]+7\S7*_\
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M@   < #M734G[-<D2$N;4J66EV6G1JEI;1Q #&57D_4U<HI:Y6[[F@E+110
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MB7;G.)P,^M9\G^ND_P!\_P ZZ$>345D2+>74:A$N950<!0YQBE^W7G_/W/\
M]]FJ]+3L3SR+MI?7?VVW!NYCF5>KGUKW>+)A0G^Z*\!M/^/ZV_ZZK_.O?X?]
M0G^Z*Y<3;0]S*&VI78^BBBN8]H7%&*2B@!<4E%% #9(TE0JZ*RGJ&&:YK6O
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MY17D7_"0ZO\ ]!&?_OJC_A(=8_Z",_\ WU6?L9%>T1Z[17D?_"0ZQ_T$)_\
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M(-7T\7^(HP NL71 [%J;P4MTR?K*6Z/HNBOG?_A-?$G_ $%[G\Z/^$U\2?\
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MBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML]134[QQYFH!TQ*0W'0^ZYK"<YQ>AI%19R5KH6K7HE^S6$TGE-LDVK]UO0U
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MSX12>S"H=.U:VMI]+G>YA\R&TEW MP&.>*7/(I8:EI[VYR TZ];R=MM*3/\
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M\CL>9^(_&8N+=M*T-6M=.4[6<</-]:X[I7L/_"H=(S@7UWCTR*7_ (5#I/\
MS_WGYBNJ&(HP5D82HU),\=HKV'_A4.D_\_\ =_F*7_A4.D_\_P!=_F*M8ND3
M]7J'CV:*]A_X5#I/_/\ 7?YBC_A4&D_\_P#>?F*/KE(/83/'J.U>P?\ "H-)
M_P"?Z[_,4?\ "H-)_P"?Z[_,4?6Z0?5YGC])7L7_  J'2?\ G_O/S%)_PJ#2
M?^?^\_,4?7*0?5YGCW'X48KV'_A4&D_\_P#>?F*/^%0Z3_S_ -W^8H^MT@^K
MS/'BH]!1@8P *]B_X5#I/_/_ '?YBD_X5#I/_/\ 7?YBCZW2']7F>/8%&!7L
M/_"H=)_Y_P"[_,4?\*ATG_G_ +O\Q1];I=Q?5ZAX[M!ZA:7 QZ>OO7L/_"H-
M)_Y_[O\ ,4?\*@TG_G_O/S%'UND/V%0\>P,YXS1^->P_\*ATG_G_ +S\Q2_\
M*ATG_G_O/S%'URGW$\/,\>HKV'_A4.D_\_UW^8H_X5#I/_/]=_F*/KE(/J\S
MQ[-)7L7_  J'2?\ G^N_S%'_  J'2?\ G^N_S%'UND'U>H>/9HKV'_A4.D_\
M_P!=_F*/^%0:3_S_ %Y^8H^MT@^KU#QZD->P_P#"H=)_Y_KO\Q5K3OA7HMC>
MQW$DDURJ<B.0_*3[T/&4K:#]A,\^\/>$#?0?VIJ\AL]+3G<>&E]E%:&L>(!<
M6XTW2XA::9'P$7@R>[5Z+K'@Z#6IPUQ>W"1(,1PQD!4^@K-_X5CIG_/Y=?F*
MY774W>1RXG#XB:Y*:LCR[%+BO4/^%8Z9_P _EU^8I?\ A6.F?\_EU^8JO;P.
M#^R\1Y'EU%>H?\*QTS_G\NOS%'_"L=,_Y_+K\Q1[> ?V7B/(\OQ17J'_  K'
M3/\ G\NOS%'_  K'3/\ G\NOS%'MX!_9>(\CRZBO4O\ A6.F?\_=S^8H_P"%
M8Z9_S]W/YBCV\ _LO$>1Y;2UZA_PK'3/^?NY_,4?\*QTS_G[NOS%'MX!_9>(
M[(\OP/2DP/3\Z]1_X5CIG_/W=?F*/^%8Z9_S]W7YBCV\!_V7B.WXGEV!Z48Y
M/>O4O^%8Z9_S]W/YBC_A6.F?\_=S^8I>W@']EX@\M([\9Z4N!G->H?\ "L=,
M_P"?NY_[Z%'_  K'3/\ G[NOS%/V\!?V9B>R/+L#OCGO1@'M7J/_  K'3/\
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M?2 T7"QQDKZY96CRRW<K+(JF1G 'E_.<[??;BI]/GN=4\/ZU&ES-.,NEO(P
M8C;TX]ZZJ6&.>-HY45T/56&1388(K:,1PQK&@[*,47 XF-?$T%W%;QSLJ)$H
MC#)G<-@SD],@TL4&LWL<#S2W#/#/)\Q4 ,/+/;TSQ7==*._6BX6..@37T_TC
MSI%*;56 J F-G/ZT[P]J5S=:Z+=[V6=!;%YT<#:LFX# ([5UQY!!_&H8+.VM
MG9H($1FZE1C-%PL3X.:6D%+2&%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%)@^M "T4F#ZTG/\ >H =13<'
MUHP?6@"GJ&G1:AY'G%L0OO&._&/ZUFQ>%[=9(FFN99C 1Y.X ;%'\/O6\ ?6
MC!]:+BL59[".XO8+MF(>%&1<=/F&#61_PB-L/+5;F58TC\O: /F&<\GKWZ5T
M6#ZTFT^M%QF5;Z!:VVF7&G([_9)00(_[F>N*IR>%5ECD\[4)I)754\PHN0HZ
M #^M=#M/K1M/K3NPL<]-X0M;B21I+F8JV"J\<,.C'U_&E'A. "'_ $J0.C!W
M=4 ,A_I^%=#M]Z3:?[U%V%C#M?#,%O="X-S([+(TBK@ +D8Q@?SI+GPK97,/
ME2.^/+V+[?-NS^=;VWWHV^]%V*QBVOARVME?,K/(\+0N^T+N!.<\59M-(ALX
M9XD=R)D5&SV 7;6CM]Z,'UI7'8YY_"5FTL;"5MH15D0J#YFW@9]*EM_#,$#E
MFN)7_>B51@ +@$8P/K6WM/K1M/K3NQ6,:'PW:PP3Q"1V68*&S_L__KJCI.B7
M]MKD4TTF+2TC>.&/T#8Z?_7KJ,'UHP?6BX6%HI,'UHP?6D,6BDP?6C!]: %H
MI,'UHP?6@!:*3!]:/QH 6BBD.>U "T4G/K2<^M #J*;@^M&#_>H KWUE'?6X
MAD)"A@W'M5"TT&&TO4F6XD:&(L88"!MC+=>>];&#ZTFWWHN!R<OAR[N=8='?
M9IIF:8H.A)'YYJZOA2 [Q<74LX8(JA@!M53D"M_:?6C:?6G<5CGF\)P3*Z7%
MW-,@7;$K 8C .1CUP:NVFAQ6NFSVAE+F?F27:%+=NU:FT^M&WWHNPL8DOAFT
MDL[FW\QP)W20M@$J5  /Z5&/"L2Q*L-Y+%(8VCF=5&95)R01VK?VGUI=OO1=
MC,>/P];1RQ2*[YC=6 _W5VC]*CNO#%G=JHD=\K&T:GTR<Y_2MS!]:,'UHNPL
M8MGX<MK-UD$K/*(GB+[0-P8Y/2K%MHUM;6\T +.DJA&!/85H[??Z4;3Z_I2N
MP.<?P?;RC_2+R:9E4+"6 _=8Z8]:F@\-1VA1[6\DAFY\V14'[W/J.U;NWWI=
MOO3NQ6.?D\*6[O&1<RHJ\D*!EL>]/'AFW$B@7$OV;S!,T&!AI!T;/6MS;[T;
M3ZT786,2;PS;2VZ0K,Z[$VJQ4'')/3\:T]/LUT^QBM4=Y%C&-SG)/>K 4^M+
M@^M(=@I:3!_O48/K0 M%)@^M&#ZT +128/K1@^M "T4F:6@ HIISZTG/K0 ^
MBFX/K1SZT .XI*3GUHP?6@0%05(/0\5R^H^$VELVCANI'8,OD*V,1#=DD>M=
M1@^M&WWH&<U<>&)S=6\\%](+DS^;/<E1N.%VCCITJ9/"EM$&2*XE2*5@UR@P
M?.8'.3Z?A6^ ?6C:?7]*=Q6,M="MEABAW,5BF:8#U+9R/UJF/"<)?,MY-(BH
M8XD( \M<@X]^E= %(_BHV^]%PL8TWANTGDE=I),RJRG'^T03_*H+KPE:7$HE
M$SI+N8EMH.0V,CGZ5T&TXZT;3ZT7"QD6/AZ"PU+[7%,X4*56$ !1GOQUK8%)
MM/K2X/K2&+128/K1@^M "T4F#ZT8/K0 M%)@^M&#ZT +128/K1@^M "T4F#Z
MT8/K0 M%)@^M&#ZT +1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MKQJUBEL-=\-W>HVEM;0L0L;6F-SGL7KV3/>IK4U!JQ5.?,M1U%%%9&@4444
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MWVZ'_:_*C[=#_M?E0!9HJM]NA_VORH^W0_[7Y4 6:*K?;H?]K\J/MT/^U^5
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M;26MM+=JL?DS<OUSD>G%!\=7-WLB-BD4%XLGV>42_,N.[#L::HS>PG5BCO\
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MRA\V)1/(R^</FRH_K5^TTE&\423QRJH@&Y\9WNS=<GT]J5K;FD9J33C$UIM
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M&8HR #$I Z J.*4QH008U(/48I]% $9BC(4>4F!T&WI3@JAB0H!/4@=:=10
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M&!%"[0H"_P!T#BJ$6BVD.JS:@B8DFC$3)@;<#VK2HH3:"R(EMX5P%AC&.F%
MQ2&"'+-Y*;F^\=@R:FHH"R(O)CW;O*3/KM%4]-T>VTN*=(@S^?(9)&DY+$^M
M:-%.[%9"*H50   .@%+112&%%%% !1110 A%0W,"W5M) ^=KKM./2IZ*!-7*
MMI8PV=LD$<:A5&.@R?KZU*\*2 ;XU;'3*YQ4M%.X**2L8]_X>M-1NEGG:3'
M:,?=8#UK46%$3:J #&,8J2BB[)4(K5(B^SPA"GDIL/5=HQ1Y$>0?+3*]#MZ5
M+12N59$301, &B1@#D J.M.\M"?N#GKQ3Z* LB-XTD7:Z*R^C#-(88VQNC0X
MZ97I4M% 61&(U&<(HSP>*/*CP08UP>",5)10%D1K#&F-L: #IA>E."*&)"@$
M]2!UIU% [!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img33530786_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,H!S@# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTE% "[C1N-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE%
M"[C1N-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE% "[C1
MN-)10 NXT;C244 +N-&XTE% "[C1N-)10 NXT;C244 +N-&XTE% #P<BEI%Z
M4M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<\9XKJ',$:Y4"++ L0,<GCGZU91 @]^]"E;8+7*6GVK6=JL49'EA>0.,GO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA."29@"IZ<8X_E5^UFW':3R.*EE%VBBBD 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 !Z5#FICT-09H 7-&:3-&:8A<T9I,T9H 7
M-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3
M-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&:
M%S1FDS1F@!<T9I,T9H 7-&:3-&: %S1FDS1F@!<T9I,T9H 7-&:3-&: %S1F
MDS1F@!<T9I,T9H E3[M.IJ?=IU(84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!Q'C\SS:AX;L(KRZMHKN]\N4V\IC8K@=Q7-WK:39ZK=Z?
M'<^,[N6U<)*UM,74'&>N:Z;QO_R,?@__ +"/]!3O!_\ R-WC'_K\C_\ 037;
M3ERT[^7ZG#4CS56N[_2YRZ7%AQ^Z\=?B3_C4Z3V/_//QK^)/^->J45F\1?I^
M)HL-;K^!YDL]G_SS\8_B3_C4BSV?_//Q?^)/^-=)>>-+2WO)X8+*]NX[9MMQ
M-!'E(SW&<]JWK.[@O[2*ZMG#PRKN5AW%1*3ZH4:<9.R?X' ">T_YY^+?S/\
MC2^?:?\ //Q9^O\ C7H<DB11L\C*B*,EF. *KVFI65_N^R7<,^W[WEN#BLF[
MC=!;7_ X,SVG_//Q;^!/^-,,]GC_ %?B_P# G_&O2:*FQ#P=^OX'F33V?_//
MQC^!/^-3Z7#I^K:@UBEWXFMIQ$90+F8ID#CU]Z]&KE9_^2D1_P#8,;_T.I:,
M)X7V;BVT[M+;_@DO@2>:?PO$T\TDSB61=\C%F(#'')KI:Y?X?_\ (K)_UWE_
M]#-=151V1V836A#T04444SH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *CF^X:DID@RAH R)F:.59&D)5AP7X"D=0./K^-
M+%(TBQB!D(9LB23DNHZ^F#5A@T@V'#*3T*YQWS_*JQD\S:)9B1,P1&C7!SZ<
M_C5$F4NCQ3:C)=S!Y$E9RL; A@/4^W;\JAT75X)IKE3;RQ!0 '0]!GO6VQ2Y
M9XRKDJ.0LFU@HZC .?\ ]=4M/T2S6.?9.9/,' 4X*#WQWJ[Z:BMV-$(DTX=)
M=R[?F*-P>>.GXU(\/S84!2!\IY_'-4;."ZB-PD#PA0P!)4XW <X%6!>9MS.\
M; HQ5D!Y# XP/7-2T,K:EI N[=(_M#11(V\D\]*MB8N(X4253C(W_+N4>X_"
MFSRS^6(YHD1)3L+!L[<^HJ98O+=6>1I' (3< ,#C/2BX"RVR7%MY,Y+ K@G^
MOUJE);RB5")O.4KL*D !3TSGJ*DL;]KN2X#02QA'VCS!C(]13D<"=058Q\[3
MZ4:H"N3YLP2-)MJ L1@@@<]\]ST]A4FEN7<MZG-.GF(L'D#."ZG&X '.<>E.
MTF/;&#4L:-<=*6@44AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 AZ&H<U,>AJ"F@%S1FDHH$+FC-)10 COLC9\$[03@=3BO'=+O
M/%7CJ;4;VU\2?V>]N^(+&-RF[N!@$?3)SS7L+ML1F +;03@=37C\]EX&\3-?
M:A:W\NA7\1+,LDBH&;U"Y]?0CZ5<"9'HOA"XUR;05'B*W,%_&Y1F.WYU&,,<
M< ]1^%>:7'CK6AXLDUB.YF_X1^*_%L8@?D*XQT]< GZXJQH_C+48/A=JLUY<
M/+-')]DLYW^\VX<\]]HR:RX=!\7GP*=+30[8Z?*?M?F[AYI.,@_>]!C&*I*S
M=R6^Q[%K]\;+PUJ-[#)AH[5WC=3WV_*1^.*XGX5^,+K64N],U2Y>>[C_ 'T4
MDARS)T(_ X_/VJB?$7]H_!"X9WS/"JV4GKD,,?FN*R9=-NO#7AOPQXNTR(&>
M*/9<ICA@Q.TGVP<'\*2CI8;>MS2\?>.;VT\7VNG:9>20P6C+]I\LXWL2"0?8
M#^9K:^*6L:EIUKHYTN^EM&N9F5FC.,C"XS^=</JWAV6#X:C7KQ2=0OK];AW8
M?,(V# ?F3G\:WOB9,;_PWX4F1]IG(8,.V43FJLKH5W9BZ])XQ\!BTU.X\0_V
ME;/+Y<D,B\'C..?QY%:]]KVH-\5=#LX+N9-/NK597M\_*<JYY'X#\J8/AE=W
MUY;OKWB2ZU&WA;<(6SS[9).*H^(KFUT_XSZ+/<S16]M%;+N=V"JHQ(!SVI:,
M-4=QXPNY['P?JMU:RM%/% 6213@J<CD5PGA[1_&/B#0[;5$\92P+."1&P)(P
M2.OX5T_BO6M+U7P1KB:?J-K=,EMEA#*'*C(ZXKSSPUX?\-7FAVMS?>+6LKEL
ME[?[0B[,,>QYI16@WN>V644L%C;PW$WG31QJLDO]]@.3^)KS37-1US7_ (@W
M/AZTULZ-;6L>Y&5BID.T'J""<Y]>@KTVWEBGMHI895DA= R2*<AE(X(/>O'?
M+TGQ5X^UD^*K];-+,F*WB,@B!56(Y8]<#G\:4>K'(]!\)ZD!"^C7VMQZEJUJ
M29BJD;1G@9Q\WUK8UF9X-"U&:)BDD=K*Z,.H(0D&O'O ]OX</Q&NQ'=%;>%\
MZ<7EQYC;@ .?O9!.!7KVO?\ (NZI_P!><W_H!HDK,(NZ/,/"UGXS\4:*VI6_
MBR6$K(R"*3)R1[_C73^!/%6I:A?7V@:ZJ_VI8Y)< #S%!P<XX[CD=0:Q_ACX
MBT;2?"#Q:AJ=K;2B=V\N20!L8'..IJGX;U1+OQIXF\9JC+IMO;N%9AC><*%'
MXA<_B*IJ]R5T#QYXJUS_ (2:ZM]#NIHK;2H5>Y\LX!)89SZXW ?@:[&_AU3Q
M=H.EWNAZT=,\Q/,D*@G=D=./0YKS?PW:^+KS3M4OK#2+:\@UG>LTL[ $C)SC
MYAW)_*NM^$FH31V=_P"'KP%+G3YB0AZA2<,/P8'\Z&K+3H"=WJ<_X<3Q?XBU
M;4["/Q9<0M8-M9VR0_S$<>G2NF\>:QJVF:?HNA:7=R'6+LJK2QG#,% !/MN;
M^1K/^&?_ ".'BK_KJ?\ T8U9%Q>ZYK_Q*O-6T"QBO?[,/DQB9L(HY7/4<YW&
MCJ'0[GX<Z_/KGAK%[*TE]:2M#,S_ 'CW!/\ +\*V?$]S-:>%=5N;>1HYHK61
MT=>JD#@BO-?!]UJ?A_XD3V>LVJ6;ZPI<QQG*;R25(Y/?<.O>O1?&'_(F:U_U
MYR?^@U+7O%)Z'E]C+XMNO!TOB1?%SH(@[?9Y&^8[3C'ISV&*ZFX\3:G>_!^3
M6_,:WU#8!YL?RDD2!=P],C^=<+H>A>$;OP<]YJFMM:ZB!(1")UZ@G;\F,G-;
M5IJ5YJ/P/U+[9R+>1887QC<@9"/K@DC/M5M(A,Z27QE+H7PQTS5IV-SJ%S$$
MC,ASN<YY;Z 5EV_AOX@ZG9KJDOB9[6ZD7S$M-S*H!Y ('RCZ8-9WB'3;BZ^$
MOAR^MT,@L5#R+C.%.1G\"!^==S8_$+PU=Z2E])J<%NVS,D$C8D4]P%ZG\*G;
M8K?<H^"/%U[K$>H:5K""/5[ '>0,;P.,X'<'TXY%<=X=?Q9XDL-0O8_%TEJ+
M60KLE;[W&>O:M7P()=<\8>(?%"1-%9RQO#%N&-V<?J HS]:Y7PCHOA;5+/4)
M-?U<V4J3;8U%PJ;EQUP0<\T[)7%?8],^&OB'4/$7AZ6343YD]O,8A, !Y@P#
MVXR,_P JXSQ-XTUQ?%=[>:7=2C2-+FCBEC5OD<YP<_4AA3_!7B>71O"?B+$I
MFLK#_CRD9<9=B0H_'@_G69HFC^+YO"-W;6FCVUQ9:K^^>>5QYC>A'S#N,].Y
MIV2;87;2/5/$^INO@6_U/3YV1C:B6&5#@C.""/SKDO 'C6YU?0=3L+^Z9]2M
MH))HI6/S.NT_JI_F*HZ+J[7WP<UK3YB1<:=&T+*>H4D%?ZC\*Q3HUQ:^ M)\
M5:6-MS;+)%<@#[T;%AD_3.#['VI**M9@V]SJO#&NZI=_"O6]1N+Z:2\A$OES
M,V67"@C!K%3QUJ\_@_2M*L+N:XU^_E8-+G+HN\@#ZG'X 59\(?\ )&?$'TG_
M /0!7+^'EO?"4>E>+T@6YL9F>&8;>8_F*D9[$@9!^HIV6HKO0]UT6RN=/TBW
MM[V\DO+I5S+-(<EF/7'MV%:&:JZ?J%MJEA#>V<HEMYEW(P_SUJS61J+FC-)1
M2 7-&:2B@":/[M.ID?W*?2&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M $,UU%*.R'A/X$/1!1115'0%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,^HSTJ_244 +1244 +1244 3Q?<I],B^Y3(KJ*:>6%6_>1'#*?YU(R:BBB@
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M2:&19(W&5=3D$5Q^B:?93^'-2FFM())1+/AWC!88SW-:_@[_ )%+3_\ </\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *KW$6]3CK5B@C(H P;ZS;441=^V6/(P3@$$8J W,VC6:1W164D%
M4$9/ZDUL7$!SO3AAWK.OH8=0MV$P99HE+#;5)]&2UU**Z[;J@8Q,&( \M#CD
M=R:U#,+NU@NH$\P*^[9T)Z@X]ZY6QMA>7D4!;:'/4#IQFNJ4Q:5 L7S&,GY<
M=15R26PD-,S75Q&\<9C\G+$RC&<C& .M"9W!5122VXC;C()]N!_GBI9?+&UV
MD.P<8QG-1W][%:%1@M,>54=#]:BXQ]]=K:Q# !F;A5Z_Y%5]-M#GS'Y9CDDU
M%:6LES,9YB69O7M6]#$(U  J2AZKM&*=110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "-]T_2JN:M-]T_2JN:: ,T9HS1
MFF(,T9HS1F@ S1FC-&: #-&:,T9H ,T9HS1F@ S1FC-&: #-&:,T9H ,T9HS
M1F@ S1FC-&: #-&:,T9H ,T9HS1F@ S1FC-&: #-&:,T9H ,T9HS1F@ S1FC
M-&: #-&:,T9H ,T9HS1F@ S1FC-&: #-&:,T9H ,T9HS1F@ S1FC-&: #-&:
M,T9H ,T9HS1F@"Q%]S\:X_4KB6UUV:6)BKJW7\!77P_ZO\:XO6O^0O<?[W]!
M1'<4MCJM,U.+48<C"RK]]/3W'M5ZO/;>XEM9EEB8JZ]Z[33-3BU&'(PLJ_?3
M^H]J&K G<O4445)04444 %%%% !1110 4444 %%%% !1110 4444 <5XW_Y&
M/P?_ -A'^@IW@_\ Y&[QC_U^1_\ H)IOC?\ Y&/P?_V$?Z"G>#_^1N\8_P#7
MY'_Z":ZU_!^7_MQQ_P#+[Y_^VG9US'CH@:-:DD "]AY/UKIZJZAIMIJMFUI?
M0+- Q!*DD<CW'-<T'RR39TU(N46D<]XCGAFUSPZ(I8W(O#G:P/84GAB>&*]\
M0B25$)U&3 9@*T;+PAH.G7<=U:Z>J31G*,79L'Z$T77A'0KVZDN;C3U::0[G
M8.PR?7 .*IRC:QER3YN;2_\ P/0Y&R95TCP^Q8!1JQ))/'WJZ/498Y?&>B&.
M1'PDV=K ]JTW\.Z3)IL>GM9(;6-MR)DC!]<YSWIMAX:T?3+D7-G9+', 0&WL
MV/S-2W<E49I):=/P,;09X4\,ZDCRQJQEN/E+ 'O6EX._Y%+3_P#</_H1HF\'
M:!<3/+)IZEW)9B)'&2?8&M>VMH;.VCM[>,1PQC:JCL*D*5*<9)RM9*Q+7*S_
M /)2(_\ L&-_Z'755RL__)2(_P#L&-_Z'28\3M'_ !(=\/\ _D5D_P"N\O\
MZ&:ZBN7^'_\ R*R?]=Y?_0S744H[(>$_@0]$%%%%4= 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$@4TR "@!]%0F=1W
MIIF)Z C\* )7(QS5153>S\9Q@^U/)#+N9OE(SZ<5RC7E]:L;R\N5@C1  @&?
M,!R <=ZJ,;B;L= T,=JQEMK1"\AY;. *E9BS$/Y;*1E!U)-5M-=6M4,+QRHP
MY99"<<>_3Z40HL!,;0M\C8C=V!SGK@T")84F68>8&&Y><-D9JK>1174G[DEI
M;<88=>/ZU:AFBNU64;H]K8*MQFI 5C^;9L=OF8 9S^- Q;%T\L5?!K/DBC3,
MH<18Y)/ _&GQ3N8PZX=",AE.0:D9>HJLMTIZ\?6I!.I'6@"6BFB13WIV: "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&^Z?I53-
M6V^Z?I5.F@%S1FDHIB%S1FHIIXK>,R2N%4=S6#>Z[+)E+8>6G][^(_X4)";L
M;L]U!;#,TJI['K^59LWB&%<B&)G]VX%<ZS,[%F8DGN3255B>8UW\073'Y$C4
M?3-0G6[XG_6@?\!%9U%.PKLT/[:OO^>H_P"^11_;5]_SU'_?(K/HHL%V:']M
M7W_/4?\ ?(H_MJ^_YZC_ +Y%9]%%@NS0_MJ^_P">H_[Y%']M7W_/4?\ ?(K/
MHHL%V:']M7W_ #U'_?(H_MJ^_P">H_[Y%9]%%@NS0_MJ^_YZC_OD4?VU??\
M/4?]\BL^BBP79H?VU??\]1_WR*/[:OO^>H_[Y%9]%%@NS0_MJ^_YZC_OD4?V
MU??\]1_WR*SZ*+!=FA_;5]_SU'_?(H_MJ^_YZC_OD5GT46"[-#^VK[_GJ/\
MOD4?VU??\]1_WR*SZ*+!=FA_;5]_SU'_ 'R*/[:OO^>H_P"^16?118+LT/[:
MOO\ GJ/^^11_;5]_SU'_ 'R*SZ*+!=FA_;5]_P ]1_WR*/[:OO\ GJ/^^16?
M118+LT/[:OO^>H_[Y%']M7W_ #U'_?(K/HHL%V:']M7W_/4?]\BC^VK[_GJ/
M^^16?118+LT/[:OO^>H_[Y%']M7W_/4?]\BL^BBP79H?VU??\]1_WR*/[:OO
M^>H_[Y%9]%%@NS0_MJ^_YZC_ +Y%']M7W_/4?]\BL^BBP79H?VU??\]1_P!\
MBC^VK[_GJ/\ OD5GT46"[-#^VK[_ )ZC_OD4?VU??\]1_P!\BL^BBP79VNB7
M$MUI_F2MN;>1G&*YG6O^0O<?[W]!70^'/^04/]\_TKGM:_Y"]Q_O?T%2MRGL
M4*EM[B6UF66)BKKT-1451)W.F:G%J,.1A95^^G]1[5>K@].6Z:]C^R9\W/!'
M3'O[5W:[MHW8W8YQTS425C2+N+1114C"BBB@ HHHH **** "BBB@ HHHH **
M** .*\;_ /(Q^#_^PC_059O/ 5I<ZK=ZA#JNJV<EVX>5;:?8I(&/2F^-M+U6
M]N=$O=)M8[F6PNO.:)Y F1CU/TI@UKQOW\+6O_@:*ZHN7)'D:7S7<Y)*//+G
M3?R?8>O@)%_YF+73];O_ .M3QX'0?\Q_6S_V]?\ UJ8NL>,SU\,VP_[?!4@U
M;Q>>OARV'_;V*3=3JU]Z&E2_E?W,>/!:C_F.ZS_X$_\ UJ</!RC_ )C>L?\
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M ,]A_P!\#_"C_A(-1_Y[#_O@?X5ET46079J?\)!J/_/8?]\#_"C_ (2#4?\
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M?\)!J/\ SV'_ 'P/\*/^$@U'_GL/^^!_A67119!=FI_PD&H_\]A_WP/\*/\
MA(-1_P">P_[X'^%9=%%D%V:G_"0:C_SV'_? _P */^$@U'_GL/\ O@?X5ET4
M6079J?\ "0:C_P ]A_WP/\*/^$@U'_GL/^^!_A67119!=FI_PD&H_P#/8?\
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M*X:;IL6G0;%^:0_??U_^M5VBBLS0**** "BBB@ HHHH **** "BBB@ HHHH
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MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
M^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*
MC^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__
M .?:3\J/[(O_ /GVD_*NZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4
MX7^R+_\ Y]I/RH_LB_\ ^?:3\J[JBCF#E.%_LB__ .?:3\J/[(O_ /GVD_*N
MZHHY@Y3A?[(O_P#GVD_*C^R+_P#Y]I/RKNJ*.8.4X7^R+_\ Y]I/RH_LB_\
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MOAJUA.JKJB*#Y=TO\29X'4].E#C9 G=F[1114E!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>\LH+Z$Q
MS+GT8=5^E6** .$U#3Y=/N/+?E3RK#H15.N^OK*.^M6AD'NK?W3ZUPMQ ]M.
M\,@PR'!K1.YFU8CKK] U'[5;&"0_O8AQ[K7(5:T^[:RO8YAT!^8>H[T-70)V
M9WM%(K!E#*<@C(-+69H%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% %21PC.QZ 5F7]M)=1H8IA')N)96;%:CXWL",@C'3W%5E59E:
M/H$X]>M-"96>1_L@B%PP(4#S@OZT+IB*V-X9G'S$KGCO@=LTYU:,A7[\+A@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(SAOSK1:.,_>0,>N#58J8Y%,2;H]N.#G'L!0@&7P/]GD$='7!]1Z_K5O3_\
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MC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 7K7_ %/XFIJ@M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ0!'.X>-64C:&&:9 0 V,;=W\)YJTT:LC+T#=<<54MU"@NN"2Q&0,]/_ -5
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MGPS9V$-OIBS>2BY\JVM9'\O/4-@'#>N>:JZ?%;^.I;FZU&=I+"&8QPZ:'*8
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M4%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNE5Y&*NN0"HSD'J,=^E=ZEI8^MM?5%:^N1<643*-I,F&4D$C@^E6;'<(G52
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#@=0_Y"%Q_P!=&_G5:K.H?\A"X_ZZ-_.JU:F1K^'/
M^0LO^XU=A7'^'/\ D++_ +C5V%1+<N.P4445)04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%%  >E9U]=Q6,$MS-DH@&=HR>N/ZUHGI521$D+HZAE(
MP01D&A S)M7TAMEW%$$=SY@.PYR15?6/$@L'CCMHUE9AN8MD "MJ26*UBQP
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M'(#8&:V)%_=4SM,R\T^-;A[NUC*WI4D2KT.!T.>.:Q(/$41GCC*RJR':AX8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!P.H?\ (0N/^NC?SJM5G4/^0A<?
M]=&_G5:M3(U_#G_(67_<:NPKC_#G_(67_<:NPJ);EQV"BBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *JRJ2L@'4J1QU[5:-5)7*EL>G?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M59\ Z+#K,RPWMR8)A<1D*7XFPP(&WN1CK57_ (2R[GC3[<Q:_DM0MFUG,BA
M?^>A_#H<8_&NT\!:9!JFK6^LO;3&+2%?;<O<9\U^B#R^PR6/X=ZFHX--HN/-
M?E9L_$&5II$MHE+O+<LRJHR3C@?SJ/P]X7GM$\^6-OM3#@;<A%],^OO78VVG
M17$JS%4-PN/GQE@,Y(]LUHBP59T(MXF5B=['J*\U0][F8?5(NNZ\]7T\AMK
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0+K_ (\Y_P#KFW\J\_;[Q^M7$B0E:VB])OPK)K6T7I-^%42C5HHHI%!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ.6*\]B,U6,2) "[N0AWY+'/%-"9*Y*IQ5.\DV6,HSG?A5Y]?_K4ZSU%+PR
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MK+_2NKO?"_FZC/J%EJ=U97,V-_ED%"0,#([_ )UQUK:0WVG:-:S@F*74YE8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!FX&.X%2RS)9VZ*Q=B%PI"%LD#VJ:,N6?<%V@X7%1W%P8,?*2",!AV- RO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6$37#!GDPHWXVX!/]T]>N<^]7=*.YV/J2:)*P(WATI:0=*6I&%%%% !1110
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MM,C21)(RF0!22 >PS3?B'#';^&K2&%%2-+A555& !M:NS1%CC5$4*B@!0.@
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MNW4TJX*;E+V;5I:M-7U[HY?X<:5+#'<ZE*A195$<6?XAG)/TZ5WE( %4*H
MX  Z4M:0CRJQUX:@J%-4UT"BBBJ-PHHHH **** "BBB@#3LO^/?\:LU6LO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME6E\*_"5KXBU>XNM0C$MI9!3Y1Z2.V< ^PP3^5>\2V\$-A)%%#&D:QD!%4
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MY)__ %4VUM_*DEE\PMYA_K5G<,X[TVP,TJ65HV X'(/)/_U\]ZT(U<#+-DX
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M2;\*R:UM%Z3?A5$HU:***104444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!IV7_'O^-6:K67_'O^-6:A[EA1112 **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5] )8C]1W4^E-JP)W+%%%%2,**** "BBB@ HHHH **** &R?ZM_H:\]^#O\
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M^LO"QOK>/RHWWG 7!'3IW-/G%RGDMDNJ^(9=/^']XKHFFSN;N4'[T2?=_#G
M^JUU?P@DV:#J5CWMKYACT! _P-=^MM D[SI#&LSC#2! &8>YZFJ&D>'M-T*6
M\DT^%HVNY/,FRY8%N>F>G4TG*ZL"C9W-2BBBH+"BBB@ HHHH **** "BBB@
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MB1@[JWT^Z*D8ZBBB@ JO.@/.,U8I",T 9T<.;AG P">E:*C I @%.H ****
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M/9+8P"9!+(0)>>@)48_6LGXS?\>>B?\ 7TW\A75^-_\ D0-6_P"O4_THTLM
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M<2$./D^OI3EN(6A$RS1F(]'##;^=>?:AX3T6W\<Z+90V:QVES!*;B!6(28H
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MQ!M#X@\9>&K:<&!KVS0,!SY99F_D3345?5"<M-#O?%GC)?#3:5Y=HMVNH2%
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M4L_^$9NY8]IO&N2)S_%C V_AU_6O0Q%;?;#*$B^U% "^!OV9X&>N,YI2LM+
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MH **** "J&L_\@BX_P!T?S%7ZH:S_P @BX_W1_,4UN)['#T44J(SN%4$L3@
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M%[C_ 'OZ"NOLO^/?\:Y#6O\ D+W'^]_04EN.6Q0HHK5TC2'OY/,DRMNIY/\
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ME5=.TV+35\F!0RJ"V]OO%C_]:K@ES@;,2$XQ[_6LI6OH:+;4SK@>9JP&<[$
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M[0]DOV?KGRR!CZT*#>H.21UU%5M/NS?64=P87B+#[K?YZ59J1A1112 ****
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M1+,APRQ@DM@^I'%'**YZ,FHV#W)MDO+9IP<&)95+?EG-3RRQ0INFD1%R!EV
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M*.4+G; Y&116+X:O="DT];'0KV.X@M5"X60N5!SC)//K6U4LH**** "BBB@
MHHHH **** "H;@?)4U1S?='UH R+G4O+N#$8@R#ALGK3(-0@6?9' $1N,@<T
MFK0H%CF5<%N&(^E5].6%Y-[@L0P"C.!]?>M+*Q/4V]O+$GD\ XZ"JMU:APSG
MYF)7YL9* ?W<?YYJ5;I7VL/N'C/7)_"GF13D@@@<5.PSDQ'<Q^*+N2&:XX3I
MM!.,#MC&/PK0EU!KXPPNJAE^<E#D>G^-:5G<Q7,DCQY+< DC%4Y%235VV* %
M !P,<TY.XDC:LTVQ"K510+MC%2U!0AY%49%+>;$#@LO%7ZJRC$RGWZT <U/!
M);R;)!@_7K5_3H/*0W<CJL>TCD]O4U:O+2*YF7=(4?& /44Z6PAFT]K)]WE,
M,'!YZYK3FT)L/WAT5T8,A&00>,5*N:R/-@\/0)#.2UKSY3X!8'KM([_6M"QO
MK?48/.MG+J#@Y&"#Z&I:"Y4N=7MM/W1WC8PW&%R,>],M,/J$KCH6)%.FTJ!+
MH7EW=L47=Q*1MPQZ9-%@ ;R8C&/,;&/3-#MT&KFZGW13J1>E+4C"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (;K_CSG_ZYM_*O/V^\?K7
MH%U_QYS_ /7-OY5Y^WWC]:N)$A*UM%Z3?A636MHO2;\*HE&K1112*"BBB@ H
MHHH BN)?)B+!=SD[47U)Z"BWA\B$)G+=6;^\QZFHX_\ 2+DS<^7'E8_<]V_I
M^=6:8!2CJ*2@=12 XJ*-3X>U=NXG!_\ 'O\ ZYKJM*P-)M-O3REZ5AV]HO\
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M)(C;K&J)NR&SWQBMJLS1-(&E6S!F#S2'+L.GL!6G42M?0I7MJ%%%%2,****
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M,,MN(4$4B&,#"X;M3_-C_P">B?\ ?0I#;PL26AC)/<J*3[-;_P#/"+_O@4:
M.\V/_GHG_?0H\V/_ )Z+_P!]"F_9K?\ YX1?]\"C[-;_ //"+_O@4: 58;&S
MAL9;19/W4N[=E\GYNM6+=8+6VC@CD&R-=HW-DXIWV:W_ .>$7_? H^S6_P#S
MPB_[X%.X6'>;'_ST3_OH4>;'_P ]$_[Z%-^S6_\ SPB_[X%'V:W_ .>$7_?
MI: .\V/_ )Z)_P!]"H+-@TEQY9W0[\H1TS_%CVS_ %J7[-!_SPB_[X%2@ #
M  '84 %%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH T[+_CW_ !JS5:R_X]_QJS4/<L****0!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445&UQ K%6FC!'4%A0!)147
MVJW_ .>\7_?8H^U6_P#SWB_[[% $M%1?:K?_ )[Q?]]BC[5;_P#/>+_OL4 2
MT5%]JM_^>\7_ 'V*/M5O_P ]XO\ OL4 2T5$+F D 31DGL&%2T %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !141N8%)!FC!
M'4%A1]JM_P#GO%_WV* ):*C2>*1MJ2HQ] P-24 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M-.R_X]_QJS5:R_X]_P :LU#W+"BBBD 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9&L:.MZAFA $X'_ 'U_]>M>BA.P-7/.G1HW*."&!P0:
M;78:QHZWJ&:$ 3@?]]?_ %ZY%T:-RC@A@<$&M$[F;5AM%%%,04H!8@ $D] *
M "Q  R3T KJ]%T46H%Q<+F8_=4_P?_7H;L"5PT711:@7%PN9CRJG^#_Z];=%
M%9MW-$K!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <#J'_(0N/\ KHW\ZK59U#_D(7'_ %T;^=5JU,C7\.?\A9?]QJ["N/\
M#G_(67_<:NPJ);EQV"BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ IDGW#3Z;)]TT <KKXD-S:HNZ3>& C Z'UJOIFE.[2BZ
M5T7C9U!/KU[4FNV]Q-K-I]FC=96&%ES@9R?RQ5FV:\M]0B%Y<&3;$48;2VYL
MD@9[GW]JV^SH1U+(T#3W4LT#&0?\M=Y!'OZ<4JZDML%^ULWF(ORONXD&<?\
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -.R_P"/
M?\:LU6LO^/?\:LU#W+"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !61K&CK>H9H0!.!_WU6O10G8&KGG3HT;E'!# X(-( 6( &
M2>@%=?K&CK>H9H0%G _[ZJ/1M%%J!<7"@SG[J_W/_KUIS*QGRNX:+HHM0+BX
M7,Q^ZI_@_P#KUMT45#=RTK!1112&%%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 :=E_P >_P"-6:K67_'O^-6:A[EA1112 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[PP3BJBKNQG5FX0<D'_"4Z>>42Z=>S+;L0?I43>)6N+I+;3;"6>5E+$3?NL
M>F>M=  % 50 !T [5@ZH\UGX@M;X6D]Q$('C/DKN()(JH\K>QSU?;0C=RZJ]
ME_P_Y$G]H:[_ - 5/_ E:AGUZ_L&B?4-*\J!WV;HY0YS]!UI8-;%O%Y::1JF
MW)/S1Y/)SU)JI//)?OIUM;Z;?1+#<K(SSIP #D\YII=T92J/E]R;;]%_\BB_
M_P )18_\\;S_ ,!VK0L-2M-2C9[67=M.&4C#*?<&K>:PY46#QE;-& IN+9_,
MQ_%@\&IT>QT-U:;3DTTW;:V_S-RBBBH.D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#3LO^/?\ &K-5
MK+_CW_&K-0]RPHHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 445%+=6\#!9IXHR1D!W _G0
M!+13(YHYEW12(Z^JL"*(YHI@3%(C@'!*L#@T /HJO)?6<4PADNH$E/1&D ;\
MJF=UC0N[!5')8G % #J*:CI(@=&5E/1E.0:CN+NVM0#<7$4(/3S'"Y_.@":B
MFHZ2('C964\AE.0:CN+NVM0#<7$4(/0R.%S^= $U%-21)(Q(CJR$9#*<@TD4
MT4R[HI$D7IE6!% #Z*KM?V:3^0UW )O^>9D&[\JL$X&3TH **9%-%.I:*5)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M<#J'_(0N/^NC?SJM5G4/^0A<?]=&_G5:M3(U_#G_ "%E_P!QJ["N/\.?\A9?
M]QJ["HEN7'8****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@"I(/WN/7BJ[/%'*JF0 YYS5FX!#*1US66ZLO[L !NC$CK
M[TT)EVZ6,Q[I$5E7+;F&0N!UK+?4D$<LN?-P%4/C:B^O&?U^E.OM1^PP)#<1
M;A(2@YZ\=?S-44%O9N =Y *'SG!!7_@/?_Z]6D2V7[>Y=].8[L[MYW8X(Z +
M_GL:N:4/W8-5)X@EC).N=S.06*E2P)]#T[?E[U>TP8B%1+<I&G1112&%,E^X
M:?37^Z: ,^=(7M@LZ!UZ ''6HK8%)PLBX.W"'V]*=<Q%U3:075B0F[!(-0QS
M%;@&5&4*N0H&?;K5+80[5KI+.T::1B5 X0+DLP.1^%8D,?G7LE\C1[W D8K(
M1M'<#\JVKK4H5C=-KY'WLH" ._7K5*,R)=Q1"%2JG,:O'M+ CDG';\*I:(EB
M3AEN8(FWA<%T#G) .,Y_&N@M1B(5ANA_M$1EMVP8ZD@=^,_6M^ 8C%0RT2T4
M44@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (;K_CSG_Z
MYM_*O/V^\?K7H%U_QYS_ /7-OY5Y^WWC]:N)$A*UM%Z3?A636MHO2;\*HE&K
M1112*"BBB@ HHHH *Q?$'^NTG_K]7^1K:K%\0?Z[2?\ K]7^1JX;F&)_A/Y?
MFC:J%[NWCNX[5I5$\@+*G<@=:I:E#J*3I=Z=('<+L>WD/R,/4>A%.TO3/L>^
MXN)//OIN993_ .@CT I65KC<YN?*E\^EOZ^[\YKS5++3V1;JX6(N,J"#S5;_
M (2/2/\ G^C_ "/^%37ZW[.GV.&TD7!W>?G(^E4_+UK_ )]=+_6FDK$5*E52
M:CMZ-_J6(_$&E2R+&EZC.Q"J,'DG\*K7?_(X:?\ ]>\E:=K"WD(;F&!9_P"+
MRUX'TK,N_P#D<-._Z]Y*%:^@JG/R)S[QZ6Z^K-NBBBH.H*0D*"20 .232UR/
MC:_F1;?3X6($PW/CN,X _G51CS.QCB*RH4W4?0V)/$VCQR^6U\F[.,J"1^8&
M*T4N8);;[1'*CPX+;U.1BN?M?!>FI:*ER)))R/FD#D8/L.GYU-8:$-%TV_ N
M7E\R-OE/"@8../6J:AT9A3J8J_[R*MY=/4U;+4K/45=K2=90A 8@$8_.EO;^
MUT^)9+N81(QV@D$Y/X5S'@'_ (]+W_?7^53^.O\ D%6__7;^E/D7/RB6*F\)
M[>VMOU-Z74K."R2\EG5;=\;9,'!STJ2*\MY[/[7%*K0;2V\=,#K7*ZS_ ,B%
M9?2.LWP[JAM[2]TZ<D1S0.\6>S;3_.G[.ZNC.6/<*JA):-7^9W%GJ=G?QR26
MLZRK']X@'C\Z++5++46<6EPLI3&[ (Q^=<QX(_Y!NH?7_P!E-0^"91#_ &I*
MW1(PQ_#-)P2OY#I8V<O972]Z]_D==>ZE9Z<H:[N$BST!ZG\!S4-EKFFZA)Y=
MM=H\G9#E2?H#UKC]$TX^*-2N;V_D<QJ1E0<9)Z#V %;5SX+LGGADM)9+8*V6
M 8MD>Q/0T.,5HWJ$,3B:J]I3BN7\7^ATQ( ))P!U-4;36=.OY_)M;I)),9V@
M$<?C5/Q->_V?H$H5CYD@$2DGDYZG\LUQUO#+H%UI.HOD).N]O89P1^1!HC"Z
MN/$XQTJBBEIU\KNQZ)=W<%C 9[F01Q @%B/6EM;J&\MUGMY!)$V<,._:L;Q@
M0WAN4@Y!="#^-2^$_P#D6K7_ (%_Z$:GE]VYNJ\OK/LNEK_B;5%%%0=(4444
M %%%% !1110 4444 %%%% &G9?\ 'O\ C5FJUE_Q[_C5FH>Y84444@"BBB@
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M1+<N.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %>Y'RY]*BE).<8'!()'2K$WW<U5FW-;E-A?<A! ;';&,TT)F9%
M:W3VUNS-'.[L7:8XRHP<<'.?PQ5N&P#6T8OBES,O)D9?Y5EZRDL.C)!IPF$<
M+;9<$Y QT)I/#;W*V,HN3(L1YB:3@>^,U=M+D]2UJ"$6P+!B3.0I<YPN.WMQ
M6IIZXB'TK.U ,(;5&;<2Q.?7_.:U;(8B'TJ&6BU1112 *1ONFEI#TH P=6OX
MM.,3M 99G<B/'&!CGFJJW_VFV@N8XV*.F0&.3D'!SQT!K2U6S%Y93Q\"0(6C
M8]F%5'MMD-J%?(*85,XQP,X['OU!JU:Q+O<<ED+FW23RSPNX;LY)]/I]:LVW
MEAA(&=B00<G/>FV,R"XFMR^94QE03@#^A]LU::"$OO*@,.20<?G2; SH<RZG
M,Y'\9%;R#"BL'2_WDC2$?>)-;XZ5)0M%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% $-U_QYS_]<V_E7G[?>/UKT"Z_X\Y_^N;?RKS]
MOO'ZU<2)"5K:+TF_"LFM;1>DWX51*-6BBBD4%%%% !1110 5B^(/]=I/_7ZO
M\C6U6+X@_P!=I/\ U^K_ "-7#<PQ/\)_+\T;5%8WB*3R+>&:*X>.\1_W$:<^
M:Q_A*]Q_*F:!-)<S74UY*XO]VV2W/ B4= !_6ERZ7!UU[7V5M?Z_'R^9N45C
MZU-;12PBXU6>R)4X6+'S>YX-9GVO3O\ H9[S\Q_\334+JY,\3&$G%_FO\SJZ
MQ+O_ )'#3O\ KWDIUE8&=(KJ'6KV:(G<,E<-@].E-N_^1PT__KWDH2LQ5)N4
M$VK:K\S;HHHJ#J"N4\9Z9-<0PW]NI9H 0X7KMZ@_A75TUW1/ONJY_O'%5&7*
M[F.(HQK4W"74Y6U\<6GV-3<PRBX48(0 AC['M5O3-:GUG2[YY;0Q(B/M<'Y6
MX/'U%:#:7H\\V\VMJ\AYX Y_ 5=*PQ0^61&D6-NTX QZ53<>B,*=+$7_ 'DT
MTNRW]3@?"NNV>CV]PEUYF9&4KL7/05>\4ZC;ZIX?M[FVW>7YY7YA@Y KHETO
M1V(5;6T)[  58.F6)@$!M(3"&W!-HP#ZU3G'FYK&$,)65!T7)6L<QK/_ "(-
ME_VSJC=Z3]I\(6.H0K^]@0A\=TR?Y5VMQ#8"V6WN%@$(QMCD( X] :EBA@6V
M$4*((,8"J/EQ252R^9<\"JDGS/[*7S74Y+P1_P @[4?K_P"RFH?!$:S-J<3?
M==%4_CFNOBM[*Q5DBCA@#\D#"YIMM#I]JS?9EMXB_780,T.=[^84\&X>SNU[
MM_Q.)TV]F\):I/:WD+-!)W7N!T8>M:LWC6.2YABT^TDGW-A@PP3[*/6NDN8+
M.['DW*0R^B/@D5';6.G6,F+>""&0^F-W^-#G%ZM:A##5Z:Y*<[1]-5Y'(^*9
MI-5URTTN'AE !![.W7./0?UJ'5?#6JV^G-/<7R7$5N,A S' Z<9%=P+"T6Y-
MR+:(3DY\S;\V?K4A,-PC1DI(I&&7(.1[TU4M9(4\O51SE4>KV_0XNXO_ +=X
M ^9LR0ND3?@1C],5)H7BC3M.T:"UG,OF)NSM3(Y)-=/'8:;Y3P1V]N8V(+HH
M&"1ZBHSI.D!MAL[4,?X2HS1SQ:LT"PU>,U4C)72L78)DN;>.>/.R10RY]#4E
M-1%C1410JJ, #H!3!<P-)Y8GB+_W0XS^59'HIV2N2T444AA1110 4444 %%%
M% !1110!IV7_ ![_ (U9JM9?\>_XU9J'N6%%%%( HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***QK_Q"EEK46DQ:?>7EW+
M;@+!Y8 0'!R7=>] &S16=H^M6NM0S/ LL4L$IAG@F7;)$X[$9(_$$@^M:- !
M116=HNLV^NV!O+5)4C$KQ8E !RK$'H3QQ0!HT453LKF]GGNTNK#[+'%+M@D\
MY7\]/[V!]WZ&@"Y1110 4444 %%9VCZS;ZW:S7%LDJ)%.\#"0 $LAP2,$\5H
MT %%%% !115/3+F]NK9GO[#[#*)&41^<LN5'1LCU].U %RBLKQ'K/_"/Z!<Z
MI]G^T>1M_=[]F[<P7K@^N>E:M !1110 4444 %%1SS+;V\L[@E8T+D#K@#-5
MM)U.'6=)MM1MUD6&X0.BR !@/?!(_6@"[1110 4444 %%9.DZW_:FHZM:?9_
M*_L^X$&[?N\S*@YQ@8Z^]:U !13)6=(G:-/,<*2J9QN/89[5!IT]U<Z?#->V
M?V.Y89DM_-$FPYZ;AP: +5%%5-4U.UT?39]0O9/+MX5RS 9/)P !ZDD#\: +
M=%9UAJLM[/Y4VDZA9$Q^8K7"H589'&49L'D<-@]<=#B/PWK/_"0>'[35?L_V
M?[0I/E;]^W#$=<#/3TIV U:***0!14<\OD6\LN-VQ"V,XS@9JCX?U;^W=!L]
M4\CR/M*;_+W[MO)&,X&>GI0!I4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P.H?\A"X_ZZ-_.J
MU6=0_P"0A<?]=&_G5:M3(U_#G_(67_<:NPKC_#G_ "%E_P!QJ["HEN7'8***
M*DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@!D@RAJE+.EM:O-(<(F2:O-]TUGS!6AF639Y>"&#=""*:$S(9KU6;-RS2$D^
M447!/ITSCMUJ\DT5]IX,FXP2)EN.W3;^']*J0:==&V6&2[A=F4X;:6)3(YZ]
M>G-3Q211QM''*C10E50(X&[VQZ5;)([B(13VT"XVQIA0!T&?_K5NVPQ&*QKA
M<ZMQGH*VX1A!699)1110 4444 9.K2RP6=P\*;Y/+.!_6L32+X-%%;B]C,4:
M##[?F!/8$UT\P_>K_GM5.XT^*X W*J,/XU4 _P"?K5)JUB6M2&WL8+.25X1(
M#+@MO<MD^OZU--(8[69@,_(:PIM<EM+@P7"1W#1R! \3;<Y]NYP?SK=O@([&
M7N&POZTY)K<$T1Z0F(Q6T*S-,7$0K3J"@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ANO^/.?_KFW\J\_;[Q^M>@77_'G/\ ]<V_
ME7G[?>/UJXD2$K6T7I-^%9-:VB])OPJB4:M%%%(H**** "BBB@ K%\0?Z[2?
M^OU?Y&MJL3Q&0ATR5CA$O$+-V'!%7#<PQ/\ "?R_,V6C1W5V12R9VL1ROTH$
M:"0R!%$A&"V.2/3-.HJ3>R$(!Z@&C:O]T?E2T4 '3I6)=_\ (X:=_P!>\E;=
M8EP0_C*S53DQ6SE\?PY/&:J)AB-H^J_,VZ***@W"N0\>?\>ME_OM_*NOKD/'
MO_'K9?[[?RK2E\:.+,?]VG_74S;_ ,-+8:''J<=X^_:C[2,=<=#^-/U2]FO_
M  5933L6D%QL+'JV >:L6O@N2ZMX)9M2;RW17V!3QD9QR:L>+;2&Q\-VEM N
MV..8 ?\ ?+<UKS)M*]SS70G&G.?+RQY=KWN^YE2>&EC\.+JJW;!_+$FQA@<]
M@:U+#Q!/;^#WNY3YD\<AAC9N=QXP3ZXS^E<U=V,UI!8R7$LC6=PBOE3]WU&/
M45U>LZ7"_A"---&^*+$RXY+CN?KS1*VB?<5#F7/*DN5J.U]WW,O3/#5QKT!U
M"_O'7S22O&YC[\]!34>\\(:S'#),9;.7!/H5SC..Q%:WAKQ%8+I,-K<SI!+
MNWYS@,.Q!K(UZ\3Q'K=K:6&71?D#XZY/)^@Q0G)R:>PY1HPHQJ4G^\TZZM]2
M;QN ^L6*EL*T0!/H"QYJW:>$[!;N)XM5,CHP<(I4YQSVJIXUC#:QI\1/!B"Y
M_P"!8K<TOPK::5?+=Q32NZJ1A@,<TN:T%J:QH^TQ4[PNKKKL8TQ_XN2/]]?_
M $6*-8_Y'RS_ -Z+^=$O_)25_P!]?_18IFNR)#XXM99&"(AC+,3P!FFMUZ&<
MW:$_^OAW1Z5P_@/_ (_+W_<7^9KJX-6T^ZE$-O>0RR$$A5;)-<IX#_X_+W_<
M7^9K.*M&1VUY1EB:+B[_ !?D8UGJ;Z5XA>Y!)02LLB^JD\UKZE(LOCNQDC;<
MCM"RD=P:J:1IT>J:MJEJ^ 6C<HW]U@XP:HZ8LT?B2QAGR)(KA(R#VPW2MFE?
MY'D1E.,(Q?PN6GJF=%XIU.[GU&/1K%BK-@.5."Q/09],4Q_ ;"VW1WI-R!G!
M7"D_7K4.O^9I'BZ'4V0M"Y5ACV&"/KBK&MMI^IL-0CUQ84$8'E+G<2,]L]>:
MA725CLFH3G4=97DGHKVLNZ.GTRTGLM/B@N+AKB11R[?RJW7&>!X[B6:ZNI'D
M:(*(UW,2"<Y/\OUKLZRFK2L>IA*BJ45)*R"BBBH.@**** "BBB@ HHHH T[+
M_CW_ !JS5:R_X]_QJS4/<L****0!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Q>J/>)\3[(V,$$\O\ 94F5GF,2X\P<Y"-S
M[8KM*J-IEF^JIJC0YO$A,"R;CPA.2,9QU[XS33L#.!\4:'<:?X5U"YO+@&^U
M+4K>68V^0L7SJ%5">3@=R.?2M7Q%I]KIZZ'H]I"MKI]_?B*\,0V&<;#\KL,$
M[\8.>3CZUU.HZ99ZM:_9KZ'S80ZR;=Q7YE.0<@@]12ZAIMGJMFUK?0+-"Q!V
MG(((Z$$<@CU'-/F%8Y:YTRQTWQMIEE86L$5IJ-K<)?6<<8$3J@4JQ0<9R2,X
MY!Q6%HL<>D_#/6-6TZUAAU%#<HMQ'$!(%\PC[P&<# /IP/2O0+#1+#3;B6XM
MXI#<2J%>:>9YI"HZ+N<DX]LXIMKH.G64MR]O RK<[C+$97,3%OO'RR=@)]0*
M.8+'+6'AN^WZ->V%AI=BT,B23WD%X[RW,1'SJ_[H;RW!^8]16)K'_(M>/<$@
M_P!IQ\CJ/FCKO[3PSI5E)"\$,VV%MT43W,KQ1GGE8V8JN,G&!QVITWAK2)[:
M_MY;3=%J$HFN5\QQYC@@@]>/NCIBGS!8YZ_TZTT+QGX:;3H1 ]T\\-RX)W7
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MWC^/2G)W$D:=@N(A5VJMF,1"K524%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% $-U_P ><_\ US;^5>?M]X_6O0+K_CSG_P"N;?RK
MS]OO'ZU<2)"5K:+TF_"LFM;1>DWX51*-6BBBD4%%%% !1110 5#=6L-Y;/;W
M$8>)Q@J:FHI@TFK,Q%\.&,!8M6U%$'W5$O04O_"/R?\ 09U'_O[6U15<[,/J
MU+M^+,7_ (1^3_H,ZC_W]H_X1^3_ *#.H_\ ?VMJBCG8?5J7;\68O_"/R?\
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M06WN3)&QX& ,D=<C.*JW6H>(;'1=*TN]2]%Q=:@]N'26+[3); $K\P;:)",
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MDD5PN5,PW8(/;C-9-D-07X7IXC?6M1?4X8?/C=[AM@"L?D9,[7S@Y+ DYZX
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M>W5_=QQF*&2Y* 1*3EMJHJJ"<#)QG  SBM6J<&JV5SJ=WIL,VZ[M AGCVD;
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MMW:XN94DP)<<+%M!R0<DG(QQZUM44@*]]90:C87%E<IO@GC:.1>F01@UE?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!IV7_'O^-6:K67_ ![_ (U9J'N6%%%%( HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH Y[Q)J=Y8:GX?AM9O+CN[X0SC:
M#O3:3CD<=.U90N]7U^RU^\@U/[+!:S36MO;"%&CD$8^9I"1N^;)'RE<8'6N@
MUC1/[6O=*N/M'E?8+H7&W9N\S@C'48Z]>:H-X7NHWU.&QU7[-8ZE*TT\7V?=
M(CL,.8WW +N]U..<8JDT(YS2M<GL?#'A+2[>6:#[;;L\L]O;-/+&B8.$0*W)
M) R00!GCI5R;7]9M=(\1E9+QX[2V$UE?W=B8')(.5*LBJQ!'4+WK4A\(&UTS
M1H[:_P#+U#25*PW1ARKJW#JZ9Y4CT8$'!S5R]T6_U30]1T^_U.-WO(S$K0VN
MQ(ACJ%+%B?7+>F .<NZ%J8[ZAK6FKX<OKG4S=+J5Q';W%N846-?,0D%"!N&,
M=V.?;I3=#L;C_A8?B4_VK>8C^R,PVQ8E!5R%;Y.@Z#;@^I)YK;OO#WVVTT6#
M[5L_LRYAN-WEY\SRU*XZ\9SUYI4T2XMO$MUJUI>1HEXD2W4$L!<MY>0"C!AM
MX/<&E=#L<-K=[?ZSX O;B[OY=T.K&$*B1@,HF4*#\O;MC'OFNK%[?:-XNM+"
M^U&2YT^]M7\F2=(U99D.Y@2BJ,%#Z=OK4;^"M_AJZT?^T,?:+XW?F^3]W]X'
MVXW<],9S^%5_B7:K>:%9P12&/4)+Z**S9>N]\J1GL-I8GZ"G=/01J^$=1O-8
MTR?4[J4M#<W,C6B%0NR ':O09.<$Y/K3= U.\O=?\16UQ-OAL[E(X%V@;%*
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MZ>EU&RQ1L\N\$[FWAAM7;C QR3S5*PUS6?[-\'RSWLKR:I/_ *3YD48W*4)
M&%&!P"._/4U3U&RT6?QMK(UJ]@TU$CMQ;K<PVY$RA#ED,T;# /RX7N#GT&SI
M-G?^)M/T+5-1E,,UC<O*A,&TW*8*JY7(V%AST^@ (HT$3:9<:MXC_M"]@U9[
M"**ZDM[:&."-T(C."TFX;CDYX5EP/?FE\47[:>EW(?%4&G7"P&2UM"(1OP#]
MX2 LV6!'R[?3DC)L0>';_3IKU=)U:.UM+R9IVBDM/,>)V^\8VW #/4 JP!_*
MHI_"MU]LUB2SU2."'5L?: ]KYDBX7:0C[@ ,=BIQSBEI<9FC4'U;Q%X$U"1
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M>TWPP"1X+8,H)5 /F*@]P??I1JGB&>+P/<:KHFOKJ!^T1)%<20IN3+*&1P%
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M8[[-)C04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .!U#_D(7'_71OYU6JSJ'_(0N/^NC?SJM6ID:_AS_ )"R
M_P"XU=A7'^'/^0LO^XU=A42W+CL%%%%24%%%% !1110 4444 %%%% !1110
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M/+B51AMX(^@%)H+FQ144+[E!J6D,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@"&Z_X\Y_\ KFW\J\_;[Q^M>@W(W6LP'="/TKSX]35Q(D)6MHO2
M;\*R:U=%/,P^AJB4:U%%%(H**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH T[+_CW_&K-5K+_CW_ !JS4/<L****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4449'K0 449'K1D>M !11D>M&1ZT
M%%&1ZT9'K0 449'K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <#J'_(0N/^NC?SJM4]ZP>^G8=W;^=05J9&OX<_Y"R_[C
M5V%<?X;!.J@^B-785$MRX[!1114E!1110 4444 %%%% !1110 4444 %%%%
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M_P +1YN9Y.RH%_,__6KJ*R/#EOY.F^81S(V?PZ?XUKUG+<TCL%%%%(84444
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M444 %%%% !1110 4444 :=E_Q[_C5FJUE_Q[_C5FH>Y84444@"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P]:T47(:YMEQ,.64?Q?
M_7K<HIIV$U<\Y(*D@C!%(!DX%=7K6BBY#7-LN)ARRC^+_P"O3-%T3RMMS=+\
M_5$/;W/O5\RL1RNX:+HOE!;JZ7Y^J(>WN:WZ**ANY:5@HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:[I$A=V"JHR2>U "32I!$
MTLC;449)KA=0O'OKQYFZ'A1Z"KFLZN;Y_*B)$"G_ +Z/K636D58B3N%2V\+W
M%Q'"@^9V %15TOAO3RH-Y(O7Y8P?U--NQ*5S?AB6"%(D^ZBA13Z**R-0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,[7K@6
MGA[49R<>7;2-G_@)KQ;2+.[\+^&=&\::?$9'\R6*Z3LZ,Q52?;(_/%>Z7=K!
M?6DMK<Q++!*I5T;HP/:FV5C:Z=91V=G D-O&"$C4<#G/\S51E9$N-V>)-HTV
M@W/A+7KTM]OO[_S[DMU 9E('Y$_G6[XLO]1U?XE6EOI&G?VD-$42O!Y@13(>
M<DGT^7\0:]*U'1].U=85U"TCN!"^^/>/NMZBBTT?3K"\N;RUM(XKFY.Z:11\
MSG.>:KGZBY3SGX?7E[I/C#5M$U.R-B]]F\BMRX8*W< C@Y'_ *#7#Z7<^(K#
MP/-/9W_E:--=&"Z6.)6=,@9;.,X(XX/\Z]^GT;3KG5(-3FM(WO8!MCF(^91S
MQ^I_.HK?P]I%IIDVFP:?"EG.29(0/E;/K^5'.@Y6>9^.=*L=-^&>@V>F7'G6
M[7B,EQ_?+(YW?KTJ[\.;M?#&K7?A358$@OI9/-AN.UP".!GZ=/Q'6N\;PQHK
MZ;#IS:=";.&3S8X3G:K<\CGW/YU)J&@:5JLT$U]8Q32P?ZIV'S)WX(I<RM8.
M76YY))"DWQ)\2!_$YT'#C][O"^9T^7EA]:]3T-XF\-(D.K+JHC1D:[#AMYYZ
MD$\_C3+SP;X=O[N2ZNM)MY9Y3N=V!RQ_.M'3])L-)LS9V%K'!;DEC&G3)ZT2
MDFAI6.*^#G_(E/\ ]?3_ ,A4WQ=_Y$27_KXC_F:Z_3=*L-'M3;:=:QV\)8ML
M3ID]Z74=,LM7M#:ZA;)<0%@Q1^F1TI<WO7"WNV/-/&=E!J/B+P597*;X)T$;
MKZ@[16'H\.H:9\3M#T'4"7&FR21P2'^.)E9E_#_]7:O8Y]%TVYN;2XFLXWFL
M\?9W(YC^GY4L^CZ=<ZG!J4UI$][ ,13$?,HY_P 3^=4IZ6$XZW/+;:SUR]^*
M/B1-"U.*PF&#(\D0?<OR\<@XYJYK/@V;P_\ #O7GDN6OM0NW2>YE"X&%;/ ]
MLDUZ/;Z1I]IJ-QJ$%K''=W Q+*.K_6KC*KJ590RL,$$9!%+G'RGD7B?Q-H]]
M\);+3[:^BEO6BMXOLZG+ADV[LCJ.AKJO$\,EO\))H95*R1V$2,I[$!016O;>
M#/#EI?B]@TBU2X!W*P7A3Z@=!6M>65MJ%I):7<*S02C#QMT84<RZ!9]3'\$?
M\B/HO_7HG\JWZAM;6"QM8K6VB6*")0J(O10.U35+W*04444@"BBB@ HHHH *
M*** "BL+5-<GL+PPI%&R@ Y;.:I?\)1<_P#/"']?\:?*Q<R.JHKE?^$HN?\
MGA#^O^-'_"47/_/"']?\:?*Q<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\
M&CE8<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\ &CE8<R.JHKE?^$HN?^>$
M/Z_XT?\ "47/_/"']?\ &CE8<R.JHKE?^$HN?^>$/Z_XT?\ "47/_/"']?\
M&CE8<R-K5M-74+7 P)DY0_TKBG1HG*.I5E."#VK;_P"$HN?^>$/Z_P"-9U_?
MF_D$CPQH_<IGGZU2NB6TRG0#@Y'6BBF(T[7560!)P6']X=:U8IHYEW1N&'M7
M+TJLR'*L0?4&@=SJJ*Y^/4KI./,W#_:&:F&L3]TC/X'_ !H"YM45B_VQ/_SS
MC_7_ !H_MB?_ )YQ_K_C0%S:HK%_MB?_ )YQ_K_C1_;$_P#SSC_7_&@+FU16
M+_;$_P#SSC_7_&C^V)_^><?Z_P"- 7-JBL7^V)_^><?Z_P"-']L3_P#/./\
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M7_GFWY4>1+_SS;\J (Z*D\B7_GFWY4>1+_SS;\J (Z*D\B7_ )YM^5'D2_\
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MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2B
MB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#TH
MP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH
M,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#T
MHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]
M*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]***
M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7V;9SNSOW9^E;%2QH****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img33530786_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )H!*0# 2(  A$! Q$!_\0
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MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB@$$9% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11GG%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4449H **** "BBB@
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MG4[:72=,CO=+\O$L83>78]0PZ@=,8]Z[NBH6(TBG%-*_XE.AK)IV;M^!Y/\
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MG):2ZFUX.U,MX#TN_P!3O,LT69)[B3J=Q'+&NE!# $'(/((KRRZ&?@-:<?\
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MZ73=/N42.."5=C3..3*5[>E=M112J3YW<<(<JL%%%%06%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %(:6B@!,TF:"*BWX.#0!+FC-
M,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S
M1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F@!^:,TS-&: 'YHS3,T9H ?FC-,S1F
M@!^:,TS-&: 'YHS3,T9H ?FC-,SBA26/% $E+110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%+'N&1VJ6B@"DL
MI4[6J7=1<0;QN7K5-)C&VQ^G\JJUR=BYFC-,SFC-(8_-&:9FE!Y% #LT9KPJ
MTU3XA^(_%.OVFA:]Y:Z?,<12A -I8@ 97V[UT?A/QWK]KXJ'A3QE;I'>R#_1
M[A  &.,@''!SSR/I6KI-=3-5$SU+-&:\SL_$6KR?'"^T-[Z0Z9' &6WP-H.Q
M3G.,]2>];7Q)\3R^%_!\]S:R;+V=A!;GN&/4CZ#)J>1W2[E<ZLWV.RS1FO,O
MA'XPU#Q!9ZAI^M7+3:E:2!P9%"N4/'( '0_SK8^(?CD>#=+A6VB6?5+LE+:)
MN0/]HCN.V/6ATWS<H*:Y>8[;-)FO&[?PW\5]3M_[2G\1QV=PPWI:LV"/08"X
M'X_C79^ =0\67=K=P>*[%89;:01QSC ,WJ<#@CW'!IN%E>XE.[M8['-&:\,T
M3XGZEI_Q(O-/UJ^:;2I+E[==X $!W?*<@=.QKJ/B7XBU;1M?\,0:;?/;PW=Q
MMG5 ")%W(.X]":;I--(7M%:YZ7FES7 _$/QW-X9%KIFDPK<ZU?$"&,C(0$X!
M([DG@5S+>'/BREM_:8\11-=CY_L089_W?N[?UI*G=7;L-SL[)7/8\TN:X'P!
MX^D\3Z?>P:C L.L:>K&>%1@.!GD#MR,$5P.DZQ\0?&9U#6M'UN*.6TFPNF @
M';GT(QCZFA4G=WZ ZBTL>]YHS7FWC@>.DT&SU/3]1@L7M;0R:@D1!#/_ +.0
M:S?AA=^-=;,6N:GK'VG1V25/*;:&WC@' %'L_=YKAS^]RV/6\TN:\Q^%OBG4
M-3T+7+[7=0:=+.Y;$D@ V(%R>@%8D'B'QQ\2;^X/AN=-(T:%R@G?JWU."2>^
M!TH]D[M/H'M%9>9[3FDS7D]A_P +,\+:Y9VMVR:_IUQ($9U/^K]3N(!7'OQ7
MJN:F4;=1QE<?FC-,S1FI*'YH+ #)J-G"C)/%1INGDP!Q_*@39,NZ1N*LJH48
M%(B!%P*=2&D%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *JW5J)063AJM44T[ 8L5P8F\N3@>_:KF[/
M2EOK(3J73AQ^M9D%RT+^5+D#ISVJ[7U1%[:,TLTJGYA]:BW9&12AL'-24>4_
M"O\ Y*!XV_ZZ+_Z,:JGQ#FBU/XL^%[/3W66\@>/S2C9V@2;L'Z $UI7GP=CN
M=6O+^'Q'?6S74ID=85"]3G&0>:WO"'PYTGPE=27J2S7NH."/M,^,J#UP/7WK
MH<HI\R9CRR:Y3F;$_P#&1VI'_IV_]IK6'\5/$=K=?$+3K"YCDGT_2BKSQP\L
M['!8?E@?B:])@\%Q0>/[CQ8+Z0RS1^7]GV#:/E"YSU[5'X:\"6F@:OJ>J3W/
M]H7=^VYFFB4;,DD@?4X_*DIQ3OY X2:MYGEUCXWL%^+T&O65O/9V-]M@NDG4
M#!(VD\=N%-=-\3I$TKXC^%-:OHR^FQMM<XR 0W/^/X5V7B_P78^+=)CLF<6;
MQ2B5)H8ER".*NZCX;LM:\-IHVKYNXUC53+C:^Y1@./0T<\;I_(.25FB'Q1<>
M)Y]+M+CP9]BN9)'+2/,P*&/'!!)]:XWP5XU\7:MX^?0=7:P>*V1VN#:Q@A2.
M@W@XZU7_ .%-W]L?(L/%UY#9'K&=P('M@XKN/"'@[3/!MB\-COEGF(,]S+]^
M0_T'M2]Q1MN-<S?8\H\/^%8/%VK^/-/D"K<+*LEM*?X) [X_ ]#6'=>(+[4K
M[POH^JQR+J&CWOD2,_5EWKMS[C!'X5[9X8\&0^&=:UC4H[V2=M38,R,@ CPQ
M/&.O6J'B+X:Z=KWBBVU];I[2XB9&E6- 1*5.03Z' Q5JJN;78ATW;0YSQ9<1
M:-\<M#U/4@5L9( B2L/E5L,O7V)!/IFO73(HB\XNHB W>9GY<>N?2L+Q/X7T
MSQ;I?V'4HR0IW12H</$WJ/\ "O/O^%,WI;[.?%UW_9^,>5\V<>F,[:S]V25W
M:QI[T6[*X>!KJ'5_C'XEUC3QC31&09<84G@?J034?B_PT=$DF\>^"=0CC2%B
MUW%$P,9Y^;'8C/5:]$T/PGI'A_07T:SM\VTJD3ES\TQ(P2Q_SBN!D^"A666V
MM/$EU!I,K;FML$GZ=<'\:M3CS7N2XNUK'476NKXD^$5WJP01M<6#ET'17'!%
M5/@Z?^+9VW_76;_T*NC/ANTC\(-X;M6:&U^SFW5^K 'O[FH_"7AJ/PIX<CT>
M*Z>X1&=O,=0I.XYZ"LVURM+N4D^9-]CRSP);3WGPQ\:V]NI:5I7VJ.IPH)'Y
M"NS^#6I65UX#M[&W91=6CNL\?\62Q(;'<8(YK7\%^#H?!MI>P17LET+J;SB7
M0+MXQCBN=USX1VMUJ<NI:%JD^D7$IRZ1YV9[D8Y'TJY2C*Z9*C*-F>B7.HV=
ME/!!=74,,UPVV&.1P#(?0"K&:\RT7X1V]MJ<.I:]J]SJUQ"=R(Y(0-U!R3G\
M*]*S64DELS2+;W'YI&<(I).!4;2!%+,< 57C$E[* !A1^GN:EA*5B9 ]U)@#
M _E6E'&L2;5_$^M$42PIM7\3ZT^I'%6W"BBB@H**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S
M]1T\7*EX^)!^M:%%-.VHFKG,6UVUNYAFR #CGM6D&!&0>*=JFF"Z0R1#$H'Y
MUBVMZUM(8)\A0<<_PUK925T1?E=F;.:,U&&!&0<BC-0429J*>ZM[5-]Q<10H
M?XI7"C\S5?4;Y--TR[OI!E+:%I6'J%&:\>\->%[SXG37'B+Q)?3"R:0I;V\3
M8''8>BC\S5QBFKO8F4K.R/:+>]M;M2UK=03@=3%('Q^1J;->8?\ "J#I&L6=
M_P"&-9N+#9(//20[LIWQZ_0TSXD:SJNH>(-.\%:-.;>2\4/<3 X.T]!D=L D
MT^1-V3%SM+5'HXU73C-Y(U&S\W./+\]-V?IG-6\UY:_P2T,V&Q+^]%[MXN2P
MQN]<>E2?#'7]2BU;4?"&M3&:ZT\GR9&.25!P1GT'!'UH<%:\6"D[V:/1AJ-D
M7V"]MBV<;1,N?YU)-<PVZAIYHXE)P#(X4'\Z^;-(TOP[J-QK\NN:S+I\T,KF
MVV-]\Y/;'/.*[/P;H[>.OAQ]DUJZNO)L;IC;2H<,RA>F3U )-5*DEU)C4;Z'
MK:ZC8NZHE[;,S' 59E))]N:5]1LHW*27MLCC@JTR@C\,UX;\)?"-CK<\FKW,
M]PL^G7B-$J,-K8Y^;\JS[ZT\/7WQ,\0)XEU.:PM%=FB>/)+/D<< ]LT_9*[5
M]@]H[)V/H(7]F8C*+NW,0."_FKM!],YJ9)$E17C=71N0RG(/T->?^$_#WA*_
M\(ZGI.CZA+J&GW+XEDD!#(^.,9 Z=:X:#Q=K?@/3=5\'SQ22WR/LT^;J KG'
M&>HYR/>I5.^B&YVU9[K'=VTI<1W,+E.7"R [?KZ5CMXST))2IO'V [3.()/*
M!_W]NW'OG%<=IWA.3PM\.IO.WO>W<D<NI."2PBW#<OT Z_C5#^SY8]2GU2&*
MW33?[<"B5%??Y!]#G9Y6.O'XT*$>X.;/75D5T5T8,K#(93D$>HI<USG@TC^P
M#Y6[[)]IF^R;O^>.\[,>V.GM6_FLVK.Q:=T29IKR+&I9C@"HWE6-"S' %4XU
MFU*X"H,(/R%2W84I6T6Y-&LE_, HP@_3W-;D$"01A$'U/K26]NEM$$0?4^M2
MU(XQMJ]PHHHH+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHJ.6011/(P)"*6('M0 _-&:\R/QLT+_H':C^2?\ Q5-/QKT/_H&ZC^2?_%5T
M_4Z_\IS_ %JC_,>G9HW5YA_PNK1/^@=J'Y)_\52?\+IT3_H':A^2?_%4?4Z_
M\H?6J/\ ,>H;J-U>7_\ "Z=$_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\
MH?6J/\QZANHW5Y?_ ,+IT3_H':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_
M "A]:H_S'J&ZC=7E_P#PNG1/^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*
M'UJC_,>H;J-U>7_\+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\
M,>H;J-U>7_\ "Z=$_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZ
MANHW5Y?_ ,+IT3_H':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S
M'J&ZC=7E_P#PNG1/^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H
M;J-U>7_\+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>
M7_\ "Z=$_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_
M ,+IT3_H':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S'J&ZC=7E
M_P#PNG1/^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H;J-U>7_\
M+IT3_H':A^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>7_\ "Z=$
M_P"@=J'Y)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_ ,+IT3_H
M':A^2?\ Q5'_  NG1/\ H':A^2?_ !5'U.O_ "A]:H_S'J&ZC=7E_P#PNG1/
M^@=J'Y)_\51_PNG1/^@=J'Y)_P#%4?4Z_P#*'UJC_,>H;J-U>7_\+IT3_H':
MA^2?_%4?\+IT3_H':A^2?_%4?4Z_\H?6J/\ ,>H;J-U>7_\ "Z=$_P"@=J'Y
M)_\ %4?\+IT3_H':A^2?_%4?4Z_\H?6J/\QZANHW5Y?_ ,+IT3_H':A^2?\
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M_/C>_P#CG^-'_"U=*_Y\;W_QS_&CVD>X?VAA?YT>@[J-U>??\+5TK_GQO?\
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M_/C>_P#CG^-'_"U=*_Y\;W_QS_&CVD>X?VAA?YT>@[J-U>??\+5TK_GQO?\
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M5>5WL%%%%0<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBB@ HHHH **** "BG+&[@E$9@O)(&<4V@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.KM\Z@Y^[TSQUHT%S4];M;=%_P #^NYD4445)R!1110 4444 %%%% !1110
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M]BL=0A\II);N 0)(7_U:[@3Q[XQ6;11222U&VV%%%%,04444 %%%% !1110
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MF]#52E[.+U17M)+1FZ6\/VM[9I:W.H$(Y:6^0!&']W8F>Q[YR:3Q1J5IJ5[
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M>RN-<UWYM&@BM++.!<W(R7]PM;L/ASQ,$#+XFQ)_=, V_P"-6Z=MW8Z55O\
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MVKMC\*/N,/\ P8>B_(Z:UZ"KZ]*H6O05?7I5&P^BBB@!#52^_P"/*X_ZY/\
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M.*9 %('/7'7K5K_A-=86.:.$VENDZ,DRP6RH)0PP2V.IJ72FXV?YLI587O\
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M5J0Z?TXI+Z[&GO!:VULUWJ%SGR+=#C('5F/91ZU8AT7Q+(A>?6K6V<C(B@M
MZK[$MR:I0TNW8ASULE<<]O#:V\D\[K'%&I9W8X"@=S6;;/K.M1B?1["""S;[
MEQ?E@9!V*H.0/K4.LQ:M!-IUMXB:WET?[2K3W=NA4,1]U)%[*6QSTKOUQM&W
M&W'&.E4TH*^]R4W-VVM]YQ$R>(-*4S:AI]M>VJC+R6!;>@]=C=1].:T;=+>_
MM([JUD66"5=R.O0BNGKS#Q!XI@^'OB*[M/L+W%K?*MW%&CA1&Y)#_@2,X]Z<
M8^UTBM12G[+63T.DEL/]FLG4=&AN[=X;B%9(V'((K.TKXM:)J%R(+ZUFL-W
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MM!_JXF;(7Z55HHH&Y-[FC?WD%SI6EVZ9,ELDBR97C);(QZ\5)IEY9BRNM.U
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M>CPVDERXM;TSW$DD>-XPO*C\.E<M11S,:Q$EK97[FO<:A;R::L"EO,%_)/\
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M (,/1?D=-:]!5]>E4+7H*OKTJC8?1110 AJI??\ 'E<?]<G_ /035LU4OO\
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M%E^ZCCJ-WKTI^U747LWT.;HHHK0S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KJO"%OD3S^X45RM=SX1C TS=_><UQ9A*U%^9V8"-ZM^QV%A#DCBNJT
M^' %86FQYQ6MK#/;^%M3EBR'6V<@CJ.*\&*N['M2=DV5[2ROO$>MOJFEWLFF
MV"1FU:XC +W>&_A!&  <@-UZULGPG(BAK?Q#K,<X_P"6C7 <$^ZD8K8TJWBM
M=(LX( !%'"BKCTP*N5I*H[V6QG&DK7EN</J6I:SD>%[ZQM[J\OE*6]X5 @=
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M=ESRZE'P,J0:+=642*L-G?3P1[1C*ALC^>/PKI&Z5G:!IC:/HL%I(X>?EYI
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M_@*XQ7=1\KL.<\''--I\Q?UIK5+73\#J$TFZ@TC7+"*&2>2.>#'E(6W+\Q#
M#L1BHK/3[UO"VJ6RV=P9UNH"T0B;<!M?J,9K 6>9#E)I%)XRK$4HN9PQ83RA
MFZD.<FBZ%[6&FG1K[[_YF]96%SH^DZE=ZA$UN+BW-O#%)\KR,QZ[>N!US5;Q
M)P=*_P"P=%_-JQWDDE.9)'<^K,32%BV,DG P,FE?2Q,JJY>1+0ZVYE2,:1I$
MY*P3:>JOS@!W8LK?@<?G5FT']E:W8>'8V&[;(MXR'(>5T(Q] ,"N)+,Q!+$D
M<#)HWMNW;FW==V>:?,:+%6=[=ON['3I'J \,V\6C"4E97%ZMOGS-X;Y<XYVX
MQCM6O++K-O%X>DN[<W-ZAN/W6X"0K@#D_P!_'([]*X-)9(V+1R.A/4JQ!H\V
M3<&\Q]P.0=QR#0I!'$I+KTZZ:->7D=L([RWU.1 FHW45Q:1ABI N[92WR@]S
MR.?8\USUY8SR^*I;,WT;W!FVBX=MH+=LD=#V^M90FE$AD$L@<]6W')_&F$DG
M)/-#=R:E=325NO<ZZ]MYIK2RO]4M3;:HM\D)8KM:Y7NQ'J, ;N]6K\>*&\7R
M21&8Q"=MC)_Q[B/=SG^'&,YSS7'17,BW4,TC/)Y3JP#,3T.<4^\OI+J[N95>
M1(YI6D\O><#))Q1S&GUB-NNZZ]NYV%JUCY.LC38KJ1C=_,+!U63RL<;<@DKN
MST]J9=/:_:-%CU.VNHU$V0]_*K/Y?8,  =N?7WKBD=XVW([(WJIP:'=I&+.S
M,Q[L<FCF%];]VUO\M[G4LGBL:G<._G!-K;VE_P"/?R_Q^7&.F*AM)Y_^$5@3
MSI-G]IA=H<XQM''TKG3-*8_+,LA3^Z6./RINY@,;CC.<9[T<Q#KZZ7^;.VEO
MI[OQSJ@EF#7,8F2R60_(L@X7 / /I[U1A754TK5?[<%P+4Q-M^U Y,_\.S/.
M<^G&*Y<L2VXDENN2>:=)-++CS)7?'3<Q.*.8;Q-[MWZ]>_<['4-7OT\3:1;I
M<.D*0VZ>6IPK!E&<COG/>HK:^N;WQ#JUI+(QM##.@MQ]Q53.T =!C%<B68L"
M6)(Z'/- 9@20Q!/4YHYF#Q4G*[[W_P" =Q"8VT/2EL;?5I(Q&-YT^10/._BW
MC!.?KQ41N&'C>,1++;RFW83CS0Q=Q$W+%,#/K[UQR32Q B.5TSUVL1FFAF#;
M@Q!]<\T<Q3Q>VFUOP.CN]2O8O".F)'<2J)+B9W8,<L01U/>K=Q+'%:3^)58>
M?>1"&,#^&<C$I_($_P# A7(DD@#)P.@STJY>WXN;2SM8HS'%;(1@MG<Y.6;\
M>!^%',2J^[?96]5I?\RE1114G*=GHO\ QY6_^[_4UV6F]JXW1?\ CRM_]W^I
MKLM-[5VQ^%'W&'_@P]%^1TUKT%7UZ50M>@J^O2J-A]%%% "&JE]_QY7'_7)_
M_035LU4OO^/*X_ZY/_Z"::W$]CY*/6B@]:*^L/F0KL/A?+:Q>/K W6/F#K$3
MV<KQ_6N/IR.T;JZ,5=3E64X(/J*BI#G@X]RJ<N22EV-;Q%8:I!XFO(-1CF>^
M><G)!)D)/!'KGM7I6K[K?4/AS::BP.I1R1^>K'+*I*@;O\]C7+6_Q8\2PVRQ
MN;.XE086>:#,B_B"!^E<I?:QJ&HZH=3NKJ22\+!Q*3RI'3'IBN;V52=E))6_
MRL='M*<+\MW?_AST_P .6SQ?&'Q$)(L*L<SG*\ '!!_6JEUK%SHOP>T::Q\M
M)KF22!I3&"P0EB<$].E<]??$WQ'?Z9+9226Z><GERSQPA9'7T)_PK"N?$%_=
MZ!::)*Z&RM'+Q*%P03GJ?Q-0L/-M.=NGX)E.O!)J/G^+10M@/M< _P"FB_S%
M>E^-+&WU+XM:3971 @FC@60GN.>/QZ5YBC%)%=>JD$?45I:SX@U#7=334+R0
M?:4145XQMP%Z=.]=%2G*4TUV?XF,*BC!I]T>PWOB#2=.UZ;2[K6+1-,A)B?2
M?[)8@(!TW8Y]<]*YS0$TW1]#\4>(]#MDO9;6Y\NR>5,^7$<?-@\]S^58"_%'
MQ(MOLW69N-FS[6;<&;'U_P#K5B:%XHU7P[>RW.GW 5IN)D=0R2?45S1PLU%K
MTZ[_ ('1+$P<D_7Y?B:>M^,=6\2:;;1:G96S!9\I>+!M;M\H(X[UZ=XA\5W6
MG?$S2M%@MK4VUV(DN6>,%Y Y(Z^W:O*=?\;ZOXBMHK6Z^SPVL3B18;>((N[U
M/>J]]XKU74?$-MKEQ)&;ZV*&-@F -IR.*J6&YK7BEOIZDK$<M]6]OP/2= ,&
MA_\ "P98+6%X[23='%(H*]&(&/2LC6=0?Q9\-+'5-3CA%XFIBV\Z- IV'&>G
MU_2N/'B_5@FKH)(\:MS=?)UZ]/3K53^W;[_A'?["W)]A\_S]NWYM_P!:%AI<
MW,][K\K,'B(VY>EG^9Z?KGB*^\*^*;'PSH^F6PTO;$OEM!N-P&^\<U/)I=GH
MU_X\M; !8/L,<GEKT0L"2H]JX>Q^)GB.PL([59;>8PKLBFFA#R1CV;_&LBU\
M4ZK:C5-LX=M37;=/(NYF_'MUJ5AIVMI_GJG<IXB%_P"M--CNK_6+CP)X5\/K
MH-K;XOK<3W%V\6\R/_=S^-:CZ!I-_P#$#P]=W5E%;RWUB;N>R(PK2@<#'^?N
MUY_H7C[6] L!8V[03VJG=''<Q;Q&?5?2HK;Q!/JGBZWU76]3N86WC-S /FAQ
MTVKZ>WUIO#S5WMOKU=Q*O!V7IIT1Z/X0\6ZSKWC2XL-2TN!8(5D*@0;6M<#
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M3:)HL^Z1LI<W"'[H[JI]?4UXU7JX#"M?O9_(\_&XE6]G'YA1117JGEA1110
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MM<6Y:)WZF)HVP"/:BR+="%^5=[?B<M11C'%%2<84444 %%%% !1110 4444
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M:;?!)]7T8W5\BA?.BG,8EP,#S%P<GW&,U4.MAM/U2U%G'']NFCE B^5(MA/
M7TYH2G\]/S);AT-V?P_X;@\3#P^+G4'N))1$MR"@CC=N@*XR<9 )R*RHM(T^
MPL#>ZR]RV^9X8+>V*JS[,;F+$$ <@=*@?7 _BT:[]G( NUN?)W^A!QG'MUQ6
MSI&W6[&XAEM;>]3[4\RVINA!/#N[H[<,IQR,=JE\\4KOM<I<LGHO0SM6TO2(
M_#UIJNES79\ZX>%XKC;F/ !ZCKUZUS]=?XIFMK70=/T>."WMYHIY)FAAF\TH
MI  WOT+'GITKD*UI-N-V9U4E*R"BBBM#,**** "BBB@ HHHH **** "BBB@
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M<>+?)OH;B2%2WGQ3Q8BA&TX*C&%]MM5;FYURU\!Z(^DK(D1,XFGMU_>C]ZV
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M')%'+<J-!34;:=_S_K\3BR"I(8$$=012['VAMC;3P#C@UV=S]AOKC2&U&&]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRN/^N3_^@FK9JI??\>5Q_P!<G_\ 0336XGL?)1ZT4'K17UA\R%%%%( HHHH
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MJ%74X(-<-2FX,^4QF#GAIV>J>S&4445!QA1110 4444 %%%% !1110 4444
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M^11_PA%M_P _,W_?(KT;^S?]FC^S?]FCZY7_ )@^JT?Y3SG_ (0BV_Y^9O\
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MFC^S?]FCZY7_ )@^JT?Y3SG_ (0BV_Y^9O\ OD4?\(1;?\_,W_?(KT;^S?\
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M?]\BC_A'8_\ GK)_WR*[?^S?]FC^S?\ 9H]G'L']G87^1'$?\(['_P ]9/\
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MW_9H_LW_ &:/9Q[!_9V%_D1Q'_".Q_\ /63_ +Y%'_".Q_\ /63_ +Y%=O\
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M-@H ROL0]*/L0]*U=@HV"@#*^Q#TH^Q#TK5V"C8* ,K[$/2C[$/2M78*-@H
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MF1TB6P'8582("LG4+V[B\5Z9IL,JI#=6UP[Y4'YEV[3^&37/,GBY?%L>A_\
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MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:1F
MQ0 R1N/>H=M2'FDQ3$,Q1BGXHQ3 9BC%/Q1B@!F*,4_%&* .<UGQ=::-JT>F
M-8W]W=/!]HV6D)DPF<9/XBI-&\5:;K=Y+90K<V][$@D>VNX3$^WU /4?2L'5
M[R_LOBO%)I^F-J$IT7#1K,L>T>;UR:OV&FZWJGB^+7]7LH-.BM+5X+>W242R
M.7ZEV'  QP*NRL1=W-W2-5MM;L!>VF_RC(\?SC!RK%3^HJ]BN7^'0_XI)?\
MK[N?_1K4?$+Q /#_ (6E,<Z0W=XPM;=VZ*6X+?\  1DTN7WN5#YO=NS8TC6K
M#7;>>?3YQ+'!.\#GT=>#^%8^L^.;/0[QK>ZTO56 D$2S1VQ,;L>@4]\UROA?
M4O#WASQA9:9HNJ6]S8:G;+#($<Y2Y0<.<_WQG\174?$'/]F:3_V%[7_T(U7*
ME*W0GF;C<EN?&=I9Z3;W]QINIQ_:+C[/';M;GS6?!/W?3BK6C>)$UF[:W72M
M3M"J%]]W;E%//0'UYK+^(;W<3>'I+*!)[I=50QQ2/L5CM;@GM4\^K>*8M(U:
MYU'1[6S6WL998GANO-8R*N0,8I630[NX_4?&EG:ZA-IVGV%]J]]"<316,>X1
MGT9CP#[5+H_BZQU6_P#[.FM[O3=2V[A:7L>QF'JIZ-^%+X$L8++P3I7D ;KB
MW2XF?O)(XW,Q/<Y-4OB3;Q#PE)J6\17FG2I<6LW\2N&'R@_[73%%HWY0N[<Q
M>UOQ7::'J,%@]E?7=S-$952TA\PA0<$G\Z=H_BO3=:OI+"-+JUOHT\PVUW"8
MG*^HSU'TKF?%.N76B>-K#58M+FOBFD2O+!$X5D7<I)YZX]*OZ-;:GXF\4:=X
MKN[:WL[&WLW2T2.<2O-YF,EB. !CI3Y5RW%S.]CJ8=0M9]1N=/CE!NK94>6/
MN%89!^E2W5Q#96DUU<.(X(4,DCG^%0,DUYDUS<6'B_5_&0=C:V^HC3;M >#;
M!0H;_@+G/TKI/&).O7-CX1M)2!J"F>\E0_<ME_\ BFP/SI.&J'S:'4VMQ%>6
MD-S VZ*9 Z-Z@]*EQ7/> ;@W/@;2L_>AB,!^J$K_ $KI,5#5G8I.ZN,Q1BGX
MHQ0,9BC%/Q1B@!F*D4]C28HQ2 E&<>M.J-&[5)2&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)0 $TP\T_%&*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@
M48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%
M% !@48%%% !@48%%% !@48%%% !@48%%% !@48%%% !@4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
4% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img33530786_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "W M # 2(  A$! Q$!_\0
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MDUIZ5X5TC49/#CQV\1G2TBGO[=AQ-&ZD;_<AAS]10ZT%JT-4Y/J>=?VGJ/\
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M,V"A!/7O4*I%J]CHE@ZT9.+GKK;?6VMS!_M"]_Y_+G_OZW^-']H7O_/Y<_\
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ME_[_ #?XT?\ "!Z!_P ^TO\ W^;_ !KS/;1/TGV;/)J*]9_X0/0/^?:7_O\
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M>@?\^TO_ '^;_&CVL.P<DCR:BO6?^$#T#_GVE_[_ #?XT?\ "!Z!_P ^TO\
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M1110 4UW6-2SL%4=23@"G52UBUCO=&O+>6%9T>%OW;+N#'&1Q]<4UJP98%S
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M*0PK+TS6X]3OKRV2WFC-JVTNX&"<D?@>.A[5J5S^G>%ETW4ENX[^=P"<QL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M='-I=K=+I2_:'_T"17CP/OD*1@US&KR:1;-JT%OJ]TC3L_FZ7$G,LQ&/EXR
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MBKYXR@H7M_P[_P RSEH^=(\6M'_Q['Q /+QTSN3=C\:[32G8^+O$2EF*J+?
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MMC1_MWV'_B8($F$CX4  *F?E''' Q5SJQDK)6,Z5&4)7<KE^BBBL3H"BBB@
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M!DWNOP6=XUJL,DTJ+O<)C@>V>IQS@5!>>*K*R$KR)*8UL&OHW &)54X91_M
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: '14@    P!110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img33530786_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '^!*@# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.?\ V%'_  NP_P#0O_\ DY_]A1[6'</[-Q7\GXK_ #/6J*\E_P"%V'_H7_\
MR<_^PH_X78?^A?\ _)S_ .PH]K#N']FXK^3\5_F>M45YEI'Q>74]6M;%]%\E
M9Y AD^U;MN>^-@S^=>E12K*@93D&J4D]4<]:A4HOEJ*S'T444S$**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)Q_.NW#I<NK/FLZ;]M'T/4Z*\X_X55+_ -#7JGYG_P"*H_X55+_T->J?F?\
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M4O\ T->J?F?_ (JBR[A=GH]%><?\*JE_Z&O5/S/_ ,51_P *JE_Z&O5/S/\
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M;MN/.!3XY8_^%C3(P\Y_[.0(R\^1AV+!O[N[(/OBNEJ8Q3=S:K6G&*BNJO\
M\!=ET\PHHHK0XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\MUNZNOB+XJ/AW3II(M$L6S?3I_RT8'H
M/7D8'OD\X%=AXYUI]!\(7]["<3[1%$?1F.,_ADG\*K?#O0ET/P?:*1_I%THN
M9CWRP! _ 8'US5+17$]=#?TO2[/1M/BL;"!8;>,855[^Y/<^]7***D85Y+\;
M.NA_]M__ &G7K5>2_&SKH?\ VW_]IU%7X&=V6_[U#Y_DSR:BBBN ^N"BBB@
MHHHH **** "N\T=SIGPFUF]@^6>\NEMF<=0F!Q^K?G7!UW7A22'6/!>M>&WF
MCBN2PN[;S&"AV&,KD_0?G5PVDO+^OP.7%_#%O9-7^\;X0N[W6+6/0[C0$U?3
MHR</CRWM\G)(E[=2<'K3_P#A#-+N/'UMI&F:C]KLL>=<G()B53\REAP3T&?>
MN9D\0ZL-'CT873Q646X&&/Y=Q)).XCD]>]+X;U^?PWK,>H01K+@%)(GX#H>H
M]JI2BVKF<J%5<\H.U[V2_/U]/G<[#XBV*ZK$OB+3-2AO-,A*V@BB4K]GQT'N
M">_'45MEM-\166GZ/X?\47=M?VMB%CB@+I%(0.=W3G^5<;K'C2VGTN/3-%T>
M+3;3SQ<RJ7\SS''(SD=.!Q["KR_$'3[8/>V'AFUM-9>+RC<QO\B\8R$Q@'_.
M33YHZ^?^7^?<YG0K>SBDG=7MM\N;_@#=!\4PP+IEM)IMY/J^GEX;-89ML<C.
M3]\=<Y/;K5[5;#7]2TIM$TLS:@('!U&Z><8EGZ^4A8\A?0=ZY'1M9AT>"\NH
MTD?5Y!Y=O*0-L(/WG'.=_8<<5=T3Q3:6&G16FHZ8U[]EN3=6SK.8RLG'WL Y
M' -)235I/^OZU-ZE"49N=..SZ_/S6EW^+?1&M\/1)<P^(M!N581363NT;C[D
MB'&<=CS^E<#7H?AZ^%AHWB/Q7?21)=7ZO#;Q*PRS.220.N <?D:\\J9]+[V_
MS-L/K4J/I=??;4****@Z@HHHH **** "BBB@"_HG_(<LO^NR_P Z^DM#_P"0
M>GTKYMT3_D.67_79?YU]):'_ ,@]/I790^$^;SK^-'T-*BBBMCQPHHHH ***
M* "BBB@ HHHH **** "BBB@ KQ#4_!-LWQ6M=(?4+QA>1-=R7!*^9O\ G;@X
MQU4=J]OKSC4O^2[Z1_UX-_Z#+5P=KB9Z+$K)$B,Y=E4 N>K'UXIU%%0,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .=\3NMI=Z)J,W%M;7F)G[('1D#'T&2/SK?DFBBA
M::21$B5=S.QP /7-$L4<\+Q31K)&XVLC#(8>A%8:^"]#5E!MI6A4Y6W>XD:(
M'_<+;?PQBILT]#=2A**4[JW]=P\(9DTJYO-I$=Y>SW,61@E&<[3^(Y_&M74M
M0ATK3;B^N"?*@0NV.I] /<GBK*J%4*H  & !VJ"]LK?4+4VUU'YD3,K%<D9*
MD,.GN!32:5D3*<9U.:6U_P ##@TO6-8C%SJNI7%BK_,ME8L$\L=@TF-Q/KC
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M2L%CNH'8]ED!-%F%RQ1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY4G_ #S?_ODT>5)_SS?_ +Y-?2?_  C%I_=H_P"$8M/[M'U==P_MN7\GX_\
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M-GE2?\\W_P"^31Y4G_/-_P#ODU])_P#",6G]VC_A&+3^[1]77</[;E_)^/\
MP#YL\J3_ )YO_P!\FCRI/^>;_P#?)KZ3_P"$8M/[M'_",6G]VCZNNX?VW+^3
M\?\ @'S9Y4G_ #S?_ODT>5)_SS?_ +Y-?2?_  C%I_=H_P"$8M/[M'U==P_M
MN7\GX_\  /GO1(I!K=D2C >:O;WKZ/T08T]/I55?#5HK [:U[>!;>((O05K"
M'(K'GXS%O$S4FK6):***LXPHHHH **** "BBB@ HHHH **** "BBB@ KSC4O
M^2[Z1_UX-_Z#+7H]><:E_P EWTC_ *\&_P#09:J/43/1Z***D84444 %%%%
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M^[)V..*ZWP--=>)+VX\4WT9CW1+:6T9/"A?]8P^K9_*FX"YCN:***@H****
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M^!QZ5HT44 %%%% !116#+J-_JEY+:Z04BAA;;+>.-PW>BCN::5Q-V-ZBL/\
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MO1IG+X_ \5KT4^9[7%9!1112&%%%% !1110!AZ5_R,NN_6#_ - -;E8>E?\
M(RZ[]8/_ $ UN54MQ1V"BBBI&%87AX>1<ZK9I_JH;DE!_=##.*W:P]$_Y#&M
M_P#7=?\ T&J6S$]T;E%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %#7/^0#?_P#7N_\ (T_2/^0+8?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *&N?\@&__P"O=_Y&GZ1_R!;#_KWC_P#013-<_P"0#?\
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M!KBC\+=. :"'6-8AL&.6LTN?W?TQCI]:['[?'_SQN?\ OP_^%'V^/_GC<_\
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M -?>+F?8["BN/_L6[_Z J?\ @Q>C^Q;O_H"I_P"#%Z.5=_Z^\.9]CL**X_\
ML6[_ .@*G_@Q>C^Q;O\ Z J?^#%Z.5=_Z^\.9]CL**X_^Q;O_H"I_P"#%ZC;
M3_LUQ:K>:3Y<4\RP[DOW8@GV_"GR+N',SM**Q?#2".WOHE+%([V1$#,3@#&!
MDUM5#5G8:=PHHHI#"BBB@#SCXN_\>6A_]?X_E7H]><?%W_CRT/\ Z_Q_*O1Z
MI[(2W"BBBI&%%%,DFBA ,LB)GIN8#-#=MP2OL/HJ#[=:?\_,/_?8H^W6G_/S
M#_WV*GGCW*Y)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MU
MI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P
M_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MU
MI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P
M_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MU
MI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P
M_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MU
MI_S\P_\ ?8H^W6G_ #\P_P#?8HYX]PY)=B>BH/MUI_S\P_\ ?8H^W6G_ #\P
M_P#?8HYX]PY)=B>BH5O+9V"K<1%CT <<U-UIII["::W"BBBF(**** "BBB@
MHHHH **** "BBB@ HHHH *HR:-ITNL1:L]JAOXD\M)^=RKSQ^I_.KU% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[R]BLHU:3<S.<)&
M@RSGT JQ6;9K]JU2[NWY\E_L\0/\( !8_B3^E9U)-6C'=FE.*=W+9"B35Y1O
M$%I"#T21V9OQ(&*6+49$N%M[Z#R)7.(W4[HY#Z ]C[&M"H+RU2\M7@DZ,.".
MJGL1[@U+A.*O&5WY]2E.#=I*R\B>BJ>EW#W6F032?ZPKACZD'!_E5RM(24HJ
M2ZF<HN,G%] HHHJB0HHHH **** "BBB@"AKG_(!O_P#KW?\ D:?I'_(%L/\
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M^=7&01Z58JEIUOLTRV25065 >1TK#\4^(];T6[@BTOP[/JD<D99Y(]V$.>G
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M:U"BBBD!C:CX6T?5M7AU/4+1;F>"/RXUDY0#).=O0GGOFLGQLJH-/50 H#@
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M11RQS)OBD5UR1E3D9!P1^=/JMI]E'IVGP6<62D*!<GJQ[D^Y/-6:3&@HHHH
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MHK=_X1B[H_X1B[H_LG$]E]X?VIA^[^XPJOZAJ;:E'!YL2B:)=AE!Y<>]7O\
MA&+NC_A&+NJ668M1<5:S\R'F.&;4G>Z,,LQ !)('3)Z4E;O_  C%W1_PC%W4
M_P!DXGR^\O\ M/#^?W&&&(! ) /49ZT!BIRI(/J*W/\ A&+NC_A&+NC^R<3Y
M?>+^T\/Y_<8BNR.'5BK Y# X(-(S,[%F)+$Y))Y-;G_",7='_",7=']E8GR^
M\/[3P_G]QE6MR+>[CGDC$VPY"L>">U%]>27]Y)<R_><YP.@'85J_\(Q=T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH \X^+O_'EH?\ U_C^5>CUYQ\7?^/+0_\ K_'\J]'JGLA+<****D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !11VKFM.UF62QL;;3K5[FXDA,S?:KHX
MC3<1EI-I)).<#';MB@#I:*Y%?$LFGR:M/J49B=+F&"*"2<! S(.CG "GDYP/
MIGBIX?&,#+>)(+*2>WM7NE%E>B='5>HW;05/3J._&:=@.GHK$M];O'GLQ<Z:
ML$-Z#]G;[1N8-M+ .NW"Y /0M65IFH7TJ6OVZ-_,?5+B*+R[QB#CS3M;Y1E1
MMP!]#QC%%F*ZM<["BN+T"]F5[.XU$SK).]W(6%\\D>$.#E"  !T ' QGO4\/
MCJUD,,[FP6TF=57;?JTZAC@%HL<=1D!B1Z4<KO8+]3K:*R=*U>;4[JY3[+&D
M$,CQ[A/ND#*V,.F!MSU')X]*XCQ;K%Y:Z]KD7VZ^BMX;>U9$MI]A4M( 2.#C
M/?UH2NTNXV[)OL>FT5YW%XNETOQ/KUD_VC4+J2ZABL;(2<\IEB.RKW)J]K/Q
M!_LS5)M/@TZ*XFM45KHO?1PA"1G:F_ES] *+/05SMJ*\]O/%LT^NZ5J6F>?/
M9RZ7/<_8_,V!RIZ'J-PP?RK?M/%UOJ.H:3:6,!G-];&ZD;?CR(_?CDYXQQTI
M\K_KY_Y!=?U\O\SHZ*XKQ1J^IZ=XTT2+3X)[SSH)\V<<HC61@!@L3P .N33F
M^(4%MHUY<W^G2VM_:7"VTED9%)\QAE</TVD G/L:5KJ_];V'UM_6USLZ*X>T
M^(T<MMJ7VG3TBN[*V-T(8;Q)TE0=<.O /MBG6_C:XOI/LEYH]QIPO+"2YM)A
M<*S.H7)X ^4XY&<]N*'%K^OZ[ FG_7]=SMJ*X#1_%]VNEZ1I^FZ;=ZQ?RVGV
MF4SW2JR)N(RSD<G/]*F'Q$=M-@N4T.=IYM0:P6V\X!PX&?3'7C'ZTW!IV_K>
MPE)6O_7<[FBL'PWXBDUQK^"ZT]K"\L91%-"91(!D9!# #-;U)JP[A1112 **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:Y_R ;_\ Z]W_
M )&GZ1_R!;#_ *]X_P#T$4S7/^0#?_\ 7N_\C3](_P"0+8?]>\?_ *"*K[(N
MHNJ:C#I.EW.H7(<PV\9D<(,L0/05#H6M6WB#1X-3M%E6&;.%E7##!(.?Q%:#
M*&4JP!4C!!'!I(XTBC6.-%1%& JC  ^E2,YV\U>\L?%%PI_>:9%:1/,@'S1[
MF<>8/4#:,CTY[<@UM[;4-4QONLW$,5I"K##,\8. >@'4D^F:UDT[9K5QJ)DS
MYUO'#Y>WIM9CG.>^[ICM68OA." 7)L[EX'>X2Y@)7<('5=N ,\KC(QQP<#'&
M&K=?ZU$]_P"NW^9-_;TEG++%K%HEHR0/<*\,QE1T7&X E5.X9'&._!JCJ>K:
MP+.TDDT[[)%/=6ZAX[G=(@,B\2+M &1D<%NN*NG0IK^2636;F*<M;O;I';Q&
M-45\;CRS$L<#G/&*CFT35KN&WMKO5XF@MYHI08[;:\NQ@P#G=CMV YY]J:M=
M?UU!WL66UU5T*^U/[.<6K3*8]_WO+9EZXXSMK-E\1+I4VJ/<R!RU\D%NDLPC
M0$PHV"QX5?O$_P B35B?P_>21W5C'?Q)IEU*TDD9@)E 8Y=5;=C!.>2,C-2W
M'ATRS7%Q%=".X:Z6ZA8Q;A&1&(RI&?F! .>G7VS25OZ^0?\ !_X :-XDAU2^
MEL6:S-RD?F@VEV+B-ESC[V 00<<$=^]5-0>:'Q(/MM[>6MM*8Q92Q/B'=_%&
MXZ;F/0M^&#6MI]E>PW$MQ?7<4KNH58H(O+C0#O@DDD^N?PJIJFBWVI&>V;44
M&GW#*TD3P;I$ QD(V0 #CN"1S^#TN@ULP_MG4;B]OK>PTJ.46<HC>2:Y\L.=
MJMA<*V3\W? Z<^E<>(;0W"7[K=(@L99'C+G"E)%5E*="^[C/X=Z2UL-934]8
MEM+J*WCFN@56YMRXQY:#>F&7W'.1QVJ4>%+<Q"&2YD>/[));N2,.S.X<R9['
M<"<8[TE;3^NG^8^_]=2Y;7NK/-%]ITF.*"7^*.Z#O'QGYU*@>WREJC&O*?#T
M.K?9SB1D7R]_3<X3KCWS4EK:ZRL\7VO4[>2"/J(K78\O'&XEB!Z\ ?ATJDGA
MZ[6*.P-]$=+CG$RQ^0?-P'WA"V[& <<[<X&/>GI<6I'::Q<1>?;QQM>7DU_<
M1PQO)M544\DM@X4<= >HXI+[6]1^SZK9G3U@O;>R,ZNMR2A!W#*MMSQ@GD#G
M\ZLMX?EC?[1:WBQWB7,L\;O%N7;)]Y&7(R.!R".0*1="O)I[^XO=1226[M/L
MNV.#:D0^;D L2?O=S^5)[?+]!K?Y_K_D5+?639A+C4(YO.738Y&2.X,BN6?:
MH"D ;R<<^^/>M&+5[V&\MX-3TZ.V6Y)6&2*X\T!P"VU_E7!P#TR..M1S^&X[
MD$27+ ?8X[8%%P59&W!P<]<XX]J?'I6H7%Y;3:G?03):DO$D$!CW/@KN;+-T
M!/ QUJI-/;S_ #9*32_KLBK:>);JXL[/4)-+$-A<R)&'-QF12QV@[-N-N2!G
M=GG.*Z.L=="VZ!9Z7]I_X]FA;S=GWO+<-TSQG&.M;%2[=!A1112&%8>B?\AC
M6_\ KNO_ *#6Y6'HG_(8UO\ Z[K_ .@U2V8GNC<HHHJ1A1110 $X&3TKGK3Q
MSX:O[Z&RMM5C>XG.V-=CC)],D8!]C70,,HP'4BO.;+PGJL'A/P[9M8JMW::J
MMS<*)$RJ;V);.<'@KP,FG%)O7R%+1:'4S^,_#MKJO]F3:K"EV&V%2&VJWH6Q
MM!]B:DU?Q9H>A7,=MJ.H1P3R#<J;68X]3@' ]SBN*F\/^(8=&U'PO%HT,\-Y
M<M(NIM.H4*S9W,OWMPK3ETO6]!\27=Y8Z2FL0WUK%!N:98VB9%V_-NZJ>IQ3
MLK?U_2!O5_UU-7PSXNAU?2].EOGAAO+]YEABC5L.(R<XZ]@#R:+_ ,71+JFE
MVNG-%.EQ?O97)96!C91D@=.?S%<Q8>'-?T?2/#=XFEB>\TR>X,UFLR E9"<%
M6R1QZ5-8>%M:$VDWD]F(Y&UB:_N8UE4^0CC !.>3QVS565_Z[_Y"N[??^O\
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MZ+%9W^G1V4MJ/* A93'(HZ,N#D ^AP:V:F22>@U>VH4444AA1110!YQ\7?\
MCRT/_K_'\J]'KSCXN_\ 'EH?_7^/Y5Z/5/9"6X4445(PHHHH **** "BBB@
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M7C.,9[UNU@IHERGAC3],WP^=;O SMD[3LD5CCC/0'M6]4NW084444AA1110
M5AZ)_P AC6_^NZ_^@UN5AZ)_R&-;_P"NZ_\ H-4MF)[HW****D84444 %%%>
M7:Z=$?QCJJ^-))U@6-#IH)D$>S'S%=G\6::U=@Z'J-9VJ:S:Z1)8I<K(3>7"
MVT6P X8],\].*X#7O['.J:$NM27A\+FQ)@:9I<--GCS#][.WIFL72F@9++[*
M\SVP\4KY)F)+;-HQG//3UJE"[_KO8ERLOZ[7/:J*\BMCX<>^O6\6S7B>(A>D
M)M:4.J[OD\K;QMQ_GI5O7]3@T;6O%]O>22Q/J-E$+%2K'S3Y97 ]\FERZ#OK
M;^MST%=9M6\0/HH63[4EN+DG V[2<=<]<^U:->/W\6J6MQ<16:RK?Q^&8%(3
M.\8==^/?&:981>%I_%7AVVT![AXIDF6\1GDP28B.<]&ZYQ3Y.WG^O^0N;K_6
MR_S/4]%UFVU[3A?6BR+$79,2  Y4X/0GTK0KQ6PM(+3P5ISRB>/2)]3D&J-$
MSDF-20N<<A?7'\Z;?^0VGZK%H,MP/#INK58&+/M64M\_EEN<>OX4^2[LOZV_
MS!NV_G^O^1[915>PL;;3+&&RLXA%;Q+M1 2<#ZGFK%9LI!1110 4444 ><?%
MW_CRT/\ Z_Q_*O1Z\X^+O_'EH?\ U_C^5>CU3V0EN%%%%2,**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7\4FG&SLKE+V.&*,W*2)Y6T$;TD4G) &2" 3D\&NHHHH;N)*P4444AA1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% '"_%JP:[\$O<(#OLYTF!'7'W3_Z%G\*ZK0]135]!L=01@PN(%<X
M[-CD?@<C\*M7=K#?6<UI<('AF0QNI[J1@UYOX%U";PGKMSX*U8E09#)83-]U
MP>P^O4>^1UJMT+9GIU%%%2,*XCXC_P#'E:?5_P":UV]<1\1_^/*T^K?S6A S
MS:BBB@ HHHH ***U_#5G9:AK4=G?;O+F!52K8PW:@-C(HKH=$T!+G7[FTO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO^MQE?OX^7TZ?C3<;*]Q7.;HHHJ"@HHHH *DMYGMKB.>,X>-@ZGW!S4=%"T
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M7_H#Z7_WVO\ \<H_M#XJ_P#0'TO_ +[7_P".4<OF%ST>BO./[0^*O_0'TO\
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MM#XJ_P#0'TO_ +[7_P".4<OF%ST>BO./[0^*O_0'TO\ [[7_ ..4?VA\5?\
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MS8,6A(D7'/K^\YP>1Z&M7^T/BK_T!]+_ .^U_P#CE4U=(2/1Z*\X_M#XJ_\
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M33_.O;R%KN[VPLH7$O/([UL6UL+6+RQ))(,YS(V30T!-1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 )M&X-@;@, ]ZXGXC_\ 'E:?5OYK7;UQ'Q'_ ./*T^K?S6A
MSS:BBB@ HHHH **** "BBB@ HHHH Z?7K.WTK2--TV*VC:^G0332[,OST4?C
M_*HHO#4=E$MQKUVME&1E;=/FF?\ #M^-6O&I9KS3-0B)$<MJAC<=B.?ZBJR>
M(K;4D6#7[,7&!A;N$!9E_HU'?U#L6_"FEVUXNJ7?]G_;4A $$#M@L23W]<8I
M\$=G<ZS<1MHEO9W<,&(;.XD^21\]23C/!X%5M'M%N;&XBL/$7V)_-.89G,89
M0>&R#UQCM2^)9$US7K.SL95N94A6%YQT=AU.?0>M'5!W-1[70DNI))M)MA%;
M0K)=2QSN460_\LU4'!.:YFQU&V_X2);F>QMS:22;6@\L;54\<>X]:UK:\TT:
ME#I2M";&V5RCS<1SW&.&?_9SP/:JNNV\$]]I\%NMI]OD&V=;+_5[BWRXQQG'
M6FOB0/9E+Q+IBZ3KUS:Q_P"JR'C]E/(']*R:Z7QW*LGB9T4Y,42(WUQG^M<U
M4QV&PHHHIB"BBB@ HHHH **** -#1_\ C]/^X:]>T/\ Y!Z?2O(='_X_3_N&
MO7M#_P"0>GTH TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "FO&D@ D17 (8;AG!'0TZB@ HHHH CGB$
M\$D3='4J?QJEHTIDT_R9/]9 QB<?3_ZU:-8%U.=)UWSL'[/<K\^.Q'?_ #ZT
MT)EO3&^R3S:<_&PEX2>Z'_"I[ZSDF>*XMG"7$6=I;HP[@T7MHM[%'+#($F3Y
MHI1_GI44.ILVZWN%6"\ X#_=8^H/I1Y@0W,^LRPM%'9)&Q&"XD!_*EM9+ZTM
MD@CTOY4&,FX'/OTJ;.L_]./Y-_C1_P 3G_IQ_)O\:8!]LU+_ *!8_P# @?X4
M?;-2_P"@6/\ P('^%'_$Y_Z<?R;_ !H_XG/_ $X_DW^-("M;G4H+JYF_LX-Y
M[ X\X#;@?2M2VDFEBW3P>2^?N[]WZU4_XG/_ $X_DW^-6[;[1Y7^E>5YF?\
MEGG&/QH8(FHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N(^(_P#QY6GU;^:UV]9F
MLZ7#J<"B6(.R [<]!G';\!0!XE17H3>%)=QQ##C_ *YK_A2?\(K-_P \H?\
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MRA_[]K_A0!Y]17H/_"*S?\\H?^_:_P"%'_"*S?\ /*'_ +]K_A0!Y]17H/\
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MZ4 Y&1THJ"@P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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:1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img33530786_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %) M # 2(  A$! Q$!_\0
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M (5_X4_Z =K^1_QI?7H=F'U:7<^;*::^E?\ A7_A/_H!VOY'_&D_X5_X3_Z
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M 'O:K&=:_NV'_?3_ .%174.L75I-;M]@42HR$@OQD8]*$#)(TU9XU?[7:#<
M<>0W_P 54EI<W'VM[.[$9E""1'BR RYQT/0@_P ZN1KLB1"<[5 J@?\ D9!_
MUZ'_ -#%+<9HT445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+<I!1114C"BBB@ KGQ_Q46I;NNEVC\>D\H[^ZK^IJ+Q'K$*SII*W/D>;S<3
M$^6GH,?Q&K-OX@T&TMX[>"Z5(HU"JHC;@?E5J+2O8EM-V-RJFI7=M9:?+/=
M-$!@H1G>3T4#N35/_A)]&_Y_E_[X;_"J]FIU_4%U&4'^S[=C]D0C_6-WD/\
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M=#]:X/[1X:_Z!=__ -_?_KUK36A$]S4\K5O^AML_^_\ _P#6H\K5O^AML_\
MO_\ _6K+^T>&O^@7?_\ ?W_Z]'VCPU_T"[__ +^__7K2W]61-S4\K5O^AML_
M^_\ _P#6H\K5O^AML_\ O_\ _6K+^T>&O^@7?_\ ?W_Z]!N/#0'_ ""[_P#[
M^_\ UZ+?U9!<] TB82:?%&U[%=S1J%EDC<-EJ:?^1D'_ %Z'_P!#%&D:19:5
M"_V-'59L,P9BW:@_\C(/^O0_^ABN?2[L:]#1HHHJ1A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!EZCHL6H2!W8@^QJC_ ,(G;_\
M/1_^^C7144 <[_PB=O\ \]'_ .^C1_PB=O\ \]'_ .^C7144 <[_ ,(G;_\
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M:3<PZ5=S^1;WS.N&8G )3J 3T-2V'@J&SNK1I]3O+RTL239VLQ79%Q@<@9;
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M "BBB@ HHHH **** "BBB@ HHHH **** "D;[I^E+D#&3UZ4C?=/TH YM_\
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M.,#K3-.\>V5_J%O;FW,4-T_EP2F=&8MVW(#N7/;-7K?PK;06VCVYN9)$TSS
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M04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]-$_,_X4 ,HI^S_IHGYG_"C9_P!-$_,_X4 ,HI^S_IHGYG_"C9_TT3\S_A0
MRBG[/^FB?F?\*-G_ $T3\S_A0 RBG[/^FB?F?\*-G_31/S/^% #**?L_Z:)^
M9_PHV?\ 31/S/^% #**?L_Z:)^9_PHV?]-$_,_X4 ,HIQ3 SO0_0FFT %%%%
M &CI/^MD^@K6K)TG_6R?05K5F]RD%%%%(84444 %%%% !1110 4444 %%%%
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MZBBBI&%%%% &CI/^MD^@K6K)TG_6R?05K5F]RD%%%%(84444 %%%% !1110
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M44459UA1110 4C?=/TI:1ONGZ4 <V_\ K&_WC3:<_P#K&_WC3:U6Q(5S6I^
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M@_XUUM%%V%CDOL>L_P!V'_O@_P"-'V/6?[L/_?!_QKK:*+L+')?8]9_NP_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img33530786_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C M # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFIW3V.E7=VBJSPQ-(%
M;H2!FK=9OB#_ )%S4O\ KVD_]!--;@SAO^%DZE_SXVGYM1_PLG4O^?&T_-JX
MSM177[./8PYF=G_PLG4O^?&T_-J/^%DZE_SXVGYM7&44>SCV#F9V?_"R=2_Y
M\;3\VH_X63J7_/C:?FU<911[./8.9G9_\+)U+_GQM/S:C_A9.I?\^-I^;5QE
M%'LX]@YF=G_PLG4O^?&T_-J/^%DZE_SXVGYM7.Z'I\.IZB;>>22.)87E)C W
M?*,X&:T8/#]G>QQ7=E<7,EG(L@(9%62.1%W8/."".XI.,%T'>1H_\+)U+_GQ
MM/S:C_A9.I?\^-I^;5A1>&M5FM1<"",*8O.VM*H<)C.[;G.*(O#6JS6PN%@C
M"F+SMK2J'V?WMN<XHY:87D;O_"R=2_Y\;3\VH_X63J7_ #XVGYM6#+X<U2&R
M-X\*>4(A/\LJEMA_BVYSBFS^']3MK4W$MN BA2ZAU+H#T++G(HY8!>1T'_"R
M=2_Y\;3\VH_X63J7_/C:?FU8\?ARXBENHKT%)(K5YPD,B.05QPPSQU^M4-0T
MN[TMT2[6-'<9V+(&9?J!TZ]Z%&##FD=/_P +)U+_ )\;3\VH_P"%DZE_SXVG
MYM7&44_9Q["YF=G_ ,+)U+_GQM/S:C_A9.I?\^-I^;5QE%'LX]@YF=G_ ,+)
MU+_GQM/S:C_A9.I?\^-I^;5QE%'LX]@YF=G_ ,+)U+_GQM/S:C_A9.I?\^-I
M^;5QE%'LX]@YF=!/\6]6BGDC&FV1"M@$L_\ C4?_  M_5_\ H&6/_?3_ .-<
M%>?\?LW^^:AKNCAJ5E[IS.K.^YZ'_P +?U?_ *!EC_WT_P#C1_PM_5_^@98_
M]]/_ (UYY13^K4OY1>VGW/0_^%OZO_T#+'_OI_\ &C_A;^K_ /0,L?\ OI_\
M:\\HH^K4OY0]M/N>A_\ "W]7_P"@98_]]/\ XT?\+?U?_H&6/_?3_P"->>#&
M1GIWKK;SPG:SC3XM">\GNKRU^V!;HQHJQ#@Y(_BS^&*F5&A'=#52H]F:W_"W
M]7_Z!EC_ -]/_C1_PM_5_P#H&6/_ 'T_^-<O%X2UF>W\^*WB=3O\M1.FZ4+U
M*+G+#CJ.M.L/!^MZE;0SV]M'MG4O$LDZ([J.K!2<X]Z7LL/Y#YZITW_"W]7_
M .@98_\ ?3_XT?\ "W]7_P"@98_]]/\ XUC3>!K][/3I+!HIY;BU:XF0W" (
M <<'/3!'/KFJD_@S7;:"::2VB*11><=DZ,7C R64 Y8#/44E3P[[!SU3I/\
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MT_X61J/_ #XVOYM_C1_PLC4?^?&U_-O\:XNMGPYH@UV^FMVE:,)"7##'WL@
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M9X9VHKL/^%<:M_S]V7YM_A1_PKC5O^?NR_-O\*Z_:1[F'*SCZ*[#_A7&K?\
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M/^%1:Y_S_:?_ -]/_P#$UHL112LI$.E4;O8X"BN__P"%1:Y_S_:?_P!]/_\
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MO[ M?^?G4?\ P/F_^*H_L"U_Y^=1_P# ^;_XJG:/<-35HK*_L"U_Y^=1_P#
M^;_XJC^P+7_GYU'_ ,#YO_BJ+1[AJ:M%97]@6O\ S\ZC_P"!\W_Q5']@6O\
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MY/\ XJC^QX/^>][_ .!<G_Q5%H]PYJO\J^__ (!H45G_ -CP?\][W_P+D_\
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M&ZN(==8).0B"']V)3N(;>#M3H?X23V J>\\10Z?JT]G<Q2%$2#RVB4N[O(7
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M:25@2Q P.@ _'J>]:-/\I_[M'E/_ ':")2<G=C**?Y3_ -VCRG_NTR1E%/\
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MS=:G'<V[::CVL"VPC,&%)P6R=_;J!TI+'Q7J-QX72:5U344N8%<[!AXI&&&
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MO##L:[ZM+#>S2A+5?B<5*I7]I><='^!Z?YK_ -[]*/-?^]^E,HKSCN'^:_\
M>_2CS7_O?I3**8#_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_2F44 /\
M-?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_2F44
M /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'FO_>_
M2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]^E'F
MO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U_P"]
M^E'FO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910 _P U
M_P"]^E'FO_>_2F44 /\ -?\ O?I1YK_WOTIE% #_ #7_ +WZ4>:_][]*910
M_P U_P"]^E'FO_>_2F44 /\ -?\ O?I4D4C,^">,5!4L'^L_"D!GZMI\>K:9
M=6$Q*I.A7<.JGL?P.*\Y_P"$4\71:;)X?C6V;3Y)O,,V\8_Q'0'&*]2/WC]:
M2NBCB)TE9:^O<Y:^$IUWS2;3VT[=CC=4\&W'_"'Z=I^E21OJ.EW<5_;F4[4E
ME1LE3Z @D>W%<_?6^J^*OB#'INO:='I<-SH%W"L"7 GDC5F0&1B !R<8'^S7
MHFKZ1::YI[6-[YWE%E<-#,T3JRG((92"*IZ'X5TSP_/<7-J+F:[N%"RW5Y<-
M/*RCHNYCPH]!6,FY-M]3HA%0BHQV1D^&9_&&E6UAHFJZ)#=1VVV ZI!?($:)
M> YC(W;L 9'>JD'AG54\ >+M):!1>:E<W\ELGF##K*?DR>@S[]*[NBI*.#ET
M#7]#US3O$.BVT-[(=,BL-1T]YQ$7V 8='/&0<CGM]:WI=5\0G2$N5\+A[II2
MDEBU_'N$>/O;L;22?X:WJ* . T+PC?+;^+7DL+?18M;A\J#3H91(D+>6RF1M
MOR@L6&0OI4$VC>)-3^'%MH%SHR6MY8262*PNT=)UB=2SC'W>%S@\\UZ-39&*
M1.RH795)"C^(@=*0SF?B#HNH:_H<-OIR+<".]CGN;)Y?*6\A4G=$6[9X//'%
M8VB>%=37Q7?:G+H^FZ+87.D-8PVMHRL8V+9R^T $GDY'0 "J?_"<:VR(D5U8
MRF6.!WF$2HMJ[I*QC<LP7AD5<D@]>^*MS^+O$%MY\TBVA4M/$(EA+" QB(F3
M<#\X&]SVR%% &IX,M-<L?"::#JVDI:O8VGV:*XCNED2YX(! '*\8Z^M4[KPI
MJ+:5H1MT5;JW6.&\CWC#(K!@<]"0?YU!_P )1KTTK1VUW:-%"X07(M=RW*FY
M6$./FP!AB>."5]*9%XGU+[4/.FMK5I?*MY]0>$[(@)+A=Y4MM&[RU [ OWXK
M:G6E3^$PK8>%7XC8O-*U&RGU6&VTV#4]/U"0S!'D5&AE(P20W!&>:CN=,U4>
M%K;0CH]O>#[(L9F:< 0R\\X//'!R*;XKUK4M'OK2YLKM9(O[.N)1;>6"MQ(I
MCPV<]E9FP.RFJ$GB;6S%Y,EY:JT]M<"VDLQ'-(\BARCNJL=HPHY7(W @XR*I
M8F6FBT]?\R'A(ZV;UTZ;/Y'<V$$EKIUK;RRF62*)4:0_Q$#!-6*S]!G>Z\/:
M=<2W(NI)+:-GF  WDJ,GCWK0K!RN[G2DDK(**** "BBBF 4444 %%%% !111
M0 4444 %%%% !1110!0UJ:2WT>>6)RCC8 P;;C+J#SVX)YK(M=7NDNO)>5&/
M$6^5\QH?,D^8L,;OE"KGC)]*Z5E5E*LH93U!&0:3RX]FSRTV8QMVC&/3'I0!
MB'7I?*E<);+Y,;.2[G$^&*XB/?.WWZ@>]*VJSRWUFBO#"CWK0M"6_?856^\/
M? /TQR:V7$2)OD$82(;@S 80 =?;BLV#Q!H%RDUS!JNG2K"@:6595.Q>@+'L
M*I)O9";2W9JT5%!<P75LES;SQS0.-RR1L&5AZ@BEMYX;NWCN+>5)H9!E)$.5
M8>H-39CN.<XC8CJ%)KEM.UB^CLXY)=[R.(8S'-)OP6!;S<G&%(X SUXXKK,'
MIBFF)2"#&I&,$%>,>GTHN!@/XAN(T5FMX,&-F&U]VXJQ!^Z3M&T9Y]QGCF/5
M=6NC<3I93HB1*P613N5SF'GCN-Y%=%Y:*V1&H(&W.T9 ]/I[4"-%4*L:!1T
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M144 2^>_M1Y[^U144 2^>_M1Y[^U144 2^>_M1Y[^U144 2^>_M1Y[^U144
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M%^09."1AO3BKU4(=*2&X@D6XG,=N7\F$D;5W#![9/7C)XJ_2 **** "BBB@
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MC'M0 448]J,>U !11CVHQ[4 %4D2\MY)Q'#!(DDS2*6E*G!QQC::NX]J,>U
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M_K1]H_V?UJ"BBP&)KWBZ;0KI8Y-+:2&09CF$V WJ,8X-9/\ PLQ?^@2W_?\
M'_Q-=/J.GV^J64EI<INC<=1U4]B/>O/K3P9>R:Z]E<96UBPSS@<.O;;[G]*U
M@H-:D2YKZ';Z!XDFUQ))O[.-O;KP)&EW;F] ,?K6W]H_V?UJI!!%;01P01B.
M*,;55>@%25F[7T+5R?[1_L_K1]H_V?UJ"BE8"?[1_L_K1]H_V?UJ"BBP$_VC
M_9_6C[1_L_K4%%%@)_M'^S^M'VC_ &?UJ"BBP$_VC_9_6C[1_L_K4%%%@)_M
M'^S^M'VC_9_6H**+ 3_:/]G]:/M'^S^M0446 G^T?[/ZT?:/]G]:@HHL!/\
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M"JGOG!';O6E5*/2K6&99(@\8!!\M7(0D#:"1] /RJ[2 **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ;(VR-WQG:I./H*Q;#Q)'-:+<S[%C
M?8$:'.&D(.8_FQRN.3TK;90Z,IZ,"#]*HC1K-4"HLB;2A4J_*LJ[0P]]O!]1
MUH :OB"Q<%DED950.Q"_=!;;@^^<BHK_ %[[)<20Q0O.8\*X'4-OC7 ]1B0&
MII=(LI/+\XRN%0QH'E/&>I'?)_I[4O\ 8]H26<2N['+.[Y9CN5LG\47\!1H!
M8M;R&]61X=^U',9++C)!P<?C4]06]G%;23R(7:2=@\C.V22!@?D*GH ****
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M/_Q5'EW_ /S\V_\ WX/_ ,55JB@"KY=__P _-O\ ]^#_ /%4>7?_ //S;_\
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I$_NC\J-B?W1^5%% !L3^Z/RHV)_='Y444 &Q/[H_*E"J#D "BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img33530786_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img33530786_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,?!Q8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!7?# QCK-G!+'RD[4T>@7WQ=U&8D0&11_LJJ#^IK"N/B)K4YSYK_ / IG/\
M6LN/P^<9EG ]E%/72[/^!9YO<$ ?G6JA0CT,^;%3ZV+5OXQU:>Y5'D7!^O\
MC6HGB?4X_NSL/]UV']:S;#3;1;R/?9RXYY5]W;ZUOII&G3INCW8Z<-T/XUY>
M.J\M1*&BL<M:.+4O=F26WCW6+?'^DS$>\F[^>:W['XHW*D"Y2.0?[2[3^8X_
M2N7D\/0G_5S.I_V@#5.;0;J/F,I(/8X/ZUR+$2ZZD+%8ZGOK_7D>P:;X\TF^
M $C- Q[GYE_,?X5TD,\-S$)()4D0]&1LBOFMXY[23YE>)ORK6TKQ1J&ES!XI
MG'J5.,_4=#6BJPEOH=='.(M\M56/H*BN'T#XAVM\%BO\1OT\U1Q^([5VT<B2
MQK)&ZNC#(93D&K:L>O"I&:YHNZ'4444BPHHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KAO%_Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFJ*BMKB*\M8;F%MT4R+(C>JD9!_*N7^(WB.7PUX3FGM9 E[.X@@;NI/);'L
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M-U:3.(O-D'[R(DX!SW&>N>:]SKGKT)T96D;T:\:T;Q"BBBL#8**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK-U[4!IFBW
M-SG#A=J?[QX'^/X4TKNP-V/)?BOXE-Q=_P!GP/\ (N4X/;^(_B>/H*\[TRW5
MY3/(I,<9&%_O-V%-U6\;4-3FGR2&;"?0=*UH8DM$2-R%$4>]R3@;FZG]/UKV
M5'V-)16YXR?MZSD]D.F+ET:<AD8X*#[JGM]?QI7^SHK QH=N/E"COTJ*3#2,
MJ[@&Y8$<'W%1AD=_D8[AR,]#BL+G:70'AYB)*CK&3P?IZ59C9)$$B]#[<U01
MY9EVJP4+PSGDYJQ;?NYGBR2"H?GUZ'^E4F!9. .>E,Q_=4C\<4_'.3^'M3'8
MEPBG'J:8AKE@N&''J?\ ZU.C&%SD'//%)Y9/5V/UJH-2MD&"7SSGY>E(#6L/
M^/V/\?Y5N5R^G:G;M=;P'PG^SUSZ?G6LVMV0(&Y\-W"_E7E8[6HO0YZJ?,:)
MX!I+8?N![U%(CJC'S"1CH:LQ@"-<=,5Q&(ZLZ]D6"1F8X7;N)K1KG_$3_O(8
MQT;K]!D_THCN..YF7-U)>,2^1%_#'_CZFLHQ26]U)=.Y\I5/RC^57I"PC8H,
MMCBJ%E+<3ETN5RGN,5JC9%RRO/- N+=FBD!QD<$?XUTD<JZWISQ. MS'SQZ]
MB/8USL4*0KM10!5_293%JL&.DF4/TQG^8%*2(J04XM,@MIGM+I7Y!4X8?SKW
MKPIJXU?18W9MTT6$<^OH?Q']:\3UVU\F[$RCY9>OUKJOAKK!MM2%J[?)+^[.
M?S7]>/QK6C*Z<3ERNJZ-9T);/8]>HHHK0^A"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O.?BV2--TT G!E?(]>!7
MHU><_%S_ )!VF?\ 75_Y"HJ?"SAS+_=9_P!=2Y\*69O"MP&8D+>.!D]!L2N@
M\7,5\(ZHRD@BW;!!KSGP1XWTWPUHLUG>07<DCW#2@PHI&"JCNPY^4UJ:]\2=
M'U30;VQ@MKY99XBBEXT"@GUPQJ(SCR6N<E'%T8X-0<M;&'\+G9?%I4,0K6[Y
M /!Y%>@^-O%'_"-:2I@VF]N"5A#<A<=6(]LC\2*\]^%__(WC_KW?^E/^*5T\
MWBI(#]R"W4 >Y))/ZC\JF,N6GH<M"O*CE[E'>]BAHOAS6?&UW-=R7)**<27,
MY)Y_N@=_IT%:^K?"N_LK-Y[&]2]*+N,?E>6Q'MR<UWG@6U2U\&Z<J* 9(S(Q
M'<L2?\_2NBJHTDUJ==#*Z,Z*E4NY-7O?N>.> ?%]U8:G!I5[,TEC.PC3><^4
MQZ8)Z#/&/QKMOB#X@GT+05%FQ2YNG\M9!U1<9)'OT'XUY/XEB6Q\6:DD'R".
MZ9DQ_#SD?E7IGQ$TNYUGPM;7MLA>2W(F>-1G*%>2/IQ^&:F+?*UV.;#5JWU:
MK23NX[?J</X6\%7?BR.>\>]$$*2;#(RF1F? )XR/4<Y[UT6D_#_6-!\3V%W#
M/'<6J2_O'C;8P7OE3U_ FN7\)^,[OPNSQ");BSE;<\1."#TRI[' _2O6_#_B
MS2O$:$6DI2=1EH)>''N/4>XHIJ#]18"E@ZL8W=IKS_I'(>)_AWJ^M>(KO4+>
M[L_*F*E1,[AAA0,<*?3UK@->T*Z\.ZE]ANY(7EV!\Q$E<'Z@>E?15>+?%#_D
M;S_U[I_6BK!)7*S3!4J=-U8[M_F,TWX;:QJFFV]]!<V*Q3H'4/(X8 ^N%->J
M^%]*GT3PY::=<R))-"&W-&25Y8D8S@]#BH_!_P#R*&E?]>ZUMUI""6J/0P6#
MI44JD-V@KQ_XIZG<3:_'IVXBWMXE8(#PS-R2?PP/S]:]@KS#XKZ9;9M-36>-
M+DCRFB)^9UZA@/;)!^HHJWY19K&3PSY?F-T?X96.H>'K>]FU"=;BXA652@78
MF1G!!&3^8KD_!MQ/9>,=/$$A&^<1/M/#*3@_AWI+?Q3K9T2/0+:<B%F*#:/G
M8-_!GTS_ #]*[KPEX-C\-1OKNNR(DT*%U0?,(1CDG'5L>GZUBDI-<J/(I0A7
MJ4W0C;E^)GHE%9.D>)M(UV62+3;SSWC7<X\MUP/^! 5K5TII['TT)QFN:+NB
MAKA(T#4B#@BUEP1_NFO'OAN[#QK:@,0&23<,]?D/6O8==_Y%_4O^O67_ - -
M>.?#C_D=K/\ W)/_ $ UE4^.)Y&8?[W1]?U1UWQ:ED72M/C5V"/,Q90>#@<9
M_.O,;6>[TN>VOK>1HGSOC=3Z'&#^72O3/BY_R#M,_P"NK_R%<M)I7VKX8V^H
M(N7M+QPW'\#8'\]OYFLZBO-G#F$)3Q4W'=)/[K'LNFWT>IZ9;7T7W)XU<#TR
M.GX5@?$#67T?PO+Y,A2YN6$,;*<$9Y8_D"/Q%97PKU7[5H<^G.V7M)-R G^!
MN?Y@_F*YKXF:FVI>)HM-@)9;50@4'K(V"?\ V4?A6LI^Y<]+$8S_ &+VBWEI
M\^OZG$R)(H21P?WHWJ3W&2,_F#7T#X4E>;PGI<DCL[FW7+,<D\5Y+X\TY=(O
MM)L% _<Z;&K8[MO<L?Q)->K^#_\ D4-*_P"O=:BDK2:.3*J;I8B<'T1X/,L]
M[J,Y+-)*S.[%CDG )/Z UZ/\*M;DE^U:1/*S!%$T 8YP.C ?F#CZUR'A)%E\
M<64;J&1IG5@>X(:GV;OX/\>!7)"6MP4<^L;<9_[Y.:B#Y7S'#A)NC.-?I>S_
M *_K8]XKP;QAJT^O^)[MHW:2WA+)"N> B Y('O@FO7?%VK_V-X7O+M&Q*R>7
M$?\ :;@$?3K^%>4^%]*\WP_XAU5U^6&T:&,G^\W)(^@'_CU:U7=\J/4S2;J2
MC0CYM_(TOA/(X\27<8=O+-FS%<\$ATP?U/YUI?%YB%T=<G!\XD?]\5E_"?\
MY&FZ_P"O)_\ T-*U/B__ ,P;_MO_ .TZE?PCFA_R*Y>OZHW?AD[-X/3<Q.V=
MP,GH..*Z+6R5T#464D$6LI!';Y37-_##_D3U_P"OA_Z5TFN_\B_J7_7K+_Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 ?+W_-0O^XK_ .U:^H:^7O\ FH7_ '%?_:M?4->GF/V/0\_
M?;]3Q;XY?\A'1_\ KC)_-:['X2?\D_M?^NTO_H1KCOCE_P A'1_^N,G\UKL?
MA)_R3^U_Z[2_^A&BK_N4?7_,*?\ ODO3_(Z#Q;_R)NN?]@^X_P#1;5XC\(O^
M1^@_ZX2_RKV[Q:0/!FN9_P"@?/\ ^BVKQ'X0C_BOH/\ KA+_ "I87_=JG]=
MQ/\ O%,ZOXY_\>FB?]=)OY)7$ZCHQE^&.BZS&O,-Q-;RG_99B5_(@_\ ?5=M
M\<_^/31/^NDW\DJWX-T@:[\&)M-P"\WG>7_OAB5_4"M:53V>&A+S_P S*K3]
MIB)Q\O\ (T_A)K7]J>#4M)&S-8.83Z[#ROZ9'_ :X7XPZP^I^*K?2+<ETLD"
ME5YS*^"?TVC\ZS?AGXEC\,^(;H7C%+6:W<2 \89 67\>&'_ J=X!LY?%?Q(6
M_NP7$<C7TWID'*C_ +Z*_@*M452K3K/9*_WDNJZM&%);MV^XH^/])70M6T_3
M% !M]/B5\=W)8L?Q8DU[(-0?2_A!;WL9(DBT:+81V8Q  _F17E_QC_Y'K_MT
MC_FU>CZA"\_P11$&6&C0MCV$:D_H#6=9\U.DY=6:45RU*BCT1Y5\+=.BU'QY
M9"90Z6ZM/M/JH^7\B0?PKZ/KYZ^$$RQ>/8D8\RV\B+]<;OY*:^A:QS)OVR7D
M:Y>E[+YGFWQHL(I_"EM>E1YUM<A5;OM8$$?F%_*LCX&WCD:S9')0>5*OL?F!
M_D/RK=^,L\<7@E(F8;Y;M @[G 8G^5<_\#;9_.UFZQ\@6*,'U/S'_#\ZN'^X
MN_?]41+_ 'Q6_K0Y'XI?\E'U;_MC_P"B4KV>S\9^&]/\/6;SZW89CMHPT<<Z
MN^0HXVJ2<UXQ\4O^2CZM_P!L?_1*5?UOX5WNF>&5UNUOEO(Q"LTL7E;&12,D
MCDYQGGI71.G3J4J4:DK:+\D8PJ5(5*C@KZ_J<_!"_B?QT180LHOK]I$3'^K1
MG+<X]!_*OJ*O%/@UK=A%J,VDRV5O'>3(6AN@/GDQR4)/MR,8Z5[77'F$VYJ%
MK)'3@8KD<[ZL****X#N"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *\W^+>K&TTA+5&PS L?J?E'Z;J](KP;XN7YGU[R ?E
M1L?]\@#^9-=&%AS54<^*GR4FSA])@\_4$R/E3YS^%;=U"DL[)(,I(@X]<'G^
M8JGH$86*:8\<A<GT')I$O/M^J;$;:BJ?*/OZ_C7HUI7E8XL+&U._<<1LD9?+
M=$!V@LWWN.H]J9'$$<-O# ?= '-7% ,^9.)0.$/;W'K40C9IY&3 97[_ $YK
M&QTBQ)(8]\4J@$YVD9 J:R$IE8S%"ZKM)08&2<_RQ48#+<,(,,6^\O93ZGTJ
M]#$(H]N<GJ3ZGUII Q]0N2LN0,DCI4U12<2(W:J8A-KM]YL#T6G>6@W?*/FY
M/'6G4V,ED!/>D!9T]56[C 4 #/ 'M6T1&&VE5S]*Q;%L:A$,=<\_A6VZ*X^8
M?C7E8[^(O0YZOQ#9C\FT=6.!4X&% ]!5>W0,Q<DD X7)JS7"S%A7-:]\]SO'
M2(@'Z8_^O72$@ D]!7/,1.\C,,B0DD'T-5$J.YCNZQKECQ]<5#]H1X9&B()
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M1#/WO5?Q_H*(J].R*P]*53+91CO_ ).Y4^%Y!\'C!Z7#Y_2NCUY@OAW4V8@
M6DN2?]PUXOX=\4ZGX/N9[?[/NC=OWMM,"I##N/0U?\1_$._\0636$%HMI!*0
M'"N7=_;.!QGVIJHE&Q5',J,,+R/XDK6*_P -P3XVM"!T20G_ +X-=?\ %K_D
M"V'_ %\'_P!!-)\-O"MSI@EU:_B,4TJ>7#$X^95)!+$=B<#]?6G?%H$Z)8D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-X=LHI%#1O:1JRGH04&11=:#HU]<FYN])L+BX.,RRVR.W'3DC-7P H    X
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MM3_TS%8FNC&I'W04^IQX]?N_F>H_#*?S-*GC_N[&_,$?TKNJ\X^%C'R;D?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN+$8RCA]*CU/5J*\DM?BUJ2R#[7IUI(F>1$60X_$FO1?#_B*P\1V)N;)R"A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#Q7]BU2W\^W^SN^S>R\@C!RI![UGAJ%.5.4ZE]"\16J1J1A3ZGI/_"[/#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQLSLRVA.A0Y:BL[A1116AWA1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0LZ%N2QX QQGN>:U(8EAC 7GU/K4$FE7:Q!5E2?L2PVM_@?TJRD=PJ*BVS#
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M5]_R_P C'^T^)/\ H$Z5_P"#.3_XQ1]I\2?] G2O_!G)_P#&*V**.9=E^/\
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MTK_P9R?_ !BC[3XD_P"@3I7_ (,Y/_C%;%%',NR_'_,.5]_R_P C'^T^)/\
MH$Z5_P"#.3_XQ1]I\2?] G2O_!G)_P#&*V**.9=E^/\ F'*^_P"7^1C_ &GQ
M)_T"=*_\&<G_ ,8H^T^)/^@3I7_@SD_^,5L44<R[+\?\PY7W_+_(Q_M/B3_H
M$Z5_X,Y/_C%'VGQ)_P! G2O_  9R?_&*V**.9=E^/^8<K[_E_D8_VGQ)_P!
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M^#.3_P",4?:?$G_0)TK_ ,&<G_QBMBBCF79?C_F'*^_Y?Y&/]I\2?] G2O\
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M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
MW3O_  /?_P",UJ446#DE_,_P_P C+\_7?^@;IW_@>_\ \9H\_7?^@;IW_@>_
M_P 9K4HHL')+^9_A_D9?GZ[_ - W3O\ P/?_ .,T>?KO_0-T[_P/?_XS6I11
M8.27\S_#_(R_/UW_ *!NG?\ @>__ ,9H\_7?^@;IW_@>_P#\9K4HHL')+^9_
MA_D9?GZ[_P! W3O_  /?_P",T>?KO_0-T[_P/?\ ^,UJ446#DE_,_P /\C+\
M_7?^@;IW_@>__P 9H\_7?^@;IW_@>_\ \9K4HHL')+^9_A_D9?GZ[_T#=._\
M#W_^,T>?KO\ T#=._P# ]_\ XS6I118.27\S_#_(R_/UW_H&Z=_X'O\ _&:/
M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
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M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
MW3O_  /?_P",UJ446#DE_,_P_P C+\_7?^@;IW_@>_\ \9H\_7?^@;IW_@>_
M_P 9K4HHL')+^9_A_D9?GZ[_ - W3O\ P/?_ .,T>?KO_0-T[_P/?_XS6I11
M8.27\S_#_(R_/UW_ *!NG?\ @>__ ,9H\_7?^@;IW_@>_P#\9K4HHL')+^9_
MA_D9?GZ[_P! W3O_  /?_P",T>?KO_0-T[_P/?\ ^,UJ446#DE_,_P /\C+\
M_7?^@;IW_@>__P 9H\_7?^@;IW_@>_\ \9K4HHL')+^9_A_D9?GZ[_T#=._\
M#W_^,T>?KO\ T#=._P# ]_\ XS6I118.27\S_#_(R_/UW_H&Z=_X'O\ _&:/
M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
MW3O_  /?_P",UJ446#DE_,_P_P C+\_7?^@;IW_@>_\ \9H\_7?^@;IW_@>_
M_P 9K4HHL')+^9_A_D9?GZ[_ - W3O\ P/?_ .,T>?KO_0-T[_P/?_XS6I11
M8.27\S_#_(R_/UW_ *!NG?\ @>__ ,9H\_7?^@;IW_@>_P#\9K4HHL')+^9_
MA_D9?GZ[_P! W3O_  /?_P",T>?KO_0-T[_P/?\ ^,UJ446#DE_,_P /\C+\
M_7?^@;IW_@>__P 9H\_7?^@;IW_@>_\ \9K4HHL')+^9_A_D9?GZ[_T#=._\
M#W_^,T>?KO\ T#=._P# ]_\ XS6I118.27\S_#_(R_/UW_H&Z=_X'O\ _&:/
M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
MW3O_  /?_P",UJ446#DE_,_P_P C+\_7?^@;IW_@>_\ \9H\_7?^@;IW_@>_
M_P 9K4HHL')+^9_A_D9?GZ[_ - W3O\ P/?_ .,T>?KO_0-T[_P/?_XS6I11
M8.27\S_#_(R_/UW_ *!NG?\ @>__ ,9H\_7?^@;IW_@>_P#\9K4HHL')+^9_
MA_D9?GZ[_P! W3O_  /?_P",T>?KO_0-T[_P/?\ ^,UJ446#DE_,_P /\C+\
M_7?^@;IW_@>__P 9H\_7?^@;IW_@>_\ \9K4HHL')+^9_A_D9?GZ[_T#=._\
M#W_^,T>?KO\ T#=._P# ]_\ XS6I118.27\S_#_(R_/UW_H&Z=_X'O\ _&:/
M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
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M/UW_ *!NG?\ @>__ ,9K4HHL')+^9_A_D9?GZ[_T#=._\#W_ /C-'GZ[_P!
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M_A>O_4N?^3W_ -KH_P"%Z_\ 4N?^3W_VNCZCB/Y?Q7^8?7:'\WX,]@HKQ_\
MX7K_ -2Y_P"3W_VNC_A>O_4N?^3W_P!KH^HXC^7\5_F'UVA_-^#/8**\?_X7
MK_U+G_D]_P#:Z/\ A>O_ %+G_D]_]KH^HXC^7\5_F'UVA_-^#/8**\?_ .%Z
M_P#4N?\ D]_]KH_X7K_U+G_D]_\ :Z/J.(_E_%?YA]=H?S?@SV"BO'_^%Z_]
M2Y_Y/?\ VNC_ (7K_P!2Y_Y/?_:Z/J.(_E_%?YA]=H?S?@SV"BO'_P#A>O\
MU+G_ )/?_:Z/^%Z_]2Y_Y/?_ &NCZCB/Y?Q7^8?7:'\WX,]@HKQ__A>O_4N?
M^3W_ -KH_P"%Z_\ 4N?^3W_VNCZCB/Y?Q7^8?7:'\WX,]@HKQ_\ X7K_ -2Y
M_P"3W_VNC_A>O_4N?^3W_P!KH^HXC^7\5_F'UVA_-^#/8**\?_X7K_U+G_D]
M_P#:Z/\ A>O_ %+G_D]_]KH^HXC^7\5_F'UVA_-^#/8**\?_ .%Z_P#4N?\
MD]_]KH_X7K_U+G_D]_\ :Z/J.(_E_%?YA]=H?S?@SV"BO'_^%Z_]2Y_Y/?\
MVNC_ (7K_P!2Y_Y/?_:Z/J.(_E_%?YA]=H?S?@SV"BO'_P#A>O\ U+G_ )/?
M_:Z/^%Z_]2Y_Y/?_ &NCZCB/Y?Q7^8?7:'\WX,]@HKQ__A>O_4N?^3W_ -KH
M_P"%Z_\ 4N?^3W_VNCZCB/Y?Q7^8?7:'\WX,]@HKQ_\ X7K_ -2Y_P"3W_VN
MC_A>O_4N?^3W_P!KH^HXC^7\5_F'UVA_-^#/8**\?_X7K_U+G_D]_P#:Z/\
MA>O_ %+G_D]_]KH^HXC^7\5_F'UVA_-^#/8**\?_ .%Z_P#4N?\ D]_]KH_X
M7K_U+G_D]_\ :Z/J.(_E_%?YA]=H?S?@SV"BO'_^%Z_]2Y_Y/?\ VNC_ (7K
M_P!2Y_Y/?_:Z/J.(_E_%?YA]=H?S?@SV"BO'_P#A>O\ U+G_ )/?_:Z/^%Z_
M]2Y_Y/?_ &NCZCB/Y?Q7^8?7:'\WX,]@HKQ__A>O_4N?^3W_ -KH_P"%Z_\
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M /"]?^I<_P#)[_[71_PO7_J7/_)[_P"UT?4<1_+^*_S#Z[0_F_!GL%%>/_\
M"]?^I<_\GO\ [71_PO7_ *ES_P GO_M='U'$?R_BO\P^NT/YOP9[!17C_P#P
MO7_J7/\ R>_^UT?\+U_ZES_R>_\ M='U'$?R_BO\P^NT/YOP9[!17C__  O7
M_J7/_)[_ .UT?\+U_P"I<_\ )[_[71]1Q'\OXK_,/KM#^;\&>P45X_\ \+U_
MZES_ ,GO_M='_"]?^I<_\GO_ +71]1Q'\OXK_,/KM#^;\&>P45X__P +U_ZE
MS_R>_P#M='_"]?\ J7/_ ">_^UT?4<1_+^*_S#Z[0_F_!GL%%>/_ /"]?^I<
M_P#)[_[71_PO7_J7/_)[_P"UT?4<1_+^*_S#Z[0_F_!GL%%>/_\ "]?^I<_\
MGO\ [71_PO7_ *ES_P GO_M='U'$?R_BO\P^NT/YOP9[!17C_P#PO7_J7/\
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M &%'M8=P_M3"?S_@_P#(].HKS'_A;_\ U O_ ";_ /L*/^%O_P#4"_\ )O\
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M_P"H%_Y-_P#V%'_"W_\ J!?^3?\ ]A1[6'</[4PG\_X/_(].HKS'_A;_ /U
MO_)O_P"PH_X6_P#]0+_R;_\ L*/:P[A_:F$_G_!_Y'IU%>8_\+?_ .H%_P"3
M?_V%'_"W_P#J!?\ DW_]A1[6'</[4PG\_P"#_P CTZBO,?\ A;__ % O_)O_
M .PH_P"%O_\ 4"_\F_\ ["CVL.X?VIA/Y_P?^1Z=17F/_"W_ /J!?^3?_P!A
M1_PM_P#Z@7_DW_\ 84>UAW#^U,)_/^#_ ,CTZBO,?^%O_P#4"_\ )O\ ^PH_
MX6__ -0+_P F_P#["CVL.X?VIA/Y_P '_D>G45YC_P +?_Z@7_DW_P#84?\
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M_P#["CVL.X?VIA/Y_P '_D>G45YC_P +?_Z@7_DW_P#84?\ "W_^H%_Y-_\
MV%'M8=P_M3"?S_@_\CTZBO,?^%O_ /4"_P#)O_["C_A;_P#U O\ R;_^PH]K
M#N']J83^?\'_ )'IU%>8_P#"W_\ J!?^3?\ ]A1_PM__ *@7_DW_ /84>UAW
M#^U,)_/^#_R/3J*\Q_X6_P#]0+_R;_\ L*/^%O\ _4"_\F__ +"CVL.X?VIA
M/Y_P?^1Z=17F/_"W_P#J!?\ DW_]A1_PM_\ Z@7_ )-__84>UAW#^U,)_/\
M@_\ (].HKS'_ (6__P!0+_R;_P#L*/\ A;__ % O_)O_ .PH]K#N']J83^?\
M'_D>G45YC_PM_P#Z@7_DW_\ 84?\+?\ ^H%_Y-__ &%'M8=P_M3"?S_@_P#(
M].HKS'_A;_\ U O_ ";_ /L*/^%O_P#4"_\ )O\ ^PH]K#N']J83^?\ !_Y'
MIU%>8_\ "W_^H%_Y-_\ V%'_  M__J!?^3?_ -A1[6'</[4PG\_X/_(].HKS
M'_A;_P#U O\ R;_^PH_X6_\ ]0+_ ,F__L*/:P[A_:F$_G_!_P"1Z=17F/\
MPM__ *@7_DW_ /84?\+?_P"H%_Y-_P#V%'M8=P_M3"?S_@_\CTZBO,?^%O\
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M /4"_P#)O_["CVL.X?VIA/Y_P?\ D>G45YC_ ,+?_P"H%_Y-_P#V%'_"W_\
MJ!?^3?\ ]A1[6'</[4PG\_X/_(].HKS'_A;_ /U O_)O_P"PH_X6_P#]0+_R
M;_\ L*/:P[A_:F$_G_!_Y'IU%>8_\+?_ .H%_P"3?_V%'_"W_P#J!?\ DW_]
MA1[6'</[4PG\_P"#_P CTZBO,?\ A;__ % O_)O_ .PH_P"%O_\ 4"_\F_\
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ME=(\QHK>L_"&JWWBJ3P]%&GVV)V61MWR(%ZL3Z?XBNS?X1645R+*7QA8I?D
M_9FB4-^7F9Q^%.>(I0TDQ0H5)ZI'EU%6=1LGTW5+NPE96DMIGA9EZ$JQ!(]N
M*K5LG=71DU;0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O8?@5_S'_^W?\ ]J5X]7L/P*_YC_\ V[_^U*Y,
M=_N\OE^:.K!?QX_/\CV"BBBOGCW0KYN^*7_)1]6_[8_^B4KZ1KYN^*7_ "4?
M5O\ MC_Z)2O1RS^*_3]4<&8?PEZ_YG'T445[9XX4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX(Z&@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4455GU*PMKN*TN+VVBN9O]5#)*JN
M_;Y5)R?PH M45%<7$%I;O/<S1PPH,O)(P55'N3P*6WN(+N!)[::.:%QE)(V#
M*P]01P: )**** "BLS2O$.E:W/=PZ;=K/):.$G 1AM)R!R0,_=/(STIZZ]H[
MW?V1=6L3<YV^2+A-^?3;G-.P&A1112 **** "BBN B\?W3ZT(3;QBV+CY/*(
M/EF01@B3?@O\P)39T_BII7%<[^BH+N]M;"W-Q>7,-M"" 9)I B@GIR>*S_\
MA*_#G_0?TK_P,C_QI6&:]%16]S!>6Z7%M/'/"XRDD3AE8>Q'!J6@ HHHH **
MI:GJUCH]E-=W]P(H85#2'!8J"0H.T G&3CI5J*:.9-T;AAWP>G&>?3@B@!]%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!YCJGQ0O[#QV=%33(GM$N%@;.[S6)P-P
MYQWX&.?6O3JJOIMA)?+?/96S7:#"SF)3(![-C-6J;:Z"1#=W M+*>Y*[A%&T
MA7.,X&<5Y3X0M=+U/2M1\;>+RETQG*YG0R)$@P.$ /=L8QP!7K,T27$$D,@R
MDBE&'J",&O,_#ZZY\/);O2Y]%O=4TIY3+;W%BGF.,X!ROT ].0>N:J.P,W/#
M-_X%N-6N;GP]]FCO$MV,QBA>("+*Y." O4+TK*B\;^)]6TZ_UO1M+T_^Q[-F
MXN6?SI549)7!P..?\:@\+Z3J>J>.=?UFZTR[T^RO[-X4^TIM<%B@^[]%)KGM
M)\+VND1SV/B'P3JNI7:R'RKJR,C1NO;)5@!]?>G9$W9UNN?$:XL_#6A:UIUI
M$Z:A(5EBER2NTX8*01SD$9/Y5(?&'B/2O$VDV&OZ;8Q6NJ,$A^S.S/&Q(&&)
M."067.!WZUB^,?#]T_A7PW;:5H%S;K'<,[VD6Z<P[CGYFY/XGITK<\>Z=>WG
MBOP;-:V=Q/%;WQ:9XHRRQKOB.6(Z# /7T-%D/4GU'Q9K%YXKG\/>&;2RDFM(
M]]S<7K-Y:GC@!3GN!]<^E9TNNZOXN\%^(],2T^SZY9$0S10,<.-W.W//(5QC
M_&LC7O"JV?CN_P!1U3P[>ZUI5X-Z&RW%XG.,Y52,]^O8BNAT".+0=(U'4=%\
M%7UJS/&HMY9SYTZCJVUBQ7&X\=Z-$M U.=\#:CX,FAT[3-0TR*SUJUD4K--'
MM9Y5;(.\<YS_  MQVIFL-X@_X73;"V.F_;O*?[*)#)Y7E;),>9CG=MSTXSBK
M'BJUO?'UYI\%AX9U#3IXY,SWU];B':O3&>K =?PZ5H^)[/4-+^)^E^)(M,O;
M^R2 I(MG%YCJVUUQC_@0/..]/J(?XA\<>(=)\46^A6>FVE[=36J,$0-S,<YP
M<_<&">>W<5M?;_&T^FV @TC3HKV1&-T]S*1%$P8@*%4ECD8.<FL.6QU&Z^,6
MCZM_9MW':?8LR2-$=L9,4GRLW0') Q2?$'3[^Z\4:7+<:?J6H^'UA(GMK#)8
MR9;)*C_@'IT/-*RT0R_H?BS7]3U#6=!N+33HM:L4W1NI?[.W('/5L<C_ .M7
M-_"0ZV;B_P#(-@;#[3F[\S?YN[!QY>./SJY\/-&N=/\ &^JW T2[TS3Y;;]P
MDX8A1N7 W'J>"<9XJ3X?0:EX9UC4M(O=&U _:;K<EVD/[@* >2_OQCZT.UG8
M1U7Q _Y$/6/^N']17G_P\NG\,:YI]K*Q_L[7[5)(F/19EX(_/(_X$M>B>.+:
M>[\%:K;VT,DTSPX2.-2S,<CH!UKEIO"MYJ7PJTN!8)(-7L(Q/;JR[75P22N#
MT)';UQ2B]+#>YBZ)JT^A^&?'6H6IQ/'?;4;^Z6?;G\-V?PK3T+3/"GAWPG8:
MQXHCAGNM342M/=P&XR6&X ##8XQS]?I4'@_PUJ&L^%O$]EJMG/82ZC.)$\Z)
MD^;[P(!Y(#8K0\/Z]KOA;28]&U?PQJET]JI2&>PB\Y)%_AR1T],_I5/R$A\T
M.BZKX$UZ/P(J^;+M$B0JZ%B""0%;'5,CCK6)X&U'P9-#IVF:AID5GK5K(I6:
M:/:SRJV0=XYSG^%N.U:'@2TUSPOX;U:^ET*XFFFN5>.TW!9&3H3CGIGIWQ53
MQ5:WOCZ\T^"P\,ZAIT\<F9[Z^MQ#M7IC/5@.OX=*/(/,ZNX\+K)\2+75QI=L
M;-;0F2;8G_'QORK8ZEL8^;'XUQD7P_\ $ L(K,6P2VNHY);Z,S)S+&\IB'!Y
M#!H_RYZ5[%14*315C(\+6-QIOA73+*[C\NXAMU21-P.T@<C(XKSSXP:1IMAH
MMC/9Z=:6TTET0\D,*HS?*3R0.>:]:KSOXNZ9?ZIH=A'865Q=.MSEE@C+D#:>
M2!VIQ?O":T.DU)M$\%Z->:O!IEK;B- &6VA2-I"3A5R!ZFN6E\<>*=,TNQU[
M5=*TX:/=NHV0,_GQJPRK')QR.?\ "NG\<Z)/XA\(WMA:X^TG:\0)P&*L#C\0
M"/K7G6G:#I)L;>UN?AUK$FJ*%25S)+' YZ%M^_ SUQBB-K:@[G6:QXSU0^+A
MX>T./35E$*RF;4'8+)D A5VD<X(_7TK$^*,NNS>"K%[^WL[>,S 7,2.S.)?F
MV[3TVD#///(J[XYLK*\GFLY_!^I74L4(2SOK%"PSMX#$= #QSFJ>J>&O$5U\
M(;:PN8Y+C48)A,(,[I!'D@+[D!LX]..U-6T8F;;Z5X@UOP$MG?V^D7,[^4;=
M5>54$>!\S'(.\=>#BL+P3X0U>S\0?;[N(3107DT?F7@ECD7 _P!;&"<,'SC)
MSTZUW?A349=0T6%9M,OK!K=$A*WD7ELY"C) ],]ZW*GF:T*L07UR+/3[FZ(!
M$,32$'V!/]*\\^%ELTO@[5=0;,EU?3REV[MA>/U+?G7H&I6QO=+N[4=9H7C'
MXJ1_6N#^$]VZ>"+V&*'S+NTN)/W!;:6.T$#/;)R,^U"^%@]SFO"U]H/AW0(H
M?%/A2Y\UYF(O+G3%9,'H-S<GZ 5ZI+I.A^(+6PN9;2WO+:--]KN7,85@/X>A
MX ZCBN,\5:UJWBC09="L_">K175RRJ[W,(6*/# Y#YP>G7BF^)X]>\/>!-,\
M.:197EW/)"8[FXM86<(/X@,#C))&?053U%L97A&"!OC'J+Z$FS2H5<2"/A/N
M@8';&_) ]![5ZAK^KQZ#H5YJDJ&1;>/=L!QN/0#\R*X_P-=V>BVUMH]KX:\0
MP23-^_O+FPV*S^K-NX'8>E;7Q#G%OX#U4F6*,O$$4RC(;) P!ZD9QZ'GM2>L
M@6QREYXV\:VEII%X]EHB6^K.JVX(E9DW8V[\-Z$'C/\ 2MS5/%FLGQ)#X:T2
MTLIM46 2W<UPS"&/@'@#YL<C\Q7 V,?_  CMMH^L:]X?U62PB*&W:74DDCC8
M\[EAV@KG!;!-;/B?PX)?'!U^ZT.ZUO1;^!"4M"WF1L$4 X4@GA1[<GTJK*XK
MLZ'3?&^H2V'B.WU"SMX-8T:WDE*QDF*3"D@CG.,@=^A%9$/CSQ;=>$SXB@TK
M3!9VYQ/O9]TGS8)10> ,@<DU9TS1K$>'?$KZ3X3O]*:6PDAA^TN[2W!*-\HC
M))&#M^N?:H-*TG48O@I>6$EA<K>,LFVW,3"0Y?(^7&:6@]3<UCQ]'8^$]-U6
MUM#-=ZGM6WMV; #'KD^@/'OQ4-OXK\0:7XET[2O$UC8*FI9$$UD7PK\?*VXG
M)R0#CU'6N<UCPGJFH_#CPWY5A++<Z?DS63@H[*QY&.N>!QUYJYH&CZ')KE@]
MEX"U:RECD#O<WDDD:0D<@C<QW\@=J+*P79=@\:>(=;UO4K70K/2O*L)3'Y%W
M*RSS8)!*X.!T/7I7H,99HU9UV,0"5SG!],UY#XOTTZQ=SFR\':M::]]H_=WD
M Q X#??+CC)'L#SUKJG\1ZQ8>*] \-".WNI);-'OY2"75@"&8$' ^[GD'K2:
M[ F=;J%[#ING7-]<'$-O&TKGV S^=<7HOB7QEK]M'JUGI&F#2Y)=J0O*PG9
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MCK3/BAX<O=<TVPN+&V-V]E,6DM@<&1&QG'Y#IZUEZ!H^AR:Y8/9> M6LI8Y
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MN'8]_P :M5',[6*MU"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!B^*]<?PYX:N]4BM_/DA"[4
M[9+ 9/L,UB_#SQG=^+[.]-[:10S6KJ-\((1PV> "3R,<\]Q7921I-&T<J*\;
M##*PR"/0BHK.QM-/@\BRM8+:'.?+AC"+GUP*=U874GKSCXMV,D>G:;X@M>+C
M3;E3N'9200?P8+^=>CUGZ[IB:SH5]ISXQ<0L@)[-C@_@<&B+LP:NCA?B/K1U
M3PEI%C8<RZY)&44'.5X./^^BE:6J:[<>'+G1_"'AZT@N=1>!0IG)$<:*"-S
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M;G&!Z5T\;%XU8J5) )4]1[4ZHYG:Q5M;A1114C"BBB@ HHHH **** "BBB@
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M%NK$ 1JC (>2>1C/?L16[12O8#,U[P_IWB33C8ZE"9(MP92IPR,.X/:LK3/
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ML2,9X)'K0E<#;HKG](\7V&K:FVF-;7MA?A/,%O>P^6[+ZCD@UT%#5@"BBB@
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MIUPTLH<D%@0/NX!YX[XI77,/H9%JE_XE\=Z=K7]EWFGV&FPR*&O4\N29W!7
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MEUN:QM==O]/?3+299F-LCB6Y*_=W@\+[X_\ U:MKH%S!X\OM>:2$VUQ9I J
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MOZ5TU%%V.Q1U/1].UBQ^Q:A:1SV^00C#&TCH1CD?A5#2O!V@:+=B[L=.2.X
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M0 4444 0Q6EO!---#;Q1RS$-*Z( TA P"Q'7CUJ:BB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5?C#J"W]NEQ'#81RI'(,KNR "1T. 3UIEB/[#U+XB1:8H@CM;>*X@C085)#
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M8L?A#-$C$M+JOEB$9S/F0?NQCU_I7I6C>%;'1KV6_$UW>7\J;&NKV;S)-O\
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M0/QR ><<5!H_BK1->F>'3;])ID&6B*LC@>NU@#BJM_XZ\.:;J$UC=:@RW,!
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MIKQ%ENXT,:L6P X SCYB#GD=^E:WA[5[NQ\4VWAZ/6H-<T^2V:1)DVF2W"]
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M3_$/BX7M];6Q;4F($TRID<\\FIM+G3Q-\27UFQR^F:=9FU6X ^6:4L2=I[@
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MH(;N]01V^X$'<K9.3Z< \_A71>([,7/B3P;X9NG,UF \DP;D3&*/Y=P_ _\
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MQR#COCI7HR:;816)L8[*V2T.<P+$HC.3D_+C'6H[?1=*M#&;;3+*'RF+Q^7
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MCWG"\[1TK$UEKW1=8U?PC9(P37IHY;1QTC60XF_#@_A7JDUG:W,T,T]M#++
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M]"8;NWAN(CR4E0.I_ TRRTZQTV,QV-G;VL9.2L$2H"?H!4W3&>5:[X@U#7/
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MX\&V\$S;I+*22U+>H1N/T(%*V@'6T444AA1110 4444 %%%% !1110 4444
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M]($.WR_L<6-O3[@KB?$8?Q+\4+7PU>S2KI45N97@C<KYK;2>2/P_ 'UK2L_
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MA/)6*)-W\6Q3@MQU]SZU'X=\%PZ)X3NM GNOMD5R9"[^5LX90,8R>F/6A-)
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M&&U@PP2".H':FI"L<-K-[J_BCPU!X;A\/ZA;7%P8EN+B6/\ <1HI#;EDZ-G
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M9A:)ODB=2,';W! '^>K;(7^J>)KSQ3<VDNEV=KI[6]LMXNUV.=QD9>H ]/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=W67KFOV/A^TCGO#(S2N(X884WR2N>RKWK4KFO%WA^]UA;"]TN>*+4M-F,T
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MH>-O#T=M\.;FPTBW;R[9EG$)=I-P#[FY8DGJ3U[5LZGX*\/ZQJ#W]]8M)=2
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MF;36DM<G3?\ CT^=OW? 'KSP!US3YD*QS^GD+\6M84\%M.A90>X! )J+3_\
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MR:AI<F]!<;O+<%0&!(Y[>E=111=A8Y:^T#5=3UKPSJ=U+9K+IK3-=+$6 8N
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M'Z"G9;"N=-X1URYU_29KNZCB21+J6$"($#:IP.I/-8W_  G%U_PG0TLV\/\
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MSG/J:[>DU9C04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHJOJ%K]NTVZL_,:+SX7BWKU7<",CZ9H ;::E87[2+9WMM<M$
M<2"&57V'T.#Q5JO.O /PZO\ PIK5Q?WE_#(K1&*.. MA@2#EL@>G3GZUZ+3:
M2>@D8WBS5Y]!\+WVIVR1O-;H"BR E22P'."#W]:YNY\4>)]$M+#5-8M])GTR
MY>-7^Q^8LD>\9!PQ(-:GQ(_Y)]J__7-/_0UKD]=TG7[;PK8:M>:O!J>GV*Q7
M+:?);>2K  8!922V,]^/KTJHI6$STRXU&QM)/+N;RWA<H9-LDJJ=HZM@GH/6
MFQ:KIT_V;R;^UD^U;OL^R93YVW[VS!^;'?'2N"UF"S\1?$+PL;F'?:W%@TYA
M?HW!<!AW&<<>U:>MV]M8>//!45O#%;VZM>A4C0*H+1CL..2?S-*P[G7M=VR7
M26K7$2W,BEDA+@.RCJ0.I%<UX4UR[O[CQ(=1N5,-AJ4T,3,%01Q+ZD < #J:
M@U$C_A;.BC//]GS<?C7!I,W]NZM:ZDTD7AVX\03K>21'!+Y^17/9">OT]J:B
M)L]F6_LWL1>I=P-:$;O/$@,>/7=G%-LM3T_4E9K"^MKI5X8P2JX'UP:XKQS%
M(VK>%-(LX;,VLLLK"WN"5@9D1=BMM!XY.!CDXJSI_AO6X_%]EK$UOHUE#%%)
M%<)8.^9E(^7(* <-@TK*P[G42:UI41Q)J=DA\TP8:=1^\&,IU^\,CCKS3M4&
MI&Q;^R3:"[R-INPQCQGG.WFN&\$Z-IU]KOBJ[O+.&XE35YD0S('"#<3P#P#G
M'/L*]%I-68+4X"'7?&T_BBYT%?\ A'Q<6]NL[2&.;802!@?-G/-=%%<ZPFKZ
M9;7E[I"[X':Y@1F$DCCH8E/.T<9S6+I__)8M6_[!D?\ Z$M&K_\ )7/#W_7G
M/_)JH1U$VMZ3;+(T^J642QR>4Y>X10K_ -TY/!]J=<:QI=HD+W.I6<*S#,1D
MG51)_NY//X5POA30],U3Q/XMFO[*&Z9+]XT$R[@H;.< \ GCGKQ5;P7X9TF[
M\':K+<VB3RF2>!'F&\QHN=H3/W>3GCO1RH=V>ES7,%M;M<3S1Q0*,M([A5 ]
M23Q6=/J,FIZ;(_AJ^TRYN%8#?))YD0]<[#G.*XNPTG4/$7PS\.26S0S7%G(L
M_P!GN2?+G",RA&_#%=)X6U:UO+J_LCHRZ3JEL4^U0*JX8$?*P91AAUI6L%S&
MAUWQM/XHN=!7_A'Q<6]NL[2&.;802!@?-G/-:NK>)-1TF/3=,6T@OO$-\#MB
MA)2%<=7)/(4?T-4M/_Y+%JW_ &#(_P#T):34&6#XQZ7),0J3:6\4);H7#L2!
M[XIB':AKWBSPW NH:U9:7=::K 3G3S()(@3C=A^".G_UJM^*O$E_IYT2/119
MR/JDXB22Y5B@! (/RD'O4_C^>*W\"ZNTSA0T!1<]V/ 'YUR?B*UNTTOX?VB3
M?9;Q9(8Q(R;_ "W$:#)4]<'M0K,&=E8)XM+3#49]$13'^Z:WAE8A\C[P9AD8
MST([5SLWBWQ##X1M]85-.N+FYO#;10+;N@ 5Y%//F').P8Z8SWKJ-'T_6K.:
M1M4UQ-1C9<(BV:P[3ZY!.:FCT#3(K.UM$ML06MQ]IA7S&^63<6W9SD\L3@\<
MTKH9S^G^-)=5\6V=C9Q0MI=Q;LWGD'>9 BN0#G& )$SQUS795E6/AK2--DMW
ML[)8FMC*T6UV^4R8W]^<X'7ICC%:M)VZ @HHHI#"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)(D,;
M22NJ1J,LS'  ]2:BL[ZTU"#S[*Z@N8<X\R&0.N?3(K,\5Z&_B/PU=Z7%<>1)
M,%VOVR&!P?8XK%^'G@R[\(6=Z+V[BFFNG4[(22B!<\@D#DYYX["G96%U.TID
MTL=O!)-*P6.-2[,>P R33ZX[XE:E):>%FL;=9'NM2D6UC2)2SD'EL*.3P"/Q
M%"5W8;(_!GC.]\0:C<6FHVL-L7A%W9! 07A+%<MDG)X'2NLGU"RMIO)GO+>*
M789-DDJJ=@."V">F>]>8ZMKD&GZUX;U.VT?6+&WT\BSGDO+-HT\A@% STR.2
M*UM?TZTU3XLZ1;7L*S0?V>SF-ONL0S$9'<9P<>U4UJ3<[6#5M.NK22[M]0M9
MK:($R31S*R( ,DE@<#%8_AOQGIWB$S1K-:PW*W,D,4'VE7>55YW@<'!&3QGI
MUK)TO3[.R^*&KV-M;116=QIB22VZH!&QW;?N].F?S-'PXT^Q%GJ=P+2W\^+5
M+A$E$:[D7@8!QD#!Z>]*RL.Y:U+6=5M/!NO7_P#:&GRW=M-(()+([Q$H*X5P
M>-XR<CZ5KZ3KUE<6.G17.I6G]HSVT3M"94$C,R@_=SGG/I7GMG_R3+QK_P!A
M.X_]IU=U?P[HMK\)%O(+.".Y2UAN%N@!YGFG:<[^O).,4[(5STBZN[:Q@,]W
M<0V\(ZR2N$4?B:99ZA9:C$9;&\M[J,'!:"57 /U!K@P@U_Q[HEKK42R0PZ*M
MXD,N&629B Q(Z''/'^S5I[*UT?XJZ;'I<4=LE[92_:H85VH0N2K%1QG/&?:E
M8=SKYM6TVVO$LY]0M(KI_NPO,JNWT4G)K \%^(GU#P[;7&KW\/VN>YEBCWE8
MS)AB J@8R<>E8O@C0])UWP[?W^KVD%U=7=W,;B69<LN#P 3RN!SQBLC3=.DN
MO@^MS9DF[TV[DO;=AR<QN2?_ !W/Z4[+85SU:>[MK5HEN+B*%IG$<0D<*78]
M%7/4^PJOK5Z^FZ%J%_$JM);6TDRJW0E5) /MQ7(6U]%XP\<:3-#AK/3;$7C#
ML)I0-JGW Y_"NF\5_P#(G:Y_V#Y__1;5-M1W,;P'XNNO$UM<QZC#!!?0;)-L
M.0K1.N58 DGZ\^E1>//&=[X:\F#2X+>:Z,37$WGABL<0(4' (.2QP/I6!IC#
M0$\&^(,[;:ZM5T^\/0 'F-C]#^@J'5 =7\'^+?%$@)6]98+//:WCD4 _B<G\
M*NRN*^AZ7=ZI'8:#+JMS@)%;^>X'?Y<X'\JP?!/BB_UX7EMJ]M!;7]N(Y=D(
M(!BD0,IP23GU^HK*\>7^=#T31$BN)SJ#QF:*V0O(88P&?"CD]OR-4Y=?2#XB
MZ3J<>EZGI]M>1?V?<&]M3"I).8\9XSG'X"DEH%]3K(M?NI/B#/H!CA^RQZ>+
MH/@[]^\+C.<8P?2F^-M?O?#VC07-A';O/-=1P#SP2HW9YX(/:LRW_P"2TW?_
M &!1_P"C5H^*'_(OZ?\ ]A.#_P!FHMJA]!U_KGBWPY"+_6+'3+S34(\]M/,B
MR1+TW8<\CZ?IUJ]K?B>6RNO#@L!#+;:M<K&SN"3Y; $%<$<\]\U=\77,%KX0
MU>6Y91']DD7YNY*D ?B2!7"26\UKI7PXBG!$@NHR0>H!P0/R(H23$]#U6BBB
MH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *Q])\-6&D:7=Z="99;>ZDDDE$Q!
M)WC##@#C%;%% &-H/ABP\.Z(^E61E,#LS.\C NQ;@DD #I@=.U.L]*M/#WA8
MZ=#'/=6MM ^(V&^20<DK@ 9)R1@"M>BG<#C_ (;: ^A>%E-Q \-U=R&:2.0?
M,@Z*ISZ #\S5FX\#6+W]Q=V6HZKIC7+;YX[&Y\M)&[DC!P?<8KIZ*+N]Q6,&
M\\(Z=>Z)9Z2\ERMO:S+.C+)ERP)/S%@<Y).:=K?A6QUR\@O7FN[2^@79'=6<
MOER!>NW."".O;N:W**+L=C&T/PS8Z$\\T+W%Q=W!'G75U)YDKXZ GT]A4-IX
M.TFU\.7&A,LL]E.[.XE8%LL<\$ 8P0,?2M^BB["QQY^'.ERQ1I=:AJMV82I@
M:XN0YA"D'"#;@ X /&<=ZZZ5#)$Z!V0LI&Y>J^X]Z=10VV%C.T+1;3P]I$.F
MV6\PQ9.Z0@LQ)))) &3S5.?PGIMQJNHW\AGW:C;"VN(E<!& QAN!D-@8SG\*
MW:*+L#F]/\%6-EJ5O?37^IZA+;9^SB]N?,6'/&5&!SCUS5>7X?Z9,[))?:HU
M@TOFG3S=$VY.<XVXSC/;-=911S,5D86I>%;34-334HKN^L+Q8O),ME*$+IG(
M4@@C%2:%X9L?#T][-9R7#M>,C2^=)O\ F48SG&<G))R3R>U;-%%V.QP_A70B
M/&WB+7WLIK:.28P6RS(5+=#)( 1T8@$'W-=Q110W<#E?!UC<Z+=:UH\EO*MK
M%=F>TF*'8\<G.T-T)4C!^M;&NZ);>(=,-A=O*D1=7)B(#94Y'4'TK2HHOK<5
MC*U[P]8^(K2."]$BM$XDAFA?9)$P[JW:JVD>$[+2=0?46N;V_OF3RQ<7TWF.
MB^B\ #\JWJ*+L=B&\M8[VRGM)2PCGC:-]IP<,,''YURD'PZLH;-+$ZYKKV*C
M;]E-V%C(],*HXKL:*$V@L9-SX<TZX\.2:#'$;:Q>/R]L& 5&<\$@\^YS5F72
M[6?1CI4Z&6U:#R&#=2N,?G[U=HHN!RT7@'2HO#*^'Q/>&Q%P)VRZ[G(.=I.W
M&W@=L\=:Z<HI385!0C&W'&/2G44-W R] T*V\.:8-/LY9WMUD9T$S E-QR5&
M .,Y_.N'U?3[I?&NJ7M_'XAA@F2-;:70U.'4#GS"G)(/K_A7IE%"8K''>%+#
M4;RQU:UUI;V?2IW"6D>IX,Y3!W;\<XSC'?BIK?P%8V_E1_VMK4EG$P*6;WA\
MD8.0,  X]LUU=%',PL9;Z#:/XFCU\O-]KCM?LH4,-FS<6SC&<Y)[TZ'0[:#Q
M#=:TCRFYN85A=21L 7H0,9S^-:5%%QG)GP!I\<LWV+4M7L+>9BSVMI=[(B3U
MP,9'X&KVH>$[.]BLEBN[^QDLHO)AFM+@HX3 &TDYST'6MZBB[%8R]#T"R\/V
MLD-H9I'FD,DTT[[Y)6/=C6C-$D\$D,J[HY%*L,]01@T^BD,K6%A;:780V-G%
MY5M"NV--Q.!]3S4&MZ1#KVCW&F7$LT4-P '>!@KX!!P"0>N,'CH36A10!R=K
MX%6SCBB@\2^(4AB "1+=(% '; 3I6AJWAE=4O?M2ZQJ]BQ0(R65UY:L!GJ"#
MSSU%;E%.[%8SM%T.PT"R-K81%59B[N[%GD8]68GJ:76](M]>T>XTRZ>5(+@
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MKI.MV$#7,FDW7G20(,L\9QNP/7BNQHHOK<+:')Q_$+1KP1Q:6MU?7TA %I'
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MAN>/3H?PJAX[UW1]9\&OI^G7=O?7=^T:6L$#!G+;P<X'*X /7Z4DDP;)]?\
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MM:7%K6BWFFS'"7$13/\ =/8_@<&C1+>\M-$LK;4'B>[AB6.1XB2K$#&>0#R
M#]:OT4K@0VMG:V,/DVEM#;Q;BVR) @R>IP.]$-G:VTTTT%M#%+.P:5T0*9#Z
ML1U/UJ:JFH:G9Z5!'->S>4DDJPI\I8L['   !.30!);V=K:&4VUM#"97,DGE
M(%WL>K''4^]-73K%+::V6SMU@G+-+$(E"R%OO%AC!SWSUJ*]UO2=-F6&_P!3
MLK65EW!)[A$8CIG!/3@_E4EEJ5CJ<;26%[;74:G:S02JX!]"0>M/4"M!X<T*
MUF6:WT73H95.5>.U16!]B!537]#N-;U+1PSQ#3K.X^U3H2=TCJ/D &,8R3G)
MK0;6M*2]^Q/J=DMWG;Y!G4/GTVYS5J>XAM8&FN)8X8D&6>1@JK]2:+L1)156
MRU*PU)&>PO;:Z13AF@E5P/K@U:I#"BBB@ HHHH **** "BBB@ HHHH **S)_
M$>A6L[P7&M:=#,AP\<ETBLI]""<BGVNO:/?2F*SU:PN)%4N4AN4<A1U. >E.
MS T**K66HV.I1-+87EO=1J=I>"57 /ID&EO+ZTT^#S[VZ@MH<A?,FD"+GTR:
M0%BBJESJNG65M'<W5_:P6\N/+EEF55?(R,$G!XYI++5M-U/=]@U"TN]GWO(F
M63'UP: +E%%% !1110 4444 %%%% !1110 4444 <MIVCWT'Q%UG59(-ME<V
MT4<4F]3N8 9&,Y'3N*W-8MY+O1+^VA7=+-;21H,XRQ4@5=HIW X#09?&.D>'
M+32(?"\:S01^6+F>_CV YZE5R>_2MK0/"%MI^B26>JI;ZE<7,[75T\T0=7E;
MJ0&';_'UKI:*&Q6.3\7>&$N/!&I:7H.FVT4]P8V$4")$'(D4G/09P#UJ?2-4
M\0M-:VEYX6DM8 H1[@WT3A<#KM!R>GZUTM%%]+!8\_\ $(\4:EK>EW$'A9S%
MIEVTJM]NA_?+T&,GY<]>:[?3Y[FYL8IKRS-G<,#O@,@DV<_WAP>.?QJS10W<
M+'$ZY9:Y:_$&VUW3='.HVZ:=]F95N8XB&WL?XCZ$=JTSJOB2?1K^1?#;6U^B
M@6L37<4@D8YY)!  7@\]:Z.BBX6//[+PAJ?AC4-*U/2\WMS(#%JZ&0+YVXEC
M(-Q RI/U( ]ZJ17.L6GQ4\33:5I\=^!';": S")R/*7!5CQP>H/K7I=4H-(L
M;;5;O4X8-MY=A%GDW$[PHPO&<# ]!3YNX6.1L_#FKSZ7XKU#4((DU76K=XX[
M9) PC C*HI;IGD9/3@5M:1HDO_"!6^AWP,,KV)MI@"&*%E*GD<'&:Z&BE<+'
M#Z3+XRT32H='_L"WO3:H(8;T7JI&R#A25/S<#%:NNR:V%BA30+/6;.2$">'S
MEC*R=S\_!7T[UT=%%PL<3H.E:_X<\*R1VUC:S7$EZ\_]GM.=L4+?\LD<\9&,
MY/')J/0= U$:]JFJOI$&C07-E]G6RBF5_,DSGS&V_*#VX]?K7=44^8+'G=KX
M.U8_#C1[';';ZUIER;N%)&#+O$CL%++D<AA^.*M:C9^)O%RVFG:CH\6E6*3)
M-=2FZ69I0ISM0+TR>Y__ %]U11S!8Y>'1[Y/B=<:P8?] ?2Q;K+O'^L\Q3C&
M<] ><8I^FZ5>V_CW7-3EAVV=U! D,FX'<57!&,Y'XBNEHI7"P4444AA1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]=/2#27>)UM%<,SKSU8D$'H.^:JR^--;M-+36KA=$:S(622QBG)N40GUS@L
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M%O\ ,V^7@#G&#GK[5MUQ'C3_ )&_P;_U^2?R6LYM%MM>^*FN6M^TSVB6T#M
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M# 1IMJ<Y&$YD(]BV*[*DU884444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHH **** "BBB@"KJ.G6NJV3V=[%YMO(073<5#8.0#@CC(Z=ZL@!5"J  !@
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MA]TNX.7Q]*["BCF861B6_AX0>,+OQ!]I+&XMEM_(V?=P0<[L\].F*R%\!!?
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M /Q='_"V-=_Y]-._[]O_ /%UPE%'M)=P^OXG^=G=_P#"V-=_Y]-._P"_;_\
MQ='_  MC7?\ GTT[_OV__P 77"44>TEW#Z_B?YV=W_PMC7?^?33O^_;_ /Q=
M'_"V-=_Y]-._[]O_ /%UPE%'M)=P^OXG^=G=_P#"V-=_Y]-._P"_;_\ Q='_
M  MC7?\ GTT[_OV__P 77"44>TEW#Z_B?YV=W_PMC7?^?33O^_;_ /Q='_"V
M-=_Y]-._[]O_ /%UPE%'M)=P^OXG^=G=_P#"V-=_Y]-._P"_;_\ Q='_  MC
M7?\ GTT[_OV__P 77"44>TEW#Z_B?YV=W_PMC7?^?33O^_;_ /Q='_"V-=_Y
M]-._[]O_ /%UPE%'M)=P^OXG^=G=_P#"V-=_Y]-._P"_;_\ Q='_  MC7?\
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M_P"H%_Y-_P#V%'_"W_\ J!?^3?\ ]A7F%%'M9]P_M3%_S_@O\CT__A;_ /U
MO_)O_P"PH_X6_P#]0+_R;_\ L*\PHH]K/N']J8O^?\%_D>G_ /"W_P#J!?\
MDW_]A1_PM_\ Z@7_ )-__85YA11[6?</[4Q?\_X+_(]/_P"%O_\ 4"_\F_\
M["C_ (6__P!0+_R;_P#L*\PHH]K/N']J8O\ G_!?Y'I__"W_ /J!?^3?_P!A
M1_PM_P#Z@7_DW_\ 85YA11[6?</[4Q?\_P""_P CT_\ X6__ -0+_P F_P#[
M"C_A;_\ U O_ ";_ /L*\PHH]K/N']J8O^?\%_D>G_\ "W_^H%_Y-_\ V%'_
M  M__J!?^3?_ -A7F%%'M9]P_M3%_P _X+_(]/\ ^%O_ /4"_P#)O_["C_A;
M_P#U O\ R;_^PKS"BCVL^X?VIB_Y_P %_D>G_P#"W_\ J!?^3?\ ]A1_PM__
M *@7_DW_ /85YA11[6?</[4Q?\_X+_(]/_X6_P#]0+_R;_\ L*/^%O\ _4"_
M\F__ +"O,**/:S[A_:F+_G_!?Y'I_P#PM_\ Z@7_ )-__845YA11[6?</[4Q
M?\_X+_(^G:***ZSZ\**** "O%=&!TC3[?Q3&#ML=9G@NR.\$FT$GZ$_F:]JK
MD=$\'R6OA35=%U)X9!?3S2!HB2%#@;3R!R",U478313\0./$'BZ#34.^STFW
M:_N"#P92I$0_ '=^-4-'\/2^(_A/HD%M<+!=VTGVFW=QE?,5WQN]N36[X0\*
M76@:!=V][<13ZC=D^9,C$C 7:@R0#@ >G<TW3=!\0Z-X1TO3M.OK&.]M"WFB
M5&>&8$DXS@,.HY%._1"L&C^+;X:S#H7B/3?L.HS*3!+&VZ&? R=I['VY_I5;
MP+_R,'C#_L)G^M6K7P_K>H^(['5_$-S8@6 ?[-;6(?;N88+,S<_A_DV?#^B3
MZ#?^(+Z\F@\F]NFN4*,?D3G[V0,'Z9HT&4/ +B*Z\3:>G^JMM6E,8_NANWZ5
MV=<?\.XGETB^UB52K:M?2W:@]D)PO\C^==A4RW!;!1112&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !61K7B?1?#S0KJM^ENTWW%*LQ/OA0<#W/%:]<9XT^'MOX
MPO;:\-^]I-"GE-B/>&3)/3(P>3S35KZB?D=A%+'/"DT3J\<BAD=3D,#R"#3Z
MJ:9I\.DZ7:Z?;[O)MXUC0L<D@#J:MTAG+^']7OI?%?B#1M0G\PVTB36OR*,0
MN,@< 9QP,GFLG1?%U_>_$>_TR=P=+<RPV8VJ/WD6W?@XR?XCS2^*[M/#'C73
MO$#\07%G-:S^A*#>F?J>/PK(EL7T3P1X7U]U/GV=VMW<MW*3GY\^G515V1-S
MKO[5OKGXB_V5;S;;"TL?.N4V [I&.%&<9''/!%<WX)\=Z99^$[0:]K3->O)(
M292\K@;B!N(!P/3-;?@8?;IM<U\Y/]H7S+$Q[PQ_(G]:Q/ %I;GX3W9,$9,R
M7'FG:,OC(&?7%&@'?W.J6%GIO]HW%W#'9[0XF9AM(/0@]\]L=:S=+\9>']:O
M!:6&HI)<$96-HWC+#VW 9_"N!)5O"?@!;PC^S3=KYY<_)N&=F[MC[W6NC\?^
M2;GPT+?;_:7]J0FWV8W;.=W_  'IGM1RH+EG2[Z[D^*&NV;W,S6L5I"T<)<E
M$) R0.@/-7[GQMX<M+M[:;4T#QOL=EC=D1O0N!M!^IK @,P^)7BLV^[S_P"S
M8_+V]=VP8Q^-9WA#2=2U7P'%%;^(;.&RECD2>!M/5RA).[<Q<9/?)%%EU"YZ
M>K*Z*Z,&5AD$'((KDM5UG5M2\4-X<T&:*T:VB$U[>R1B0Q[ONJJG@D@@\_TK
M<\/6 TOP]862W8NUAA55G P)%[$<GC&.]<MH<Z:5\4/$=E=L(WU)8)[9F.!(
M%4@@>IRQ_(TEU&S?T>V\0V5^\.IZA!J5DT19+CR1#*C@CY2J\$$$G(]*C;QQ
MX;2Z-NVJQ[@_EEPCF,-Z>9C;^M2^)-0B32-3L;>X7^TFT^>6*%#E^$(!Q]2*
MX[0]#O\ 6/A[;01^)+*+2YK79)&=.4^7Q\P+;QR#GGCGFA)/5@;OB:^NK?QK
MX1@@N98X+B2X$T:.0L@"KC<.AQD]:/#%]=W/C;Q=;SW,LD-O+;B&-W)6,%6S
MM';.!TK,UFV^Q^)_A[:_:/M'DK-'YW_/3$<8W=3UQGK5OPE_R/WC7_KK;?\
MH+T^G]=Q=3K[Z_M=,LI+R]G2"WB&7D<X KAM8\96&K:GX>CT/5G;=J<:7$:;
MXRR$'AE(!*G\JM_$7R_+\/K=X_L\ZM#]IW?=QSC=[=:B\;FR_P"$G\(@>3]M
M_M!,8QO\K/\ Z#G%$4ALZ/6/%6B:!-'#J=^D,LB[EC",[8]2%!('7D^E<[H&
MN2WM_P",;JWOVN;:'RY+0[RZ(/*)^4= ,CI4GAWRC\2?%1N<?;0(!#NZ^5L_
MA]ONY_"LWPX;,WGCXV'E?9LC9Y.-N?+?.,<=<T60B*PO?&,W@=?%">(XYF2%
M[A[2:RC"E4)R-R@'.%K;U+QE<'0-$DTRV1M4UL*MM'*?DC. 68^H7-8/A+PS
MJFN^!=/@N/$,D6D3(VZSAME5BN\Y7S,DX//;O6AXFCM_#OBSP??[!%IEKYEF
M6Z+%N3:N3Z<_H:;M>P=#8MM/\76-U;32ZY;ZG"TBBXMY+58=J$X+(R]2.N#U
MQ63;W'B/7?%WB&QM/$)T^WTYXEB06<4N=ZD\EAGJOKWKM;K4;.RBBEN;F*-)
M76.,LWWV8X 'KG-><V7A\Z]XV\91C5-1L&1X K6<Y0,61OOC^(#'3W/K27F#
M.G\%ZY?ZM#J5KJ9BDNM.NVMFGA7"2X[X['_ZU=%=W45C93W<[;88(VD<^@ R
M:Y3X<31IH$^EFVCM[W3KEX+I4!^=P>'YY.1W]J9\2KN<Z';Z+91M+>:K.L"1
MJP4L@^9L$\#L.?6DU[UAWT*G@GQ+K5[J[6>NR _;K1;^Q7RPNV,L1MR ,\8/
M/-=5J?B31]&N%@U&^CMI'C,JAP<%0<$YQCKVZFN \1WVL6%YH>N7'AF33+;2
M91')(+N.7]RV%*X4YZ=/K6QK<-O>?%?PWYB1S1_9)9%R PR Q!_K3:3U%<Z?
M1O$FD>(/-&F7JSM#_K$VLC+_ ,!8 X]ZI7'CSPQ:WC6LVKQ"57V,0C,BMZ%P
M-H_.J"1I'\8Y"BA3)H0=\?Q'SP,G\ !6'J.KW^N> ]4N]/TK2K30'AFV>?,5
MD?!(W*JK@-N' )Y.*.5#N;OC"_N;?6O"BVMU+'%<:@%D$4A D7C@XZCFNCL-
M6L=3ENXK2?S)+28P3J492CCJ.0,_4<5Y_J+,]C\-78Y9I+<D^I\M*LZUJ*^"
M?&=_J##%IJM@TH&.#<Q#@?B#^9HMT%<ZUO%&BI:WMR]^BPV4QMYW96 60=5'
M'S'Z9J.+Q%IFKZ9J+V&H-&;>$F25H'5H<J<-M8 G&"?PKF;3PH)/ ND64NH)
M9ZJUPNHQR28.ZYY;!4XW8!P0/2K*^(-0N[#Q)HFL6]NFH65B[F6U8F*160X.
M#R#[&E9=!W-BQUW3].\*66H7^LBZA=0%O'B*-.23C"#G/MC/%:&DZYI^MQ22
M:?.95B;:X:-HRI]PP!KB-)T<ZOX%\+&UU"*SU2U!N+/S &#D$[@5ZD8QR.E=
M)X8U^]U2ZU/3=3MH(=0TUT29K=RT3AP2"N>1T.0>E#0)G1T445(PHHHH *X3
MXL?\BM:_]?J?^@/7=UPGQ8_Y%:U_Z_4_] >HJ?"SCQ_^[3]#QVBBBN,^-"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"YI-HE_K-C
M9R,RI<7$<3,O4!F ./SKO/%/PXL]*T*:_P!,GNI9(,-(DS*P*=R, 8QU^@KB
M_#?_ "-.D?\ 7[#_ .ABO8+C6EMO'W]C7)!MKZS7:&Z;P7X_$<?@*UIQ36IZ
MV!HT:E&7M%JW9/M<\X\"^%K+Q/<7L=[+<1K BE?)90223UR#Z5BV&AW>JZXV
MF6*;Y [#<W 50<%F]!7IG@C1GT'Q7KUBP/EJL;1,?XD);!_I]0:B^&5NGVS7
MKG&9#<",>PRQ_P /RIJ%[(J&!C-4H25FW*_R,JZ\&>$]"1(M<U^=;DC)6$#_
M -!"L<>YK*\0>%-(M=%;5M$U@7D$;JDD;D%AGIR,8^A%4-,LH?%.LWLVJ:S#
MISMF7S)\'<2?NC+#I_2M/Q!X!31= .K0:NEY%E=H6':&#'@A@QS2W5TM#.45
M4IRE3I+E5];ZKSW_ $)=!\#64V@'7->OWL[-AN18\ [<X!)(/7L /2J>NZ+X
M6AT9K[1-;>XE5POD3$!F!X.!M4^_2NG\,>(-"USPM%X<UB18)%018=M@< _*
M5;L>G'K6%XL^'LNAVC:A8W!N;)?OAQ\\8/0\<$>_%-Q7+=(TJ4(?5U*C!25M
M7U3.(HHHK$\<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** -3PW_R-.D?]?L/_ *&*^B:^=O#?_(TZ1_U^P_\ H8KZ)KHH;,^CR3^'
M/U"BBBMSVSS'XO\ _,&_[;_^TZ\PKT_XO_\ ,&_[;_\ M.O,*Y*OQL^0S3_>
MY_+\D%%%%9G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#^5='4<T\5M \\\J111J6>1V"JH'4DGH*+L+"PPQ6\$<$,:QQ1J$1%& J@8
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M16M?^OU/_0'KNZX3XL?\BM:_]?J?^@/45/A9QX__ ':?H>.T445QGQH4444
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M1NGT&/QCX>B.V2]GCDLT'?[00K@?3I^%>LU@ZGX0TW5?$=AKEP9A=66W8J,
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M@+J/_@*_^%'_  C>N_\ 0%U'_P !7_PKZ)HH]@NX?V)3_G9\[?\ "-Z[_P!
M74?_  %?_"C_ (1O7?\ H"ZC_P" K_X5]$T4>P7</[$I_P [/G;_ (1O7?\
MH"ZC_P" K_X4?\(WKO\ T!=1_P# 5_\ "OHFBCV"[A_8E/\ G9\[?\(WKO\
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M=HH]AYA_8?\ T\_#_@GS%17T[11[#S#^P_\ IY^'_!/F*BOIVBCV'F']A_\
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M0 45FZOK^E:#"DNIWL=NKG" Y+-]%&2?P%)H_B'2=>21M,O4G,?WUP59?JK
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MP)<7NI:7=ZS>3S.NH74DMO%(Y(BA!PH4'IT/Z5U5)JPPHHHI %%%% !1110
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M1AY 6'!'!(Z@\XKUBVLK2SMA;6MK#!;C.(HHPJ\]>!QS2PV=M;6@M(+:&*V
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M*],?6/"NIV$8)DE@;RP.[#E1^8%8$MM-XV^%$-K921)<W%O"A,S$*KQNNX'
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M1M/TR[C6YTH@QO<9VR<#.<9QR >_I7=T4^9A8HZ2-4&GI_;#6C7I)+_9 PC
MSP!NYZ5>HHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 57O[ZWTVPGO;I]D$"&1VQG
M%6*KW]C;ZE83V5TF^"=#&ZYQD&@##\,>-](\62W$6G^>DL W-'.@4E<XW#!/
M'^-=)7-^&/!&D>$Y;B73_/>6<;6DG<,0N<[1@#C_  KI*;M?02\SDOB!=7FF
M:/9ZO9SSQBQO(I)TC<A98B<,K =1R*I_$G4K]='L;/1;F6*\O)&E22"0JQCC
MC+M@CGTKJM<TY=7T*^T]@#]H@:,9[,1P?P.#7GW@*\?Q'K5C+.C$:-I8M7##
MI,S%3GZHE4MK]A,W-8\32-\+O[8MI&6[N[9(XRG#"5\*<8Z$$D_A6-J]VOAW
MQOX6?4);B=H-.>-V :6260J5XZDDM6=I$;R:YI_@MP3'I>KS73 ]/)0;X_S+
MGBNGU@ _%SP[D XLYS^C4]@-O1/%5EK=[<6*VUY9WMNH=[:\B\M]IZ,!D\=/
MSJG=>.K"&\N;:UL-4U'[*VVXEL;;S$B8=03D<CVS4  'QB) '.@9/O\ Z167
MX UG3=%T"\T_5;Z"TO[6[E-REPX1F)/WL'KD>F:5EN%R?QSJ]GK?PHU"_P!/
MF\R"018/0@^<@(([&N@N_$%IHMAIR3I//=72!8+:W3?)*0H)P/;N2:\[N$)^
M#_B:[6)HK6]U,W-JK C]TTT07&>W!K4\11I%XO\ #US>ZC=:992Z>8%O('5-
MDG7!9@0 1BG;H%SL]'\2VFL7<]D+>[L[V!0[VUW%L?:>C#!((^AJ76=%765A
M4ZCJ-EY1)S97)B+9Q]['7I6%H6G:(/%)O+;Q)=:MJ4=J4*R7$<H2(L.I11CG
ML3WKL:AZ/09YEX5T6XUF[UV.Z\1>( MAJ,EM%LU!QE%/&?4UTU_XYTZQUF[T
MA;/4;J_MBF8+6 2,X9=V5YZ 8SG'48S6?\/_ /D(>+?^PU/_ #HT$#_A:_BQ
ML#(AM0#_ -LUJGN[B1L:AXLMK">.V33M4O+IHEF:"TM2[1J>F[) !Z\9[4MO
MXNTRZ\-76NP^>;:U#^=&4Q(C+U4@GKR._>LG5?$.H3>*[G1+74K#2(;6!)7N
M;I-[2[AGY0648'>N8TN4S>!O'<GVI;H/<3/YZ)L60E1\X7MGK1RA<ZL?$C1O
M+AN#:ZD+"1E0WQMOW",>Q;/;H< BM?5_$MKI-W;V?V>[O;R=3(EO9QAWV#JQ
MR0 /QKEM<51\#8@% ']FVIQCO^[-6=:@TN:\TV9?$":-KMM9*T4KE=KQ-D88
M-\K#(/ .1^5%D%V=#+XDLK70&UB_CN;"!,AH[J+;(#G &WG)/;%5]*\60:K?
MI9G2]5LI)$+Q&\MMBR >A!/ZXKB=3UN\UKP9H^L:@B/!8:W&;IX4.R:)"1Y@
M]N<8KT.V\0Z->W<5I:ZG:W$\JETCAD#DJ.<\=/QI-6'<R-+\>Z=K-S%#86&I
MS[I/+D=+<%(#N(!D(/ .,]^/2H='UW2].\/Z[JD4NJ7%O:7\WG_:65W#C;D1
M\XV<C )]:@^%0 \(R$  F]F)]^17-V?_ "3+QK_V$[C_ -IT[*]A7.L/Q&T<
M+'.;74A8.X3[>;;]PK'L6SGKQD BJ_B/Q=>Z7XQT>QM['49;1Q,9T@MU?[5^
M[!7RR3D[2<G&/QK(U?Q%HUU\)4LK>[AENI+6&V2U4CS/-&T8V=>",Y_^M5_5
MV&D>(/ 4NH2K$EO%/#-*[ *KF%5&2?4T607.BU#Q78Z7IMG=WD%Y'-><067D
MYN&;NNT'J/K3=)\76.JZD=->UOK"^V>8MO?0^6SKZKR0?SK!U^^M+3Q_X<UF
MZN(O[*>WEBBN=P,:R$'G<.!D$#/^!IVIWMIKGQ%\.)I,T=R]B)Y;J:!MRQHR
M@ %AQR>,>_O18=R_/\0-,CO+VSAL=3N[JSE>.6&VMP[87J_7&WMS@\=*C/Q(
MT62T%S9V^HWT2Q^9.;6VW?9Q_P!-,D =#Z^M0>!0/^$A\8''/]IGG\ZB\!QI
M_P (3JHV+AKJZ#8'7M19"NSI[CQ'I=MH,>M/<9LI%5HV526<MT4#KD],54L?
M%UI=:G#I]S8ZAIUQ."8!>PA!+CDA2"><=C@UY]*DG_"K_"-V\MQ':6UZKW$L
M!^>)=[@.,@CCMQWKI8M/\/76KZ4[^,;W4KB.<2VL#7<4F6 ST5,@8'M1RH+G
M8:K<3VFCWUS:Q^9<16\DD28SN8*2!^)KA_"=E/X@TFUU>'QAJ3ZB2'N(A,&B
M0YY0P] *[V]O;?3K*6\NY/+MX5W2/@G:/7CFO,_&?_"-Q6J:YX;OX(M>>1/(
M&GR@M<$L,AD!]SGCKUS2CV&SN]7\26FD7<%F8+J[O9E+I;6D6]RHZL<D #ZF
MET?Q'8ZREUY:S6TUH<7%O=)Y<D61D%AG&,=\XKBM5C$7Q)9]5U:ZT=+O3XQ#
M<02K&K,I^9"S @<Y./IZU>BTG2Y+/Q-+I&N76KZG+IS02L\Z28)1M@RBCG@]
MS3LK"N7O^%D:/Y4ES]EU/^SU+*M]]E/D2,.P;/<\#( SZ5JMXIL4BT.0Q7&-
M9V_9QM7*[E##?SQP>V:XY?$NA+\(?LOVJ#[0=-:U^R@@R>;L*G*]1S\V>PYI
M-2F2QT#X>ZC<'9:6YMQ+(>B!HA@GVX-'*@N=Y>:U;6.LZ9I<J2F?4?-\EE V
MCRUW-N.<C@\8!JA?>+;2TU&:PMK'4-1N+< SK8P!Q%GD!B2!G'89-86I:SI^
MJ?$WPK!874=RUL+OS6B.Y5W0\#<.,_*>*R=)AM8O$?B2TU+Q'?:-<G49)TC2
MXCB26)N58;U.3CWZ8HY0N=I-XQTJ+PK)XB4S2V41 =43]XK%@NTJ2,$$BJD?
MC_27O;:%K?4([:ZD\JWOI+<K;RMT&&)SSZXKF?$%EI5E\)M>_LC49;^">[66
M2>1PVZ0RQAL$  CCMZFM;QX /!.F  8%U:X]J+(+LW]:\466B7<%FT%W>7TZ
MEX[6SB\R0J.K8R !P>_8UC:_XBTO4/!=W>W8UJP@BN%AE6%/)N4?*G'/&.14
M!O+;1_BS>RZG/';QWFGH+:68A5.TC<NX\9R,_P"14'Q(U2QU7X>7\FGW45S'
M%<QQ.\3;E# J2,]#P1TH2U0-G1ZYXOTWP_J,%C>)<M-<1F2,0Q[]V#@* #DL
M3T&*?HGBJRUN]N+%;:\L[VW4.]M>1>6^T]& R>.GYUB:P ?BYX=R <6<Y_1J
MF;Y/B^S!23_PC^<+U/[^E96'<=>?$33;6WN+J/3=5NK&WD,;WEO;J8MP.#@E
MAGGC.,5TNFWPU+3X;P6\]N)1N$5PH5UY[@$_7K7DVB2W-YX-_P"$>;6]!L;*
M9Y$:.YN"+N!3(24*' )Z\GUKUVUBC@LX(86W11QJJ'.<@# YHDD@3N34445(
MPHHHH **** "BBB@ HHHH HZQJUIH6E3ZC?.4MX0"Q R22<  >I)K/\ #'B[
M3/%MM--IQF5H&"R13*%9<]#P2,'![]JT-8TFTUW2I].OD+V\P 8 X((.00?4
M$5G^&/".F>$K::'3A,S3L&DEF8,S8Z#@ 8&3V[T]+"UN;U96O^(=.\-:?]MU
M*4I&6V(J+N9V] *U:\V^*O\ HVH^%M1G1FL+6])N#@D?>0@'\%:B*N[ ]$;?
M_"8P:MI.K16]IJ>GWD-A)<(+N#RFV[3AE.3WQ7!Z5%J]S\.KKQ,/%.LQWML[
M$(]VS1,%(XVGN<^OX5Z)J7B+1]5T35K73]1M[J8:?-*5A;=A=I')' ZCCK7"
M_#_P79>(_"23:A?ZF8/M#@V:7&V XQSMQU]\U:T0F=7I'CE4\&:1J6JQ7,]]
M>AT6&T@+O*48J2 .!T![=>*TM"\:Z;KNI3::D%[97\2[VMKV'RWQQVR?4<5A
M^-==N_"S:'HVCO;:9;7!,9NI8]R0JN!CGCODYKG?#4[S_&(-)K4>L,+9E-Y'
M"L:MA>@"\''J.M'*FKA<[%/B1H\UTT<%KJ4]LDODM?16VZ!6SCELY_2K.K>.
MM,TO5I-,2UU"_NX4WS)8V_F>4/5N1V(_.O.)-0C\&^3>>#_$L5_975P/^)4X
MW/S[=1T S@'IUK6\5+9:=K6IZ]HOB>/3-9B0?:K&4@^:P4':H/7.!V(SZ4<J
MN%S6\<3/?Z3HNL:;J^J6D=U<PP;+>=H04<G)*_WATK'UG5]7\,^)M0N8+Z^O
M+/3HK:U\B:8OO,D#!78="V]%)..<GUKT'PGJEUK7A;3]1O81%<3QY=0, X)
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MX0ZC9?\ "*II_P!JA^V>?(_D;QOV\<[>N/>O1:F6XUL%%%%2,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH-4LI8FE$(=+A&4R'HF0?O'TZT6 OT54M-4TZ_EDBL[^UN9(_P#6+#,KE/J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2(]8CC>3^QA(L4O1I@_IT) +''M[5I:'X&T>#3M*FO=+C&H06\)E'F$J)50
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
D% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>bdsx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-14T04:24:33.5987+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://biodesix.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:bdsx="http://biodesix.com/20211231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" namespace="http://xbrl.sec.gov/country/2021"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bdsx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets" id="Role_StatementBalanceSheets">
        <link:definition>100010 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" id="Role_StatementBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" id="Role_StatementStatementsOfOperations">
        <link:definition>100030 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" id="Role_StatementStatementsOfCashFlows">
        <link:definition>100060 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" id="Role_DisclosureOrganizationAndDescriptionOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" id="Role_DisclosureRecentAccountingPronouncements">
        <link:definition>100090 - Disclosure - Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinations" id="Role_DisclosureBusinessCombinations">
        <link:definition>100100 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue" id="Role_DisclosureFairValue">
        <link:definition>100110 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100120 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100130 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100140 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt" id="Role_DisclosureDebt">
        <link:definition>100150 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" id="Role_DisclosureConvertiblePreferredStock">
        <link:definition>100160 - Disclosure - Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock">
        <link:definition>100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity" id="Role_DisclosureEquity">
        <link:definition>100180 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" id="DisclosureRevenueAndAccountsReceivableCreditConcentration">
        <link:definition>100190 - Disclosure - Revenue and Accounts Receivable Credit Concentration</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation" id="Role_DisclosureShareBasedCompensation">
        <link:definition>100200 - Disclosure - Share Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1" id="DisclosureNetLossPerCommonShare1">
        <link:definition>100210 - Disclosure - Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100230 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100240 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" id="Role_DisclosureDefinedContribution401KPlan">
        <link:definition>100250 - Disclosure - Defined Contribution 401(k) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables" id="Role_DisclosureFairValueTables">
        <link:definition>100270 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100280 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100290 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100300 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables" id="Role_DisclosureDebtTables">
        <link:definition>100310 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables">
        <link:definition>100320 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationTables">
        <link:definition>100330 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" id="Role_DisclosureShareBasedCompensationTables">
        <link:definition>100340 - Disclosure - Share Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables" id="DisclosureNetLossPerCommonShareTables">
        <link:definition>100350 - Disclosure - Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100370 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Organization and Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" id="DisclosureRecentAccountingPronouncementsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Business Combinations - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" id="Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
        <link:definition>100420 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" id="Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails">
        <link:definition>100430 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" id="Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails">
        <link:definition>100440 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" id="Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails">
        <link:definition>100450 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" id="Role_DisclosureFairValueAdditionalInformationDetails">
        <link:definition>100460 - Disclosure - Fair Value - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" id="DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
        <link:definition>100470 - Disclosure - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
        <link:definition>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
        <link:definition>100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
        <link:definition>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
        <link:definition>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
        <link:definition>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" id="Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails">
        <link:definition>100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" id="Role_DisclosureDebtAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" id="Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
        <link:definition>100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" id="Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Convertible Preferred Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
        <link:definition>100580 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" id="Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
        <link:definition>100590 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" id="Role_DisclosureEquityAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
        <link:definition>100610 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" id="DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
        <link:definition>100630 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" id="Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Share Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100650 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" id="Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails">
        <link:definition>100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" id="Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails">
        <link:definition>100670 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" id="DisclosureNetLossPerCommonShareAdditionalInformationDetails">
        <link:definition>100680 - Disclosure - Net Loss per Common Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100690 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" id="DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
        <link:definition>100700 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" id="DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes">
        <link:definition>100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" id="Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail">
        <link:definition>100770 - Disclosure - Defined Contribution 401(k) Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100780 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessAbstract" name="OrganizationAndDescriptionOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AccruedClinicalTrialExpenseCurrent" name="AccruedClinicalTrialExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" name="AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" name="AdditionalTenantImprovementAllowancePerRentableSquareFeet" type="dtr-types:monetaryPerAreaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AdvanceDeposits" name="AdvanceDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" name="AreaOfLeasedPremisedObligatedToPayBaseRent" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BaseRentPerMonthFromCommencementDate" name="BaseRentPerMonthFromCommencementDate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" name="BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" name="BusinessAcquisitionContingentConsiderationNumberOfInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" name="BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationFinalPayment" name="BusinessCombinationContingentConsiderationFinalPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_BusinessCombinationContingentConsiderationShares" name="BusinessCombinationContingentConsiderationShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" name="ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_CommitmentSharesIssuableOnConditionalBasis" name="CommitmentSharesIssuableOnConditionalBasis" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentValueRights" name="ContingentValueRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ContingentValueRightsPercentage" name="ContingentValueRightsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentValueRightsShares" name="ContingentValueRightsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" name="ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ConversionOfPreferredStockIntoCommonStock" name="ConversionOfPreferredStockIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" name="ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" name="DebtInstrumentAdditionalInterestExpenseFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentBackEndFacilityFeePercentage" name="DebtInstrumentBackEndFacilityFeePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentInterestAddedToPrincipalValue" name="DebtInstrumentInterestAddedToPrincipalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DebtInstrumentMaturityDateExtended" name="DebtInstrumentMaturityDateExtended" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" name="DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" name="DebtInstrumentPercentageOfStatedInterestRatePaidInCash" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" name="DebtInstrumentPrepaymentPenaltyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" name="DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DescriptionOfOfferingPeriodUnderPlan" name="DescriptionOfOfferingPeriodUnderPlan" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" name="DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DirectCostsAndExpenses" name="DirectCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_DirectOfferingExpenses" name="DirectOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" name="FairValueMeasurementWithUnobservableInputsInterestExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" name="FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" name="FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_IncreaseToPutOptionLiability" name="IncreaseToPutOptionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" name="IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_InterestRateOnExtraAllowanceAmount" name="InterestRateOnExtraAllowanceAmount" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" name="LandlordContributionTowardsCostOfConstructionAndTenantImprovements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_LeaseAgreementNumberOfOptionsToExtend" name="LeaseAgreementNumberOfOptionsToExtend" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LeasedPropertyBuildingCapacity" name="LeasedPropertyBuildingCapacity" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LicenseAgreementExpiryDate" name="LicenseAgreementExpiryDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" name="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" name="MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MilestonePayment" name="MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_MinimumAnnualVolumePercentageThereafter" name="MinimumAnnualVolumePercentageThereafter" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_MinimumLiquidityRatioCovenant" name="MinimumLiquidityRatioCovenant" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" name="NetProceedsPercentageOfCashPaymentToCVRHolders" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfCancerTest" name="NumberOfCancerTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfCommercialBloodBasedTest" name="NumberOfCommercialBloodBasedTest" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" name="NumberOfEqualAnnualInstallmentsForAwardVesting" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" name="NumberOfPreferredStockConvertedIntoCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_NumberOfSARSCoV2Test" name="NumberOfSARSCoV2Test" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" name="OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PartialRepaymentsOfDebt" name="PartialRepaymentsOfDebt" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" name="PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PaymentsToAcquireOncimmune" name="PaymentsToAcquireOncimmune" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PayrollCostsExcludesCompensationOfEmployee" name="PayrollCostsExcludesCompensationOfEmployee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_PercentageForNonPayrollCosts" name="PercentageForNonPayrollCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfConversionPricePerShareOfCommonStock" name="PercentageOfConversionPricePerShareOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" name="PercentageOfConversionPricePerShareOfConvertiblePreferredStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" name="PercentageOfDevelopmentAndRegulatoryCosts" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" name="PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfFeePaymentsOnNetSales" name="PercentageOfFeePaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" name="PercentageOfFullyDilutedEquityForBonusAwarded" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" name="PercentageOfLicenseIncomeGeneratedFromLicensing" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfMinimumRevenueRequirement" name="PercentageOfMinimumRevenueRequirement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" name="PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" name="PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" name="PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" name="PercentageOfRoyaltyPaymentsOnNetRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" name="PercentageOfRoyaltyPaymentsOnNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" name="PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" name="PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PeriodOfEscalationsOfSales" name="PeriodOfEscalationsOfSales" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PrepaymentFeeWaivedAmount" name="PrepaymentFeeWaivedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PrimarySourcesOfRevenueDescription" name="PrimarySourcesOfRevenueDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockNet" name="ProceedsFromIssuanceOfCommonStockNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" name="ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" name="ProceedsFromIssuanceOfTermLoanAndNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_PurchaseAgreementTerm" name="PurchaseAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PutOptionLiabilityCurrent" name="PutOptionLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" name="ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" name="ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_RemainingEstimatedObligation" name="RemainingEstimatedObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_RentAfterFixedEscalationProvisions" name="RentAfterFixedEscalationProvisions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RevenueMilestone" name="RevenueMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_RevenueShareExpenses" name="RevenueShareExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" name="SaleOfStockSharesIssuedAsCommitmentFee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayShares" name="SaleOfStockStockIssuablePerDayShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SaleOfStockStockIssuablePerDayValue" name="SaleOfStockStockIssuablePerDayValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_SharesIssuedAsCommitmentFeeValue" name="SharesIssuedAsCommitmentFeeValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" name="SharesIssuedOrIssuableThresholdLimitDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_StockIssuableDuringPeriodValueCommittedShares" name="StockIssuableDuringPeriodValueCommittedShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" name="StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" name="TermOfRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" name="UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" name="UpperLimitOfEmployeeSalaryToReduceForgiveness" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" name="ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" name="YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DefinedContributionPlanNameExtensibleList" name="DefinedContributionPlanNameExtensibleList" type="xbrli:tokenItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" name="FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessLineItems" name="OrganizationAndDescriptionOfBusinessLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AtTheMoneyOfferingMember" name="AtTheMoneyOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" name="AugustTwoThousandAndNineteenConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_AVEOOncologyMember" name="AVEOOncologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BDX004Member" name="BDX004Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BioRadLicenseMember" name="BioRadLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_BonusToOptionsProgramMember" name="BonusToOptionsProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CARESActMember" name="CARESActMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CashCollateralizedMember" name="CashCollateralizedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CellCartaLicenseMember" name="CellCartaLicenseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" name="CentennialValleyPropertiesILlcLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CenturaHealthcareMember" name="CenturaHealthcareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CommonStockPurchaseAgreementMember" name="CommonStockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ContingentValueRightsMember" name="ContingentValueRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_COVID19DiagnosticTestRevenueMember" name="COVID19DiagnosticTestRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_CurrentPortionOfContingentConsiderationMember" name="CurrentPortionOfContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" name="DecemberTwoThousandAndNineteenConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DeferredRevenueMember" name="DeferredRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DiagnosticTestsMember" name="DiagnosticTestsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesMember" name="DirectCostsAndExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_FiclatuzumabMember" name="FiclatuzumabMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_IntegratedDiagnosticsIncMember" name="IntegratedDiagnosticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_JanssenResearchAndDevelopmentLLCMember" name="JanssenResearchAndDevelopmentLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LabcorpDdFormerlyCovanceMember" name="LabcorpDdFormerlyCovanceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LincolnParkMember" name="LincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LitigationClaimsAndAssessmentsMember" name="LitigationClaimsAndAssessmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LossMember" name="LossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_LungDiagnosticRevenueMember" name="LungDiagnosticRevenueMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" name="MarchTwoThousandAndTwentyConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_MedicareMember" name="MedicareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NotesPayable2018NotesMember" name="NotesPayable2018NotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_NSCLCPOCTrialMember" name="NSCLCPOCTrialMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OncimmuneLimitedMember" name="OncimmuneLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OptionsAndRestrictedStockUnitsMember" name="OptionsAndRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OptionsToPurchaseCommonStockMember" name="OptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OtherMember" name="OtherMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PerformanceConditionOptionsMember" name="PerformanceConditionOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_POCClinicalTrialsMember" name="POCClinicalTrialsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PPPLoanMember" name="PPPLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ProductLifeAndPatentLifeMember" name="ProductLifeAndPatentLifeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PurchasedTechnologyMember" name="PurchasedTechnologyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_PutOptionLiabilityMember" name="PutOptionLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RepurchaseMember" name="RepurchaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_RevenueShareAgreementMember" name="RevenueShareAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA1PreferredStockMember" name="SeriesA1PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA2PreferredStockMember" name="SeriesA2PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesA3PreferredStockMember" name="SeriesA3PreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesB1ConvertiblePreferredStockMember" name="SeriesB1ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" name="SeriesEConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" name="SeriesGConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ServiceConditionRSUsMember" name="ServiceConditionRSUsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SharesCommittedUnderESPPMember" name="SharesCommittedUnderESPPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TestingServicesMember" name="TestingServicesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TheBigTenConferenceMember" name="TheBigTenConferenceMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandAndSixteenPlanMember" name="TwoThousandAndSixteenPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandSixPlanMember" name="TwoThousandSixPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandTwentyEquityIncentivePlanMember" name="TwoThousandTwentyEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" name="TwoThousandTwentyOneTermLoanAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_TwoThousandTwentyOneTermLoanMember" name="TwoThousandTwentyOneTermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_WarrantLiabilityMember" name="WarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" name="ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" name="BasisOfPresentationAndEstimatesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_DirectCostsAndExpensesPolicyTextBlock" name="DirectCostsAndExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_InitialPublicOfferingIPOPolicyTextBlock" name="InitialPublicOfferingIPOPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_PutOptionLiabilityPolicyTextBlock" name="PutOptionLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" name="FairValueLiabilitiesMeasuredOnRecurringBasisTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_OrganizationAndDescriptionOfBusinessTable" name="OrganizationAndDescriptionOfBusinessTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" name="ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_AtTheMoneyOfferingPolicyTextBlock" name="AtTheMoneyOfferingPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="bdsx_WarrantsForConvertiblePreferredStockTextBlock" name="WarrantsForConvertiblePreferredStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>bdsx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-14T04:24:37.5296+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:label="bdsx_DebtInstrumentMaturityDateExtended"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsMember" xlink:label="bdsx_ContingentValueRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommonStockPurchaseAgreementMember" xlink:label="bdsx_CommonStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:label="bdsx_PercentageForNonPayrollCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityMember" xlink:label="bdsx_PutOptionLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:label="bdsx_IncreaseToPutOptionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PPPLoanMember" xlink:label="bdsx_PPPLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PartialRepaymentsOfDebt" xlink:label="bdsx_PartialRepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:label="us-gaap_InterestBearingDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReverseStockSplitPolicyTextBlock" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumLiquidityRatioCovenant" xlink:label="bdsx_MinimumLiquidityRatioCovenant"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMoneyOfferingPolicyTextBlock" xlink:label="bdsx_AtTheMoneyOfferingPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityPolicyTextBlock" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" xlink:label="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectOfferingExpenses" xlink:label="bdsx_DirectOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfMinimumRevenueRequirement" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrepaymentFeeWaivedAmount" xlink:label="bdsx_PrepaymentFeeWaivedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration by Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vehicles</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VehiclesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vehicles [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Arrangement Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase agreement term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchaseAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Testing services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Testing Services [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TestingServicesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Testing Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets research and experimentation tax carryforwards subject to expiration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and experimentation tax carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Covenant Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance deposits.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advance Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdvanceDeposits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Debt Instruments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Long-term Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Long term debt maturities repayments of principal in year five and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Diagnostic tests.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diagnostic Tests [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DiagnosticTestsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diagnostic Tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additional stock awards granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for grant under all plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, covenant compliance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCovenantCompliance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Covenant Compliance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value, 200,000,000 authorized; 30,789,649 (2021) and 26,561,504 (2020) shares issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessor, Operating Lease, Lease Not yet Commenced, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk&#8209;free rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities Of Long Term Debt [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bdx004.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">B D X004 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BDX004Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BDX004</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Issued1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesIssued1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of common stock allowed to purchase by counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage of Common Stock Allowed to Purchase by Counterparty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of common stock allowed to purchase by counterparty.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Payments To Acquire Businesses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to acquire license rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Income And Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price per share of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price Per Share Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price per share of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prior to Second Anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net change to contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity for Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument maturity date extended.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date Extended</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentMaturityDateExtended_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended debt instrument date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer discretionary contributions amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument prepayment penalty percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Penalty Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, prepayment penalty</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of put option liability to additional paid in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Put Option Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of put option liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Exercisable - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Six Years And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases future minimum payments due in six years and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable, net of allowance for doubtful accounts of $158 and $180</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Receivable, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Weighted Average Assumptions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum annual volume percentage thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Annual Volume Percentage Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum annual volume percentage thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities By Industry [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets after valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining estimated obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Estimated Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RemainingEstimatedObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining estimated obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease agreement number of options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease agreement number of options to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of depreciation and amortization expense related to property and equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense Related to Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets subject to amortization, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Finite-Lived Intangible Assets, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Finite-Lived Intangible Assets, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA2PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares of common stock issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Redemption, Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RoyaltyExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series F Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series F Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted Other Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents, and restricted cash &#8209; end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents, and restricted cash &#8209; beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Purchase Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommonStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock purchase agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Interest On Income Taxes Accrued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest related to uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non&#8209;current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Service-condition RSUs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service Condition R S Us [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ServiceConditionRSUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Service Condition R S Us</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock under employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of number of shares of common stock issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation related accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lung diagnostic revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lung Diagnostic Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LungDiagnosticRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lung Diagnostic Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary Of Significant Accounting Policies [Line Items].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upper limit of employee salary to reduce forgiveness.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upper limit of employee salary to reduce forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs exercised using opt-out right.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development and regulatory costs exercised using opt-out right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets subject to amortization, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finite-Lived Intangible Assets, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued legal contingency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Accrual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Loss Contingency Accrual, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Loss Contingency Accrual, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series C Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Year of ending royalty payments from first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Year Of Ending Royalty Payments From First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Year of ending royalty payments from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments for proceeds from patent costs and intangible asset acquisition, net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Patent costs and intangible asset acquisition, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series E convertible preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">August two thousand and nineteen convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">August Two Thousand And Nineteen Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August 2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued or issuable, threshold limit description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued or Issuable, Threshold Limit Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued or issuable, threshold limit description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">March two thousand and twenty convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">March Two Thousand And Twenty Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">March 2020 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment of Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, maturity date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Effective income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unamortized debt discount and debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Reclassified To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassified to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of valuation allowance equal to net deferred tax assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of valuation allowance equal to net deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Share Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion Converted Instrument Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue share expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Share Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RevenueShareExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue share expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bonus-to-options program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bonus To Options Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BonusToOptionsProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bonus-To-Options Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bio-rad license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bio Rad License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BioRadLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bio-Rad License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding - December 31, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding - January 1, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: current maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write-off of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Write off of Deferred Debt Issuance Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument frequency of periodic payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Landlord contribution towards cost of construction and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Landlord contribution towards cost of construction and tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basis of Presentation and Estimates.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Estimates Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument converted to common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LabCorp DD (formerly Covance)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">LabCorp DD formerly Covance [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">LabCorp DD (formerly Covance).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to settlements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimate of Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage for non-payroll costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage For Non Payroll Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageForNonPayrollCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage for non-payroll costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for initial public offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Initial Public Offering I P O Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering ("IPO")</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and developments credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to the current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ficlatuzumab.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ficlatuzumab [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiclatuzumabMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ficlatuzumab</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 diagnostic test revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Diagnostic Test Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Test Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of put option recorded at issuance of convertible notes payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value Of Put Option Recorded At Issuance Of Convertible Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Value of put option recorded at issuance of convertible debt payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total consideration amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2021 and 2020) issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Classified As Equity Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration estimated fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of cancer test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Cancer Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCancerTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of blood based lung cancer test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision For Doubtful Accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for doubtful accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, Marketing, General and Administrative Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisaggregationOfRevenueLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disaggregation Of Revenue [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration arrangements common shares redemption amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration arrangements, common shares, redemption amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series G convertible preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2006 Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining life of outstanding performance condition options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal balance outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Annual Principal Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Offering Expenses Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and offering expenses payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, percentage of stated interest rate added to principal value of notes payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate added to principal value of notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Contractual Life (Years), Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Put option liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put Option Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase to put option liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase To Put Option Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IncreaseToPutOptionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase to put option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Net Of Cash Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Businesses, Net of Cash Acquired, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash collateral account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Collateral for Borrowed Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited/canceled, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PPPLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">PPP loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PPPLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P P P Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PPPLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">PPP Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Outstanding - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant, exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PartialRepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Partial repayments of debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PartialRepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Partial repayments of debt.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentrations of Credit Risk and Other Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Asset Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-lived intangible asset, useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Payments For Other Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestBearingDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Bearing Deposits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestBearingDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest-bearing Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Examination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax examination details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price,Outstanding - December, 31, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Outstanding - January 1, 2020, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Explanation Of Change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance, deferred tax asset, explanation of change</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Stock Options, Outstanding - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Stock Options, Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of outstanding stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of outstanding stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series H Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesHPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series H Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Final settlement payment to third parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration number of installments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Number Of Installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration number of installments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets subject to amortization, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial blood based test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Commercial Blood Based Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfCommercialBloodBasedTest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial blood-based test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Intrinsic Value, Outstanding - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Aggregate Intrinsic Value, Outstanding - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Aggregate Intrinsic Value, Outstanding - January 1, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intrinsic value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leased property building capacity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LeasedPropertyBuildingCapacity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Leased property building capacity.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Remaining Discount Amortization Period1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early amortization of loan payment schedule</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DeferredRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of warrant liability to additional paid-in-capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Warrant Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of warrant liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-The-Market Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenues, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration final payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Final Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business combination contingent consideration final payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Assets And Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other long-term assets and liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one term loan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Term Loan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of term loan and notes payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Term Loan And Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from term loan and notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OtherMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of tax credit carryforward expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock and convertible notes payable converted to common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock and convertible notes payable converted into shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for reverse stock split.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration gross margin target period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Gross Margin Target Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upper limit of employee salary to reduce forgiveness.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upper Limit Of Employee Salary To Reduce Forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upper limit of employee salary to reduce forgiveness</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value measurement with unobservable inputs interest expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest, amortization of debt issuance costs and other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Interest Amortization Of Debt Issuance Costs And Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued interest, amortization of debt issuance costs and other.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Deductions From Total Cost To Investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discounts and commission</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Portion Of Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Portion of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued as Commitment Fee, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued as commitment fee, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about liabilities measured at fair value on recurring basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of preferred stock converted into common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Preferred Stock Converted Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of preferred stock converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at December 31</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at January 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance condition options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Condition Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PerformanceConditionOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance Condition Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Notes payable 2018 notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable2018 Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NotesPayable2018NotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of term loan and notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Long-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series E Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series E Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct costs and expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Inventory Supplies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherInventorySupplies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock&#8209;based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fee payments on net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fee Payments On Net Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fee payments on net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Voting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockVotingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, voting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment, useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CARES act.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C A R E S Act [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CARESActMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock may be issued under incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of license income generated from licensing.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of License Income Generated From Licensing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of license income generated from licensing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in value of the warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid&#8209;in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution 401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indefinite lived intangible assets excluding goodwill gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of contingent consideration excluding accretion expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Contingent Consideration Excluding Accretion Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development and regulatory costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development And Regulatory Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Responsible percentage of development and regulatory costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and restricted stock units.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options And Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, percentage of stated interest rate, paid in cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Percentage Of Stated Interest Rate Paid In Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of interest rate, paid in cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability reclassified from non-current liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Reclassified From Non Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reclassified from non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of offering period under plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Offering Period Under Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of offering period under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loss [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of fully diluted equity for bonus awarded.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Fully Diluted Equity For Bonus Awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fully diluted equity for bonus awarded</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of SARS-CoV-2 test.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of S A R S Co V2 Test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfSARSCoV2Test_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of SARS-CoV-2 test</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Goodwill Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Base rent per month from commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Base rent per month from commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization expense related to definite-lived intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reported Fair values of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Poc clinical trials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">P O C Clinical Trials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_POCClinicalTrialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">POC Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets not subject to amortization, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired From Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition contingent consideration gross margin target</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-3 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A3 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA3PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A3 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Notes payable, total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock&#8209;based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll costs excludes compensation of an employee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll Costs Excludes Compensation Of Employee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll costs excludes compensation of an employee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Carrying Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan principle amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Notes/Loan payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2016 Plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Sixteen Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandAndSixteenPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2016 Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Description Of Acquired Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business acquisition description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants for convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants For Convertible Preferred Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Exercisable - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Long-term notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term notes payable, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Notes Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash and cash equivalents and restricted cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of earnings used for purchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Service [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServiceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of voting power or value of stock for employee participation in offering period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of voting power or value of stock for employee participation in offering period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalty payments not required to pay on net revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalty Payments Not Required To Pay On Net Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalty payments not required on net revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allowance For Doubtful Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for doubtful accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accounts Receivable, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accounts Receivable, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Stock Options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, number of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, stock issuable per day, shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds percentage of cash payment to the cvr holders.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds Percentage Of Cash Payment To C V R Holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds percentage of cash payment to the CVR holders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit subject to contingent reduction over the term of the lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Line of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LineOfCredit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Line of Credit, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Convertible Conversion Price1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Centennial Valley Properties I, LLC Lease Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Centennial Valley Properties I, LLC Lease Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumLiquidityRatioCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum liquidity ratio covenant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumLiquidityRatioCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Liquidity Ratio Covenant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MinimumLiquidityRatioCovenant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum liquidity ratio covenant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Money Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Money Offering [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the money offering policy text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of fair market value of common stock for purchase under plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and other accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Maturities Of Long Term Debt Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scheduled Principal Repayments (Maturities) of Long-term Obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Units Total Cost To Investors</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term of royalty payments from first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Of Royalty Payments From First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term of royalty payments from first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets and liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2020 equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of performance-condition options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Centura Healthcare.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Centura Healthcare [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CenturaHealthcareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Centura Healthcare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue and Accounts Receivable Credit Concentration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent after fixed escalation provisions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RentAfterFixedEscalationProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rent after fixed escalation provisions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants, expires period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put Option Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for put-option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions related to a lapse of statute</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Pre-tax Share-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes Payable To Bank Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NotesPayableToBankCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current portion of notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expenses [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, Marketing, General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Sales, Marketing, General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncurrent Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Long-term Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After Second Anniversary, Prior to October 19, 2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ContingentValueRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent value rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense limitation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Contingent Consideration and Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable and Allowance for Doubtful Accounts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reported Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Money Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At-the-Money Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AtTheMoneyOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At-the-Money Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Collateralized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CashCollateralizedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash collateralized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense Related To Distribution Or Servicing And Underwriting Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lincoln Park</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lincoln Park Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LincolnParkMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lincoln Park.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">CellCarta License.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cell Carta License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CellCartaLicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CellCarta License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of RSUs granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fair value of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Not Settleable In Cash Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated air value of warrants issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant issued to purchase shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Description of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The Big Ten Conference.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">The Big Ten Conference [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TheBigTenConferenceMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The Big Ten Conference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, Net Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized remaining stock based compensation balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product life and patent life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Life And Patent Life [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProductLifeAndPatentLifeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product Life and Patent Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairments loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Estimated Amortization Expense of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of escalations of sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Escalations Of Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PeriodOfEscalationsOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of escalations of sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation permanent items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments to acquire Oncimmune.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Oncimmune</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PaymentsToAcquireOncimmune_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments to acquire Oncimmune assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B-1 Convertible Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B1 Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B1 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common stock net.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement expiry date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Expiry Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LicenseAgreementExpiryDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License expiry date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuances of convertible notes payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series G Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesGPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series G Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Janssen Research and Development, LLC.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Janssen Research And Development L L C [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Janssen Research and Development, LLC</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Debt, Maturity, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument interest added to principal value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Added To Principal Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest added to principal value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Debt instrument description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instruments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on debt extinguishments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on debt extinguishments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Gain (loss) on debt extinguishment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and description of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Description Of Business [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements And Changes In Accounting Principles [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Finite lived intangible assets amortization expense year six and thereafter.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Future Amortization Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument additional interest expense fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Additional Interest Expense Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, additional interest expense fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_RepurchaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Extra allowance amount per rentable square feet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvement allowance per rentable square feet</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Warrant Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Weighted average exercise price, Forfeited/canceled, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration risk, percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of accumulated amortization of intangible assets, excluding goodwill.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Accumulated Amortization Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets, Accumulated Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt into common stock upon initial public offering, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest rate on extra allowance amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate on extra allowance amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling General And Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales, marketing, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct costs and expenses policy.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Costs And Expenses Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct Costs and Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inventory Supplies Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InventorySuppliesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of equal annual installments for award vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Equal Annual Installments For Award Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of equal annual installments for award vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Equity financing costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Fee Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Facility fee amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Securities Industry [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquitySecuritiesIndustryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Industry Sector</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Committed Under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Committed Under E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SharesCommittedUnderESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares committed under ESPP.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Intangible Assets, Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Amortization Expense Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary Equity Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary Equity Balance, Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Claims and Assessments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Claims And Assessments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Litigation claims and assessments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Redemption, Period Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash debt issuance costs included in Accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Direct offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Direct Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DirectOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Direct offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aveo oncology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">A V E O Oncology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AVEOOncologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AVEO Oncology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Integrated Diagnostics, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Integrated Diagnostics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_IntegratedDiagnosticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Integrated Diagnostics, Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited/canceled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Debt Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Debt, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Gross Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Gross (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination contingent consideration shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Name Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan Name [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitment shares issuable on conditional basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitment Shares Issuable on Conditional Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitment shares issuable on conditional basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Dividends, Common Stock, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total pre-tax share-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for approval of amended and restated certificate of incorporation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Approval Of Amended And Restated Certificate Of Incorporation Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Approval of Amended and Restated Certificate of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">December two thousand and nineteen convertible notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">December Two Thousand And Nineteen Convertible Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 2019 Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of leased premised obligated to pay base rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of leased premised obligated to pay base rent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuable per day, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Stock Issuable Per Day, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of Stock, stock issuable per day, value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Prior to First Anniversary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Redemption Period One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trial expense current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trial Expense Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical trial expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollateralDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collateral Held [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of conversion price per share of convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Conversion Price Per Share Of Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of conversion price per share of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series D Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series D Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reductions for tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from sale of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued as commitment fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Shares Issued as Commitment Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock, shares issued as commitment fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of warrant liability to additional paid-in capital, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Note Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of preferred stock into common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Preferred Stock Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Up-front Payment Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UpFrontPaymentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Up Front Cash Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Primary sources of revenue, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Primary Sources Of Revenue Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrimarySourcesOfRevenueDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Primary sources of revenue description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Maturities Repayments Of Principal In Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchased technology.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchased Technology [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PurchasedTechnologyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchased Technology</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Patents [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PatentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Put option liability current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Put Option Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Put option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PutOptionLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated value of put option liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders' Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Common Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Nsclc poc trial.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">N S C L C P O C Trial [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_NSCLCPOCTrialMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NSCLC POC Trial</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Noncurrent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non&#8209;current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable, committed to purchase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issuable During Period, Value, Committed Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issuable during period, value, committed shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Term Loan Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Term Loan Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Twenty One Term Loan Amendment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible debt into common stock upon initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible notes and accrued interest into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised, warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other (expense) income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Standards Not Yet Adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of minimum revenue requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Minimum Revenue Requirement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of minimum revenue requirement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trademarks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TrademarksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trademarks</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Recurring</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentFeeWaivedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayment fee waived amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_PrepaymentFeeWaivedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayment fee waived amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Discount Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of convertible notes debt discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Medicare.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Medicare [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_MedicareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Medicare</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-1 preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A1 Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_SeriesA1PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-1 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Oncimmune Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Oncimmune Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_OncimmuneLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Oncimmune Limited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument back-end facility fee percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Back End Facility Fee Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, back-end facility fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value of Outstanding Borrowings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from the sale of common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from the issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesMember" xlink:to="bdsx_DirectCostsAndExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchaseAgreementTerm" xlink:to="bdsx_PurchaseAgreementTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TestingServicesMember" xlink:to="bdsx_TestingServicesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantDescription" xlink:to="us-gaap_DebtInstrumentCovenantDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdvanceDeposits" xlink:to="bdsx_AdvanceDeposits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DiagnosticTestsMember" xlink:to="bdsx_DiagnosticTestsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCovenantCompliance" xlink:to="us-gaap_DebtInstrumentCovenantCompliance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:to="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_MaturitiesOfLongTermDebtAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BDX004Member" xlink:to="bdsx_BDX004Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesIssued1" xlink:to="us-gaap_NotesIssued1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPaymentsToAcquireBusinesses" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentMaturityDateExtended" xlink:to="bdsx_DebtInstrumentMaturityDateExtended_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SecondAmendmentMember" xlink:to="bdsx_SecondAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:to="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumAnnualVolumePercentageThereafter" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RemainingEstimatedObligation" xlink:to="bdsx_RemainingEstimatedObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA2PreferredStockMember" xlink:to="bdsx_SeriesA2PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsMember" xlink:to="bdsx_ContingentValueRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommonStockPurchaseAgreementMember" xlink:to="bdsx_CommonStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueMilestone" xlink:to="bdsx_RevenueMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ServiceConditionRSUsMember" xlink:to="bdsx_ServiceConditionRSUsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LungDiagnosticRevenueMember" xlink:to="bdsx_LungDiagnosticRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeaseCommencementDate" xlink:to="bdsx_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareAgreementMember" xlink:to="bdsx_RevenueShareAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentRate" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RevenueShareExpenses" xlink:to="bdsx_RevenueShareExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BonusToOptionsProgramMember" xlink:to="bdsx_BonusToOptionsProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BioRadLicenseMember" xlink:to="bdsx_BioRadLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentMember" xlink:to="us-gaap_PropertyPlantAndEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LabcorpDdFormerlyCovanceMember" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageForNonPayrollCosts" xlink:to="bdsx_PercentageForNonPayrollCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:to="bdsx_InitialPublicOfferingIPOPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiclatuzumabMember" xlink:to="bdsx_FiclatuzumabMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_COVID19DiagnosticTestRevenueMember" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:to="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCancerTest" xlink:to="bdsx_NumberOfCancerTest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsShares" xlink:to="bdsx_ContingentValueRightsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanMember" xlink:to="bdsx_TwoThousandSixPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationPolicyTextBlock" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityMember" xlink:to="bdsx_PutOptionLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IncreaseToPutOptionLiability" xlink:to="bdsx_IncreaseToPutOptionLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCollateralForBorrowedSecurities" xlink:to="us-gaap_CashCollateralForBorrowedSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PPPLoanMember" xlink:to="bdsx_PPPLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PartialRepaymentsOfDebt" xlink:to="bdsx_PartialRepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestBearingDepositsMember" xlink:to="us-gaap_InterestBearingDepositsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesHPreferredStockMember" xlink:to="us-gaap_SeriesHPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfCommercialBloodBasedTest" xlink:to="bdsx_NumberOfCommercialBloodBasedTest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LeasedPropertyBuildingCapacity" xlink:to="bdsx_LeasedPropertyBuildingCapacity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DeferredRevenueMember" xlink:to="bdsx_DeferredRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMarketOfferingMember" xlink:to="bdsx_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ClassOfStockDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyOneTermLoanMember" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OtherMember" xlink:to="bdsx_OtherMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardDescription" xlink:to="us-gaap_TaxCreditCarryforwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ReverseStockSplitPolicyTextBlock" xlink:to="bdsx_ReverseStockSplitPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CurrentPortionOfContingentConsiderationMember" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesIssuedAsCommitmentFeeValue" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PerformanceConditionOptionsMember" xlink:to="bdsx_PerformanceConditionOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NotesPayable2018NotesMember" xlink:to="bdsx_NotesPayable2018NotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpenses" xlink:to="bdsx_DirectCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherInventorySupplies" xlink:to="us-gaap_OtherInventorySupplies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFeePaymentsOnNetSales" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockVotingRights" xlink:to="us-gaap_CommonStockVotingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CARESActMember" xlink:to="bdsx_CARESActMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityPolicyTextBlock" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsAndRestrictedStockUnitsMember" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LossMember" xlink:to="bdsx_LossMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfSARSCoV2Test" xlink:to="bdsx_NumberOfSARSCoV2Test_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BaseRentPerMonthFromCommencementDate" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentConsiderationMember" xlink:to="bdsx_ContingentConsiderationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_POCClinicalTrialsMember" xlink:to="bdsx_POCClinicalTrialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA3PreferredStockMember" xlink:to="bdsx_SeriesA3PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantLiabilityMember" xlink:to="bdsx_WarrantLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandAndSixteenPlanMember" xlink:to="bdsx_TwoThousandAndSixteenPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRightsPercentage" xlink:to="bdsx_ContingentValueRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayShares" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MinimumLiquidityRatioCovenant" xlink:to="bdsx_MinimumLiquidityRatioCovenant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMoneyOfferingPolicyTextBlock" xlink:to="bdsx_AtTheMoneyOfferingPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CenturaHealthcareMember" xlink:to="bdsx_CenturaHealthcareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RentAfterFixedEscalationProvisions" xlink:to="bdsx_RentAfterFixedEscalationProvisions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityPolicyTextBlock" xlink:to="bdsx_PutOptionLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableToBankCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ContingentValueRights" xlink:to="bdsx_ContingentValueRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MilestonePayment" xlink:to="bdsx_MilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OptionsToPurchaseCommonStockMember" xlink:to="bdsx_OptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AtTheMoneyOfferingMember" xlink:to="bdsx_AtTheMoneyOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CashCollateralizedMember" xlink:to="bdsx_CashCollateralizedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LincolnParkMember" xlink:to="bdsx_LincolnParkMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CellCartaLicenseMember" xlink:to="bdsx_CellCartaLicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TheBigTenConferenceMember" xlink:to="bdsx_TheBigTenConferenceMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProductLifeAndPatentLifeMember" xlink:to="bdsx_ProductLifeAndPatentLifeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PeriodOfEscalationsOfSales" xlink:to="bdsx_PeriodOfEscalationsOfSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PaymentsToAcquireOncimmune" xlink:to="bdsx_PaymentsToAcquireOncimmune_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LicenseAgreementExpiryDate" xlink:to="bdsx_LicenseAgreementExpiryDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesGPreferredStockMember" xlink:to="us-gaap_SeriesGPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_RepurchaseMember" xlink:to="bdsx_RepurchaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" xlink:to="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_InterestRateOnExtraAllowanceAmount" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventorySuppliesPolicy" xlink:to="us-gaap_InventorySuppliesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="us-gaap_EquitySecuritiesIndustryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SharesCommittedUnderESPPMember" xlink:to="bdsx_SharesCommittedUnderESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtFairValue" xlink:to="us-gaap_LongTermDebtFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_LitigationClaimsAndAssessmentsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DirectOfferingExpenses" xlink:to="bdsx_DirectOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AVEOOncologyMember" xlink:to="bdsx_AVEOOncologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_IntegratedDiagnosticsIncMember" xlink:to="bdsx_IntegratedDiagnosticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_BusinessCombinationContingentConsiderationShares" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DefinedContributionPlanNameExtensibleList" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:to="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockStockIssuablePerDayValue" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_AccruedClinicalTrialExpenseCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralDomain" xlink:to="us-gaap_CollateralDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:to="bdsx_ConversionOfPreferredStockIntoCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UpFrontPaymentArrangementMember" xlink:to="us-gaap_UpFrontPaymentArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrimarySourcesOfRevenueDescription" xlink:to="bdsx_PrimarySourcesOfRevenueDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PurchasedTechnologyMember" xlink:to="bdsx_PurchasedTechnologyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PutOptionLiabilityCurrent" xlink:to="bdsx_PutOptionLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_NSCLCPOCTrialMember" xlink:to="bdsx_NSCLCPOCTrialMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" xlink:to="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PercentageOfMinimumRevenueRequirement" xlink:to="bdsx_PercentageOfMinimumRevenueRequirement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_PrepaymentFeeWaivedAmount" xlink:to="bdsx_PrepaymentFeeWaivedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_MedicareMember" xlink:to="bdsx_MedicareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_SeriesA1PreferredStockMember" xlink:to="bdsx_SeriesA1PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_OncimmuneLimitedMember" xlink:to="bdsx_OncimmuneLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>bdsx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-14T04:24:38.3065+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="bdsx-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20211231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebtFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityMember" xlink:label="bdsx_PutOptionLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsMember" xlink:label="bdsx_ContingentValueRightsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PPPLoanMember" xlink:label="bdsx_PPPLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:label="us-gaap_InterestBearingDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PPPLoanMember" xlink:label="bdsx_PPPLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumLiquidityRatioCovenant" xlink:label="bdsx_MinimumLiquidityRatioCovenant"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfMinimumRevenueRequirement" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PartialRepaymentsOfDebt" xlink:label="bdsx_PartialRepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrepaymentFeeWaivedAmount" xlink:label="bdsx_PrepaymentFeeWaivedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:label="bdsx_PercentageForNonPayrollCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:label="bdsx_DebtInstrumentMaturityDateExtended"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:label="bdsx_IncreaseToPutOptionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InterestBearingDepositsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_InvestmentTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_RevenueMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumLiquidityRatioCovenant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfMinimumRevenueRequirement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashCollateralForBorrowedSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PartialRepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentFeeWaivedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageForNonPayrollCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentMaturityDateExtended" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseToPutOptionLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectOfferingExpenses" xlink:label="bdsx_DirectOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DirectOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_DisaggregationOfRevenueTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommonStockPurchaseAgreementMember" xlink:label="bdsx_CommonStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" xlink:label="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralDomain" xlink:to="bdsx_CashCollateralizedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CommonStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_PurchaseAgreementTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CollateralAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>bdsx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-14T04:24:38.0900+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="bdsx-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="bdsx-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:href="bdsx-20211231.xsd#Role_StatementBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="bdsx-20211231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="bdsx-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="bdsx-20211231.xsd#StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="bdsx-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:href="bdsx-20211231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="bdsx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" xlink:href="bdsx-20211231.xsd#Role_DisclosureRecentAccountingPronouncements" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:href="bdsx-20211231.xsd#Role_DisclosureBusinessCombinations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValue" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:href="bdsx-20211231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:href="bdsx-20211231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebt" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:href="bdsx-20211231.xsd#Role_DisclosureConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity" xlink:href="bdsx-20211231.xsd#Role_DisclosureEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="bdsx-20211231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="bdsx-20211231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:href="bdsx-20211231.xsd#Role_DisclosureDefinedContribution401KPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="bdsx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:href="bdsx-20211231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="bdsx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureFairValueAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20211231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:href="bdsx-20211231.xsd#DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:href="bdsx-20211231.xsd#DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" xlink:href="bdsx-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:href="bdsx-20211231.xsd#Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="bdsx-20211231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableToBankCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_DirectCostsAndExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" xlink:label="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_17"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_18"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_19"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_20"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_17" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_20" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" xlink:label="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsTotalCostToInvestors" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ConversionOfPreferredStockIntoCommonStock" xlink:label="bdsx_ConversionOfPreferredStockIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" xlink:label="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" xlink:label="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ConversionOfPreferredStockIntoCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinations" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantsForConvertiblePreferredStockTextBlock" xlink:label="bdsx_WarrantsForConvertiblePreferredStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="bdsx_WarrantsForConvertiblePreferredStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ReverseStockSplitPolicyTextBlock" xlink:label="bdsx_ReverseStockSplitPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" xlink:label="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_InitialPublicOfferingIPOPolicyTextBlock" xlink:label="bdsx_InitialPublicOfferingIPOPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" xlink:label="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesPolicyTextBlock" xlink:label="bdsx_DirectCostsAndExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventorySuppliesPolicy" xlink:label="us-gaap_InventorySuppliesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationPolicyTextBlock" xlink:label="bdsx_ContingentConsiderationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantLiabilityPolicyTextBlock" xlink:label="bdsx_WarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityPolicyTextBlock" xlink:label="bdsx_PutOptionLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMoneyOfferingPolicyTextBlock" xlink:label="bdsx_AtTheMoneyOfferingPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ReverseStockSplitPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_InitialPublicOfferingIPOPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_DirectCostsAndExpensesPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventorySuppliesPolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_ContingentConsiderationPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_WarrantLiabilityPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_PutOptionLiabilityPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_AtTheMoneyOfferingPolicyTextBlock" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" xlink:label="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtInstrumentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessTable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:label="bdsx_OrganizationAndDescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCancerTest" xlink:label="bdsx_NumberOfCancerTest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfCommercialBloodBasedTest" xlink:label="bdsx_NumberOfCommercialBloodBasedTest"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMoneyOfferingMember" xlink:label="bdsx_AtTheMoneyOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfSARSCoV2Test" xlink:label="bdsx_NumberOfSARSCoV2Test"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" xlink:label="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessAbstract" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCancerTest" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfCommercialBloodBasedTest" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMoneyOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessTable" xlink:to="bdsx_OrganizationAndDescriptionOfBusinessLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_NumberOfSARSCoV2Test" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_OrganizationAndDescriptionOfBusinessLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="bdsx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TestingServicesMember" xlink:label="bdsx_TestingServicesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProductLifeAndPatentLifeMember" xlink:label="bdsx_ProductLifeAndPatentLifeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherInventorySupplies" xlink:label="us-gaap_OtherInventorySupplies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_TestingServicesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_ProductLifeAndPatentLifeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OtherInventorySupplies" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPaymentsToAcquireBusinesses" xlink:label="us-gaap_OtherPaymentsToAcquireBusinesses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:label="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_StatementGeographicalAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_OtherPaymentsToAcquireBusinesses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="us-gaap_LongTermDebtFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_LongTermDebtFairValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_CarryingReportedAmountFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CurrentPortionOfContingentConsiderationMember" xlink:label="bdsx_CurrentPortionOfContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:label="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_CurrentPortionOfContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable" xlink:to="bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentConsiderationMember" xlink:label="bdsx_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityMember" xlink:label="bdsx_PutOptionLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_WarrantLiabilityMember" xlink:label="bdsx_WarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsMember" xlink:label="bdsx_ContingentValueRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" xlink:label="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentConsiderationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_PutOptionLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_WarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="bdsx_ContingentValueRightsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LossMember" xlink:label="bdsx_LossMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" xlink:label="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember" xlink:label="us-gaap_OperatingExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RepurchaseMember" xlink:label="bdsx_RepurchaseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" xlink:label="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationFinalPayment" xlink:label="bdsx_BusinessCombinationContingentConsiderationFinalPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" xlink:label="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsShares" xlink:label="bdsx_ContingentValueRightsShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRights" xlink:label="bdsx_ContingentValueRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContingentValueRightsPercentage" xlink:label="bdsx_ContingentValueRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" xlink:label="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="bdsx_LossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OperatingExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="bdsx_RepurchaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_InterestExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationFinalPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_CounterpartyNameAxis" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRights" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_ContingentValueRightsPercentage" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="bdsx_MilestonePayment" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableMember" xlink:label="us-gaap_AccountsPayableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_AccountsPayableMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchasedTechnologyMember" xlink:label="bdsx_PurchasedTechnologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" xlink:label="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_TrademarksMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_PurchasedTechnologyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="us-gaap_DebtInstrumentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PPPLoanMember" xlink:label="bdsx_PPPLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OtherMember" xlink:label="bdsx_OtherMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_OtherMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermNotesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CARESActMember" xlink:label="bdsx_CARESActMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestBearingDepositsMember" xlink:label="us-gaap_InterestBearingDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" xlink:label="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" xlink:label="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" xlink:label="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SecondAmendmentMember" xlink:label="bdsx_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NotesPayable2018NotesMember" xlink:label="bdsx_NotesPayable2018NotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodFourMember" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodFourMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PPPLoanMember" xlink:label="bdsx_PPPLoanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" xlink:label="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentInterestAddedToPrincipalValue" xlink:label="bdsx_DebtInstrumentInterestAddedToPrincipalValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueMilestone" xlink:label="bdsx_RevenueMilestone"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentPrepaymentPenaltyPercentage" xlink:label="bdsx_DebtInstrumentPrepaymentPenaltyPercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumLiquidityRatioCovenant" xlink:label="bdsx_MinimumLiquidityRatioCovenant"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfMinimumRevenueRequirement" xlink:label="bdsx_PercentageOfMinimumRevenueRequirement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantDescription" xlink:label="us-gaap_DebtInstrumentCovenantDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCovenantCompliance" xlink:label="us-gaap_DebtInstrumentCovenantCompliance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MilestonePayment" xlink:label="bdsx_MilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PartialRepaymentsOfDebt" xlink:label="bdsx_PartialRepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrepaymentFeeWaivedAmount" xlink:label="bdsx_PrepaymentFeeWaivedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:label="us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentBackEndFacilityFeePercentage" xlink:label="bdsx_DebtInstrumentBackEndFacilityFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" xlink:label="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" xlink:label="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="us-gaap_DebtInstrumentDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PayrollCostsExcludesCompensationOfEmployee" xlink:label="bdsx_PayrollCostsExcludesCompensationOfEmployee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageForNonPayrollCosts" xlink:label="bdsx_PercentageForNonPayrollCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" xlink:label="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesIssued1" xlink:label="us-gaap_NotesIssued1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DebtInstrumentMaturityDateExtended" xlink:label="bdsx_DebtInstrumentMaturityDateExtended"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentRate" xlink:label="us-gaap_DebtConversionConvertedInstrumentRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfCommonStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PutOptionLiabilityCurrent" xlink:label="bdsx_PutOptionLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" xlink:label="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IncreaseToPutOptionLiability" xlink:label="bdsx_IncreaseToPutOptionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="bdsx_CARESActMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InterestBearingDepositsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_TwoThousandTwentyOneTermLoanAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_SecondAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_NotesPayable2018NotesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="bdsx_PPPLoanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_InvestmentTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentInterestAddedToPrincipalValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_RevenueMilestone" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentPrepaymentPenaltyPercentage" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MinimumLiquidityRatioCovenant" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfMinimumRevenueRequirement" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantDescription" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCovenantCompliance" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashCollateralForBorrowedSecurities" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_MilestonePayment" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PartialRepaymentsOfDebt" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PrepaymentFeeWaivedAmount" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WriteOffOfDeferredDebtIssuanceCost" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentBackEndFacilityFeePercentage" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescription" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PayrollCostsExcludesCompensationOfEmployee" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageForNonPayrollCosts" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesIssued1" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_DebtInstrumentMaturityDateExtended" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentRate" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfCommonStock" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PutOptionLiabilityCurrent" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="bdsx_IncreaseToPutOptionLiability" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:label="us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="us-gaap_LongTermDebt" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA1PreferredStockMember" xlink:label="bdsx_SeriesA1PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA2PreferredStockMember" xlink:label="bdsx_SeriesA2PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfPreferredStockConvertedIntoCommonStock" xlink:label="bdsx_NumberOfPreferredStockConvertedIntoCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesA3PreferredStockMember" xlink:label="bdsx_SeriesA3PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesEPreferredStockMember" xlink:label="us-gaap_SeriesEPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="us-gaap_SeriesFPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesGPreferredStockMember" xlink:label="us-gaap_SeriesGPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesHPreferredStockMember" xlink:label="us-gaap_SeriesHPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesB1ConvertiblePreferredStockMember" xlink:label="bdsx_SeriesB1ConvertiblePreferredStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA1PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA2PreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_NumberOfPreferredStockConvertedIntoCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesA3PreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesGPreferredStockMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesHPreferredStockMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="bdsx_SeriesB1ConvertiblePreferredStockMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesEConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesEConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" xlink:label="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesEConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SeriesGConvertiblePreferredStockWarrantsMember" xlink:label="bdsx_SeriesGConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="bdsx_SeriesGConvertiblePreferredStockWarrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDisclosuresAbstract" xlink:label="us-gaap_ClassOfStockDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AtTheMarketOfferingMember" xlink:label="bdsx_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="us-gaap_CommonStockVotingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" xlink:label="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectOfferingExpenses" xlink:label="bdsx_DirectOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockNet" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockNet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" xlink:label="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="bdsx_AtTheMarketOfferingMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockVotingRights" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_DirectOfferingExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DiagnosticTestsMember" xlink:label="bdsx_DiagnosticTestsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_DiagnosticTestsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_Revenues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="us-gaap_DisaggregationOfRevenueTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="us-gaap_DeferredRevenueArrangementTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UpFrontPaymentArrangementMember" xlink:label="us-gaap_UpFrontPaymentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PrimarySourcesOfRevenueDescription" xlink:label="bdsx_PrimarySourcesOfRevenueDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DeferredRevenueMember" xlink:label="bdsx_DeferredRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_COVID19DiagnosticTestRevenueMember" xlink:label="bdsx_COVID19DiagnosticTestRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LungDiagnosticRevenueMember" xlink:label="bdsx_LungDiagnosticRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdvanceDeposits" xlink:label="bdsx_AdvanceDeposits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" xlink:label="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeDomain" xlink:to="us-gaap_UpFrontPaymentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_PrimarySourcesOfRevenueDescription" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="bdsx_DeferredRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_COVID19DiagnosticTestRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherNoncurrentLiabilitiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_LungDiagnosticRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_AdvanceDeposits" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="srt_MajorCustomersAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisaggregationOfRevenueTable" xlink:to="us-gaap_DisaggregationOfRevenueLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TheBigTenConferenceMember" xlink:label="bdsx_TheBigTenConferenceMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CenturaHealthcareMember" xlink:label="bdsx_CenturaHealthcareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MedicareMember" xlink:label="bdsx_MedicareMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_JanssenResearchAndDevelopmentLLCMember" xlink:label="bdsx_JanssenResearchAndDevelopmentLLCMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LabcorpDdFormerlyCovanceMember" xlink:label="bdsx_LabcorpDdFormerlyCovanceMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_TheBigTenConferenceMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_CenturaHealthcareMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_MedicareMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_JanssenResearchAndDevelopmentLLCMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="bdsx_LabcorpDdFormerlyCovanceMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PerformanceConditionOptionsMember" xlink:label="bdsx_PerformanceConditionOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanMember" xlink:label="bdsx_TwoThousandSixPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandAndSixteenPlanMember" xlink:label="bdsx_TwoThousandAndSixteenPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" xlink:label="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsAndRestrictedStockUnitsMember" xlink:label="bdsx_OptionsAndRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" xlink:label="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ServiceConditionRSUsMember" xlink:label="bdsx_ServiceConditionRSUsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DescriptionOfOfferingPeriodUnderPlan" xlink:label="bdsx_DescriptionOfOfferingPeriodUnderPlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" xlink:label="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" xlink:label="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsCommonStock" xlink:label="us-gaap_DividendsCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_PerformanceConditionOptionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_EmployeeStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandTwentyEquityIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandAndSixteenPlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_OptionsAndRestrictedStockUnitsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_ServiceConditionRSUsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_DescriptionOfOfferingPeriodUnderPlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_PercentageOfFullyDilutedEquityForBonusAwarded" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_DividendsCommonStock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BonusToOptionsProgramMember" xlink:label="bdsx_BonusToOptionsProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" xlink:label="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="bdsx_BonusToOptionsProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpensesMember" xlink:label="bdsx_DirectCostsAndExpensesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="bdsx_DirectCostsAndExpensesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntegratedDiagnosticsIncMember" xlink:label="bdsx_IntegratedDiagnosticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" xlink:label="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BusinessCombinationContingentConsiderationShares" xlink:label="bdsx_BusinessCombinationContingentConsiderationShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_IntegratedDiagnosticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="bdsx_BusinessCombinationContingentConsiderationShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OptionsToPurchaseCommonStockMember" xlink:label="bdsx_OptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesCommittedUnderESPPMember" xlink:label="bdsx_SharesCommittedUnderESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_OptionsToPurchaseCommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bdsx_SharesCommittedUnderESPPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" xlink:label="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="us-gaap_TaxCreditCarryforwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" xlink:label="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_TaxCreditCarryforwardDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_6"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OncimmuneLimitedMember" xlink:label="bdsx_OncimmuneLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BDX004Member" xlink:label="bdsx_BDX004Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="us-gaap_EquitySecuritiesIndustryMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiclatuzumabMember" xlink:label="bdsx_FiclatuzumabMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AVEOOncologyMember" xlink:label="bdsx_AVEOOncologyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_NSCLCPOCTrialMember" xlink:label="bdsx_NSCLCPOCTrialMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareAgreementMember" xlink:label="bdsx_RevenueShareAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCosts" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCosts"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LitigationClaimsAndAssessmentsMember" xlink:label="bdsx_LitigationClaimsAndAssessmentsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_POCClinicalTrialsMember" xlink:label="bdsx_POCClinicalTrialsMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" xlink:label="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BioRadLicenseMember" xlink:label="bdsx_BioRadLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CellCartaLicenseMember" xlink:label="bdsx_CellCartaLicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RemainingEstimatedObligation" xlink:label="bdsx_RemainingEstimatedObligation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetSales" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" xlink:label="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" xlink:label="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LicenseAgreementExpiryDate" xlink:label="bdsx_LicenseAgreementExpiryDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfFeePaymentsOnNetSales" xlink:label="bdsx_PercentageOfFeePaymentsOnNetSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" xlink:label="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" xlink:label="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MinimumAnnualVolumePercentageThereafter" xlink:label="bdsx_MinimumAnnualVolumePercentageThereafter"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PeriodOfEscalationsOfSales" xlink:label="bdsx_PeriodOfEscalationsOfSales"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RevenueShareExpenses" xlink:label="bdsx_RevenueShareExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="bdsx_OncimmuneLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="bdsx_BDX004Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="us-gaap_EquitySecuritiesIndustryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquitySecuritiesIndustryMember" xlink:to="bdsx_FiclatuzumabMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_AVEOOncologyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_NSCLCPOCTrialMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_RevenueShareAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_LitigationClaimsAndAssessmentsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_POCClinicalTrialsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_EquitySecuritiesByIndustryAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_BioRadLicenseMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="bdsx_CellCartaLicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RemainingEstimatedObligation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetSales" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_LicenseAgreementExpiryDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfFeePaymentsOnNetSales" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_MinimumAnnualVolumePercentageThereafter" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_PeriodOfEscalationsOfSales" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="bdsx_RevenueShareExpenses" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyAccrualAtCarryingValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DefinedContributionPlanNameExtensibleList" xlink:label="bdsx_DefinedContributionPlanNameExtensibleList"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="bdsx_DefinedContributionPlanNameExtensibleList" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LincolnParkMember" xlink:label="bdsx_LincolnParkMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommonStockPurchaseAgreementMember" xlink:label="bdsx_CommonStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralDomain" xlink:label="us-gaap_CollateralDomain"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CashCollateralizedMember" xlink:label="bdsx_CashCollateralizedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollateralAxis" xlink:label="us-gaap_CollateralAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_StockIssuableDuringPeriodValueCommittedShares" xlink:label="bdsx_StockIssuableDuringPeriodValueCommittedShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" xlink:label="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PurchaseAgreementTerm" xlink:label="bdsx_PurchaseAgreementTerm"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayShares" xlink:label="bdsx_SaleOfStockStockIssuablePerDayShares"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockStockIssuablePerDayValue" xlink:label="bdsx_SaleOfStockStockIssuablePerDayValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedOrIssuableThresholdLimitDescription" xlink:label="bdsx_SharesIssuedOrIssuableThresholdLimitDescription"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" xlink:label="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SaleOfStockSharesIssuedAsCommitmentFee" xlink:label="bdsx_SaleOfStockSharesIssuedAsCommitmentFee"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_SharesIssuedAsCommitmentFeeValue" xlink:label="bdsx_SharesIssuedAsCommitmentFeeValue"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_CommitmentSharesIssuableOnConditionalBasis" xlink:label="bdsx_CommitmentSharesIssuableOnConditionalBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" xlink:label="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseCommencementDate" xlink:label="bdsx_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeaseAgreementNumberOfOptionsToExtend" xlink:label="bdsx_LeaseAgreementNumberOfOptionsToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LeasedPropertyBuildingCapacity" xlink:label="bdsx_LeasedPropertyBuildingCapacity"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_BaseRentPerMonthFromCommencementDate" xlink:label="bdsx_BaseRentPerMonthFromCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_RentAfterFixedEscalationProvisions" xlink:label="bdsx_RentAfterFixedEscalationProvisions"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" xlink:label="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" xlink:label="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" xlink:label="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_InterestRateOnExtraAllowanceAmount" xlink:label="bdsx_InterestRateOnExtraAllowanceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="bdsx_LincolnParkMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CommonStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralDomain" xlink:to="bdsx_CashCollateralizedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralAxis" xlink:to="us-gaap_CollateralDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_StockIssuableDuringPeriodValueCommittedShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_PurchaseAgreementTerm" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockStockIssuablePerDayValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CreditFacilityAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SharesIssuedOrIssuableThresholdLimitDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CollateralAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SaleOfStockSharesIssuedAsCommitmentFee" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_SharesIssuedAsCommitmentFeeValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_CommitmentSharesIssuableOnConditionalBasis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeaseCommencementDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeaseAgreementNumberOfOptionsToExtend" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LeasedPropertyBuildingCapacity" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_BaseRentPerMonthFromCommencementDate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_RentAfterFixedEscalationProvisions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="bdsx_InterestRateOnExtraAllowanceAmount" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_LineOfCredit" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>bdsx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-14T04:24:38.4782+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets" xlink:href="bdsx-20211231.xsd#Role_StatementBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations" xlink:href="bdsx-20211231.xsd#Role_StatementStatementsOfOperations" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows" xlink:href="bdsx-20211231.xsd#Role_StatementStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:href="bdsx-20211231.xsd#DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="bdsx-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" xlink:href="bdsx-20211231.xsd#DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LongTermNotesPayable" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_Goodwill" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableToBankCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableToBankCurrent" xlink:label="us-gaap_NotesPayableToBankCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_DirectCostsAndExpenses" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_DirectCostsAndExpenses" xlink:label="bdsx_DirectCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense" xlink:label="bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="bdsx_PaymentsToAcquireOncimmune" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" order="14" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="16" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet" xlink:label="bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan" xlink:label="bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_PaymentsToAcquireOncimmune" xlink:label="bdsx_PaymentsToAcquireOncimmune"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable" xlink:label="bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther" xlink:label="bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill" xlink:label="bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter" xlink:label="bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="bdsx_AccruedClinicalTrialExpenseCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_AccruedClinicalTrialExpenseCurrent" xlink:label="bdsx_AccruedClinicalTrialExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_LongTermNotesPayable" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter" xlink:label="bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="bdsx-20211231.xsd#bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter" xlink:label="bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681294248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001439725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biodesix, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-3986492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2970 Wilderness Place<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">417-0500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BDSX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,307,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Denver, CO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Portions of the Company&#8217;s definitive Proxy Statement for its 2022 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681716984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 32,712<span></span>
</td>
<td class="nump">$ 62,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $158 and $180</a></td>
<td class="nump">3,656<span></span>
</td>
<td class="nump">15,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,245<span></span>
</td>
<td class="nump">8,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">43,613<span></span>
</td>
<td class="nump">86,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non&#8209;current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">11,617<span></span>
</td>
<td class="nump">13,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">15,031<span></span>
</td>
<td class="nump">15,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,657<span></span>
</td>
<td class="nump">3,461<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non&#8209;current assets</a></td>
<td class="nump">32,484<span></span>
</td>
<td class="nump">34,930<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">76,097<span></span>
</td>
<td class="nump">121,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,662<span></span>
</td>
<td class="nump">8,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">7,665<span></span>
</td>
<td class="nump">7,789<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">3,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current portion of contingent consideration</a></td>
<td class="nump">17,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableToBankCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">11,840<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">28,960<span></span>
</td>
<td class="nump">32,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non&#8209;current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable, net of current portion</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="nump">15,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">16,028<span></span>
</td>
<td class="nump">29,932<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">1,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non&#8209;current liabilities</a></td>
<td class="nump">27,410<span></span>
</td>
<td class="nump">47,779<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">56,370<span></span>
</td>
<td class="nump">79,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2021 and 2020) issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 200,000,000 authorized; 30,789,649 (2021) and 26,561,504 (2020) shares issued and outstanding</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid&#8209;in capital</a></td>
<td class="nump">321,669<span></span>
</td>
<td class="nump">299,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(301,973)<span></span>
</td>
<td class="num">(258,814)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">19,727<span></span>
</td>
<td class="nump">41,166<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 76,097<span></span>
</td>
<td class="nump">$ 121,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1),20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685455896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 158<span></span>
</td>
<td class="nump">$ 180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">30,789,649<span></span>
</td>
<td class="nump">26,561,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">30,789,649<span></span>
</td>
<td class="nump">26,561,504<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298775931288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 54,506<span></span>
</td>
<td class="nump">$ 45,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectCostsAndExpenses', window );">Direct costs and expenses</a></td>
<td class="nump">30,518<span></span>
</td>
<td class="nump">21,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">12,789<span></span>
</td>
<td class="nump">10,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, marketing, general and administrative</a></td>
<td class="nump">50,517<span></span>
</td>
<td class="nump">34,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense', window );">Change in fair value of contingent consideration</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">95,446<span></span>
</td>
<td class="nump">68,491<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(40,940)<span></span>
</td>
<td class="num">(22,934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(4,508)<span></span>
</td>
<td class="num">(7,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,252)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishments, net</a></td>
<td class="nump">2,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other (expense) income, net</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">440<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(2,219)<span></span>
</td>
<td class="num">(8,416)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (43,159)<span></span>
</td>
<td class="num">$ (31,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (6.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">27,365<span></span>
</td>
<td class="nump">4,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of contingent consideration excluding accretion expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680702776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="num">$ (225,139)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 2,324<span></span>
</td>
<td class="num">$ (227,464)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary Equity Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118,766,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary Equity Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 193,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">63,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">63,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering</a></td>
<td class="nump">193,959<span></span>
</td>
<td class="num">$ (193,959)<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">193,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(118,766,000)<span></span>
</td>
<td class="nump">20,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Conversion of convertible debt into common stock upon initial public offering</a></td>
<td class="nump">26,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">26,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock', window );">Conversion of convertible debt into common stock upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,848,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering</a></td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">368,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8209;based compensation</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,350)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">41,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">299,953<span></span>
</td>
<td class="num">(258,814)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,562,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="nump">15,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">15,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,757,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock&#8209;based compensation</a></td>
<td class="nump">$ 4,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(43,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,159)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2021</a></td>
<td class="nump">$ 19,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 321,669<span></span>
</td>
<td class="num">$ (301,973)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Common Stock Balance, Shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123466103&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684749736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors', window );">Discounts and commission</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsTotalCostToInvestors', window );">Direct offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deductions from cost to investors of capital shares or other capital units for fees, loads and other charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost to investors of each class of capital shares or other capital units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680838856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (43,159)<span></span>
</td>
<td class="num">$ (31,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,178<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of convertible notes debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishments, net</a></td>
<td class="num">(2,298)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock&#8209;based compensation expense</a></td>
<td class="nump">4,944<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in contingent consideration</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther', window );">Accrued interest, amortization of debt issuance costs and other</a></td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">11,454<span></span>
</td>
<td class="num">(10,308)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">1,369<span></span>
</td>
<td class="num">(6,588)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other long-term assets and liabilities</a></td>
<td class="nump">875<span></span>
</td>
<td class="num">(1,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="num">(7,425)<span></span>
</td>
<td class="nump">11,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,682)<span></span>
</td>
<td class="nump">2,249<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash and cash equivalents and restricted cash used in operating activities</a></td>
<td class="num">(28,223)<span></span>
</td>
<td class="num">(21,366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(2,241)<span></span>
</td>
<td class="num">(1,945)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet', window );">Patent costs and intangible asset acquisition, net</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PaymentsToAcquireOncimmune', window );">Payments to acquire Oncimmune assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash and cash equivalents and restricted cash used in investing activities</a></td>
<td class="num">(2,547)<span></span>
</td>
<td class="num">(2,927)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock</a></td>
<td class="nump">16,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">1,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuances of convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable', window );">Proceeds from term loan and notes payable</a></td>
<td class="nump">30,078<span></span>
</td>
<td class="nump">3,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan and notes payable</a></td>
<td class="num">(45,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment of debt issuance costs</a></td>
<td class="num">(164)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Equity financing costs</a></td>
<td class="num">(664)<span></span>
</td>
<td class="num">(8,243)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash and cash equivalents and restricted cash provided by financing activities</a></td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">81,131<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents and restricted cash</a></td>
<td class="num">(29,508)<span></span>
</td>
<td class="nump">56,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; beginning of period</a></td>
<td class="nump">62,306<span></span>
</td>
<td class="nump">5,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash &#8209; end of period</a></td>
<td class="nump">32,798<span></span>
</td>
<td class="nump">62,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ConversionOfPreferredStockIntoCommonStock', window );">Conversion of preferred stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible notes and accrued interest into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital', window );">Reclassification of put option liability to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable', window );">Value of put option recorded at issuance of convertible debt payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,676<span></span>
</td>
<td class="nump">1,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital', window );">Reclassification of warrant liability to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Non-cash debt issuance costs included in Accrued liabilities</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued interest, amortization of debt issuance costs and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ConversionOfPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ConversionOfPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for proceeds from patent costs and intangible asset acquisition, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PaymentsToAcquireOncimmune">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to acquire Oncimmune.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PaymentsToAcquireOncimmune</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of term loan and notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of put option liability to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to additional paid-in-capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of put option recorded at issuance of convertible notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685161144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract', window );"><strong>Organization And Description Of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 1 &#8211; Organization and Description of Business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biodesix, Inc. (the &#8220;Company&#8221;, &#8220;Biodesix&#8221;, &#8220;we&#8221; &#8220;us&#8221; and &#8220;our&#8221;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#8217;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) granted Emergency Use Authorization (EUA) of the Bio-Rad SARS-CoV-2 Droplet Digital&#153; polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Blood-Based Lung Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company offers </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> blood-based lung cancer tests across the lung cancer continuum of care:</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Diagnosis</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify XL2&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nodify CDT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#174; tests, together marketed as part of our Nodify Lung</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.</span></div></div><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Treatment &amp; Monitoring</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat ddPCR&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">VeriStrat&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">tests, </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">marketed as part of our new IQLung&#153; testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#8217;s immune system to establish the patient&#8217;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GeneStrat NGS&#153; (NGS) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, our 72-hour blood-based NGS test, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner. The GeneStrat NGS test is marketed as part of the new IQ Lung testing strategy with the GeneStrat ddPCR and VeriStrat tests.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Tests</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We operate and have commercialized the Biodesix WorkSafe&#153; testing program, under which the Company offers </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> SARS-CoV-2 tests:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bio-Rad SARS-CoV-2 ddPCR </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, which is authorized by the FDA to be performed by Clinical Laboratory Improvement Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Platelia SARS-CoV-2 Total Ab </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">cPass&#153; SARS-CoV-2 Neutralization Antibody </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">test</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or a previous SARS-CoV-2 infection. This test was commercially introduced during the second quarter 2021 in partnership with GenScript Biotech Corporation.</span></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#8217;s testing services are made available through its clinical laboratories.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2020, the Company completed its initial public offering (IPO), in which it issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the IPO, all shares of the Company&#8217;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,939,025</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, and all then outstanding warrants to purchase the Company&#8217;s Series G convertible preferred stock were automatically converted into warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock.</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">At-the-Money Offering</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685331384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 2 &#8211; Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we maintained cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and we have $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in principal balance outstanding on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan (see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Note 8 &#8211; Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balance. We have taken steps to improve our liquidity through raising debt and equity capital during 2021, amendments to our 2021 Term Loan and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiation with certain creditors to modify existing terms of arrangement to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bede26c1-bcbf-4c97-9e63-739d552d824e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#8217;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 11 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These expenses consist principally of salaries, bonuses, employee benefits, travel, stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million restricted cash, respectively, which was included in &#8216;Other current assets&#8217; in the accompanying balance sheets.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expenses'. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_407518a8-f622-40ce-9fc1-00bcdbe09352;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accumulated impairment losses.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.823%;"/>
        <td style="width:2.083%;"/>
        <td style="width:86.094%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 4 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for further discussion related to estimated fair value measurements.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the completion of the Company&#8217;s IPO in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#8217;s IPO in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Put Option Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020 and 2019, the Company issued convertible debt with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an IPO. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate. The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our IPO, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share&#8209;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service-condition RSUs. As a result of our IPO, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 12 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information related to share-based compensation.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until the Company&#8217;s IPO in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#8217;s losses. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685166984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>New Accounting Pronouncements And Changes In Accounting Principles [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 3 &#8211; Recent Accounting Pronouncements</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current analysis we expect the adoption to result in the recognition of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_edabff51-0ce4-48c5-96f3-64ef856b5af6;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">right of use assets</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and associated lease liabilities, inclusive of both lease and non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685289560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 4 - Fair Value</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recurring Fair Value Measurements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, based on interest rates currently available for similar borrowings and were (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.854%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.611%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.331%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.331%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.925%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our IPO in October 2020, the warrant liability, put option liability and contingent value rights granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:13.765%;"/>
        <td style="width:0.677%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:12.708%;"/>
        <td style="width:0.677%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,764</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,028</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in contingent consideration for the year ended December 31, 2021 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.082%;"/>
        <td style="width:1.892%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.837%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,622</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,238</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,792</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:10.338%;"/>
        <td style="width:0.909%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.975%;"/>
        <td style="width:0.918%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.975%;"/>
        <td style="width:0.918%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:9.356%;"/>
        <td style="width:0.918%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the Year Ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Put<br/>Option<br/>Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrant<br/>Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br/>Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,114</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,261</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">818</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,252</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassified to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,624</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (Indi APA). The contingent consideration arrangement </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. Under the terms of the agreement, when the gross margin target was met the Company was required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. For the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in cash over </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eight</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal quarterly installments. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal and consecutive quarterly cash installments totaling $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company met the gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make six quarterly installments of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million beginning in January 2022 and a final payment of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in July 2023 for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to make these payments are subject to consent from our lender under the 2021 Term Loan and related amendments (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">). We obtained consent and subsequently made the first milestone payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in January 2022 and we are in discussions with our lender to obtain consents for future payments.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#8216;Current portion of contingent consideration&#8217; while the remaining amount to be paid is recorded as &#8216;Contingent consideration&#8217; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule. The net change to contingent consideration recorded as operating expenses during the years ended December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was a loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The amount recorded as &#8216;Interest expense&#8217; during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Put Option Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#8217;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#8217;s IPO in October 2020 and reclassified to additional paid-in capital.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrant Liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613,333</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series G convertible preferred stock, at an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.75</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 23, 2028</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The estimated fair value of the warrant on the issuance date of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#8217;s IPO, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#8217;s IPO, the preferred stock warrants were automatically converted to warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,326</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.46</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and were also transferred to additional paid-in capital. During 2020, the Company recorded an increase in the value of the warrant liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Value Rights</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#8209;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> CVRs originally valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. One CVR represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.00375</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#8217;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 15 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Commitments and Contingencies</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for a discussion of the Co-Development Agreement with AVEO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Non-Financial Assets and Liabilities</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685348632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 5 &#8211; Property and Equipment</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.837%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.837%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,784</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,730</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,339</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,845</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">700</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">871</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">391</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">651</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vehicles</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">381</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,928</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,724</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.781%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.839%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.829%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">614</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">361</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">614</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">478</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,228</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">839</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685383208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 6 &#8211; Goodwill and Intangible Assets</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.774%;"/>
        <td style="width:1.039%;"/>
        <td style="width:1.197%;"/>
        <td style="width:5.936%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.234%;"/>
        <td style="width:9.47%;"/>
        <td style="width:0.798%;"/>
        <td style="width:0.835%;"/>
        <td style="width:1.197%;"/>
        <td style="width:6.382%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.197%;"/>
        <td style="width:5.936%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.197%;"/>
        <td style="width:9.591%;"/>
        <td style="width:0.798%;"/>
        <td style="width:0.714%;"/>
        <td style="width:1.197%;"/>
        <td style="width:6.382%;"/>
        <td style="width:0.733%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">566</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,474</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,138</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,617</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,448</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.583%;"/>
        <td style="width:2.152%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.457%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.832%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,051</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,064</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future estimated amortization expense of intangible assets is (in thousands):</span></p>
    <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
     <tr style="visibility:collapse;">
      <td style="width:77.393%;"/>
      <td style="width:1.874%;"/>
      <td style="width:1.206%;"/>
      <td style="width:18.924%;"/>
      <td style="width:0.603%;"/>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of <br/>December 31, 2021</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,975</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,969</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,959</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,954</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,941</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,719</span></p></td>
      <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
     <tr style="height:10.0pt;">
      <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,517</span></p></td>
      <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
     </tr>
    </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685297560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 7 &#8211; Accrued Liabilities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.784%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.832%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.832%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,029</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,975</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">870</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,099</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,665</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,789</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685399224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 8 &#8211; Debt</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our long-term debt consists of notes payable associated with our 2021 Term Loan, 2018 Notes and Paycheck Protection Program, each of which is described in further detail below. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable were as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.308%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.386%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.755%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 Notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,972</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Paycheck Protection Program</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,107</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,840</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,993</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,926</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Term Loan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan provides for an &#8220;interest-only&#8221; period from the Effective Date through February 28, 2023, with interest due and payable </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">monthly</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s final payment, due at maturity on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 1, 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, shall include all outstanding principal and accrued and unpaid interest, lender fees and expenses, of which the majority will include a final payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and all other sums, if any, that shall have become due and payable hereunder with respect to the 2021 Term Loan. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million final payment will be amortized as interest expense over the term of the 2021 Term Loan. The Company has the option to prepay, prior to maturity, the total outstanding principal amount plus accrued and unpaid interest, subject to a prepayment penalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid prior to the first anniversary of the Effective Date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid on or after the first anniversary but prior to the second anniversary of the Effective Date, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the principal amount if paid on or after the second anniversary but prior to October 19, 2025, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% thereafter.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company granted the Lender a security interest in substantially all of the Company&#8217;s assets. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.95</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s projected revenue performed at the end of each reporting p</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">eriod.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (First Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three month period ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the benefit of our lender if the balance of our cash and cash equivalents declines below $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million January 2022 milestone payment under the Indi APA, repay $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in outstanding principal on December 31, 2021, waive the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> prepayment fee on the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million Term Loan repayment</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement to not less </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% for the three months ended March 31, 2022 and not less than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on a trailing six month rolling basis for each quarter thereafter of the Company&#8217;s projected revenue performed at the end of each reporting period</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Lender agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially prepay the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in outstanding principal, thereby eliminating the restricted cash collateral account. The Company recorded a loss on extinguishment of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million resulting from the write-off of debt issuance costs associated with the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million repayment of our 2021 Term Loan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Term Loan contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. Failure to comply with the covenants and loan requirements may result in an event of default. As of December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company was in compliance with all restrictive and financial covenants associated with its borrowings.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property without charge.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Notes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2018, the Company issued long-term debt of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes). Innovatus is also a holder of the Company&#8217;s common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the time of issuance, the Company paid a facility fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued a warrant to Innovatus, with an initial estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, for the purchase of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613,333</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes. The 2018 Notes bore annual interest at </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%, of which </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% was payable in cash, with the remaining </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% added to principal through December 31, 2020. Total interest added to principal was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of March 31, 2021 and December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 19, 2021, in connection with entering into the 2021 Term Loan agreement with SVB, the Company repaid all outstanding principal, accrued and unpaid interest, and prepayment fees in the amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due under the 2018 Notes and contemporaneously terminated the related Loan and Security Agreement, dated as of February 23, 2018, as amended, between Innovatus and the Company. As a result of the extinguishment of the 2018 Notes, the Company recognized a loss on debt extinguishment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the three months ended March 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Paycheck Protection Program Note Payable</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The PPP Loan had a maturity date on the two-year anniversary of the funding date, April 2022, and included a fixed rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), were scheduled to commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the </span></span><span style=""/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pay any facility charge to obtain the PPP Loan.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Note and Agreement contained customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All or a portion of the PPP Loan may be forgiven by the SBA upon application by the Company. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, prorated annually. Not more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or less annually are reduced by more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. During the second quarter of 2021, the Company determined that it would apply for forgiveness under the SBA&#8217;s Loan Forgiveness program, a change from its previous intent to repay. Subsequently, in July 2021 the Company applied for loan forgiveness and on August 17, 2021, the Company received legal release and formal notification that the PPP Loan was forgiven in full. During the three months ended September 30, 2021, the Company reduced the &#8216;Current portion of notes payable&#8217; and recorded a gain on extinguishment in the statements of operations for the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million forgiven.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.397%;"/>
        <td style="width:1.911%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.883%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,017</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,818</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,206</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,075</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298770233352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_WarrantsForConvertiblePreferredStockTextBlock', window );">Warrants to Purchase Convertible Preferred Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 9 &#8211; Warrants to Pur</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">chase Convertible Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. Through the closing of the Company&#8217;s IPO, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.005%;"/>
        <td style="width:1.196%;"/>
        <td style="width:0.983%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.196%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.163%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.196%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.19%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series E</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series G </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The warrants to purchase Series E convertible preferred stock were not exercised and expired during the three months ended June 2020.</span></p><div style="font-size:6.7pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our IPO, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants to purchase common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which have an expiration date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 23, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All common stock warrants remain outstanding as of December 31, 2021.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantsForConvertiblePreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants for convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantsForConvertiblePreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684195624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 10 &#8211; Equity</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The holder of each share of common stock is entitled to one vote per share.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in a registered IPO at a price to the public of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The net proceeds to the Company were </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and direct offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 30, 2021, the Company raised approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in gross proceeds from the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,756,994</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> common shares at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per share in an at-the-market offering. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preferred Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s Restated Certificate of Incorporation authorizes the Company to issue up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock with a par value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of preferred stock were issued or outstanding.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685396760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue and Accounts Receivable Credit Concentration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 11 &#8211; Revenue and Accounts Receivable Credit Concentration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, historical price concessions granted to groups of customers, and its historical collection experience using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:13.765%;"/>
        <td style="width:0.677%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:12.708%;"/>
        <td style="width:0.677%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,919</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,569</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,506</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,557</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Deferred Revenue</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#8216;Revenues&#8217; in the statements of operations. Of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in &#8216;Deferred Revenue&#8217; recorded in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was recognized in revenues. During the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was added to 'Deferred revenue' for up-front cash payments received for which revenue recognition criteria have not been met. The 'Deferred revenue' of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million recorded in the balance sheet as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in non-current deferred revenue, respectively, recorded within &#8216;Other long-term liabilities&#8217; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.832%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.43%;"/>
        <td style="width:2.003%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:12.354%;"/>
        <td style="width:2.003%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s total revenue for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively. The Company is subject to credit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.844%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.423%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:12.347%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684186408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 12 &#8211; Share Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Predecessor 2016 and 2006 Equity Incentive Plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional awards may be granted under the 2006 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#8217;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> additional awards may be granted under the 2016 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 Equity Incentive Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective upon the closing of our IPO, the Company&#8217;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan.</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The number of shares reserved for issuance under the 20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,893,395</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors. Up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,893,395</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> sh</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#8217;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">630,685</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Employee Stock Purchase Plan</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective with our IPO in October 2020, the Company&#8217;s Board of Directors and its stockholders approved the Company&#8217;s Employee Stock Purchase Plan (ESPP). A total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">338,106</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of their earnings for the purchase of the Company&#8217;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of the fair market value of the Company&#8217;s common stock on the first or last day of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">offering </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">period, whichever is lower. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,855</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the ESPP leaving </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">295,251</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares remaining for future issuance.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Description of Awards Granted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-statutory stock options, which may be issued to employees, non-employees and directors, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are granted at an exercise price per share equal to the closing market price of the Company&#8217;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Performance-based options vest in </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> equal annual installments beginning one year after the grant date</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#8217;s common stock on the grant date. On January 1, 2019, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,466</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance-condition options, with an exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.77</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and a term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the year ended December 31, 2021 and 2020, the performance-conditions w</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ere met and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,156</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> opti</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ons and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,155</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options, respectively, vested. During the year ended December 31, 2019, the performance-conditions were not met and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,155</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> options were forfeited.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> holders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he Company has granted service-condition RSUs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bonus-To-Options Program</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also has a Bonus-to-Options Program (the &#8220;Bonus Option Program&#8221;), is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#8220;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8221;. Bonus Options issued must be exercised within a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> term.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.344%;"/>
        <td style="width:1.122%;"/>
        <td style="width:0.594%;"/>
        <td style="width:14.376%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.679%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.856%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.679%;"/>
        <td style="width:0.603%;"/>
        <td style="width:14.431%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.679%;"/>
        <td style="width:1.196%;"/>
        <td style="width:10.666%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; January 1, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,723</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.67</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022 and 2021 by the Compensation Committee of the Board of Directors. In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Compensation Expense</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-tax share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.362%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:20.603%;"/>
        <td style="width:0.974%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1.206%;"/>
        <td style="width:20.603%;"/>
        <td style="width:0.993%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">572</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">589</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,120</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,944</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,709</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unrecognized remaining share-based compensation expense for options and RSUs was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and is expected to be amortized to expense over the next </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.57%;"/>
        <td style="width:1.113%;"/>
        <td style="width:0.992%;"/>
        <td style="width:13.542%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.552%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.002%;"/>
        <td style="width:13.57%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.314%;"/>
        <td style="width:0.992%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,321</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.82</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,580</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.87</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.22</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">408</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,878</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.08</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,288</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,428</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.02</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,849</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#8217;s common stock and the general and industry-specific economic outlook. Subsequent to the Company&#8217;s IPO, the fair value of the Company&#8217;s common stock is determined based on its closing market price on the date of grant.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:</span></p><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. </span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span></div></div><div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Yield</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> dividends have been declared as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.</span></div></div><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"/>
        <td style="width:1.623%;"/>
        <td style="width:0.603%;"/>
        <td style="width:20.254%;"/>
        <td style="width:2.003%;"/>
        <td style="width:2.467%;"/>
        <td style="width:0.603%;"/>
        <td style="width:20.254%;"/>
        <td style="width:2.003%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.73</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk&#8209;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.79</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the year ended December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,707</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> service-condition RSUs. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">150,811</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs outstanding, with a weighted average grant date fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685297560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 13 &#8211; Net Loss per Common Share</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the Company&#8217;s stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. If the gross margin target was met, the Company was required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock. The Company met the gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for three consecutive months during the three months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which all parties agreed to forgo the issuance of common stock. As a result of the achievement of the gross margin target, the Company included the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,520,108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share from the date the gross margin target was met until the amendment was executed. These shares are not included in the statements of convertible preferred stock and stockholders' equity (deficit) or shares issued and outstanding in the accompanying balance sheets.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.306%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.702%;"/>
        <td style="width:0.946%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.739%;"/>
        <td style="width:0.965%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,159</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,365</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,838</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The potentially dilutive securities as of December 31, 2021 and 2020 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan and would be subject to the treasury stock method when dilutive the terms of which are described in further detail in Note 12 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.154%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.603%;"/>
        <td style="width:15.686%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.603%;"/>
        <td style="width:15.686%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,251</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,495</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,535</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,677</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685353240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 14 - Income Taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception, the Company has incurred net taxable losses, and accordingly, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> current provision for income taxes has been recorded. </span><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.411%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.816%;"/>
        <td style="width:13.75%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.816%;"/>
        <td style="width:12.414%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="font-size:11.0pt;font-family:Calibri;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.721%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.209%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.873%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,874</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,860</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">554</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">279</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,977</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">865</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,618</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,406</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,538</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,457</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,083</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">267.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expire beginning in 2026</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of net deferred tax assets.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2021, the Company determined that it now has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span></span></p><div style="font-size:11.0pt;font-family:Calibri;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"/>
        <td style="width:2.681%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.793%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.448%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">609</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685336408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 15 &#8211; Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases facilities under non&#8209;cancelable operating leases. Rent expense </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"/>
        <td style="width:1.892%;"/>
        <td style="width:1.206%;"/>
        <td style="width:18.302%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of <br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">775</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Co&#8209;Development Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#8217;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#8209;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#8209;of&#8209;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2020, the Company exercised its opt-out right with AVEO for the payment of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in remaining obligations related to the AVEO agreement as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Following the Effective Date, the Company is entitled to a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% royalty of net sales of ficlatuzumab and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of license income generated from the licensing of ficlatuzumab from AVEO.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> expenses related to this agreement for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Expenses related to this agreement for the year ended December 31, 2020 were approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#8217;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#153; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 2024</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Either party may terminate for the other&#8217;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. Royalty expense under the Bio-Rad License was not significant for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly Caprion Biosciences, Inc.) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.675</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% on future Nodify XL2 test net sales worldwide for </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years from the first commercial sale, ending in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2034</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Royalty expense under the CellCarta License for the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of recognized revenue for non-screen tests up to an annual minimum volume and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% thereafter, with an escalating minimum </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">through the first four years of sales</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Royalty expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were incurred for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, respectively.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Litigation, Claims and Assessments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. In September 2021, we reached a settlement agreement with the plaintiffs, which received preliminary approval from the Circuit Court of the City of St. Louis, State of Missouri (the Court) on November 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, regarding a dispute involving the Telephone Consumer Protection Act (TCPA). On January 31, 2022, the Court approved the final settlement payment to third parties of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">210,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> which was accrued as a legal contingency during the year ended December 31, 2021. We are not presently a party to any other legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685193528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Note 16 &#8211; Subsequent Events</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock Purchase Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 7, 2022 (the Effective Date), the Company entered into a purchase agreement, dated as of March 7, 2022 with Lincoln Park Capital Fund, LLC, an Illinois limited liability company (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#8217;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#8217;s sole discretion, over the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36-month</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period commencing on the Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, but that amount may be increased up to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, depending upon the market price of the Company&#8217;s common stock at the time of sale and subject to a maximum limit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#8217;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasda</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">q rules.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.99</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of its common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the Effective Date, the Company issued </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">184,275</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock to Lincoln Park as a commitment fee and, upon the available amount being reduced to an amount equal to or less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the Company will be required to issue </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,426</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares (collectively, the Commitment Shares).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Centennial Valley Properties I, LLC Lease Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space located at 919 West Dillion Road; Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#8217;s current leased premises at </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2970 Wilderness Place, Suite 100 in Boulder, Colorado</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and the Company intends to move its corporate headquarters to the Leased Premises by mid-2023.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he initial term of the Lease wi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ll extend </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 1, 2023</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">two</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> renewal </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">options to extend</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the term of the Lease for an additional </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cd5e018e-3c53-41fb-bbd2-697f64fb59f7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ten year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> terms for each renewal.</span></span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Lease, the Company will lease approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">227,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month and escalating, based on fixed escalation provisions, to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">326,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,980</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million toward the cost of construction and improvements for the Leased Premises </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the Company exercised its option for an additional tenant improvement allowance of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.00</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per rentable square foot (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% per year over the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial Term</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature, including maintaining a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#8217;s obligations under the Lease. The $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million letter of credit has to be cash collateralized by the Company through a restricted cash account for the benefit of the Landlord.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680721080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_InitialPublicOfferingIPOPolicyTextBlock', window );">Initial Public Offering ("IPO")</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Initial Public Offering</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2020, the Company completed its initial public offering (IPO), in which it issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the IPO, all shares of the Company&#8217;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,939,025</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, and all then outstanding warrants to purchase the Company&#8217;s Series G convertible preferred stock were automatically converted into warrants to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock', window );">Basis of Presentation and Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation and Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Certain prior period amounts have been reclassified to conform to the current period presentation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we maintained cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and we have $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in principal balance outstanding on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#8217;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#8217;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan (see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Note 8 &#8211; Debt</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balance. We have taken steps to improve our liquidity through raising debt and equity capital during 2021, amendments to our 2021 Term Loan and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiation with certain creditors to modify existing terms of arrangement to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#8217; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segment Reporting</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_bede26c1-bcbf-4c97-9e63-739d552d824e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">single</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> operating segment focused on providing diagnostic testing services to customers. All of the Company&#8217;s revenue and long-lived assets were derived or located in the United States for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 11 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectCostsAndExpensesPolicyTextBlock', window );">Direct Costs and Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Direct Costs and Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#8217;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Sales, Marketing, General and Administrative Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales, Marketing, General and Administrative Expenses</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These expenses consist principally of salaries, bonuses, employee benefits, travel, stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk and Other Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk and Other Uncertainties</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Substantially all of the Company&#8217;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 &#8211; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue and Accounts Receivable Credit Concentration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash consists of deposits related to the Company&#8217;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million restricted cash, respectively, which was included in &#8216;Other current assets&#8217; in the accompanying balance sheets.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounts Receivable and Allowance for Doubtful Accounts</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventorySuppliesPolicy', window );">Inventory</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inventory</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expenses'. Inventory is stated at cost and reported within &#8216;Other current assets&#8217; in the balance sheet and were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_407518a8-f622-40ce-9fc1-00bcdbe09352;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> impairments for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there were </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> accumulated impairment losses.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:11.823%;"/>
        <td style="width:2.083%;"/>
        <td style="width:86.094%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for identical assets and liabilities.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices in active markets for similar assets and liabilities;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inputs other than quoted prices that are observable for the asset or liability.</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unobservable inputs for the asset or liability.</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 4 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for further discussion related to estimated fair value measurements.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#8217;s shareholder upon attainment of a three-consecutive month gross margin target of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#8216;Interest expense&#8217; in the statements of operations resulting from the passage of time and fixed payment schedule. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_WarrantLiabilityPolicyTextBlock', window );">Warrant Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrant Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the completion of the Company&#8217;s IPO in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#8217;s IPO in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityPolicyTextBlock', window );">Put Option Liability</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Put Option Liability</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During 2020 and 2019, the Company issued convertible debt with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an IPO. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate. The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our IPO, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share&#8209;Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#8217;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units (RSUs)</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company grants service-condition RSUs. As a result of our IPO, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See Note 12 &#8212; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Share-Based Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for additional information related to share-based compensation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Common Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until the Company&#8217;s IPO in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#8217;s losses. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Not Yet Adopted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Issued Accounting Standards Not Yet Adopted</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2016, the FASB issued ASU No. 2016-02</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">, Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on our current analysis we expect the adoption to result in the recognition of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_edabff51-0ce4-48c5-96f3-64ef856b5af6;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approximately</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">right of use assets</span></span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and associated lease liabilities, inclusive of both lease and non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements. </span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basis of Presentation and Estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectCostsAndExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct costs and expenses policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectCostsAndExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InitialPublicOfferingIPOPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InitialPublicOfferingIPOPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for put-option liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventorySuppliesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventorySuppliesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681277864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of Fair Value of Outstanding Borrowings</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020, based on interest rates currently available for similar borrowings and were (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.854%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.611%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.331%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.331%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.187%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.925%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Carrying Value</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Borrowings</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Reported Fair values of Contingent Consideration</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:13.765%;"/>
        <td style="width:0.677%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:12.708%;"/>
        <td style="width:0.677%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;Description</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current portion of contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,764</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,028</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total contingent consideration</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,792</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Contingent Consideration and Financial Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in contingent consideration for the year ended December 31, 2021 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.082%;"/>
        <td style="width:1.892%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.837%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,622</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,238</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,792</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.42%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:10.338%;"/>
        <td style="width:0.909%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.975%;"/>
        <td style="width:0.918%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:8.975%;"/>
        <td style="width:0.918%;"/>
        <td style="width:1.113%;"/>
        <td style="width:1.205%;"/>
        <td style="width:9.356%;"/>
        <td style="width:0.918%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the Year Ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Level 3 Rollforward</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Put<br/>Option<br/>Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrant<br/>Liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contingent<br/>Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Beginning balances - January 1, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,114</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,261</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,389</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">818</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,252</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassified to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,650</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,624</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ending balances - December 31, 2020</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,932</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684431736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.837%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.837%;"/>
        <td style="width:0.983%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,784</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,730</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,339</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,845</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">700</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">871</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">391</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">424</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">600</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">651</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vehicles</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in process</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">381</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,928</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,902</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,749</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,724</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock', window );">Schedule of Depreciation Expense Related to Property and Equipment</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation expense related to pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">operty and equipment was:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.781%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.839%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.829%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">614</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">361</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">614</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">478</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,228</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">839</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of depreciation and amortization expense related to property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685307400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets, Excluding Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets, excluding goodwill, consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:39.774%;"/>
        <td style="width:1.039%;"/>
        <td style="width:1.197%;"/>
        <td style="width:5.936%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.234%;"/>
        <td style="width:9.47%;"/>
        <td style="width:0.798%;"/>
        <td style="width:0.835%;"/>
        <td style="width:1.197%;"/>
        <td style="width:6.382%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.197%;"/>
        <td style="width:5.936%;"/>
        <td style="width:0.733%;"/>
        <td style="width:0.733%;"/>
        <td style="width:1.197%;"/>
        <td style="width:9.591%;"/>
        <td style="width:0.798%;"/>
        <td style="width:0.714%;"/>
        <td style="width:1.197%;"/>
        <td style="width:6.382%;"/>
        <td style="width:0.733%;"/>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:7.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Accumulated<br/>Amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;">Net Carrying Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets subject to amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">566</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,189</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,474</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">494</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchased technology</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,572</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,900</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,694</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,206</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets not subject to<br/>&#160;&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Trademarks</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,755</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,138</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,617</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,448</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,188</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Amortization Expense Related to Definite-Lived Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization expense related to definite-lived intangible assets was (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.583%;"/>
        <td style="width:2.152%;"/>
        <td style="width:1.206%;"/>
        <td style="width:11.457%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.832%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,051</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,064</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685334168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued liabilities consist of the following (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.784%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.832%;"/>
        <td style="width:0.974%;"/>
        <td style="width:1.596%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.832%;"/>
        <td style="width:0.974%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compensation related accruals</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,029</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,975</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued clinical trial expense</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">870</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,766</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,099</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;Total accrued liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,665</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,789</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684425592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Summary of Long-term Notes Payable</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable were as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.308%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.386%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.577%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.755%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 Term Loan</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2018 Notes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,972</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Paycheck Protection Program</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,107</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unamortized debt discount and debt issuance costs</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,012</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,766</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current maturities</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,840</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term notes payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,993</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,926</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Scheduled Principal Repayments (Maturities) of Long-term Obligations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:79.397%;"/>
        <td style="width:1.911%;"/>
        <td style="width:1.206%;"/>
        <td style="width:16.883%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of<br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,017</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,818</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,206</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,075</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685334168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Warrants And Rights Note Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Activity for Convertible Preferred Stock Warrants</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.005%;"/>
        <td style="width:1.196%;"/>
        <td style="width:0.983%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.196%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.163%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.196%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.144%;"/>
        <td style="width:0.983%;"/>
        <td style="width:1.215%;"/>
        <td style="width:1.206%;"/>
        <td style="width:9.19%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series E</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Series G </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; January 1, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">925</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of warrant liability to additional paid-in capital</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">613</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.75</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our IPO, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> warrants to purchase common stock at $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.46</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, which have an expiration date of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 23, 2028</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All common stock warrants remain outstanding as of December 31, 2021.</span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684026424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenues consisted of the following (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.237%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:13.765%;"/>
        <td style="width:0.677%;"/>
        <td style="width:1.605%;"/>
        <td style="width:1.364%;"/>
        <td style="width:12.708%;"/>
        <td style="width:0.677%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Diagnostic tests</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40,919</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Services</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,569</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,638</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,506</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45,557</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.832%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.43%;"/>
        <td style="width:2.003%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:12.354%;"/>
        <td style="width:2.003%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.844%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:13.423%;"/>
        <td style="width:2.004%;"/>
        <td style="width:1.586%;"/>
        <td style="width:0.603%;"/>
        <td style="width:12.347%;"/>
        <td style="width:2.004%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medicare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Janssen Research and Development, LLC</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">LabCorp DD (formerly Covance)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Big Ten Conference</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Centura Healthcare</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678556888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Pre-tax Share-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-tax share-based compensation expense reported in the Company&#8217;s statements of operations was (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.362%;"/>
        <td style="width:1.614%;"/>
        <td style="width:1.206%;"/>
        <td style="width:20.603%;"/>
        <td style="width:0.974%;"/>
        <td style="width:2.44%;"/>
        <td style="width:1.206%;"/>
        <td style="width:20.603%;"/>
        <td style="width:0.993%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Direct costs and expenses</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">572</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">589</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales, marketing, general and administrative</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,323</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,120</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,944</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,709</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.57%;"/>
        <td style="width:1.113%;"/>
        <td style="width:0.992%;"/>
        <td style="width:13.542%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.552%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.002%;"/>
        <td style="width:13.57%;"/>
        <td style="width:0.992%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.206%;"/>
        <td style="width:10.314%;"/>
        <td style="width:0.992%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding - January 1, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,321</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.82</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.4</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,580</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.87</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.22</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">408</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.51</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,878</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.08</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,288</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,428</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.02</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,849</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted Average Assumptions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.19%;"/>
        <td style="width:1.623%;"/>
        <td style="width:0.603%;"/>
        <td style="width:20.254%;"/>
        <td style="width:2.003%;"/>
        <td style="width:2.467%;"/>
        <td style="width:0.603%;"/>
        <td style="width:20.254%;"/>
        <td style="width:2.003%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.01</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.73</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk&#8209;free rate</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.79</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.34</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recorded the following activity related to the Bonus Option Program during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 (in thousands, excepted weighted average exercise price and weighted average contractual life):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.344%;"/>
        <td style="width:1.122%;"/>
        <td style="width:0.594%;"/>
        <td style="width:14.376%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.679%;"/>
        <td style="width:1.196%;"/>
        <td style="width:13.856%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.679%;"/>
        <td style="width:0.603%;"/>
        <td style="width:14.431%;"/>
        <td style="width:0.594%;"/>
        <td style="width:1.679%;"/>
        <td style="width:1.196%;"/>
        <td style="width:10.666%;"/>
        <td style="width:0.594%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Number of<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Life (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; January 1, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.11</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.9</span></span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,723</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">266</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.67</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited/canceled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.03</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.69</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercisable &#8209; December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">373</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.00</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298687814376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic and diluted loss per share for the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">December 31, 2021 and 2020 were (in thousands, except per share amounts):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.306%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.702%;"/>
        <td style="width:0.946%;"/>
        <td style="width:1.466%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.739%;"/>
        <td style="width:0.965%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,159</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding used<br/>&#160;&#160;&#160;in computing net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,365</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,838</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share, basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.58</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.154%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.603%;"/>
        <td style="width:15.686%;"/>
        <td style="width:0.603%;"/>
        <td style="width:1.531%;"/>
        <td style="width:0.603%;"/>
        <td style="width:15.686%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,251</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,495</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Shares committed under ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Warrants</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">151</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,535</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,677</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681207288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.411%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.816%;"/>
        <td style="width:13.75%;"/>
        <td style="width:1.995%;"/>
        <td style="width:1.401%;"/>
        <td style="width:0.816%;"/>
        <td style="width:12.414%;"/>
        <td style="width:1.995%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and developments credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Permanent items</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.721%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:14.209%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.595%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.873%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,874</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,372</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,860</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense limitation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">554</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">215</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">279</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,977</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">865</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,618</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,406</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,538</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Valuation allowance</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,457</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56,083</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax assets after valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,153</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,455</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets and liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):</span>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.68%;"/>
        <td style="width:2.681%;"/>
        <td style="width:1.206%;"/>
        <td style="width:13.793%;"/>
        <td style="width:0.798%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.206%;"/>
        <td style="width:12.448%;"/>
        <td style="width:0.798%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at January 1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to the current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">609</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions for tax positions related to prior years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to settlements</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reductions related to a lapse of statute</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">843</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">715</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685396760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations are as follows (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.996%;"/>
        <td style="width:1.892%;"/>
        <td style="width:1.206%;"/>
        <td style="width:18.302%;"/>
        <td style="width:0.603%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">As of <br/>December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">775</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">149</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2027 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">937</span></p></td>
        <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678511304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Test </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfCancerTest', window );">Number of blood based lung cancer test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfCommercialBloodBasedTest', window );">Number of commercial blood-based test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfSARSCoV2Test', window );">Number of SARS-CoV-2 test | Test</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering | $</a></td>
<td class="nump">$ 63,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock', window );">Convertible preferred stock and convertible notes payable converted into shares of common stock</a></td>
<td class="nump">21,939,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock</a></td>
<td class="nump">103,326<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMoneyOfferingMember', window );">At-the-Money Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems', window );"><strong>Organization And Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,756,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Gross proceeds from sale of common shares | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock and convertible notes payable converted to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCancerTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of cancer test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCancerTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfCommercialBloodBasedTest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of commercial blood based test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfCommercialBloodBasedTest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfSARSCoV2Test">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of SARS-CoV-2 test.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfSARSCoV2Test</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_OrganizationAndDescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and description of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_OrganizationAndDescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMoneyOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMoneyOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682513064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,712,000<span></span>
</td>
<td class="nump">$ 62,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="nump">3,532,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Product Life and Patent Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherInventorySupplies', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Principal balance outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventorySupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventorySupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_ProductLifeAndPatentLifeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684313032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Recent Accounting Pronouncements - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Assets Noncurrent<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Lease liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682828664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Installment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount', window );">Contingent consideration arrangements, common shares, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock | Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Contingent consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements common shares redemption amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684040936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details) - Fair Value, Recurring - Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 10,012<span></span>
</td>
<td class="nump">$ 27,766<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Borrowings</a></td>
<td class="nump">$ 10,012<span></span>
</td>
<td class="nump">$ 27,766<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678152920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 33,792<span></span>
</td>
<td class="nump">$ 29,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember', window );">Current Portion of Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">17,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total contingent consideration</a></td>
<td class="nump">$ 16,028<span></span>
</td>
<td class="nump">$ 29,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_CurrentPortionOfContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678483448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Changes in Contingent Consideration (Details) - Fair Value, Recurring - Level 3 - Contingent Consideration - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">$ 29,932<span></span>
</td>
<td class="nump">$ 29,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense', window );">Interest expense</a></td>
<td class="nump">2,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balances</a></td>
<td class="nump">$ 33,792<span></span>
</td>
<td class="nump">$ 29,932<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value measurement with unobservable inputs interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680731640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Schedule of Changes in Financial Liabilities (Details) - Fair Value, Recurring - Level 3 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="nump">$ 29,932<span></span>
</td>
<td class="nump">$ 29,114<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">1,622<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balances</a></td>
<td class="nump">$ 33,792<span></span>
</td>
<td class="nump">29,932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Put Option Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital', window );">Reclassified to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,650)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital', window );">Reclassified to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,624)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Contingent Value Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_PutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=bdsx_ContingentValueRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674995848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 19, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net change to contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,622,000<span></span>
</td>
<td class="nump">$ 818,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants, expires period</a></td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 23,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Increase in value of the warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant issued to purchase shares | shares</a></td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRightsShares', window );">Contingent value rights shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRights', window );">Contingent value rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ContingentValueRightsPercentage', window );">Contingent value rights percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders', window );">Net proceeds percentage of cash payment to the CVR holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember', window );">Series F Preferred Stock | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares | shares</a></td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember', window );">Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember', window );">Second Amendment | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net change to contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating Expense | Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net change to contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Net change to contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity', window );">Business acquisition description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount', window );">Contingent consideration arrangements, common shares, redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment', window );">Business combination contingent consideration final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock | Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments', window );">Contingent consideration number of installments | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Contingent consideration cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange', window );">Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration number of installments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration arrangements common shares redemption amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration final payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ContingentValueRightsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent value rights shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ContingentValueRightsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds percentage of cash payment to the cvr holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put option liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesFPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=bdsx_LossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=bdsx_LossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bdsx_RepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678103064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 10,928<span></span>
</td>
<td class="nump">$ 9,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(6,749)<span></span>
</td>
<td class="num">(6,724)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">4,179<span></span>
</td>
<td class="nump">3,178<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">6,784<span></span>
</td>
<td class="nump">5,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,339<span></span>
</td>
<td class="nump">1,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">391<span></span>
</td>
<td class="nump">424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Process</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678180776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details) - Property and Equipment - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="nump">$ 839<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">614<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Selling, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 614<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682303160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 11,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, Cost</a></td>
<td class="nump">18,755<span></span>
</td>
<td class="nump">$ 18,448<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill', window );">Intangible assets, Accumulated Amortization</a></td>
<td class="num">(7,138)<span></span>
</td>
<td class="num">(5,188)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, Net Carrying Value</a></td>
<td class="nump">11,617<span></span>
</td>
<td class="nump">13,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross', window );">Intangible assets not subject to amortization, Cost</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets not subject to amortization, Net Carrying Value</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">1,755<span></span>
</td>
<td class="nump">1,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(566)<span></span>
</td>
<td class="num">(494)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">1,189<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember', window );">Purchased Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets subject to amortization, Cost</a></td>
<td class="nump">16,900<span></span>
</td>
<td class="nump">16,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Intangible assets subject to amortization, Accumulated Amortization</a></td>
<td class="num">(6,572)<span></span>
</td>
<td class="num">(4,694)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 10,328<span></span>
</td>
<td class="nump">$ 12,206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indefinite lived intangible assets excluding goodwill gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_PurchasedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674915064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,950<span></span>
</td>
<td class="nump">$ 2,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense related to definite-lived intangible assets</a></td>
<td class="nump">$ 1,945<span></span>
</td>
<td class="nump">$ 2,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298686211016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Finite Lived Intangible Assets Future Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2023</a></td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2024</a></td>
<td class="nump">1,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2025</a></td>
<td class="nump">1,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2026</a></td>
<td class="nump">1,941<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter', window );">2027 and thereafter</a></td>
<td class="nump">1,719<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets subject to amortization, Net Carrying Value</a></td>
<td class="nump">$ 11,517<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite lived intangible assets amortization expense year six and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684761960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related accruals</a></td>
<td class="nump">$ 4,029<span></span>
</td>
<td class="nump">$ 3,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AccruedClinicalTrialExpenseCurrent', window );">Accrued clinical trial expense</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">3,099<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 7,665<span></span>
</td>
<td class="nump">$ 7,789<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AccruedClinicalTrialExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial expense current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AccruedClinicalTrialExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682835832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Summary of Long-term Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discount and debt issuance costs</a></td>
<td class="num">$ (63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (313)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, total</a></td>
<td class="nump">10,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current maturities</a></td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable</a></td>
<td class="nump">9,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,107<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Notes/Loan payable</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_CARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_CARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674656776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 19, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">32,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,712,000<span></span>
</td>
<td class="nump">$ 62,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,298,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PutOptionLiabilityCurrent', window );">Estimated value of put option liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,676,000<span></span>
</td>
<td class="nump">$ 1,844,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Debt instrument converted to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Debt instrument frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_RevenueMilestone', window );">Revenue milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantDescription', window );">Debt instrument, covenant description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than 70% of the Company&#8217;s projected revenue performed at the end of each reporting period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCovenantCompliance', window );">Debt instrument, covenant compliance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company was in compliance with all restrictive and financial covenants associated with its borrowings.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 2021 Term Loan provides for an &#8220;interest-only&#8221; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Prior to First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt instrument, prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Prior to Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt instrument, prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | After Second Anniversary, Prior to October 19, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt instrument, prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage', window );">Debt instrument, prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MinimumLiquidityRatioCovenant', window );">Minimum liquidity ratio covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfMinimumRevenueRequirement', window );">Percentage of minimum revenue requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember', window );">2021 Term Loan | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfMinimumRevenueRequirement', window );">Percentage of minimum revenue requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanAmendmentMember', window );">2021 Term Loan Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCollateralForBorrowedSecurities', window );">Restricted cash collateral account</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanAmendmentMember', window );">2021 Term Loan Amendment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember', window );">Second Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MilestonePayment', window );">Milestone payment</a></td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt extinguishment</a></td>
<td class="num">(100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PartialRepaymentsOfDebt', window );">Partial repayments of debt</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PrepaymentFeeWaivedAmount', window );">Prepayment fee waived amount</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of debt issuance costs</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,972,000<span></span>
</td>
<td class="nump">$ 23,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Facility fee amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Estimated air value of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash', window );">Percentage of interest rate, paid in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable', window );">Percentage of interest rate added to principal value of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DebtInstrumentInterestAddedToPrincipalValue', window );">Interest added to principal value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember', window );">2018 Notes | Series G Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant issued to purchase shares</a></td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">613,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The PPP Loan had a maturity date on the two-year anniversary of the funding date, April 2022, and included a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), were scheduled to commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | Interest-bearing Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Loan principle amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,107,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (loss) on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageForNonPayrollCosts', window );">Percentage for non-payroll costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness', window );">Upper limit of employee salary to reduce forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness', window );">Percentage of upper limit of employee salary to reduce forgiveness</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember', window );">PPP Loan | Minimum | CARES Act</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PayrollCostsExcludesCompensationOfEmployee', window );">Payroll costs excludes compensation of an employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentInterestAddedToPrincipalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest added to principal value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentInterestAddedToPrincipalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of stated interest rate added to principal value of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, percentage of stated interest rate, paid in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DebtInstrumentPrepaymentPenaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument prepayment penalty percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DebtInstrumentPrepaymentPenaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumLiquidityRatioCovenant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum liquidity ratio covenant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumLiquidityRatioCovenant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PartialRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partial repayments of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PartialRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PayrollCostsExcludesCompensationOfEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll costs excludes compensation of an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PayrollCostsExcludesCompensationOfEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageForNonPayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage for non-payroll costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageForNonPayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfMinimumRevenueRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of minimum revenue requirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfMinimumRevenueRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upper limit of employee salary to reduce forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrepaymentFeeWaivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayment fee waived amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrepaymentFeeWaivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PutOptionLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Put option liability current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PutOptionLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RevenueMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RevenueMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upper limit of employee salary to reduce forgiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCollateralForBorrowedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCollateralForBorrowedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCovenantDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCovenantDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_TwoThousandTwentyOneTermLoanAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_SecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_NotesPayable2018NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesGPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=bdsx_PPPLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InterestBearingDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InterestBearingDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bdsx_CARESActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bdsx_CARESActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682321880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Maturities Of Long Term Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2025</a></td>
<td class="nump">4,818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2026</a></td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter', window );">2026 and thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 10,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long term debt maturities repayments of principal in year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680723304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember', window );">Series E Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding - January 1, 2020, warrants | shares</a></td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited/canceled, warrants | shares</a></td>
<td class="num">(925)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding - January 1, 2020, warrants | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/canceled, warrants | $ / shares</a></td>
<td class="num">$ (5.00)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember', window );">Series G Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding - January 1, 2020, warrants | shares</a></td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease', window );">Reclassification of warrant liability to additional paid-in capital, warrants | shares</a></td>
<td class="num">(613)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding - January 1, 2020, warrants | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice', window );">Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants | $ / shares</a></td>
<td class="num">$ (0.75)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in the number of shares under non-option equity instrument agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesEConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298685421368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details) - Series G Convertible Preferred Stock Warrants<br></strong></div></th>
<th class="th">
<div>Oct. 27, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock | shares</a></td>
<td class="nump">103,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrants expiration date</a></td>
<td class="text">Feb. 23,  2028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, exercise price | $ / shares</a></td>
<td class="nump">$ 4.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=bdsx_SeriesGConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682384600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, voting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The holder of each share of common stock is entitled to one vote per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,343,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 18.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="nump">$ 63,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees', window );">Underwriting discounts and commissions</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DirectOfferingExpenses', window );">Direct offering expenses</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember', window );">At-The-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common stock issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,756,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_ProceedsFromIssuanceOfCommonStockNet', window );">Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable', window );">Underwriting discounts and commissions and offering expenses payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DirectOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Direct offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DirectOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_ProceedsFromIssuanceOfCommonStockNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common stock net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_ProceedsFromIssuanceOfCommonStockNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions and offering expenses payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expense related to distribution, servicing and underwriting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=bdsx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298686990920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 54,506<span></span>
</td>
<td class="nump">$ 45,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember', window );">Diagnostic Tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">48,937<span></span>
</td>
<td class="nump">40,919<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 5,569<span></span>
</td>
<td class="nump">$ 4,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bdsx_DiagnosticTestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298686114200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PrimarySourcesOfRevenueDescription', window );">Primary sources of revenue, description</a></td>
<td class="text">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="nump">$ 3,532,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Minimum | Customer Concentration Risk | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Long-term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Non-current deferred revenue</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember', window );">Up Front Cash Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation Of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PrimarySourcesOfRevenueDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Primary sources of revenue description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PrimarySourcesOfRevenueDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674532024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details) - Customer Concentration Risk - Minimum<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | The Big Ten Conference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Centura Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | The Big Ten Conference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Centura Healthcare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Janssen Research and Development, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | LabCorp DD (formerly Covance)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_TheBigTenConferenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_CenturaHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_CenturaHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_JanssenResearchAndDevelopmentLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bdsx_LabcorpDdFormerlyCovanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bdsx_LabcorpDdFormerlyCovanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298677255448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 29, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,944,000<span></span>
</td>
<td class="nump">$ 3,709,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">RSUs outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember', window );">Options and Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized remaining stock based compensation balance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember', window );">Service Condition R S Us</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Performance Condition Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Performance-based options vest in three equal annual installments beginning one year after the grant date<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting', window );">Number of equal annual installments for award vesting | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of performance-condition options granted</a></td>
<td class="nump">168,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price | $ / shares</a></td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,156<span></span>
</td>
<td class="nump">56,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan | Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock may be issued under incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,893,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember', window );">2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember', window );">2006 Plan, 2016 Plan and 2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Additional stock awards granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">630,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of number of shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Percentage of earnings used for purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate', window );">Percentage of fair market value of common stock for purchase under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod', window );">Description of voting power or value of stock for employee participation in offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#8217;s stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DescriptionOfOfferingPeriodUnderPlan', window );">Description of offering period under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of December 31, 2021, 42,855 shares have been issued under the ESPP leaving 295,251 shares remaining for future issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of common stock may be issued under incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfOfferingPeriodUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of offering period under plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfOfferingPeriodUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting power or value of stock for employee participation in offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equal annual installments for award vesting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on offering date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_OptionsAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_ServiceConditionRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_PerformanceConditionOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandAndSixteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298677168520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2021</a></td>
<td class="nump">2,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(225)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2021</a></td>
<td class="nump">2,878,000<span></span>
</td>
<td class="nump">2,321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2021</a></td>
<td class="nump">1,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2021</a></td>
<td class="nump">$ 1.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">17.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">7.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2021</a></td>
<td class="nump">8.08<span></span>
</td>
<td class="nump">$ 1.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2021</a></td>
<td class="nump">$ 5.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding - January 1, 2021</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2021</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2021</a></td>
<td class="nump">$ 42,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2021</a></td>
<td class="nump">6,288<span></span>
</td>
<td class="nump">$ 42,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2021</a></td>
<td class="nump">$ 3,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember', window );">Bonus-To-Options Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - January 1, 2021</a></td>
<td class="nump">173,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock Options, Granted</a></td>
<td class="nump">266,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Stock Options, Forfeited/canceled</a></td>
<td class="num">(46,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock Options, Exercised</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock Options, Outstanding - December 31, 2021</a></td>
<td class="nump">373,000<span></span>
</td>
<td class="nump">173,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock Options, Exercisable - December 31, 2021</a></td>
<td class="nump">373,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - January 1, 2021</a></td>
<td class="nump">$ 11.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">20.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited/canceled</a></td>
<td class="nump">20.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">7.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding - December 31, 2021</a></td>
<td class="nump">17.00<span></span>
</td>
<td class="nump">$ 11.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable - December 31, 2021</a></td>
<td class="nump">$ 17.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Life (Years), Outstanding - January 1, 2021</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Contractual Life (Years), Exercisable - December 31, 2021</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - January 1, 2021</a></td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding - December 31, 2021</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2021</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bdsx_BonusToOptionsProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684036904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">$ 4,944<span></span>
</td>
<td class="nump">$ 3,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember', window );">Direct Costs and Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">572<span></span>
</td>
<td class="nump">589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Sales, Marketing, General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total pre-tax share-based compensation expense</a></td>
<td class="nump">$ 4,323<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bdsx_DirectCostsAndExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681771176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Based Compensation - Summary of Weighted Average Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 days<span></span>
</td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.50%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk&#8209;free rate</a></td>
<td class="nump">0.79%<span></span>
</td>
<td class="nump">0.34%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674881016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,365,000<span></span>
</td>
<td class="nump">4,838,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Business acquisition contingent consideration gross margin target</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod', window );">Business acquisition contingent consideration gross margin target period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember', window );">Integrated Diagnostics, Inc | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BusinessCombinationContingentConsiderationShares', window );">Contingent consideration shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,520,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration gross margin target period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BusinessCombinationContingentConsiderationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination contingent consideration shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BusinessCombinationContingentConsiderationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_IntegratedDiagnosticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298681257080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (43,159)<span></span>
</td>
<td class="num">$ (31,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</a></td>
<td class="nump">27,365<span></span>
</td>
<td class="nump">4,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (1.58)<span></span>
</td>
<td class="num">$ (6.48)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674947800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,535<span></span>
</td>
<td class="nump">2,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember', window );">Options to Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">3,251<span></span>
</td>
<td class="nump">2,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember', window );">Shares Committed Under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_OptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bdsx_SharesCommittedUnderESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298674927976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">267,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration', window );">Research and experimentation tax carryforwards</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Description of tax credit carryforward expiration</a></td>
<td class="text">expire beginning in 2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange', window );">Valuation allowance, deferred tax asset, explanation of change</a></td>
<td class="text">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets', window );">Percentage of valuation allowance equal to net deferred tax assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">$ 11,400,000<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Accrued interest related to uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets research and experimentation tax carryforwards subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of valuation allowance equal to net deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684760840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and developments credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(6.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(26.00%)<span></span>
</td>
<td class="num">(16.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation permanent items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298682440024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 61,874<span></span>
</td>
<td class="nump">$ 53,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">3,372<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense limitation</a></td>
<td class="nump">554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total</a></td>
<td class="nump">69,610<span></span>
</td>
<td class="nump">58,538<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(67,457)<span></span>
</td>
<td class="num">(56,083)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets after valuation allowance</a></td>
<td class="nump">2,153<span></span>
</td>
<td class="nump">2,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,153)<span></span>
</td>
<td class="num">(2,455)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">$ (2,153)<span></span>
</td>
<td class="num">$ (2,455)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298684586488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at January 1</a></td>
<td class="nump">$ 715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions for tax positions related to the current year</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at December 31</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298677938792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>May 13, 2021</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Dec. 02, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,789,000<span></span>
</td>
<td class="nump">10,818,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember', window );">Revenue Share Agreement | Oncimmune Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests', window );">Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MinimumAnnualVolumePercentageThereafter', window );">Minimum annual volume percentage thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PeriodOfEscalationsOfSales', window );">Period of escalations of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">through the first four years of sales<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_LitigationClaimsAndAssessmentsMember', window );">Litigation Claims and Assessments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Accrued legal contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_LitigationClaimsAndAssessmentsMember', window );">Litigation Claims and Assessments | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Final settlement payment to third parties</a></td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember', window );">Bio-Rad License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue', window );">Percentage of royalty payments not required on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LicenseAgreementExpiryDate', window );">License expiry date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2024-08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember', window );">CellCarta License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue', window );">Percentage of royalty payments on net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.675%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfFeePaymentsOnNetSales', window );">Percentage of fee payments on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale', window );">Term of royalty payments from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale', window );">Year of ending royalty payments from first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_RemainingEstimatedObligation', window );">Remaining estimated obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember', window );">AVEO Oncology | NSCLC POC Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts', window );">Responsible percentage of development and regulatory costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember', window );">Ficlatuzumab | AVEO Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight', window );">Percentage of development and regulatory costs exercised using opt-out right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales', window );">Percentage of royalty payments on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing', window );">Percentage of license income generated from licensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LicenseAgreementExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement expiry date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LicenseAgreementExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MinimumAnnualVolumePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum annual volume percentage thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MinimumAnnualVolumePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development and regulatory costs exercised using opt-out right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfFeePaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of fee payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfFeePaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of license income generated from licensing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments not required to pay on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PercentageOfRoyaltyPaymentsOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments on net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PercentageOfRoyaltyPaymentsOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PeriodOfEscalationsOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of escalations of sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PeriodOfEscalationsOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RemainingEstimatedObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining estimated obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RemainingEstimatedObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Year of ending royalty payments from first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_RevenueShareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=bdsx_OncimmuneLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_LitigationClaimsAndAssessmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_LitigationClaimsAndAssessmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_BioRadLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_CellCartaLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_AVEOOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=bdsx_NSCLCPOCTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=bdsx_FiclatuzumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298680663384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2025</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2026</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 937<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140298678303112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 11, 2022 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>RenewalOption </div>
<div>$ / ft&#178;</div>
</th>
<th class="th">
<div>Mar. 07, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription', window );">Shares issued or issuable, threshold limit description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#8217;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember', window );">Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription', window );">Lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial term of the Lease will extend twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock Purchase Agreement | Lincoln Park</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_PurchaseAgreementTerm', window );">Purchase agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty', window );">Maximum percentage of common stock allowed to purchase by counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee', window );">Shares issued as commitment fee | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_CommitmentSharesIssuableOnConditionalBasis', window );">Commitment shares issuable on conditional basis | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Common Stock Purchase Agreement | Lincoln Park | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_StockIssuableDuringPeriodValueCommittedShares', window );">Common stock issuable, committed to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayShares', window );">Stock issuable per day, number of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SaleOfStockStockIssuablePerDayValue', window );">Stock issuable per day, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_SharesIssuedAsCommitmentFeeValue', window );">Shares issued as commitment fee, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Centennial Valley Properties I, LLC Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">Apr.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LeaseAgreementNumberOfOptionsToExtend', window );">Lease agreement number of options to extend | RenewalOption</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend', window );">Lease option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LeasedPropertyBuildingCapacity', window );">Leased property building capacity | ft&#178;</a></td>
<td class="nump">79,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_BaseRentPerMonthFromCommencementDate', window );">Base rent per month from commencement date</a></td>
<td class="nump">$ 227,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_RentAfterFixedEscalationProvisions', window );">Rent after fixed escalation provisions</a></td>
<td class="nump">$ 326,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent', window );">Area of leased premised obligated to pay base rent | ft&#178;</a></td>
<td class="nump">19,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements', window );">Landlord contribution towards cost of construction and tenant improvements</a></td>
<td class="nump">$ 18,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet', window );">Extra allowance amount per rentable square feet | $ / ft&#178;</a></td>
<td class="nump">25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_bdsx_InterestRateOnExtraAllowanceAmount', window );">Interest rate on extra allowance amount</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Centennial Valley Properties I, LLC Lease Agreement | Letter of Credit | Cash Collateralized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Long-term Line of Credit</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Centennial Valley Properties I, LLC Lease Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Centennial Valley Properties I, LLC Lease Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1', window );">Lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional tenant improvement allowance per rentable square feet</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:monetaryPerAreaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of leased premised obligated to pay base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_BaseRentPerMonthFromCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Base rent per month from commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_BaseRentPerMonthFromCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_CommitmentSharesIssuableOnConditionalBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment shares issuable on conditional basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_CommitmentSharesIssuableOnConditionalBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_InterestRateOnExtraAllowanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate on extra allowance amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_InterestRateOnExtraAllowanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Landlord contribution towards cost of construction and tenant improvements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseAgreementNumberOfOptionsToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease agreement number of options to extend</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseAgreementNumberOfOptionsToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease commencement Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_LeasedPropertyBuildingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leased property building capacity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_LeasedPropertyBuildingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of common stock allowed to purchase by counterparty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_PurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_PurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_RentAfterFixedEscalationProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rent after fixed escalation provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_RentAfterFixedEscalationProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockSharesIssuedAsCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, shares issued as commitment fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockSharesIssuedAsCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, stock issuable per day, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SaleOfStockStockIssuablePerDayValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, stock issuable per day, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SaleOfStockStockIssuablePerDayValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedAsCommitmentFeeValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued as commitment fee, value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedAsCommitmentFeeValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_SharesIssuedOrIssuableThresholdLimitDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued or issuable, threshold limit description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_SharesIssuedOrIssuableThresholdLimitDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bdsx_StockIssuableDuringPeriodValueCommittedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuable during period, value, committed shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bdsx_StockIssuableDuringPeriodValueCommittedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bdsx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessor's operating lease that has not yet commenced.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919359-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bdsx_LincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bdsx_LincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAxis=bdsx_CashCollateralizedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAxis=bdsx_CashCollateralizedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>bdsx-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bdsx="http://biodesix.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bdsx-20211231.xsd" xlink:type="simple"/>
    <context id="C_a728943e-0005-498d-bf19-caa91ad50029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="C_5d6b3d47-9c02-4894-9b66-a374b4ec92de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_2b6cb7b5-b083-4ec5-b29c-9ae0101aa74b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_70269112-fe2a-430e-be5e-df5d73c366d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9923eaf7-8b89-4851-b161-00aa62740c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3f722d28-c570-4810-8fc4-68f71db16286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd80bb2e-8eca-4461-9d92-d498ba929922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">us-gaap:UpFrontPaymentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_be6ca8b8-4a35-4cad-b184-8b65c4c20b91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_ec1496fb-b414-4020-84e5-09472bae83a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1355f790-e2f7-4e53-b996-2166830c4202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:LitigationClaimsAndAssessmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-31</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_55faf862-904e-4749-90ab-5601a8d113a1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:ServiceConditionRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_87d5899a-2fad-4727-bf84-4cd4bb1daada">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_69b62320-c88d-472b-b26b-8b37a1a5a0b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="C_826b69bf-89e7-459f-b550-a6811c484337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandAndSixteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_98732f46-6752-47d9-bc3f-82fa1ccee5a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1521a2fc-d6fd-463e-a4d0-5ff13f834737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_79ecbe49-ef52-4aab-acc0-1a7416b448df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e272dfed-04df-4966-8eea-8a8670605352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5f9b32d4-40ac-442c-bd25-14dd2c52ccb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_03721b15-782d-4e40-bfe2-237a592136a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_624583b0-5d27-4880-a354-cf2da9d3adee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_46156cf8-97c8-49b0-9c37-c83a12d710ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_75d6eb43-fbcb-4d67-83f4-dade72088b51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0c2b5021-3880-4a79-86df-3e22efd61deb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2d8d257d-2c7e-4c61-95ab-cfad10d07908">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_da0bc552-b359-4652-9ba1-d8e29a01881e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_610d8971-4d2b-4f1e-a390-dfe80b599dfb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_75149308-b918-457f-8ee9-7f3492120224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_547a9002-43fc-4570-ad79-1223f9f65e63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_79311547-11e0-4926-93f9-d08f788a5f28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_a0bd65dc-a53d-46d1-bb23-8dd79665bc2d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4841ec21-e13f-4543-9fc7-01050702bdab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3fa48f27-8cf4-4782-b6a4-0cea10e6953e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_367888ff-2937-4bf4-a0e7-2638e425e939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:SharesCommittedUnderESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ca090c1c-03b5-4f4f-bb08-20bb2d2a2b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_21dd0a17-272e-43c9-926c-8361d449c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CollateralAxis">bdsx:CashCollateralizedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_7388a94f-fccb-4085-aaf4-6b5e7ca6360d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="C_5e31d38e-c781-4c35-a556-26cdca8b81b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cea9870b-55e4-4464-845c-28e908ce7ebd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_6d377042-8c80-4077-9d06-ae158bc05d91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8d547382-c6f4-454f-8385-5aac59c66fbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_351c91ef-f104-49d7-9d7f-d572749a1c07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:BioRadLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_2e24974c-f120-44e6-86d6-efe03fc47db4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cbb42c62-9833-417a-a5af-55f85ae20dd0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8aafb945-b385-4de6-9940-2ec65935d0bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f1ea6781-dd41-46fb-8136-21495568924f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMoneyOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_427d2811-f473-4d72-b6e7-7528519f151a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_4d3ebbe2-4eae-4d8f-8107-5bbc08d2d099">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a29723b5-20cb-4e63-a0da-30a2983860b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="C_5852124a-5af9-43ed-b3c2-0ff2fe0b33b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a136b0aa-9769-4cf4-9832-546661048e81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:LitigationClaimsAndAssessmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2af95b4c-4f7e-4e7e-9808-928b36f0a3d9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_66cad3c3-9239-41d0-b072-1849ca46dde8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_70caefc6-3ec4-4c3c-872d-2ca7c3a4dd74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_233385c2-cf9b-4c0e-ab38-fbc8fe271a49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_62628f3e-204a-4e47-888d-80b800906159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-27</instant>
        </period>
    </context>
    <context id="C_fba42090-b52d-468d-87b6-b763c9054b8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9919b40f-119b-49c1-a2ac-2b76d5a098a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_06bff184-ac5d-48a3-b2c8-c2f0e2ca06b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0e5ba80b-b01d-424c-b1c0-f4822ff4bb56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1b2acc98-6825-4199-91a5-077e16b3afd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_001d92ef-337f-44d0-9202-4f278bb0fa67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_10bed5db-cad0-4d81-95a0-1793592b5166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c77d5c42-d4c0-47d9-86be-96adc70e0b54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:NSCLCPOCTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="C_98e59e9a-da90-42c6-9029-2c28be33926b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_462729a6-5e59-40a9-995d-eddd6dbf59aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bd35d5ad-8efe-4775-803e-5923630c295d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5bb21277-4d96-4ddb-9ba4-3f3d05e4f337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_894dacc7-f9c8-465f-bb3e-677c3cff01e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_479edcde-8115-401c-b300-335b4e160d8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_83cbaa1a-e64a-4c26-b830-afa34cebed4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cb16d514-420d-4abb-9a34-052d761abec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:ProductLifeAndPatentLifeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2b727503-f6ad-446e-9456-ccd781d7dcdc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_09226d1e-919a-4649-b557-d8d34553ce34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_80a34980-9af4-46a5-ab87-825a03cf6961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_03977998-feb5-4ba1-9a39-98aa6bcd1820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_320c8bd8-4ae2-4caf-892d-f84cf7a846c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3e8e4408-1447-42cb-bbca-6204beddc1bb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_ffcdd51b-98b2-4868-af53-a0434a4dc1dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentValueRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_2fde2582-8789-4b20-b26a-e76c33d3ce5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_22af9de2-1e40-4b4f-b58e-22e115d6077d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_80994f88-01c2-4120-9cc2-79754d8c1bc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:JanssenResearchAndDevelopmentLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f8907904-d558-4f3f-8e7e-17a1beefe665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1b5736c7-1ac5-4a03-9e32-a0ecc2616053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b4423134-5dfd-4ff0-b0de-41bf317abf38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a2edad21-1169-40d3-81f2-27f946978341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3c75df96-50d6-49ea-8d24-017d2bbea9a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b477c33a-377c-4327-9710-03e518e2ecbe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ee59665c-33bf-4b10-9799-81bdb60203c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-11</startDate>
            <endDate>2022-03-11</endDate>
        </period>
    </context>
    <context id="C_a21cae4c-4605-4cd5-b0d4-b15582d30357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_848353f5-4aab-4165-b023-6cc47cbe6d8d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1b296b71-3c6b-456d-b731-b251aa4ad227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_be505f23-bf3c-4be3-8972-80834ee53690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:SecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_21e9a711-1b6a-4991-8e79-b6cc008e7545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d29dc415-dc05-49ca-b2ef-a00ef315776c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandSixPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-02-29</instant>
        </period>
    </context>
    <context id="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:LincolnParkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-07</endDate>
        </period>
    </context>
    <context id="C_016d7540-660c-40c6-93d0-aeabbf4df993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d257b176-1b0a-4664-adfe-14f34c0c1a52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_7d46f5a7-a39a-4c26-9184-61e4e53c8f05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_89b9d305-cd7b-433d-9431-082e759b7f72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_577649de-5c2b-46f6-b8d5-5679a06e7577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_cd2c7fce-711f-4dae-a54c-036949770fed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f406a25c-1311-429f-acab-1fbc603fcfb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="C_ab23c5df-8c6e-46f4-83d5-abf0ca403590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:CenturaHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_54f8436f-4f07-4679-9f01-6b88613fe77b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b5d3e429-66cd-4136-bc88-3e646c9bc008">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_07202086-28e8-435f-adff-fe19436c69b0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_93914a7c-1f7d-4779-a324-6676f6a64acb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_10d387cc-753c-46a2-9b2a-9b1890b49bdb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_883404a9-e780-4066-b552-a0e49d50d630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bdsx:AVEOOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">bdsx:FiclatuzumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-02</startDate>
            <endDate>2020-12-02</endDate>
        </period>
    </context>
    <context id="C_939cfa52-44fa-40af-9e11-eaed7a69e39b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_53c549cf-8442-4882-99fb-2cabbc0b4a81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_01ea5af0-61c2-43e8-83f4-995b808a9869">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_afa76821-90e9-46a2-abff-2d96c1240f4d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6b886bcd-bd24-4350-8fd7-27742802fadf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesEConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3926ceff-39bd-4d7e-94cc-3a867487d940">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bdsx:RepurchaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_8ff8a944-a271-4148-9c58-ee869ad37333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:CurrentPortionOfContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_24b5491d-ac78-49f4-af90-1e06570e8d91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9acde59f-b452-4eee-bf70-79e2b788507e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMoneyOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb0c87cc-2dbf-4d30-9a38-bfb702341b31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:LabcorpDdFormerlyCovanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_14445421-ccca-421e-9c3f-7d1d23b7cde7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_d1d55fa8-853c-4dce-a4aa-f84151407d63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:TheBigTenConferenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_dc89134f-48d3-4944-93af-a1d690ce60d2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_706d9a9e-6a0d-4d6c-8f9b-08761cf3807f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a948fe3c-6e1a-4be0-9898-30610de47069">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0ce3a578-735a-4075-87ce-b954e21a6041">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bdsx:DirectCostsAndExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8a6364fe-eb05-498f-8396-31e93f9646a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_34f7bf9b-9a78-44bf-9b7d-69e71e140c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:PutOptionLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_c0b9fafd-8fca-406e-9064-e1666d07eb7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_154e51e6-162c-45e3-bd64-e6953dba0c5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_72bbc621-8c29-4345-9567-e3a8ec5494ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_394f3bb1-4c63-47eb-b527-f498fe718a44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c137ab7e-b733-4793-ad80-a153a9ec42f6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bdsx:CARESActMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="C_dce01a48-8efc-4803-9957-bfa88c6b1299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-19</instant>
        </period>
    </context>
    <context id="C_78ad82cd-de66-4f58-ab74-efd387f2e192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ab45d19d-f12a-40a2-85e6-c11af3ecf535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_030eae36-c23d-4bad-9c99-3d09f8369ed2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_162734b5-e9c9-4193-b4c1-2b7ff33ee96f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_93b97cad-4f53-455d-a681-c9c0907bb9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_612986b7-0cbc-4490-8560-a7436c79aa80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_2a45a1ed-39d8-491b-b8f4-7363b3b51b79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bdsx:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_932b3ab0-8853-42c8-a37c-36341f8a9210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:OncimmuneLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:RevenueShareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d049bfe6-5f3b-4066-8ad9-a9ca88059623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesGPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="C_fe826522-5651-4f06-9c96-09860263bc0d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="C_c47916fb-71bf-444f-a33a-35da68f40857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">bdsx:SeriesGConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_c8f3232a-4dcd-431e-b582-72448f737920">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e6943b1f-ff25-4706-9e32-e38b76243a20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_809d867f-6c56-4037-8eba-8f755ea5fa57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_88dca331-7477-419b-b234-6230d9c7f1f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:OptionsAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:CellCartaLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-13</startDate>
            <endDate>2021-05-13</endDate>
        </period>
    </context>
    <context id="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-27</startDate>
            <endDate>2020-10-27</endDate>
        </period>
    </context>
    <context id="C_661f4aa1-a621-4d97-add7-7f08a6309ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8f45d621-66e2-469e-81de-170b52163c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_36978c15-7cae-4bbc-a497-ec47b32704f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e458ef0f-2999-44aa-a713-1bddf0308c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="C_337f9ff9-e36d-4674-9452-b807a7edb7f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bdsx:OptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eeac8352-9485-4d28-a4b8-6c7dcaf0bab3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bdsx:CentennialValleyPropertiesILlcLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-11</instant>
        </period>
    </context>
    <context id="C_be2758e9-5945-4245-bf58-cd5421da5cb6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:PerformanceConditionOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_928809ae-df57-4571-ac21-764ca2a55ad5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f4a0f9f9-1aed-4b51-a28b-499431427de3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aaa061c9-7669-4ee2-8139-c6567d310fe6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b402d595-7ac8-45f1-be4c-8e6d1bdb6938">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">bdsx:IntegratedDiagnosticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9a21cd39-7714-46bd-8caa-1643fbfd5aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_bcbcd9a8-1029-4466-92ef-98684be0f3eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0104f2bd-d332-41e4-b969-1fde8368c3ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bdsx:DiagnosticTestsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8df4046d-0fe5-4898-9781-f03f716cfbc0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_605a1f05-b224-4c9a-a68f-b4ebf4f58a59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_65d95f34-c5e6-4335-9e70-651be939c9e0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bdsx:BonusToOptionsProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2f88e0dd-ea33-4f83-a540-f014f811689b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dc019ec1-5478-4ebc-a4e8-0c7a3e9bf2db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ea5e3fdf-996d-4c05-8f7c-0456bb8ec3b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">bdsx:LossMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_02073a80-e7d4-420b-a2a9-04056034b97e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_9aed1045-15a0-4022-9dcf-4923b612a501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">bdsx:PurchasedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6eb42b97-11c3-44ad-9689-15a6c7ffc9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_695b6e0d-d079-4a22-b7f4-5eba3c5f5ec8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:ContingentConsiderationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_9f0f230b-11a1-485f-b548-212c085d2be9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e65faf54-05c3-4544-989f-b6ba7475a88f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bdsx:TwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_635f9c56-917e-4e2a-96b7-a3121ec435e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">bdsx:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_be8dd81f-cfc5-46e4-b488-457166af9cbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cad7d434-2ef5-46b9-aa6d-b243e79c1d26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:NotesPayable2018NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e357cb78-de71-44ba-be5d-e72858c2520f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">bdsx:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0e3023eb-44b0-4fc0-a3c5-71c2b1aa3636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_12147dfe-e917-4369-b593-468bf48cc6b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:TwoThousandTwentyOneTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-19</startDate>
            <endDate>2021-03-19</endDate>
        </period>
    </context>
    <context id="C_f68dea5d-5219-4f85-b2dc-32544a35182b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17de90cc-7d15-42d1-b8bb-764245d80c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001439725</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InterestBearingDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">bdsx:PPPLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <unit id="U_Test">
        <measure>bdsx:Test</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_Segment">
        <measure>bdsx:Segment</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UsdPerSquareFoot">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>utr:sqft</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Installment">
        <measure>bdsx:Installment</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_RenewalOption">
        <measure>bdsx:RenewalOption</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_e59d62d4-9d9f-4d04-a8c9-59db6bc180ed">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ab46d256-df52-4f77-8d90-e3095403b859">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_bede26c1-bcbf-4c97-9e63-739d552d824e"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <dei:AmendmentFlag
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_66ac4874-d4f0-401e-a7bf-7f2f9e7f0fb6">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockValue
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      id="F_e28ee59e-2ec0-403a-86b7-fd43d6ed7b38"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      id="F_edabff51-0ce4-48c5-96f3-64ef856b5af6">http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiability</us-gaap:OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      id="F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87">http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <dei:EntityCentralIndexKey
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1bc620bb-3e6b-402e-8838-283423ba32f6">0001439725</dei:EntityCentralIndexKey>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      id="F_830ca1b5-f04d-4413-9871-696b9cc2f4f6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      id="F_639add45-6192-49bc-b32f-a9b5c8b2fcec"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      id="F_0b6261a9-728a-45c1-9cff-b460d2223b68"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20"
      id="F_407518a8-f622-40ce-9fc1-00bcdbe09352">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_c0b9fafd-8fca-406e-9064-e1666d07eb7c"
      id="F_cd5e018e-3c53-41fb-bbd2-697f64fb59f7">P7Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <dei:DocumentType
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a5462b55-ea1c-4ea5-bd8f-2222a018bf99">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_88faae8a-c60f-431b-8a8f-696d49b31d5e">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a0119293-f68a-49ff-9f94-cf4cea6b14e6">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_b29ef097-86ac-42ec-b79f-13b187048af4">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_f6ffe8d9-1b5b-4468-8575-49318405c9ad">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_45d29eb8-9b27-49c8-b78c-8221563c556b">001-39659</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6caabd6c-073a-400f-a605-2e21b75ba48e">Biodesix, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_3bbb5cc3-a906-4fd6-8160-7a046e8ddcdf">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cd707062-49ae-4084-9e87-805db5fadbaf">20-3986492</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a99fe405-ab72-4c16-b695-3f448d64ae6c">2970 Wilderness Place</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_b9f48a41-7c4d-4c44-ab72-3e3a19fadc8e">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1984a7eb-55a5-4d2f-be54-201f99dbd6e6">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a61b697d-dec3-4568-b610-dcd80705453f">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_d0af45ed-5f5e-4150-92f6-ced1f6b459e7">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_b9e74f90-2e14-4162-95a5-4de6dd930c37">303</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1f48a5de-cb66-4078-b07d-a208005ea6b5">417-0500</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_457bfb8b-35db-4c50-a7cd-5f0abeb3f65f">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_5e07ecc0-bc2a-4c4d-8b0d-41400bf1477c">BDSX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_d5a8314b-abd9-402c-8475-7a1cf0d808d7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_3712829c-b4fd-4a15-a66d-c19a6454d0df">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_887ae845-6dec-4bcc-bd34-b88e4a10c405">Yes</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_28436b64-b787-4df5-8850-309bec6bb130">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_0531cd42-4a6b-4a6c-8d0c-718010a9027e">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_04b2971b-9be0-469d-851b-6491bde5d5d4">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_e38eddb5-aea3-47e0-94f8-98942d863c1f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cdcd01f5-fd2a-46a3-bf02-7eba79cff251">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_d8ab46c1-22db-44ed-974f-b4d90b1ca662">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_8f38885d-1ad1-470e-bbf9-d56a2b186a35">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_28d4ccc2-8fcc-4331-8179-aabec9374630">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_fba42090-b52d-468d-87b6-b763c9054b8c"
      decimals="-5"
      id="F_b94eea19-fee5-4da0-9f3f-0ce3a26590ff"
      unitRef="U_USD">196500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_fe826522-5651-4f06-9c96-09860263bc0d"
      decimals="INF"
      id="F_8ad500a7-c735-424e-bcf4-bd88f615e8c7"
      unitRef="U_shares">31307853</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a1b785c3-6cf9-456c-aa88-8d34cc177fd4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Portions of the Company&#x2019;s definitive Proxy Statement for its 2022 Annual Meeting of Shareholders are to be incorporated by reference into Part III, as specifically set forth in Part III.)&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6d30694e-bcd4-4785-a3fd-77d1310227ea">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a82babb5-5fc1-4e72-840d-1ab6724bc858">Denver, CO</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_47b89904-5eed-46eb-8925-7f420becbab5">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c97a060c-38e1-4c70-819e-c9c099c2946c"
      unitRef="U_USD">32712000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_fa006dbb-1b9d-42cd-863f-b9cc3713c84b"
      unitRef="U_USD">62126000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_705efec6-7fe4-498b-8154-f6f942b3c647"
      unitRef="U_USD">158000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_a6d056a0-8957-4d6a-9458-807af481982b"
      unitRef="U_USD">180000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_e5deee8a-c735-4409-b396-5c61d59ef62f"
      unitRef="U_USD">3656000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_c312136d-9c60-4bf5-9611-777a112395f5"
      unitRef="U_USD">15304000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_d2d7924b-23e8-4dec-87dd-e0b289172b28"
      unitRef="U_USD">7245000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_365d0f09-5cfc-4f36-b286-b903bf860966"
      unitRef="U_USD">8710000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_4bf7ec2d-003a-4693-ade0-d553bcbdd098"
      unitRef="U_USD">43613000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_d4c7b19d-0dcd-4c44-a92d-3418ff3f9b10"
      unitRef="U_USD">86140000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_d52b2dca-ed09-4ef5-8fb6-3ddde77e932b"
      unitRef="U_USD">4179000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_3dfd5fbb-94e2-4aa2-b78f-9a30f9fd6163"
      unitRef="U_USD">3178000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_8625fa79-f682-45b6-981c-ed6fd4cbe1ed"
      unitRef="U_USD">11617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_e293c8c1-b1df-402e-93ad-552530a276c9"
      unitRef="U_USD">13260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c07db3c3-2f98-42bf-92b8-eb0be7b02ba6"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_d7ba7f49-85df-4b67-9422-a9add0ebeaf6"
      unitRef="U_USD">15031000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_032ae51e-3dcb-44ad-89c5-c3fb8bd8d0ea"
      unitRef="U_USD">1657000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_b2cd5302-0d1d-40e7-ba22-af95513af5ed"
      unitRef="U_USD">3461000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_40e66de6-68f8-41d7-aaef-0c3956e9c3a0"
      unitRef="U_USD">32484000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_5f60d577-648e-4d1f-b9f8-ee89e3e7399d"
      unitRef="U_USD">34930000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_b4cfa0e6-2f8a-49d9-90d9-74812ff538d3"
      unitRef="U_USD">76097000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_9f5b1e43-834f-4477-999e-6f2646d27b87"
      unitRef="U_USD">121070000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_7f3e0413-2fe4-4be7-b703-6555c5b0a477"
      unitRef="U_USD">1662000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_3fe0f515-de85-4a6a-9caf-c82d05898da7"
      unitRef="U_USD">8964000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c615615b-914f-40f5-8298-a0fc94e96b29"
      unitRef="U_USD">7665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_1a25f82d-a135-4105-8846-beec16859d25"
      unitRef="U_USD">7789000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_b910e700-bfa7-4758-9852-3f82b682eaef"
      unitRef="U_USD">1850000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_0557bab8-ec6b-4c5a-b485-52194390dfe8"
      unitRef="U_USD">3532000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_35d7ddbe-b52b-4f2c-bfde-73941b9ccd13"
      unitRef="U_USD">17764000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_34ab67b0-f402-46e7-9d2b-fda6b4604da5"
      unitRef="U_USD">19000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:NotesPayableToBankCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_f20cebed-1944-4bd8-90e6-8e569f4a4968"
      unitRef="U_USD">11840000</us-gaap:NotesPayableToBankCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_29f698c8-f5ee-474c-b698-ac718fed6344"
      unitRef="U_USD">28960000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_bbc0fc7d-9905-4831-a1a8-d057dc0141d3"
      unitRef="U_USD">32125000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_1667083a-8f19-45d7-b975-3d80ea99cf11"
      unitRef="U_USD">9993000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_23e67a3a-3c8f-4d10-9206-96c4e75931e5"
      unitRef="U_USD">15926000</us-gaap:LongTermNotesPayable>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_b2662b8d-bff3-4e45-bb4d-8b4046c4cfdd"
      unitRef="U_USD">16028000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_ca481b70-4a91-467e-8887-78bac1efeab1"
      unitRef="U_USD">29932000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c220aed6-6c31-44e8-898e-bcf40b63e409"
      unitRef="U_USD">1389000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_73bf2955-0027-49b4-b6c2-c6448ec9dca1"
      unitRef="U_USD">1921000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_8aeb57f5-f6fe-400f-94e0-44d90ea5af18"
      unitRef="U_USD">27410000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_b6114d46-e89a-400d-9984-fd5504931c00"
      unitRef="U_USD">47779000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_7ca4c190-908a-4f71-9521-c65acf1e7e28"
      unitRef="U_USD">56370000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_3da121dc-6f89-4277-8798-cd7e964f10aa"
      unitRef="U_USD">79904000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_a2544811-f089-4a6c-9171-e4b1a8104b51"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_067f41f5-8947-4baf-86da-39dba7af7af6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_9d4cc2aa-6b95-41a7-81d1-0669cfaee431"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_6842d37d-1e4e-455a-a9d5-a7908ea1ba71"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_75e835f0-2797-477d-bbda-7e02dd2db677"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_26210952-89ff-4612-834a-2a69ccb80074"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_4b68c146-b3ee-4c16-8118-7f6fadbaecc6"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_6f4f3ca0-c526-4f5d-b6fb-a45e3b1fe476"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_5fae82ac-37d4-412f-b89f-d099a31dc32e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_246ec85f-c335-4e2f-a5eb-09a382b45178"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_bb96377f-9a30-451e-8cdf-937e03942a7a"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_81c66f84-85f5-4ebd-8e34-7061942a058c"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_c04edd4d-9bdc-4057-881e-06ed7c0917b9"
      unitRef="U_shares">30789649</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_5c9aa52c-8fce-4899-864e-62b2485dbe18"
      unitRef="U_shares">30789649</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_0b4d9ff3-067c-42da-a57c-da9a47428e4d"
      unitRef="U_shares">26561504</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_09e00fa0-cd54-4019-b3a5-fcd9b0d3d623"
      unitRef="U_shares">26561504</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_333306e4-a00c-4c6b-9cd8-feb529c5300d"
      unitRef="U_USD">31000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_406ea035-c487-450a-b38e-c05bda194998"
      unitRef="U_USD">27000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_2ddce792-0fe6-4afc-8db0-9f508700971b"
      unitRef="U_USD">321669000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_0612c151-ed01-44aa-9ca6-d63d6013d026"
      unitRef="U_USD">299953000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_87c2e490-652a-4377-a6bd-4ff4d3d7ea93"
      unitRef="U_USD">-301973000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_769834fa-a9ac-4b28-9e94-be321b2df59a"
      unitRef="U_USD">-258814000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_2dd8ac2e-8b9b-4ba8-aae3-df2fad43e9b6"
      unitRef="U_USD">19727000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_740800a4-0dca-40ec-8421-d153739d5521"
      unitRef="U_USD">41166000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_60f21456-d50f-4791-9f70-dbfdf9b9d506"
      unitRef="U_USD">76097000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_92510354-a913-4fb9-a28b-a5780a9e273e"
      unitRef="U_USD">121070000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_778fe8b9-c1bb-4e60-87ba-dcb8ac52bd88"
      unitRef="U_USD">54506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_af2460c8-7a2e-440a-a7e8-b815599aa86d"
      unitRef="U_USD">45557000</us-gaap:Revenues>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_30e73413-c3a7-4a32-9025-8ff14f3e3e27"
      unitRef="U_USD">30518000</bdsx:DirectCostsAndExpenses>
    <bdsx:DirectCostsAndExpenses
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_59e37158-79a7-4c28-8e82-be840b7a90a5"
      unitRef="U_USD">21998000</bdsx:DirectCostsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_a1993b80-353a-4165-bb83-803843044870"
      unitRef="U_USD">12789000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_c8340d21-11df-4e0e-9b5f-9cdba13cb7a6"
      unitRef="U_USD">10818000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_626976af-8a4e-4c06-a6eb-0d30555235b7"
      unitRef="U_USD">50517000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_2333f51f-a18a-4354-bead-d931a4024db6"
      unitRef="U_USD">34857000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_0291282c-e631-45ed-9fc5-f2d977394360"
      unitRef="U_USD">1622000</bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense>
    <bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_a977ba4f-d6b7-421f-a7ca-3024ad848b92"
      unitRef="U_USD">818000</bdsx:ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_e7a0cb64-6ccc-4c62-be32-361a88f16545"
      unitRef="U_USD">95446000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_2b0b6931-e22e-4463-83ab-1ed287af0e1a"
      unitRef="U_USD">68491000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_b2d44788-6279-4090-afd4-18016ebe140b"
      unitRef="U_USD">-40940000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_de74d6cf-f4a2-465b-9b36-a833f7de4e68"
      unitRef="U_USD">-22934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_fc066dc2-e17c-415c-82d6-6a3512874c48"
      unitRef="U_USD">4508000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_d09904ff-8c05-4d8e-a182-c7c356b03bcb"
      unitRef="U_USD">7604000</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_ec428b01-4e0a-4076-accf-dafde67697fd"
      unitRef="U_USD">1252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c93dc31a-5892-4417-8e9d-5951d1c5ca82"
      unitRef="U_USD">2298000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_f0371225-bbd4-41b5-aa1e-dc40376a3797"
      unitRef="U_USD">9000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_7d18bc84-605f-4431-a679-555f6dc83c63"
      unitRef="U_USD">440000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_37d2e0ea-575f-4eac-b8ef-60bd9c71a390"
      unitRef="U_USD">-2219000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_8dd43783-85a2-478c-ac04-4940432ca0d0"
      unitRef="U_USD">-8416000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_d6200d4e-af09-429c-817c-69a328b17e03"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_25069897-48ff-47de-9538-fc09cf43159f"
      unitRef="U_USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_3d88e464-eb1e-4cc8-bb5d-5acf08b46add"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_9c2bf116-05b3-4f7e-8a29-25cbb7b2e383"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c3fe6400-9fda-49d5-bd3c-8c30be30dd2a"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_621033b1-8bba-4cf5-9c84-7941e1b27802"
      unitRef="U_shares">4838000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea"
      decimals="INF"
      id="F_9e996c48-ca78-4742-968c-3e6a905269c1"
      unitRef="U_shares">118766000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_884f7f3d-6262-4f55-85a0-e19ff22cf4ea"
      decimals="-3"
      id="F_09601a98-2aa7-4701-bab5-520488bda399"
      unitRef="U_USD">193959000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6"
      decimals="INF"
      id="F_ba51245d-b41d-4b0c-8a81-1773aaf30be3"
      unitRef="U_shares">255000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e11969ed-68d2-4660-93c8-2e91c2e4e5b6"
      decimals="-3"
      id="F_451d1e8f-42ab-4687-924a-52877f26a712"
      unitRef="U_USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_07202086-28e8-435f-adff-fe19436c69b0"
      decimals="-3"
      id="F_554afdd8-21e0-4dad-ae81-c6d6404b368b"
      unitRef="U_USD">2324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_14445421-ccca-421e-9c3f-7d1d23b7cde7"
      decimals="-3"
      id="F_30a681c0-9278-451c-a1b1-978514e7aee3"
      unitRef="U_USD">-227464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc"
      decimals="-3"
      id="F_f9c444cb-0ec1-4c47-b98a-49ee48c7658c"
      unitRef="U_USD">-225139000</us-gaap:StockholdersEquity>
    <us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_881c015e-3e12-4e28-b31a-afe29171b98c"
      unitRef="U_USD">5040000</us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_792d8089-c5d2-4103-9fb4-49282bd5ace0"
      unitRef="U_USD">3203000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="INF"
      id="F_be7d56e4-e468-4818-a875-2a38b7ec5ce7"
      unitRef="U_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="-3"
      id="F_c88051c3-ed20-4d05-9ede-5d77758b1183"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_f3c31bfc-1bbf-49c8-b7f1-10837e5cc16b"
      unitRef="U_USD">63753000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_c4eeb78a-2966-4164-a585-9c3264b35879"
      unitRef="U_USD">63757000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_80a34980-9af4-46a5-ab87-825a03cf6961"
      decimals="INF"
      id="F_bce0269a-c355-4346-831e-b31b4e8e3234"
      unitRef="U_shares">-118766000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_80a34980-9af4-46a5-ab87-825a03cf6961"
      decimals="-3"
      id="F_c97da2d7-8337-48e6-8f68-71013f6e7e53"
      unitRef="U_USD">-193959000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="INF"
      id="F_81556e0f-92f3-4325-8fab-ea863d142c9b"
      unitRef="U_shares">20091000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="-3"
      id="F_cf98d3e0-5df7-4252-a8fd-e109c9566e31"
      unitRef="U_USD">20000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_7da11809-5bc8-46e1-bffe-970cce6a8ecd"
      unitRef="U_USD">193939000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_7f91fd82-ad0e-4c83-8a56-75d9aaa14cc4"
      unitRef="U_USD">193959000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="INF"
      id="F_7c6ddd66-699a-4a79-9935-61cd66ed5d86"
      unitRef="U_shares">1848000</bdsx:StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="-3"
      id="F_1e29ad72-0e57-4ded-a36c-904901115837"
      unitRef="U_USD">2000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_d82ee9d4-b2d1-4919-a663-4cb8c23f52cc"
      unitRef="U_USD">26614000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_141db9ff-23aa-4006-9a59-b37de8c62491"
      unitRef="U_USD">26616000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_f0a76af3-cd5b-4833-b820-0a5f05429c5c"
      unitRef="U_USD">8274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_b6ffa636-2500-4df6-8810-ab905e96322c"
      unitRef="U_USD">8274000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_aaa061c9-7669-4ee2-8139-c6567d310fe6"
      decimals="INF"
      id="F_1e92bb17-e553-424b-bc09-abcf45242b07"
      unitRef="U_shares">368000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_151fcd91-3a48-4cd2-8823-33f442bfd2c3"
      unitRef="U_USD">1340000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_5f975b3b-03ac-42a4-b210-de37e953eae0"
      unitRef="U_USD">1340000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_809d867f-6c56-4037-8eba-8f755ea5fa57"
      decimals="-3"
      id="F_88b4d96b-496c-43a3-98c8-067b435c831c"
      unitRef="U_USD">3709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_055d8f93-0be8-4e91-9a9f-164d776b82fc"
      unitRef="U_USD">3709000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_da0bc552-b359-4652-9ba1-d8e29a01881e"
      decimals="-3"
      id="F_0ae9c62b-d123-4415-8a0e-d166974edb0b"
      unitRef="U_USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_2858d8e1-0339-4d39-aa29-4031ffc41ec3"
      unitRef="U_USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a"
      decimals="INF"
      id="F_aecd0145-ceb2-4182-b3b6-304f2ea1d249"
      unitRef="U_shares">26562000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_5d3df58f-b415-4eab-a73d-5073b62b2e3a"
      decimals="-3"
      id="F_0b921fe2-7472-48f2-a8e1-7dde47b9d96d"
      unitRef="U_USD">27000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_233385c2-cf9b-4c0e-ab38-fbc8fe271a49"
      decimals="-3"
      id="F_23e990b1-c969-4924-b2fa-5044e656369b"
      unitRef="U_USD">299953000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_162734b5-e9c9-4193-b4c1-2b7ff33ee96f"
      decimals="-3"
      id="F_72336864-afb2-47a8-8bac-f9e5ec49d842"
      unitRef="U_USD">-258814000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_f218ce8d-fcbd-4c94-afb4-110b86c428b4"
      unitRef="U_USD">41166000</us-gaap:StockholdersEquity>
    <us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_dcf61ca7-b309-4927-820a-d00708538ab6"
      unitRef="U_USD">664000</us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545"
      decimals="INF"
      id="F_d1b3daa8-d6cd-4887-8cf1-2d4f48dbd0fa"
      unitRef="U_shares">3757000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545"
      decimals="-3"
      id="F_87d5386f-7ebb-454c-a976-7f352daf1d25"
      unitRef="U_USD">4000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9"
      decimals="-3"
      id="F_5629fc2a-86d6-4ad6-813b-4c72df351da0"
      unitRef="U_USD">15675000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_18b0f66f-5caf-44ec-853b-877cd5276c27"
      unitRef="U_USD">15679000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545"
      decimals="INF"
      id="F_a5939728-9ff5-4a97-a0fa-1e149e247fa1"
      unitRef="U_shares">43000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9"
      decimals="-3"
      id="F_f67d98b6-4baa-4374-ac70-4267a8ec9404"
      unitRef="U_USD">328000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_0f482c65-df6d-436e-bfa0-ce6e2d1b4d27"
      unitRef="U_USD">328000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_21e9a711-1b6a-4991-8e79-b6cc008e7545"
      decimals="INF"
      id="F_b6821b58-ec25-40d1-916f-f97422750fc1"
      unitRef="U_shares">428000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9"
      decimals="-3"
      id="F_cbcf421b-8acf-4dda-b871-be1c4fd08a17"
      unitRef="U_USD">769000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_3eb6bdd1-fb32-4130-992c-9e4169696f21"
      unitRef="U_USD">769000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5e31d38e-c781-4c35-a556-26cdca8b81b9"
      decimals="-3"
      id="F_13a798c6-48b2-4e5d-9fec-ef9e647225f2"
      unitRef="U_USD">4944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_3c2e1df7-1215-4d54-ae8a-bd1f8a330cb8"
      unitRef="U_USD">4944000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_24b5491d-ac78-49f4-af90-1e06570e8d91"
      decimals="-3"
      id="F_68dc4fa1-f3b8-4c0e-acf6-410c74d5dc4f"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_94931d21-35d4-40b9-9cd9-234b3ece841b"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8"
      decimals="INF"
      id="F_61fb320b-8e23-4539-b6fa-4bf488ff99c9"
      unitRef="U_shares">30790000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_e99d74b8-d05d-4b7e-b4a7-0392f09b57c8"
      decimals="-3"
      id="F_69304e0e-e8ea-4cc5-be5e-39d13e5630b3"
      unitRef="U_USD">31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8a6364fe-eb05-498f-8396-31e93f9646a7"
      decimals="-3"
      id="F_7ee62580-d9ca-45ce-84fa-c1532fb1ebd8"
      unitRef="U_USD">321669000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2af95b4c-4f7e-4e7e-9808-928b36f0a3d9"
      decimals="-3"
      id="F_6821ae3c-abbd-45b5-acaf-1fc5876237f5"
      unitRef="U_USD">-301973000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_9b411fe8-8753-4232-a2f4-35b1a3cd3189"
      unitRef="U_USD">19727000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_d0bda03a-f312-4515-a145-d0d1a688dc6d"
      unitRef="U_USD">-43159000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_5443b5d0-5eff-4f39-b8d8-88c3079da98f"
      unitRef="U_USD">-31350000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_512bf02d-4434-4a3f-a2ce-549a6097def0"
      unitRef="U_USD">3178000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_2844d605-a984-4e57-9907-8d96ab0650a9"
      unitRef="U_USD">2903000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_ca6d9c6c-67a2-43eb-93f1-3f75ee7ee5fd"
      unitRef="U_USD">4389000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_0edb1c8e-6453-4afe-a604-b10a9365a83c"
      unitRef="U_USD">2298000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_5f5ce441-b5bc-4831-89eb-b92af7826edf"
      unitRef="U_USD">4944000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_f1555ba3-868b-44a7-9cd8-d6e7d2ada538"
      unitRef="U_USD">3709000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_2d147651-cecf-4bcb-87c1-0b79c736c6d7"
      unitRef="U_USD">1252000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c51cbd86-fde4-44d7-8693-1219310bc782"
      unitRef="U_USD">1622000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_835c29cc-1699-4381-b541-4f68a0dcf3c1"
      unitRef="U_USD">818000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_b2ffa533-cbe7-4af9-964c-449de9e5ac7d"
      unitRef="U_USD">193000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_e1dde67f-826f-4331-8be7-13665b12f8da"
      unitRef="U_USD">296000</us-gaap:ProvisionForDoubtfulAccounts>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_75eb1aea-7dcf-4383-ade6-fc7e0525221f"
      unitRef="U_USD">2706000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_6bf35a02-d910-47fe-8650-6679724def24"
      unitRef="U_USD">1418000</bdsx:AccruedInterestAmortizationOfDebtIssuanceCostsAndOther>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_7645b386-5a11-4aff-853e-47cae5639e53"
      unitRef="U_USD">-11454000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_d7affd27-2190-47ff-a88a-b35713e3f5f8"
      unitRef="U_USD">10308000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c88a1c6b-96e9-44fe-ac16-b7a2c18a7ae9"
      unitRef="U_USD">-1369000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_46a7189b-71a4-4bf7-ad04-85a331ed2e42"
      unitRef="U_USD">6588000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_63df9a6d-622b-4778-add9-2bb76d9b2c36"
      unitRef="U_USD">-875000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_e431f608-81d8-4e41-8d3a-6c266e3fad8d"
      unitRef="U_USD">1808000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_b357534c-f7f3-49f9-ae52-31d0c296d9e9"
      unitRef="U_USD">-7425000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_c4c8a214-fb2b-4da8-a5dc-e0e5eef589c8"
      unitRef="U_USD">11654000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c9963acf-4ae8-431c-9ab3-eca1d833f1c8"
      unitRef="U_USD">-1682000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_f3f7a5da-6d72-490e-8ea6-22278e412b86"
      unitRef="U_USD">2249000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_0aba40dc-2d18-4699-8fda-f124e8a2b144"
      unitRef="U_USD">-28223000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_7c2e56cc-1e8a-4cd9-ad7a-4ed4fef402ed"
      unitRef="U_USD">-21366000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_fe5a8015-61e3-4e7b-b7ba-d6017b122718"
      unitRef="U_USD">2241000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_4716bf4a-6921-4d64-bbd3-689f3a031392"
      unitRef="U_USD">1945000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_0b622401-7fca-42dd-98e1-c55135f648f2"
      unitRef="U_USD">306000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_7cf71f07-42d1-4a14-b1f8-e640836e8730"
      unitRef="U_USD">232000</bdsx:PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet>
    <bdsx:PaymentsToAcquireOncimmune
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_95ef9cd3-afdf-42b9-a1d4-ccdbb6582cd8"
      unitRef="U_USD">750000</bdsx:PaymentsToAcquireOncimmune>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_3034a289-4340-4f11-8d67-a13b023b59a3"
      unitRef="U_USD">-2547000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_d66d1608-5add-4d8c-a99a-d04b837ffc0b"
      unitRef="U_USD">-2927000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_a68b7f18-a485-49f9-86ef-2f32f26b0d45"
      unitRef="U_USD">72000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_dd4d4efb-a701-404f-8a96-08b083f92be2"
      unitRef="U_USD">16343000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_c86a6f55-8923-4b29-b181-70b5a6428489"
      unitRef="U_USD">328000</bdsx:ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_7e043977-1be6-4a71-a798-35e12fa67611"
      unitRef="U_USD">769000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_0afc4431-4097-4f2d-aa26-ad076a4ed816"
      unitRef="U_USD">1340000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_08d78d47-95bb-44c9-b76a-c8a93493d676"
      unitRef="U_USD">12955000</us-gaap:ProceedsFromConvertibleDebt>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_6163864d-a3a4-4d1f-8d3b-8495d17aac64"
      unitRef="U_USD">30078000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_4cb789ac-b567-41b0-b19b-0d2df6fe1b01"
      unitRef="U_USD">3085000</bdsx:ProceedsFromIssuanceOfTermLoanAndNotesPayable>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_b54c090b-bc86-4ad2-a352-bf7021f823c3"
      unitRef="U_USD">45428000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_60b237af-17f3-4d23-9df4-8551f7fdbe36"
      unitRef="U_USD">164000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_20277a66-1ea6-4364-a0b5-51b9c6f00bef"
      unitRef="U_USD">664000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_fc577af9-8a8e-4dd0-9cf5-2d56c03dc167"
      unitRef="U_USD">8243000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_ade2fa23-55c5-442a-acd3-3c4ff4e27351"
      unitRef="U_USD">-6000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_fb4fa72d-2564-486e-9adf-25047abe3679"
      unitRef="U_USD">1262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_fc0471f5-b848-421c-a581-3b59ad08f819"
      unitRef="U_USD">81131000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_972d2373-d591-411f-8fa7-f71a0c821f7e"
      unitRef="U_USD">-29508000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_6a489004-a373-49e6-b950-496768d520ce"
      unitRef="U_USD">56838000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_fc2d9e89-6fe6-4685-8a28-d1145f723de4"
      unitRef="U_USD">62306000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc"
      decimals="-3"
      id="F_f70ee8c6-831d-4487-a75e-59a517c3876f"
      unitRef="U_USD">5468000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_023650d6-616b-4063-b435-e66f5cfb4731"
      unitRef="U_USD">32798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_7352dd4d-39a0-4b10-879e-df51b1cdd626"
      unitRef="U_USD">62306000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <bdsx:ConversionOfPreferredStockIntoCommonStock
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_5be56280-4dfb-4a67-a3c7-5bbd44ffd4b8"
      unitRef="U_USD">193959000</bdsx:ConversionOfPreferredStockIntoCommonStock>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_d32af77d-d320-4a2e-8909-fa6894987a60"
      unitRef="U_USD">26616000</us-gaap:ConversionOfStockAmountConverted1>
    <bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_b74113d7-e903-47ba-a149-3621362f08a5"
      unitRef="U_USD">6650000</bdsx:ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital>
    <bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_bceeb9a9-3af3-4316-9092-cb52eb975d21"
      unitRef="U_USD">3389000</bdsx:ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable>
    <us-gaap:InterestPaidNet
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_d53cfc78-27f5-41d6-a6cc-7056271af848"
      unitRef="U_USD">1676000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_b3c74a15-77dc-4df8-91b3-7677fcbce212"
      unitRef="U_USD">1844000</us-gaap:InterestPaidNet>
    <bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_fbdac08f-b3e8-43b1-a74e-fd2c38750eb3"
      unitRef="U_USD">1624000</bdsx:ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_948e00c3-679d-4933-bc79-bb8eb5388958"
      unitRef="U_USD">15000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a3494f61-0d4a-43ac-a7d4-53d58fb60535">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 1 &#x2013; Organization and Description of Business&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Biodesix, Inc. (the &#x201c;Company&#x201d;, &#x201c;Biodesix&#x201d;, &#x201c;we&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;), formerly Elston Technologies, Inc., was incorporated in Delaware in 2005. The Company&#x2019;s headquarters are in Colorado, with laboratories in Colorado and Kansas. The Company conducts all of its operations within a single legal entity. Biodesix is a data-driven diagnostic solutions company leveraging state of the art technologies with its proprietary artificial intelligence platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. In addition to diagnostic tests, the Company provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company performs its blood-based diagnostic tests in its laboratory facilities, which are located in Boulder, Colorado and De Soto, Kansas. In May 2020, the Federal Drug Administration (FDA) granted Emergency Use Authorization (EUA) of the Bio-Rad SARS-CoV-2 Droplet Digital&#x99; polymerase chain reaction (ddPCR) test to detect Coronavirus Disease 2019 (COVID-19) infection. In April 2020, the FDA authorized the Platelia SARS-CoV-2 Total Ab test to detect COVID-19 antibodies. Medical products that are granted an EUA are only permitted to commercialize their products under the terms and conditions provided in the authorization. The FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, if the conditions for the issuance of the EUA are no longer met, or if other circumstances make revocation appropriate to protect the public health or safety.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Blood-Based Lung Tests&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company offers &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; blood-based lung cancer tests across the lung cancer continuum of care:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Diagnosis&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Nodify XL2&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Nodify CDT&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#xae; tests, together marketed as part of our Nodify Lung&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Nodule Risk Assessment testing strategy, assess the risk of lung cancer to help identify the most appropriate treatment pathway. We believe we are the only company to offer &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; commercial blood-based tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Treatment &amp;amp; Monitoring&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;GeneStrat ddPCR&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;VeriStrat&#xae; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;tests, &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;marketed as part of our new IQLung&#x99; testing strategy, are used following diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient&#x2019;s immune system to establish the patient&#x2019;s prognosis and help guide treatment decisions. The GeneStrat ddPCR tumor profiling test and the VeriStrat immune profiling test have a 36-hour average turnaround time, providing physicians with timely results to facilitate treatment decisions.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;GeneStrat NGS&#x99; (NGS) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;test, our 72-hour blood-based NGS test, was launched in November 2021 to a select group of physicians, with national launch in January 2022. The 52-gene panel includes guideline recommended mutations to help physicians treating advanced-stage lung cancer patients identify targeted therapy mutations, such as EGFR, ALK, KRAS, MET, NTRK, ERBB2, and others, and delivers them in an expedited timeframe so patient treatment can begin sooner. The GeneStrat NGS test is marketed as part of the new IQ Lung testing strategy with the GeneStrat ddPCR and VeriStrat tests.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;COVID-19 Tests&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We operate and have commercialized the Biodesix WorkSafe&#x99; testing program, under which the Company offers &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; SARS-CoV-2 tests:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Bio-Rad SARS-CoV-2 ddPCR &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;test, which is authorized by the FDA to be performed by Clinical Laboratory Improvement Amendments (CLIA) authorized laboratories that perform high complexity tests. The ddPCR test is designed to detect the presence of infection by the SARS-CoV-2 virus.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Platelia SARS-CoV-2 Total Ab &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;test, which is an antibody test, authorized by the FDA, intended for detecting a B-cell immune response to SARS-CoV-2, indicating recent or prior infection.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;cPass&#x99; SARS-CoV-2 Neutralization Antibody &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;test&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which is the first blood-based surrogate neutralizing antibody test with FDA EUA and uses ELISA technology to qualitatively detect circulating neutralizing antibodies to the receptor binding domain (RBD) in the spike protein of SARS-CoV-2 that are produced in response to vaccination or a previous SARS-CoV-2 infection. This test was commercially introduced during the second quarter 2021 in partnership with GenScript Biotech Corporation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These tests under the Biodesix WorkSafe testing program are utilized by healthcare providers, including hospitals and nursing homes, and are also offered to businesses and educational systems to assist in their back-to-work or back-to-school strategies, a crucial element of restarting economic activity.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In developing the Company's products, the Company has built or gained access to unique biorepositories, proprietary technology, and bioinformatics methods that it believes are important to the development of new targeted therapies, determining clinical trial eligibility and guiding treatment selection. The Company&#x2019;s testing services are made available through its clinical laboratories.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 27, 2020, the Company completed its initial public offering (IPO), in which it issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the IPO, all shares of the Company&#x2019;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,939,025&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, and all then outstanding warrants to purchase the Company&#x2019;s Series G convertible preferred stock were automatically converted into warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;At-the-Money Offering&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <bdsx:NumberOfCancerTest
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_d1c4e9ff-d2d5-4d0a-af7f-9db23edc0381"
      unitRef="U_Test">5</bdsx:NumberOfCancerTest>
    <bdsx:NumberOfCommercialBloodBasedTest
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_0d900339-1cea-4dae-8cee-80141f30c7ec"
      unitRef="U_Test">2</bdsx:NumberOfCommercialBloodBasedTest>
    <bdsx:NumberOfSARSCoV2Test
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_0e9123bb-9c76-4349-9182-65ab2d6d729d"
      unitRef="U_Test">3</bdsx:NumberOfSARSCoV2Test>
    <bdsx:InitialPublicOfferingIPOPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_3909a406-516e-442a-bd16-344eff5bb9be">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 27, 2020, the Company completed its initial public offering (IPO), in which it issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, in connection with the IPO, all shares of the Company&#x2019;s then-outstanding convertible preferred stock and convertible notes payable were automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,939,025&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock, and all then outstanding warrants to purchase the Company&#x2019;s Series G convertible preferred stock were automatically converted into warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;</bdsx:InitialPublicOfferingIPOPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="INF"
      id="F_5edc8b80-c110-42bf-85b7-0dc7c6b6219e"
      unitRef="U_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28"
      decimals="INF"
      id="F_b3e22da9-2695-4a3c-a613-d02ac4df2700"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="-5"
      id="F_dc6264ff-aadc-4bba-926a-65556663d67d"
      unitRef="U_USD">63800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="INF"
      id="F_7e903810-8ace-4e5a-b997-bb5543b1e782"
      unitRef="U_shares">21939025</bdsx:ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28"
      decimals="INF"
      id="F_ca8fe066-bb91-4697-b1bd-3335bf99e3e1"
      unitRef="U_shares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e"
      decimals="-5"
      id="F_3246f5f3-16f3-4d9b-bc3e-f84dbcebc96f"
      unitRef="U_USD">16300000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e"
      decimals="0"
      id="F_8459429b-7bba-49a3-9584-1f73eaf47386"
      unitRef="U_shares">3756994</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_f1ea6781-dd41-46fb-8136-21495568924f"
      decimals="INF"
      id="F_b3555ee6-205e-4162-8ec6-304dda965a7a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_9acde59f-b452-4eee-bf70-79e2b788507e"
      decimals="-5"
      id="F_65df139e-b143-40e7-8544-d434113e54c8"
      unitRef="U_USD">15700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_e464f26c-c023-467d-b0ee-c80c97c38b79">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 2 &#x2013; Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, we maintained cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and we have $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in principal balance outstanding on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan (see &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balance. We have taken steps to improve our liquidity through raising debt and equity capital during 2021, amendments to our 2021 Term Loan and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiation with certain creditors to modify existing terms of arrangement to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bede26c1-bcbf-4c97-9e63-739d552d824e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These expenses consist principally of salaries, bonuses, employee benefits, travel, stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million restricted cash, respectively, which was included in &#x2018;Other current assets&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expenses'. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_407518a8-f622-40ce-9fc1-00bcdbe09352;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.823%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:86.094%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the completion of the Company&#x2019;s IPO in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#x2019;s IPO in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Put Option Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2020 and 2019, the Company issued convertible debt with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an IPO. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate. The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our IPO, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company grants service-condition RSUs. As a result of our IPO, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Until the Company&#x2019;s IPO in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#x2019;s losses. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ef5d774f-8139-495a-9d87-97b86b83b728">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation and Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant items subject to such estimates include: revenue recognition; the estimation of the fair value of goodwill and other intangible assets; fair value of stock options; income tax uncertainties, including a valuation allowance for deferred tax assets; and contingencies. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recognized revenue and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. Certain prior period amounts have been reclassified to conform to the current period presentation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During March 2020, a global pandemic was declared by the World Health Organization related to the rapidly growing outbreak of a novel strain of coronavirus (COVID-19). The COVID-19 pandemic negatively affected, and we expect will continue to negatively affect, our lung diagnostic testing-related revenue and our clinical studies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, we maintained cash and cash equivalents of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and we have $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in principal balance outstanding on our 2021 Term Loan. We have incurred significant losses since inception and, as a result, we have funded our operations to date primarily through the sale of common stock in our IPO in October 2020, the issuance of notes payable, and from our two primary revenue sources: (i) diagnostic testing, which include lung diagnostic testing and COVID-19 testing, and (ii) providing biopharmaceutical companies with development and testing services. In accordance with Accounting Standards Update 2014-15 (ASC Topic 205-40), &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Presentation of Financial Statements - Going Concern: Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company is required to evaluate whether there is substantial doubt about its ability to continue as a going concern each reporting period, including interim periods. In evaluating the Company&#x2019;s ability to continue as a going concern, management projected its cash flow sources and needs and evaluated the conditions and events that could raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that these financial statements were issued. Management considered the Company&#x2019;s current projections of future cash flows, current financial condition, sources of liquidity and debt obligations for at least one year from the date of issuance of this Form 10-K in considering whether it has the ability to meet its obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our ability to meet our obligations as they come due may be impacted by our ability to remain compliant with financial covenants in our 2021 Term Loan (see &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) or to obtain waivers or amendments that impact the related covenants. Due to the continued uncertainty caused by the COVID-19 pandemic, significant risks remain with respect to our ability to meet these thresholds and any material adverse effect on our revenues, income and expenses could impact our ability to maintain compliance with these covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current operating plan, unless we raise additional capital (debt or equity) or obtain a waiver from complying with such financial covenants, we expect that we will be unable to maintain our financial covenants under our 2021 Term Loan during the next twelve months, which could result in an Event of Default, as defined, causing an acceleration and repayment of the outstanding balance. We have taken steps to improve our liquidity through raising debt and equity capital during 2021, amendments to our 2021 Term Loan and have also undertaken several proactive measures to mitigate the financial and operational impacts of the COVID-19 pandemic through the reduction of planned capital expenditures and certain operating expenses but we do not expect that these actions alone will be sufficient to maintain our financial covenants. In addition, we have entered into negotiation with certain creditors to modify existing terms of arrangement to delay near term cash requirements and extend the period of payments; however, those negotiations are not final at this time and may not result in final agreement. To maintain an adequate amount of available liquidity and execute our current operating plan, we will need to continue to raise additional funds from external sources, such as through the issuance of equity or debt securities; however, we have not secured such funding at the time of this filing and any such financing activities are subject to market conditions. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our existing stockholders&#x2019; rights. There can be no assurance that additional capital will be available to us or, if available, will be available in sufficient amounts or on terms acceptable to us or on a timely basis. If adequate capital resources are not available on a timely basis, we intend to consider limiting our operations substantially. This limitation of operations could include a hiring freeze, reductions in our workforce, reduction in cash compensation, deferring capital expenditures, and reducing other operating costs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s revenues, results of operations and cash flows have been materially adversely impacted by the items noted above. Our current operating plan, which is in part determined based on our most recent historical actual results and trends, along with the items noted above, raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. Our audited financial statements have been prepared assuming we will continue as a going concern and do not include any adjustments that might be necessary should we be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;</bdsx:BasisOfPresentationAndEstimatesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_8a040874-0bfe-4ded-aeab-14db25d4268d"
      unitRef="U_USD">32700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd"
      decimals="-6"
      id="F_c261a83d-a52b-4fe2-bbcb-f909c2667bcf"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_597119b2-dcaa-4fcc-8633-338799426b0b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_bede26c1-bcbf-4c97-9e63-739d552d824e;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; operating segment focused on providing diagnostic testing services to customers. All of the Company&#x2019;s revenue and long-lived assets were derived or located in the United States for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c82bcb7c-5397-4876-aebf-786956c85abf">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company generates revenues from (i) diagnostic tests and (ii) assay development and testing services (services revenue).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company determines the transaction price related to its blood-based lung diagnostic test contracts using a portfolio approach by considering the nature of the payer and historical price concessions granted to groups of customers. The transaction price associated with COVID-19 testing arrangements are determined on the basis of the individual contract with each customer.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Services revenue consists of various types of tests or other scientific services for a purpose as defined by any individual customer, which are often larger biopharmaceutical companies, as defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or achievement of contractual milestone(s) as defined in the customer agreements. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenues related to blood-based lung diagnostic billings based on estimates of the amounts ultimately expected to be collected from customers on a portfolio approach as discussed above. In determining the amount to accrue for a delivered test, the Company considers factors such as payment history, payer coverage, whether there is a reimbursement contract between the payer and the Company, payment as a percentage of agreed upon rate (if applicable), amount paid per test and any current developments or changes that could impact reimbursement. Variable consideration, if any, is estimated based on an analysis of historical experience and adjusted as better estimates become available. These estimates require significant judgment by management.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also provides services to patients with whom the Company does not have contracts as defined in Financial Accounting Standards Board (FASB) Accounting Standards Codification 606 (ASC 606). The Company recognizes revenue for these patients when contracts, as defined in ASC 606, are established at the amount of consideration to which it expects to be entitled, or when the Company receives substantially all of the consideration subsequent to satisfaction and delivery of the performance obligations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue consists of payments received for research, development, and testing services fees received prior to the completion of performance of these tests and services.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 11 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for additional information.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <bdsx:DirectCostsAndExpensesPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cf4c07c1-0f70-47ad-9b43-bb0da37a9798">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Direct Costs and Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of our cost of diagnostic tests and testing services consist of cost of materials, direct labor, including bonus, benefit and stock-based compensation, depreciation of laboratory equipment, rent costs, amortization of leasehold improvements and information technology costs associated with acquiring and processing test samples, including sample accessioning, test performance, quality control analyses, charges to collect and transport samples; curation of test results for physicians; and in some cases, license or royalty fees due to third parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Royalties for licensed technology are calculated as a percentage of revenues generated using the associated technology and recorded as expense at the time the related revenue is recognized. One-time royalty payments related to signing of license agreements or other milestones, such as issuance of new patents, are amortized to expense over the expected useful life of the patents. Costs associated with performing tests are expensed as the test is processed regardless of whether and when revenue is recognized with respect to that test.&lt;/span&gt;&lt;/p&gt;</bdsx:DirectCostsAndExpensesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_764261b5-2c6d-45ae-a945-d38d46302403">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include external and internal costs incurred to develop our technology, collect clinical samples, and conduct clinical studies to develop and support our products. External costs consist primarily of payments to clinical trial sites, sample acquisition costs and laboratory supplies purchased in connection with the Company&#x2019;s discovery and preclinical activities, process development and clinical development activities. Internal costs consist primarily of salaries and benefits, reagents and supplies used in research and development laboratory work, infrastructure expenses, including allocated facility occupancy and information technology costs&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company estimates and accrues its expenses resulting from its obligations under contracts with vendors and consultants in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided under such contracts.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by consultants and vendors regarding the status of each activity. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information received. Research and development costs are expensed as incurred.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_e1b86b40-61cb-48d2-b0b3-4bbcfa3a7047">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Sales, Marketing, General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling expenses consist primarily of costs associated with our sales organization, including our direct sales force and sales management, client services, marketing, and reimbursement, as well as business development personnel who are focused on our biopharmaceutical customers. These expenses consist primarily of salaries, commissions, bonuses, employee benefits, travel, and stock-based compensation, as well as marketing and educational activities and allocated overhead expenses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative expenses also include costs for our marketing and sales organizations, and other functions including finance, legal, human resources, and information technology.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These expenses consist principally of salaries, bonuses, employee benefits, travel, stock-based compensation, as well as professional services fees such as consulting, audit, tax and legal fees, and general corporate costs and allocated overhead expenses.&lt;/span&gt;&lt;/p&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a2fccb52-2dfb-4c65-9600-c44f102c2d95">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentrations of Credit Risk and Other Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Substantially all of the Company&#x2019;s cash and cash equivalents are deposited with two major financial institutions in the United States. The Company continually monitors its positions with, and the credit quality of, the financial institutions with which it holds cash. Periodically throughout the year, the Company has maintained balances in various operating accounts in excess of federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Several of the components of the Company's sample collection kit and test reagents, and certain test systems and related test kits are obtained from single-source suppliers. If these single-source suppliers fail to satisfy the Company's requirements on a timely basis, it could suffer delays in being able to deliver its diagnostic solutions, a possible loss of revenue, or incur higher costs, any of which could adversely affect its operating results.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For a discussion of credit risk concentration of accounts receivable as of December 31, 2021 and 2020, see Note 11 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_af43aeef-a14d-4a02-a536-f656e6e360f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash equivalents consist of short-term, highly-liquid instruments with an original maturity of three months or less from the date of purchase.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c5b72a1d-ca59-45a0-a12d-95ac0164056a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash consists of deposits related to the Company&#x2019;s corporate credit card and a letter of credit related to an operating lease agreement. As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million restricted cash, respectively, which was included in &#x2018;Other current assets&#x2019; in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCash
      contextRef="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98"
      decimals="-5"
      id="F_9ce19e79-5c54-4c48-88b2-d9027e374ecc"
      unitRef="U_USD">100000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f"
      decimals="-5"
      id="F_6d56923e-c6c8-4d64-8c70-ad8c4ca6c392"
      unitRef="U_USD">200000</us-gaap:RestrictedCash>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_054b9adb-08ca-4ab1-b9e2-3832e7c168e8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounts Receivable and Allowance for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts receivable are stated at the amount management expects to collect from customers based on their outstanding invoices. Management reviews accounts receivable quarterly to determine if any receivable will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value based on historical experience, customer creditworthiness, facts, and circumstances specific to outstanding balances, and payment terms.&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventorySuppliesPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ab8cae4e-a76a-48e7-b63b-494acba9f9de">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inventory consists primarily of material supplies, which are consumed in the performance of testing services and charged to 'Direct costs and expenses'. Inventory is stated at cost and reported within &#x2018;Other current assets&#x2019; in the balance sheet and were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:InventorySuppliesPolicy>
    <us-gaap:OtherInventorySupplies
      contextRef="C_e9002fe3-5d7d-4544-bfe5-b8958a38dc98"
      decimals="-5"
      id="F_7f121317-8137-4109-8d16-5097b130f429"
      unitRef="U_USD">2900000</us-gaap:OtherInventorySupplies>
    <us-gaap:OtherInventorySupplies
      contextRef="C_05d20e84-31ae-4757-b0d6-2e8e5750a20f"
      decimals="-5"
      id="F_e56ccb39-1744-45b9-84d1-38a074cb108f"
      unitRef="U_USD">3200000</us-gaap:OtherInventorySupplies>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_95e38aed-b1ba-4af8-b3ca-fa17c5c10d51">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_407518a8-f622-40ce-9fc1-00bcdbe09352;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the asset or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements and betterments are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the balance sheet and any resulting gain or loss is reflected in the statements of operations in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-lived assets to be held and used are evaluated for impairment when events or circumstances indicate the carrying value of a long-lived asset or asset group is less than the undiscounted cash flows from the use and eventual disposition over its remaining useful life. The Company assesses recoverability by comparing the sum or projected undiscounted cash flows from the use and eventual disposition of the asset or asset group to its carrying value, and records an impairment loss if the carrying value is greater than the undiscounted future cash flows. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_479edcde-8115-401c-b300-335b4e160d8a"
      id="F_6fc2f600-9db0-4359-9915-b0459d2b1444">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_473b7666-d11a-4a37-916e-4a1b7cbc2a59"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="INF"
      id="F_b3dcef61-3731-4d5f-bbbf-1d6449d4f1a8"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1f83732d-655a-4549-9cd3-909570756af6">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets primarily consist of intangible assets acquired as part of business combinations, external costs associated with patent applications that are probable of future economic benefits, and trademark costs. Finite-lived intangibles are stated at cost, net of accumulated amortization. The Company amortizes finite-lived intangible assets using the straight-line method over their estimated useful lives of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years, based on management's estimate of the period over which their economic benefits will be realized, product life and patent life. Trademarks are considered indefinite lived and are not amortized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate a reduction to fair value below their carrying amounts. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; impairments for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_ca090c1c-03b5-4f4f-bb08-20bb2d2a2b74"
      id="F_07d09f7f-c7ab-4f6e-860b-6527b9524112">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="C_cb16d514-420d-4abb-9a34-052d761abec3"
      id="F_d290808d-c2ac-4571-9d06-d87c31de6f21">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_88cb62a8-9cc6-42b2-a27f-7b4218dc5590"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="INF"
      id="F_13c80031-0fe8-4c84-aae3-d2d12e7500f6"
      unitRef="U_USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6f25f727-de30-41f6-a972-d64bf0b84532">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of purchase price over amounts allocated to acquired assets and liabilities assumed in business combinations. The carrying value of goodwill is evaluated for impairment at least annually or more frequently when events or circumstances occur indicate a potential for impairment. The annual impairment test is performed on the last day of our fourth quarter. Prior to performing a quantitative evaluation, an assessment of qualitative factors may be performed to determine whether it is more likely than not that the fair value of the reporting unit exceeds its carrying value. In the event the Company determines that it is more likely than not the carrying value of our single reporting unit is higher than its estimated fair value, quantitative testing is performed comparing recorded values to estimated fair values. If impairment is present, the impairment loss is measured as the excess of the recorded goodwill over its implied fair value. Through December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accumulated impairment losses.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_1155c48e-c344-48fd-9594-28412bedea7a"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1ad8740b-03f5-4f44-b5a8-85a61f99d3a0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. GAAP for fair value establishes a hierarchy that prioritizes fair value measurements based on the types of inputs used for the various valuation techniques (market approach, income approach, and cost approach). We utilize a combination of market and income approaches to value our financial instruments. Our financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy. Fair value measurements are categorized within the fair value hierarchy based upon the lowest level of the most significant inputs used to determine fair value. The three levels of the hierarchy and the related inputs are as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:11.823%;"/&gt;
        &lt;td style="width:2.083%;"/&gt;
        &lt;td style="width:86.094%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(255,255,255,0.01);padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices in active markets for similar assets and liabilities;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active; or&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Inputs other than quoted prices that are observable for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of certain financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 4 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for further discussion related to estimated fair value measurements.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bdsx:ContingentConsiderationPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c4246295-9c70-4661-bf3b-ddfea2f62c90">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the purchase transaction with Integrated Diagnostics, Inc. (Indi), the Company recorded contingent consideration for amounts potentially payable to Indi&#x2019;s shareholder upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period after the acquisition date. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.&lt;/span&gt;&lt;/p&gt;</bdsx:ContingentConsiderationPolicyTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"
      decimals="-5"
      id="F_7145a749-ae3b-4174-b4fa-4a43c0f35323"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"
      id="F_b80ede5a-90b6-49f6-a8de-ea069996f3c0">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20"
      decimals="INF"
      id="F_652dd579-95ce-44c3-99eb-5db2706d60c8"
      unitRef="U_pure">0.11</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_479edcde-8115-401c-b300-335b4e160d8a"
      decimals="INF"
      id="F_086a9913-801e-4173-b708-7fb2ce4c4bd7"
      unitRef="U_pure">0.135</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:WarrantLiabilityPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_d3810fc8-648a-464a-890b-e902d73b7546">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Warrant Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the completion of the Company&#x2019;s IPO in October 2020, certain warrants issued to purchase convertible preferred stock were classified as liabilities with changes in the estimated fair value of these liabilities recognized in our results of operations. Upon completion of the Company&#x2019;s IPO in October 2020, the warrants were automatically converted to warrants to purchase common stock. Accordingly, the warrants were remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;</bdsx:WarrantLiabilityPolicyTextBlock>
    <bdsx:PutOptionLiabilityPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_e183da4d-26da-4c81-8dae-ca31db06893b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Put Option Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2020 and 2019, the Company issued convertible debt with terms that provided for a conversion rate to the convertible debtholders that was more favorable than the price that other investors would pay for common stock in certain situations, including the completion of an IPO. As a result, the convertible debt is a financial instrument that was bifurcated into two instruments, a debt obligation and a put option liability, which represented the estimated fair value of the favorable conversion rate. The estimated fair value of the put option liability was separated from the convertible debt at inception and reported as a liability and debt discount, and amortized to interest expense. As a result of our IPO, the convertible debt was automatically converted to common stock and the put option liability was remeasured to an estimate of fair value and recognized in our results of operations and then reclassified to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;</bdsx:PutOptionLiabilityPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_5db77ff2-4f98-441e-a0e4-cbc16d4b9b1a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share&#x2011;Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company grants service condition and performance condition stock options. Stock options are granted with exercise prices equal to the fair market value of our common stock on the date of grant. The grant date fair value of each employee stock option is estimated on the date of grant using the Black-Scholes option-pricing model, which requires the use of assumptions, including the expected term of the option, expected volatility of our stock price, expected dividend yield, and the risk-free interest rate, among others. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. These assumptions involve inherent uncertainties including market conditions and employee behavior that are generally outside of the Company&#x2019;s control. Service condition stock options are expensed based on the grant date fair value of the awards using the straight-line method over the requisite service period. Performance-condition stock options vest based on achievement of multiple weighted performance goals, certification of performance achievement by the Compensation Committee of the Board of Directors, and continued service. For performance-condition stock options, compensation expense is updated for our expected performance level against performance goals at the end of each reporting period, which involves judgment as to achievement of certain performance metrics.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Units (RSUs)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company grants service-condition RSUs. As a result of our IPO, the grant date fair values of these RSUs are based on the closing market price of our common stock on the grant date. We estimate forfeitures and adjust these estimates to actual forfeitures as they occur. The service-condition RSUs vest based on continued service with compensation expense recognized on a straight-line basis over the requisite service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;See Note 12 &#x2014; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for additional information related to share-based compensation.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_aaacec93-07b2-4330-892b-df0387d26a34">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Common Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net loss per common share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per common share is computed by dividing net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;loss by the weighted-average number of common share equivalents outstanding for the period, if dilutive, using the treasury stock method. Potentially dilutive securities consisting of options to purchase common stock, warrants to purchase common stock, RSUs and shares subject to purchase under our employee stock purchase plan were excluded from the calculation of diluted net loss per common share because their effect would be anti-dilutive for all periods presented.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Until the Company&#x2019;s IPO in October 2020, basic and diluted net loss attributable to common stockholders per share was calculated using the two-class method. The net loss was attributable entirely to common stockholders because the participating securities did not have a contractual obligation to share in the Company&#x2019;s losses. As the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for all periods presented.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_63ed0ba9-a815-451e-8f43-46d9b11cc989">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 3 &#x2013; Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;, Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current analysis we expect the adoption to result in the recognition of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_edabff51-0ce4-48c5-96f3-64ef856b5af6;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;approximately&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and associated lease liabilities, inclusive of both lease and non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cb64db38-b758-4d45-9193-582754162a0c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Issued Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;, Leases&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC Topic 842). The new guidance maintains two classifications of leases: finance leases, which replace capital leases, and operating leases. Lessees will need to recognize a right-of-use asset and a lease liability on the balance sheet for those leases previously classified as operating leases under the old guidance. The liability will be equal to the present value of lease payments. The asset will be based on the liability, subject to adjustment, such as for direct costs. The accounting standard will be effective for the Company beginning January 1, 2022. &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Based on our current analysis we expect the adoption to result in the recognition of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_edabff51-0ce4-48c5-96f3-64ef856b5af6;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;approximately&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_38c9ca5e-9069-492b-93d8-a84d6a6b6e87;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;right of use assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and associated lease liabilities, inclusive of both lease and non-lease components, in our balance sheet and do not expect any material impact to our statement of operations or statement of cash flows. We are implementing new processes and internal controls over lease recognition, which will ultimately assist in the application of the new lease standard.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on Financial Instruments. This ASU requires measurement and recognition of expected credit losses for financial assets. This guidance will become effective for the Company beginning January 1, 2023 with early adoption permitted. The Company is currently evaluating this guidance and assessing the overall impact on its financial statements. &lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_34ceab9a-033d-4714-8e55-a25b2036ef92"
      unitRef="U_USD">1500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_c2f421b0-9815-4d0f-82f3-8fb130ccb067"
      unitRef="U_USD">1500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_34a57628-9596-4a92-8e77-d84395666e4d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 4 - Fair Value&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recurring Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our borrowing instruments are recorded at their carrying values in the balance sheets, which may differ from their respective fair values. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, based on interest rates currently available for similar borrowings and were (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.854%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.611%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.331%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.331%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.925%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The financial liabilities that are measured and recorded at estimated fair value on a recurring basis consist of our contingent consideration associated with our acquisition of Indi, and prior to the completion of our IPO in October 2020, the warrant liability, put option liability and contingent value rights granted to certain holders of our convertible preferred stock and debt instruments, which were accounted for as liabilities and remeasured through our statements of operations. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.237%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:13.765%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:12.708%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the changes in contingent consideration for the year ended December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.082%;"/&gt;
        &lt;td style="width:1.892%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balances - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balances - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.42%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:10.338%;"/&gt;
        &lt;td style="width:0.909%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.975%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.975%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:9.356%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Put&lt;br/&gt;Option&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrant&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Value Rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balances - January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassified to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balances - December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement (Indi APA). The contingent consideration arrangement &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period after the acquisition date. Under the terms of the agreement, when the gross margin target was met the Company was required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. For the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; months following the achievement of the gross margin target, Indi had the option to require the Company to redeem these common shares for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in cash over &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;eight&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; equal quarterly installments. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; equal and consecutive quarterly cash installments totaling $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company met the gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for three consecutive months during the three months ended June 30, 2021. The Company entered into an amendment to the original agreement in August 2021 in which all parties agreed to forgo the issuance of common stock and agreed that the Company will in lieu thereof make six quarterly installments of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million beginning in January 2022 and a final payment of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in July 2023 for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The aggregate amount of payments owed by the Company under this amendment is the same as if Indi had exercised the put right or the Company had exercised the call right provided for in the original agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our ability to make these payments are subject to consent from our lender under the 2021 Term Loan and related amendments (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;). We obtained consent and subsequently made the first milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in January 2022 and we are in discussions with our lender to obtain consents for future payments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The significant unobservable inputs used in the measurement of fair value include the probability of successful achievement of the specified product gross margin targets, the period in which the targets were expected to be achieved, and discount rates which ranged from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. As a result of the achievement of the gross margin target, the only significant unobservable input used in the measurement of fair value includes the discount rate since all other inputs became fixed and determinable. Significant increases or decreases in the discount rate would result in a significantly higher or lower fair value measurement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent consideration expected to be paid in the next twelve months is recorded in the balance sheets as &#x2018;Current portion of contingent consideration&#x2019; while the remaining amount to be paid is recorded as &#x2018;Contingent consideration&#x2019; within non-current liabilities. The net change to contingent consideration through the date the gross margin target was met is recorded as operating expenses in the statements of operations. Subsequent changes to the contingent consideration following the achievement of the gross margin target are recorded as &#x2018;Interest expense&#x2019; in the statements of operations resulting from the passage of time and fixed payment schedule. The net change to contingent consideration recorded as operating expenses during the years ended December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was a loss of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. The amount recorded as &#x2018;Interest expense&#x2019; during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Put Option Liability&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The put option liability was valued based on the calculated returns as a result of the various discounts included in the Company&#x2019;s convertible notes payable and the related probability assessments of the various settlement scenarios. During 2020, the Company recognized an addition to the put option liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in connection with a favorable conversion rate granted to holders of issued convertible debt. The put option liability was settled upon the closing of the Company&#x2019;s IPO in October 2020 and reclassified to additional paid-in capital.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Warrant Liability&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with entering into the 2018 Notes, the Company issued to the lender a warrant to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613,333&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series G convertible preferred stock, at an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.75&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, subject to adjustment upon specified dilutive issuances. The warrant was immediately exercisable upon issuance and expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 23, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The estimated fair value of the warrant on the issuance date of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recorded as a debt discount and as a preferred stock warrant liability. Through the effective date of the Company&#x2019;s IPO, the Series G warrants were remeasured to an estimate of fair value using a Black Scholes pricing model. As a result of the Company&#x2019;s IPO, the preferred stock warrants were automatically converted to warrants to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock with a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.46&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and were also transferred to additional paid-in capital. During 2020, the Company recorded an increase in the value of the warrant liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Value Rights&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition to the shares of Series F Preferred Stock that were issued in January 2016, investors who purchased more than their pro&#x2011;rata amount in the financing described above received a calculated number of contingent value rights (CVRs). In connection with the Series F financing, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; CVRs originally valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. One CVR represents &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.00375&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s interest in the drug ficlatuzumab. The initial estimated value of the CVRs were recorded as a liability and as a reduction to the Series F proceeds. Upon receipt by the Company or a milestone, royalty, or any other type of payment from the Company&#x2019;s ownership rights in the drug, the Company was required to make a cash payment to the CVR holders equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of net proceeds, as defined. In September 2020, the Company exercised its opt-out right with AVEO Oncology (AVEO) for the payment of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of development and regulatory costs for ficlatuzumab. As a result, the CVRs were settled effective December 2, 2020. See Note 15 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for a discussion of the Co-Development Agreement with AVEO.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Non-Financial Assets and Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our non-financial assets, which primarily consist of property and equipment, goodwill, and other intangible assets, are not required to be carried at fair value on a recurring basis and are reported at carrying value. There were no changes to the valuation methods during the periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_3dc7e661-76c0-4aa4-bb97-825e96cd10ef">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair values of outstanding borrowings, which are classified as Level 2, approximate their carrying values as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, based on interest rates currently available for similar borrowings and were (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.854%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.611%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.331%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.331%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.187%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.925%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Carrying Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_be8dd81f-cfc5-46e4-b488-457166af9cbd"
      decimals="-3"
      id="F_ed4c7655-c163-48c9-96a6-a886131cb7dc"
      unitRef="U_USD">10012000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_9923eaf7-8b89-4851-b161-00aa62740c91"
      decimals="-3"
      id="F_74897a41-612d-4cc2-8231-f0b356fffb13"
      unitRef="U_USD">10012000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_bcbcd9a8-1029-4466-92ef-98684be0f3eb"
      decimals="-3"
      id="F_bd12b3e0-8f54-40e9-8f7d-768072cfbaf2"
      unitRef="U_USD">27766000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="C_394f3bb1-4c63-47eb-b527-f498fe718a44"
      decimals="-3"
      id="F_dff430fd-cbd8-41db-8ea7-998646ba9934"
      unitRef="U_USD">27766000</us-gaap:LongTermDebtFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a94c1b53-bf1f-4dfe-aa02-9271f5b6e33b">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The table below presents the reported fair values of contingent consideration, which is classified as Level 3 in the fair value hierarchy, as of the dates indicated (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.237%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:13.765%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:12.708%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Description&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current portion of contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,764&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_8ff8a944-a271-4148-9c58-ee869ad37333"
      decimals="-3"
      id="F_393deaab-fc10-4b92-a41f-292c5150fdcd"
      unitRef="U_USD">17764000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_2f88e0dd-ea33-4f83-a540-f014f811689b"
      decimals="-3"
      id="F_49611ea0-5b29-4961-8b2b-2c566b0fbb99"
      unitRef="U_USD">16028000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38"
      decimals="-3"
      id="F_c12f2d10-19d0-460d-8bf1-094fcf53d017"
      unitRef="U_USD">29932000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5"
      decimals="-3"
      id="F_ca0f581f-972f-4939-b3c0-3c3ef4c6dc05"
      unitRef="U_USD">33792000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_5f9b32d4-40ac-442c-bd25-14dd2c52ccb2"
      decimals="-3"
      id="F_a9ac31d1-fc8b-4aa7-b2a9-8d93818ade3a"
      unitRef="U_USD">29932000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_fd406883-6f91-4a22-9159-b2df1b827f82">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the changes in contingent consideration for the year ended December 31, 2021 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.082%;"/&gt;
        &lt;td style="width:1.892%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balances - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,622&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,238&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balances - December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the changes in these financial liabilities for the year ended December 31, 2020 (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.42%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:10.338%;"/&gt;
        &lt;td style="width:0.909%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.975%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:8.975%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:1.205%;"/&gt;
        &lt;td style="width:9.356%;"/&gt;
        &lt;td style="width:0.918%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;For the Year Ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 Rollforward&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Put&lt;br/&gt;Option&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrant&lt;br/&gt;Liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Value Rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Beginning balances - January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,114&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassified to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,624&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Ending balances - December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29,932&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38"
      decimals="-3"
      id="F_bbd60dea-464a-4d4d-a396-1b97d46ec6e1"
      unitRef="U_USD">29932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_2e24974c-f120-44e6-86d6-efe03fc47db4"
      decimals="-3"
      id="F_8e312cd7-57bd-49cf-8222-5a06da88eb7c"
      unitRef="U_USD">1622000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense
      contextRef="C_2e24974c-f120-44e6-86d6-efe03fc47db4"
      decimals="-3"
      id="F_6db431e3-e2f6-4543-9405-db2f9058b130"
      unitRef="U_USD">2238000</bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_2f88e0dd-ea33-4f83-a540-f014f811689b"
      decimals="-3"
      id="F_54fdd0b7-cabd-436a-b1f7-d9219acc5817"
      unitRef="U_USD">33792000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_695b6e0d-d079-4a22-b7f4-5eba3c5f5ec8"
      decimals="-3"
      id="F_7f772dc9-1ce7-4572-b255-6c5bf4fea735"
      unitRef="U_USD">29114000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_34f7bf9b-9a78-44bf-9b7d-69e71e140c33"
      decimals="-3"
      id="F_e527da77-a9ba-4263-9262-6ad1720a3916"
      unitRef="U_USD">3261000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_351c91ef-f104-49d7-9d7f-d572749a1c07"
      decimals="-3"
      id="F_ffaf5b7c-de7a-4f5f-8428-180d1b897a59"
      unitRef="U_USD">372000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_9919b40f-119b-49c1-a2ac-2b76d5a098a0"
      decimals="-3"
      id="F_a7f41c13-7a54-488c-b0dd-b5ac2c9f4bf6"
      unitRef="U_USD">60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="C_87d5899a-2fad-4727-bf84-4cd4bb1daada"
      decimals="-3"
      id="F_36b83262-a801-4da0-b96c-7ff7b636d0f2"
      unitRef="U_USD">3389000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_f8907904-d558-4f3f-8e7e-17a1beefe665"
      decimals="-3"
      id="F_abb2c160-f024-4eda-b7ee-62dfc4cea2f0"
      unitRef="U_USD">818000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_635f9c56-917e-4e2a-96b7-a3121ec435e4"
      decimals="-3"
      id="F_304aecfc-6560-4d88-8788-29866d444354"
      unitRef="U_USD">1252000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="C_ffcdd51b-98b2-4868-af53-a0434a4dc1dd"
      decimals="-3"
      id="F_de431a39-786d-463e-b525-641c6494297f"
      unitRef="U_USD">-60000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital
      contextRef="C_87d5899a-2fad-4727-bf84-4cd4bb1daada"
      decimals="-3"
      id="F_2e61814b-34a1-4fb7-aa0f-0c9901a9b020"
      unitRef="U_USD">-6650000</bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital>
    <bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital
      contextRef="C_635f9c56-917e-4e2a-96b7-a3121ec435e4"
      decimals="-3"
      id="F_28f0264d-4868-4a4c-adcf-a05ad95349dd"
      unitRef="U_USD">-1624000</bdsx:FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_b4423134-5dfd-4ff0-b0de-41bf317abf38"
      decimals="-3"
      id="F_d2861e4c-287d-4bd9-9276-1417ea0d7d79"
      unitRef="U_USD">29932000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_6d377042-8c80-4077-9d06-ae158bc05d91"
      id="F_821fef07-221b-418d-abb2-505cff61a5ba">requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"
      decimals="-5"
      id="F_74905c39-d10e-4cd6-871e-d157ebcdedc8"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"
      id="F_aa816f01-0388-4d3f-89eb-f1623d97cb62">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2"
      decimals="INF"
      id="F_3e3a69e0-7033-4a87-92a8-df8ec3aba72e"
      unitRef="U_shares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_b402d595-7ac8-45f1-be4c-8e6d1bdb6938"
      decimals="INF"
      id="F_5e3a9818-09cb-4b91-87e1-b083be5915dd"
      unitRef="U_Installment">6</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2"
      decimals="-5"
      id="F_abe666cc-9730-48d7-828a-c3c261f7df39"
      unitRef="U_USD">37000000.0</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_8d547382-c6f4-454f-8385-5aac59c66fbb"
      decimals="INF"
      id="F_660ee890-c963-44df-9e66-ef8b88b59396"
      unitRef="U_Installment">8</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity
      contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5"
      id="F_24858df4-8b10-41a4-ade1-93f3daf8b4ea">If Indi elected to not exercise its option, the Company had 12 months to repurchase the common stock in two equal and consecutive quarterly cash installments totaling $37.0 million.</us-gaap:BusinessAcquisitionDescriptionOfAcquiredEntity>
    <bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments
      contextRef="C_3926ceff-39bd-4d7e-94cc-3a867487d940"
      decimals="INF"
      id="F_3993bfb1-e7d3-4b4c-b141-a089565dceca"
      unitRef="U_Installment">2</bdsx:BusinessAcquisitionContingentConsiderationNumberOfInstallments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="C_427d2811-f473-4d72-b6e7-7528519f151a"
      decimals="-5"
      id="F_a8b2ae33-5ff5-4003-b710-7e8b5d8b23f3"
      unitRef="U_USD">37000000.0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d"
      decimals="-5"
      id="F_1f247fe6-1f1f-4730-8c4b-747e62bdff6c"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount
      contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5"
      decimals="-5"
      id="F_c6e4baee-aca5-4778-b3e6-57b5af23f548"
      unitRef="U_USD">4600000</bdsx:BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5"
      decimals="-5"
      id="F_8e824bea-afef-4115-adda-2e56170079d1"
      unitRef="U_USD">9300000</us-gaap:RepaymentsOfDebt>
    <bdsx:BusinessCombinationContingentConsiderationFinalPayment
      contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5"
      decimals="-5"
      id="F_8df7a778-d050-4c27-9e32-d5ec1db43b1b"
      unitRef="U_USD">37000000.0</bdsx:BusinessCombinationContingentConsiderationFinalPayment>
    <bdsx:MilestonePayment
      contextRef="C_69b62320-c88d-472b-b26b-8b37a1a5a0b7"
      decimals="-5"
      id="F_1f9ba6d6-1b32-4250-bda3-2ea47aadebed"
      unitRef="U_USD">4600000</bdsx:MilestonePayment>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_e6943b1f-ff25-4706-9e32-e38b76243a20"
      decimals="INF"
      id="F_07c971a9-2258-4fda-a03a-121d160c6851"
      unitRef="U_pure">0.11</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange
      contextRef="C_479edcde-8115-401c-b300-335b4e160d8a"
      decimals="INF"
      id="F_1f20b59b-d390-48a1-a44f-314b3ba6f683"
      unitRef="U_pure">0.135</bdsx:PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_ea5e3fdf-996d-4c05-8f7c-0456bb8ec3b7"
      decimals="-5"
      id="F_14924d83-3f88-4074-81aa-bdfd3b31a652"
      unitRef="U_USD">1600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_0e3023eb-44b0-4fc0-a3c5-71c2b1aa3636"
      decimals="-5"
      id="F_b8a83e04-46ae-485e-87e5-ac7992da6d22"
      unitRef="U_USD">800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="C_5bb21277-4d96-4ddb-9ba4-3f3d05e4f337"
      decimals="-2"
      id="F_248d90a4-790e-4952-9bfe-ab50bfc4e995"
      unitRef="U_USD">2200</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <bdsx:PutOptionLiabilityCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-5"
      id="F_6ebc50e5-3634-49ae-b674-3f3f210bc70f"
      unitRef="U_USD">3400000</bdsx:PutOptionLiabilityCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38"
      decimals="INF"
      id="F_99c412d2-afab-4aff-bab1-cf4b58064234"
      unitRef="U_shares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_3d4d4b81-ba4d-4966-b68b-fe66d3243a38"
      decimals="INF"
      id="F_b0adeb0c-7fa9-48ad-b1c5-3c2ee89d9bd8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      id="F_1373e188-51fa-4287-a338-85d5c1757b17">2028-02-23</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_a00a8aa6-fb28-4325-ab85-5a2f1ddba7b1"
      unitRef="U_USD">300000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_78ad82cd-de66-4f58-ab74-efd387f2e192"
      decimals="INF"
      id="F_d616768e-7d1e-426e-b56b-6a0d2f2e9f7a"
      unitRef="U_shares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_78ad82cd-de66-4f58-ab74-efd387f2e192"
      decimals="2"
      id="F_80715f30-5dbc-43ed-ad03-889b5259be0c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-5"
      id="F_923cee1f-e051-4122-b0a7-7b1c78edd181"
      unitRef="U_USD">1300000</us-gaap:FairValueAdjustmentOfWarrants>
    <bdsx:ContingentValueRightsShares
      contextRef="C_cea9870b-55e4-4464-845c-28e908ce7ebd"
      decimals="INF"
      id="F_e5553525-e45d-40d5-bc56-59fd1e0036b3"
      unitRef="U_shares">3999</bdsx:ContingentValueRightsShares>
    <bdsx:ContingentValueRights
      contextRef="C_cea9870b-55e4-4464-845c-28e908ce7ebd"
      decimals="-5"
      id="F_6fbfe204-185d-433e-adbf-5f8b18231335"
      unitRef="U_USD">500000</bdsx:ContingentValueRights>
    <bdsx:ContingentValueRightsPercentage
      contextRef="C_e458ef0f-2999-44aa-a713-1bddf0308c7f"
      decimals="INF"
      id="F_b6819c12-1723-4f64-8799-431e7f200d8c"
      unitRef="U_pure">0.0000375</bdsx:ContingentValueRightsPercentage>
    <bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders
      contextRef="C_e458ef0f-2999-44aa-a713-1bddf0308c7f"
      decimals="2"
      id="F_5a63b2c7-e8e6-4074-9782-0f714f51ea0f"
      unitRef="U_pure">0.15</bdsx:NetProceedsPercentageOfCashPaymentToCVRHolders>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_5d6b3d47-9c02-4894-9b66-a374b4ec92de"
      decimals="2"
      id="F_c8ddf0c5-4a0d-48c4-b5e2-bd8b7ab47d77"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_681f3860-e0e6-4356-bc17-d0929a4a7b47">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 5 &#x2013; Property and Equipment&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.781%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.839%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.829%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_61bda6a8-3706-4b10-9386-a7958e94a114">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.837%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,784&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,730&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;871&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;391&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;424&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vehicles&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in process&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;381&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,928&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,902&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,749&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,724&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_54f8436f-4f07-4679-9f01-6b88613fe77b"
      decimals="-3"
      id="F_5a8cfcc2-8f9e-450f-937f-dca216bb5d34"
      unitRef="U_USD">6784000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_9f0f230b-11a1-485f-b548-212c085d2be9"
      decimals="-3"
      id="F_3946f441-320b-4631-9666-8b8543c47470"
      unitRef="U_USD">5730000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f4a0f9f9-1aed-4b51-a28b-499431427de3"
      decimals="-3"
      id="F_d157f1bd-5824-4d5c-b27c-6d614dbc5bc3"
      unitRef="U_USD">2339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_4d3ebbe2-4eae-4d8f-8107-5bbc08d2d099"
      decimals="-3"
      id="F_ce7a3bce-6309-43c8-a135-87e619ed5873"
      unitRef="U_USD">1845000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_547a9002-43fc-4570-ad79-1223f9f65e63"
      decimals="-3"
      id="F_f60f8958-2f84-458d-8b25-e2e1afc05941"
      unitRef="U_USD">700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_afa76821-90e9-46a2-abff-2d96c1240f4d"
      decimals="-3"
      id="F_db0b1d88-3c32-418c-9bd4-7389fd1b4f85"
      unitRef="U_USD">871000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a948fe3c-6e1a-4be0-9898-30610de47069"
      decimals="-3"
      id="F_062d01f5-ef8b-4527-a574-8fa4e6a86af4"
      unitRef="U_USD">391000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_610d8971-4d2b-4f1e-a390-dfe80b599dfb"
      decimals="-3"
      id="F_a1b81f2e-3d43-4ec9-8956-f0ee07506a75"
      unitRef="U_USD">424000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_70269112-fe2a-430e-be5e-df5d73c366d7"
      decimals="-3"
      id="F_80a1b4ac-4ed6-4e37-b0c7-ed29ac87178c"
      unitRef="U_USD">600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_939cfa52-44fa-40af-9e11-eaed7a69e39b"
      decimals="-3"
      id="F_2f2431fb-32c1-4f23-a1e4-09de355b69fb"
      unitRef="U_USD">651000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_d257b176-1b0a-4664-adfe-14f34c0c1a52"
      decimals="-3"
      id="F_bd1fcd84-dfab-40bd-9bc4-bfa2da86fcc9"
      unitRef="U_USD">97000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_dc019ec1-5478-4ebc-a4e8-0c7a3e9bf2db"
      decimals="-3"
      id="F_5f0522c9-3616-4364-81f8-43dcadd8d8c0"
      unitRef="U_USD">17000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1b5736c7-1ac5-4a03-9e32-a0ecc2616053"
      decimals="-3"
      id="F_6a159355-f9e4-4afe-ba4a-37608f9b517a"
      unitRef="U_USD">381000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_7a623e27-c595-451b-9f17-d4bd46525656"
      unitRef="U_USD">10928000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_740c8357-9951-461e-bca8-07f75600cf16"
      unitRef="U_USD">9902000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_4b7afb4b-fb5c-4c00-8681-76fe3acfac90"
      unitRef="U_USD">6749000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_2b473cbf-a1f9-4a5b-93f0-87bc3c18ad6e"
      unitRef="U_USD">6724000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_f7541899-acb5-4382-a2c3-a910a5307805"
      unitRef="U_USD">4179000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_086471a3-fc11-403c-919a-f99f9711feef"
      unitRef="U_USD">3178000</us-gaap:PropertyPlantAndEquipmentNet>
    <bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_5d3670c6-85cc-43c4-aa1a-c1f44ce9b2e4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation expense related to pr&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;operty and equipment was:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.781%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.839%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.829%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;361&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;478&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;839&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock>
    <us-gaap:Depreciation
      contextRef="C_016d7540-660c-40c6-93d0-aeabbf4df993"
      decimals="-3"
      id="F_a0f4e8fa-1527-4982-9fff-170962c6e898"
      unitRef="U_USD">614000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_5852124a-5af9-43ed-b3c2-0ff2fe0b33b7"
      decimals="-3"
      id="F_1a1ccc2c-bfaa-4367-ad00-3b1d137f37f4"
      unitRef="U_USD">361000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_a2edad21-1169-40d3-81f2-27f946978341"
      decimals="-3"
      id="F_5ab5916a-8d88-4104-982b-0b3eea9c7ff4"
      unitRef="U_USD">614000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_cd2c7fce-711f-4dae-a54c-036949770fed"
      decimals="-3"
      id="F_e8042d53-cd0b-4be8-9f9c-e2a38190aa94"
      unitRef="U_USD">478000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf"
      decimals="-3"
      id="F_cee0a9cd-a2cc-4b08-848e-982b0c01dc83"
      unitRef="U_USD">1228000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_72bbc621-8c29-4345-9567-e3a8ec5494ab"
      decimals="-3"
      id="F_199d610e-47b0-42fc-b471-7705c9759b68"
      unitRef="U_USD">839000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_8efb30bf-4cca-4661-91f0-5d1d5f91308b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 6 &#x2013; Goodwill and Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.774%;"/&gt;
        &lt;td style="width:1.039%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:5.936%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:9.47%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:6.382%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:5.936%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:9.591%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:6.382%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.583%;"/&gt;
        &lt;td style="width:2.152%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.457%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future estimated amortization expense of intangible assets is (in thousands):&lt;/span&gt;&lt;/p&gt;
    &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
     &lt;tr style="visibility:collapse;"&gt;
      &lt;td style="width:77.393%;"/&gt;
      &lt;td style="width:1.874%;"/&gt;
      &lt;td style="width:1.206%;"/&gt;
      &lt;td style="width:18.924%;"/&gt;
      &lt;td style="width:0.603%;"/&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,959&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,941&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,719&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
     &lt;tr style="height:10.0pt;"&gt;
      &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,517&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
      &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
     &lt;/tr&gt;
    &lt;/table&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c7624079-170b-4deb-ba9b-9205eb1ee354">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets, excluding goodwill, consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:39.774%;"/&gt;
        &lt;td style="width:1.039%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:5.936%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.234%;"/&gt;
        &lt;td style="width:9.47%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:0.835%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:6.382%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:5.936%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:9.591%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:0.714%;"/&gt;
        &lt;td style="width:1.197%;"/&gt;
        &lt;td style="width:6.382%;"/&gt;
        &lt;td style="width:0.733%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:7.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;"&gt;Net Carrying Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets subject to amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,189&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchased technology&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,694&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets not subject to&lt;br/&gt;&#160;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Trademarks&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;74&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,755&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,617&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129"
      decimals="-3"
      id="F_a7d8d682-4bff-4669-b9b1-99b43d5f442f"
      unitRef="U_USD">1755000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129"
      decimals="-3"
      id="F_ea46fe23-488b-4924-a41a-1c52bae44bdc"
      unitRef="U_USD">566000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_e8377c04-b366-46f3-a7ab-e8e8aa21d129"
      decimals="-3"
      id="F_b42add44-f2a6-4790-910a-d45d3175ba58"
      unitRef="U_USD">1189000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5"
      decimals="-3"
      id="F_f8895f30-96e9-4818-b404-477b72819343"
      unitRef="U_USD">1474000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5"
      decimals="-3"
      id="F_276a66fa-e5d9-4007-aa6b-267d7bb40e02"
      unitRef="U_USD">494000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_928809ae-df57-4571-ac21-764ca2a55ad5"
      decimals="-3"
      id="F_3eaa5896-e10a-4225-9e65-390dbe416f3b"
      unitRef="U_USD">980000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3"
      decimals="-3"
      id="F_b2306df8-7da0-4267-bc14-6982ee5944a8"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3"
      decimals="-3"
      id="F_c8c916df-f661-433d-a19b-204a7c5645fe"
      unitRef="U_USD">6572000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_43d00077-7e8a-4b0b-90fe-a13b37a942a3"
      decimals="-3"
      id="F_f66249f1-2b01-4114-8c8c-0767197f1697"
      unitRef="U_USD">10328000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501"
      decimals="-3"
      id="F_0de07b3d-9c3d-4194-bff4-35c6a0abd617"
      unitRef="U_USD">16900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501"
      decimals="-3"
      id="F_73d40dd2-726e-4114-a8d5-a3c1529cbde6"
      unitRef="U_USD">4694000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_9aed1045-15a0-4022-9dcf-4923b612a501"
      decimals="-3"
      id="F_2db07255-481d-4f78-b790-8c55bb81d761"
      unitRef="U_USD">12206000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b"
      decimals="-3"
      id="F_e6a82f76-394e-4d3e-9bd8-79b31329f200"
      unitRef="U_USD">100000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_760a600e-4a1e-4616-b3a1-4c0f320e7d9b"
      decimals="-3"
      id="F_17357625-5163-497d-9232-2f1a9fc5957a"
      unitRef="U_USD">100000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross
      contextRef="C_001d92ef-337f-44d0-9202-4f278bb0fa67"
      decimals="-3"
      id="F_39966ac4-2f40-4524-8c04-7a32e7610258"
      unitRef="U_USD">74000</bdsx:IndefiniteLivedIntangibleAssetsExcludingGoodwillGross>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_001d92ef-337f-44d0-9202-4f278bb0fa67"
      decimals="-3"
      id="F_ec7c671e-7c1d-4e20-bb13-323c59d97048"
      unitRef="U_USD">74000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_6941ad82-78e2-49c9-9c6c-90f46df8fea0"
      unitRef="U_USD">18755000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_325f97c4-0e6f-43b7-ac99-9a49ac548109"
      unitRef="U_USD">7138000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_6fd45fef-7ad9-4fff-8991-81793ace6df1"
      unitRef="U_USD">11617000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_bc412614-ccc2-4f3b-a42a-4d7e0f8fbd72"
      unitRef="U_USD">18448000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_6257eb31-e518-4ef7-89cd-d93e3116cf91"
      unitRef="U_USD">5188000</bdsx:IntangibleAssetsAccumulatedAmortizationExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_04252324-cb21-402a-afec-b9ba5776a8bc"
      unitRef="U_USD">13260000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_4f7e75bf-1853-442d-a229-9b640b7e704e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Amortization expense related to definite-lived intangible assets was (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.583%;"/&gt;
        &lt;td style="width:2.152%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:11.457%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,051&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,064&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0ce3a578-735a-4075-87ce-b954e21a6041"
      decimals="-3"
      id="F_a4fe4e5b-8e11-4755-87ad-5e17eeaa5882"
      unitRef="U_USD">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_883404a9-e780-4066-b552-a0e49d50d630"
      decimals="-3"
      id="F_8e16335e-7c56-4698-9dcb-ce4c3a44634a"
      unitRef="U_USD">13000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7"
      decimals="-3"
      id="F_ec8d3f0c-7b45-4b30-95a1-011306fc1630"
      unitRef="U_USD">1945000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_661f4aa1-a621-4d97-add7-7f08a6309ae0"
      decimals="-3"
      id="F_543973e9-a989-4329-af20-2a78c8c6ff2f"
      unitRef="U_USD">2051000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_2bf09a32-9e55-4c94-8a67-29e6e203a789"
      unitRef="U_USD">1950000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_8de7efbb-82a3-438f-906a-f335332b1315"
      unitRef="U_USD">2064000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_1b60b418-ea68-4acd-a22d-2665ac2c70e8"
      unitRef="U_USD">1975000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_4f684200-e432-4daf-be28-1b639950b3bf"
      unitRef="U_USD">1969000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_e584bacf-7bf5-4ca8-b246-3ad1388684ea"
      unitRef="U_USD">1959000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_ff2f91af-0440-4c98-9b0c-ab1e11f977e4"
      unitRef="U_USD">1954000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_ffd7c99b-6d5d-49fe-afbd-5265760554d4"
      unitRef="U_USD">1941000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_0e5274ef-a33a-4a66-84ce-6238c570be57"
      unitRef="U_USD">1719000</bdsx:FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_f87bd7a2-aa97-47e7-877b-8ce09e5b3121"
      unitRef="U_USD">11517000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_f0729588-aacb-43d1-889b-effb5643b50e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 7 &#x2013; Accrued Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.784%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_651a9aab-ba66-426c-ba5d-5c10bf5a533c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.784%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:1.596%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.832%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Compensation related accruals&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,029&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,975&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued clinical trial expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,099&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&#160;&#160;Total accrued liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,665&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,789&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_131635cb-225f-4ea0-9b42-801831bbfee3"
      unitRef="U_USD">4029000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_c85fbf07-2d86-4eed-a011-a2223c357145"
      unitRef="U_USD">3975000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_fc36a362-0115-4b17-b36b-6853b2678902"
      unitRef="U_USD">870000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <bdsx:AccruedClinicalTrialExpenseCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_b9c908e4-4960-4260-87d1-d7021b9bd434"
      unitRef="U_USD">715000</bdsx:AccruedClinicalTrialExpenseCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_0eef5e28-273a-4a0e-ba01-c14ddc64b5e3"
      unitRef="U_USD">2766000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_46f254cc-a0b9-40e7-b7f8-aeb6b44cc54c"
      unitRef="U_USD">3099000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_0e94883c-c385-40b3-9791-538c73761c44"
      unitRef="U_USD">7665000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_28697c34-4d2c-4e72-96c0-ec6b14286993"
      unitRef="U_USD">7789000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_73259ccc-640e-42f2-aa1e-dc1a3c9f2afb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 8 &#x2013; Debt&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our long-term debt consists of notes payable associated with our 2021 Term Loan, 2018 Notes and Paycheck Protection Program, each of which is described in further detail below. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.308%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.386%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.755%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Paycheck Protection Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 19, 2021 (Effective Date), the Company entered into a Loan and Security Agreement (the 2021 Term Loan) by and between Silicon Valley Bank (SVB or Lender) and the Company, as borrower, whereby subject to the terms and conditions of the 2021 Term Loan, SVB advanced to the Company an original principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Term Loan provides for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;monthly&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s final payment, due at maturity on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;March 1, 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, shall include all outstanding principal and accrued and unpaid interest, lender fees and expenses, of which the majority will include a final payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and all other sums, if any, that shall have become due and payable hereunder with respect to the 2021 Term Loan. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million final payment will be amortized as interest expense over the term of the 2021 Term Loan. The Company has the option to prepay, prior to maturity, the total outstanding principal amount plus accrued and unpaid interest, subject to a prepayment penalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the principal amount if paid prior to the first anniversary of the Effective Date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the principal amount if paid on or after the first anniversary but prior to the second anniversary of the Effective Date, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the principal amount if paid on or after the second anniversary but prior to October 19, 2025, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% thereafter.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company granted the Lender a security interest in substantially all of the Company&#x2019;s assets. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.95&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s projected revenue performed at the end of each reporting p&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;eriod.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; On September 30, 2021, we entered into the Consent and First Amendment to Loan and Security Agreement (First Amendment) to, among other things, amend our 2021 Term Loan to eliminate the revenue covenant for the period ended September 30, 2021 and modify the revenue covenant threshold for the three month period ended December 31, 2021. In addition, we agreed to establish a restricted cash collateral account for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the benefit of our lender if the balance of our cash and cash equivalents declines below $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. On December 31, 2021, we entered into the Consent and Second Amendment to Loan and Security Agreement (Second Amendment) to, among other things, amend our 2021 Term Loan and First Amendment to obtain consent for the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million January 2022 milestone payment under the Indi APA, repay $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in outstanding principal on December 31, 2021, waive the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;600,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; prepayment fee on the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million Term Loan repayment&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and waive the minimum revenue covenant as of December 31, 2021 and modify the minimum revenue requirement to not less &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% for the three months ended March 31, 2022 and not less than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on a trailing six month rolling basis for each quarter thereafter of the Company&#x2019;s projected revenue performed at the end of each reporting period&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Lender agreed to apply the full amount of funds previously established within the restricted cash collateral account to partially prepay the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in outstanding principal, thereby eliminating the restricted cash collateral account. The Company recorded a loss on extinguishment of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million resulting from the write-off of debt issuance costs associated with the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million repayment of our 2021 Term Loan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Term Loan contains certain covenants limiting the ability of the Company to, among other things, incur future debt, transfer assets except for the ordinary course of business, make acquisitions, pay dividends or make other certain restricted payments, or sell assets, subject to certain exceptions, without the prior written consent of the Lender. Failure to comply with the covenants and loan requirements may result in an event of default. As of December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company was in compliance with all restrictive and financial covenants associated with its borrowings.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In the event of a default, including, among other things, our failure to make any payment when due or our failure to comply with any covenant under the 2021 Term Loan, the Lender may elect to declare all amounts outstanding to be immediately due and payable, and may proceed against the collateral granted to them to secure such indebtedness, including a royalty-free license or other right to use all of our intellectual property without charge.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2018 Notes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2018, the Company issued long-term debt of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to Innovatus Life Sciences Lending Fund (Innovatus or Lender) (the 2018 Notes). Innovatus is also a holder of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the time of issuance, the Company paid a facility fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and issued a warrant to Innovatus, with an initial estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, for the purchase of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613,333&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Series G preferred stock. The facility fee and the estimated warrant fair value were recorded as debt discount and is amortized to interest expense over the term of the 2018 Notes. The 2018 Notes bore annual interest at &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% was payable in cash, with the remaining &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% added to principal through December 31, 2020. Total interest added to principal was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of March 31, 2021 and December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 19, 2021, in connection with entering into the 2021 Term Loan agreement with SVB, the Company repaid all outstanding principal, accrued and unpaid interest, and prepayment fees in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million due under the 2018 Notes and contemporaneously terminated the related Loan and Security Agreement, dated as of February 23, 2018, as amended, between Innovatus and the Company. As a result of the extinguishment of the 2018 Notes, the Company recognized a loss on debt extinguishment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the three months ended March 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Paycheck Protection Program Note Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2020, the Company entered into a loan pursuant to the Paycheck Protection Program under the CARES Act, as administered by the U.S. Small Business Administration (the SBA). The loan, in the principal amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million (the PPP Loan), was disbursed by JPMorgan Chase Bank (JPM) pursuant to a Paycheck Protection Program Promissory Note and Agreement (the Note and Agreement).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The PPP Loan had a maturity date on the two-year anniversary of the funding date, April 2022, and included a fixed rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), were scheduled to commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;pay any facility charge to obtain the PPP Loan.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Note and Agreement contained customary events of default, including those relating to failure to make payment, bankruptcy, breaches of representations and material adverse effects.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All or a portion of the PPP Loan may be forgiven by the SBA upon application by the Company. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during the eight-week period beginning on the approval date of the PPP Loan. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee earning more than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, prorated annually. Not more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the forgiven amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages for employees with salaries of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; or less annually are reduced by more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%. During the second quarter of 2021, the Company determined that it would apply for forgiveness under the SBA&#x2019;s Loan Forgiveness program, a change from its previous intent to repay. Subsequently, in July 2021 the Company applied for loan forgiveness and on August 17, 2021, the Company received legal release and formal notification that the PPP Loan was forgiven in full. During the three months ended September 30, 2021, the Company reduced the &#x2018;Current portion of notes payable&#x2019; and recorded a gain on extinguishment in the statements of operations for the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million forgiven.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.397%;"/&gt;
        &lt;td style="width:1.911%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.883%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ffd8bb15-6901-4b9d-82d2-e3db1f3a6fc5">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term notes payable were as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.308%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.386%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.755%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021 Term Loan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2018 Notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Paycheck Protection Program&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,107&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unamortized debt discount and debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,012&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,840&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term notes payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,993&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,926&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_3ae875ad-cbca-4a01-a964-17e3e86e65bd"
      decimals="-3"
      id="F_a463a212-b4bb-4146-b1a3-134eb20ff9eb"
      unitRef="U_USD">10000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff"
      decimals="-3"
      id="F_1a6fd8e1-2d43-4d54-a7c7-f467a3027005"
      unitRef="U_USD">24972000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_e272dfed-04df-4966-8eea-8a8670605352"
      decimals="-3"
      id="F_514cc4c9-9d70-4a03-a6af-66a6010043ea"
      unitRef="U_USD">3107000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_f68dea5d-5219-4f85-b2dc-32544a35182b"
      decimals="-3"
      id="F_974cfa85-bc2f-475d-9fd7-f6cef71826f5"
      unitRef="U_USD">75000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_83c2a474-c0df-46ab-89fd-86b128394719"
      unitRef="U_USD">63000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_85d29684-e990-4a0d-a23d-b511d8e3df7e"
      unitRef="U_USD">313000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:NotesPayable
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_94442431-c467-4da6-844e-78322e1d08ba"
      unitRef="U_USD">10012000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_82bd5617-03d9-4368-b4af-6f2803b7292d"
      unitRef="U_USD">27766000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_ee76aeed-ea98-470e-95c8-b4873e7062ef"
      unitRef="U_USD">19000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_91735e5a-70be-4f8a-9c30-d5731b1fb277"
      unitRef="U_USD">11840000</us-gaap:NotesPayableCurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c971170c-6729-444f-a525-c1c7eb91ab04"
      unitRef="U_USD">9993000</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_08fee7e6-fc3b-4530-baaa-24483be256ed"
      unitRef="U_USD">15926000</us-gaap:LongTermNotesPayable>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_dce01a48-8efc-4803-9957-bfa88c6b1299"
      decimals="-6"
      id="F_9506b9a4-025e-45d1-ac3f-9d195aa246e8"
      unitRef="U_USD">30000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8"
      id="F_046f3317-1f65-4c58-af42-f77c56c930ea">The 2021 Term Loan provides for an &#x201c;interest-only&#x201d; period from the Effective Date through February 28, 2023, with interest due and payable monthly on the first calendar day of each month. However, the Company achieved a revenue milestone of at least $65 million on a trailing twelve-month basis during the three months ended March 31, 2021 which automatically extended the interest-only period through February 28, 2024. Beginning on the first calendar day of the month following the end of the interest-only period, the 2021 Term Loan shall be payable in (i) consecutive equal installments of principal through March 1, 2026, plus (ii) monthly payments of accrued interest. The principal amount outstanding under the 2021 Term Loan shall accrue interest at a floating per annum rate equal to the greater of (i) 2.00% above the prime rate, or (ii) 5.25%, which interest, in each case, shall be payable monthly. Changes to the interest rate applicable to the 2021 Term Loan based on changes to the prime rate shall be effective on the effective date of any change to the prime rate.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6"
      id="F_87580cdc-eb4a-46a7-8b5e-f0c3936c66d1">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <bdsx:RevenueMilestone
      contextRef="C_02073a80-e7d4-420b-a2a9-04056034b97e"
      decimals="-6"
      id="F_9a83cc44-cb57-4cc8-b33c-42269a67ea7d"
      unitRef="U_USD">65000000</bdsx:RevenueMilestone>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6"
      id="F_5194cad8-037f-429c-9f90-1e40a65eb8cd">2026-03-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6"
      decimals="-5"
      id="F_339ba870-99f3-4e74-adea-73667a6b1ea9"
      unitRef="U_USD">2700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6"
      decimals="-5"
      id="F_727f342c-a435-4135-9f8f-3e93508a786a"
      unitRef="U_USD">2700000</us-gaap:RepaymentsOfDebt>
    <bdsx:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_4841ec21-e13f-4543-9fc7-01050702bdab"
      decimals="2"
      id="F_859ae49e-d51a-43a9-a380-f07533ef5d1e"
      unitRef="U_pure">0.03</bdsx:DebtInstrumentPrepaymentPenaltyPercentage>
    <bdsx:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_3e8e4408-1447-42cb-bbca-6204beddc1bb"
      decimals="2"
      id="F_c2d4002c-872e-4293-bf7b-290984db9576"
      unitRef="U_pure">0.02</bdsx:DebtInstrumentPrepaymentPenaltyPercentage>
    <bdsx:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_be6ca8b8-4a35-4cad-b184-8b65c4c20b91"
      decimals="2"
      id="F_fb682cdb-7eca-40ba-9324-5c4d542b6582"
      unitRef="U_pure">0.01</bdsx:DebtInstrumentPrepaymentPenaltyPercentage>
    <bdsx:DebtInstrumentPrepaymentPenaltyPercentage
      contextRef="C_605a1f05-b224-4c9a-a68f-b4ebf4f58a59"
      decimals="2"
      id="F_d0852ee3-e682-4048-9525-45e95d4d06df"
      unitRef="U_pure">0</bdsx:DebtInstrumentPrepaymentPenaltyPercentage>
    <us-gaap:DebtInstrumentCovenantDescription
      contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8"
      id="F_7d7e7edb-8dee-49be-b029-6ef31fb2c26e">The 2021 Term Loan requires the Company to comply with a minimum liquidity ratio covenant (as defined) by the 2021 Term Loan of not less than 0.95 to 1.00, and has a trailing six month rolling minimum revenue requirement of not less than 70% of the Company&#x2019;s projected revenue performed at the end of each reporting period.</us-gaap:DebtInstrumentCovenantDescription>
    <bdsx:MinimumLiquidityRatioCovenant
      contextRef="C_12147dfe-e917-4369-b593-468bf48cc6b6"
      decimals="INF"
      id="F_02f5aabc-5fe0-4f43-b879-6bc9cec95c2a"
      unitRef="U_pure">0.0095</bdsx:MinimumLiquidityRatioCovenant>
    <bdsx:PercentageOfMinimumRevenueRequirement
      contextRef="C_12147dfe-e917-4369-b593-468bf48cc6b6"
      decimals="INF"
      id="F_d9d4c00d-dbd9-4833-9aa8-abc7ed7f705c"
      unitRef="U_pure">0.70</bdsx:PercentageOfMinimumRevenueRequirement>
    <us-gaap:CashCollateralForBorrowedSecurities
      contextRef="C_70caefc6-3ec4-4c3c-872d-2ca7c3a4dd74"
      decimals="-6"
      id="F_87bcc55b-9b96-43d5-b6b9-c2258e4e9fe5"
      unitRef="U_USD">15000000</us-gaap:CashCollateralForBorrowedSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_848353f5-4aab-4165-b023-6cc47cbe6d8d"
      decimals="-3"
      id="F_64419dce-d17d-4f57-b80f-7df78268e9bd"
      unitRef="U_USD">40000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bdsx:MilestonePayment
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-5"
      id="F_ca47098b-9626-407f-a84d-1913c352fb66"
      unitRef="U_USD">4600000</bdsx:MilestonePayment>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-6"
      id="F_4b8fcd0b-5586-403a-9e3f-7ddbd9bb3a78"
      unitRef="U_USD">20000000</us-gaap:RepaymentsOfDebt>
    <bdsx:PrepaymentFeeWaivedAmount
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="0"
      id="F_882e4c37-4727-4154-b7bc-6373346c9454"
      unitRef="U_USD">600000</bdsx:PrepaymentFeeWaivedAmount>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-6"
      id="F_7e4fa26d-2a33-4cff-9c49-085cac29a695"
      unitRef="U_USD">20000000</us-gaap:RepaymentsOfDebt>
    <bdsx:PercentageOfMinimumRevenueRequirement
      contextRef="C_9a21cd39-7714-46bd-8caa-1643fbfd5aa9"
      decimals="INF"
      id="F_1e437c5e-2376-4db7-9d46-f6dd1cf837a6"
      unitRef="U_pure">0.75</bdsx:PercentageOfMinimumRevenueRequirement>
    <bdsx:PercentageOfMinimumRevenueRequirement
      contextRef="C_93914a7c-1f7d-4779-a324-6676f6a64acb"
      decimals="INF"
      id="F_5f00b7ca-b6d7-4c13-a9be-959ec9bf21a2"
      unitRef="U_pure">0.75</bdsx:PercentageOfMinimumRevenueRequirement>
    <bdsx:PartialRepaymentsOfDebt
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-6"
      id="F_403c2f7f-5b73-4b65-855c-955ead573da8"
      unitRef="U_USD">20000000</bdsx:PartialRepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-5"
      id="F_6f444c63-484d-480e-addd-a9f719a9ea10"
      unitRef="U_USD">-100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost
      contextRef="C_be505f23-bf3c-4be3-8972-80834ee53690"
      decimals="-6"
      id="F_998fa2af-2784-424f-a1ca-a3d4dc6da3fc"
      unitRef="U_USD">20000000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:DebtInstrumentCovenantCompliance
      contextRef="C_66cad3c3-9239-41d0-b072-1849ca46dde8"
      id="F_2034726a-ce2d-4fe3-8c78-efd22ffc7359">the Company was in compliance with all restrictive and financial covenants associated with its borrowings.</us-gaap:DebtInstrumentCovenantCompliance>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="-5"
      id="F_42ab7e99-67d7-406c-8bea-7ce14e783a07"
      unitRef="U_USD">23000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="-5"
      id="F_d3d23391-1d02-4704-b717-6b54717153b9"
      unitRef="U_USD">200000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="-5"
      id="F_eff85a36-cf30-4347-a63e-362880312847"
      unitRef="U_USD">300000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="C_d049bfe6-5f3b-4066-8ad9-a9ca88059623"
      decimals="INF"
      id="F_232ac950-59b8-40d5-84d8-0908c41d0616"
      unitRef="U_shares">613333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="INF"
      id="F_2f5d46ff-4eac-4372-859b-0e76e48e7fdd"
      unitRef="U_pure">0.10</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="INF"
      id="F_499ec967-7dc9-4c5a-9c13-2d3fac0759fb"
      unitRef="U_pure">0.075</bdsx:DebtInstrumentPercentageOfStatedInterestRatePaidInCash>
    <bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable
      contextRef="C_a728943e-0005-498d-bf19-caa91ad50029"
      decimals="INF"
      id="F_6adb858e-fd44-4008-8f93-cab69e410b32"
      unitRef="U_pure">0.025</bdsx:DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable>
    <bdsx:DebtInstrumentInterestAddedToPrincipalValue
      contextRef="C_8f45d621-66e2-469e-81de-170b52163c24"
      decimals="-5"
      id="F_8ff372c8-92bf-4748-8067-e450ce68ac76"
      unitRef="U_USD">1700000</bdsx:DebtInstrumentInterestAddedToPrincipalValue>
    <bdsx:DebtInstrumentInterestAddedToPrincipalValue
      contextRef="C_58f497bf-9bff-4813-874b-13e9e3d8e3ff"
      decimals="-5"
      id="F_27ce5d56-c9a1-439d-af34-4cadb13703b2"
      unitRef="U_USD">1700000</bdsx:DebtInstrumentInterestAddedToPrincipalValue>
    <us-gaap:RepaymentsOfDebt
      contextRef="C_98e59e9a-da90-42c6-9029-2c28be33926b"
      decimals="-5"
      id="F_2fe4b790-d841-4a68-ace6-e1b570e8ded2"
      unitRef="U_USD">25900000</us-gaap:RepaymentsOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_cad7d434-2ef5-46b9-aa6d-b243e79c1d26"
      decimals="-5"
      id="F_53534fe5-e097-438c-b00e-b9d3858ef1e0"
      unitRef="U_USD">-700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="C_dc89134f-48d3-4944-93af-a1d690ce60d2"
      decimals="-5"
      id="F_0353a6a2-607e-4c90-965f-3377ec032f55"
      unitRef="U_USD">3100000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentDescription
      contextRef="C_0c2b5021-3880-4a79-86df-3e22efd61deb"
      id="F_2130ff27-ebab-41bc-8da7-550f5bdbb8a4">The PPP Loan had a maturity date on the two-year anniversary of the funding date, April 2022, and included a fixed rate of 1.00% per annum. Monthly principal and interest payments, less the amount of any potential forgiveness (as discussed below), were scheduled to commence in September 2021. The Company did not provide any collateral or guarantees in connection with the PPP Loan, nor did the Company pay any facility charge to obtain the PPP Loan.</us-gaap:DebtInstrumentDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="C_17de90cc-7d15-42d1-b8bb-764245d80c72"
      decimals="INF"
      id="F_9f0881c9-b7d9-4e27-bc8b-4e9503c5a108"
      unitRef="U_pure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <bdsx:PayrollCostsExcludesCompensationOfEmployee
      contextRef="C_2d8d257d-2c7e-4c61-95ab-cfad10d07908"
      decimals="INF"
      id="F_bfa707fc-e789-4849-b775-e5124be0b348"
      unitRef="U_USD">100000</bdsx:PayrollCostsExcludesCompensationOfEmployee>
    <bdsx:PercentageForNonPayrollCosts
      contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6"
      decimals="INF"
      id="F_657ec7be-ab4b-4792-8bb7-0cf49099e981"
      unitRef="U_pure">0.40</bdsx:PercentageForNonPayrollCosts>
    <bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness
      contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6"
      decimals="INF"
      id="F_e6d7596d-d766-46a5-a160-805ea2beabe9"
      unitRef="U_USD">100000</bdsx:UpperLimitOfEmployeeSalaryToReduceForgiveness>
    <bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness
      contextRef="C_c137ab7e-b733-4793-ad80-a153a9ec42f6"
      decimals="INF"
      id="F_5e1beb2e-216b-4094-a2a8-d073ace61020"
      unitRef="U_pure">0.25</bdsx:PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="C_462729a6-5e59-40a9-995d-eddd6dbf59aa"
      decimals="-5"
      id="F_e391fa58-07d0-4a9b-906f-4ea72954f435"
      unitRef="U_USD">3100000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="C_f406a25c-1311-429f-acab-1fbc603fcfb9"
      decimals="-5"
      id="F_30a15258-3e8a-462b-8dab-e1d6fdf78f5c"
      unitRef="U_USD">3100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ae1d0aa4-d7bd-4e22-85c6-2ca14bb2f846">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Scheduled principal repayments (maturities) of long-term obligations were as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.397%;"/&gt;
        &lt;td style="width:1.911%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:16.883%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,818&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,206&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,075&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_6aa77d44-ee00-4175-8f1d-50177781aeef"
      unitRef="U_USD">19000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_6c68e9aa-ed15-46f8-b9d4-58b8ff604514"
      unitRef="U_USD">15000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_bf1f313c-4887-48f3-9e90-bdc79d09511f"
      unitRef="U_USD">4017000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_e10be224-8d83-4f9e-ac49-573fd966aa4c"
      unitRef="U_USD">4818000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_86e7b3e9-3e14-47b6-92f6-5473f16c818e"
      unitRef="U_USD">1206000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <bdsx:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_b53d2cb7-eff6-4e32-b0b1-bd838e4fd7ba"
      unitRef="U_USD">0</bdsx:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter>
    <us-gaap:LongTermDebt
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_c7e33c68-c876-484f-9ba9-d72561febd96"
      unitRef="U_USD">10075000</us-gaap:LongTermDebt>
    <bdsx:WarrantsForConvertiblePreferredStockTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_85af869a-e843-4386-be04-721e2bf2e2a7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 9 &#x2013; Warrants to Pur&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;chase Convertible Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company issued warrants to purchase shares of convertible preferred stock in conjunction with the sale of certain of the convertible preferred shares and issuance of debt. Through the closing of the Company&#x2019;s IPO, the preferred warrants were classified as liabilities with estimated fair value remeasured at each reporting date reported within in the accompanying statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.005%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.163%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.19%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Series E&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Series G &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of warrant liability to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The warrants to purchase Series E convertible preferred stock were not exercised and expired during the three months ended June 2020.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:6.7pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our IPO, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants to purchase common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, which have an expiration date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 23, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. All common stock warrants remain outstanding as of December 31, 2021.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</bdsx:WarrantsForConvertiblePreferredStockTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_650747cf-66a1-4c06-ab12-c62dcd3d72c1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents the activity for convertible preferred stock warrants (in thousands, except weighted average exercise price):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.005%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.163%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.144%;"/&gt;
        &lt;td style="width:0.983%;"/&gt;
        &lt;td style="width:1.215%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:9.19%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Series E&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Series G &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; January 1, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;925&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of warrant liability to additional paid-in capital&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;613&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;(1)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; On October 27, 2020, all convertible preferred stock converted to common stock at the completion of our IPO, and as a consequence, the warrants to purchase Series G convertible preferred stock were converted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; warrants to purchase common stock at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.46&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, which have an expiration date of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 23, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. All common stock warrants remain outstanding as of December 31, 2021.&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_22af9de2-1e40-4b4f-b58e-22e115d6077d"
      decimals="-3"
      id="F_81454514-eb1b-40e9-b388-c419fb029a30"
      unitRef="U_shares">925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_22af9de2-1e40-4b4f-b58e-22e115d6077d"
      decimals="2"
      id="F_93fe64a5-68d5-4f2d-a897-0edbc0348e10"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_01ea5af0-61c2-43e8-83f4-995b808a9869"
      decimals="-3"
      id="F_aae7fe6c-ca09-468c-a9b2-ffc9eb802181"
      unitRef="U_shares">613000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_01ea5af0-61c2-43e8-83f4-995b808a9869"
      decimals="2"
      id="F_4e92813b-a8db-485e-a66a-985f7ac1f80f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.75</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="C_6b886bcd-bd24-4350-8fd7-27742802fadf"
      decimals="-3"
      id="F_d8997f25-fd8f-4c8f-b010-86a2667592ed"
      unitRef="U_shares">925000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_6b886bcd-bd24-4350-8fd7-27742802fadf"
      decimals="2"
      id="F_f5978ed7-05ce-41ba-a077-c70910ea60d8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.00</bdsx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease
      contextRef="C_79ecbe49-ef52-4aab-acc0-1a7416b448df"
      decimals="-3"
      id="F_fe7c9cc2-fe1d-476a-928a-9b98150ac940"
      unitRef="U_shares">613000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease>
    <bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice
      contextRef="C_79ecbe49-ef52-4aab-acc0-1a7416b448df"
      decimals="2"
      id="F_c19fdf97-5fe9-42db-aac8-be15e585bfb7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-0.75</bdsx:ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e"
      decimals="INF"
      id="F_9e94d3bc-b964-4ceb-a375-8586fe676416"
      unitRef="U_shares">103326</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e"
      decimals="2"
      id="F_f873ec34-df61-4d21-b174-6977ef9320f0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.46</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_c47916fb-71bf-444f-a33a-35da68f40857"
      id="F_f39bc261-6fcd-41e3-9672-47ea0d9befda">2028-02-23</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_39e03c4c-4d8d-400e-aa80-1599e4f33205">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 10 &#x2013; Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The holder of each share of common stock is entitled to one vote per share.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;common shareholders are entitled to dividends whenever funds and assets are legally available and when and if declared by the Board of Directors. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;is currently subject to restrictions on the payment of dividends (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 27, 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock in a registered IPO at a price to the public of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The net proceeds to the Company were &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;approximately &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, after deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and direct offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On December 30, 2021, the Company raised approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in gross proceeds from the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,756,994&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; common shares at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;per share in an at-the-market offering. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company received net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, after deducting underwriting discounts and commissions and offering expenses payable of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s Restated Certificate of Incorporation authorizes the Company to issue up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock with a par value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of preferred stock were issued or outstanding.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_3166d777-7ec1-470b-b442-6834581f8060"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_ac741efd-1edc-4237-9d17-95958b692a2d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockVotingRights
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_71bcac94-ea87-4e2d-9738-1ea6ece509e5">The holder of each share of common stock is entitled to one vote per share.</us-gaap:CommonStockVotingRights>
    <us-gaap:DividendsCommonStock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_7c0fba96-4e2a-4431-9f51-b026898d4aad"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="INF"
      id="F_49b832a1-9905-4744-bfe4-41e3f9e913c4"
      unitRef="U_shares">4000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_79311547-11e0-4926-93f9-d08f788a5f28"
      decimals="INF"
      id="F_326a62cb-976d-48bd-b056-3266c2538560"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">18.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="-5"
      id="F_d8867cf9-b81f-4260-857b-3ea97bb26ae8"
      unitRef="U_USD">63800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="-5"
      id="F_32a6ab47-3d72-4185-a05b-a6305c95b6e0"
      unitRef="U_USD">5000000.0</us-gaap:ExpenseRelatedToDistributionOrServicingAndUnderwritingFees>
    <bdsx:DirectOfferingExpenses
      contextRef="C_35ec0f7e-ab49-4615-b4bf-60a15f10f162"
      decimals="-5"
      id="F_fcb07529-4df4-4f4d-8703-cdb191a99c48"
      unitRef="U_USD">3200000</bdsx:DirectOfferingExpenses>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f"
      decimals="-5"
      id="F_617c4516-efcf-4dad-bb92-bc924bfd1246"
      unitRef="U_USD">16300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f"
      decimals="INF"
      id="F_20384f65-feac-4e1e-b3ab-a0a2bb1843a5"
      unitRef="U_shares">3756994</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_89b9d305-cd7b-433d-9431-082e759b7f72"
      decimals="INF"
      id="F_e32b16d2-e0c0-42aa-9f26-a50d24091d57"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">4.35</us-gaap:SaleOfStockPricePerShare>
    <bdsx:ProceedsFromIssuanceOfCommonStockNet
      contextRef="C_e357cb78-de71-44ba-be5d-e72858c2520f"
      decimals="-5"
      id="F_7ed0940c-1522-4837-af2b-73abb1327eb0"
      unitRef="U_USD">15700000</bdsx:ProceedsFromIssuanceOfCommonStockNet>
    <bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable
      contextRef="C_89b9d305-cd7b-433d-9431-082e759b7f72"
      decimals="-5"
      id="F_7041410d-a33e-459f-8347-bfe7cb94ff43"
      unitRef="U_USD">700000</bdsx:UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_0d5ab358-7c65-47cd-9ebc-09bd59b50c00"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_93ce613a-cc53-4b7d-aef3-a8b2a4a55350"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_76d61d23-cca3-4969-b2e8-f85145cef475"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_3f787c3e-ef10-4765-878b-354070f3a680"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_5647cd01-22a0-4778-a85f-cc22fb472d5e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_13f7f390-4ecb-4665-bf8a-5545685e6f03"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cab09024-92bc-4ed1-b7af-0992c14a15bc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 11 &#x2013; Revenue and Accounts Receivable Credit Concentration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diagnostic test revenues consist of blood-based lung tests and COVID-19 tests, which are recognized in the amount expected to be received in exchange for diagnostic tests when the diagnostic tests are delivered. The Company conducts diagnostic tests and delivers the completed test results to the prescribing physician or patient, as applicable. The fees for diagnostic tests are billed either to a third party such as Medicare, medical facilities, commercial insurance payers, or to the patient. The Company determines the transaction price related to its diagnostic test contracts by considering the nature of the payer, historical price concessions granted to groups of customers, and its historical collection experience using a portfolio approach. The Company recognizes revenues for diagnostic tests upon delivery of the tests to the physicians requesting the tests or patient, as applicable.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Services revenue consists of on-market tests, pipeline tests, custom diagnostic testing, and other scientific services for a purpose as defined by any individual customer, which is often with biopharmaceutical companies. The performance obligations and related revenue for these sales is defined by a written agreement between the Company and the customer. These services are generally completed upon the delivery of testing results, or other contractually defined milestone(s), to the customer. Revenue for these services is recognized upon delivery of the completed test results, or upon completion of the contractual milestone(s).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.237%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:13.765%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:12.708%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diagnostic tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Deferred Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Revenue consists of cash payments from customers received in advance of delivery. As test results are delivered, the Company recognizes the deferred revenue in &#x2018;Revenues&#x2019; in the statements of operations. Of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in &#x2018;Deferred Revenue&#x2019; recorded in the balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was recognized in revenues. During the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was added to 'Deferred revenue' for up-front cash payments received for which revenue recognition criteria have not been met. The 'Deferred revenue' of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million recorded in the balance sheet as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 is expected to be recognized in revenues over the next twelve months as test results are delivered and services are performed. As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in non-current deferred revenue, respectively, recorded within &#x2018;Other long-term liabilities&#x2019; in the balance sheets which represent amounts to be recognized in excess of twelve months from the respective balance sheet date.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.832%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.43%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:12.354%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Centura Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition to the above table, we collect reimbursement on behalf of customers covered by Medicare, which accounted for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s total revenue for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively. The Company is subject to credit&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;risk from its accounts receivable related to services provided to its customers. The Company does not perform evaluations of customers' financial condition and does not require collateral.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.844%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.423%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:12.347%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Janssen Research and Development, LLC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;LabCorp DD (formerly Covance)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Centura Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <bdsx:PrimarySourcesOfRevenueDescription
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_404125b2-8754-44b0-8ad1-a7468af4343e">We derive our revenue from two primary sources: (i) providing diagnostic testing in the clinical setting (Diagnostic Tests); and (ii) providing biopharmaceutical companies with services that include diagnostic research, clinical research, clinical trial testing, development and testing services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics (Services).</bdsx:PrimarySourcesOfRevenueDescription>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_5941f7a1-cffc-43b4-b716-c62fb3832030">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.237%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:13.765%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
        &lt;td style="width:1.605%;"/&gt;
        &lt;td style="width:1.364%;"/&gt;
        &lt;td style="width:12.708%;"/&gt;
        &lt;td style="width:0.677%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Diagnostic tests&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;48,937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,569&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_3f722d28-c570-4810-8fc4-68f71db16286"
      decimals="-3"
      id="F_1c4bafe5-e438-45bf-9d80-8a8232f036d0"
      unitRef="U_USD">48937000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0104f2bd-d332-41e4-b969-1fde8368c3ec"
      decimals="-3"
      id="F_3c153983-d07d-472f-83a2-225a8e653fff"
      unitRef="U_USD">40919000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_a0bd65dc-a53d-46d1-bb23-8dd79665bc2d"
      decimals="-3"
      id="F_e385779d-fdad-4e4c-83b5-af44b1305836"
      unitRef="U_USD">5569000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_612986b7-0cbc-4490-8560-a7436c79aa80"
      decimals="-3"
      id="F_d4782bf6-3d65-4a40-8c9f-cc68a230b365"
      unitRef="U_USD">4638000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_9217db37-5422-4388-8015-1c2bf603afd2"
      unitRef="U_USD">54506000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_bd80a2ea-0ba7-40cf-985d-db8af7649419"
      unitRef="U_USD">45557000</us-gaap:Revenues>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-5"
      id="F_212187a1-25aa-403e-b4e9-1f4d0ede98ea"
      unitRef="U_USD">3500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-5"
      id="F_8b61d79f-0036-42c8-995d-447c856df8ad"
      unitRef="U_USD">3000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_cd80bb2e-8eca-4461-9d92-d498ba929922"
      decimals="-5"
      id="F_9a7cbe27-d5e0-4429-a357-6751815dab63"
      unitRef="U_USD">1400000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_c1603fa8-8369-46f4-b18d-60076fe8601d"
      unitRef="U_USD">1900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_3fa48f27-8cf4-4782-b6a4-0cea10e6953e"
      decimals="-2"
      id="F_78d45b34-6c99-47b6-a314-f71ced934b26"
      unitRef="U_USD">800</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_36978c15-7cae-4bbc-a497-ec47b32704f2"
      decimals="-5"
      id="F_e815fdd6-9ddf-4a6c-86a2-44aa4b0ba1b9"
      unitRef="U_USD">1400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_13095e9a-2665-417c-b159-f973f2f24a83">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s customers in excess of 10% of total revenue, and their related revenue as a percentage of total revenue were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.832%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.43%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:12.354%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Centura Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s third-party payors and other customers in excess of 10% of accounts receivable, and their related accounts receivable as a percentage of total accounts receivable were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.844%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:13.423%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
        &lt;td style="width:1.586%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:12.347%;"/&gt;
        &lt;td style="width:2.004%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Medicare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Janssen Research and Development, LLC&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;LabCorp DD (formerly Covance)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Big Ten Conference&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Centura Healthcare&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_d1d55fa8-853c-4dce-a4aa-f84151407d63"
      decimals="2"
      id="F_32f412b2-6e32-4d7a-8832-1fc08bcfba5b"
      unitRef="U_pure">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_cbb42c62-9833-417a-a5af-55f85ae20dd0"
      decimals="2"
      id="F_07d7491a-af0a-410e-a15a-9c7d602159f6"
      unitRef="U_pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_06bff184-ac5d-48a3-b2c8-c2f0e2ca06b8"
      decimals="2"
      id="F_da1da65f-c16f-4988-8997-fbc1daf6381d"
      unitRef="U_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_ab23c5df-8c6e-46f4-83d5-abf0ca403590"
      decimals="2"
      id="F_0ecf95bf-7b58-40f2-b846-4c6c896c42a3"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1b2acc98-6825-4199-91a5-077e16b3afd5"
      decimals="2"
      id="F_06b29edc-6034-4dab-9d4c-37ff0879d54e"
      unitRef="U_pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2a45a1ed-39d8-491b-b8f4-7363b3b51b79"
      decimals="2"
      id="F_3721b856-472e-4566-996a-a9c68b1a8670"
      unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_1521a2fc-d6fd-463e-a4d0-5ff13f834737"
      decimals="2"
      id="F_8f10f695-713f-462f-b876-7028ac51c1dc"
      unitRef="U_pure">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_706d9a9e-6a0d-4d6c-8f9b-08761cf3807f"
      decimals="2"
      id="F_de0ccd21-1fee-41ff-a64e-1ea695a1bedb"
      unitRef="U_pure">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_320c8bd8-4ae2-4caf-892d-f84cf7a846c3"
      decimals="2"
      id="F_ec73a432-8907-4f99-aac7-c8a9b12be7b2"
      unitRef="U_pure">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_80994f88-01c2-4120-9cc2-79754d8c1bc6"
      decimals="2"
      id="F_aca676c5-f4e2-4b8b-b1c4-b34816f3702a"
      unitRef="U_pure">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_fb0c87cc-2dbf-4d30-9a38-bfb702341b31"
      decimals="2"
      id="F_5e8d158b-1ec3-4889-8742-f1e61a012f3e"
      unitRef="U_pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2b6cb7b5-b083-4ec5-b29c-9ae0101aa74b"
      decimals="2"
      id="F_f1175ba5-bafe-49bc-8765-33b300b347ab"
      unitRef="U_pure">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_03977998-feb5-4ba1-9a39-98aa6bcd1820"
      decimals="2"
      id="F_b2a739c0-437e-4dc0-bdf2-fca919a9857e"
      unitRef="U_pure">0.35</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="C_2fde2582-8789-4b20-b26a-e76c33d3ce5a"
      decimals="2"
      id="F_13e31fa6-db87-4386-a464-e19acd3f9e18"
      unitRef="U_pure">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_4bb5ae99-05d7-4147-bfff-c681cfbee58f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 12 &#x2013; Share Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Predecessor 2016 and 2006 Equity Incentive Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the 2006 Equity Incentive Plan (2006 Plan), the Company was authorized to grant incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards and RSUs. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional awards may be granted under the 2006 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2016, the Company adopted the 2016 Equity Incentive Plan (2016 Plan) as a successor to and continuation of the prior 2006 Plan. The 2016 Plan provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, and other stock awards to directors, employees, and consultant&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Awards granted under the 2016 Plan or the 2006 Plan that were unallocated, expired or otherwise terminated, or were forfeited, cancelled, or repurchased by the Company, became available for future issuance under the 2016 Plan. In addition, shares subject to an award were withheld to satisfy a participant&#x2019;s tax withholding obligations, or were reacquired by the Company as consideration for the exercise or purchase price of a stock award also became available for future issuance under the 2016 Incentive Plan. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; additional awards may be granted under the 2016 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2020 Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective upon the closing of our IPO, the Company&#x2019;s Board of Directors approved the 2020 Equity Incentive Plan (2020 Plan), which replaced the 2016 Plan.&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The 2020 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, RSUs, performance awards and other stock awards. Officers, directors, employees, consultants, agents, and independent contractors who provide services to the Company may receive awards. The terms of all awards are governed by an agreement between the Company and the recipients, as administered and approved by the Compensation Committee of the Board of Directors. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Any awards that expire or are forfeited under the 2016 Plan or 2006 Plan become available for issuance under the 2020 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The number of shares reserved for issuance under the 20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,893,395&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, plus an annual increase added on the first day of each calendar year, beginning with the calendar year ending December 31, 2022, and continuing until, and including, the calendar year ending December 31, 2030. The annual increase will be equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the number of shares of our common stock issued and outstanding as of December 31st of the immediately preceding calendar year and (ii) such lesser amount determined by the Board of Directors. Up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,893,395&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; sh&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ares of our common stock that may be issued under the 2020 Plan may be issued in satisfaction of incentive stock option awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;To the extent an equity award granted under the 2020 Plan (other than any substitute award) or granted under any other equity plan maintained by us under which awards are outstanding as of the effective date of the 2020 Plan (the Prior Plans) expires or otherwise terminates without having been exercised or paid in full, or is settled in cash, the shares subject to such award will become available for future grant under the 2020 Plan. In addition, to the extent shares subject to an award are withheld to satisfy a participant&#x2019;s tax withholding obligation upon the exercise or settlement of such award (other than any substitute award) or to pay the exercise price of a stock option granted under the 2020 Plan or a Prior Plan, such shares will become available for future grant under the 2020 Plan. The total number of shares available for grant under all Plans was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;630,685&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; at &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective with our IPO in October 2020, the Company&#x2019;s Board of Directors and its stockholders approved the Company&#x2019;s Employee Stock Purchase Plan (ESPP). A total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;338,106&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock have been reserved for issuance under the ESPP. The maximum number of shares of our common stock available under the ESPP will automatically increase on the first trading day of each calendar year by an amount equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the shares of our common stock issued and outstanding on December 31st of the immediately preceding calendar year, and (ii) an amount determined by our Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Subject to any plan limitations, the ESPP allows eligible employees to contribute, normally through payroll deductions, up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of their earnings for the purchase of the Company&#x2019;s common stock at a discounted price per share. The price at which common stock is purchased under the ESPP is equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of the fair market value of the Company&#x2019;s common stock on the first or last day of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;offering &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;period, whichever is lower. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,855&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares have been issued under the ESPP leaving &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;295,251&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares remaining for future issuance.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Description of Awards Granted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has granted incentive stock options, non-statutory stock options, performance-based stock options, and RSUs.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Incentive stock options, which may only be issued to employees, are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Non-statutory stock options, which may be issued to employees, non-employees and directors, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;are granted at an exercise price per share equal to the closing market price of the Company&#x2019;s common stock on the grant date, and vest over time as determined by the Compensation Committee, provided that the term of the options may not exceed ten years from the date of grant. Accelerated vesting may occur in the event of an optionee's death, disability, or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Performance-based stock options are typically granted on an annual basis and consist of a performance-based and service-based component. The performance targets and vesting conditions for performance-condition options are based on achievement of recognized revenue targets. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Performance-based options vest in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; equal annual installments beginning one year after the grant date&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, pending certification of performance achievement by the Compensation Committee and continued service. The fair value of performance-condition awards is based on the closing market price of the Company&#x2019;s common stock on the grant date. On January 1, 2019, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168,466&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; performance-condition options, with an exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.77&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the year ended December 31, 2021 and 2020, the performance-conditions w&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ere met and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56,156&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; opti&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ons and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56,155&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; options, respectively, vested. During the year ended December 31, 2019, the performance-conditions were not met and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56,155&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; options were forfeited.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;RSUs and the related terms and conditions are awarded at the discretion of the Compensation Committee. RSU&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; holders &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;have a contractual right to receive a share of common stock when vested. RSUs vest over time as determined by the Compensation Committee. RSU agreements may provide for accelerated vesting in the event of a stock unit holder's death, disability, or retirement or other events.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Our Compensation Committee may grant other stock awards that are based on or related to shares of our common stock, such as awards of shares of common stock granted as bonus and not subject to any vesting conditions, deferred stock units, stock purchase rights, and shares of our common stock issued in lieu of our obligations to pay cash under any compensatory plan or arrangement. To date, t&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he Company has granted service-condition RSUs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Bonus-To-Options Program&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also has a Bonus-to-Options Program (the &#x201c;Bonus Option Program&#x201d;), is separate from predecessor Plans and was initially adopted by the Board of Directors in 2008, and subsequently amended and restated in 2010, 2011 and 2015. For fiscal year 2022, the Bonus Option Program is subject to the shares reserved under the 2020 Plan. The Bonus Option Program, which is limited to participation of the Chief Executive Officer, direct reports to the Chief Executive Officer and Vice Presidents of the Company, allows participants who so elect to convert all or a portion of their annual cash bonus into fully vested, non-qualified stock options to purchase shares of common stock (Bonus Options). The exercise price for the options under the Bonus Option Program equals the then current price for the shares of the common stock as of the grant date, as disclosed below under &#x201c;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x201d;. Bonus Options issued must be exercised within a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; term.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.344%;"/&gt;
        &lt;td style="width:1.122%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:14.376%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.856%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:14.431%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:10.666%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercisable &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively, associated with the estimate of options to be delivered to eligible participants under the Bonus Option Program and which were granted in February&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022 and 2021 by the Compensation Committee of the Board of Directors. In determining the amount of stock compensation to recognize under the Bonus Option Program, the Company estimates the bonus attainment for the year and determines the expected number of options to be delivered to eligible participants. A Black-Scholes option pricing model is used to determine the estimated fair value of the expected number of options to be delivered to eligible participants. The key elements in determining the estimated fair value include assumptions for volatility, the risk-free interest rate, expected dividends and strike price, utilizing the measurement date closing stock price until the grants are authorized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share-Based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pre-tax share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.362%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:20.603%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:20.603%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The unrecognized remaining share-based compensation expense for options and RSUs was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and is expected to be amortized to expense over the next &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.57%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:13.542%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.552%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:13.57%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.314%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercisable &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock underlying the stock options was determined by the Board of Directors with assistance from management and, in part, on input from an independent third-party valuation firm. The Board of Directors determined the fair value of common stock by considering a number of objective and subjective factors, including valuations of comparable companies, sales of convertible preferred stock, operating and financial performance, the lack of liquidity of the Company&#x2019;s common stock and the general and industry-specific economic outlook. Subsequent to the Company&#x2019;s IPO, the fair value of the Company&#x2019;s common stock is determined based on its closing market price on the date of grant.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated grant date fair value of stock options was calculated using the Black-Scholes option-pricing model, based on the following assumptions:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;: The expected term represents the period that the options granted are expected to be outstanding using the simplified method (based on the mid-point between the vesting date and the end of the contractual term).&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;: The Company uses an average historical stock price of selected comparable companies over the expected term of the awards as the Company does not have sufficient trading history for its common stock. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;: The Company uses the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:4.537%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.491405046981553%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Dividend Yield&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;: The Company is currently subject to restrictions on the payment of dividends (see Note 8 - &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Debt&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; dividends have been declared as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020. The Company has not paid and does not anticipate paying any dividends in the near future. Therefore, the expected dividend yield was zero.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.19%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:20.254%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
        &lt;td style="width:2.467%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:20.254%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the year ended December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71,707&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; service-condition RSUs. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;150,811&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; RSUs outstanding, with a weighted average grant date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_d29dc415-dc05-49ca-b2ef-a00ef315776c"
      decimals="INF"
      id="F_bcc26043-89b6-4280-aead-6aeaaace1da4"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_826b69bf-89e7-459f-b550-a6811c484337"
      decimals="INF"
      id="F_f94d81a1-91e4-4f5e-a666-e51de2a8726c"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_e65faf54-05c3-4544-989f-b6ba7475a88f"
      decimals="INF"
      id="F_036588fe-972e-44f7-b90a-aae326ade434"
      unitRef="U_shares">1893395</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_577649de-5c2b-46f6-b8d5-5679a06e7577"
      decimals="2"
      id="F_42f5d6af-c8b6-49c6-8183-283b25e0ff23"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_2b727503-f6ad-446e-9456-ccd781d7dcdc"
      decimals="INF"
      id="F_c8314ca1-984a-4416-83cd-5adb3fe3f4ea"
      unitRef="U_shares">1893395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0e5ba80b-b01d-424c-b1c0-f4822ff4bb56"
      decimals="INF"
      id="F_a89a81dc-dc30-47f4-80dd-f59c4d3f8838"
      unitRef="U_shares">630685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_75149308-b918-457f-8ee9-7f3492120224"
      decimals="INF"
      id="F_a0bbc8ed-781c-40c3-8bb1-d5a7fe0b520e"
      unitRef="U_shares">338106</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"
      decimals="INF"
      id="F_68fb3023-ded5-4148-86fa-23f5e4a00201"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_8df4046d-0fe5-4898-9781-f03f716cfbc0"
      decimals="INF"
      id="F_8cf712d1-c83d-462b-b6ac-c6788f6952c4"
      unitRef="U_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
      contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"
      decimals="INF"
      id="F_33192717-327c-44b6-8ff4-5daf7a795f6b"
      unitRef="U_pure">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate>
    <bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod
      contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"
      id="F_72481a48-1591-4839-875a-2d9866e67905">No employee may participate in an offering period if the employee owns 5% or more of the total combined voting power or value of the Company&#x2019;s stock.</bdsx:DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod>
    <bdsx:DescriptionOfOfferingPeriodUnderPlan
      contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"
      id="F_a5f92b92-acea-4368-9c0d-1e986a2a8b90">The initial offering period was from January 1, 2021 through August 31, 2021. On a go-forward basis, the ESPP provides for successive six-month offering periods beginning on September 1st and March 1st of each year. As of December 31, 2021, 42,855 shares have been issued under the ESPP leaving 295,251 shares remaining for future issuance.</bdsx:DescriptionOfOfferingPeriodUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="C_154e51e6-162c-45e3-bd64-e6953dba0c5d"
      decimals="0"
      id="F_03b87f3f-b7b7-4b89-96b9-fdbc866759f4"
      unitRef="U_shares">42855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_8df4046d-0fe5-4898-9781-f03f716cfbc0"
      decimals="INF"
      id="F_dca7ac85-e75d-43a9-8974-354be1d89683"
      unitRef="U_shares">295251</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_c8f3232a-4dcd-431e-b582-72448f737920"
      id="F_352d5769-2566-4573-bb80-7ab884cd3d4a">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee"
      id="F_da66cc35-f664-43c8-8ba9-38cdddbb13ff">Performance-based options vest in three equal annual installments beginning one year after the grant date</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting
      contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee"
      decimals="INF"
      id="F_4288b980-f64a-4656-999c-7c5802741355"
      unitRef="U_Installment">3</bdsx:NumberOfEqualAnnualInstallmentsForAwardVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85"
      decimals="INF"
      id="F_2d308581-fc39-4728-8143-4bf6feaeb6a5"
      unitRef="U_shares">168466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85"
      decimals="2"
      id="F_2949a6ab-087b-4084-b8c6-69d4d8a061aa"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_b6f4ff0b-9cff-4596-b24f-7882657b9a85"
      id="F_ef943d77-b482-42ba-afbf-caa38ebecd07">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_624583b0-5d27-4880-a354-cf2da9d3adee"
      decimals="0"
      id="F_41166e0a-d082-4ea9-9919-912385baf637"
      unitRef="U_shares">56156</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_62628f3e-204a-4e47-888d-80b800906159"
      decimals="0"
      id="F_4957c9a3-ca24-4c11-8f4f-79aef916954f"
      unitRef="U_shares">56155</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_be2758e9-5945-4245-bf58-cd5421da5cb6"
      decimals="INF"
      id="F_49fa3046-8204-4449-be74-eb0211ff243a"
      unitRef="U_shares">56155</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_bd35d5ad-8efe-4775-803e-5923630c295d"
      id="F_ef495dc2-5bbb-45f0-9a17-59c9b0250a79">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      id="F_b5a09821-7bd3-4b85-bddb-d9a1e594a625">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recorded the following activity related to the Bonus Option Program during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 (in thousands, excepted weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.344%;"/&gt;
        &lt;td style="width:1.122%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:14.376%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:13.856%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:14.431%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:10.666%;"/&gt;
        &lt;td style="width:0.594%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.11&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.9&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,723&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.67&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.03&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.69&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercisable &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;373&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0"
      decimals="-3"
      id="F_109ee011-3955-4684-a302-6122398795d8"
      unitRef="U_shares">173000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0"
      decimals="2"
      id="F_a4208f1b-0822-4e55-a1c3-c38475c4fdee"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">11.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462"
      id="F_81831752-bbde-462e-830a-a6bac53ff2d5">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_65d95f34-c5e6-4335-9e70-651be939c9e0"
      decimals="-3"
      id="F_440c30ab-4652-4b80-bb3a-4c7e76daaf05"
      unitRef="U_USD">1723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="-3"
      id="F_cdd547b2-c78a-460f-b515-ed863105e7c2"
      unitRef="U_shares">266000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="2"
      id="F_176b99a6-acc1-4b92-8c6c-a6296233fc5d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="-3"
      id="F_41c40cdf-f63d-4e21-9d7e-dff638553eb1"
      unitRef="U_shares">46000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="2"
      id="F_8ed04cea-ef3d-4a94-922b-f33489147e5d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="-3"
      id="F_5f34221a-afb2-48cb-acc3-e9f243138ac3"
      unitRef="U_shares">20000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="2"
      id="F_7c091fd0-bc79-48cf-868e-912f4e910e24"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="-3"
      id="F_d0ff4d44-c7f0-4ca5-abc2-23f59ba61f2d"
      unitRef="U_shares">373000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="2"
      id="F_3b2f25cc-f7d8-4b73-9588-74bce2ee7c4a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      id="F_41445e30-7d13-4b0d-94f3-a33d79de7c42">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="-3"
      id="F_e9e77969-8cfa-40b3-b765-909a9729b887"
      unitRef="U_USD">76000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="-3"
      id="F_87caafc7-3676-486e-a445-01dee1063771"
      unitRef="U_shares">373000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="2"
      id="F_e9c12ec8-b779-4a97-8b0c-a459cb9ae77d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      id="F_1666cc5c-5d6f-419a-a940-53ae97ee58e0">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_3b26b2be-61e0-4fbe-bec6-07ebd2151dff"
      decimals="-3"
      id="F_de16ee81-0bc0-43db-8277-0288a1fc6205"
      unitRef="U_USD">76000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_46156cf8-97c8-49b0-9c37-c83a12d710ae"
      decimals="-5"
      id="F_85f3e6aa-190a-4dfc-a118-36ac915f2216"
      unitRef="U_USD">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_8c9fd148-f24a-4ee4-ac93-6b9f8244f462"
      decimals="-5"
      id="F_6c6cddbe-02c6-4b92-bdab-975cd0a4b91a"
      unitRef="U_USD">3400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_621f72f0-3de2-48d6-a531-d3f49bcf8403">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pre-tax share-based compensation expense reported in the Company&#x2019;s statements of operations was (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.362%;"/&gt;
        &lt;td style="width:1.614%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:20.603%;"/&gt;
        &lt;td style="width:0.974%;"/&gt;
        &lt;td style="width:2.44%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:20.603%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Direct costs and expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;572&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sales, marketing, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,323&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,120&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0ce3a578-735a-4075-87ce-b954e21a6041"
      decimals="-3"
      id="F_13bc2db3-54e2-46a0-94d4-0ee11ee67cb9"
      unitRef="U_USD">49000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b5d3e429-66cd-4136-bc88-3e646c9bc008"
      decimals="-3"
      id="F_8c7d45c1-d656-4d1e-846b-e185a0fafd0d"
      unitRef="U_USD">572000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_10bed5db-cad0-4d81-95a0-1793592b5166"
      decimals="-3"
      id="F_ac9116dd-8510-4d6c-9ef4-0fd763176911"
      unitRef="U_USD">589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_864ff4c5-a2d6-48c2-b72a-3ac95114b2f7"
      decimals="-3"
      id="F_f44dc272-7c79-4ecb-9ff1-0d92475c4b55"
      unitRef="U_USD">4323000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_661f4aa1-a621-4d97-add7-7f08a6309ae0"
      decimals="-3"
      id="F_89993d4e-f855-444c-944c-6275dd70d5af"
      unitRef="U_USD">3120000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_9e312f6d-8884-4d44-a2b7-54e53de965d3"
      unitRef="U_USD">4944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_64b18c36-e4ce-49cc-a121-d54dd77b2a02"
      unitRef="U_USD">3709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="C_88dca331-7477-419b-b234-6230d9c7f1f8"
      decimals="-5"
      id="F_434d3855-008a-41fe-8c5a-e63a3a921ac6"
      unitRef="U_USD">7800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_3c75df96-50d6-49ea-8d24-017d2bbea9a8"
      id="F_b0df67da-180e-45b1-84f2-cf8ae529464a">P3Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_11cd6d0a-7a93-472e-8a95-3733c6dd8d23">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021, excluding the Bonus Option Program described above, was (in thousands, except weighted average exercise price and weighted average contractual life):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.57%;"/&gt;
        &lt;td style="width:1.113%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:13.542%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.552%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:13.57%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:10.314%;"/&gt;
        &lt;td style="width:0.992%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding - January 1, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.82&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited/canceled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.22&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;408&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.51&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercisable &#x2011; December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.02&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,849&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_99d9442f-9433-4220-91b3-fa55a518362b"
      unitRef="U_shares">2321000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="2"
      id="F_58973a74-a386-45bc-9eec-20c6a94c36a3"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      id="F_e027aec9-7c2c-4e4a-a8eb-f5b1916eb907">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_60f536e5-cd75-4406-a141-b7d66d3a067c"
      unitRef="U_USD">42580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="0"
      id="F_8dcbdc32-d575-416c-a4aa-4a9239569721"
      unitRef="U_shares">1190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_c52527f0-1af0-4809-adec-9638f539051a"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">17.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="0"
      id="F_427fd403-7beb-47ba-b958-6696b353de09"
      unitRef="U_shares">225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_b77e388a-a33b-410f-86df-21365f7462b0"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="0"
      id="F_b6f9a21e-6068-434f-b995-f94da3449855"
      unitRef="U_shares">408</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_61e69b68-83c1-43fa-8bbd-aafa2fc206c7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">1.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_f6999750-b2fc-45d4-943d-5fff18f8a095"
      unitRef="U_shares">2878000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="2"
      id="F_d287f169-25dc-4868-897d-de3f89823582"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_faf7bdf1-79d1-4b17-9450-dc7bbaa68483">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_2ad0bbb9-2ae4-4271-9d32-f6cc4e153fae"
      unitRef="U_USD">6288000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="0"
      id="F_dbe7d857-baa2-4173-bcce-51119d1f399e"
      unitRef="U_shares">1428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="2"
      id="F_87148521-c26d-44cf-9ba2-0ecafe816157"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6ed24b12-45f6-4271-96b1-6dfc380106eb">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_f42b397b-4958-4927-a0f3-234cc0933a91"
      unitRef="U_USD">3849000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:DividendsCommonStock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_ef543adc-28f6-4fd5-9871-e5f80143a3ec"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="INF"
      id="F_f5584c44-5cb0-4eec-bbf7-2362d5946c1e"
      unitRef="U_USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_b709d95b-7118-47b5-97c3-c2f8ccf1e935">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each option grant was estimated on the grant date with the following weighted average assumptions for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.19%;"/&gt;
        &lt;td style="width:1.623%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:20.254%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
        &lt;td style="width:2.467%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:20.254%;"/&gt;
        &lt;td style="width:2.003%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.01&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.73&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk&#x2011;free rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.34&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_b43d9300-c727-4996-977e-ff2c3178ad48">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      id="F_a5704efe-38b8-46e0-81ca-1a11bdd91fdc">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="3"
      id="F_74fd29be-5820-495d-9015-aa9f65b57509"
      unitRef="U_pure">0.685</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="3"
      id="F_7adc7778-c44a-4301-8b22-0c33e7803c3a"
      unitRef="U_pure">0.770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="4"
      id="F_d740904f-fb77-4b51-8af4-a67fb1e027a1"
      unitRef="U_pure">0.0079</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="4"
      id="F_c2e135db-2e4d-45b8-bfdc-b4a228a242db"
      unitRef="U_pure">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_55faf862-904e-4749-90ab-5601a8d113a1"
      decimals="INF"
      id="F_e378b568-fdec-40a2-8b4d-a3ec191344de"
      unitRef="U_shares">71707</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a"
      decimals="INF"
      id="F_d43dfaee-4b19-4fce-8b7a-93dfc4d53b40"
      unitRef="U_shares">150811</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_16aecce9-7ad8-4ff3-b170-3b0230983e2a"
      decimals="2"
      id="F_f4e14394-8514-4ed7-a675-144e222a5442"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">5.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_1516a025-ecb3-4999-a8ef-93a949a859a4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 13 &#x2013; Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic earnings per share (EPS) excludes dilution and is computed by dividing net loss attributable to the Company&#x2019;s stockholders by the weighted-average shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised, resulting in the issuance of shares of common stock that would then share in the earnings or losses of the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the acquisition of Indi in 2018, the Company recorded contingent consideration (See Note 4 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;) for amounts contingently payable to Indi's selling shareholders pursuant to the terms of the asset purchase agreement. The contingent consideration arrangement requires additional consideration to be paid by the Company to Indi upon attainment of a three-consecutive month gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period after the acquisition date. If the gross margin target was met, the Company was required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock. The Company met the gross margin target of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for three consecutive months during the three months ended June 30, 2021. In August 2021, the Company entered into an amendment of the original agreement in which all parties agreed to forgo the issuance of common stock. As a result of the achievement of the gross margin target, the Company included the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,520,108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock in the calculation of weighted-average shares outstanding used in computing basic and diluted net loss per share from the date the gross margin target was met until the amendment was executed. These shares are not included in the statements of convertible preferred stock and stockholders' equity (deficit) or shares issued and outstanding in the accompanying balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.306%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.702%;"/&gt;
        &lt;td style="width:0.946%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.739%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The potentially dilutive securities as of December 31, 2021 and 2020 primarily represent the shares subject to future issuance under stock options awards, warrants, RSUs, and shares subject to purchase under our employee stock purchase plan and would be subject to the treasury stock method when dilutive the terms of which are described in further detail in Note 12 &#x2013; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Share Based Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.154%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:15.686%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:15.686%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_6d377042-8c80-4077-9d06-ae158bc05d91"
      decimals="-5"
      id="F_5f7b051b-76f9-4577-834e-4c2aa0dbb224"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod
      contextRef="C_131eb09d-9424-492d-a21b-d98c3a9b0cf2"
      id="F_aeca0c44-cf3f-4eb8-a0f7-d633c8703a0e">P7Y</bdsx:BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod>
    <bdsx:BusinessCombinationContingentConsiderationShares
      contextRef="C_030eae36-c23d-4bad-9c99-3d09f8369ed2"
      decimals="INF"
      id="F_e477f12b-0924-4b1f-95ad-512aeb6ede48"
      unitRef="U_shares">2520108</bdsx:BusinessCombinationContingentConsiderationShares>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_3d34e8c8-db40-4e73-87e3-bb518a1d945d"
      decimals="-5"
      id="F_70a6591a-abbc-483d-801b-560fad6ea5c2"
      unitRef="U_USD">2000000.0</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_ec1496fb-b414-4020-84e5-09472bae83a5"
      decimals="INF"
      id="F_71e6f1c1-1a9b-4c7c-80a4-c35d11da2dbe"
      unitRef="U_shares">2520108</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_2f8306ea-df48-4c27-9297-27d7c0a70822">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic and diluted loss per share for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020 were (in thousands, except per share amounts):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.306%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.702%;"/&gt;
        &lt;td style="width:0.946%;"/&gt;
        &lt;td style="width:1.466%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.739%;"/&gt;
        &lt;td style="width:0.965%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43,159&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding used&lt;br/&gt;&#160;&#160;&#160;in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,838&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_8dbb539b-8d5b-4b1d-abd7-a19dcdc0eb8c"
      unitRef="U_USD">-43159000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_b36839fe-6a50-438d-aac8-2e3fcde7e6e8"
      unitRef="U_USD">-31350000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_5a310717-09a5-4310-ab41-4dbede3686d9"
      unitRef="U_shares">27365000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_3286821c-2133-4e52-8ae9-2b4f65cd6ad9"
      unitRef="U_shares">4838000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_58f7618a-6b11-46ee-be74-105a4d630da1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-1.58</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_c9f62c9c-6b57-481e-ab28-29e78b2b2742"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-6.48</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_cd1e1372-924a-4354-9b26-d6d1ae01ce0e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding common stock equivalents were excluded from diluted net loss attributable to common stockholders for the periods presented because inclusion would be anti-dilutive (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.154%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:15.686%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:1.531%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
        &lt;td style="width:15.686%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Shares committed under ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;151&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,677&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_894dacc7-f9c8-465f-bb3e-677c3cff01e9"
      decimals="-3"
      id="F_26065f2f-d6bd-4b71-ba20-47f4b31b9a24"
      unitRef="U_shares">3251000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_337f9ff9-e36d-4674-9452-b807a7edb7f4"
      decimals="-3"
      id="F_f058f1a5-d4ba-4995-b60f-2455515f53ee"
      unitRef="U_shares">2495000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_367888ff-2937-4bf4-a0e7-2638e425e939"
      decimals="-3"
      id="F_d0fa7332-99e9-4ae4-9849-8063b606bab7"
      unitRef="U_shares">30000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7d46f5a7-a39a-4c26-9184-61e4e53c8f05"
      decimals="-3"
      id="F_49b25dec-77b5-4c69-a12d-2facb4d08610"
      unitRef="U_shares">103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_ab45d19d-f12a-40a2-85e6-c11af3ecf535"
      decimals="-3"
      id="F_938b946c-929d-4b75-a156-786ef8ad5a60"
      unitRef="U_shares">103000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_6eb42b97-11c3-44ad-9689-15a6c7ffc9fc"
      decimals="-3"
      id="F_a78c5df1-775f-41b8-a65f-7a7c37d0694c"
      unitRef="U_shares">151000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_53c549cf-8442-4882-99fb-2cabbc0b4a81"
      decimals="-3"
      id="F_dfb1c8b7-0fe0-43f6-8f25-7d84060d22a6"
      unitRef="U_shares">79000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_f3b123f7-72ca-478b-a736-6de71ca8b0f2"
      unitRef="U_shares">3535000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_fa6eb4b4-1b65-482e-ba47-7aab851054ab"
      unitRef="U_shares">2677000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_ab4b3245-5fb3-4d25-be40-3f3a835b1b4b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 14 - Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Since inception, the Company has incurred net taxable losses, and accordingly, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; current provision for income taxes has been recorded. &lt;/span&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.411%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.816%;"/&gt;
        &lt;td style="width:13.75%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.816%;"/&gt;
        &lt;td style="width:12.414%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.721%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.209%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.873%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;267.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of federal net operating loss and research and experimentation tax carryforwards, respectively, which are set to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;expire beginning in 2026&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Internal Revenue Code contains provisions that may limit the net operating loss carryovers available to be used in any year if certain events occur, including significant changes in ownership interest.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In assessing the realizability of its deferred tax assets, the Company considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. The Company considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. As the Company does not have any historical taxable income, projections of future taxable income over the periods in which the deferred tax assets are deductible, and after consideration of the history of operating losses, the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of net deferred tax assets.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During 2021, the Company determined that it now has uncertain tax positions related to its U.S. research and development credits. As of December 31, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; accrued interest related to uncertain tax positions. The Company does not believe it is reasonably possible that its unrecognized tax benefits will significantly change in the next twelve months. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Calibri;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"/&gt;
        &lt;td style="width:2.681%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.793%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.448%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company monitors proposed and issued tax law, regulations, and cases to determine the potential impact of uncertain income tax positions. At December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had not identified any potential subsequent events that would have a material impact on unrecognized income tax benefits within the next twelve months.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_b3200757-4594-433e-9ab8-e891109f95b3"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6d0cd5e0-e749-4776-afee-5d7ef8f38a50">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The effective income tax rate of the provision for income taxes differs from the federal statutory rate as follows:&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.411%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.816%;"/&gt;
        &lt;td style="width:13.75%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:0.816%;"/&gt;
        &lt;td style="width:12.414%;"/&gt;
        &lt;td style="width:1.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and developments credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:2.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_104c5004-a81f-4e92-99d7-7702b3674356"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="INF"
      id="F_06ea8f46-f0d5-4a02-ae1e-5f18ff4e62e4"
      unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_4b45fc76-473f-4c51-a9bd-8ea652dcab65"
      unitRef="U_pure">0.05</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_c581a5b7-8fcb-418c-8308-83be6e0cef26"
      unitRef="U_pure">0.02</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_cb22459b-0d8b-4323-8497-36874ea5155f"
      unitRef="U_pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_034ad6bd-c2aa-4fcc-a72c-2eb97cecf8c7"
      unitRef="U_pure">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_084c73b6-623d-41ca-8e7b-d5e5012b9e37"
      unitRef="U_pure">0.01</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_b56d67eb-7f25-42f3-9c7b-5ddf4ef358f8"
      unitRef="U_pure">0.06</bdsx:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="2"
      id="F_d6b246ee-7524-46cc-b3e2-b511ec79968e"
      unitRef="U_pure">-0.26</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="2"
      id="F_d891242d-c27d-4ca8-9eed-ef74801973fb"
      unitRef="U_pure">-0.16</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_77e2b204-e3fd-4927-b50f-c9e82ce353d2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences that give rise to significant portions of the deferred income tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.721%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:14.209%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.595%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.873%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,874&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;53,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,372&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest expense limitation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;554&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;215&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;279&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;865&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,406&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;69,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,538&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,457&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56,083&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax assets after valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,153&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,455&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets and liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_cf7b9ada-904d-4969-8c18-9543475c826a"
      unitRef="U_USD">61874000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_b27a644f-1627-44dc-8153-5c70474e7282"
      unitRef="U_USD">53128000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_ac3fa4a6-424d-427c-a2be-53ce6d30fa85"
      unitRef="U_USD">3372000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_60651b9f-fdbf-476a-9069-f6ae5edc2079"
      unitRef="U_USD">2860000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_8043f75c-4387-42d7-bee2-15528d965080"
      unitRef="U_USD">554000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_a7ff450c-2914-4327-8416-5bd1eaf07402"
      unitRef="U_USD">215000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_96beb281-c012-432d-9180-0aecad2f4c76"
      unitRef="U_USD">279000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_d9b8b3a5-75db-4110-958f-b835e6bc94b6"
      unitRef="U_USD">1977000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_c50829cf-3dbd-4e39-86b8-8cefe774e876"
      unitRef="U_USD">865000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_405e06a8-747c-47de-84b0-b8d996953a80"
      unitRef="U_USD">1618000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_7c521fd6-1455-4a31-990e-e6f87527924f"
      unitRef="U_USD">1406000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_924c2398-ea14-4fa4-9209-a9bb12743870"
      unitRef="U_USD">69610000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_e2781f81-6a99-471e-a1af-0445ede09132"
      unitRef="U_USD">58538000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_6b0b6535-b987-4d4e-8cbb-8e51e06fc3f7"
      unitRef="U_USD">67457000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_b9a4cde6-7bb1-4c5d-9a9c-f85ae6c1a506"
      unitRef="U_USD">56083000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_54ccb579-3b5a-4de0-bffd-eca2e6cc73af"
      unitRef="U_USD">2153000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_ae6ec16f-1668-4717-bbed-59b01afe7671"
      unitRef="U_USD">2455000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_a48144ad-1c57-427e-a23f-8eab2efd3ecc"
      unitRef="U_USD">2153000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_81f6a985-98d4-4b49-a9c3-9db910b3a55e"
      unitRef="U_USD">2455000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_2f026914-2333-4421-a9b3-6bc72fbebf48"
      unitRef="U_USD">2153000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_311c9dae-af9d-4c0e-91e5-8b55837939f6"
      unitRef="U_USD">2455000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_b1afc761-e877-4e58-9a4a-c845a922d5db"
      unitRef="U_USD">267100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-5"
      id="F_c0508813-48aa-42bb-84e2-6c5691e3d6db"
      unitRef="U_USD">4200000</bdsx:DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardDescription
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_319634d6-2dd7-4c48-8a33-10c7c0ddc4e9">expire beginning in 2026</us-gaap:TaxCreditCarryforwardDescription>
    <us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_9cb08973-d2c0-4cfb-b36a-f295cf732326">Company does not believe it is more likely than not that it will realize the benefits of net deferred tax assets and, accordingly, has established a valuation allowance equal to 100% of net deferred tax assets.</us-gaap:ValuationAllowanceDeferredTaxAssetExplanationOfChange>
    <bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="INF"
      id="F_a73ad311-2575-42d5-96f6-7839ebf1a9c6"
      unitRef="U_pure">1</bdsx:PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-5"
      id="F_f5996a28-df13-43ef-b0bb-de1e589e24e2"
      unitRef="U_USD">11400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-5"
      id="F_86da0c8c-be2b-40f8-9d28-4e6e8e38eb92"
      unitRef="U_USD">7000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="INF"
      id="F_e7843014-4b4c-4168-b90d-cf4d7031cada"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="INF"
      id="F_ad31a2f1-831a-42ad-9f19-b8a93d523339"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c500205f-de75-4265-b348-b00c75d81f3e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of beginning and ending balances for unrecognized tax benefits is as follows (in thousands):&lt;/span&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.68%;"/&gt;
        &lt;td style="width:2.681%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:13.793%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:12.448%;"/&gt;
        &lt;td style="width:0.798%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions for tax positions related to the current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;609&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions for tax positions related to prior years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions related to settlements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reductions related to a lapse of statute&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;843&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_48188f59-740d-47a0-89aa-55a9b73fe333"
      unitRef="U_USD">715000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-3"
      id="F_57ef72da-66d6-4af9-8898-f2965dd9bdf4"
      unitRef="U_USD">128000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_41480ca7-c625-403a-9351-90f7e1597b30"
      unitRef="U_USD">106000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-3"
      id="F_358ab6ca-b42d-4c99-b5cc-7a82f178cefc"
      unitRef="U_USD">609000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_55a199de-e8b5-4513-a987-0dccd6d5e101"
      unitRef="U_USD">843000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9"
      decimals="-3"
      id="F_4f6bf76e-0d94-4820-9208-f9aed31d2692"
      unitRef="U_USD">715000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_6e9209db-89a1-429c-87c3-1ecf01011a30">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 15 &#x2013; Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases facilities under non&#x2011;cancelable operating leases. Rent expense &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.996%;"/&gt;
        &lt;td style="width:1.892%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:18.302%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Co&#x2011;Development Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2014 and amended in October 2016, the Company entered into a worldwide agreement with AVEO to develop and commercialize AVEO's hepatocyte growth factor inhibitory antibody ficlatuzumab with the Company's proprietary companion diagnostic test, BDX004, a version of the Company&#x2019;s serum protein test that is commercially available to help physicians guide treatment decisions for patients with advanced non&#x2011;small cell lung cancer (NSCLC). Under the terms of the agreement, AVEO will conduct a proof&#x2011;of&#x2011;concept (POC) clinical study of ficlatuzumab for NSCLC in which BDX004 will be used to select clinical trial subjects (the NSCLC POC Trial). Under the agreement, the Company and AVEO would share equally in the costs of the NSCLC POC Trial, and each would be responsible for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of development and regulatory costs associated with all future clinical trials agreed upon by the Company and AVEO. The Company and AVEO continue to conduct POC clinical trials of ficlatuzumab in combination with BDX004.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2020, the Company exercised its opt-out right with AVEO for the payment of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of development and regulatory costs for ficlatuzumab effective December 2, 2020 (the Effective Date). In September 2021, AVEO announced that the FDA has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2021 AVEO also announced plans to initiate a potential registrational Phase 3 clinical trial for ficlatuzumab in the first half of 2023. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in remaining obligations related to the AVEO agreement as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Following the Effective Date, the Company is entitled to a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% royalty of net sales of ficlatuzumab and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of license income generated from the licensing of ficlatuzumab from AVEO.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; expenses related to this agreement for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Expenses related to this agreement for the year ended December 31, 2020 were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2019, we entered into a non-exclusive license agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) (the Bio-Rad License). Under the terms of the Bio-Rad License, the Company received a non-exclusive license, without the right to grant sublicenses, to utilize certain of Bio-Rad&#x2019;s intellectual property, machinery, materials, reagents, supplies and know-how necessary for the performance of Droplet Digital PCR&#x99; (ddPCR) in cancer detection testing for third parties in the United States. The Company also agreed to purchase all of the necessary supplies and reagents for such testing exclusively from Bio-Rad, pursuant to a separately executed supply agreement (the Supply Agreement) with Bio-Rad. As further consideration for the non-exclusive license, the Company agreed to pay a royalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. On May 24, 2021, the Company entered into the First Amendment to the Non-Exclusive License Agreement with Bio-Rad which amended the Bio-Rad License such that, effective May 1, 2021, the Company will no longer pay a royalty of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on the net revenue received for the performance of such ddPCR testing collected from third parties. The Bio-Rad License expires in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Either party may terminate for the other&#x2019;s uncured material breach or bankruptcy events. Bio-Rad may terminate the Bio-Rad License if the Company does not purchase licensed products under the Supply Agreement for a consecutive twelve-month period or for any material breach by us of the Supply Agreement. Royalty expense under the Bio-Rad License was not significant for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On May 13, 2021 (Effective Date), we reached agreement with CellCarta Biosciences Inc. (formerly Caprion Biosciences, Inc.) (the CellCarta License) on a new royalty bearing license agreement for the Nodify XL2 test. The parties agreed to terminate all prior agreements and replace with this new arrangement, which has a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% fee on net sales made from the first commercial sale of the Nodify XL2 test to the Effective Date as an upfront make-good payment covering past royalties due and a royalty rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.675&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% on future Nodify XL2 test net sales worldwide for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years from the first commercial sale, ending in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2034&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Royalty expense under the CellCarta License for the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As part of the acquisition of Oncimmune, the Company entered into several agreements to govern the relationship between the parties. The Company agreed to a license agreement and royalty payment related to an acquired diagnostic test of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of recognized revenue for non-screen tests up to an annual minimum volume and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% thereafter, with an escalating minimum &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;through the first four years of sales&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Royalty expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million were incurred for the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Litigation, Claims and Assessments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, we may become involved in legal proceedings or investigations which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. In September 2021, we reached a settlement agreement with the plaintiffs, which received preliminary approval from the Circuit Court of the City of St. Louis, State of Missouri (the Court) on November 10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, regarding a dispute involving the Telephone Consumer Protection Act (TCPA). On January 31, 2022, the Court approved the final settlement payment to third parties of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;210,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; which was accrued as a legal contingency during the year ended December 31, 2021. We are not presently a party to any other legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition, or cash flows.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      decimals="-5"
      id="F_eb798a55-de2e-4726-ad2c-43e5c1e45c2a"
      unitRef="U_USD">1200000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="C_93b97cad-4f53-455d-a681-c9c0907bb9fc"
      decimals="-5"
      id="F_6e33b5ed-297c-4bfe-bcb2-a62aebb8f335"
      unitRef="U_USD">1700000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_c19413a3-5ac9-407f-a68e-e5fd41d0c0f0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Future minimum lease payments, which do not include amounts for common area maintenance, insurance, or taxes, for operating lease obligations are as follows (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.996%;"/&gt;
        &lt;td style="width:1.892%;"/&gt;
        &lt;td style="width:1.206%;"/&gt;
        &lt;td style="width:18.302%;"/&gt;
        &lt;td style="width:0.603%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;149&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2027 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(204,238,255,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;937&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_ce5f89b7-2a58-4bc4-9c91-2f1b86108113"
      unitRef="U_USD">775000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_2be389aa-7606-4302-8028-d727f338c66c"
      unitRef="U_USD">149000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_dad2c922-38f2-43f6-9c26-fd817c3cffbb"
      unitRef="U_USD">9000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_568c5153-d8ba-4f37-8a64-631c327a92c9"
      unitRef="U_USD">3000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_5450b329-e9be-4370-a810-102e7f7b742e"
      unitRef="U_USD">1000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="C_8aafb945-b385-4de6-9940-2ec65935d0bd"
      decimals="-3"
      id="F_bf8c3ef6-3547-4229-a979-7bcb772b4d24"
      unitRef="U_USD">937000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCosts
      contextRef="C_c77d5c42-d4c0-47d9-86be-96adc70e0b54"
      decimals="2"
      id="F_8ba5ef3b-daf3-4784-811e-1bcc79214770"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCosts>
    <bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight
      contextRef="C_a29723b5-20cb-4e63-a0da-30a2983860b7"
      decimals="2"
      id="F_892b91cc-339c-4cc3-9c5f-4ab741260810"
      unitRef="U_pure">0.50</bdsx:PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight>
    <bdsx:RemainingEstimatedObligation
      contextRef="C_b477c33a-377c-4327-9710-03e518e2ecbe"
      decimals="-5"
      id="F_47a41bbb-37b9-4a04-ba20-029798616fa3"
      unitRef="U_USD">100000</bdsx:RemainingEstimatedObligation>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetSales
      contextRef="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210"
      decimals="2"
      id="F_63ca21fc-fb93-4fcc-8abf-16192f6ecd9a"
      unitRef="U_pure">0.10</bdsx:PercentageOfRoyaltyPaymentsOnNetSales>
    <bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing
      contextRef="C_4119a9d6-0ebb-4cda-8d31-c70c2d848210"
      decimals="2"
      id="F_6efed886-5116-4769-a578-ce5d5d92cb75"
      unitRef="U_pure">0.25</bdsx:PercentageOfLicenseIncomeGeneratedFromLicensing>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b477c33a-377c-4327-9710-03e518e2ecbe"
      decimals="INF"
      id="F_23a715be-241c-400d-b588-b869f86ff17d"
      unitRef="U_USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_10d387cc-753c-46a2-9b2a-9b1890b49bdb"
      decimals="-5"
      id="F_c721cf37-e3dd-434e-9dde-71be916ef3ba"
      unitRef="U_USD">900000</us-gaap:ResearchAndDevelopmentExpense>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac"
      decimals="3"
      id="F_fc5b46a0-da75-4b95-b560-5252a5406a70"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue
      contextRef="C_7388a94f-fccb-4085-aaf4-6b5e7ca6360d"
      decimals="3"
      id="F_5ae2618c-865f-45b0-b369-c4881bb739d3"
      unitRef="U_pure">0.025</bdsx:PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue>
    <bdsx:LicenseAgreementExpiryDate
      contextRef="C_0df97327-8cc0-4bdb-b60f-a6c3363a5eac"
      id="F_c1d135fa-6bad-4c27-a837-77ffa74e5b68">2024-08</bdsx:LicenseAgreementExpiryDate>
    <us-gaap:RoyaltyExpense
      contextRef="C_03721b15-782d-4e40-bfe2-237a592136a5"
      decimals="-5"
      id="F_21d5411a-3e25-4707-a5e9-ac4e7a3ed612"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfFeePaymentsOnNetSales
      contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea"
      decimals="2"
      id="F_97a6761d-6790-4ad5-80d3-9c221c1711e2"
      unitRef="U_pure">0.01</bdsx:PercentageOfFeePaymentsOnNetSales>
    <bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue
      contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea"
      decimals="5"
      id="F_59c65876-0cf5-463b-92f7-e178f28ad3e9"
      unitRef="U_pure">0.00675</bdsx:PercentageOfRoyaltyPaymentsOnNetRevenue>
    <bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea"
      id="F_9e732b28-3c0a-4c65-b5c3-f3486b89aa49">P15Y</bdsx:TermOfRoyaltyPaymentsFromFirstCommercialSale>
    <bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale
      contextRef="C_ac05b01b-9d5e-4a8b-8c8e-6ee95abe8aea"
      id="F_65a32eba-7b44-4677-976b-24cd9cd204c7">2034</bdsx:YearOfEndingRoyaltyPaymentsFromFirstCommercialSale>
    <us-gaap:RoyaltyExpense
      contextRef="C_98732f46-6752-47d9-bc3f-82fa1ccee5a9"
      decimals="-5"
      id="F_eacdbf66-35d8-43b9-9211-641f5640214e"
      unitRef="U_USD">100000</us-gaap:RoyaltyExpense>
    <bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests
      contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210"
      decimals="2"
      id="F_219e6750-fcb9-422e-9e82-d79669f5a76b"
      unitRef="U_pure">0.08</bdsx:PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests>
    <bdsx:MinimumAnnualVolumePercentageThereafter
      contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210"
      decimals="INF"
      id="F_754e3f30-7bad-4689-bd9e-7018ad5920a1"
      unitRef="U_pure">0.05</bdsx:MinimumAnnualVolumePercentageThereafter>
    <bdsx:PeriodOfEscalationsOfSales
      contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210"
      id="F_70bcaf0d-ea43-458b-8df1-b15f92c50e52">through the first four years of sales</bdsx:PeriodOfEscalationsOfSales>
    <us-gaap:RoyaltyExpense
      contextRef="C_932b3ab0-8853-42c8-a37c-36341f8a9210"
      decimals="-5"
      id="F_c9cd5ef6-8da0-4d0b-bc8e-cf4c75793335"
      unitRef="U_USD">700000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="C_a21cae4c-4605-4cd5-b0d4-b15582d30357"
      decimals="-5"
      id="F_1928d5eb-f33d-418c-bd38-a01c9593e8b2"
      unitRef="U_USD">300000</us-gaap:RoyaltyExpense>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="C_1355f790-e2f7-4e53-b996-2166830c4202"
      decimals="0"
      id="F_e309f22f-473e-4d8b-8008-5b2e784a847c"
      unitRef="U_USD">210000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="C_a136b0aa-9769-4cf4-9832-546661048e81"
      decimals="0"
      id="F_3b3f356b-3895-4a40-b563-748958fadaf5"
      unitRef="U_USD">210000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_1b296b71-3c6b-456d-b731-b251aa4ad227"
      id="F_a6ba7e91-b6e6-405a-87b0-2209328e19ee">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Note 16 &#x2013; Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 7, 2022 (the Effective Date), the Company entered into a purchase agreement, dated as of March 7, 2022 with Lincoln Park Capital Fund, LLC, an Illinois limited liability company (Lincoln Park), pursuant to which Lincoln Park has committed to purchase up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company's common stock (the Purchase Agreement). Under the terms and subject to the conditions of the Purchase Agreement, the Company has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company&#x2019;s common stock. Such sales of common stock by the Company, if any, will be subject to certain limitations, and may occur from time to time, at the Company&#x2019;s sole discretion, over the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36-month&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; period commencing on the Effective Date. The number of shares the Company may sell to Lincoln Park on any single business day in a regular purchase is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, but that amount may be increased up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, depending upon the market price of the Company&#x2019;s common stock at the time of sale and subject to a maximum limit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per regular purchase. The purchase price per share for each such regular purchase will be based on prevailing market prices of the Company&#x2019;s common stock immediately preceding the time of sale as computed under the Purchase Agreement. In addition to regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasda&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;q rules.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lincoln Park has no right to require the Company to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.99&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of its common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Actual sales of shares of common stock to Lincoln Park under the Purchase Agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the common stock and determinations by the Company as to the appropriate sources of funding for the Company and its operations. The net proceeds, if any, under the Purchase Agreement will depend on the frequency and prices at which the Company sells shares of its common stock to Lincoln Park. The Company intends to use any net proceeds from the sale of its common stock to Lincoln Park to advance its growth strategy and for general corporate purposes. On the Effective Date, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;184,275&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock to Lincoln Park as a commitment fee and, upon the available amount being reduced to an amount equal to or less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, the Company will be required to issue &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,426&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares (collectively, the Commitment Shares).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Purchase Agreement may be terminated by the Company at any time, at its sole discretion, without any cost or penalty, by giving one business day notice to Lincoln Park to terminate the Purchase Agreement. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the common stock. Although the Company has agreed to reimburse Lincoln Park for a limited portion of the fees it incurred in connection with the Purchase Agreement, the Company did not pay any additional amounts to reimburse or otherwise compensate Lincoln Park in connection with the transaction, other than the issuance of the Commitment Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Centennial Valley Properties I, LLC Lease Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 11, 2022, the Company entered into a Lease Agreement (the Lease) with Centennial Valley Properties I, LLC, a Colorado limited liability company (the Landlord) for office and laboratory space located at 919 West Dillion Road; Louisville, Colorado (the Leased Premises). The purpose of the Lease is to replace the Company&#x2019;s current leased premises at &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2970 Wilderness Place, Suite 100 in Boulder, Colorado&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and the Company intends to move its corporate headquarters to the Leased Premises by mid-2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;T&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he initial term of the Lease wi&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ll extend &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;twelve years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 1, 2023&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;two&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; renewal &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;options to extend&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; the term of the Lease for an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_cd5e018e-3c53-41fb-bbd2-697f64fb59f7;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ten year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; terms for each renewal.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Lease, the Company will lease approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet at the Leased Premises. The Company will pay base rent over the life of the Lease beginning at approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;227,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per month and escalating, based on fixed escalation provisions, to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;326,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per month, plus certain operating expenses and taxes. The Company's obligation to pay base rent shall be abated, commencing as of the Commencement Date and ending on and including the date that is 12 months after the Commencement Date (the Abated Rent Period). Further, the Company's obligation to pay base rent with respect to a portion of the area of the Lease Premises equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,980&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; square feet shall be abated (the Partial Abated Rent), commencing as of the day after the end of the Abated Rent Period and ending on and including the date that is 24 months after the Commencement Date (the Partial Abated Rent Period). Pursuant to a work letter entered by the parties in connection with the Lease, the Landlord will contribute an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million toward the cost of construction and improvements for the Leased Premises &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and the Company exercised its option for an additional tenant improvement allowance of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.00&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per rentable square foot (the Extra Allowance Amount). The Company will repay the Extra Allowance Amount actually funded by the Landlord in equal monthly payments with an interest rate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% per year over the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Initial Term&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; excluding any part of the Abated Rent Period or Partial Abated Rent Period, which shall start to accrue on the date that the Landlord first disburses the Extra Allowance Amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Lease includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature, including maintaining a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million letter of credit (subject to contingent reduction over the term of the lease) to secure the performance of the Company&#x2019;s obligations under the Lease. The $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million letter of credit has to be cash collateralized by the Company through a restricted cash account for the benefit of the Landlord.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"
      decimals="INF"
      id="F_87dd8bee-2f40-49bb-b880-b304cb4f2519"
      unitRef="U_USD">50000000.0</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:StockIssuableDuringPeriodValueCommittedShares
      contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"
      decimals="INF"
      id="F_fd2e1070-f6ec-4965-90cd-1724f906047e"
      unitRef="U_USD">50000000.0</bdsx:StockIssuableDuringPeriodValueCommittedShares>
    <bdsx:PurchaseAgreementTerm
      contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"
      id="F_ca4ec026-b196-453e-b269-eb8e4f33a921">P36M</bdsx:PurchaseAgreementTerm>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"
      decimals="INF"
      id="F_d8bb8fbf-4235-4898-9969-825c81676355"
      unitRef="U_shares">50000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayShares
      contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"
      decimals="INF"
      id="F_f9dadd16-42d8-4dcb-95b7-0133a1a8d017"
      unitRef="U_shares">100000</bdsx:SaleOfStockStockIssuablePerDayShares>
    <bdsx:SaleOfStockStockIssuablePerDayValue
      contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"
      decimals="INF"
      id="F_abf288fe-a781-4968-a795-fbedd8160bc7"
      unitRef="U_USD">1500000</bdsx:SaleOfStockStockIssuablePerDayValue>
    <bdsx:SharesIssuedOrIssuableThresholdLimitDescription
      contextRef="C_83cbaa1a-e64a-4c26-b830-afa34cebed4f"
      id="F_aeee6542-0954-4e9c-95ce-527c97d7eee7">Under applicable rules of the Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the Purchase Agreement more than 19.99% of the shares of the Company&#x2019;s common stock outstanding immediately prior to the execution of the Purchase Agreement (the Exchange Cap), unless (i) the Company obtains stockholder approval to issue shares of common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.20 per share, such that issuances and sales of the common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules.</bdsx:SharesIssuedOrIssuableThresholdLimitDescription>
    <bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty
      contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"
      decimals="INF"
      id="F_8526e5c0-c1eb-48fd-84ca-dab928e4601a"
      unitRef="U_pure">0.0999</bdsx:MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty>
    <bdsx:SaleOfStockSharesIssuedAsCommitmentFee
      contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"
      decimals="INF"
      id="F_30a6a87f-ac98-4e09-9cfc-a079a93f9537"
      unitRef="U_shares">184275</bdsx:SaleOfStockSharesIssuedAsCommitmentFee>
    <bdsx:SharesIssuedAsCommitmentFeeValue
      contextRef="C_b8c8d00d-106f-42dc-b406-d3c4dc57b6e5"
      decimals="INF"
      id="F_8c9ca431-428b-4107-afa9-2c518ed5caf0"
      unitRef="U_USD">20000000.0</bdsx:SharesIssuedAsCommitmentFeeValue>
    <bdsx:CommitmentSharesIssuableOnConditionalBasis
      contextRef="C_f2facf4d-b503-4ab1-b0b3-84c7f255c5b1"
      decimals="INF"
      id="F_ea808ddb-61f6-4da1-8bb2-cdff96738ade"
      unitRef="U_shares">61426</bdsx:CommitmentSharesIssuableOnConditionalBasis>
    <us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription
      contextRef="C_75d6eb43-fbcb-4d67-83f4-dade72088b51"
      id="F_d09cc180-b37d-4949-9a6c-dbebedf51400">The initial term of the Lease will extend twelve years (the Initial Term) from the commencement date, which is the earlier of: (i) the Company conducting revenue generating business (as defined in the Lease), or (ii) April 1, 2023 (the Commencement Date), unless earlier terminated in accordance with the Lease. The Company has two renewal options to extend the term of the Lease for an additional seven or ten year terms for each renewal.</us-gaap:LessorOperatingLeaseLeaseNotYetCommencedDescription>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac"
      id="F_8cefd16f-a53e-43f3-8bf9-d96dfb63de93">P12Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <bdsx:LeaseCommencementDate
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      id="F_b568f062-9170-4b42-9e6e-4b0142fcd8fa">2023-04-01</bdsx:LeaseCommencementDate>
    <bdsx:LeaseAgreementNumberOfOptionsToExtend
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="INF"
      id="F_7d781f0b-1705-4495-b732-b2484875c8db"
      unitRef="U_RenewalOption">2</bdsx:LeaseAgreementNumberOfOptionsToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      id="F_bf396c44-b7af-4527-bc05-4b9510cec56e">true</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
      contextRef="C_09226d1e-919a-4649-b557-d8d34553ce34"
      id="F_1c9621bf-fb5b-4a61-aeb2-b8b5a6a364b9">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1>
    <bdsx:LeasedPropertyBuildingCapacity
      contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac"
      decimals="INF"
      id="F_7f8788d2-2d65-4158-9251-12b4ac3792ac"
      unitRef="U_sqft">79980</bdsx:LeasedPropertyBuildingCapacity>
    <bdsx:BaseRentPerMonthFromCommencementDate
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="-3"
      id="F_890bfdc0-99cd-407a-b46d-bc7d083abae5"
      unitRef="U_USD">227000000</bdsx:BaseRentPerMonthFromCommencementDate>
    <bdsx:RentAfterFixedEscalationProvisions
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="-3"
      id="F_08efaded-5c4e-4776-9013-5ff674da88be"
      unitRef="U_USD">326000000</bdsx:RentAfterFixedEscalationProvisions>
    <bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent
      contextRef="C_2e66404d-ec50-4dc9-aa3a-1c414c9362ac"
      decimals="INF"
      id="F_3c348d5c-7127-4ff3-bbfa-c42ce5b65315"
      unitRef="U_sqft">19980</bdsx:AreaOfLeasedPremisedObligatedToPayBaseRent>
    <bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="-5"
      id="F_48c49038-81bb-4d3d-aed8-5569f3143cc9"
      unitRef="U_USD">18800000</bdsx:LandlordContributionTowardsCostOfConstructionAndTenantImprovements>
    <bdsx:AdditionalTenantImprovementAllowancePerRentableSquareFeet
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="2"
      id="F_a1a52e59-a3ad-4376-aa1f-25c32cb5a383"
      unitRef="U_UsdPerSquareFoot">25.00</bdsx:AdditionalTenantImprovementAllowancePerRentableSquareFeet>
    <bdsx:InterestRateOnExtraAllowanceAmount
      contextRef="C_ee59665c-33bf-4b10-9799-81bdb60203c5"
      decimals="2"
      id="F_023af0d9-e444-49a5-a960-6de29682f5aa"
      unitRef="U_pure">0.06</bdsx:InterestRateOnExtraAllowanceAmount>
    <us-gaap:LineOfCredit
      contextRef="C_eeac8352-9485-4d28-a4b8-6c7dcaf0bab3"
      decimals="-5"
      id="F_e0eedc99-2b40-47fe-b34f-d304599a7e98"
      unitRef="U_USD">5000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="C_21dd0a17-272e-43c9-926c-8361d449c139"
      decimals="-5"
      id="F_6bc3ef3f-283e-41ba-b5c1-69673b120ec0"
      unitRef="U_USD">5000000.0</us-gaap:LineOfCredit>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MF*&<'S!P>^=G[2/=%X+NX3*\3P^.1;T*\YO9W2=R>SO#CE +*6_APKOG8A-
MNXI+SU%QB"&/G[B"<@3+UUN%A+=PP=TS&@L5D<FPE!".X':Q4Z96(=FM>D<Y
M^N < !1W:<\L5ASB27E94X5Z/_A\-YH^+,AD.KB?S^[G_8?1D%P_DOEH/)J/
MIH,1U"C*.D/;_-=L^'XK__Q3E[J=7[2]^1&Q2,,;%%@OK[MZ*SUV6L'4":!L
MC_WW9\%WG*?A&=#2O;>1MO#3!!Z)D63)B7@S0+4?(/P"+69,&3*93$X(TT1O
MN9\>-83A*]$\[1)D6<1YL[,/9?/?/+C&L9*>7H=IXMNSE-V-3OXUOW+KIQ=-
MS:+Y[K[NCMF(H$G(5V#JG'5 )=3N"FSW8N0VO11:2F-DE#YN.(-!VP;P^TI*
MLW^Q'>07D5?_ E!+ P04    " ! ,FY44JQ9$  &   %&0  &    'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;*U9;6_;-A#^*X07;"W@QB*IU]8QT";85F O
M0=-NGQF)MHE*HBM23K-?/U)6)%M\B8/M0V))OCL]=^3=<T<O'WCS56PIE>![
M5=;B:K:5<O=VL1#YEE9$7/(=K=4W:]Y41*K;9K,0NX:2HE.JR@4*@GA1$5;/
M5LONV6VS6O)6EJRFMPT0;561YO$#+?G#U0S.GAY\8INMU \6J^6.;.@=E5]V
MMXVZ6PQ6"E;16C!>@X:NKV;OX=MK'&J%3N(O1A_$T370KMQS_E7??"RN9H%&
M1$N:2VV"J(\]O:9EJ2TI'-]ZH[/AG5KQ^/K)^L^=\\J9>R+H-2__9H7<7LW2
M&2CHFK2E_,0??J6]0Y&VE_-2=/_!0R\;S$#>"LFK7EDAJ%A]^"3?^T <*<#0
MH8!Z!72N NX5<.?H 5GGU@V19+5L^ -HM+2RIB^ZV'3:RAM6ZV6\DXWZEBD]
MN?I 2E+G%-QI"P*\ 5_N;L"KB]?@ K :?-[R5I"Z$,N%5"_3*HN\-_SA8!@Y
M#-_0_!)@. <H0-"B?GV^>G"JOE N#GZBP4_4V<,.>]=MT]!: B*$\M-C$ \&
M<6<P=!DD8@M4:$"N+^BWENU)J=Y@#=7!5-*9THFU7V&40+1<[(\C8DK%"*)X
MD#K!&0XX0R_.]WG.6P5+Y5Q.%<;[DLY!K>H#7P-2JBSNEE_5 U#P]EZNVU*E
M5J^B1"Y@E'9N7L TL+EV>'MT[%H<Q1//3"$8X2"T>Q8-GD5>S_Z46]JH''$O
M[ %A9+P\06$T06@*I0D,[ #C 6#L!?B92U*> 3 VWAWB&.()0E,JC6'H@)@,
M$!-O6OS!ZQ]_2%&0O?/!/#&=#J93K_>WC>*:1CYVNT?GQTY5?]GM/5L04C,(
M,,DF,3"%,$Q2>PBR 6?FQ?FQEJ3>,)47O>].B)FYBV$,DPE&BQ1&L6.=8##6
MZ< +\Q?.BP=6EM9*'%CR*\!P@NQ9L5-H1Q0"STC$DM>;-Y(VE6>G]X9.$,31
M-((6*1S&+I@C T!T1CK69^WX'BXR@: P#:=X+6)AAEU+/C(,]%/, ; ''C8K
M6QQD1CA-,8A@D+CPC<P"P[,XM63DGI5,,NJK&W"LZ]!?V ?*VI%'S5=6W\V"
M#>-XRJ@6J32+';P#Q[H._85= 6Q:6K@=[S&:)3N)XRGSV*22-'-@' L[3+P8
M;^B:JN4I%._O:=W:@YB804RC8 K0E,(11@Z (SU /S\\[9X=;[J&7C4;.:\E
MJS?ZJ;H4K* -T=]9L9M< )/$N;8C&T _'5A@U5Q2_V:TU/PI==ED8.KB;S3R
M O+SPFF3\<R.1"8#()40TQ6WB&'5B48.K"-1(/C";N.\TH&.NGQ_C?]M(*&3
M11LZWOQT=:TQ,JMYEF73;LPB!:/,U:RCL>:C9\:*%Z0 LA3V.$#I%*HIAI1#
MC@1&8_E'_LEB2OO/[3W+$(#3:9K8I#+DX'XT4@KR4XJ+^Y_#;/('2D)HY(LI
M%B9)XJCA:.09=,X \1Q&DS^B&"<&1@O-9)EK!D,CSR _SUSSJF)2M_;B, X_
M;>#<A==K3Q];O14[DM.KV:ZA@C9[.EL!VP'"_V#HU.>1NE#JK6-WDN=?M[Q4
MR2E^ZF8;^>@S/)(/\I//;?/$VD*_8@XN@LL@@*J,-6!/RE85LF@>!('^ Z25
M6]ZP?VCQ#@3@E3YGZ59 GYB\!DP(W:+H![R50LTXA5H6ZX)X,;UD0?Z[H=.C
MF)$$L9\$]2947.T,&CJ$S @;#N:JU9K'87:(W^M# .-Y%,-Y%(3=4Q5,L24*
M\0MBBBT,.AW'+#(HL:<C'BD6^V>Q]T7!-%^HNK$CK.C+':M!3G9,51,K6,N\
MA50W/:W-%CE%)%F$':!'UL9^UE;]=%NU)9$JN 5=LYQ9YV]L<NX;', LF9*S
M31!%:0H=U0X?'?J=,Y*)9_._!VPAZ"Q!TP'-(A9"%7\'V)&@L9^@#?KH=N[9
MX$/C.-(V75K$K-/EXNB,6O] \#MI-JP6H*1KI1A<)LK]YG#F?KB1?-<=6]]S
M*7G576XI4:BU@/I^S56'U]_HD_#AEX_5OU!+ P04    " ! ,FY4*K[T&?0"
M  #3"0  &    'AL+W=O<FMS:&5E=',O<VAE970S+GAM;)66WV_:,!#'_Q4K
MVD,K=<0))(0*D%JJ:GN8ALJZ/4Q[,,E!K#HQLQWH]M?/=M(LH>$7#\1V[K[W
MN>.,/=YQ\2)3 (5>,Y;+B9,JM;EU71FGD!'9XQO(]9L5%QE1>BK6KMP(((EU
MRICK8QRZ&:&Y,QW;M;F8CGFA&,UA+I LLHR(/_? ^&[B>,[;PA-=I\HLN-/Q
MAJQA >IY,Q=ZYM8J"<T@EY3G2,!JXMQYMS//.EB+[Q1VLC%&)I4EYR]F\CF9
M.-@0 8-8&0FB'UN8 6-&27/\KD2=.J9Q;([?U!]M\CJ9)9$PX^P'350Z<2('
M); B!5-/?/<)JH0"HQ=S)NTWVI6V0>B@N)"*9Y6S)LAH7C[):U6(AH,W..#@
M5P[^N0[]RJ%O$RW);%H/1)'I6/ =$L9:JYF!K8WUUMG0W/R,"R7T6ZK]U/2>
M,)+'@!9&0:*K.1&0JQ04C0F[1A_1\^(!77VX1A\0S=&WE!>2Y(D<NTH'-Q)N
M7 6Z+P/Y!P(]0-Q#?>\&^=CW.MQGY[OCMKNK4Z[S]NN\?:O7/Z"W4$2!;D>%
MOJ[0(\UU$2AA:,XEM>WU\VXIE=!-]NM(L'X=K&^##0X$NV-ZM]@RZWV'$EXL
MU:I@NH5C7N2ZZ@)BH%NR9-!5UU)[:+7-KMQ.O2 :N]MF\3IL(ES;M* '-?3@
M*/1<[R<0 A*DFS!^N4$;(M"6L*(3LM2*&@"XA[&WAWG*J@4:U*#!9:"D4"D7
M]"\D7:2E6-!@"+#][+&>MFO1AC5M>!DME;+H)@W?$>PS'K-HT0UKNN%E=/J?
M7RJ]XVF^[D(<GD0\9M%"C&K$Z"CBC&>9WJ#G-&5T5E.>LFI1CFK*T064QSMR
M]*Y$/L:=/7F.90O7P__/ 7P!\.&FK&2:#'T\C$;A8+0'VV'IAT'H!7AP +9Q
M:'D7P)[HT4KK'.+WE@>(W<:):ZX[7XA8TUPB!BOMBGM#K2'*&T0Y47QC#^$E
M5_I(M\-4W[I & /]?L6Y>IN8<[V^QTW_ 5!+ P04    " ! ,FY4/R/N:W$$
M   )#P  &    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(U7VXZC.!#]%2N:
MAQFI.V # 5KI2'W92TLSNZWNF9V'U3XXX 2K 6=M)^GY^RT#@00,.R\)AJKC
M4^6ZN)9'(=]4QIA&[T5>JMM9IO7NQG%4DK&"JKG8L1*^;(0LJ(:EW#IJ)QE-
M*Z4B=XCK+IR"\G*V6E;OGN5J*?8ZYR5[EDCMBX+*'_<L%\?;&9Z=7KSP;:;-
M"V>UW-$M>V7ZV^Y9PLII45)>L%)Q42+)-K>S.WSS0%RC4$G\Q=E1G3TC8\I:
MB#>S>$IO9ZYAQ'*6: -!X>_ 'EB>&R3@\6\#.FOW-(KGSR?T7ROCP9@U5>Q!
MY-]YJK/;631#*=O0?:Y?Q/%WUA@4&+Q$Y*KZ1<=:-H0=D[W2HFB485WPLOZG
M[XTCSA3P8D2!- JDK^"/*'B-@E<96C.KS'JDFJZ64AR1--* 9AXJWU3:8 TO
MS3&^:@E?.>CIU:NFFL&Q:(7$!OVY8Y(:]RITC;Z]/J*/'SXAE5')%.(E^IJ)
MO:)EJJ[0AXOUTM' Q2 Z2;/O?;TO&=D7$_1%E#I3Z)<R9>DE@ -&M):0DR7W
M9!+QD25SY.$K1%R"+80>?E[=G:#CM8[U*CQO!.^I3$3!4.M?]/?=6FD)8?O/
M!+K?HOL5NC^"_L(.K-PSJ^-KS;#2-%E\6 5^X"Z6SN'<&T,I/PB"L)6ZH!6T
MM())HYOX*;>(O4.A44S=3!B[:%$7D\8^<@E)CQ*A($HAW%IPF_4U5'!FE^<&
M..I9/Y0B.(XCN_5ARS/\GT-1C,HDJSBF<$*YV)FCM]$,!P0P":.X1],BY49X
MA&;4THPF:;[2G$$&0]5^8^:LKM"6E7!N><6;IE!EN(E44U]MU*,!J0 \'/:H
M#Z4\/QJ+K[BE'D]2?\AHN66F]&PHE^A \STS=2N!4@*6F#2#1\73IHS9Z,=#
MGRX(Z;$?"HVZ';M=J74GV7\5&IPL!CEBK9[N@$$<^'X_BRUBB\B/\0C5LZZ
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M0$+QCB:*?=3 EY<"L+S2J1S%W523-U--5$\U/Y]YI+D;2(H?9_6$U# BW1P
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M,2P:G9\&8'8-NIN07OL[OM3$'>.'-;]I:%P [U=:TW[BVF9X)?._4$L#!!0
M   ( $ R;E2O\:+>)@@   LB   8    >&PO=V]R:W-H965T<R]S:&5E=#<N
M>&ULI5I;<ZNV%OXKC-OIM#/;VTC"&.\FF4F<]ISST#:ST_8\8Y!C=0.B2.1R
M?GV7!+9L=$FRSTL">$GZM&[?6H*+)]Y]$7M*9?1<5XVXG.VE;#\M%J+8TSH7
M'WE+&_AEQ[LZEW#;/2Q$V]&\U(/J:H'C.%W4.6MF5Q?ZV5UW=<%[6;&&WG61
MZ.LZ[UYN:,6?+F=H=GCPF3WLI7JPN+IH\P=Z3^4?[5T'=XOC+"6K:2,8;Z*.
M[BYGU^C3)LG4 "WQ)Z-/XN0Z4EO9<OY%W?RGO)S%"A&M:"'5%#G\>Z0;6E5J
M)L#Q]SCI[+BF&GAZ?9C]9[UYV,PV%W3#J_^R4NXO9]DL*NDN[ROYF3_]FXX;
M6JKY"EX)_3=Z&F7C653T0O)Z' P(:M8,__/G41$G U#J&8#' 7@Z(/$,(.,
MHC<Z(-/;NLUE?G71\:>H4](PF[K0NM&C83>L46:\EQW\RF"<O+J7N:1@%BDB
MOHLVN=A'/X-I132/_KB_C;[_]H?HVX@UT>][WHN\*<7%0L*R:O"B&)>X&9;
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M3F';0G.4>95K: >%>>?H VW^HAS Q(<*>QU?K\%WL- JP=8&;#&$TA,O.M^
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MT+0I ?A]QR'+C#=J@>/W'U?_ %!+ P04    " ! ,FY4QI\"&0L,  "Y'
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M=$.=+!J=9;K<ZL\?TCV% L,EGEZF.>^"@$-B+ZRX**+C]NG%:' 7L+G2H[+
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M*%(K*["BSQQ."^,*)F3XIR^)P[3$\D.N PP=2:"#Z#():O:T/D'N87$/6P7
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MQTG)B2M2OE,EO:]#$-V5M(*',XW$\[;#^9H(HF@IL[+ A7R[]/<U4GX5]+@
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MB_PC3I79'@_0]^N.]%U_P03A3]Y]^[]02P,$%     @ 0#)N5"R)!G?=!
M+ L  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULK59M3QPW$/XKHVM5
MM=)Q+WN0( HG':0H1"%"D#2JJG[P[7IOG7CMC>WEH+^^S]B[RY$&6E7] +>V
M9YYYYM4^WEKWV5=2!KJKM?$GHRJ$YF@Z]7DE:^$GMI$&)Z5UM0A8NLW4-TZ*
M(BK5>IK-9B^FM5!FM#R.>U=N>6S;H)615XY\6]?"W9]*;;<GH_FHW[A6FRKP
MQG1YW(B-O)'A0W/EL)H.*(6JI?'*&G*R/!FMYD>G^RP?!7Y5<NMWOHD]65O[
MF1<7Q<EHQH2DEGE@!(&?6WDFM68@T/C288X&DZRX^]VCGT??X<M:>'EF]4=5
MA.ID=#BB0I:BU>':;E_+SI\#QLNM]O$_;9/L2PCGK0^V[I3!H%8F_8J[+@X[
M"H>S)Q2R3B&+O).AR/*5"&)Y[.R6'$L#C3^BJU$;Y)3AI-P$AU,%O;"\EKDT
M@59Y;EL3E-G0E;,&W[E$Z(,_G@988=EIWB&>)L3L"<1Y1I?6A,K3+Z:0Q6.
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M52BXN([R6_', N4\)CCGW(Q.!-GF=[ YH_"O\G@2$0 #%D[L<E\I<^?J<]T
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M].QXL:%W'K4SH/V]HO$R+%R \9_#^F]02P,$%     @ 0#)N5($7&1*. @
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M+C/!<2:C!7B_5,HV-Z2@_0!\_Q]02P,$%     @ 0#)N5,FR)U7^$@  "CT
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ML%4&&N$X0BU[AX*2"6*9!9(TNB&6*\*T.LO4$N)9I7N!H:WHA?:V<+IS#>(
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M'&#R$Y O:G*S4P.>F"TI;3H;B>G\YMF]3+'%Q_T!N@.R5CE(EW+1[>_TH+1
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MO6@!WJ\, E3?T ;M![[K_P-02P,$%     @ 0#)N5,00="49#   9QX  !D
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M'R:@6+3@D:IV"=,*E;@F'ENM=ZQJC>5C?8U"V^K1!04XY"QJG#HD\;ZF2##
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M>R_E: %^SRR@UGRA [IWRY?_!5!+ P04    " ! ,FY4[PI (^\+  "J(0
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M9\8##/R1&E9EZ0;\3CS0?*$'M/\]X^+_4$L#!!0    ( $ R;E3/-<F&!"@
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MP;Z6Z%A1-&S:XG4D=B/SI1Q\N*U8!?Y.5-HS*!%JP#=&1<L;*JV+SD59!@9
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M(+&SMV!%Q7<>=^'E[&K@7RVHL.9H;23: ?\ 87Z+_Q$=S>. *S= O&FY3US
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MB*]D)-70'G$Z9L$7K 768V3+QIX-O.%6XO2/9'LD3>X!/Q4^N308J/B*==D
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MW\4O27OZY>*!$N@AV^ [#<A<DE9G1P$;]<FU8E7GL;GG.G9 ?H\"-."VA5<
MZ*>4&4X;]QRV) #569>^'\/;"&AED7'0K"]ZIREO[1$T42SW&,8&QWDVEM4X
MNI<W1-*YP6(6C(,D(>4A:-$+/+%A0K'#^(JB(E)6FOC50I_!,V%8=9*-U-W1
M6?3YQ!B,@EZ1K X37,*X,AY3'1J&9.E 0TYH* !*LE;E:LSI2[LI:RJ?_ZNI
MB;2XXFIQYO5+?III_ HD?)^'>/ITD9H:T0HP'3G>K.,\/]S&Y]E\]MAG:;&K
MFL;APP_^XOT;0K6L.B6!\&I9A\?#.FUPL;5%M$8965_P;Z$9/M?@U&F?1OH6
MGN1%6/H>KT:B I*.'$2VFL%'<='];]SAB)5O]#D;*@<_W$W'&_J*<G*;Q33F
M0T3H]%VH>,G1F&$D<.?Q'U6>J\>(6_)J2BA4ZOC7OK9W$2SS1_EXW=J%=(?_
M1$KE>?9SFLQ+/D6Z&EU$7NF!.X870T<+15%&/9/W0J5O6"8GK)O3@C!9W8L]
M81"J-_MT)GFDX\A;>N>&L, >DXQ=-QP)7_HW^X4!3FQ!Q  )L>N,RBV7+*,>
MU+>I<4WHV$LKQA7C0R+N5Z8SWWZ]L^W&7MFJHE>CU*"P,-7H_XI]2%@7^?SE
MXMY#>#)\_=NO]V T_TP)7FSD6<.CE[.O0/41Q^HO7;/')9$'NV9'/^+@%=OB
M%^#S=0.&L/R"&^"4-0+OV_\%4$L#!!0    ( $ R;E0:%U6#?P0  #<,   9
M    >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;)57;6_;-A#^KE]Q\(:A =18
MDAW;R6P#<=)@'5HL2+(6P[ /M'2VB%*B1E)Q\N]WI%ZL-+::?8GY=L]SO'ON
MQ,QW4GW3*:*!ITSD>C%(C2DNAD,=IY@Q?2H+S&EG(U7&#$W5=J@+A2QQ1ID8
M1D$P&6:,YX/EW*W=JN5<ED;P'&\5Z#++F'I>H9"[Q2 <- MW?)L:NS!<S@NV
MQ7LT?Q:WBF;#%B7A&>::RQP4;A:#R_!B-;'GW8$O''>Z,P9[D[64W^SD8[(8
M!-8A%!@;B\#HYQ&O4 @+1&[\6V,.6DIKV!TWZ#?N[G27-=-X)<57GIAT,9@-
M(,$-*X6YD[O?L+[/F<6+I=#N+^RJL]/Q .)2&YG5QN1!QO/JESW5<>@8S((C
M!E%M$#F_*R+GY34S;#E7<@?*GB8T.W!7==;D',]M4NZ-HEU.=F9YP[B"+TR4
M".\>V%J@/ID/#0';[6%<@ZPJD.@(2!C!9YF;5,.'/,'D)<"0/&K=BAJW5E$O
MXC7&IS *?8B"*.S!&[77'#F\T8^O><UU+*0N%6KX^W*MC2)E_-/#,6XYQHYC
M?(3COM(UR UTZ&CV1VFT87G"\RVLI")8&NE#8>XEL/5YH0L6XV) !:A1/>)@
M^9 B;"S=HZ73ED]V^-8MGP^[E,<I,(40"Z8UWW!,@&GXA(\H(/*!%8623YRT
MCF!2)-"8*?5L<6ITY@@H.YBM4;49 F*S@\!W)9( U1O/#9*7!A3!:=*R4I@;
M\0SLD7%AI0;44T#SC&:JXZ@#VY$MO.,Y^2%+32OZY,*[?,7N.7;+[%TUKE9Q
M[Z3@Z(ZWSP;\#&'@!Z3DSB":^M/)9#_H$<E9*Y*S?I%05TU*X71QAX54AJ)U
M\S)_5U1+Y!-%RPXU3Y!"2"WLD&)ZV8XKQKCXKVU/!K>3&VU33GVV]ND[3<5[
MG^*N3XVJN#XHJA&X%'8E"BDG6Q6GSWXM)[N?.)%P$FW,+/T;4G^-.E:\<,V]
M(X-*9V"O87=Z?+>IMHD=T^"7GV91&/WJ71T[&T[\()I!=.Z?CR+O01HF^H!'
M(W]Z[C3D#/JD,VFE,WFS=*Y21KPV8$?5XLKHAN<LCSGY^HFS-1?<<#S8>7JI
M>SJ/%,(54*VH%UJ*]TX>C91M ?;L,U(/0/OU.-!=OA?#7_:P^]1XC<SNR!'"
MVC%U ,!;X9;GN>N'3%! R*GW\#O+2]NO&Y8F5UXGN!W9AOXDBKR/35?#)WH7
M::2V&8UFWH>ZV^[17]^B%<7_"1Q-B633IE'LT_B6V 6O8G=3&^UC^-KH8%0[
M.KLM#7REILHJS=7+;XER4$4Y#&W-C?QHXL(RM84R";S+).%6%;HI1SHRFIVW
ML[9(#R9H%L[:DZ$?G47PCD#AQ+O#3FLR$EA-0^$L&$_>6WVR@MN*;NS)TI^<
MD3&-;.+'-&K8?YSK8%_W;6<Y.#K4%8:=QUR&:NN>K-1=99F;ZEW7KK:OXLOJ
M,;@_7CVI/S-%&=$@<$.FP>F4OA:J>J96$R,+]S1<2T,/33=,Z66/RAZ@_8V4
MIIE8@O9_A>5_4$L#!!0    ( $ R;E3&!'_5; ,  *@'   9    >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;)55VV[;1A!]YU<,6*.P <*\2J1428!\"5*@
M 00K31 4?5B1(W%ADLOL+BWG[SN[E&D9D-7DA=S+S)G;F=G97LA'52)J>*ZK
M1LW=4NMVZOLJ+[%FZEJTV-#-5LB::=K*G:]:B:RP2G7E1T$P]FO&&W<QLV<K
MN9B)3E>\P94$U=4UDS]NL!+[N1NZ+P</?%=J<^ O9BW;X1KUW^U*TLX?4 I>
M8Z.X:$#B=NXNP^G-R,A;@2\<]^IH#2:2C1"/9O-G,7<#XQ!6F&N#P.CWA+=8
M50:(W/A^P'0'DT;Q>/V"_L'&3K%LF,);47WEA2[G;N9"@5O65?I![#_B(1[K
M8"XJ9;^P[V7'J0MYI[2H#\KD0<V;_L^>#WDX4LB"=Q2B@T)D_>X-62_OF&:+
MF11[D$::T,S"AFJUR3G>F**LM:1;3GIZL9)47ZE_ &L*N/_>\98RKN'R,]M4
MJ*YFOB8C1M3/#X W/6#T#F 8P2?1Z%+!?5-@\1; )^\&%Z,7%V^BLXAWF%]#
M''H0!5%X!B\>0HXM7OQ_(:\J1J$NWP3^SW*CM"2N_'O&4C)82JREY!U+:VJA
MHJL0Q!9.)_I4?L]BFB:=JI;E.'>I"Q7*)W3?5A&'8')!S:.T,:]+A*VHJ =Y
MLX-+WM")Z!3)JZNILU1&AA*-]0:E2;9CDFTR'CA_L<T1Y@6,O31+Z#_RTIAN
MD7JB%%4!O&ZE>$(CI2#RXG@"H9<E(^=6U&VG"?<5)0T"R-+0^=#)ANM.HO5\
MRY_-6D$\"2&)$F<MMGK/Z'9,\N-1Z'S!DN=$3)BD\/MO611&?Q!\0R7K^BZG
MP,B+')6",(4X"YTP\"91!A-O$D3D+5VP/._JKF(:"VI@RF+.F56^-+$E$[CJ
M5U$"5\YGH5EE,$\DV(,&3482+TPG](_IG\$9XHP&XHQ^FCAWQQ[>/],T5@@/
MV+NOQ2\0ZZS-T\1Z8QP/QN6K\5;"2>;MF9HZWY#)?@J\1ZT[3NB&IXHH8Q%Z
M$\K0+#0DB\>ALZ:93:SU:.[)1]1VN<,&)17&*+&"!B,W;6LFO%5,TNQ0N0LB
M843UOX","'FJ-O[1]*Q1[NP;H<BIKM'](!U.AV=HV4_?5_'^#?O$Y(XW"BK<
MDFIPG5+*9?\N]!LM6CN+-T+39+?+DIY2E$: [K="Z)>-,3 \SHO_ %!+ P04
M    " ! ,FY4!A#/7YX#  !3"   &0   'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6R-5MMNXS80??=7$&I1)( :7:R+G=H&G'C;+M MC"3=HBCZ0$MCB5V*
M])+4.NG7=TC)BM,X[KZ8MYDS9S0WS_92?=(U@"&/#1=Z[M7&[*Z#0!<U-%1?
MR1T(?-E*U5"#1U4%>J> EDZIX4$<AEG04":\Q<S=K=5B)EO#F8"U(KIM&JJ>
M;H#+_=R+O,/%':MJ8R^"Q6Q'*[@'\]MNK? 4#"@E:T!H)@51L)U[R^CZ)K7R
M3N C@[T^VA/KR4;*3_;POIQ[H24$' IC$2@N7^ 6.+= 2.-SC^D-)JWB\?Z
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MW^;T$*)V 72>*64;PQ5HG];E7U!+ P04    " ! ,FY4S,FLADP#  !>!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R-5=MNVS@0??=7#+1%T0!J
M=/.]MH&DV<4ND&R,7-J'Q3[0TM@B0I$J2<5MO[Y#2E$<(#'Z(@[)F<,SP\/1
M8J_T@RD1+7ROA#3+H+2VGD>1R4NLF#E5-4K:V2I=,4M3O8M,K9$5/J@241K'
MXZAB7 :KA5];Z]5"-59PB6L-IJDJIG^<HU#[99 $3PLW?%=:MQ"M%C7;X2W:
M^WJM:1;U* 6O4!JN)&C<+H.S9'X^<O[>X0O'O3FPP66R4>K!3?XIED'L"*'
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MS.C? BIK0/<K*<UA8P&:_Q^C?P!02P,$%     @ 0#)N5%Y;P! K!0  <PX
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MS$N2NY+X"TG.2SH*$;K15"73SYH\## /+&CR4"US!2[7I:4RMX?]@[&EGW!
MQ93 1^CU3KS9@7;WW!M=",L)=/QR"FV_]$*'N!R)W\JA@4\?SI)V\N7@5CLF
M".6\TX/7:B3>Z4^)9AVFD"6YI+QJU>:T&73CJK^?W:LI.6=F3:]!<E<4VCKN
MG41@JLE3;9PN0K<OM:/9$<R<AC4:[T#W*ZW==N,3-.-_] ]02P,$%     @
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M6F9O_ME BSA]%]X*#6_6Z:7/J,>DF0#/=P(T*1^8U^OB_Y?%?U!+ P04
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M=\#NYTK1^\2UG>ZGD?P&4$L#!!0    ( $ R;E07FO-3=00  %P0   9
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M$/T50NBB!9I(I/PL; .QT^ &2- @N6D7%UW0$FT3I4A=DK+;O^]0DB7Y(35
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M[YAV&^#Y2BF[GS@'5<,X^PU02P,$%     @ 0#)N5+F9J#WC"   :3   !D
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MQPS7NTY7 )4O!?F>JP^?GGKB0*.RZQUB'&B(=LT0/<0-E^Y^4VUV@\9MU]P
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ME0:-[-<5D[IAYZ;3/%_W O[ 7@ ,N*0I-I> %56%O7NHO*YV^P>6TM7:[[E
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M:)K$H7L\3!0OJ@;L@2O=SE7#1'?<((R!7M]RKIXGIJ=K>OCE;U!+ P04
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MPVL!9)'G2#Q\P)0?%A:T'C<^DUVFS(:]G._1#M]@]66_%GIE-UI2DF,F"6=
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MQ/\R+\#MA[U*!N$%!2-,@10,<,(E)_SR:*79!7<Z0&)<F#,+_#H<P.G)&9P
ME_ M4W-C4S#MD"PKEULX+AG<% R2/0SB!)Z4I,S K4PQW00(;3FJFB3+FMPD
M!Q$'.+Z 6GP.293$.Q+J_[][=""=6B51S>/5]N#=^9K"OIK^?+3V\$"8FU\'
MHM6K:'4?K;XGVH;&6&JL5QJG2XV%SX>O\F$^GUT"%A%;/J+K*^_=^*IA2_.^
M7M3/1DG4K%=&&V0:%9G&03(#KFV[@+XRME#NAI>7UAPH5+/";AY!EE85K75T
M68J(C;6*-[8T^6P1UW8K<EGQN#S(8\@$FG-X8OH-B<OI.=RC1,V*!M1+;8OC
MAC1SS?U V:ZJ<%='$"F.5MTT.KI,9<C-OT]]6ZH=5DG4B+?4"M<F18YZZ@>H
M@;&:2RH:9'5:#>F>'TU;YS=N>/L)M((I)K^5=LJE 8$3"QE=M.SUT<4P+3:D
M9GX>C139Z>:7F?T 0>T,[/N)4K3<N #5)TWW'U!+ P04    " ! ,FY4,]X#
MR:P"   ;!P  &0   'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6R%E5%/VS 0
MQ[^*%?$ $B--VC0M:BL5.C:D;4)TL(=I#VYS;3R<N+,O%/;I=W9"5(9+7Q+;
M\=WO?Q??>;15^L'D ,B>"EF:<9 C;L[#T"QS*+@Y4QLHZ<M*Z8(C3?4Z-!L-
M/'-&A0SC3J<?%ER4P63DUF[T9*0JE**$&\U,511</U^ 5-MQ$ 4O"[=BG:-=
M"">C#5_#'/!N<Z-I%K9>,E% :80JF8;5.)A&YQ=#N]]MN!>P-3MC9B-9*/5@
M)]?9..A802!AB=8#I]<C7(*4UA')^-/X#%JD-=P=OWB_<K%3+ MNX%+)'R+#
M?!P, I;!BE<2;]7V,S3Q)-;?4DGCGFS;[.T$;%D95$5C3 H*4=9O_M3D8<<@
MCO88Q(U!['37(*=RQI%/1EIMF;:[R9L=N%"=-8D3I?TI<]3T59 =3CXIE6V%
ME(R7&;LND9=KL9# IL8 &O:!S>D89!6MJ!6;%DJC^,M=/F]!<H2,H:*A_?VB
M7+-O=(S>>FE]T-[&![#C&2 7TIRP(R9*]CU7E2$19A0BQ675A<LFAHLZAGA/
M##-8GK%N=,KB3AS=S6?L^.CDM9>0LM*F)FY3$SNWW3UNKR@D!/:%3HTO-5<5
M5AI>Y^3C$Q6+ ?9SNC"HZ<3]>D='M]71=3IZ>W105+$O*;55ZJQL[3U.HF&:
MC,)'#ZO7LGJ'6%T?J[9*7K'Z0S\K:5G)(5;/QTH\K&0/J]^R^H=8B8_5][%Z
M?E;:LM)#K+Z/E7I8O<C/&K2LP2%6ZDH7<Z">O$+0/O3@+3J-]J1TV**'[Z)W
M*H+7%6&JQ6]JMK;*^4Y5G+JN<,FU?K8MXI[+"GPBAV_/<Y1$Z7\JPYU>9Z^-
MKURO16F8A!79=<Y2BE+7K;B>H-JX]K=02,W4#7.ZO4#;#?1]I12^3&Q';>_#
MR3]02P,$%     @ 0#)N5((Q !R! @  ? 8  !D   !X;"]W;W)K<VAE971S
M+W-H965T-3 N>&ULC97?;YLP$,?_%0OUH96V0B! 4Q&D--&T2:L6->WV,.W!
M@4NP:G!FFZ;][W<VA*4)B?H"_G'?N\\=]I%LA7Q6!8 FKR6OU-@IM-[<NJ[*
M"BBINA8;J'!G)61)-4[EVE4;"32WHI*[ON=%;DE9Y:2)79O+-!&UYJR"N22J
M+DLJW^Z B^W8&3B[A0>V+K19<--D0]>P /VTF4N<N9V7G)50*28J(F$U=B:#
MVVED[*W!3P9;M3<F)I.E$,]F\BT?.YX! @Z9-AXHOEY@"IP;1XCQM_7I="&-
M<'^\\_[%YHZY+*F"J>"_6*Z+L7/CD!Q6M.;Z06R_0IM/:/QE@BO[)-O6UG-(
M5BLMRE:,!"6KFC=];>NP)Q@,3PC\5N!_5!"T@L FVI#9M&94TS218DNDL49O
M9F!K8]68#:O,5UQHB;L,=3J=9)FL(2??&5TRSC0#13Z3!1Z6O.9 Q(KT65S.
M0%/&U17:/BUFY/+BBEP05I''0M2*5KE*7(UT)H:;M21W#8E_@F0&V34)!I^(
M[_F#'OGTXW+OO=S%FG2%\;O"^-9?<,+?G+[1)<=<)U7>U(!R17Y/EDI+/'M_
MSH0(NA"!#3$\$6(J2KR,BNKF1G"JL<RT#=57P,9=;-V9Z_F2#CU_E+@O^V4Z
M-@I&<=@9O2,==J3#LZ2[,Y#A!LLH)UHR?,*KX8<^U,9?N$=Q$WL'I,<V\> $
M:-B!AF=!?^@"Y(ZKMX;A45 _CJ(#LF.CP!N-^M&B#BTZB_8H-):,MI7D_V]3
M'V5T]!$1,CR@[#&*;PXIW;W>8/KR/95K5BG"884R[SK&+&73ZYJ)%AO;+I9"
M8_.QPP)_#R"- >ZOA-"[B>E W0\G_0=02P,$%     @ 0#)N5*M3Y8F$ P
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M>S9[.@ >? =<QX4]\(D9_A?B P"3L_#IY=F='OB=&7Z[4]D]YRQ\9H;/\'(
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M*VGHDY=KT]9:37XF?97I.(>&3I*3O>,=1!T(A$[[CG!>L!3&U=O ,%_8>>7
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M 9.VN_:T_3-K>R<*W">79M+.<]S(DN:X)CUW7Y*>DS_( ^Q9B0:Y4R!P!<
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M&CN8'1;XRP!I O!Y+H1^GY@VUO^$DC]02P,$%     @ 0#)N5$U2^/A$ P
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M<HEN9S.J+G&,WJ?%I%=_O'D@$M-8_' UD&" $C.(2F5WA3*G1=G/..TCR[Y
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M>/%Z97$CV2I_NV_*I&1)?KDD&&Q2#>#_.6-R=Z->&*Q><KWY%U!+ P04
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M+4D<_RJCH\)G.K'\^<7Z;UGP,I@'DM 5"W\$:[&['GDCL*8;<@C%5W;\@ZJ
MIJD]GX5)]A<<U5A[!/Q#(EBD)DL$41#G_\F32D1I IJV3$!J GH]P6F9@-4$
MG 6:(\O"NB&"S*\X.P*>CI;6T@]9;K+9,IH@3I?Q3G#Y;2#GB?G=CG *EC(1
M:[!BD=P="<GR>P'N\I4%; /N!/-_@B_[[)M%FOE /(.S&RI($";G<O#]W0TX
M>W<.W@$+)*G-! 0QN(\#D;R7+^7G;SMV2$B\3JXL(8&G[BU?@5SF(%$+2(C
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MD4'VGL!'&5LMHYV6L^@DXP+2'HG#2Q(%47@@H/G'X<&)<.*VM+'CBX^5MBI
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MW8/$.[>/4K 2*L5$122L9\ZM?W/G1\:AL?C!X*!.KHE)927$L[FY+V:.9XB
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MY%3*5ZS, Y5VW=J(:1/1U.=^GOA9&DW=_:D\0ZLX](.LM_H#-^IQHU'<1U!
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MBFA1[-\85ECSEGI#-U$M+?6WJ Y')[M<&P9Z(W_42K9?D^T[R*X@RX%,%U0
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M1E,F\0;X?2*$7E_@B^G-_URX^A-02P,$%     @ 0#)N5&[,)7DI P  $A,
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M$D75/KBW'X6;?2IL_P4;_P902P,$%     @ 0#)N5)>*NQS     $P(   L
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MHVQ826T&QX?KLN[<$!_86N6UM@9.AA-/6CW[]^OA4*RTUU-=ZOKE:-!^+]5
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M15:#(FN%(FN%(FN%(FOUE;+>.;?_S_'3L^QM.[SDL^E_I.L_4$L! A0#%
M  @ 0#)N5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " ! ,FY4 .[Y).\    K @  $0
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M=#(N>&UL4$L! A0#%     @ 0#)N5"J^]!GT @  TPD  !@
M ("!7A4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( $ R
M;E0_(^YK<00   D/   8              " @8@8  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " ! ,FY469H=%(0%   A&0  &
M        @($O'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ 0#)N5 82F9Y, @  ,04  !@              ("!Z2(  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $ R;E2O\:+>)@@   LB   8
M              " @6LE  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " ! ,FY4QI\"&0L,  "Y'   &               @(''+0  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 0#)N5"3J_(>*(P
M_FX  !@              ("!"#H  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( $ R;E0LB09WW00  "P+   9              " @<A=
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ 0#)N5!HO
M;W;[#0  N2<  !D              ("!W&(  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " ! ,FY4><A-DDD#  #M!@  &0
M    @($.<0  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M $ R;E3TQ[A=NP,  $4(   9              " @8YT  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ 0#)N5($7&1*. @  = 4  !D
M             ("!@'@  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " ! ,FY4> N3Y140  #0*P  &0              @(%%>P  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $ R;E14:P^M<@0
M ,,*   9              " @9&+  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ 0#)N5.UMPCY(!   :PH  !D              ("!
M.I   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " ! ,FY4
M>6AD?'<(   ,%@  &0              @(&YE   >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( $ R;E3)LB=5_A(   H]   9
M      " @6>=  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ 0#)N5(L=E"&L!@  ,1   !D              ("!G+   'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " ! ,FY4%=B-A\@'  #L$P
M&0              @(%_MP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( $ R;E3$$'0E&0P  &<>   9              " @7Z_  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 0#)N5.\*0"/O
M"P  JB$  !D              ("!SLL  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " ! ,FY4SS7)A@0H  !XA   &0
M@('TUP  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( $ R
M;E0:%U6#?P0  #<,   9              " @2\  0!X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ 0#)N5,8$?]5L P  J <  !D
M         ("!Y00! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " ! ,FY4!A#/7YX#  !3"   &0              @(&(" $ >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $ R;E2&*+%3C0(  &8%
M   9              " @5T, 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ 0#)N5,S)K(9, P  7@<  !D              ("!(0\!
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " ! ,FY47DN4
M0K,#  "!"   &0              @(&D$@$ >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( $ R;E2CM)#*G0,  (L(   9
M  " @8X6 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M0#)N5%Y;P! K!0  <PX  !D              ("!8AH! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " ! ,FY43PA+,ZH#  ")"   &0
M            @('$'P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( $ R;E1K\%N6\00  '4,   9              " @:4C 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 0#)N5-4HF0#4 @
M"@8  !D              ("!S2@! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " ! ,FY4+?JT5HH$  "+$0  &0              @('8
M*P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( $ R;E2$
MD QHCP4  -@8   9              " @9DP 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ 0#)N5&59,].* @  0 8  !D
M     ("!7S8! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $ R;E3N;D3(R ,  #P.   9              "
M@5U& 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ 0#)N
M5+F9J#WC"   :3   !D              ("!7$H! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " ! ,FY4S+I: )@#  #/#P  &0
M        @(%V4P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( $ R;E27#E^7S@(  %T(   9              " @457 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ 0#)N5"F<[7N> P  5 \
M !D              ("!2EH! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " ! ,FY4S:"&GNL"  #>"   &0              @($?7@$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( $ R;E0SW@/)
MK (  !L'   9              " @4%A 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ 0#)N5((Q !R! @  ? 8  !D
M ("!)&0! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " !
M,FY4JU/EB80#  #[#   &0              @('<9@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $ R;E3(,P4^6PP  %TY   9
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M970U-BYX;6Q02P$"% ,4    " ! ,FY4;:%0Y[("  #?!P  &0
M    @(&DA $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M $ R;E3*GZ7C-00  *\,   9              " @8V' 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ 0#)N5#&2^A.Y P  )A$  !D
M             ("!^8L! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " ! ,FY4O>U@;(D(  #P*@  &0              @('ICP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $ R;E0ZS8[#>@4
M -(<   9              " @:F8 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ 0#)N5"H92XL@ P  M0H  !D              ("!
M6IX! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " ! ,FY4
M^Y!T%;$"  !$!P  &0              @(&QH0$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( $ R;E2.)5]&>@,  ,D+   9
M      " @9FD 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ 0#)N5 VZY';L @  C@<  !D              ("!2J@! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " ! ,FY4.)V/HDX#  "6"P
M&0              @(%MJP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( $ R;E0Z,M*)O0,  )(*   9              " @?*N 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ 0#)N5&(S*<W4
M @  G0@  !D              ("!YK(! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " ! ,FY4!N5YY8(#  !B"P  &0
M@('QM0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( $ R
M;E0K$,\RUP(  %8'   9              " @:JY 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ 0#)N5*;A834Z!@  +AP  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " ! ,FY4EXJ[',     3 @  "P
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52P4&     %$ 40 N%@  W-P!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>214</ContextCount>
  <ElementCount>516</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>97</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Revenue and Accounts Receivable Credit Concentration</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Share Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation</Role>
      <ShortName>Share Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1</Role>
      <ShortName>Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Share Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables</Role>
      <ShortName>Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Organization and Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails</Role>
      <ShortName>Recent Accounting Pronouncements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Business Combinations - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails</Role>
      <ShortName>Business Combinations - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails</Role>
      <ShortName>Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails</Role>
      <ShortName>Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails</Role>
      <ShortName>Fair Value - Schedule of Changes in Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value - Schedule of Changes in Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair Value - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails</Role>
      <ShortName>Fair Value - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Schedule of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails</Role>
      <ShortName>Debt - Summary of Long-term Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails</Role>
      <ShortName>Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails</Role>
      <ShortName>Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails</Role>
      <ShortName>Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails</Role>
      <ShortName>Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Share Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Share Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Share Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails</Role>
      <ShortName>Share Based Compensation - Summary of Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Net Loss per Common Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss per Common Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bdsx-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="bdsx-20211231.htm">bdsx-20211231.htm</File>
    <File>bdsx-20211231.xsd</File>
    <File>bdsx-20211231_cal.xml</File>
    <File>bdsx-20211231_def.xml</File>
    <File>bdsx-20211231_lab.xml</File>
    <File>bdsx-20211231_pre.xml</File>
    <File>bdsx-ex10_132.htm</File>
    <File>bdsx-ex23_1.htm</File>
    <File>bdsx-ex31_1.htm</File>
    <File>bdsx-ex31_2.htm</File>
    <File>bdsx-ex32_1.htm</File>
    <File>bdsx-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img33530786_0.jpg</File>
    <File>img33530786_1.jpg</File>
    <File>img33530786_2.jpg</File>
    <File>img33530786_3.jpg</File>
    <File>img33530786_4.jpg</File>
    <File>img33530786_5.jpg</File>
    <File>img33530786_6.jpg</File>
    <File>img33530786_7.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="641">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "bdsx-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 36,
   "contextCount": 214,
   "dts": {
    "calculationLink": {
     "local": [
      "bdsx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bdsx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "bdsx-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "bdsx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bdsx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "bdsx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 769,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 9,
    "http://xbrl.sec.gov/dei/2021q4": 4,
    "total": 13
   },
   "keyCustom": 101,
   "keyStandard": 415,
   "memberCustom": 50,
   "memberStandard": 46,
   "nsprefix": "bdsx",
   "nsuri": "http://biodesix.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Fair Value",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and Equipment",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued Liabilities",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Debt",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Warrants to Purchase Convertible Preferred Stock",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock",
     "shortName": "Warrants to Purchase Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Equity",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Revenue and Accounts Receivable Credit Concentration",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration",
     "shortName": "Revenue and Accounts Receivable Credit Concentration",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Share Based Compensation",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation",
     "shortName": "Share Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Balance Sheets",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Net Loss per Common Share",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1",
     "shortName": "Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Commitments and Contingencies",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Subsequent Events",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:InitialPublicOfferingIPOPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:InitialPublicOfferingIPOPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Property and Equipment (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Debt (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Balance Sheets (Parenthetical)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Warrants to Purchase Convertible Preferred Stock (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables",
     "shortName": "Warrants to Purchase Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Revenue and Accounts Receivable Credit Concentration (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables",
     "shortName": "Revenue and Accounts Receivable Credit Concentration (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Share Based Compensation (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables",
     "shortName": "Share Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Net Loss per Common Share (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables",
     "shortName": "Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Test",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Organization and Description of Business - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "bdsx:NumberOfCancerTest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_Test",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Recent Accounting Pronouncements - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails",
     "shortName": "Recent Accounting Pronouncements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "div",
       "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Business Combinations - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
     "shortName": "Business Combinations - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Statements of Operations",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "lang": null,
      "name": "bdsx:DirectCostsAndExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_be8dd81f-cfc5-46e4-b488-457166af9cbd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails",
     "shortName": "Fair Value - Summary of Fair Value of Outstanding Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_be8dd81f-cfc5-46e4-b488-457166af9cbd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
     "shortName": "Fair Value - Schedule of Reported Fair values of Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_09ab7cd0-bfcb-44d2-8c18-ec4d5594e1d5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_b4423134-5dfd-4ff0-b0de-41bf317abf38",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Fair Value - Schedule of Changes in Contingent Consideration (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
     "shortName": "Fair Value - Schedule of Changes in Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_2e24974c-f120-44e6-86d6-efe03fc47db4",
      "decimals": "-3",
      "lang": null,
      "name": "bdsx:FairValueMeasurementWithUnobservableInputsInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_b4423134-5dfd-4ff0-b0de-41bf317abf38",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Fair Value - Schedule of Changes in Financial Liabilities (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
     "shortName": "Fair Value - Schedule of Changes in Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_34f7bf9b-9a78-44bf-9b7d-69e71e140c33",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair Value - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
     "shortName": "Fair Value - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_cea9870b-55e4-4464-845c-28e908ce7ebd",
      "decimals": "INF",
      "lang": null,
      "name": "bdsx:ContingentValueRightsShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Property and Equipment - Property and Equipment (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
     "shortName": "Property and Equipment - Schedule of Depreciation Expense Related to Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "bdsx:ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_c6703402-36eb-4f43-b20c-cf1ef0e69ebf",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets - Intangible Assets, Excluding Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Expense Related to Definite-Lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Amortization Related to Remaining Net Intangible Assets Schedule to Amortize (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_913ad8d8-0481-4a0e-a6ed-604c4af89cbc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Schedule of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Debt - Summary of Long-term Notes Payable (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
     "shortName": "Debt - Summary of Long-term Notes Payable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsNotSettleableInCashFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Debt - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
     "shortName": "Debt - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DebtInstrumentDescription",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_37e648f9-7b09-4e16-9fc7-b9eb2b1625e6",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFrequencyOfPeriodicPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails",
     "shortName": "Debt - Scheduled Principal Repayments (Maturities) of Long-term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_22af9de2-1e40-4b4f-b58e-22e115d6077d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
     "shortName": "Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_22af9de2-1e40-4b4f-b58e-22e115d6077d",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails",
     "shortName": "Warrants to Purchase Convertible Preferred Stock - Summary of Activity for Convertible Preferred Stock Warrants (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "bdsx:WarrantsForConvertiblePreferredStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_fd72ccaa-6db9-4f4c-a4c5-174cff90bd1e",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Equity - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
     "shortName": "Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:CommonStockVotingRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_3f722d28-c570-4810-8fc4-68f71db16286",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:PrimarySourcesOfRevenueDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_d1d55fa8-853c-4dce-a4aa-f84151407d63",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
     "shortName": "Revenue and Accounts Receivable Credit Concentration - Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "div",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_d1d55fa8-853c-4dce-a4aa-f84151407d63",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CapitalUnitsDeductionsFromTotalCostToInvestors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Share Based Compensation - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
     "shortName": "Share Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_16aecce9-7ad8-4ff3-b170-3b0230983e2a",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Share Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Share Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails",
     "shortName": "Share Based Compensation - Summary of Pre-tax Share-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_0ce3a578-735a-4075-87ce-b954e21a6041",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails",
     "shortName": "Share Based Compensation - Summary of Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Net Loss per Common Share - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
     "shortName": "Net Loss per Common Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_ec1496fb-b414-4020-84e5-09472bae83a5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Common Share - Schedule of Computation of Basic and Diluted Loss per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss per Common Share - Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Statements of Cash Flows",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_0d4f03ea-fc15-4f0a-a7b4-8cae39692ea9",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesRentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_8aafb945-b385-4de6-9940-2ec65935d0bd",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_83cbaa1a-e64a-4c26-b830-afa34cebed4f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:SharesIssuedOrIssuableThresholdLimitDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_83cbaa1a-e64a-4c26-b830-afa34cebed4f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "bdsx:SharesIssuedOrIssuableThresholdLimitDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Description of Business",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "bdsx-20211231.htm",
      "contextRef": "C_1b296b71-3c6b-456d-b731-b251aa4ad227",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 97,
   "tag": {
    "bdsx_AVEOOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aveo oncology.",
        "label": "A V E O Oncology [Member]",
        "terseLabel": "AVEO Oncology"
       }
      }
     },
     "localname": "AVEOOncologyMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AccruedClinicalTrialExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trial expense current.",
        "label": "Accrued Clinical Trial Expense Current",
        "terseLabel": "Accrued clinical trial expense"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenseCurrent",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AccruedInterestAmortizationOfDebtIssuanceCostsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued interest, amortization of debt issuance costs and other.",
        "label": "Accrued Interest Amortization Of Debt Issuance Costs And Other",
        "terseLabel": "Accrued interest, amortization of debt issuance costs and other"
       }
      }
     },
     "localname": "AccruedInterestAmortizationOfDebtIssuanceCostsAndOther",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_AdditionalTenantImprovementAllowancePerRentableSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tenant improvement allowance per rentable square feet",
        "label": "Extra allowance amount per rentable square feet"
       }
      }
     },
     "localname": "AdditionalTenantImprovementAllowancePerRentableSquareFeet",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryPerAreaItemType"
    },
    "bdsx_AdvanceDeposits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance deposits.",
        "label": "Advance Deposits",
        "terseLabel": "Advance deposits"
       }
      }
     },
     "localname": "AdvanceDeposits",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for approval of amended and restated certificate of incorporation.",
        "label": "Approval Of Amended And Restated Certificate Of Incorporation Policy [Text Block]",
        "terseLabel": "Approval of Amended and Restated Certificate of Incorporation"
       }
      }
     },
     "localname": "ApprovalOfAmendedAndRestatedCertificateOfIncorporationPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_AreaOfLeasedPremisedObligatedToPayBaseRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of leased premised obligated to pay base rent.",
        "label": "Area of leased premised obligated to pay base rent"
       }
      }
     },
     "localname": "AreaOfLeasedPremisedObligatedToPayBaseRent",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdsx_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Offering [Member]",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At-The-Market Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AtTheMoneyOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-Money Offering [Member]",
        "label": "At-the-Money Offering [Member]",
        "terseLabel": "At-the-Money Offering"
       }
      }
     },
     "localname": "AtTheMoneyOfferingMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_AtTheMoneyOfferingPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the money offering policy text block.",
        "label": "At-the-Money Offering [Policy Text Block]",
        "terseLabel": "At-the-Money Offering"
       }
      }
     },
     "localname": "AtTheMoneyOfferingPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_AugustTwoThousandAndNineteenConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August two thousand and nineteen convertible notes.",
        "label": "August Two Thousand And Nineteen Convertible Notes [Member]",
        "terseLabel": "August 2019 Notes"
       }
      }
     },
     "localname": "AugustTwoThousandAndNineteenConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BDX004Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bdx004.",
        "label": "B D X004 [Member]",
        "terseLabel": "BDX004"
       }
      }
     },
     "localname": "BDX004Member",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BaseRentPerMonthFromCommencementDate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent per month from commencement date.",
        "label": "Base rent per month from commencement date"
       }
      }
     },
     "localname": "BaseRentPerMonthFromCommencementDate",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BasisOfPresentationAndEstimatesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis of Presentation and Estimates.",
        "label": "Basis Of Presentation And Estimates Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Estimates"
       }
      }
     },
     "localname": "BasisOfPresentationAndEstimatesPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_BioRadLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bio-rad license.",
        "label": "Bio Rad License [Member]",
        "terseLabel": "Bio-Rad License"
       }
      }
     },
     "localname": "BioRadLicenseMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BonusToOptionsProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bonus-to-options program.",
        "label": "Bonus To Options Program [Member]",
        "terseLabel": "Bonus-To-Options Program"
       }
      }
     },
     "localname": "BonusToOptionsProgramMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration gross margin target period.",
        "label": "Business Acquisition Contingent Consideration Gross Margin Target Period",
        "terseLabel": "Business acquisition contingent consideration gross margin target period"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationGrossMarginTargetPeriod",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_BusinessAcquisitionContingentConsiderationNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition contingent consideration number of installments.",
        "label": "Business Acquisition Contingent Consideration Number Of Installments",
        "terseLabel": "Contingent consideration number of installments"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationNumberOfInstallments",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration arrangements common shares redemption amount.",
        "label": "Business Combination Contingent Consideration Arrangements Common Shares Redemption Amount",
        "terseLabel": "Contingent consideration arrangements, common shares, redemption amount"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsCommonSharesRedemptionAmount",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration final payment.",
        "label": "Business Combination Contingent Consideration Final Payment",
        "terseLabel": "Business combination contingent consideration final payment"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationFinalPayment",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_BusinessCombinationContingentConsiderationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination contingent consideration shares.",
        "label": "Business Combination Contingent Consideration Shares",
        "terseLabel": "Contingent consideration shares"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationShares",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CARESActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES act.",
        "label": "C A R E S Act [Member]",
        "terseLabel": "CARES Act"
       }
      }
     },
     "localname": "CARESActMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_COVID19DiagnosticTestRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 diagnostic test revenue.",
        "label": "C O V I D19 Diagnostic Test Revenue [Member]",
        "terseLabel": "COVID-19 Test Revenue"
       }
      }
     },
     "localname": "COVID19DiagnosticTestRevenueMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CashCollateralizedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash collateralized.",
        "label": "Cash Collateralized"
       }
      }
     },
     "localname": "CashCollateralizedMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CellCartaLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CellCarta License.",
        "label": "Cell Carta License [Member]",
        "terseLabel": "CellCarta License"
       }
      }
     },
     "localname": "CellCartaLicenseMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CentennialValleyPropertiesILlcLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centennial Valley Properties I, LLC Lease Agreement.",
        "label": "Centennial Valley Properties I, LLC Lease Agreement"
       }
      }
     },
     "localname": "CentennialValleyPropertiesILlcLeaseAgreementMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_CenturaHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centura Healthcare.",
        "label": "Centura Healthcare [Member]",
        "terseLabel": "Centura Healthcare"
       }
      }
     },
     "localname": "CenturaHealthcareMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of contingent consideration excluding accretion expense.",
        "label": "Change In Fair Value Of Contingent Consideration Excluding Accretion Expense",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInFairValueOfContingentConsiderationExcludingAccretionExpense",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_CommitmentSharesIssuableOnConditionalBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitment shares issuable on conditional basis.",
        "label": "Commitment Shares Issuable on Conditional Basis",
        "terseLabel": "Commitment shares issuable on conditional basis"
       }
      }
     },
     "localname": "CommitmentSharesIssuableOnConditionalBasis",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock purchase agreement member.",
        "label": "Common Stock Purchase Agreement Member",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration.",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentConsiderationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contingent consideration.",
        "label": "Contingent Consideration Policy [Text Block]",
        "terseLabel": "Contingent Consideration"
       }
      }
     },
     "localname": "ContingentConsiderationPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_ContingentValueRights": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights.",
        "label": "Contingent Value Rights",
        "terseLabel": "Contingent value rights"
       }
      }
     },
     "localname": "ContingentValueRights",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ContingentValueRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights.",
        "label": "Contingent Value Rights [Member]",
        "terseLabel": "Contingent Value Rights"
       }
      }
     },
     "localname": "ContingentValueRightsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ContingentValueRightsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights percentage.",
        "label": "Contingent Value Rights Percentage",
        "terseLabel": "Contingent value rights percentage"
       }
      }
     },
     "localname": "ContingentValueRightsPercentage",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_ContingentValueRightsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights shares.",
        "label": "Contingent Value Rights Shares",
        "terseLabel": "Contingent value rights shares"
       }
      }
     },
     "localname": "ContingentValueRightsShares",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability reclassified from non-current liabilities.",
        "label": "Contract With Customer Liability Reclassified From Non Current Liabilities",
        "terseLabel": "Amount reclassified from non-current liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityReclassifiedFromNonCurrentLiabilities",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ConversionOfPreferredStockIntoCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of preferred stock into common stock.",
        "label": "Conversion Of Preferred Stock Into Common Stock",
        "terseLabel": "Conversion of preferred stock into common stock"
       }
      }
     },
     "localname": "ConversionOfPreferredStockIntoCommonStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock and convertible notes payable converted to common stock.",
        "label": "Convertible Preferred Stock And Convertible Notes Payable Converted To Common Stock",
        "terseLabel": "Convertible preferred stock and convertible notes payable converted into shares of common stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockAndConvertibleNotesPayableConvertedToCommonStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_CurrentPortionOfContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of contingent consideration.",
        "label": "Current Portion Of Contingent Consideration [Member]",
        "terseLabel": "Current Portion of Contingent Consideration"
       }
      }
     },
     "localname": "CurrentPortionOfContingentConsiderationMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DebtInstrumentAdditionalInterestExpenseFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument additional interest expense fee percentage.",
        "label": "Debt Instrument Additional Interest Expense Fee Percentage",
        "terseLabel": "Debt instrument, additional interest expense fee"
       }
      }
     },
     "localname": "DebtInstrumentAdditionalInterestExpenseFeePercentage",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentBackEndFacilityFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument back-end facility fee percentage.",
        "label": "Debt Instrument Back End Facility Fee Percentage",
        "terseLabel": "Debt instrument, back-end facility fee"
       }
      }
     },
     "localname": "DebtInstrumentBackEndFacilityFeePercentage",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentInterestAddedToPrincipalValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument interest added to principal value.",
        "label": "Debt Instrument Interest Added To Principal Value",
        "terseLabel": "Interest added to principal value"
       }
      }
     },
     "localname": "DebtInstrumentInterestAddedToPrincipalValue",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DebtInstrumentMaturityDateExtended": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument maturity date extended.",
        "label": "Debt Instrument Maturity Date Extended",
        "terseLabel": "Extended debt instrument date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateExtended",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "bdsx_DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of stated interest rate added to principal value of notes payable.",
        "label": "Debt Instrument Percentage Of Stated Interest Rate Added To Principal Value Of Notes Payable",
        "terseLabel": "Percentage of interest rate added to principal value of notes payable"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfStatedInterestRateAddedToPrincipalValueOfNotesPayable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentPercentageOfStatedInterestRatePaidInCash": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, percentage of stated interest rate, paid in cash.",
        "label": "Debt Instrument Percentage Of Stated Interest Rate Paid In Cash",
        "terseLabel": "Percentage of interest rate, paid in cash"
       }
      }
     },
     "localname": "DebtInstrumentPercentageOfStatedInterestRatePaidInCash",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DebtInstrumentPrepaymentPenaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument prepayment penalty percentage.",
        "label": "Debt Instrument Prepayment Penalty Percentage",
        "terseLabel": "Debt instrument, prepayment penalty"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentPenaltyPercentage",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_DecemberTwoThousandAndNineteenConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December two thousand and nineteen convertible notes.",
        "label": "December Two Thousand And Nineteen Convertible Notes [Member]",
        "terseLabel": "December 2019 Notes"
       }
      }
     },
     "localname": "DecemberTwoThousandAndNineteenConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred revenue.",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets research and experimentation tax carryforwards subject to expiration.",
        "label": "Deferred Tax Assets Research And Experimentation Tax Carryforwards Subject To Expiration",
        "terseLabel": "Research and experimentation tax carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsResearchAndExperimentationTaxCarryforwardsSubjectToExpiration",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DefinedContributionPlanNameExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan.",
        "label": "Defined Contribution Plan Name Extensible List",
        "terseLabel": "Defined Contribution Plan Name [Extensible List]"
       }
      }
     },
     "localname": "DefinedContributionPlanNameExtensibleList",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "tokenItemType"
    },
    "bdsx_DescriptionOfOfferingPeriodUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of offering period under plan.",
        "label": "Description Of Offering Period Under Plan",
        "terseLabel": "Description of offering period under plan"
       }
      }
     },
     "localname": "DescriptionOfOfferingPeriodUnderPlan",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting power or value of stock for employee participation in offering period.",
        "label": "Description Of Voting Power Or Value Of Stock For Employee Participation In Offering Period",
        "terseLabel": "Description of voting power or value of stock for employee participation in offering period"
       }
      }
     },
     "localname": "DescriptionOfVotingPowerOrValueOfStockForEmployeeParticipationInOfferingPeriod",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_DiagnosticTestsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Diagnostic tests.",
        "label": "Diagnostic Tests [Member]",
        "terseLabel": "Diagnostic Tests"
       }
      }
     },
     "localname": "DiagnosticTestsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DirectCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses",
        "terseLabel": "Direct costs and expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpenses",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_DirectCostsAndExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses.",
        "label": "Direct Costs And Expenses [Member]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_DirectCostsAndExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct costs and expenses policy.",
        "label": "Direct Costs And Expenses Policy [Text Block]",
        "terseLabel": "Direct Costs and Expenses"
       }
      }
     },
     "localname": "DirectCostsAndExpensesPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_DirectOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct offering expenses.",
        "label": "Direct Offering Expenses",
        "terseLabel": "Direct offering expenses"
       }
      }
     },
     "localname": "DirectOfferingExpenses",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "negatedLabel": "Permanent items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisLineItems",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueLiabilitiesMeasuredOnRecurringBasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liabilities measured at fair value on recurring basis.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsInterestExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value measurement with unobservable inputs interest expense.",
        "label": "Fair Value Measurement With Unobservable Inputs Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsInterestExpense",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, measurement with unobservable inputs reconciliation reclassified to additional paid-in capital.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Reclassified To Additional Paid In Capital",
        "terseLabel": "Reclassified to additional paid-in capital"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationReclassifiedToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_FiclatuzumabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ficlatuzumab.",
        "label": "Ficlatuzumab [Member]",
        "terseLabel": "Ficlatuzumab"
       }
      }
     },
     "localname": "FiclatuzumabMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite lived intangible assets amortization expense year six and thereafter.",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Six And Thereafter",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearSixAndThereafter",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IncreaseToPutOptionLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase to put option liability.",
        "label": "Increase To Put Option Liability",
        "terseLabel": "Increase to put option liability"
       }
      }
     },
     "localname": "IncreaseToPutOptionLiability",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IndefiniteLivedIntangibleAssetsExcludingGoodwillGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indefinite lived intangible assets excluding goodwill gross.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill Gross",
        "terseLabel": "Intangible assets not subject to amortization, Cost"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillGross",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_InitialPublicOfferingIPOPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for initial public offering.",
        "label": "Initial Public Offering I P O Policy [Text Block]",
        "terseLabel": "Initial Public Offering (\"IPO\")"
       }
      }
     },
     "localname": "InitialPublicOfferingIPOPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_IntangibleAssetsAccumulatedAmortizationExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets Accumulated Amortization Excluding Goodwill",
        "negatedLabel": "Intangible assets, Accumulated Amortization"
       }
      }
     },
     "localname": "IntangibleAssetsAccumulatedAmortizationExcludingGoodwill",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_IntegratedDiagnosticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Integrated Diagnostics, Inc.",
        "label": "Integrated Diagnostics Inc [Member]",
        "terseLabel": "Integrated Diagnostics, Inc"
       }
      }
     },
     "localname": "IntegratedDiagnosticsIncMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_InterestRateOnExtraAllowanceAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate on extra allowance amount",
        "label": "Interest rate on extra allowance amount"
       }
      }
     },
     "localname": "InterestRateOnExtraAllowanceAmount",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_JanssenResearchAndDevelopmentLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Janssen Research and Development, LLC.",
        "label": "Janssen Research And Development L L C [Member]",
        "terseLabel": "Janssen Research and Development, LLC"
       }
      }
     },
     "localname": "JanssenResearchAndDevelopmentLLCMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LabcorpDdFormerlyCovanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "LabCorp DD (formerly Covance).",
        "label": "LabCorp DD formerly Covance [Member]",
        "terseLabel": "LabCorp DD (formerly Covance)"
       }
      }
     },
     "localname": "LabcorpDdFormerlyCovanceMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LandlordContributionTowardsCostOfConstructionAndTenantImprovements": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Landlord contribution towards cost of construction and tenant improvements",
        "label": "Landlord contribution towards cost of construction and tenant improvements"
       }
      }
     },
     "localname": "LandlordContributionTowardsCostOfConstructionAndTenantImprovements",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LeaseAgreementNumberOfOptionsToExtend": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease agreement number of options to extend",
        "label": "Lease agreement number of options to extend"
       }
      }
     },
     "localname": "LeaseAgreementNumberOfOptionsToExtend",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease commencement Date",
        "label": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "bdsx_LeasedPropertyBuildingCapacity": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Leased property building capacity.",
        "label": "Leased property building capacity"
       }
      }
     },
     "localname": "LeasedPropertyBuildingCapacity",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "bdsx_LicenseAgreementExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement expiry date.",
        "label": "License Agreement Expiry Date",
        "terseLabel": "License expiry date"
       }
      }
     },
     "localname": "LicenseAgreementExpiryDate",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "bdsx_LincolnParkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lincoln Park.",
        "label": "Lincoln Park Member",
        "terseLabel": "Lincoln Park"
       }
      }
     },
     "localname": "LincolnParkMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LitigationClaimsAndAssessmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation claims and assessments.",
        "label": "Litigation Claims And Assessments [Member]",
        "terseLabel": "Litigation Claims and Assessments"
       }
      }
     },
     "localname": "LitigationClaimsAndAssessmentsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long term debt maturities repayments of principal in year five and thereafter.",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Five And Thereafter",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveAndThereafter",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_LossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss member.",
        "label": "Loss [Member]",
        "terseLabel": "Loss"
       }
      }
     },
     "localname": "LossMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_LungDiagnosticRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lung diagnostic revenue.",
        "label": "Lung Diagnostic Revenue [Member]",
        "terseLabel": "Lung Diagnostic Revenue"
       }
      }
     },
     "localname": "LungDiagnosticRevenueMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MarchTwoThousandAndTwentyConvertibleNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "March two thousand and twenty convertible notes.",
        "label": "March Two Thousand And Twenty Convertible Notes [Member]",
        "terseLabel": "March 2020 Notes"
       }
      }
     },
     "localname": "MarchTwoThousandAndTwentyConvertibleNotesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of common stock allowed to purchase by counterparty.",
        "label": "Maximum Percentage of Common Stock Allowed to Purchase by Counterparty",
        "terseLabel": "Maximum percentage of common stock allowed to purchase by counterparty"
       }
      }
     },
     "localname": "MaximumPercentageOfCommonStockAllowedToPurchaseByCounterparty",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare.",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_MinimumAnnualVolumePercentageThereafter": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum annual volume percentage thereafter.",
        "label": "Minimum Annual Volume Percentage Thereafter",
        "terseLabel": "Minimum annual volume percentage thereafter"
       }
      }
     },
     "localname": "MinimumAnnualVolumePercentageThereafter",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_MinimumLiquidityRatioCovenant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum liquidity ratio covenant.",
        "label": "Minimum Liquidity Ratio Covenant",
        "terseLabel": "Minimum liquidity ratio covenant"
       }
      }
     },
     "localname": "MinimumLiquidityRatioCovenant",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "bdsx_NSCLCPOCTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nsclc poc trial.",
        "label": "N S C L C P O C Trial [Member]",
        "terseLabel": "NSCLC POC Trial"
       }
      }
     },
     "localname": "NSCLCPOCTrialMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NetProceedsPercentageOfCashPaymentToCVRHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds percentage of cash payment to the cvr holders.",
        "label": "Net Proceeds Percentage Of Cash Payment To C V R Holders",
        "terseLabel": "Net proceeds percentage of cash payment to the CVR holders"
       }
      }
     },
     "localname": "NetProceedsPercentageOfCashPaymentToCVRHolders",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_NotesPayable2018NotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notes payable 2018 notes.",
        "label": "Notes Payable2018 Notes [Member]",
        "terseLabel": "2018 Notes"
       }
      }
     },
     "localname": "NotesPayable2018NotesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_NumberOfCancerTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of cancer test.",
        "label": "Number Of Cancer Test",
        "terseLabel": "Number of blood based lung cancer test"
       }
      }
     },
     "localname": "NumberOfCancerTest",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfCommercialBloodBasedTest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial blood based test.",
        "label": "Number Of Commercial Blood Based Test",
        "terseLabel": "Number of commercial blood-based test"
       }
      }
     },
     "localname": "NumberOfCommercialBloodBasedTest",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfEqualAnnualInstallmentsForAwardVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equal annual installments for award vesting.",
        "label": "Number Of Equal Annual Installments For Award Vesting",
        "terseLabel": "Number of equal annual installments for award vesting"
       }
      }
     },
     "localname": "NumberOfEqualAnnualInstallmentsForAwardVesting",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_NumberOfPreferredStockConvertedIntoCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of preferred stock converted into common stock.",
        "label": "Number Of Preferred Stock Converted Into Common Stock",
        "terseLabel": "Number of preferred stock converted into common stock"
       }
      }
     },
     "localname": "NumberOfPreferredStockConvertedIntoCommonStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_NumberOfSARSCoV2Test": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of SARS-CoV-2 test.",
        "label": "Number Of S A R S Co V2 Test",
        "terseLabel": "Number of SARS-CoV-2 test"
       }
      }
     },
     "localname": "NumberOfSARSCoV2Test",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "bdsx_OncimmuneLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncimmune Limited.",
        "label": "Oncimmune Limited [Member]",
        "terseLabel": "Oncimmune Limited"
       }
      }
     },
     "localname": "OncimmuneLimitedMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases future minimum payments due in six years and thereafter.",
        "label": "Operating Leases Future Minimum Payments Due In Six Years And Thereafter",
        "terseLabel": "2027 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInSixYearsAndThereafter",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_OptionsAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and restricted stock units.",
        "label": "Options And Restricted Stock Units [Member]",
        "terseLabel": "Options and Restricted Stock Units"
       }
      }
     },
     "localname": "OptionsAndRestrictedStockUnitsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options to purchase common stock.",
        "label": "Options To Purchase Common Stock [Member]",
        "terseLabel": "Options to Purchase Common Stock"
       }
      }
     },
     "localname": "OptionsToPurchaseCommonStockMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessAbstract",
     "nsuri": "http://biodesix.com/20211231",
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Line Items]",
        "terseLabel": "Organization And Description Of Business [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessLineItems",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_OrganizationAndDescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and description of business.",
        "label": "Organization And Description Of Business [Table]",
        "terseLabel": "Organization And Description Of Business [Table]"
       }
      }
     },
     "localname": "OrganizationAndDescriptionOfBusinessTable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other member.",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_POCClinicalTrialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Poc clinical trials.",
        "label": "P O C Clinical Trials [Member]",
        "terseLabel": "POC Clinical Trials"
       }
      }
     },
     "localname": "POCClinicalTrialsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PPPLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PPP loan.",
        "label": "P P P Loan [Member]",
        "terseLabel": "PPP Loan"
       }
      }
     },
     "localname": "PPPLoanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PartialRepaymentsOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partial repayments of debt.",
        "label": "Partial repayments of debt"
       }
      }
     },
     "localname": "PartialRepaymentsOfDebt",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments for proceeds from patent costs and intangible asset acquisition, net.",
        "label": "Payments For Proceeds From Patent Costs And Intangible Asset Acquisition Net",
        "negatedLabel": "Patent costs and intangible asset acquisition, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromPatentCostsAndIntangibleAssetAcquisitionNet",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PaymentsToAcquireOncimmune": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments to acquire Oncimmune.",
        "label": "Payments To Acquire Oncimmune",
        "negatedLabel": "Payments to acquire Oncimmune assets"
       }
      }
     },
     "localname": "PaymentsToAcquireOncimmune",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PayrollCostsExcludesCompensationOfEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll costs excludes compensation of an employee.",
        "label": "Payroll Costs Excludes Compensation Of Employee",
        "terseLabel": "Payroll costs excludes compensation of an employee"
       }
      }
     },
     "localname": "PayrollCostsExcludesCompensationOfEmployee",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PercentageForNonPayrollCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage for non-payroll costs.",
        "label": "Percentage For Non Payroll Costs",
        "terseLabel": "Percentage for non-payroll costs"
       }
      }
     },
     "localname": "PercentageForNonPayrollCosts",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfConversionPricePerShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price per share of common stock.",
        "label": "Percentage Of Conversion Price Per Share Of Common Stock",
        "terseLabel": "Percentage of conversion price per share of common stock"
       }
      }
     },
     "localname": "PercentageOfConversionPricePerShareOfCommonStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfConversionPricePerShareOfConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of conversion price per share of convertible preferred stock.",
        "label": "Percentage Of Conversion Price Per Share Of Convertible Preferred Stock",
        "terseLabel": "Percentage of conversion price per share of preferred stock"
       }
      }
     },
     "localname": "PercentageOfConversionPricePerShareOfConvertiblePreferredStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs.",
        "label": "Percentage Of Development And Regulatory Costs",
        "terseLabel": "Responsible percentage of development and regulatory costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCosts",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development and regulatory costs exercised using opt-out right.",
        "label": "Percentage Of Development And Regulatory Costs Exercised Using Opt Out Right",
        "terseLabel": "Percentage of development and regulatory costs exercised using opt-out right"
       }
      }
     },
     "localname": "PercentageOfDevelopmentAndRegulatoryCostsExercisedUsingOptOutRight",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfFeePaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fee payments on net sales.",
        "label": "Percentage Of Fee Payments On Net Sales",
        "terseLabel": "Percentage of fee payments on net sales"
       }
      }
     },
     "localname": "PercentageOfFeePaymentsOnNetSales",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfFullyDilutedEquityForBonusAwarded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fully diluted equity for bonus awarded.",
        "label": "Percentage Of Fully Diluted Equity For Bonus Awarded",
        "terseLabel": "Percentage of fully diluted equity for bonus awarded"
       }
      }
     },
     "localname": "PercentageOfFullyDilutedEquityForBonusAwarded",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfLicenseIncomeGeneratedFromLicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of license income generated from licensing.",
        "label": "Percentage Of License Income Generated From Licensing",
        "verboseLabel": "Percentage of license income generated from licensing"
       }
      }
     },
     "localname": "PercentageOfLicenseIncomeGeneratedFromLicensing",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfMinimumRevenueRequirement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of minimum revenue requirement.",
        "label": "Percentage Of Minimum Revenue Requirement",
        "terseLabel": "Percentage of minimum revenue requirement"
       }
      }
     },
     "localname": "PercentageOfMinimumRevenueRequirement",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of probabilities of contingent consideration successful achievement milestone discount rates range.",
        "label": "Percentage Of Probabilities Of Contingent Consideration Successful Achievement Milestone Discount Rates Range",
        "terseLabel": "Percentage of probabilities of contingent consideration successful achievement of specified product gross margin targets discount rates range"
       }
      }
     },
     "localname": "PercentageOfProbabilitiesOfContingentConsiderationSuccessfulAchievementMilestoneDiscountRatesRange",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue share payment related to acquired diagnostic test recognized revenue for non-screening tests.",
        "label": "Percentage Of Revenue Share Payment Related To Acquired Diagnostic Test Recognized Revenue For Non Screening Tests",
        "verboseLabel": "Percentage of license agreement and royalty payment related to acquired diagnostic test recognized revenue for non-screening tests"
       }
      }
     },
     "localname": "PercentageOfRevenueSharePaymentRelatedToAcquiredDiagnosticTestRecognizedRevenueForNonScreeningTests",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments not required to pay on net revenue.",
        "label": "Percentage Of Royalty Payments Not Required To Pay On Net Revenue",
        "terseLabel": "Percentage of royalty payments not required on net revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsNotRequiredToPayOnNetRevenue",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net revenue.",
        "label": "Percentage Of Royalty Payments On Net Revenue",
        "terseLabel": "Percentage of royalty payments on net revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetRevenue",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfRoyaltyPaymentsOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty payments on net sales.",
        "label": "Percentage Of Royalty Payments On Net Sales",
        "terseLabel": "Percentage of royalty payments on net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltyPaymentsOnNetSales",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upper limit of employee salary to reduce forgiveness.",
        "label": "Percentage Of Upper Limit Of Employee Salary To Reduce Forgiveness",
        "terseLabel": "Percentage of upper limit of employee salary to reduce forgiveness"
       }
      }
     },
     "localname": "PercentageOfUpperLimitOfEmployeeSalaryToReduceForgiveness",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of valuation allowance equal to net deferred tax assets.",
        "label": "Percentage Of Valuation Allowance Equal To Net Deferred Tax Assets",
        "terseLabel": "Percentage of valuation allowance equal to net deferred tax assets"
       }
      }
     },
     "localname": "PercentageOfValuationAllowanceEqualToNetDeferredTaxAssets",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "bdsx_PerformanceConditionOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance condition options.",
        "label": "Performance Condition Options [Member]",
        "terseLabel": "Performance Condition Options"
       }
      }
     },
     "localname": "PerformanceConditionOptionsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PeriodOfEscalationsOfSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of escalations of sales.",
        "label": "Period Of Escalations Of Sales",
        "terseLabel": "Period of escalations of sales"
       }
      }
     },
     "localname": "PeriodOfEscalationsOfSales",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_PrepaymentFeeWaivedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayment fee waived amount.",
        "label": "Prepayment fee waived amount"
       }
      }
     },
     "localname": "PrepaymentFeeWaivedAmount",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PrimarySourcesOfRevenueDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary sources of revenue description.",
        "label": "Primary Sources Of Revenue Description",
        "terseLabel": "Primary sources of revenue, description"
       }
      }
     },
     "localname": "PrimarySourcesOfRevenueDescription",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock net.",
        "label": "Proceeds From Issuance Of Common Stock Net",
        "terseLabel": "Net proceeds from sale of common shares after deducting underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNet",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common stock under employee stock purchase plan.",
        "label": "Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProceedsFromIssuanceOfTermLoanAndNotesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of term loan and notes payable.",
        "label": "Proceeds From Issuance Of Term Loan And Notes Payable",
        "terseLabel": "Proceeds from term loan and notes payable"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfTermLoanAndNotesPayable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ProductLifeAndPatentLifeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product life and patent life.",
        "label": "Product Life And Patent Life [Member]",
        "terseLabel": "Product Life and Patent Life"
       }
      }
     },
     "localname": "ProductLifeAndPatentLifeMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement term.",
        "label": "Purchase Agreement Term",
        "terseLabel": "Purchase agreement term"
       }
      }
     },
     "localname": "PurchaseAgreementTerm",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_PurchasedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased technology.",
        "label": "Purchased Technology [Member]",
        "terseLabel": "Purchased Technology"
       }
      }
     },
     "localname": "PurchasedTechnologyMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PutOptionLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option liability current.",
        "label": "Put Option Liability Current",
        "terseLabel": "Put option liability",
        "verboseLabel": "Estimated value of put option liability"
       }
      }
     },
     "localname": "PutOptionLiabilityCurrent",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_PutOptionLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Put option liability.",
        "label": "Put Option Liability [Member]",
        "terseLabel": "Put Option Liability"
       }
      }
     },
     "localname": "PutOptionLiabilityMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_PutOptionLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for put-option liability",
        "label": "Put Option Liability Policy [Text Block]",
        "terseLabel": "Put Option Liability"
       }
      }
     },
     "localname": "PutOptionLiabilityPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of put option liability to additional paid in capital.",
        "label": "Reclassification Of Put Option Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of put option liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfPutOptionLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of warrant liability to additional paid-in-capital.",
        "label": "Reclassification Of Warrant Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of warrant liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RemainingEstimatedObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining estimated obligation.",
        "label": "Remaining Estimated Obligation",
        "terseLabel": "Remaining estimated obligation"
       }
      }
     },
     "localname": "RemainingEstimatedObligation",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RentAfterFixedEscalationProvisions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent after fixed escalation provisions.",
        "label": "Rent after fixed escalation provisions"
       }
      }
     },
     "localname": "RentAfterFixedEscalationProvisions",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repurchase.",
        "label": "Repurchase [Member]",
        "terseLabel": "Repurchase"
       }
      }
     },
     "localname": "RepurchaseMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue milestone.",
        "label": "Revenue Milestone",
        "terseLabel": "Revenue milestone"
       }
      }
     },
     "localname": "RevenueMilestone",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_RevenueShareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share agreement.",
        "label": "Revenue Share Agreement [Member]",
        "terseLabel": "Revenue Share Agreement"
       }
      }
     },
     "localname": "RevenueShareAgreementMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_RevenueShareExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue share expenses.",
        "label": "Revenue Share Expenses",
        "terseLabel": "Revenue share expenses"
       }
      }
     },
     "localname": "RevenueShareExpenses",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ReverseStockSplitPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reverse stock split.",
        "label": "Reverse Stock Split Policy [Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "ReverseStockSplitPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_SaleOfStockSharesIssuedAsCommitmentFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, shares issued as commitment fee.",
        "label": "Sale of Stock, Shares Issued as Commitment Fee",
        "terseLabel": "Shares issued as commitment fee"
       }
      }
     },
     "localname": "SaleOfStockSharesIssuedAsCommitmentFee",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SaleOfStockStockIssuablePerDayShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock, stock issuable per day, shares.",
        "label": "Sale of Stock, Stock Issuable Per Day, Shares",
        "terseLabel": "Stock issuable per day, number of shares"
       }
      }
     },
     "localname": "SaleOfStockStockIssuablePerDayShares",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SaleOfStockStockIssuablePerDayValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, stock issuable per day, value.",
        "label": "Sale of Stock, Stock Issuable Per Day, Value",
        "terseLabel": "Stock issuable per day, value"
       }
      }
     },
     "localname": "SaleOfStockStockIssuablePerDayValue",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of depreciation and amortization expense related to property and equipment.",
        "label": "Schedule Of Depreciation And Amortization Expense Related To Property And Equipment Table [Text Block]",
        "terseLabel": "Schedule of Depreciation Expense Related to Property and Equipment"
       }
      }
     },
     "localname": "ScheduleOfDepreciationAndAmortizationExpenseRelatedToPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second amendment.",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA1PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 preferred stock.",
        "label": "Series A1 Preferred Stock [Member]",
        "terseLabel": "Series A-1 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA1PreferredStockMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA2PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 preferred stock.",
        "label": "Series A2 Preferred Stock [Member]",
        "terseLabel": "Series A2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2PreferredStockMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesA3PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-3 preferred stock.",
        "label": "Series A3 Preferred Stock [Member]",
        "terseLabel": "Series A3 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA3PreferredStockMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesB1ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B-1 Convertible Preferred Stock.",
        "label": "Series B1 Convertible Preferred Stock [Member]",
        "terseLabel": "Series B1 Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesB1ConvertiblePreferredStockMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesEConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E convertible preferred stock warrants.",
        "label": "Series E Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series E Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SeriesGConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G convertible preferred stock warrants.",
        "label": "Series G Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series G Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "SeriesGConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ServiceConditionRSUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service-condition RSUs.",
        "label": "Service Condition R S Us [Member]",
        "terseLabel": "Service Condition R S Us"
       }
      }
     },
     "localname": "ServiceConditionRSUsMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non-options forfeitures and expirations in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "negatedLabel": "Weighted average exercise price, Forfeited/canceled, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price,Outstanding - December, 31, 2020, warrants",
        "periodStartLabel": "Weighted average exercise price, Outstanding - January 1, 2020, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options exercises in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options grants in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award non options reclassification of warrant liability to additional paid in capital weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Non Options Reclassification Of Warrant Liability To Additional Paid In Capital Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Reclassification of warrant liability to additional paid-in capital, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsReclassificationOfWarrantLiabilityToAdditionalPaidInCapitalWeightedAverageExercisePrice",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "bdsx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term1.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Life (Years), Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_SharesCommittedUnderESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares committed under ESPP.",
        "label": "Shares Committed Under E S P P [Member]",
        "terseLabel": "Shares Committed Under ESPP"
       }
      }
     },
     "localname": "SharesCommittedUnderESPPMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_SharesIssuedAsCommitmentFeeValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued as commitment fee, value.",
        "label": "Shares Issued as Commitment Fee, Value",
        "terseLabel": "Shares issued as commitment fee, value"
       }
      }
     },
     "localname": "SharesIssuedAsCommitmentFeeValue",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_SharesIssuedOrIssuableThresholdLimitDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued or issuable, threshold limit description.",
        "label": "Shares Issued or Issuable, Threshold Limit Description",
        "terseLabel": "Shares issued or issuable, threshold limit description"
       }
      }
     },
     "localname": "SharesIssuedOrIssuableThresholdLimitDescription",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_StockIssuableDuringPeriodValueCommittedShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuable during period, value, committed shares.",
        "label": "Stock Issuable During Period, Value, Committed Shares",
        "terseLabel": "Common stock issuable, committed to purchase"
       }
      }
     },
     "localname": "StockIssuableDuringPeriodValueCommittedShares",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities classified as common stock.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities Common Stock",
        "terseLabel": "Conversion of convertible debt into common stock upon initial public offering, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecuritiesCommonStock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items].",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "bdsx_TermOfRoyaltyPaymentsFromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of royalty payments from first commercial sale.",
        "label": "Term Of Royalty Payments From First Commercial Sale",
        "terseLabel": "Term of royalty payments from first commercial sale"
       }
      }
     },
     "localname": "TermOfRoyaltyPaymentsFromFirstCommercialSale",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "bdsx_TestingServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Testing services.",
        "label": "Testing Services [Member]",
        "terseLabel": "Testing Services"
       }
      }
     },
     "localname": "TestingServicesMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TheBigTenConferenceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Big Ten Conference.",
        "label": "The Big Ten Conference [Member]",
        "terseLabel": "The Big Ten Conference"
       }
      }
     },
     "localname": "TheBigTenConferenceMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandAndSixteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Plan.",
        "label": "Two Thousand And Sixteen Plan [Member]",
        "terseLabel": "2016 Plan"
       }
      }
     },
     "localname": "TwoThousandAndSixteenPlanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2006 Plan.",
        "label": "Two Thousand Six Plan [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand six plan two thousand sixteen plan and two thousand twenty equity incentive plan.",
        "label": "Two Thousand Six Plan Two Thousand Sixteen Plan And Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2006 Plan, 2016 Plan and 2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSixPlanTwoThousandSixteenPlanAndTwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 equity incentive plan.",
        "label": "Two Thousand Twenty Equity Incentive Plan [Member]",
        "terseLabel": "2020 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandTwentyEquityIncentivePlanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyOneTermLoanAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Twenty One Term Loan Amendment.",
        "label": "Two Thousand Twenty One Term Loan Amendment [Member]",
        "terseLabel": "2021 Term Loan Amendment"
       }
      }
     },
     "localname": "TwoThousandTwentyOneTermLoanAmendmentMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_TwoThousandTwentyOneTermLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one term loan.",
        "label": "Two Thousand Twenty One Term Loan [Member]",
        "terseLabel": "2021 Term Loan"
       }
      }
     },
     "localname": "TwoThousandTwentyOneTermLoanMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions and offering expenses payable.",
        "label": "Underwriting Discounts And Commissions And Offering Expenses Payable",
        "terseLabel": "Underwriting discounts and commissions and offering expenses payable"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissionsAndOfferingExpensesPayable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_UpperLimitOfEmployeeSalaryToReduceForgiveness": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of employee salary to reduce forgiveness.",
        "label": "Upper Limit Of Employee Salary To Reduce Forgiveness",
        "terseLabel": "Upper limit of employee salary to reduce forgiveness"
       }
      }
     },
     "localname": "UpperLimitOfEmployeeSalaryToReduceForgiveness",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of put option recorded at issuance of convertible notes payable.",
        "label": "Value Of Put Option Recorded At Issuance Of Convertible Notes Payable",
        "terseLabel": "Value of put option recorded at issuance of convertible debt payable"
       }
      }
     },
     "localname": "ValueOfPutOptionRecordedAtIssuanceOfConvertibleNotesPayable",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "bdsx_WarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant liability.",
        "label": "Warrant Liability [Member]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityMember",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "bdsx_WarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrant liability.",
        "label": "Warrant Liability Policy [Text Block]",
        "terseLabel": "Warrant Liability"
       }
      }
     },
     "localname": "WarrantLiabilityPolicyTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_WarrantsForConvertiblePreferredStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants for convertible preferred stock.",
        "label": "Warrants For Convertible Preferred Stock [Text Block]",
        "terseLabel": "Warrants to Purchase Convertible Preferred Stock"
       }
      }
     },
     "localname": "WarrantsForConvertiblePreferredStockTextBlock",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "bdsx_YearOfEndingRoyaltyPaymentsFromFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year of ending royalty payments from first commercial sale.",
        "label": "Year Of Ending Royalty Payments From First Commercial Sale",
        "terseLabel": "Year of ending royalty payments from first commercial sale"
       }
      }
     },
     "localname": "YearOfEndingRoyaltyPaymentsFromFirstCommercialSale",
     "nsuri": "http://biodesix.com/20211231",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "U S",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r664"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r667"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "terseLabel": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r661",
      "r662",
      "r663"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r69",
      "r71",
      "r120",
      "r121",
      "r271",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r190",
      "r357",
      "r363",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r270",
      "r313",
      "r385",
      "r388",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r608",
      "r612",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r270",
      "r313",
      "r385",
      "r388",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r608",
      "r612",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r190",
      "r357",
      "r363",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r187",
      "r357",
      "r361",
      "r566",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r187",
      "r357",
      "r361",
      "r566",
      "r607",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r270",
      "r313",
      "r373",
      "r385",
      "r388",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r608",
      "r612",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r270",
      "r313",
      "r373",
      "r385",
      "r388",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r608",
      "r612",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r70",
      "r71",
      "r120",
      "r121",
      "r271",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r136",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r136",
      "r140",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r357",
      "r362",
      "r610",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r357",
      "r362",
      "r610",
      "r639",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r136",
      "r140",
      "r243",
      "r386",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r48",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableMember": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations incurred and payable to vendors for goods and services received.",
        "label": "Accounts Payable [Member]",
        "terseLabel": "Accounts Payable"
       }
      }
     },
     "localname": "AccountsPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r35",
      "r191",
      "r192"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $158 and $180",
        "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r45",
      "r233"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r36",
      "r425",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid In Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid\u2011in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r421",
      "r422",
      "r423",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r266"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt",
        "terseLabel": "Conversion of convertible debt into common stock upon initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r389",
      "r391",
      "r428",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock\u2011based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r265",
      "r327",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments To Additional Paid In Capital Warrant Issued",
        "terseLabel": "Reclassification of preferred stock warrant liability and put option into additional paid-in capital upon initial public offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r391",
      "r417",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total pre-tax share-based compensation expense",
        "verboseLabel": "Stock compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r193",
      "r202",
      "r203",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Allowance For Doubtful Accounts Receivable",
        "periodEndLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Accounts Receivable, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r84",
      "r101",
      "r290",
      "r532"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization Of Debt Discount Premium",
        "terseLabel": "Amortization of convertible notes debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r101",
      "r216",
      "r224"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization expense related to definite-lived intangible assets",
        "totalLabel": "Amortization of Intangible Assets, Total"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r117",
      "r170",
      "r179",
      "r185",
      "r198",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r484",
      "r488",
      "r519",
      "r547",
      "r549",
      "r575",
      "r597"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r68",
      "r117",
      "r198",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r484",
      "r488",
      "r519",
      "r547",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r117",
      "r198",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r484",
      "r488",
      "r519",
      "r547"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets Noncurrent",
        "totalLabel": "Total non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r392",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r384",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r384",
      "r387",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "With respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.",
        "label": "Business Acquisition Description Of Acquired Entity",
        "terseLabel": "Business acquisition description"
       }
      }
     },
     "localname": "BusinessAcquisitionDescriptionOfAcquiredEntity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r475",
      "r476",
      "r478"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination Consideration Transferred1",
        "terseLabel": "Total consideration amount",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r100",
      "r480"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1",
        "terseLabel": "Change in contingent consideration",
        "verboseLabel": "Net change to contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Current",
        "terseLabel": "Current portion of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "terseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Noncash purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsDeductionsFromTotalCostToInvestors": {
     "auth_ref": [
      "r623"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deductions from cost to investors of capital shares or other capital units for fees, loads and other charges.",
        "label": "Capital Units Deductions From Total Cost To Investors",
        "terseLabel": "Discounts and commission"
       }
      }
     },
     "localname": "CapitalUnitsDeductionsFromTotalCostToInvestors",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsTotalCostToInvestors": {
     "auth_ref": [
      "r622"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost to investors of each class of capital shares or other capital units.",
        "label": "Capital Units Total Cost To Investors",
        "terseLabel": "Direct offering costs"
       }
      }
     },
     "localname": "CapitalUnitsTotalCostToInvestors",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired From Acquisition",
        "terseLabel": "Business acquisition contingent consideration gross margin target"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r42",
      "r103"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r104",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r97",
      "r103",
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash \u2011 end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash \u2011 beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r97",
      "r523"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCollateralForBorrowedSecurities": {
     "auth_ref": [
      "r581",
      "r604"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.",
        "label": "Cash Collateral for Borrowed Securities",
        "terseLabel": "Restricted cash collateral account"
       }
      }
     },
     "localname": "CashCollateralForBorrowedSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Stock Disclosures [Abstract]"
       }
      }
     },
     "localname": "ClassOfStockDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r114",
      "r117",
      "r143",
      "r144",
      "r145",
      "r147",
      "r149",
      "r156",
      "r157",
      "r158",
      "r198",
      "r254",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r311",
      "r312",
      "r316",
      "r320",
      "r519",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Warrants expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r337",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "terseLabel": "Warrant, exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Warrant Or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right",
        "terseLabel": "Warrant issued to purchase shares",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "terseLabel": "Warrants to purchase shares of common stock",
        "verboseLabel": "Warrant issued to purchase shares"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r337",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class Of Warrant Or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Axis]"
       }
      }
     },
     "localname": "CollateralAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of collateral or no collateral, from lender's perspective.",
        "label": "Collateral Held [Domain]"
       }
      }
     },
     "localname": "CollateralDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r60",
      "r242",
      "r582",
      "r603"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r249",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r124",
      "r125",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "verboseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value, 200,000,000 authorized; 30,789,649 (2021) and 26,561,504 (2020) shares issued and outstanding",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockVotingRights": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.",
        "label": "Common Stock Voting Rights",
        "terseLabel": "Common stock, voting rights"
       }
      }
     },
     "localname": "CommonStockVotingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r190",
      "r516",
      "r517",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r190",
      "r516",
      "r517",
      "r621",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk By Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r162",
      "r163",
      "r190",
      "r516",
      "r517",
      "r621",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk By Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r159",
      "r594"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentrations of Credit Risk and Other Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r162",
      "r163",
      "r190",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk Percentage1",
        "terseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r164",
      "r516",
      "r518",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r162",
      "r163",
      "r190",
      "r516",
      "r517",
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in Process"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified As Equity Fair Value Disclosure",
        "terseLabel": "Contingent consideration estimated fair value"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r339",
      "r340",
      "r358"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r339",
      "r340",
      "r358"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Non-current deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion Of Stock Amount Converted1",
        "terseLabel": "Conversion of convertible notes and accrued interest into common stock"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r311",
      "r312",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r161",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentRate": {
     "auth_ref": [
      "r106",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments.",
        "label": "Debt Conversion Converted Instrument Rate",
        "terseLabel": "Conversion rate"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r113",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r284",
      "r291",
      "r292",
      "r294",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the total principal payments made during the annual reporting period.",
        "label": "Debt Instrument, Annual Principal Payment",
        "terseLabel": "Principal balance outstanding"
       }
      }
     },
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r116",
      "r122",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r300",
      "r301",
      "r302",
      "r303",
      "r535",
      "r576",
      "r578",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r27",
      "r295",
      "r578",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Debt Instrument Carrying Amount",
        "terseLabel": "Loan principle amount",
        "verboseLabel": "Notes/Loan payable"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r269",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument Convertible Conversion Price1",
        "terseLabel": "Conversion price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument Convertible Remaining Discount Amortization Period1",
        "terseLabel": "Early amortization of loan payment schedule"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentCovenantCompliance": {
     "auth_ref": [
      "r27",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States whether the entity was in compliance with the debt covenants throughout the reporting period, and describes facts and circumstances of any compliance failure.",
        "label": "Debt Instrument, Covenant Compliance",
        "terseLabel": "Debt instrument, covenant compliance"
       }
      }
     },
     "localname": "DebtInstrumentCovenantCompliance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCovenantDescription": {
     "auth_ref": [
      "r27",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.",
        "label": "Debt Instrument, Covenant Description",
        "terseLabel": "Debt instrument, covenant description"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentDescription": {
     "auth_ref": [
      "r25",
      "r27",
      "r328",
      "r576",
      "r578",
      "r589",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.",
        "label": "Debt Instrument Description",
        "terseLabel": "Loan description",
        "verboseLabel": "Debt instrument description"
       }
      }
     },
     "localname": "DebtInstrumentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument Fee Amount",
        "terseLabel": "Facility fee amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "auth_ref": [
      "r58",
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual).",
        "label": "Debt Instrument Frequency Of Periodic Payment",
        "terseLabel": "Debt instrument frequency of periodic payment"
       }
      }
     },
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r56",
      "r270",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument Maturity Date",
        "terseLabel": "Convertible notes, maturity date",
        "verboseLabel": "Debt instrument maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r58",
      "r116",
      "r122",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r300",
      "r301",
      "r302",
      "r303",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument Name [Domain]",
        "terseLabel": "Debt Instrument, Name"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument Redemption Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodFourMember": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period four representing fourth most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Four [Member]",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodFourMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period One [Member]",
        "terseLabel": "First Tranche",
        "verboseLabel": "Prior to First Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After Second Anniversary, Prior to October 19, 2025"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument Redemption Period Two [Member]",
        "terseLabel": "Second Tranche",
        "verboseLabel": "Prior to Second Anniversary"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r58",
      "r116",
      "r122",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r280",
      "r281",
      "r282",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r300",
      "r301",
      "r302",
      "r303",
      "r328",
      "r331",
      "r332",
      "r333",
      "r532",
      "r533",
      "r535",
      "r536",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Debt Instrument [Table]",
        "terseLabel": "Debt Instrument [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r280",
      "r296",
      "r300",
      "r301",
      "r534"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net",
        "negatedLabel": "Unamortized debt discount and debt issuance costs",
        "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "localname": "DebtInstrumentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Non-cash debt issuance costs included in Accrued liabilities"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r29",
      "r30",
      "r446",
      "r577",
      "r595"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred revenue arrangement.",
        "label": "Deferred Revenue Arrangement Type [Axis]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredRevenueArrangementTypeDomain": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.",
        "label": "Deferred Revenue [Domain]"
       }
      }
     },
     "localname": "DeferredRevenueArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "terseLabel": "Interest expense limitation"
       }
      }
     },
     "localname": "DeferredTaxAssetInterestCarryforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets Liabilities Net",
        "totalLabel": "Net deferred tax assets and liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Total deferred tax assets after valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets Property Plant And Equipment",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r451",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r448"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer discretionary contributions amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution 401(k) Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDefinedContribution401KPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r101",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "totalLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r101",
      "r231"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation Of Revenue [Line Items]",
        "terseLabel": "Disaggregation Of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r357",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue [Table]",
        "terseLabel": "Disaggregation Of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Summary of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Share Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r334",
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Dividends",
        "totalLabel": "Dividends, Common Stock, Total"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Basic And Diluted Other Disclosures [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r150",
      "r151",
      "r152",
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r435"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r118",
      "r435",
      "r463"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "Federal statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r435",
      "r463"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r435",
      "r463"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r435",
      "r463"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits Research",
        "terseLabel": "Research and developments credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation related accruals",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r418"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized",
        "terseLabel": "Unrecognized remaining stock based compensation balance",
        "totalLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r74",
      "r75",
      "r76",
      "r124",
      "r125",
      "r126",
      "r130",
      "r137",
      "r139",
      "r155",
      "r199",
      "r327",
      "r334",
      "r421",
      "r422",
      "r423",
      "r456",
      "r457",
      "r498",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r613",
      "r614",
      "r615",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities By Industry [Axis]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Equity Securities Industry [Member]",
        "terseLabel": "Industry Sector"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExpenseRelatedToDistributionOrServicingAndUnderwritingFees": {
     "auth_ref": [
      "r584"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense related to distribution, servicing and underwriting fees.",
        "label": "Expense Related To Distribution Or Servicing And Underwriting Fees",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "ExpenseRelatedToDistributionOrServicingAndUnderwritingFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r101",
      "r307"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment Of Warrants",
        "negatedLabel": "Change in fair value of warrant liability",
        "terseLabel": "Change in fair value of warrant liability",
        "verboseLabel": "Increase in value of the warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "verboseLabel": "Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r500",
      "r501",
      "r502",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r500",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r500",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r501",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r500",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r500",
      "r501",
      "r503",
      "r504",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Fair Value By Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r282",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r374",
      "r375",
      "r380",
      "r381",
      "r501",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r501",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).  Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value Liabilities Measured On Recurring Basis [Text Block]",
        "terseLabel": "Schedule of Reported Fair values of Contingent Consideration"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r505",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r505",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Schedule of Changes in Contingent Consideration and Financial Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Fair Value Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement Policy Policy [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r506"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Ending balances",
        "periodStartLabel": "Beginning balances"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r282",
      "r300",
      "r301",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r554",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r508",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value Measurements Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfChangesInFinancialLiabilitiesDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite Lived Intangible Asset Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r223"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Intangible assets subject to amortization, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite Lived Intangible Assets Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Amortization Expense Related to Definite-Lived Intangible Assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite Lived Intangible Assets Amortization Expense Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r217",
      "r219",
      "r223",
      "r227",
      "r567",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Future Amortization Expense [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r223",
      "r571"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "terseLabel": "Intangible assets subject to amortization, Cost",
        "totalLabel": "Finite-Lived Intangible Assets, Gross, Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r223",
      "r567"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance",
        "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance",
        "totalLabel": "Intangible assets subject to amortization, Net Carrying Value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationRelatedToRemainingNetIntangibleAssetsScheduleToAmortizeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Net [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r101",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gains Losses On Extinguishment Of Debt",
        "negatedLabel": "Gain on debt extinguishments, net",
        "terseLabel": "Gain on debt extinguishments, net",
        "totalLabel": "Gain (Loss) on Extinguishment of Debt, Total",
        "verboseLabel": "Gain (loss) on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r209",
      "r211",
      "r549",
      "r574"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill And Intangible Assets Goodwill Policy",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill And Intangible Assets Intangible Assets Policy",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r101",
      "r210",
      "r212",
      "r214"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Goodwill impairments loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "I P O [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r101",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment Of Intangible Assets Excluding Goodwill",
        "terseLabel": "Impairment of intangible assets",
        "totalLabel": "Impairment of Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r101",
      "r230",
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r118",
      "r436",
      "r445",
      "r450",
      "r461",
      "r464",
      "r466",
      "r467",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationDescription": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.",
        "label": "Income Tax Examination Description",
        "terseLabel": "Income tax examination details"
       }
      }
     },
     "localname": "IncomeTaxExaminationDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r138",
      "r139",
      "r169",
      "r434",
      "r462",
      "r465",
      "r606"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase Decrease In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities",
        "totalLabel": "Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r100",
      "r564"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase Decrease In Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.",
        "label": "Increase Decrease In Other Noncurrent Assets And Liabilities Net",
        "negatedLabel": "Other long-term assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r218",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r226"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill",
        "periodEndLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Ending Balance",
        "periodStartLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Beginning Balance",
        "terseLabel": "Intangible assets not subject to amortization, Net Carrying Value",
        "totalLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r218",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets Gross Excluding Goodwill",
        "terseLabel": "Intangible assets, Cost",
        "totalLabel": "Intangible Assets, Gross (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r215",
      "r221"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, Net Carrying Value"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestBearingDepositsMember": {
     "auth_ref": [
      "r572",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash on deposit with financial institutions that earns interest, either at a fixed or market rate.",
        "label": "Interest Bearing Deposits [Member]",
        "terseLabel": "Interest-bearing Deposits"
       }
      }
     },
     "localname": "InterestBearingDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r77",
      "r168",
      "r531",
      "r534",
      "r585"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest Expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r95",
      "r98",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid Net",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventorySuppliesPolicy": {
     "auth_ref": [
      "r66",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for supplies to be consumed directly or indirectly in production. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average).",
        "label": "Inventory Supplies Policy",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventorySuppliesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investment Type Categorization [Member]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]",
        "terseLabel": "Lease option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal for lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LessorOperatingLeaseLeaseNotYetCommencedDescription": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessor's operating lease that has not yet commenced.",
        "label": "Lessor, Operating Lease, Lease Not yet Commenced, Description",
        "terseLabel": "Lease description"
       }
      }
     },
     "localname": "LessorOperatingLeaseLeaseNotYetCommencedDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52",
      "r117",
      "r180",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r485",
      "r488",
      "r489",
      "r519",
      "r547",
      "r548"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r40",
      "r117",
      "r198",
      "r519",
      "r549",
      "r580",
      "r601"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r117",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r485",
      "r488",
      "r489",
      "r519",
      "r547",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities Fair Value Disclosure",
        "terseLabel": "Total contingent consideration"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueScheduleOfReportedFairValuesOfContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r27",
      "r28",
      "r117",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r485",
      "r488",
      "r489",
      "r519",
      "r547",
      "r548"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities Noncurrent",
        "totalLabel": "Total non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Noncurrent [Abstract]",
        "terseLabel": "Non\u2011current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License Rights"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r27",
      "r578",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Letter of credit subject to contingent reduction over the term of the lease",
        "totalLabel": "Long-term Line of Credit, Total"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Final settlement payment to third parties"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r27",
      "r281",
      "r297",
      "r300",
      "r301",
      "r578",
      "r598"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long Term Debt",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long Term Debt Fair Value",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r122",
      "r252",
      "r286"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r122",
      "r252",
      "r286"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r122",
      "r252",
      "r286"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r122",
      "r252",
      "r286"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r122",
      "r252",
      "r286"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long Term Debt Maturities Repayments Of Principal In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtScheduledPrincipalRepaymentsMaturitiesOfLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Long Term Notes Payable",
        "terseLabel": "Long-term notes payable, net of current portion",
        "totalLabel": "Long-term notes payable",
        "verboseLabel": "Long-term notes payable"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Longterm Debt Type [Axis]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r58",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Longterm Debt Type [Domain]",
        "terseLabel": "Long-term Debt, Type"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "periodEndLabel": "Loss Contingency Accrual, Ending Balance",
        "periodStartLabel": "Loss Contingency Accrual, Beginning Balance",
        "terseLabel": "Accrued legal contingency"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities Of Long Term Debt [Abstract]"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r97",
      "r99",
      "r102"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash and cash equivalents and restricted cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r76",
      "r79",
      "r102",
      "r117",
      "r129",
      "r133",
      "r134",
      "r135",
      "r136",
      "r138",
      "r139",
      "r146",
      "r170",
      "r178",
      "r181",
      "r184",
      "r186",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r499",
      "r519",
      "r583",
      "r605"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income Loss [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements And Changes In Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r127",
      "r128",
      "r131",
      "r132",
      "r140",
      "r141",
      "r142",
      "r196",
      "r197",
      "r200",
      "r201",
      "r368",
      "r369",
      "r370",
      "r371",
      "r424",
      "r458",
      "r459",
      "r460",
      "r497",
      "r520",
      "r521",
      "r522",
      "r546",
      "r568",
      "r569",
      "r570",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "New Accounting Pronouncements And Changes In Accounting Principles [Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Issued Accounting Standards Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NotesIssued1": {
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of notes issued in noncash investing and financing activities.",
        "label": "Notes Issued1",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "NotesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r27",
      "r578",
      "r598"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "totalLabel": "Notes payable, total"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_NotesPayable",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable Current",
        "terseLabel": "Less: current maturities",
        "totalLabel": "Notes Payable, Current, Total"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtSummaryOfLongTermNotesPayableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableToBankCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of the total carrying amount as of the balance sheet date due within one year or the operating cycle, if longer, on all notes payable to banks paid on an installment with long term maturities. This can include the amount of any loans from the applicant firm. This does not, however, include any mortgage balances.",
        "label": "Notes Payable To Bank Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableToBankCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating Expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r170",
      "r178",
      "r181",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease liability.",
        "label": "Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r541"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due Current",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r537",
      "r539"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases Future Minimum Payments Due In Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumLeasePaymentsWhichDoNotIncludeAmountsForCommonAreaMaintenanceInsuranceOrTaxes"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r538"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases Rent Expense Net",
        "terseLabel": "Rent expense",
        "totalLabel": "Operating Leases, Rent Expense, Net, Total"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r10",
      "r11",
      "r53"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesScheduleOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r67",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other long-term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r493",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income And Expenses [Abstract]",
        "terseLabel": "Other (expense) income:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInventorySupplies": {
     "auth_ref": [
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.",
        "label": "Other Inventory Supplies",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "OtherInventorySupplies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Long-term Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other (expense) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPaymentsToAcquireBusinesses": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.",
        "label": "Other Payments To Acquire Businesses",
        "terseLabel": "Payments to acquire license rights"
       }
      }
     },
     "localname": "OtherPaymentsToAcquireBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]",
        "verboseLabel": "Patents"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments Of Debt Issuance Costs",
        "negatedLabel": "Payment of debt issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "negatedLabel": "Equity financing costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r87",
      "r479"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments To Acquire Businesses Gross",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments To Acquire Businesses Net Of Cash Acquired",
        "terseLabel": "Contingent consideration cash payment",
        "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r392",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueSummaryOfFairValueOfOutstandingBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r33",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r33",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.001 par value, 5,000,000 authorized; 0 (2021 and 2020) issued and outstanding",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds From Convertible Debt",
        "terseLabel": "Proceeds from issuances of convertible notes payable"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds From Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the sale of common shares",
        "terseLabel": "Net proceeds",
        "verboseLabel": "Proceeds from the issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Gross proceeds from sale of common shares",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r91",
      "r94"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds From Payments For Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r89",
      "r420"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r2",
      "r72",
      "r73",
      "r76",
      "r96",
      "r117",
      "r129",
      "r138",
      "r139",
      "r170",
      "r178",
      "r181",
      "r184",
      "r186",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r483",
      "r486",
      "r487",
      "r490",
      "r491",
      "r499",
      "r519",
      "r586"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r45",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r237",
      "r642",
      "r643",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r44",
      "r232"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r20",
      "r21",
      "r234",
      "r549",
      "r587",
      "r602"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r234",
      "r642",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r20",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r20",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Property, plant and equipment, useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r80",
      "r204"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision For Doubtful Accounts",
        "terseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r41",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables Trade And Other Accounts Receivable Allowance For Doubtful Accounts Policy",
        "terseLabel": "Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r92"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments Of Debt",
        "terseLabel": "Repayments of Debt"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments Of Long Term Debt",
        "negatedLabel": "Repayment of term loan and notes payable",
        "totalLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r432",
      "r565",
      "r656"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r109",
      "r573",
      "r599"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash, Total"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r334",
      "r425",
      "r549",
      "r600",
      "r616",
      "r620"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r124",
      "r125",
      "r126",
      "r130",
      "r137",
      "r139",
      "r199",
      "r421",
      "r422",
      "r423",
      "r456",
      "r457",
      "r498",
      "r613",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Deferred Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r360",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue From Contract With Customer [Text Block]",
        "terseLabel": "Revenue and Accounts Receivable Credit Concentration"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentration"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r78",
      "r117",
      "r166",
      "r167",
      "r177",
      "r182",
      "r183",
      "r187",
      "r188",
      "r190",
      "r198",
      "r254",
      "r255",
      "r256",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r519",
      "r586"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues",
        "totalLabel": "Revenues, Total",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r162",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Sales Revenue Net [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueAndAccountsReceivableByThirdpartyPayorsAndOtherCustomersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Common Stock Equivalents Excluded from Diluted Net Loss Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule Of Carrying Values And Estimated Fair Values Of Debt Instruments Table [Text Block]",
        "terseLabel": "Summary of Fair Value of Outstanding Borrowings"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r58",
      "r122",
      "r300",
      "r302",
      "r328",
      "r331",
      "r332",
      "r333",
      "r532",
      "r533",
      "r536",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule Of Debt Instruments [Text Block]",
        "terseLabel": "Summary of Long-term Notes Payable"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r143",
      "r144",
      "r147",
      "r149",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r391",
      "r416",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r391",
      "r416",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Pre-tax Share-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r217",
      "r222",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments Which Do Not Include Amounts for Common Area Maintenance, Insurance, or Taxes for Operating Lease Obligations"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Excluding Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule Of Maturities Of Long Term Debt Table [Text Block]",
        "terseLabel": "Scheduled Principal Repayments (Maturities) of Long-term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r45",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r392",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r397",
      "r408",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Weighted Average Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r61",
      "r114",
      "r156",
      "r157",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r320",
      "r325",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r337",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]",
        "terseLabel": "Summary of Activity for Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r444",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Scheduleof Finite Lived Intangible Assets Future Amortization Expense Table [Text Block]",
        "terseLabel": "Schedule of Future Estimated Amortization Expense of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r160",
      "r162",
      "r163",
      "r164",
      "r516",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Summary of Revenue and Accounts Receivable by Third-party Payors and Other Customers"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling General And Administrative Expense",
        "terseLabel": "Sales, marketing, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling General And Administrative Expenses [Member]",
        "terseLabel": "Selling, Marketing, General and Administrative",
        "verboseLabel": "Sales, Marketing, General and Administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfAmortizationExpenseRelatedToDefiniteLivedIntangibleAssetsDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentScheduleOfDepreciationExpenseRelatedToPropertyAndEquipmentDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfPreTaxShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling General And Administrative Expenses Policy [Text Block]",
        "terseLabel": "Sales, Marketing, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock"
       }
      }
     },
     "localname": "SeriesCPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series D Preferred Stock [Member]",
        "terseLabel": "Series D Preferred Stock"
       }
      }
     },
     "localname": "SeriesDPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series E Preferred Stock [Member]",
        "terseLabel": "Series E Preferred Stock"
       }
      }
     },
     "localname": "SeriesEPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series F preferred stock or outstanding series F preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series F Preferred Stock [Member]",
        "terseLabel": "Series F Preferred Stock"
       }
      }
     },
     "localname": "SeriesFPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesGPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series G preferred stock or outstanding series G preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series G Preferred Stock [Member]",
        "terseLabel": "Series G Preferred Stock"
       }
      }
     },
     "localname": "SeriesGPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesHPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series H preferred stock or outstanding series H preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series H Preferred Stock [Member]",
        "terseLabel": "Series H Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesHPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationSummaryOfRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock\u2011based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights",
        "terseLabel": "Vesting term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on offering date that participants pay for shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date",
        "terseLabel": "Percentage of fair market value of common stock for purchase under plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "verboseLabel": "Number of RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value, Beginning Balance",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk\u2011free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Percentage of earnings used for purchase of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised",
        "terseLabel": "Exercised, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures",
        "negatedLabel": "Forfeited/canceled, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted",
        "terseLabel": "Granted, warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r398",
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number",
        "periodEndLabel": "Outstanding - December 31, 2020, warrants",
        "periodStartLabel": "Outstanding - January 1, 2020, warrants",
        "terseLabel": "RSUs outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in the number of shares under non-option equity instrument agreements.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Period Increase Decrease",
        "negatedLabel": "Reclassification of warrant liability to additional paid-in capital, warrants",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureWarrantsToPurchaseConvertiblePreferredStockSummaryOfActivityForConvertiblePreferredStockWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Number of shares available for grant under all plans",
        "verboseLabel": "Additional stock awards granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Stock Options, Exercisable - December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercisable - December 31, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period",
        "negatedLabel": "Stock Options, Forfeited/canceled",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited/canceled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "terseLabel": "Options forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Stock Options, Granted",
        "verboseLabel": "Number of performance-condition options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Aggregate Intrinsic Value, Outstanding - December 31, 2021",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding - December 31, 2021",
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2021",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - January 1, 2021",
        "verboseLabel": "Intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r399",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Stock Options, Outstanding - December 31, 2021",
        "periodStartLabel": "Stock Options, Outstanding - January 1, 2021",
        "terseLabel": "Number of outstanding stock options granted",
        "verboseLabel": "Number of outstanding stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding - December 31, 2021",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding - January 1, 2021"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Percentage of number of shares of common stock issued and outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period",
        "terseLabel": "Number of common stock may be issued under incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r390",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Exercise price",
        "verboseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r392",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r412",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r419"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding - Exercisable - December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Contractual Life (Years), Exercisable - December 31, 2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Contractual Life (Years), Outstanding - January 1, 2021",
        "verboseLabel": "Remaining life of outstanding performance condition options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares",
        "terseLabel": "Options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares Outstanding",
        "periodEndLabel": "Common Stock Balance, Shares",
        "periodStartLabel": "Common Stock Balance, Shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short Term Debt Type [Axis]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short Term Debt Type [Domain]",
        "terseLabel": "Short-term Debt, Type"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r110",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r114",
      "r117",
      "r143",
      "r144",
      "r145",
      "r147",
      "r149",
      "r156",
      "r157",
      "r158",
      "r198",
      "r254",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r311",
      "r312",
      "r316",
      "r320",
      "r327",
      "r519",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r64",
      "r74",
      "r75",
      "r76",
      "r124",
      "r125",
      "r126",
      "r130",
      "r137",
      "r139",
      "r155",
      "r199",
      "r327",
      "r334",
      "r421",
      "r422",
      "r423",
      "r456",
      "r457",
      "r498",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r613",
      "r614",
      "r615",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r155",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r63",
      "r285",
      "r327",
      "r328",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period Shares Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock upon initial public offering, shares",
        "verboseLabel": "Debt instrument converted to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r33",
      "r34",
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan, Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r327",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock, shares",
        "verboseLabel": "Shares of common stock issued and sold"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r34",
      "r327",
      "r334",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Stock Options, Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options, shares",
        "verboseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r64",
      "r327",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period Value Conversion Of Convertible Securities",
        "terseLabel": "Conversion of preferred stock into common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r33",
      "r34",
      "r327",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r327",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r327",
      "r334"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Common stock issued upon exercise of stock options",
        "verboseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r38",
      "r39",
      "r117",
      "r195",
      "r198",
      "r519",
      "r549"
     ],
     "calculation": {
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r312",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r334",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders Equity Reverse Stock Split",
        "terseLabel": "Reverse stock split, description"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r530",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r530",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r530",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r530",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r550",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndDescriptionOfBusinessAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureShareBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardDescription": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of the origin, nature, and characteristics of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Description",
        "terseLabel": "Description of tax credit carryforward expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r254",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Carrying Amount Attributable To Parent",
        "periodEndLabel": "Temporary Equity Balance",
        "periodStartLabel": "Temporary Equity Balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Convertible preferred stock, issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "periodEndLabel": "Temporary Equity Balance, Shares",
        "periodStartLabel": "Temporary Equity Balance, Shares",
        "terseLabel": "Convertible preferred stock, outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureConvertiblePreferredStockAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/StatementStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsExcludingGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r433",
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at December 31",
        "periodStartLabel": "Balance at January 1"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions",
        "terseLabel": "Reductions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities",
        "terseLabel": "Reductions related to settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions for tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits Interest On Income Taxes Accrued",
        "terseLabel": "Accrued interest related to uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations",
        "terseLabel": "Reductions related to a lapse of statute"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UpFrontPaymentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of deferred revenue by arrangement wherein all amount due is received from customer before delivery of goods or services, and revenue will be recognized upon customer acceptance of delivered goods or services.",
        "label": "Up-front Payment Arrangement [Member]",
        "terseLabel": "Up Front Cash Payments"
       }
      }
     },
     "localname": "UpFrontPaymentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureRevenueAndAccountsReceivableCreditConcentrationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r449"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetExplanationOfChange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A description of and reason for the change during the period in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Explanation Of Change",
        "terseLabel": "Valuation allowance, deferred tax asset, explanation of change"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetExplanationOfChange",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfCommonStockEquivalentsExcludedFromDilutedNetLossAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants And Rights Note Disclosure [Abstract]"
       }
      }
     },
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.",
        "label": "Warrants And Rights Outstanding Maturity Date",
        "terseLabel": "Warrants, expires period"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "auth_ref": [
      "r500"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity.",
        "label": "Warrants Not Settleable In Cash Fair Value Disclosure",
        "terseLabel": "Estimated air value of warrants issued",
        "verboseLabel": "Fair value of warrants issued"
       }
      }
     },
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureFairValueAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted",
        "verboseLabel": "Weighted-average shares outstanding used in computing net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetails",
      "http://biodesix.com/20211231/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfComputationOfBasicAndDilutedLossPerShareAttributableToCommonStockholdersDetails",
      "http://biodesix.com/20211231/taxonomy/role/Role_StatementStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "auth_ref": [
      "r84"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.",
        "label": "Write off of Deferred Debt Issuance Cost",
        "terseLabel": "Write-off of debt issuance costs"
       }
      }
     },
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://biodesix.com/20211231/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124267575&loc=SL82921835-210448"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466103&loc=SL6014347-161799"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1),20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919359-209981"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=117340910&loc=d3e59706-112781"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(b)(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r657": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r658": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r659": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r661": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r662": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r663": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r664": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r665": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r666": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r667": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r668": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0000950170-22-003495-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003495-xbrl.zip
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M7'#NCT4]NKY?94RTF@L$QP7[]4$BK3E.IRJ%9L)CZU_]]GVA\Z_?6-E<M,^
M)3DC M)8:L0UM4@SKX!5<2^-M#*H_.Z3:+2SG?BY#AMU'49=.(_1<:B:Q=2?
MRJ%K^>I<IT&LDQ1;BUA(I()I0$HQA:ABG#)K&(U7Z.[#$,3/^29,7YG!]M"'
MKW\+YP^C/PSZ"F<ZIV(^(E0,.T.L0!%SCS@G#&D%+Y'P+NT<C?PF"F^6)R?%
MJ.%_&T.?Q", $0R((MS@ATLEQFM;D4P;[P'PDFB0/]HZ0 $:D=%6.&5I=,$]
M@)_,A4\+V@*VDDIB-,JI,@!CD%+:Q8A LF* +^".O,$2[P&-I6[E*@EPG NB
MC$)1@EG'@4$B#3B ,+;.VX#A;?0F,$I@":/SW8$9CF O'T#_.DT; Z80QX./
M1;P!G" U9Y9$%".%'>48=A08!9U#V5Q2S@S%-X6I'U<7PO3@N HA.P=%J9Z+
MMIT7 1,5@ P%0YQ$BZSU% @FCY)'*W2\P>D^!N BX1I_3?_Z5([^&48)@@"P
MX/?",'PQ@X-0G9#K.W78ZFBB1RHZ0 TL&U[+42!22H_S8'-W]T[K<!:&W]CI
MFZM::$,5:4GU;[\DXW"];LP?6$K6&(OKR0SX]55=G)P.DBW4? <'"2M-BCV:
MZO!K7VN?,.;J'.WK9M_1_%F7XZKYJS&&UR?;;XY]\]  10"H R 0!D!K!=PO
M$HV<,9H8+S"F^M7TT=#PT^E?A4]_QR)46;.$<*NMN+G]MZO<\_K#T^GJ5F-K
M__3PLJ^G@\(5HS]"TA$S7YPDX90<*Q?@+X='(X#I^V!'R8C8^%K4KWY+![4.
M"!#J77-N0)B!3:J:O]N9?GESZPM^FZ[L8AUO;MOT::-.7QQ!8[:.?DNO:,QG
M=;&_R2_3OZ?/O;D"A-MA(KRTS'/0GQW,R0$^2%LID6$YMSPX37WH*DPN](O-
M@:GKG=CP_Q8P%T/@*$*]=55$? <VWWT_&*[ L<$>#M6I 5[W"1C%##YL_/W#
MSL[0E8/RZ'SQ: "@KD;)&/RMM> U:#H7\US\=@$P?V4HPY>O:']Y",Y0*YW-
M0=^P6 '[#* R@U[CD#; 53$H,H Z7<.9!+,_S'^5U>:X'I7 ,>L9B'TTUI75
MZ7LP72OX:7"^69XE#]$B$&7/@"1OW]6LH1@6)^.3Q\Y\J3C ,I/*F:3X7E'_
M^>[\DCM=#)IL^<;@):[B'4B%XQ-37:/'#=<XDNJ]X$)QECCF\BF$S$TA$S_)
MXRDDQU1JD)XH!@J"GN& ; #+RD?A<^882/N\:Q3R70WN-M3:+^/HBZD"C)M^
M? \JRJ!LGM@LZ]%2)2'8>5=@]AA)J#4%(R?F2%D%YJ\28)81F;1=8R3-0?W5
MI*LPVS)%U1@^[\XO/OX'S&@J=WS^,0'D*M@N!FT/3\>CNAE!%\4-9A;S!RC(
MXZJ1T>],7=175_&A'A6@Z8:=>/'(Q8?+6ZKE+FNK"G^-@5>=?^. 9H8FIC6N
M*E#^5P6E6<PI]50A)W(,*$UPLCPXDBKFQ -V4R6[AM))2 (+\F,WVJE ?3LK
MW*QR];XP1T-@*X4["$MA+E>D!YE?>I#%20_G%;8V.9Q",A,Y,"'M-44>3"9K
M- 5.1;L&MBGAO)\HVGO)4!V'C:I*^D^:Y*;P^'RZ5<'&P71*O\\,717ZLD$Z
M ^("<</ H'4&#%JB.$@0*1QW%,S]SHJ,.PS:@R_EP7$YKLW0'WR!6<]WAB'Y
M,SZ69K@H;IQ>NPU'7S771WO!AY/3I#VV5TA7\>3NL8WS9_E\@"&BY^,#5X8^
MA@\$1[B6R3G%"4\N:&#?/ @PY'A.K0F*&=%5]+JPS9/Z. *#ZN2T'#;^S:NF
M27ER4@X78I5/IWPWKHMAJ.L-!V]N+QMF<'L;#O@(#)7@+R5)O3UT+U*0$"9$
MS-/U+06]%E"'(:NU1)1(F2X-.+RNJPB4>-).G!$*L_8Z0/6H,38W!Z8X23[S
M=,=3UXV:MBA$VA_;NE$.1Q_.;I5?UP8L&85H>Z4U#PI=&_H8% ($,E%)BC3F
M ?&<:_AD+!(2$Z,\(<QT5L1M@#GJK\FVB4:Y60Y]PQKV]C^_3"52Y5XHK0VB
M$=02$!@YLA%T$^X\MY9X8[SI*N!F3+6+*^S&QSL#R-WQ:*?1 BY&+,%0?+ Q
MS7X(J[4#GC:IK:0,9G1*-6@.VA*5%E1PEAMBA,&VLYZV!0N81:C^^P&.UU_$
M$#V%2)L/918HTA3@!Z!-1$H'T(J$CL@*@9&1BA#'%6>LLRB3G++7KIMFK+7D
MA2V^CD(8IG%+O8*4S17DA9GS*,>KRAF-7"*9IYC#W&MD'0/P@.0BSH4@3&>O
MA;>*83$*'XNSX,&R %4U132U\4; L)O[IFMR:S,,!IN Y^8CJ"'#^@DLU^<P
M/ 0EAD:'O(S E24+R'"/D8B1L*@8S[M'8OUEW:,OZ^8ZXV_>POX1?.',=QW^
MJTD1N0[.!K">0A-8;<"$,LZ!(F1R3J3E7/G8-8JXP)@VO.(?)AGCHYVJ"?.\
M:E,5H?X=$.LL5*/$ :_&6TP>7+:=]3P*J)(\1NX$,M3+%#],D<VI0<PX+0CA
MEL;.L;HI8+>'#HCPPE7WL73FTEUV&4(S&(#U\'L8@@DT2*X6?P)\L6XXR%GX
M\/4TB;&7:40'FE,?@T>8^XBXEA*I$ Q21LD<2RQ2!&1'@7O5:SZK@6SL?=C?
M<$]A3NSN[LYQ:?"X^QR\N/L<$;5E*4^'8^,0Y]0AZZE A'M/G:#.V<Z"N_=:
M/"_N8)938HE N:*@\@:.D8T!;"26&Z$I8;*[ES7WMV+>%>6>\4]CPCR38XER
MH9@%F\73'.2ZPL@PP9&+U!OMF?&ALX&QMSF^=T/5!)8/9YS?K0-U81<F=SLG
MVJOD]CIPNS%! -^6XZ?H@.; )1'2185T[E1*9,%(.Y8CIY@AU.<$FY5"GW?E
M<%P?E!.,V:W*H\I\SS!>3<CEPLM@.4/1.HNXESE2+'+D@>)SBI6RHK,W7G==
MFJ;4M# <%F8 PG80SB=QGF"Y;7\<N":59>.H"DL*P.D 8+&C5J0966+FW.0:
M*0EJ/0N4AN@E\:%S8>O/J6-W &34*]"_<X^HRP/B+D7""6-!"!M/L,>YQJIK
M(%N^'_%%6W;753\^?WX+7U!^B_#,1Z%2RF9*> W)5Y<SCP3.F974TL Z>W6^
M\+BKSAA8WF#KA*#(,J$1E_!)6T.05X%J@XE2I+,:U9Q0V0LC4PR#_V"J(9B^
M+]-A*H%Q*YT34*THZ%<Q%;1@&B,?@\)6:.UC9\7PO7)CML8 Q=&X28[9*KZF
M3\M-AED@L>6"<,VP0E83,%]$'I/C4Z,\,JXI21?RO*M 2E$3A2],=;YO!N'6
MM- /)Z>#\CR$)V& >%'1YLHIC[&'&65$G'H' @I+Y)GCWHG<RM Y#]-MRI#Y
MNDAEZ*F#:+Z3_/NQ2)F_PUU3+>S"]DZC[E*.[XXK=_R$1EQ3Z _G\TB/:T,?
MI9OQW&B<4M59=(DQ860\6'*$4A9UE")(UC4B>)#T2#K"&)#L8M"J),7DFA$"
M8$*$!)S*"$FD 33(8Q5SI8R(M',VVSU$Q_;NSO(%!LT7 0E0F+T4(":,8"D*
MQQ-D+65(>: 8*85UU'<-$M]._YLIZ9"^?)'^#J5X!!7+(TEE*K\G!%+"8!2(
MCI%2%\$8[1K$[E&-XYL1(DL-5=2+XVU<<1(<0#P0!BJ8X"Q51,H!4;# .:;6
MF\[:+HO+N-L9+BPI>SE9B L@_F=(]V,FJ%P8CYQ-:;\&&)#1DB.2!Q:4#,"P
M.\>N.P?'9272&ZXBS9$"%HQXKBBRTO!4,](0'*06K+.^IW=FD"Y]]X]#^$:$
M5U,D\;(\XC2AIEBRNV*1\)&@6:H8$=4L1]P"D P..:*2J<"I")IU-H1\ V;P
M12IU?A;V4]1+<_(?OKK!V >_594GK2G0 &XG3GV#P(KWCTT5WIW?/L%L?&8:
M5[<U!D?!?QYZ,"OV=W=?I KE#-;8$0=\V:9JE3R"THL52K4\J:>&VKQSGJOE
M7QG=/\)GHH2G@HU@JNZ:4<,9XLO4NRGQ'AL"#".G 7'F- *[U2'%)/&<:T>Z
MRS^>Z,Y_[O5L@E)?C+:,:Y(RKTJ:CP$84+43VS&+RV@8# #R*3IY9NNF/K[\
MH?COX#OJ<7R<$&W;;2S&<<.4,AKX970I\ 4K@8P!22JM"+DSDDG<6?VSVQ&,
MP-'$W$SMRM!'N4H#(Q[T'^1R11!W#. IA 2ER/FF; VQG65J<UZ8;O@VD-$,
M=DT!D-\TI\7(#%ZDC )30ZL<6R1$*E3/P3)47#A$5=!8N9"'[IJ'2ZK4^CB_
MD+R:4OP8UBD]RW/,*=B'*;0,YSG2'DMD A'*.BQ\=PM!]?5R+MVO7G"0@A0Y
MF<Q\ ;)0I2KKPA@GM),RVLZZ]_J"2U<*9"_.M2"(TR2 5D0PX(3VB;3SB+S(
M:<ZU(0YW-K]OGCHJD^3,OHI*!_*1%GE5@7W4.6M<EJDSC_4668DC,M(Q)ID1
MP;C.XFV7M7D $E;SR:9VZ()<%(%RG7,'?(@"/'F0*7I=(E"7,(N.Y]YVSJ]U
M'SYTT?1D!)]J>&M;H*!G1\]:U.F93!UK.76IZ)QBJ3]+;L!R-1$LGZB$"11[
MC[N*Z_.7UT@A)O6D3NZGL)# M&_6UC@X#N^*HX,PA.5-6K8LXGTK7"_EL93Q
M3-4FYFJ,MES*>+9;ODB"D<F7Y3TGB*?*N(JP5,Z4:R&DTI1WMH;*'9%E;=.8
M$9#H'V"QG>]$(- 5*C+/:>ZI(@1%L)T!)?-T-QYRE NJ!-&1"-+9F*7MX5FH
MF[YKUX(6]L+I))QV8;<&/[Q]?D6)5G.SS^O&_*.RLCT+U@::DKH"X*J*P$%P
MCH2U#BM//=:==8G?*WJXN=H[+@=^^^2T*L]:I7%5DD^8YYY;X//6I'Z6J>J.
ME<JB&*3T+#4$9-V-()[7T_W[8GN2=;%/W2*EC*$ J13107&ZG$S-G@WV!C$,
MORBF9 ?KO"ZN3]S<X&^%RV44T+OS[:$'#;DZGWGQ5N$&9C3^[_&)L<O7DI^A
M09U0@A+*#0*C42/.@@=]V5&$8Z0Q8,M8]Y!EKIILDQ8X57!M;ZTD!N:KOS;W
M^V=\$XW';<9/\UU)]")-+@,FAL7&()VGMM@I !08#D6"2RD)YBJHSM[M+:V)
M0F?D @4*%Y8[Q&.J$!'@7UIAA315ELF(#?.=U>@ZDQ6^'-!(Z8QGC@$L&! .
M\1A9#-8A45P[PZ7WH;-J7&?BV3O@C<VQ,R$ZB5APJ7\$<TCE--5D,;ECH*+[
M[D74/A*.2RR OR0VR!A3 E0<%S6HQPX'9"Q3J8:5BH'FQ/!59X-/%NNU'*,V
M9?2IR (8,*"8\L!SI%++"H6MPEAC241G(=37$WQV+33ZG#H'6JCT5J>T!H=,
MJCI-<M!(H\;6=[?Z37?KAR\G[SI:PRF0-+(BE8*5B<IS*Y'-)7,:"V[5TD,O
M[BN)L)RQO1_71IEHRW%$A"1)I!U!AAJ'*.S>"X.U,IV]N[U?G$(SLL'E91C?
M?93"<P1-21MCZN!JG #*588A2YU"CD8<0-^%WSMKLG0S\"!E((TK\Q_!#$;'
M<W3WF.MM/W#8P3/U0= :C#RKD,>)+FP>D.4F1YAIH QM1>XZ2Q<=JXBX0*,/
M!V$-V _(8@)0H: 36N(PBEQ1&B.W5G2NO?M\NOU^\34-N/K-M*_91M+]G\,,
M6 X4B07UR&F%I*("<:(UTL0(A/,\$&F9B;YS9=TZ(7-66 H\3J:^Z$99@*=>
MTQ 18WE$/'6-TS35>XLT5];B:&2'[^Y\B/>)7;^XIZF,#XEH5B9&@V ;O/ 6
M.0,0XEXUE;GA!;EF0E,KB.RL[)FK[=5>J$,RNT#:O$]F5=G<<$YN6U^DB\GE
MN1>.4^1YRAA)?3B5M %I:;S+<<!6=,[/_PPA%O=/3OFTO_EQ<W=G\Z JENNO
M)G)QU6:U"D(';9 W&K"!.HDTIAI11Y4-#!1_V=E<R.</@NI .3$N:4ZUD4B$
M5"\=&] K-5AOP7LOO8U"F\[&Y;[H#@=7_:YZ07Y7SCS (L]1'I0!$QW,0HUC
M0(:PU I=<VHZ6QCW =6))M'9_B"XX^$\_+TS]I[U3/A4YD\%  _/<X$49@&!
MUL0DPXX"D78-4,LOX_UC]YP2UE)"@7BYUQ+^!7JUMH8C%H&J1>"QPRWIY]*F
M4Y9!%>HGTI^?J7J$YMXXEZ.H4\LW*5+E.2!LF>>.N1@Q"=V]X1\NNPCAA(H/
MRBGK7JK#M0/HP',=O/,!*9*Z"&'BD&48U',F+ ]$8J\ZIW\]F,^O)H@4<]88
M8E"0*2;'48FL8AB9:!AWP0;?O83"OO_$,Z>F$^D%X6 18X^XL2"I 5D0%M3G
MDA@;7.?4[.5K;WUYT;NC,VU.<P&6?92@]W,N ])<2.2<SQ7Q.8B)SM5B>8+.
M/<^6$=O-P,)GNF_1E$I/ ".)!ADHN496B!QYY1D7@KG .N?U[5KIVY7K<O4X
M9\@":\XJ#,)3*PQ"-%7<DT8@8U6.%!4&@]$DM>QL<E6W&IYTX ()PQ'G6BL4
M0RJ]GIIS@FZDD5;&2.L\4;1SH9]]U9S%!B[</S)DP[EDSJ1@T5"<I7N9%TD<
MC&*GK%=@,Z3Z$\Y$I#3U*"KN8FX4EZMA./3(>B]D?1P#^M]F"$;4\/98A(\?
M-U^D1LJ""IQCA0CG>;IYMLBFCDB28FZ#]XYTMPKO<O)&YW[]XGI\P6I?Y*VX
ME9''F"Y'74P=W+1$EO*(<J6H%+G51G4VVK)/P[M:A77> E+7ACXJ#2\Z[P4!
M]%$6I+B2"IDH4BT:SKCAP)M\YRYO^^RFE<MNZH*^ZAD/RBGD+<>IL 9#*@\,
M1+$@RA"O>??"%+I<\2X),3Y_$QBYH%)(-$C),?<H.)'B=)U&QC"#B..$.\TD
M[6X9\*ZX]UZZ$X[E07(5-<HMUBC=3;==;:T.EEHBJ0B=C>7N;*&69]!M:?2!
M"D6!42N HP5Q8*DT*.2IYK]G+HB5B#A8C(OA:=-2?QB'QFIJ,S35"0/J0"0D
M;<:FKJ!"!41I($1XB?.\L]K,?.4S/CQK^8Q%)N$3:8)S <212>[2&$'I)#E&
MS&+*L%8LT,ZQL6^8Z#/)1*.J<*,)1#X/"Z"X_<^K$K*LL-8\JE2SV8'5FQJ0
M: >?<IT+[I4CUG5.0>A]US^V[_J9RC0IC7,-AIX7(O$N%I%*-2E);H@-(56P
M[JQ[L>_2TWN([E>X0.1,@IU(C!.(&[!C=& 4&0SBFTHBL>C<C>:#BNDG5!]5
M8Y<P?7O8Y*&$>F4RM2WGE!'&D?#1)W4JE6'U <2XC0SX$OR[L[5;>I:T0BQI
M.>AK:/#&)VV6I/+;V#.D2*2(YE%SJ7/%>&<CQ.9*C=H/@P' X_<P;#K8#_V&
M/P%%M6Y4NK/PX<>I[_Y,X08N!\ZH)1+82\1U,$AYFESUN:?6!J--9_GC;3?"
MD]M?@-MM5N>+!*'E*<6.&<3@OXBGKJ<Z)Z 5L2"("C0XV[GBJ(NK7+&:, M!
M:#"&'&+,1L0M@$OG6@-SM]Y*$"',==92ZB^F[D2H:U=3=R'4M:&/ZM-!B3,A
M=8( PP-QYT72<SFR!$QQZAEFHK,YU'=?6 ,?*$Y.QL/PL3@I@)LO"FWN0N-)
MJ;8FN_>I,OJ>J:4F5TRPF"Q88\$JD@EO*$/2.9Z#X)!>=>YJ8/D))S]*XP1B
MJ98V)X@Y"= 7TB.;,X(L%<08#I8'73K76 V!;8/ (@)AV,B R=H AACL""D,
M)AA(<R9UY[([YL#F_0#;]$O$VVN@NP*/I\H_)4&;G,",5AHP<31)7FF-+/ X
MC.&CX)W5M;I0OK<#U.>I]HX3@;Q+VHUV!EA4B,A@'"(C(L]E9^.XYJKUN]3;
M:8DP150O0F!$&HV+',1$2NCFQH*LP!9X(7=YI$(X83OKCUJPG?!8&_?'J571
MF#DXGX=G7!OZJ'Q,(CVP=HRDQ""Q<2KAR#Q&)AAK 86CUIV]H.G;8'9. (G<
MDER"#H%3G0#)D?$Q(,(CXPX[8@3M*C+=Z[;O[^&X<(/5Z8R<>RZC,#DR3$^*
M&.G4PD22P$$K=RKBSBIW2RT[-GW))/[M15*ETE9[!AJA\SF8KXQYI#F8KUA1
MT.JUS6/>6:I,R@8 SU3GJ3G E?H)K0M\=' <_@#E((QV8@Q+O[1<($TF=9QK
M'Y!P%, B8RHLY@42,M<&2P!-WEE?9%^6IPN$[3P%>\(%!&9[1-R;@(S@#I1#
MJ;G.<QQ#Y[R2_;7W"KF](\?24.$0880@3G5$QAF+2+1.8A9=M)VM5OJBRX-?
M9S[Y_$F#>D%)@\92YH2/2#D9DOCB2#&?2C-%[ S'3'37U?L"6Q*]P$RFU>29
M@D?%F01Y'($L.2AS2$=8B+1*2<)BR//.5B:YEPV\1-&WI*+ZPK, 0@Q)Z3SB
MA('"[91"+$@NG;;IFJ.KD.E\.Z)G*DR9)^)5$E$5%)BV(B:'4T0Q$#!QI9/:
M=E8(S6E#/4-+^T4FZFFF"3<YJ) Q]ZF3A4:&40XTF(/%:R0WKK/L\)D*-?U@
M!=8)]DSESJ%<I)@!,#B0MM3 OXC2V')M?><PI#N!F<\4#Z48Q]QH%'*%$5B)
M,A4$;M)ZN/8I2)IUEN\NZ=9H-0&)M;&Y\QC9Z&SJI$G!GB,*!<>]$)H'TMW&
MLGW6S?/JT\Q2::D-Z18)F$"$3S8XB7 >K*=$$-#$NHH[S]A*:CG T(09K[Q"
MF"N2$BT#,C)X)#%WW$2EG5UZ[,^S*9F<$&VT!]0+UJ:P[I2>PPAR.7;4*ZXH
MZ9PX>H:NI*VA<7D%^NY\>^C']:@ZGWGQ5N$&9C3^[_&)L4L7>8 !F,XM\BZ'
M/D;D@47BH@%EA?-H4L_+B'0@! 43?&ZD#DQW3M]\D(-FOXRC+RDT?^BG'V?<
M HUZLU3NML $3RP\Q4%QF,ZD?H@B3WD;8/8'%40NL*&XLZ+FG1FDRJO[QR%\
MPV^S,SH.U28(_W11T33$616X@,4F.) 34IRG4J<*;#<=+:+.6.O >#.JLX&.
M3Q)7\F1%?;I@2Y!@A(D8],%4 8@%A12+/'44M@HKHY7L[&WA?/6S?G\Q];-,
M-+D$M0AI''3K=#$V1D2]EHY0CB/O;.C />MR)!H.U=/<5BR0M3;W1=9Y9%.B
M.6<"(Q5]CFB><ZHPC<9W5N1UMQI=!]@DTU2Z +0&>J9'W.>IT9MSB!DE<ZYR
MKWGGC)5+W]D9"+3TT#7;>2^<3L+E%V6L/%^(65<J0\]P?K7 .GTQ@BCF'!F:
M$\0)5T@[H5 (()Z-9SECG0WX[ZK'[]MUAUJE?K>L6B7RZ>H0_2A.2,HM6"#$
M(^-RA;@&?=-$#>PZ8"ERL!F][JP%,B>+VPLC PS)3RV0%WD+J(WS0>B(+$^N
MF1 "LC''*->!VEPI@?/.E6>Y7Y Z@/9\>3'J'0!AM-@U%[G4IVHMGJ6.C4P!
M'&V.*>/$LLZ1XIUA<Q^-=65U^MYOE17\-  */3-]?[_'K*(K%<:?*=2!<RXX
MS.B<,P@^@.KO6$2Y)YZR=!$;5CWE8_G":CD.$8" $-$HI)HH%.\",MR8U'J1
M",)Q[F5GU>)G#6?N&Z,^64#S,R7U.J4)XR#1E6>@88/IJ)F)R! O-79!8M_9
M],$7G01RQ>^(^4Q>QZ-2A24V$N. N"$IKX-(9)DAB#L<&<4A]]V]'MT>^A"!
M(8S"Q^(L^.TAG,)1<B^VMVI@%3?,ZF9:UT%E?$CL<G4RNK'TVNB I,')BR@=
M4E%;A%4NB8M,X;QS[N$59]]=T'L?)Y+_"+Z8(_UG-?WJ1G,5 RAO,A"3:H^!
M^:FT K8H"?:! \5T]OKQ7E=:6V-0K4?C)K!CJ_B:/JT,VP)]@1F1*Y0SD8)O
M<H%4#KJVU8('2D#RK&BE[N<+''ZFHA)&,LEC0,$VM<941(II";,'S:*67)I5
M-V6?(?-FD:06-,84&"(2/F7>"-#;;0P"6:6%,DQYISN;[M:YF*E%ADWSF-ND
MJFF3;BRXC4A;@)#4(2>!<.Q6X@+NFW=>N^-1&T)],6()UUN=NO[K\EW;(GUD
M3N:8<0S3R6 1CYPA2[%#+I(0<0 $MIVS.5:@ML<S^:)!4ENL4RVH%%^DJ4>&
M$HN\5HX9;;&+G77K="5"8Q:,1,T-QNOA'(_2PYR./@5Q1,I-NC?ER#C-D+0Z
M*LJ!2&5GP?B,23@=L%<=!A"9Z)&*Z3((RX TEAP%(J7T*8DJ[VRUWJXTMUB^
M1^GYVV8LIY\[ 7M;D" 1D=2!=0!V@O4)^Z06S%N#G>AL / =\187J4XGIX/R
M/(276^P[I]8Z"3,J1S7BC NDA<Q18$:%E)7!36?]]!U6QIXK)IA'9FVZ99$,
M<>#]R J:HY@<*V 6*L/Y"@#SP5897:Y5]L[4Q37\^@!:X0F :R=>/'+QX7U1
MNT&9'O[!C,5%YB\XPG)C\Y!:I224!IW4>(61(0+,B^ XC9WK!_Y#7!M?9W=\
M;G9WY8[Y<2$% 1,#1HL*$90/E;H"ZY33&8U23EI"=6>O:I93%.BQWLFD%RZD
M=46N@$JI\\@'*1&/0B&@8M +8ZK2$VD@NK/VY!QZX?;NSJKXB8WEPA/M422T
MR5.G2 E0V!TA)K+@HF"=+<WR@FJV/U,N+</!! ;0ILPC;HU'VFF-F,<Z*B9U
MZ&[059^YU0&_()CU.>-6H !X@S@!]<MR1Q"U>8R,A:!E9WWU'0PU7J1FK)G5
MN0.*!ND*FK$0'AFI"'+:88US:W7L0JF>#G!!"8J@DC9'V%G0$[G&( (EV!!Y
M*NZ9:V-4YU)EDP]RMRK]V(UVJOU0G17NNL>P_?)%RBUJN# D>,2T3^EXQ"*K
M(D<YD\PR*XC-.ZO9O\"JX-V(B_QQ8Q(UHY89"VQ+)59/'5A3+'<(J(&3E(?=
MP<)D\RE3/TJ_Z6?*N<!<VPC&GHC,MO55P2[7R&AGE,)"2]K9&*$+[6U2!>06
M*WQ23>=JT8\G\*E]*D>AWC7G*= ZJ=O-WTN-OE%-4U&U"+4Q!D6EH!0)*4CJ
M+B"322@1!A4)4Q"O#B_]QNX!UY5X(6XIQW--9+0H)RFWF/,(C)09Q(0'W3ER
MK$1GPTV[6UOJ>C5&C.A<_4>O#7U4%(2*C++DX/*I*0,C 5FA*,HIYRKF+->T
M<Q+RP07:YT:9OLO93!RSU)Q9$E&,5*"4QH%T8!0%IFPN*6=F-3!D+HU^-4&D
M,%A[,H](.B%!76$Y4L$:! 0L1# BFNYRYZXE W3 :E'*.Y"N!.4\SY/O$(QX
MRC@"I1-[[?((IDM7P7E;3.$DF'!CZ&\KQ[DR]T$."XN)1=J+E)VK+%).!21#
MT,+8H$PP787*UGV2<B=1A(/!)F"[^5BXIVE?)!!A\_'-*T,?%?8C@L,Q#\A8
MGJIP$H%LR@>1V! 1"8ZDN\&[SW79V@&=54H2N3$$F11_Q[W.D?$^1WG$*2T.
M:Q,ZIY$\0]_5%15^D0N?X"IEH$"3.B!%?$ DQU90(IFCG0W%ZY+KHPU*65#*
MG-2Y<L =<Y?*OUOKD.% =<'QW#*:8][A7)7Y4AD_E4/79C-.T^:*)<-G@3>:
M@0L5(HZ(:@UR+-5-,CEAB%CO(V98N>X5H[BWNW+K7N[*1S(_(N>/&FB&+B@.
MF>51QZC!N)8^-2_E2*=ZC%;AW.3!VSQVEODM->9HUHXX*'<GM8[G#V%935D8
M@G&* ?PU5P(4':J [UH%9GX.%F+$UMC.7D-T)47IP@L,C*,8;1G7I$1?93 ?
MPPC$]DYLQ_2I2]_IXQMH#O)&(P&\"7$*_[(I3M7Y5%O1&^%L9R/+;W-/  >*
M9762M(3-<MBZF2:LYD7[DXF>7\;I!=[)4Z62B89\%#GB(@<[SH&VFDON##5"
MF ZW/'Q(<;-=.*DEMR99:*\GST%G# ;%I/'#YZ1,6HX4Z/Y,2TV#67H(T;-M
M/G*#00,#=#<AQ?T*0$ZJ+.):<T8XS7WHK,2]5Q&K1L@>EP._?7):E6=MDM/*
MN&*-P9(X#3Q#ZI1T3Y$B3",GA<P](SB&SDJ@A4=GKZ9J:SFF7FB!<E!Q00I$
M@FS@#JD@/9BM5FK6V3N./L!^23U4#27. QWG.>%@_5J?A(Y!1'(6;?3"+%_R
M/!0G5JU7_5PS7R#Z/BBE!@!Y^9;I-UME%9RIEQT&2.=G4O2JW_-13,I9Y[51
MB."4X\^E1*#^1*255*G 961A%7+\5R@M?--4U7DQ/-H+IV4%C&SC)-5G[3/#
M%^HM)D2G!#8DE4\W+!(CS4 (TZ")HX$'T5W[O0O:TW**NV&2;E% Y'G& "HD
M<&0!3(A$'Q23RK'0N7)$W\ZUF91CG6HA!V$IS8X[H,<J'SGFTB.<:GOR5/!8
MYXH@,*%C3J2+UG7V+OKYZ_@L1X^46!@2L4"6IM)Z3IN4X)=:6P4;4TJ]$;T>
M.4_EC;W@PTGC"=UMCO\J;MP]=JL<5\L/&IHMN_"=H*'9H8^*/A%>B\@X<JD:
M &=,(!URC*0@-J3F]KJ[T2?/6/%O.;H,C4H%[#T*)E6YB8HA(S@&]DO@#T*D
MZFZWC+D:6#Y9P\J^HN\S2"KO0(<,CB#!4RWJT 36!(6PRPT+VD;J.XN^]VP#
MW@@*EY!W>]@PF5"OC+\Y&!%8]&#XZQ26X4"U4#%W"',AK57!,=O9^/JY @YW
M3AO&,CR:A!8N[-+]=O8UBR%MI\=R&<C0@<P,H2+7>5-B/J8.7H0AE7.+"%!W
M8%X!6G4V,JM3T8R+O."D.&=&811R#^8!Q189:C10,Q82,VYU=UO==J;ZV<-I
M:V'>66V")\""$1$&(YX\O]J[F&JI,RL)-0)WMI?-_1,RIC%O_B"XXV$Y*(^^
MU]>A,P0G@^44J H1XE@*3_5(@V*>X"9='J-[@H([#[:8EAG5>%E)Z69:U-[^
MYRY1[>)J"FEA)9ALR.-<(VZ :E-4*Q+!&N9$%,%U]N*WM]A6TF);I)M>1QPI
M Y6!D-244XF(K. *44(=5L)3&SKK6[R7Q;;$@M]+NM:2(IHH.,(B29G4;TLK
M#>"1UN0\%T:ISJK:G8D/79)#GHFH4VJZ)GE /% #"H#-D6&$DN X$Z&S:0WS
M\/Q)A9"^X=:S,?L.W 3:H+Q7)"(7G4!<I@M<KE03X2RE 0*PG>WHT0>+K#X)
M+(=U.^-SSQE'-,2$U58C8Z1'EG(6<NV(IYT-%GE^!U8'O"2!B=S97"$?<I+:
M71ID@_ HY%0)Y:B@N+-JT1T!"@T4-T8'Q^$/4_T91CLQAB<0+<]C,^/ ,&6I
MYR.W&/'H,$JV,LJ)HY88PR3K+!$NX_YA-14$T'5Y[E/+9E"#$6=2@^FHP521
MRD:NG)/=C;M;M?#F!=#Y,X261*E\,,"<!24Z13.D$";O$*-@S1HFB**=O0Z^
M T.: @NKHO $Q?+<85#>66K (B-#)C<6!164,91X0COKX.EL>N("X4-R'S1V
M#N4^I2=23Y!5UJ;T4<J%5]CEG:U%\NAV4_>0NF>A'J7EW?3LI32A"GY]%TS2
MF-Z#]50ONP[;M>95]T. ,6!U _W/ARF0^ *Z)ZUA-1%#\,OT^>D/T[_3!+=,
M=@IC;DPV61!\O.=L]5_QYM+&HVH]_7#/N?;;4[Y]IY,?[[N\=!U5?V.[[8_W
MG/%S[=,UUU]C>':K+"]7ZXLSH);9)SZ-3Y*"5U;77U_4):<D7_^\__ZNM]]X
M/GWY/@S+DV)XV[3S'/N5Q]]<7?G=&T]!KV8P^#:$9@;<]TP3 _>-MESOQ W8
M=>',^W(P,%7=7"AVZ)#G19V''_1>&(8O9M"&IMY^U%>&W/>P]]_?F'3.LX(_
MBJ_KL/%R7+E0MW\>!^,;5@F[^^U?LNR7TZP>G0] S"1NAHIA$B'K> W_V]L(
M' [5Q7^'=0)_GX[>GICJJ!BB47FZWGXQ*(8!'8=4JWJ=K!'1/A+-23$X7S\
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M]2#N,(CGD;G_,/4QR,Y1.7R=O5_;7,LH%EPO#:SS+.F;8)T<=)(!Z[R!ZPU
M3U6!"3#(Y>N>$OH35>5R$3AI*W4Y*/QT?-6\:V87=R'+$ZH#"]0%Z(LE+#7'
M26[M[/V1W49']YSG%[ $AN6PL:8*UY@:6X=&<$FM$"@8XA /1B#K5404_C&8
M*!NU?I5-_!Y[(3:>+DM3E Q!S$F+N$BWKCDCR%)!C.'&4YJ_RH8F^;%\*-;?
MEVX\]?AT](P)1G^[8!97SNFWA7&P&V0TU\IZ'O8R>!A[(;;A->J:"X5_2E?A
MV<XP_+PL=> AE#1*,1;7? +IC4 QZ_AM\RL:F/-R/%J/Q=?@WWXI_.@80-O
M>O* 2RZPTSJLU^'4I!)7\"*8'&:OIE.?%771AM^M3T=/!L$H?V%[-I/S-#5
M\<W(?V.$EM>&P(?J^BLG&-:>RLUW?0<OOL#6D*V"^7.]^3=*7UPPDX;AP!$0
M7 S?-HW)G!E,D! 0_6)<2]/3@;#@;]'-O7D27M-,TH4[GNZ'3;=*4Z6B,4$9
MY"2.J6F91<J -)5:>JXM(UZ$14G3C>%P; 9MB-FKK"D4._KU50%;K(,#^B@'
MU@P&Y<B67[O)%O[]7W7.Y=OOB%T@UENIH<,XK)X-A3L"V8U/GSYO?,SV/NSN
M[!UDNY_W]C]O?#K(#G:R_0^;!V#L9X1E.WL9$3_YG[.=K>S@/SYD,RZ""_?
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M-X;<X7R:X,*"O$_7#/06';YAH]^"'EVZ=_^>>O%P0X19:X5S#!F-)>+12Z0
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M*K<2F+ED3F/!K7(W^?ANHW)O#4HS>@5*?='.]OGP\_[[5UGM3#I8^0IT!E?
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MRK:WMYMV=/4I<-4X*>9>M_K1Z#AYI:;#UGZ^<IEXW3X'+O(=W65Z&3N!'GE
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MK:9R"<"3Z_:OX ]'JYFI-14H>[.;NB(]#BH#MHEK?GP]"<YOW5W9-KP5+!<
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M)Q%].+.J_#\.#O<>N]^DN;?M-QAOVYU^87=Q(?&RC$OUZ?^Y< XV VG"4B/
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M>R2 /Q\)0.KL/ZCJWFZ3&E[M?QS3G;'^\J 1'" ]<DB2[,O@.![O/7[\9]_
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M1Z[V&D0;/T'H]#>UOZG;NG:=&0G<4BA+_N'E;W5Z%6?<R/@ ;N?184@.S,6
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MYG,Z V_)X.IYY.[:^:HF9^4L1? '!:8D]TBCC?O*)(X)S3D"B] 1B)D?Q4&
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M!+BH,EBOZQE:A+GA28890#\Q:@,(JL;%#/6_BA?L)C?PXR73P93*HQH+;04
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MHZZAQQ,R4 GAJEFZX+@:K,M@KWD?62BIO;K/F Q2M2I'1B4&?XW>.HKSCV&
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M'+TH8!^3''Q?9_,BQT^:^-JY>/]V=RW]99]0E Y0 RDK(%@TWJM&YUI^*U@
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M ,2PO9%+&V+RLL@R[CGRL$QDM/1VQ_UYARX'VR_IW9U"G\B^?>.N:\:)FZQ
M-_.I=@#<2&UPHT7?UO5)"09S$S72US-)H"]#0@]%HY5&_*EPBERY>@9;ALU/
M%(G;8(C*1<*MKX5RH&SHM6J6.(Q6VJ$(D<![XE#/)X9K89O=F7-RD+B^<TFV
ML%F6*RU6)]U.&ZP-6G&CY'0> TX.75)QB3'K!C5:,X7<VO@J5S^E5RC@)%GE
M?_.^*!K1L[VN5,T?>!RC_A[?_1XWO?G6)FMMJG7@]40'WQC/2%T*&9CTIR(2
MP*"H[D_QN 8+V Q\.:VK3!KY-A_C6VC!HM:+B@(4$RVELBVLMI52:K<*5S6L
M5<D3M":Q,<,?D"]_!G6#6^V?'G-&:N@R4AQ?<)$"I[D=#H<P$\\1IDE28.QR
MA-[BNCD+Q1='S\Q<JY70'K=FRC@6[. W4D#M*;-E(M;%UCHFZ3GA$BS79"KU
M4K2KM,G<MTQ#*NHE/8M?1-=G8?@.\1]8/BBGWK*!V]*P$H'HI1Q-EFC/16.D
M]7@O>A\:<%)\7;5.X  44C&8_! 7D\*EW%'[H5LLO8HSC^O@$ 1F<3:1M05L
M9?<+(-G6)NAE//9G$"6T$[EP+G"&1?,,5NG17XI\*E1YNB1[T:EC.!VL]<2U
M!&O8YNM#('+R$XL;(;F2)K.Z&Z=.6";JWB8#[5S3O>C%*JHKFS!J*:\)$\PV
M2],&H29=KW-LI*A<Q[K>4=[KM99V0;'#5!=%X<Y3*D>!CB?"AB.=I&N#SY 7
MU#BB7A@,MC>5[S]$)PZ:=6,:- !R<N3/XUG.F<A!AQ^WX8MO:3WXT]I%<N&\
MQ<;S'%MHVQBBG_V)9??)6D?R_#<GK\_.AY?%+^NF4@#@<LN XY_5+?$=GKW+
M+XAFV-:R9M?5>L\3.J-4,_HSXSJZFJU<MB_MQN:MTS,2G@B9Z*=%A7.+Z,W]
M;'R<NRZ%QJR_O-%M+<K];5CAWSU1V^F[?YR?#0^>]7+DOL(]KE3DGT7Y\2*>
MF,BNL0M/O@>C:#SOU_S.6!YMO%^WQ+:5?."4*4O5N%R2"0"I*<8=;=+P0YPP
M$[7GQQ/.:/2_KNVAE:8+V3KIZ*C&*=NDY)>$\=E/"XC7BJQY9V(XEXF$K/;O
M>%8^\F;+F"S[>LS"VW Q @P,1K%">%ZH_?PH.5<<O%+TE$UJ7YQ\N!B>%O\8
M'D;27Z] QC7*%>Q*B;\F%5[6N]"I8V7"AWCKS/:+I!+':I0V-0#VI>Z"8]+B
MY 6/H^G:BC7G^Z+DZY>SD^CEKR? NIP5)>]% <*7570P8,:7@?L3[T3@X@7
M/5RZ8547;':GZR(ZNN3=G+X^/V$G7KXO[%6! M3&W4M&4!\7JDGM\KQ'X426
MQKWV>Z#YY$=]/ODAYI.W7BD% NZR "3*R6A-9.:1P_"]461&+X;H;NQ*1?C7
M#!R5.>-&C(UPV$BYZY?)V!/Z4A8=/A,QV_N4=\VLBSL/S9A+AZU2%##%65U:
M'&U!KR._4=047,<UH^3:P(U3WC%A4F.E[S5]8$#4B&W_L_6E4:DAM\JU9!8.
MND)JT\-B["BI'0[*%]DUMS1KI.X^0!W$BW1B\90+XWCB 2ZE3L1:0!5YI4:_
MYES38J&1'5D4]F;!&S%W)ANO3&GF@/G Z%)VN)GC,T/Q-%\?O*)9)$:?/F20
MBT=/-3KC0\/]#;DKQ8D+ ]]H9KIPG+6VHDW2M>(S(X? >/#?.YGT_:;>%;E
M&RSJM=W5 IN*'3!)])3M=><=]!&JB8E)'JD\P/6T5#3B/UW1HB0B,S7=-0AR
M02I@N:6^F"RO8^4W5>P@AM&?6\Q^B:D)B@_]AA,/].@X)+)FN%J&-.4_QPQT
M8_D7BR!;8[P#HJ>1.7+'69S./8PI/;E&!HODH23\X\H_CS[C8W,KT>I3 3A=
M 4\W'Z?&2[G090GD82CTR'U1RAJ?<BH-IP.1%M,()HV@5@4$R\"I"EUITU A
M4!SILEV1I'1J#=',%5#O <:J0CY4?A8:33U6]WB^O%KX3N.>(]%JYI8AJ, E
MB4O>Z9P.H!1UY.#M\,AO(/1IMT:YS;:%O%AZWNH;]M:.L>/(AJ5=7+H?5RZU
M&FY&^S2Y,\G(3?FTL$5;7-\1H#@!:*(R1CBS:U:?O73Z:JQCNMZU-8JT3X\M
MM2H2*_QO,+:/]MD*/F"Q-#+3.+?1H["P\&)<XAR1G(,I%)U:O%8Q;9JQFMMW
M%A\>'P_L?P[^T%7"BH3E5./W<5610WA\]%.H>]^:FH1=)@&8D]"7X9-<,4-N
MR8DI[W=HY$1"33CMW,U7U25=)LB7/'QHTT'BY78^2XZ8& W\Y>OSBY,@?8<E
M9S2Z)0.A@RZ&?:D&%6#76YCD2P*('UZ<6431:@$:-IL)I%L=+( #GM<*)LZH
MA/[9%>D3UQ93>JJ7SOA7?Z?OG+QS*D.">K>R\'CCN GGWZ)N!5=UK/N)DIZR
M84Y8>%/Q<7)R N2W<QO-95D.&"1FLA:],8(99"H+"PKD=(LA*A5$?.: $BW!
M2BD1Q.+2=@X%8]3_NQK/BB*S $$21H[&Y%/!PS)27"T-9(Y%'D%+KH3DT"O9
M!P&>:9[3_N'8S@',#)48A,;%N'"A=-<_+.A0:;Z$"X4@QI1$Y]QQ-''(F2%Y
M0,MJFV"DS"=HT0KL!9@N<:ZWS^K9:Y1JTB$AL[$]!!_97C(-0[.PVCJ-!1?!
MF%S'"ZT+60,<R$:%M#4A _PE^_P7Z32Z-."9S:V9%"]GF;&#IA^T=-JB\[*0
M*^?6MK70L!KT(9>9S8DB;RJ7_N;?9[IMLR/9+_/=JR,^DPABL?<Q!Q!]W,P&
MT5VZ2DN41_$'V]S+N#*!MK9Q3VDCS>MQ9EATI<HW&P8\\=7/9;2DQE!![!K/
M9GC9&YX/YC:%AD?EI)0>\NND\FM!HJ  '^NN5?JIVOG>E0J9F83^KD (0W6^
M^&+:Y<K@L!RUM76;(3?OS%:EM#I&P+!:,$8X!%LJ33QY]!LVIAE%#A>N"GAK
MK)G#]%-V;28T'EAB4]D3#8)QS*[('38#BW$?I0F\WR1Z=ORCLLN-5]$5??71
MDQ]Y1+*.4I ^_FE49Q_EY^2GZ,/EL%'8A47@#F787?RU9HZQDN9I7NE;5,%@
M.036-Q('F..PN3U&7, 7YQ5K'T;9B';^<?EFEX<PV%Q#(V$.68=[K*?Y;+68
MU3D=-6&DJ<K5 MN .&=F"\LV!C#EE'>VM?:JZ=Y4TXW1RQXEXNO4TV=#P]%.
M6T61:RK^HG)K.S]S=TU)(:(52\8N97$4@I(&,MR3 'J.5'PIB1<L2+N;B=8J
M-+XXE\<ZJ8'*7G0YO8&?&T]C@-5X'6I+'$2/0%31(CQ[^J/0=JG"L+]^]J-V
M"S$ D>#CX$F8% N0:C5?T&%"UR/> 9^?P3U3]O^A6&4CT J0%<VA(8Z7<BVX
M119R4Q8E.EEK! F^/69;O1*'?>Q7G1V?, AQ>RMDR><([Q@&.\6V0S&.%U6:
MA /8.9^^&D3GTS<\V/.I<+C-ZCFN#J/88RNSN)K'WE((AA94B!Y%\]<!AKTH
M(<N4\GF-YQM@4UX7*'BGL"HS3X<: *=?K@51[JS*UC@0;EGVW-).FU72%VB^
MK<59V-ZJ4':A%K2J<WHHH)YI@\^\KWZFS,NTW&=!!!\'TQZV"PGY5=$+#7WT
M>NVK6_,YEV+B1(L6PZX3U^HJ 29\DJ,Y0PGZ+.CO3,?'?6HC$V)F)VG%#6D5
MAVM<?RS?>UJ<8@Y!JIU#8S1P2J:$<_ND6N+DBN0>$\*B+TU,]""NH[%?'TR3
M_AK24HP>3:^ #:I-G]JB+JZ5F])>=)'2ZL2EXV3Q!06^[T8/G@VU#?B3H[5C
M' PM\<<X:1UC!\)MC[%]+!/]P5R6 '9P*4[)93"?&H3F-*]/2\,(X#19FSR3
M7KT$S$JV'[:Q0W98-J5%<^ 2C=+1C\!;J\M<:= 8[TUVU"Y&.!W7W6<QV_\I
M8%?3'(D([G?N_)X-D++:8'D?E"U=SU:<9$>($YD2A"4-'PN_\47&&'@T:O*H
MIAQ28RAWKG_)_+3\/O#"!,E>C.%?@M753* XB"F-&M(__)L? N3W=LJ:@^.^
M$/(!%$+JR7Q(6NRR0,:UE-Y88[N@M3C,VI)TGZTRLCR6G&.AYR1E/0U))&#N
M:QJ?Q!!9NUD!S $(&O8%+-8))](#&(@@J(3BE)SE#A [,3?2G2-AAK8-V^$P
M;@,*H2JUS9/14-6!C%5X5E94#-$2F-YLY:ON9#'+:1>?AV+OIUGNSG,YVD<>
MB2%AI7N>5,QX9IW7L.8FL-B=FMNIC&1E(/G)[BBN=WF%XZ"(T*HWCOR9!??:
M F.&+!.I</22?5D4F0PD[+C@7X3F21YGJ\HWJ2M AC"0-722F=!7E\PNM9RQ
M^7\=*C-IS.<^R0 <T+YGX+4L%"C"?%GL"C9DG=QDI;"1=R[4QZ*Y74%1F^!K
MK?W"0JXR.H;FM@/X (7ID"*U N'3AC$6 L<64G.0:N2SH=$OP9[MDU\.G-=;
M#D$)I9V.T6"W0A,PK-" [)P@@Q=0G)4F=_2:>3T?P=2;6!NATMY8]C*9YF3H
MQH B)5G'8,SAIFI1A46?0KFJ #,ZB,1\;I:>!&X=E,K.T:[B7W1U@^F+_:#
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MWWM?FC:R=J809U"6UZ7%F9'^<V_& ,-XR38E0@6",4",I.>VQ8E%^!39JNK
M]U#4)9(!/HF(ZN(:.2.V(]H-4OLMCY>'*ZUEH 7D1;'PP$7A>,^ >/#R]/3T
M,#SL./NN9)Q!)?ONX-S<-IP%3QD8S86/P_";ATLO^LFFH7Q72,YQ,\AP>!";
M58[G'L,6_]5WI]6J\Z@)N]OT'M F@4.]WW*CW:WU:6QA[+0E<\Q59_MZT.T5
M143+@MD'O<#.([_([3CP(",[EQR @BTK<].J3C544I3K[WRT6.5'3NVQ+C=@
M4YFZ.SV\NU.P^!>%(GXQJ0RV07#'>8?("@V56^^OI<FSYWT+PP['[[2K@.\H
MK2ZNJ+O[.-"*4*+O_"?8BH)EN\NE='5"ED0+RC07:=5!0WPA24-"H@8,&D4[
MNZ7>D?<)\46"RPE*U**=J'=9LF1N,O@><$CEX@'[F3F/UO5=./FSESZP/,WT
M)_5J@U(N[HVZI-[JEI9SNM6,(KRPCA2(42(D;GT83A$2B($K!D:>\.9N/<G_
MBA-4(+]1#7LA(3SA[H39$#</"*07-E(C"7*FVD_.ZYMMP29-D'344$KI9(3X
M4(%?_" U)KSXNK-^T(/V4G]."/33HH!%OZ'I<^H)0>!$VF BG+?0]73)  #5
M)NDRDJS7;5.#I]BYM%O_9ZQ+/#Y?&H<MD-RAU"([M:U35N-7E$-@!J8<RH6$
ME5/\%\M:L.3"<[5Y406RT6D!/DD\]?6(<!JH[ZRX*ZJEY#*#?%J26GO(ZRNU
MIH((P.&*#E:@]%9&/VDI7VF[%#K_+5%X77_-]NS"&HULKD;L6-N(^ %D1+]B
M6M(_0_$AR^J?;MNPJ+'3CNXW91V:VEN%<B?^T*"U %^3=A?0HIAQ@\SW8/<X
MIMB&\<EMM<FLEN@O?8$"Y(VE\G#5"^P*R:O2'W:;<1=[(BXO%JQC >FP5-,/
MQTRLM#=\Y6G>9MK(0!?/%J'30A%/B^C51\/P=NBT&0+-N*,M11X+&TY":9OB
M5*;C^NO(2Q_:U_S!-*\/%H,[X*Y9<&5]\Q_/U[&-B@?3H^[+^]M2.R2D_HP=
M_A^*Z[@,C,_[+_A:48T)X_9'[Y$I15;WUAYI1VA[3I2!7<<OW+TSB!!ME56[
ME0' .BX8-X,P,O]2K,ITM'^EH_W=3CE^5'MD?=6<*7P>K8Z$QRV7:-'Q:44^
MR38*EE%T9,)A 2'RCI&S$_F(Z4_BTN7H0M/548&2]&7S4!K+5L[#ZB=65PJA
M,WA6&*W[(;S/2847D@0@GMNZ #($FMI4DA10\?B1-HMOP4V4-I+MB$'CODBL
M'@-:R 0-?#JU2G:L0G'LDD&<6INV[R+")3-^+LF*ZKZ_^[A!3&'>!X1Y1RI%
M7WGJE4G@/#SR*P@#G@3O*>5#]V30^4Q.OM?# 3- 4[\9+9=''Y6C*!5[]L/%
M:>9,<^TL.5)Z(FG9M!#^#'4<@@7P:;Q+GP8[.#N]/ 0W#5J,;) KPM?^-\B"
MA,QM%-!X\/?_OCI_]?VA^?=K9)]8O(:O5 (G]ZR+JU?9R=//OWKV#;J=.=NI
M($M["%EJUM;'-%_'(!&X*Z]#>=NE CBB='/@??+3@JAW@W("R=DMU7+J-H%@
MR8"S,DXGO[[)SMS W&/KJLC=Z-KMTGU'[L1477?;Y5W!WY/7Y1;YQ8L.?R=9
MDC,3UV3GB7*?49Y<7$_F=]>;^!H9A"(Y=#N)5TRSC;1&6Z/F\DW#F+GV !>5
MQKL;1Z/O6VM_@!1?N2D4X$N!7;H-,&?HS>F\5754]$1,@6_)K?W"N8XZ6?HL
MZU406+.242;=8[Z6>KR0GL9:H$=--B^V:A5'F@+7>6ZE\/:=8H6$L$M?OOL2
M,F*@BF'1%K]6*<,?$?CY9 )^3L#/WP@D'U(+>=*5E^HQFUV>7EVEZG)#X)QO
M^*'V^E 8-B.D, _3H6"G&2GLK+2@U.G,HT1E4AL^0F68C(#%Z0_2<Z^#_HK4
MEE+.J4:)^7_V+<;H;)_'RBYH1U%XR5.OHW8*HECWV$UE,?^G\X$VC*L\*A7X
M[/>J O^ DNK2[[5*"T8#JB&3RO 4R/A//=$DM)3FR(Q$NB'DP=@T.*!!-6-0
MIK +$T(N-4 -:3G<N\CL@3_<M!;95*)1AA4LMSN/D(6/U?1YS$[S54]@^MFM
M6X3IW#S816[!:DI\>H P@O#92;N4%K!2*#YR7ZS>5\8[*R^/;HIZ@O2&0W=Z
MKJCJ4/[<F=#=H4VC&@BQ0?]<E%?J2*R_LG1$C5HK[40*I4]I^<Y2<U\\R]@M
M'8U A/ 81U/@J5W)AI0+-T&BX+KDJY:-K_Q[/P;LS$GV@MC<F9, T@8VF:I
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MKGXUPE!/6$-1&9^R/<0[2LTD:BDB.@U,LOOBPI8Z"4UC ENKQ,<S,M\^6J;
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MR+)]PI(\5H7ZJ.&8"B:"423F7F3E_4#T'I;@=63.3>KED]R?>=E5[[+O $
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MT:([,7'2$81T*_WU9^X(;'DRA35TX$G%]VBKES4./0_/JMALD R+Z  6;M,
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MB0/_-S=#\V8EH\$5D64Z=_:$:,BT^;@O0\;TY+ CG8(4Z?/CWZ1O4:0(J=B
M]^QLK10QC+5AUV@QB_%RX*]O2BZ/0$+M/$6F:YXL/6:-_;"6/.8J+9__:"1_
MD5;?_>H!XDJ-*<7&)XN0FYTGZ<#$II/=N)LGC"J?=)EA0Q3+[;_<1F N3A/^
M"TU%[&;\DS$<AV7'U8-/V;&"HI8:8OJJ>1]66M,?.L,X6!(P<$L7Z,D&QNV
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M#F$3'+^E.9A'0FWI6(_=UNF.FEC$]0V-(=XFI0L628T^ZJZ  D#9[3KVEH3
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MG KE<=AC>!VIQ];-:K#.@'&L.;&(HNC-OP?FR)#$EO;0N=?+A)B??K(I&4%
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M6?!KVPOWG7#5H6;D .N!%]7F#-5_/3'NI^17*K 4$UE>H M4>VWQZ=C)?F4
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M3-_9B4?=KF L2XBVYO4_K_^[OO[Y0.&D6[\MV_49X#@'HC*H2DJE.1::<#7
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M'Q*TTG37R[@Z=9FW93-TDY4IDW"^4;_-A+>5G7:W1 .BVRXVD&,X7SQ-VVV
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MQ9+$/F*,>@XEYHUTYS?2-1I%UL4UUE6O!FH.!ZO&H@=-$WT=X"NAHN,^6*W
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MS]3QTQ:Q?_@8Q)AQ-$$]=/R9(-*T>_(&$*?,B [ > U778>H750$=\DO&\'
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M%H)P95?Z&^=IK7&X&(M7LN V+NWG*D0)Q-;U@8 F(:^HR:#L![?$5>."O3X
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MY%N!0;$&8!3%)2;Y*4EO1DFS.L[)\\_W,LYIZ3OHM4F.> ,[X3H>A=I#YU<
MTRD 4#4XJ2)-E4M99,LVS%MFH/(U<6W*BI)#-N&[3WNF':Z0-9\%'D#%7.:;
M.W!Q,9BA$*!<(MS%N;[:NH(:_#YF3_\/E_-H-^Q!G4O'YKR ;E_7"/NS%D0E
M'2U*GH-%%,EKXLXF7YGX7Z4*4J3\Q6%6.EIUF-+8E5;GNX(DWEC:7.)*(A_
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M]U'F[8J0"QOYK6:=8><O<R4U_<=;T&+'PTW/3[$A88^5%4G=T%. IBVLZH6
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MY,E7#Y\\^.+!DS]\]<>'7WP1Q@<5]7>/'CQZ9#5U-Z?I4]W5L?O-GR)OWH<
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MG]/7![5M.[YMTM#+&97Q@\83D!@]R/*U;/()\A%>X2(X!F?+PYG^-WMN. ]
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M3D$5N *42]G35D(VPKTF)2?>K<:B$_P*(M5?Y=TVS$%#;<)AAG?^%G&<K*T
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MY<VU'=>H3$43@\K$M)Y]*.KD!AY"D5J*8",S/P9*8N8N2%>EC6CXM 03FZK
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MK<R)ZX#55:;'TR4L'*V2_O_S5IBWPGU9NS_\&;' <,QMO!$T6)PZ\S&1@U/
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M>';PU?[(^!XRH8Y=_ V9>G2K$B!S*4N-CD)S.FZW>N _E1Q2.X5N,V29,N<
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MX =^5#S7-_KP9Z)SHLW"8G Q(UN,:\KF[TI@MVXG294F=Q1VT>(?E]4V</4
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MCOU3;:3MU#QR/*C1"!13++CY*.5/D/\%2'\GLZ%.T#JGPU8R!#O4ESV99ZU
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MAQ1;Z_?IZ**.$+1MTD2A7^W09ISWQ;PO/II]D>A-ND//(ERS8M9LP1^!!6L
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M@\TK^X71,),[S:/T9-0CF_OAV7_^[N&3\!JN,+&]M%>CKT,!L;:03ABK!YY
M?9M"(],8OWY<5 !XW^H\!]\-+480&&/)([S\\Y/XIO8M[.&0_+ RI L!>Y=N
M366FE&*(Q6LJT9PWA6Y#2KLGCL^97X5!P7HG"W<G.@']/:W!DR^*Q>,O/_]L
M\8"^"-!E(0J0JSR<NB 9Q 7SP_ 4R]2X@=J'AW66==047Y"UX&4S]+!=K)OK
M^B0>>VO=&_)4)_K6Y09 YB48YLEU+Q2]GK\HO$[SG?,(]4<Z0OUX'J&>1ZA_
MB[87>;S\$%8)BK&W1OPIYV4,Q?#Q0UA=UG3+%SCM5Y=T\JR85U-G-Z:OQVX.
MEV'FWP"$^UNN4PM2O"UYZBA]ZI\]8X)T"%)#9:9!])'R K3P4[?!\:9BB];E
MH91XD0[A U;*<[]W_1Y)G_.^R?>NYCGL]\"+Z['%YS>0V9BLX  0)V6<$/SU
M <KTY%YD/#*3!Q41)(H8',XLOPZ&S&;ATA8*I'I,@ GY,&RC$--E*RH<5HV9
M90<3DWKN"W8-EY:A+'Y06P%6FXZZ1=$"10Q;XL%(%ZEI)4L-F_SP!>@HF7:/
MDJ(T+[BM-O3N:.%D90O[P3[6H%N,AY)A@\UOGH+X,/4,T+;2FVRNQ0TB!U$.
MH\0T'=.-/3D>XWVJ.C&)=0_Q25RB])C>E@)H?NWTR;!U9D\Y2\-:D&)!*;24
M"DK*KY72 O!A'X0F<FK>*8,LSE\#HX"6K&1%F$10)9]2[JF.*Q+ _C=KH8H4
M*Z7_%*1]:23R-HOIU@L-0DNYL'CJ'DPC^73QT@)[X?2B93*92_B.II%QU.=M
M?[$XRQF^7J4BRXN:5E1^RO*N].DGCQX_63R@]_GJQ1DR@L&BR!@DF%6]RIOL
M65$J'BRN2H]E;]-GJ1A*2KF-I9P\FAFOX1+9-;(4-S.59:.CUW&ME'G',HG3
MA3PK"ZM03K1%C4L^/_DT>WI_3.6X9/[SEF\?X\#NX;K,VJ:O(GM!>?D2?Z@N
MB,@PW[XB:7[.+8Y\\+;'S9=N]GGOX?/D_:3Z">T ?[9I]<;I:]#Z7QPN;U0Z
M0\*S@S#.Q9IPJ1PZ2OB/%)G>PLTTUE =:ZK=8D9>BJN^ #E/],QMIONX=G_X
M,X\FDC-*6B?KL"/;/>#$5!_7D:_J-CIT[^@;5?S9:7*X24NF_I#TB-85?-%\
MY'$/I1.Q^6;M^'@G6=<14_O\RI%AQ! \8\68@0GS?KO?^TV95#&#G@6,&#77
MOJ!,V%F>A+_+M&;RO,\&_0=,38#Z<)U!M(KRC\P;9=XH]WNC&#9-@C6.XJ"2
M9.HY&G/)T= ARFM9?%<ZW\*S4M&#J5K<>-/,.V#> ?=[!^ DB Y\RN]K7[6J
MNWXCXM,'7SX^PGXFZJ-6[9OWP;P/[O<^N#U%L0PB[HU$2[8,==A4AVZ L6KZ
M ^XG8K/FLV#> _=\#^0%7 4L21.K-04V!C)>"ZB0#P:N0HJZJ<_/$XYGAD'/
MAO]Q&'ZD\A74GM5>(_/:0/DSKU YZT_:P;%*M6S62I:I%&^.$%FTZ] &JR&U
MPOS%1IX>CQM$:.D.P#)9<<NUR^,R4=F;",AF//>'ZG\RJ%&$HI7PEE^M\)^V
M39E3S>Z;Z\#2DC_DVJ]'M(;=R\WTFH;T^V,]85'PN='F.+2?O,JY A+Q)Z9@
MTW#_%=-<IN4[MP]F]WP?U^X/?Q[I.T]H(?;<"=@RP[+]1.F@P<?'@Q9,,'TP
M6;#X5RJXZ!04"Q"J2A=UU08%,HN88M1/G(/Y>=/<[TW3AGU9M86IO F!7ALV
M=&M1.E0&$:I_0:)\,ZE,/!OZ;.CWV]"5X 8#Z,RJ8%X<Y7D>R(T:NJ(!W!SX
MAY?]@3%B;/8ZE3-3,<S&?N^-G?*S2A!![*P5?R:,[%/$[4?FN^CC/*LVPD.D
MN33:/\-I-I%AW%$N:_ TT2&QX;;;KC9OK'ECW>^-90JZLCO>?2]U-MQWQ9CF
M-I3K&YGRNVBA)/L5?6PV_MGX[[7QK]J*P<(0D.K"JL]1PW/%\$Z+>M:9P#,C
M2I8-@X.G-$W>JM$H>BX#B952I**AH!79 *0PN:43M^XD('9E1+Z,B8OF4@3G
MW[]RZH]3JH^F3_%;"S^F^OI@Z68,^UT%ARZK;1C9W;5H,ZKI20]BQ]/;PFT1
MI;F&)>HI-<9;%7&<=+<[4U&BKL"$\6Z".:>+%YN1X@V/:H[U-G2@(GYM1ZYM
M6[9# \->U&\/,G+FR_+3D&/3[MF4JZR)H]5!U FC*[52(:@,S-*+Q8N?G\L2
MGC]_XV#(K-P!6<VHY22[98(]1)7)1TN>R>@60Y%=)R^SX=(/YIX@@<[3HQ=0
MI$NWI*.#(B.&ZYA<U$8$R^B)TKC154B375&QT(U)G"Z^?D/WJNT/87MP>_]8
MXT->CTR< 8('$UCV'==LI79+5JIT+'(U-4YNE<CH962__3 >Y+]Q5/_)/*H_
MC^K_3H+5XKRXD0G<R3J0&UV#$ O]&P_/@ELK(O/-L90M%3TH?A(=3AVNVS2M
M.E/F3J)C)1RMBH3ZDJ\G;NG6HH<<KRSGMF0)R578'Q)/EN:.:/CS0#XX7+CO
MC]FP-H@8Z>*B+Y$\#L7E^*I(*\>L.#J6YBL\35K.R9#2-:15^B^1=[U-^>_8
M==5C2[^.Y6:3VW;OCLSO.G/E<W1W5ZX!A '"WJ?$/'Y=8["W["M^+XM]M0]'
M\@P1E .DQ/1!H8B*"<4$>HG92@_K[UA^:60'IXLSD2HL<#NVFV' LJ4MP#B^
ML]]A9YXNOFVNZ:_;&.QP(,G[#C%18U^\Z7D\UE_W%JW+M_J,D3/@^S_J$!
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MQSF/&HRY['<PF^C']6M-'6Q,<4_^7^GE=^5K$1]9-ZM>R$<&%/WD.Z\O \Y
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MX621D),'2RA1[9FXZAT\&YE-/19T4>U1C<W+::?'AYS,I=Q Q6H48F<*-_]
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ML"I(<ZH&&)H:MD-O #Z 0IQ11!33PW'1< ZYFU  C0X_^D<6! V!(/ABS+I
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M H,&CE4V$$(BF_9C4&?17X-1V''JS5JOIE-M9(:T6T9=G+X4T-HE=2FL:?K
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M/QIUL37#.-!4\?1(&9\MLP(IOVPM2OI75*XT:F8')[E,SUB4"<BX8;FP&EU
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M,6J;UE7@E@35)OVO/<#!\:T*F*1Z,$-(*:)C,@TB/^?_,\2'$]5!4U;EVXU
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M\&O.[7Y\_L_O7L8LX^,Q!7:_\0?E-G)I"Z5%4>T9@\8ES06UN5;/$(20%A=
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MD!_'Y@E91T+E'A1ET_)'3B)M/(HAV '_P<[%AZEL/5B_OG_K42,'<^'![-C
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MU[1=PAA)%+$8<&,_:Q 3P[V&<SNEA/R JZO*!QKJT-0$_*D!"&O. )NQM'\
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M&#@A03H6-$(7KL]\]5U@3&@CQNV8/88.!"##:A,.R,1QQ0Y:?1O7(:D[JKS
MT:<C8*SP39J2"WKTF/?D2&$JJD(1(2&/0JP"7;.E'0=6QX(&%6>'<>,X4'J;
MXTW47K E'@(M6>%:WMK\"FQ$=O*HM&G"=F<HO4X,3]B9Q1)"(B,9<7+19:-S
M23"_,=H$0)@*!J% XRY#9OX0>)\H8&?PEX&;4698\_0.%E@9SR-A$S@,. #^
MU7EW!E)*T\P6L;-DP$1IC21NF)+;!7^LB,K3^Z!(5!EE36BS.FYN%+O'>J$R
M2Z2?)T@H2=-?D_<2TA'BVAFF;**[2B*FIBZNJX0> 18N80*8YIWV.0S4<_
MD[(!/>1R#Z<R%02&%WQU;HCW*PH SI7BMS#;P]#'H"PX)9RB@%DZ^^VE:_=P
MP8B&%+*[?BHVX"IM(?F 'PM#AFC;(;&A\(IA!IJY32VO20G[$.7C:5W#(3N
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M%<%7/<Z@A%OUVDJCB1804LKKIE67%,U!]+4%[0  "C=H=1Q/;]NIB8<CV,]
MG=R(RI;57E3$>O\22;5.[<D9.WTJ=OJK&3M]'>ST[.QG9W\7UNYC.GN<81LK
M72M2;A5FB!&/57.S,YP.<[ T[Y^[O7],[@5G%X0H1*HE30"#Y$L+?_Z5Q.T;
M@07\OV4=[1!G"ZC1AT0NP;3TKZJPS-MGWCYW>_ODF"?OJJ8AZC<1?1^>1=/!
M/PO!PU%4N!3["5'J,&^#>1O<]6T0V6L@PJL O* 0/R[P;5R1"8P BV:E]A&1
M?D-;I&E O*,8"2);5IO4'Q<EM.JY1K\RP#?MWD?MMWD#S1OH;F^@T^R8DQ9H
MZ,(LKM\:#KA"&#P6Q!8,_7Q^)6*<#R2!G!#>I#1LD&MX(I:L3^O (X?47.&7
M#.;S!C,\JBPO]>QM^DME*5,8UC7OY7DOW_&];)#HRH7*6!I.<?QF;)&:R.9'
MVLVB#0F'X6SKLZW?;5L/X"SJ7X9JPB:MMQ%^8=9DF WZ[ALT.^_5IJH:&G-1
M.C.=EH=&'/(W&0R.-N8C&+R/8$0))6$.4DNSAZ0AW5*GF'H_I(7F:<84X8B;
ME2$^D+=:F1$1B']1W2HURC3P\G: ?!^A8WNG\96???,#S5PL?H(9@K\1?'C&
M1-[:6#G,=:Y8<8)5:E81C27PYK75ZAV5+M=%!VZI[7/@@=D?JFYL,!/F)>'?
M@ DA!49# BBER^K2F9^$;P.-B? W;&?DZP<@7RF%/O(VD5=%N VA5.=_T/_'
M)8Y#(:4GP56G7CCHH!(K(A!?K:C3J@6]&8$Z1WUW<>T^^\8;>+<E\U[Y=:BV
M,&:2OU=)>,%')B? +.$B,<[2F_Z<R<];X&YO 1X+I-HLC[Z.D1[!*>W*#1".
M$94VZ?]L^%^)YE#*UXU4<_W![!>WGB7@YWUPQ_=!T/N2%HSIK P'^1CX1=:N
M\CPSJ&7> I_N%N@1@[/])S)H;ICR5M 11.Y)R-UV,+-/DG]0#L-1=*(? $$!
MRATP 8%S!56KZ!P9BL%!5245&DMOI/F\:^9=<\=WC3!D%[GL'9GKDH,DJ-#-
MUCQ;\]VVYE\[_YP.^($NTSI/E9@,2=M&*02P0%<1Z_@<_,]6_RE:/?"(I,A"
MUZ#$P'J4M0T]^GJV]M__C<W6_B'6OMJDB*/UAAMIUUDU"J3X(G+.-FT[G5(W
M28#$_0TG 8IKGW? O ,^F1T T%;D[8."_5:85H$8>>NW1<;; >1KW*JK"?*:
MEFEQ\ ?"#&V:C?WN&SOS5$H11M$IEJUSV+25/RVZLG8%B2AQV9-B?YAI<C6"
MQ+D0A')^X_^X[D]LS,BE#WRK+Z$@!_P*I-J2\%D-W7Q&S!MM%V*F?>]?2>ZP
M\.8?%-CS&!( =L"M4.GPDSXLX$#PN]7:[QL:E@[V ..??@_4%?)>5R7S4AXU
M PJ>E3/W;/%M7:5:("3Z:XJCU0!)8DLI+H, ?7L"M"%A7:T"F;3HWU.JSX_>
M8S( K]2.Z/L!VU"[MJM10.D@W-U-NV5P8!=HO5 XM0%M=1R?+>"7>]^8 2TW
M-_Q 42E,16G3)E!W ^(\:F.&HAM*T1@#!H+*O.W @H6N,G X[]$^S5D_V#KP
MOZH,C8GQ,5#SR\O(%,\6;\(ES*TLD6._-?2UBW55%-4>S#"^'&*D<#_C%?N&
MC,;O;P7A4UU!L8LMT6!S-ORTD/,>X106'DTB_=]T3"T\!6P,^T=^U7 2^W>5
M$E.S-,<:PTO,N$@2PF668@.FG/?&+4'ZW@QCUD"5#.Q>S88HOA&>IW-E& #O
MB$]Z675#/D*XAGR_K*)9,4#"%$5,R4H,B3V#QHBA3C.V?#A\L.FT@C<V6\!-
MO2.HJ<FRLD<2-%,$^>/N'@<.O6\@NA,)IWT\0&X/X!Y5D.E@VJMH%%%LANGK
M^!BOK =1*Q3K(?OJF@&3+=)Z\[PB<@57!7,$RS58&JMT^^(@7'7DR ]6<:PI
M0#FZ N\#?,/AEA%F#_380@6N-^</ ;W!R+9U,PRQL'A.;%)8A2)EF13O?=O"
MS<+*GR8YV)</9W*P65CY(QA6B"8)5M3U&,Q#>I-'@(QTY4]S(@J&8965#WJC
MOEP041 YC6U5!]5Z)F< 86($:SLGOZ&E+Q4=):V8O:@\VH"X"JT.\9CJ2D4K
M00+4R*/BA\#5BRBA/Q7XB8@.8CP208X)$J"E 1S0*@%O' 23!Z%R/]2@59'8
M DC?JQ)_%!>(;M:<+(N52S%+Y0/"?X# C;)V<CC(B:<36UW#%?*:M:GHES$?
M!,'4I8;W(7F5EP]_A.SRCQ8SC3FA.QPRTUC*V)2$$!6SA F$59GS=H YD&IL
M_"MMLO37Q0]%M?0!SQL'<,#%CQ171>R=3-\@%T#MP!X/?RQ<,%)S0.IBBGG.
M;BW.N)V%7-Q.X/$G/!].-T'_D>M:(#GF99ZQ1]DY'L4:_;VL<@U7P;8H-J-S
M6H;P5FX J@F9=\E-;.=GBQ^]EP4/B;E&[8@.&P1].@(1RM$D:8<,B[5PC*4J
M+2<G5C/ZDUSQ"$^V]GEHXR^'\3]X6W]L;+MMT ;F2LW+L?$VN$V:A:(%=JRH
M7>3^RQFKG@R_)G*)0T$-S3*N',;2PZK&4XB%\LX6KSHZ@#J]-;HQ*$?^Z_F;
M[Y[__Z1C0A5][R12/*1 ARR<WKU$SW_AUZXB50(6#SMY_/4FONG/ZPIN;48S
MQ9-C066UU3.W=362*OH;WK<;R8#IG[-G/'TNGVZVP*(EY1T:=J:,.?H"I?99
M1QC=9E40+H9W#B'BC0, ;:O1VZ#"DS? B9\5>5",5P<; 4N=G+8C]V3%%E;-
M8M(W/EQ.MB!C$0U(%*+D)V_K?[SZ]LWB^:I5[37RU"HX9N0'W7M00]9V8^V]
MJ5O3604(PZIKI'83C,/:F6U)DEGJOP7:152C*ZE"C94B3#5"V2E<&GRSOUAK
MI5Z4_A1B=W"I>#C03?D,!6BT\'S-ZZW_<]UT+-KTAL5CGCQ\(@G/F[1>IJ5K
M'KQZ7[@#+!'\RZ.'#Q\M[HW_^WU<0SGY:+5H>;#AU!5"$;0*9TNU:P/S_&NZ
M4?:T*$#'-_P*/#8RAWU;^3.2EXZ\/R ;$,0#BT&/5E=M /^D_C3U&YS7F9IZ
M^-FJ#@5]6E8X"\)2 UR(WMPS>Z0WW?(7'IT9<2R5?X0+_O&0UOG% ,5C%D!S
M94/'%/=&J ^C=J,RK.\/T3W 7^4^>!9= P!_,TA56%;E,B>:3F_#.0JM758(
M!2FG[J+BQ PNX.P0!"7 %_#G$O@^TM6F:Z%%=2"_*3*%8/J%H*AFP:V;1\N\
M"[^XE]Z_]^C^O6_OZV8,88_?: DF;/ .BP.\:2R]P$0*=CO\6X<8+6P>C2RQ
M)D(QU;[R_YU<Y_1=I2"P6J0L$@$[EV<LQ3^._>0"_E!PKSS\E:++()(,)_"!
MM'WS2ZBBA+;Z;$PW/AVIX5M0T*Y)B#W:L$ &;1 0#//12<GJ?.21X#MD92>;
M&,5<%=F'I9<_*0X#P=,KPS!NE@165;3'L7O!1R>!WMAM&A>NHNWYEL\(EC,!
MP<4+W&@G/7;#&ROJWD2D>/#;DP\EE3,-(?%??&8<%'SU8&*U2PO='OXLE@-5
M@]BOF?+W03E/I-Y$7QPLHQR/>N2E3<4T?89-B%M(5!T2Y%R5'N%>'#)*&PW7
M\#7 J0 *"$XGH_4[>"Y_05HI^ (>>7AVS6[BYFX"=X9414X_$,2S.P">^E"8
M-"<JJ(.#_=S+[U.9 6K[61K(J?SF]\$%0+W"RQ0[1*OU.Z9<_-?YV<,O%DM_
M:QPHI6798?Q[Z<K./?/7YQ\ (6>XP*_^GX', CF7Y2$*_WK0.WA?4"/4"PC*
MZI 1H&-+D;?<W^=_??'PX6++/^IO&"R]C0"S2/V\!-Q!^2#UNZL #>8&;\?>
M3]5_,N*73D3.&50PW0-<!/*U2>_9[:/#;_EM!6@4Y&C/W+(U]T21X;W\\NH%
M9P9W[/3Q/Z[A^<L2L"X-,'KRM]#O.ZL@_O+UJWF7?6"J6C35*26,B7SU)=2T
MSA_>6]^_=XZAX4\ZYK!X\^"_SQ9OKBA.3.>VQS,9D[GZF'%;0:-*N)W+"R)$
MOLRI@55"(+>O",N).00GJ6.)5<@8Q?],%E@.QN&<Y%-@C4R54NM[MCA#Y>GQ
M/>T#HY5S_FS_KT=/@U-(%;+F .:QIO,=?CDDDWYK5F4F=\5SB"CRXZ-ZPFU&
MSDQ^RB_2?YT;!Y1U@3N1]Z/+HH?M56)/>\:Q1[1^[\:/>+9X6X60$NO@0XO#
MI[G2W%IJ(L%^N2H<,N9$WGPB<M!@"%NQ6U&\F'W:C=&K7, D/K6<44]7U3UC
M^ZBAL< 5^/'Z&@J3AQI1J->]7!.,2PNI)]Z#T620+H[THOBS?*\G0,\$ZF4;
MVW Q[F.#I2UA_H8C&V&AFVWNMB3)R1=$ T^_=-G%5F3I"=7+XQXKB)? 7YD4
M;E?Y*V%QW[\?F#K")A0T],06J62)8U:LW7LI72L4MO592YOTQDD$QT*53FC?
MF>X=45-*@7(]-H[%XP-LV E?#ZZ,9Z285P2^F.[#S>;V 8R3_G)0^I1(>/38
M08D*3&8A6\!#Z(?GSU]+IMP8#+F*L :;Q;Y6W^ ,:L('7!V9,T1$% I.GH!X
ML16'3& P985HJ/\AZ^YOEW*QR<'&<%L8-!<ZME+[&G2D#FYR#ZJ#WDOKAH ^
MKP\P($GQKX]SC%5>K[HMU$I6C@L&!MQ/P1JL';7S@2H'G:U?);C_L)T)LXI7
M3.L:'PX#'HHRF\9!.4*X2["F0NE;(G$6,?:\A\IWOS#C;SS+J8:=AB(%/3:#
M^_V),R*5A?T:;R-M*F,<#"C;X7G#2WG1Y1GB ^!P</X8@$$D:.P 09#V[>WZ
M!H<#.#0:\XD6D@LJ,R3W$X7DGL^0W!F2^Q$,2T>0C#>9"D\D[AV'^,S!RQTQ
MA-N)E5\A#PQ$J_A6*LB&@?2%FLT^E,UW&$IH)Y@G!LW *K22*6C>NUI'1 VV
MC4]5PY;.;WD)Y6$\*XE^AO6&Z7PU/SF_[1MN^U=8=:=7FH3W?.SMNM0'7O ?
MF.5J]?GI7R:P?$@'2N-  D[!EO][#";]7S___.RQ?MG':M@>XPJ>R9GQ]7_G
M5FZ[]&__\7FR>/3PT7G4UDL8'&GO-V'$YP%LS<>;%PZL)QE +<V(E8V[,3!>
MK].\MGA4+"RB(5<-V&W;PLH$>,D8,**/XY$V(V)8HX6W4 J[C7S6N*MP6@![
MKKQWSA9O?3 .]P_!2T@YJGWI;VJ3[UB5B&&K E]<4UL>BZ\UXC$<I;:I!I'K
M\,+@41%(,PK0OM(9GW2+'[CU/^E0]I-V/;>NO@$P1^@'6N,W2G(XJ]T725TZ
M,M[!'*0VR >F^[O+UWS2;_V&>D/Q6^,.H>E3^.W_RKM"\/'>OS]$$$;?+L0
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M71!%,[,D$KGDT(4QW?C:\D>QPR)R?B 4W[/FD&A.%DC(#PQ5P/M]X?#:Y.Y
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M:QGUOU6NUG?&U?H8L@^>G(+-#^.>+N,"=ARRR@UZ=)*PT[@B0:VJ[JNS:'7
M@ZI).=!S*I.(JJQG,_DS*&$-89=OR+JW)U=Y.VE6"%G-&[%>B*OT"14E0%LW
MD4*/XT8?%2B#*6C\"=Q>&O*A'16CX<E_.^_1-[L]5AP$S0B >Y'E6/G1CB^?
M41/5&20C&/V(DI7Z&#V1A#8L1L#!K[#"39!')TF6?<)[:ET:O%HJO+$608I_
MQ3H9568Q/K^ZW5"@4=9JC@];5.;5T4\MK_[T&8R[="FL-4[K:^#$UX@-&CWG
MAN.#>N@F1E]4Q927Q_(37_,2S*"\H)HA(0<>9K@$85&29Y5)C>NEHAC]NZ:
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M4JSH_"%<6,P]RC&;2?<3*#G0"-LU60ILI*7 ]*7$JV+.SA^AL&-$9<1>P^]
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M[@,*9?9)Z*VHO-2"_8BF?S#MG$(A^-UDBY#<(>LT\Y(L7<*^2-LB7\0-M7;
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M5%6%)-77_98/TV;;*F-J7]89BEC3@]-Y:2=%EE4#VVD=B9$-;OTLN#,/ZP(
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M'IVU[;3A#FK#;ZE5M^I85&G"JIA*)XH@2S?-[CAS4V?]LI>UZWKRE>TN .Y
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MU)J6)_KZP,GG_U+BB%-&=.$7F#E!XGC[-[5Z-9.3)?7^DZ2P("*-D^^-2(J
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M-AX8Y6>>;8,$MD(VERIQKCD'0>[QW6_ 1AU(%R(J'T<N5 DEBBYIG!7\%P5
M4BZ601YQ!>'"5,=KH7%#TX/";)EBBR[^G K4:BENG"_MB#0>6JS,Q%TK0"E]
M+,-F5?I&8! X513NH^$%QZY<G=@14ZR 3=L-=TS;#-WX'_83KE(@HN56#>F$
M^XZ U:,*%,0C^T%J)10D8<D*U_Z,+EL1+J4V(RV$V(NF40T#"B2>:B=*UB0W
M[:JK>;$-\H'W#C@2/:OOAYDG;UFZ5*/*[=WUC3):H*R4,Z.&62VK[' BS>\-
M,&"K.D<I'/!'] %,%JII$P6J""J^2;RPC.E"];.DT1(WIC&+-0RS@A8BAP;
M<K=>UNC42?C&I@(O++K#<&P(>@ *5&NM&2+F[OOJ:_6QF[5O$0WH$5C Y7"8
MKE&OX 1@:,@8_\U3;Y<\A!9@P4TV,OPTMP)RK>[[6>PT&[IB)]?J_CM<+#0
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M0=0W)#A!= 3C.CV]_Z2^1RB)>DQH#K0=X&$."1U @A,D1PD29](\;4)SH.T
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MKFU/PB-! 322"TOI@?5(SR+%:!4D"WR7E8./YO>6PC0B;007WP#W)N5R+Q!
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M>X$V/=9RP]GJT-$>0M*=ZOY W#@^5M?M'.?_9OSI-R$!;>&*@/\&KFV2;=8
M/@?AP]A##9Y1!4^+\"J>,*Z'*$87]\(3B*;0#-O1R:JMB?4FR;9"T*=@WVP<
MX9GF(A6+F!RZ[.^NNV73+#T) [D"S&3AIQ.V+NJ+[-I?8&JEDDUG#@K@MJ[1
MJP*;@G^4<[BL?.J4S:1JIRL11"%@OM"&3[X/ \!&9):F(O$]@!X:CPF:N@LI
M"N1\8$BJ)25LEKSTL!^C@19@&25=T3G/>D<7Y W(DB2[(7%!(0A9KO'N_4>P
M1P!-WSP%4#."U3_XFMED(??2!;Y(DN0%6=Q9*>$WTJ< SH8N #J]@Z60+R\;
MB%0[8K I8*/[]C(HBTPG52!48/N7PU?T^$D2;+.RN%S$GT7TZB:.BA4 @["O
M7@  )\%&BDLIX,K!A=9XI+P57ON'9@GQ=2SC>9S$Q?92O]]22,R?.YT-1I/S
MYXCWMNP2M:?!Z.(+GIG=]<QL<#H\N^.9X6 Z.WVR^X'+=^=^SF<7WV _7W*N
M\\%L>L<C8]C.75O>W<Y#M7+>;9SNQJ>ZQC?W,0GZS$V"?O@X\B&3H/\75>.?
M=O2%;O=EZ1^Z'8-S#,XQN(=@<*]70;J\SS$-CI\Y?M9%?N:,$G?''_L=K\OL
ML9/9_939Z*QT$MMQLTZ!U7&SGMWX#G&SCO>Y[1]N'3=SW,QQLX?@9@>V]G&L
MS+$RQ\H<*^L2*VMM5N%8F6-E3XB5N1D-_6FN\Y-. -2YLI>'D8GK_'8O<O\(
M,/>PJ=A#\WX'[9Y NTNP=2S$76H'[=Y!NTNP=2S$76H'[=Y!NTNP=2S$76H'
M;><R[ GS^ Z)I#80U1H'^0_MPM21!:J.X:<[+L77]?)MU9[+E*Q3<;$C+,>M
MG@8UW&=N0P]E=7<0-?:'9_>9(=PEU#B^Y(#:7Z!VAX<X9M\;9G]Z<> $U$=)
M0HXO.:#V ZC=X2&.V?>$V;\X'9\Y"NH@8EXZK#AAX8#J>/TWY/4CI]9W$2\O
M[[,PHNMHZ4LLK1$V=A&U!R*>=\5*6+UZCXB@N>R6+N98?'EAGD-"!Y#@%+0C
M>-G$OQ@]](3V+RJ5[!).'QFI.=!V@(LY)'0 "4Z4'!7$NQA/NH=<)TJ<*'D,
MH'6BI%=(<*+D"%$R.S0;Q F21T)H#K0=X&$."1U @A,DQ[BWIMW#;/_D2'?P
MZ<*6_0M;&N#;0!Q_HX#EV 4L[\;RQZR@EF+'!RP=(74E+<D!U>5Z=8O+3/V+
M<U>QUW,*<$!U0.T'4!VO/HI73PY-^W 4T!4*<$!U0.T'4!VO/H97NSX8?;__
M#J@.J/T JN/41W#JD6/4742+"QKU+VCD1LU\;ZIXFS9&S;@<GXX)<)?C\U20
MX+2N(QC9F3\;770/N?U+\^DQJ3G0=H"+.21T  E.E!P5%IL.G2AYVJ3F0-L!
M+N:0T $D.%%RC"_8/W6--9XXJ3G0=H"+.21T  E.E!S36./ =LE.CG03GRX>
MV;]XY-<!WT4BO[X\+1=2!'FXH@%UD;@62;99 \".C$\ZJNE*:E%=IHP'XRG*
ME"@KYXGHF<[6'=JYSZD77X% I^\=XSH8^^<7LTXAMG_J7B]9I .JDSM.[CBY
M\T!R9^A?')I)X^1.GUFD ZJ3.T[N.+GS4*'2V;TV#G%BIR,<T@'5B9VG#'\G
M-8Z1&LY2>2Q*G0N(WG= %/X;P-6E'_>!X_FMT#AK@<;HT=Y1?ACW=!D7L-T0
M-OHA2(3TO;\&^2=1Q.G2]_XD4I$'"44PKZ)UG,:RR(,BOA86+KH$\G^5LH@7
MVZY"W<!X7<%X:<$XJ,'8!(J]. V!#4@1><]&T\&Y!XLG<99Z6>Z=3I]["_AO
ML1+>5@2Y)P#XD?=&A&(]%[DW&?G>>#@>>6&VW@0Y_*G([GIX./ ^KN+JL]Y-
M(+THARVEWB:/8?-P.&^^-0_@HYY8;Y)L*P1]"?8-9X MXK'F<,1%7$@OD#(+
MXZ" ;][$Q0H/&*223K*@3;W&3:;;W__N\W@XFKV2'C"^3W"\4-!"%1S2+#T)
M [GRY H.=3*G7]8^K(#7/ K\'"2209 +628%?KMV$%S;.HQLV7@BE@IE&<W.
M7 B!#WF!M29^ 3 )YZ/]+/)L#7\'^%W#.H@%^ >(VSADU*3;@2.J;\7*7J^"
M="D0F3\'<>[]/4A*@3AY#<\"U6$6!OPH8]"!Z+8XR!_&SBHX+Q#.UQK.807G
MT(:SS<F&@PN;D<TNOA,C$W7B;U!HV'8"6#D7BT2$!3VS ?(/EG2P D#@JY>(
M642Q# $3A0<'A+\ #[@128+_%8"[-?Q2PEK+((\ 'KR:R.,,>9D'2 E77@%W
M0 "/*58!? Z,E*7(U6>WE"]T&SQO (# 7[T@7,7B&D" /$F6<RG^7<+3P*8W
M01PQ&.#*2.GQE5-?)<Z^AO]&9:[W5ZQRX'MK^.)**KC^I4R%-QDR GBQ%%Y2
ML -H[=T?+):5RQ4M'!'?NV,C,8(K1.LD0B!F&UH)MF8)0UI$%K <PD<B@-1S
M\.V!]\$<WR!*796]VUQD29+=: @H8&K@[]LR7,+:7EEJ7;RB1A2 ?;UE+<WN
MVKFZF;@+$A8M5X_0NX@_PP?U[9#A2D1E(HSTL#G%/;("[YOPT-'XFS/1RA/1
M31XZFS0@MS*IG1M /=N!)\$"#G$9)#?!5K[ZP?O#$3!NL_N^O:7S7>R^)RJ<
MYUD2':\4_0IZ[3O#3W_:S4)]HM#]5DJGX?L*M ZR1S1RLN2G%PFC-$X&HYKU
M._I^UB]\%<'.QF^I+#:]%38:&_O,14(F(BM$Y*Y#=VJ:%6CSL[9W Z_HO^I'
MUZ!L 1JR\)-7;K)4J2I@@8I"V<99F7MOW[]##>)=6&2X6]RISUZ#:E<M&@0H
MLG$:I"'^4JT$VUY[21:D/OPU*NE/*0#DA/Y@CD6F[\!['\ Y@@14R6RQD*(H
M6$VR(!1+^I)1LV]3"+]*83I*(;)UVEOO!BSU;#P8ZWOES/#O;H;_(\CS %#U
M2QS,XR0NM@[DA['*-U]TQ8%/W+"ILDQA:>088!B!#6-X9V4%:ZLU:ECTR#=N
M%-H2C3:;XZD_@GTF92G(O@7*3\&&9CNU6-$:'\#ZA4/\R0,H+$2.+)DY'U+A
M:# Q5.C]M%C@R]>"7Z9M)IFT^%B<QLB9M!L-V),@<.QP27S7[ _VNBES.#%P
MJKV[(38=E' K HJY />K,6U[M2#\=QD35[<8.?(EVC(\N,5-&4C6-L.G/C,R
MC;X+F$J S<6+F#\61!'Y$/&H8,V?(&B##5*9XU7?C%?]*0"P @;>B#EJ<"AU
MREBN4*3XZ.UPD/Z>+&JTRZ) )AMN0.ZFI<)0A!@2-0RQ3TI%#RP=X[9WB/9L
M?=)B9KA;]O'#+TFG(3TC U1<BU1(J0GY?; %=0/H_7T.6A[S.OAQF0=K[Q?0
ML,BQ6":)\L#A;E"?W#1T*@RF &]#]]8MFQU:H1_<#_S"WGV+ZJ=U(N)&H-R!
M)FBKE*A]>5*$)3*^#;P&O#O+MZ2Q,M=]FZ;9=5"4TC"TFQRO"6P;%Z&=(L,'
M!7-?K 0Q.33;W%2;,IL '>PC:IZ_*)54;ICQ)RXD\NWXVSL*5+U0*O9+U-8S
M]&4[UG8P:V.0*H@2)+_,& 5[J0JC!D61Q_.2TA?8QD1&0&P@EIM, @\"0@'B
MW(#RL24R%*!O;)CM\18L7'[)#H;,@_9N06(6$,5+:%W%4&ZJ/ZA@!9P\SEG5
M([\VL-TT4HPBSB/OWR6P.?@L[)^^RL:J8<EW'Z^K+N5.N_Y^^.,O,4 PBA4X
M7[.JZ/TF)+#;T'G\#B7W?P@*^028ZB#P*$L,"]V B%,!? 0WA0!E&:Y\;Q5<
M(QD62%*<Y0%2%:Y\3$8-92\LDNQ&,GW9$2SX$KV\*(E^44I6@;  92.L(6P2
MUG&VRM=3/:9=3T#-21D)#Q"P8LFMJ:W8&N,)OOZV:3[=&'<4!1C1$^5;^D;,
MZAG0<"A$1*I1L(%_?29#$C;W[&QBQ7HID@'?C\JP8&-.F6VD/O@>GCE'+0-_
MI\.KK'^@A07:!@'I482[GB 5*7O@K]0:0SDQO662S<FZ!;BMP90GGRM:P2A>
MYEL2+__(\B3R_BR"!*[ONWP9@*&@?8HUQ1WV&4=P[9 XZ8*5!<70Z&*";@N*
MI8<Y5G'*H?4<+.OK. <=]\7K=W]_^^9D-'LY\*YV<P7T]GP[5PFNZ+7(E;&.
M24Y1'"Q3N,IPC *]*;"#N=BB9$Q*NM$[?X9]:]HDEP'>_1# (45^'8><N*(V
MUO+ZP/M1P(U(%2ER"-\6OY4/9">]RBRKMZ(^*6'+ &#<&:HW>2Q0OR? :IZG
M=/L- E9]=A'GLK _.WKEK;(; ?#QK:0$QA,J0? N<1=B=M6'4$O@;QD/<[J[
MU1S634MAZS%UE 7> NZ=!*H Y(0!NZ(![Z%.MM"?)27&RMS LV3I,F.(ZMP1
M:PO701AJ4RJG%(\@I 0!?/-O@P_$0[771H%>OVON> H09BL'6"*ZND3$_OP;
MAD58>.M@JSSI''_8><4GV;#G7IUHNM"0HGPU>!YARA>L*",0$"1P#,*E8$,<
ML+;%W]:OU@(6 ,3;=XOR-'#9#*1C8R](Q@D2")*G0/-0?$8I@?[%YFT9[CR+
M&]ZY&QH@4;5+Y>DGY1HVTX2'/O\RA_MP.GO>?-X.#G$ Z,_ZUI*];^6.E,9^
MMAF"$;_6#<EC=/#YBK)-:DEE'*\R28J9YF*RS#%51=O9,>P)KH *!ZU%1!B#
M$\NM+,2Z*=2;.*5U-F6R!N8&$-K@M4?"YML(NU8.C=LN$"=OQMEF%0"G#T59
M8TL24"/15:#QP)8 Q\RTNY<O<E!E0!)[PL!-%=6"Z[>*$^9]Z"M!ADUVATX*
MW2$=X!UE^BG-;H"XXL+<"-F@$0U"^(QV6*,J!OR+TZ3@,(+^.B]E3%Z=V_;/
M($6%! RT,D<0%^W'L40'@QL$Z1H61YV Y40P!X#QU5X%I%,%$4H1N.E$UXAV
M7$[=7*UM-1.&2"<R>J1SEAP<<*[4D5%#W6T).]0=5D1$E-<+>O<&LX+7E ](
MWL5AS5]7N?244@\O9<H+9V*RM-ZS\70PJT(AZ#ML?!7O/&@PP+P NG".G$1"
MG*\Y=1P),FTR(/-+*R.13AJ3^XXE^@;^&9(G( EN^(K!TV42L"RSG'=%\%G0
M^D -RO\'=SA8HB,B*Y3B$H)9CYH67F3<#:^WR7(EPRET0LEP ^]G%"W(=8LO
M.J^F=.M<2;R."\-K#<W[B!1$('E+0/< .X<  SA8E 40,]E#/N=K@SF"?%HH
M8;6I?"H9P@P_#39)SDD FG5@3O\GP;$@SOC6O](0P AW'J.8UT!4X)"L=N '
M24WZ%^6=9A7H:!-L&;;<! 5#65-*.:]@ TQ0Z6E86+ NX8H9WP Q$0,[[P6I
MW& _5@Z=^H=>XG&1W2>"-!WX]' PF^*G1H.ARD58D0Z&RG5"ZF3\^80R2;T\
M2Q);:[,PO[ON^?#YWHH ,"S_1<I2I0"*'!"T1K;*#%D@K05 S]5%XZ1;9S3V
ME$-;023E9;2MC(8])CC20<P;;@0H"#=9":8CLK8MT;(=R"%W RWPX<>KZIH1
M:?UL/;?AJ([/P7.,EI,^@Q8?'/0ZSDI)J3-LWU"4PTY%3K;(<+R_E+ %HBM[
MR\1T!>MC6@:8#Y/6GGI7Y1*PY(W._98S@P8F8DS_;@U: <")(Z,5I+*R%:6\
M?_^>3XH&M_YH%;.Z8F>.TA1-<OBCH**GF&E\ZC*-7:;Q=[A8M6*1#Z"LJ'#3
ML)U7166H-&N= ?BZS'/DG"2NV;ZFK$G4E% 7-1F!K#[NA/<;P?*["BTT-ZN%
M_S7[<V;4H>'0M!7WZ,ZB!$_4*Y6+%HOO=%["S^0'N@(\16LE/4DDX=\^8&X"
M*JM72Y [].<7+<:!>?GE7F4_P$?:S#=T<:+9D.KJ)*U6&LU8WQ95N+7OEM.&
MUUD$.&I?!V6G7&5)0YIRJ55]]9V8<<.C"# -$"+DL@*[ F@$[CY[';2108X!
M0#_Z *G ..1"-;(O1U/[WM-F5)6NMG(308I1S&KX/$C(Q%-_I+6-]P%5^>L@
M(4)3'EMT("?9C??L=+B35]MKM>%ITG5U']M9>A!C=GXCZC<ZLQ*X@"5S#9T)
M$QIWH"0WW,*;^.?3,W\V.S69E%C;36ZV8"?'<Y,K!\.ST\%DBM3#C^.'D'D4
M)[#T"=?9F[=VTL18:6Y&+^M%]LUXY9?%)UEMU[LUQ8M*GNF8UNM&Y;<CC1Z3
MQNA+)=X'-F&_7.0U7SA S.V1M-F<7$RAVIU1C$ZMG.2_!&F)3B]8D8HD0,1D
M:56>7!G0;],H]J[>7_EL_M;R_E!/*PN05&FDR%>Y2[-V$ ;HV*.MG T!A\.A
MG3FX$$('1NQOV#XQ]:B*J)G5M!ML1S@'1/F[N5H-H=Y\WW9C8?!!N['.K;8<
M+075[&Y6'QG31QH>,'@?>4_-E>;576GS0,:LRY*S2WM$\#X(9EI'^M#@]78W
M&K'17UA!J/00]J^8*$[E!\<TELI+ L\8C47EB"I]_0N4%TS>-[FS?"-VKL&^
MJ^8S:(#U:H5/^Y3N_K#VA;1<55L0HAN%R*GA5$\2\PV\B5RT1)DZ\(G*?=U,
MG47GTCS+.8_!Q7<.Y=)[40>,>@WL#UF@1GVK4DNQG'$C^UKG+3P;U:Y>Q=FT
MS@SL 3Y  :2TA357Z5X4D* :%"MG0:6%RQB7PO^WT7UU?#OAH<JCV$T:0W4$
M"(?Z+^RFC-DJ6*V$)4[WUQU25%/G?3>M=6:ZG-6&Y88WF?KLUO ;E8IXZ;V(
M7[9$GIO1[=L"U,W$$/[ZBQ@6!CYW'1,3V(UB<\X>1LJ)U.P!/9PM7T^(80,L
M1,]#1==7S!SPN0_(;H(<^-S?-@1H8+6G)V!FO;CZ\-K[F&U@U^/A].1T^-+W
MVM2]KI!+6^[X>YQEE!8F]^%GP[L^5"Z6$^]/E#$#FDXH\O32>V-"Y?C.WU(5
MSZ+,Q6 .+!H5]9_@WX4EFJZJ0/UKG?E"U[RV>)<!^,,?ZS*!.IJ0EL#6.A:"
MX06Y60FENF'-5RPI0PIN$96T82?&0D&).F=58 EK8.$LI9#!TBZN[1 P%??&
M:_47OM5J1UH8[F@+7_9MC':FP9)5H4K!P,V;% 5-]JSPD+E%<7$%DD@GVK";
M0_^1;A>%+$**XY"UN1=:1QQ!ZR*HW5+Z/&M15N\:5HZDL*2WY62\841B^>,
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M]*=KE8_S1BP"LBJJK""?B(^U;M2$1:)[>B@W@VUT*]NGLFV*X)/ ZR$V9(L
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ML*N3\3H]ENF'/[Z&O^9J<M@[@/#2&N((ZN@Z9C.B&\*N[Q.:U#RE^IPFMA*
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ME\54QI6+"V&FGA5%4J'<5KR\S&*4KRR7X1\1<!!(5G*P_^-:6LA+9X,T\1Y
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M2$[ /9G\GE 'O:_)Q< #454*!7(&2VT6AI(UDRF:5ML*>B_Y(*V3T/-%.B<
M'PP<8V<WHER$+<]$[Q.YQ0FUGXG:-^GX;+3N([6TM"3*B9Q?5;%KN.*23XN9
M$ ^1MVRN[%G&/S#OI%LNH:.UXE(9D*[0?L, !V!GPL'QE6E"IEV!#UZ#H;=(
MV$:\ON+PF[F\81]_6P%? M%%R.0!R-Y[;0&.(F_; =Q<W*9='[ %OE'D'.SN
M20NC"XWV6%UPT+D^/9KT7Z2^GB'LP0JF6#H NI'!;6(^ET$*&7S!T 18QB7B
MXA0=(":3++B0DK.JR%F$T:,*- '6F<KD,SA+1;GP9#*L,(C+^>I-] ,+?D]K
M/674 %B@((KMNM?($)"1G?,<! %TE:C<%JL [(7_YO#22<D G4$O5U? #N$5
M().+2\%&+>>=@:*AO,M'M!40P(;F1T+L-04_3K#80<=,9B+R1CRO6!> ^RMJ
M7.T#!L#$R9S_Q,@74?Z)B-ZC=-RG=,_@:BI-FJ!MS^!!&>$@I\4U1[,O ;LF
M!DM)HB06U78?HAA> !9(!)#17G$C+4$^RN<W )DN';<JXL)7K 1;^F,3X6AD
MNUFU^+":K/@J9VBLXL<2BCHU!08LQF%RD'S<4_"")4,:ZD*XX;8(&I>-;R ,
MM@J(WSX7D2@KDA[<+O >OW#9@+J\K'T'@/A9$_Z5*]Y;WMGM@H19WF.*O%@&
M6?H0V 6EJQLO)[_6J9M9640M(-^$T=X]1 D0N"(7HCZL4SA->$2P"I$6*)4)
MKT?NB7F>U5)3W& NL*''WAY;YE470IH659-JD!5.TJ[OUS8U"A-O 9_+&TJ-
MWKTM[,*'L_(V9Q9;1'@AK9F.7$C!!YJ7;=8B04F^E5! _TCHZ.4OB @@*/@X
MGI-.>$;4%E4S\NW]%%:EG\3G!=IK$HATW#?(S(L"+"JQ#UKFW48"@1H]H9*W
MZ*!#"G+CF57+*2KAH%^P9,D%E5%<_!G+D;&6K;G99/'198$G*J/<26PJL^IW
M/<6*_U)4JN7)XMHDPZH'^,UUQJ<"Z:;3XFH1;+UI4&<8\T5W= Z&4 R_387W
M.Q$?OB\0\>#*#QT>GPN1;CSLY X"+<D>B$T'RN+#)6EEO1S=2BGMP <S5M?-
M/;LP=Q<07_58$. $(R<'XMHV0HN6Z2*!UN=0+.NU@0 R2;E()[8;(NFI!& Q
M *%89-75059W*<&V:0H!ITQ:LW!5DHS$?&UY+ZQX!$8>R9+5?FE 6>0%=IZI
M7*FB/*X>Y=I''I5->:[I273ZN'_ROJT2WC_Y5?M<[(E/=<.::*MR&*J\T*H]
M)'JR*I57_>HOVNO]DP/M6P$.MA8XUAL9Q\CABK-Y)HLR+EB68T82,/&J  0&
MU!,1PZY&7G:GO6T B3=_7^BS&>A-+*^;(66Z3Y>[Q.1OL8^MJM!0%X9@WI2B
M+]*F3!;HZ46JHU:&I?"Z*>P6=P"_N+4R&^R/FAJS2M28R0!#4;6+[+<#M&\F
M+?-;S7=ML38 ^#3IJ"/IM7AJ:\ "PK-IK^>@P@!.A_]RK6UM>%,]+MZE_?Z2
M*]+=?K+4*"",0;S#I N(X_M)_Z?INY.W7H 7J(H\0<7<+50H*M1FZ8T*R44E
M?5M&;XJ^"FM/>__P3=V?:V*^Z-9>LAOF92E#=VQZC<9XFP!'ZB2-'29V&D;
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MV-[J>OT3RS6#69\S#Z'C\C;3<H[B(G,&5ZQ:$E+9(8$MBMW09LQM]/L=N9@
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M06S5NR_%EZG0V$M95N(]LUQCTZEV 1>4>"E\/(,G5C=O,2NJK!92D&H]BC^
MX(M7J^932>D,_UB4,.,5^*L'40H6#,R!SR^0UE=9?:[]NG>RIYWQ'&XXG5[C
M_N$S)");F(BS,H/WF$UYI<K@JC$@XU\+I.U! 0):YELUE5:M;CW&TRZB\K>;
M*+P22@1P1QQ$$QX]8PB0K*KF%_B%^IS52SAQE0'*X"B*+)]S1 VFG8G=$\O=
MLZ?M5UJ25?&\JN!&(.48G-<LC,[?!6:3I2><PTVK>9H*)Q%,^GE9XOVG!=P0
M *4L+FYB3LYY(L+_)<LJ6%22"(B#9S1(#B"4\*@&8)KAKL)+TWD#5HM[[6E
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M*#\TI&Z9\[7CS5I0U'2#.R%4S5TJL0A#8>/?<,Q+#-=CX.J&K@^;QV,Z;*5
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MQIJ.S5[%!8IRD%(GI4Y*?7>4>IBZD<D=6P]L)]4=Q_=!08=<]U++<[S$\J/
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M]0#?R95M&]$$-00U!#4[P97!)?5H&MOV[-DCW-.\JMLJ97(<E5'91%15B#I
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M>Q)K,+V0*!IKM+=!"J!B4U Q*&5$M!A348AHR.W?8EY$,%I@M( GP6@=^&*
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MYTRE1"O,BE$V]C^T^7;*,=K)E@?,9/'(XTX##NT,A[/ [Y9GIH&L931.Q)U
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M3?8Z$<ND:MN56"ASO<ZJC5RZ6/;2#V> ]% TMAE C074";HZ\; 2U%$/0PD
M5 !U&J!.D*X/*S)5QD@N7"@JK(LR"6:(ISQ#2N:9>Z'(=7;CE)8?CDR#L[L5
MCO[6.[I'RY/>S7UGCS=.;ABY_+[S<<<YH&5&RK$Z?($ZH+IZP'%I&"#K:Z5>
MG]8]O)#"B<S6 K0Q0@O.S)Z;PG*BK"I*E!4V1Q1KYAP3I5"1YBPKL+ EO;$]
M"<N,,UE@1)0_IBYG;K4+@I',<BP$%3K+BNM-82<]+?H,^ENS'&<?THP58W6
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M62=OPCT_%@7=Y5:]=?VPQO.:1.CJTYW27NMTT]O5N6DJU6>;!*&<6H91JJE
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MM"C.VO^1PU38YN*#HP7YWX2?CKGZ.E:]=:(Q>4NIV7%VM8D:U8 /K!*)42R
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M9JZ4;V;U-"&&WKCT]1GUJU#)>&:;8&P/?"1; E]Q-G[9FOB;9H1<NDFJO8H
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MDQH2+&$87!"G>;=H7&"UZ?&TQ19RZX##6RCQ$42^G7^9/(\(GME 8.I8_Q'
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MIQ O.?QCN46*R1(1+2O+2V=*1_91==R%_)LX?Y@]\8_QXG(KO%^OQ_?K]6Q
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MRDUF^.>R7HS]S7#U?W\;1BX1?C1/E!\M9J/K^:[4Q'#6ORLR-_JHZA>[EGV
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MS53DR5()495E#(*LE)#QW""LA;>>&BO-5F!6%-^#%=_Z <>",,->>9^FOE3
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MC+.9FY^^Q/$X__?JFG(F/B/7@<S\CUWBKBZHDQ']5B1HJ^\^+-;]_9_!%QR
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M&C 3-B+^W_'//>!.?-MVEN2'^L?CUSU& G>5#LC*F Q0MD(22XJ(I(9P7X9
MZ'7=B]%^IIQ'W!*#6!4J9*3CB%="Z;+R B[8VZ[ZJF[E77BWF(/KEWB<M/B_
M]-?Z?'&^GWJ6F\M9AJFEWR_]K"WLZ[<C-IF[WGF-$-A[<;,K*D8O;W-X>SM?
M/K8^/_<.G&@_N2RB/^W3#9OZ%A_W0PUZTBY _7O5T>= 'C ,O@L@7KF+NQS"
MOU]$Q3MZ-;.28F9C\$HR#1"'0<VH=8AK9VCP-#"_U5J4&$$$+RD*@(%P3P4
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M[;IO:JPY/VN\'UM<KX/R54>;*PIM9*E\WZ8CEK%<P^Q1;@QBO*:K?K=Q%E
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MIO&^>!NCV(",Q>\ BZ.S%E&%F_@N(;Y+O7R7)NW;;C4#2^=CPW&(&_5YW*'
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MCYFQ ]!RA'1JGM.L]?_)(;V!P7TF[U#)FWVJP_I43C#P@UA P0B!F.'@4^G
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M<=V]>]D<E R">Z-@/POP%Z6NN,(::6,L8A)$4)8XY=>"=I77W&Z%(ZD#]P"
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M_M]PG/E7?CH[CRV$'E)0EL]Z#+7^.1,Y2V\F[ @)F\U"EMY1$O;1@X"Y9.Q
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M;N A#D6/L89N,'J;QJ#[\XM9HYO+?N*YGUJX:7ZFY\6G&*%HZA;NF:5@91W
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MVT=J7H9.V"?4_^1\)N(O.9%9,&K9SM!YX!8QO)1$V8"H,PXQV.PC61D)&W_
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M>PS__':* +5TU>I<(XC64$RS"@[KE.<I[CL"8HQ]RXX',Y,>;A;!>*1N$//
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M4EO#X0!H_/7QX;>#-Z9=XK\Y>,% #JV6\+O@'Y* )9&VK0'I/E\FO2XD9R$
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M":HQ_IM)?2TKIC,DC'71%JBM>@H8S?UIR@F-C?(RZKZX2/TD237A<>*A69[
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ME8#UT-LR](FI5.S\=4RVHH?'R;-T)><A-'"JJ;WGS8N#1$Z8*U(EP2)G4I'
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MO"8ZYG^ U2]*=?GK?_SMKZ?-6?[K_P=02P,$%     @ 03)N5+0<K9L%'@
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M&A%K=J]&)&:Q;R-B)4'M/U756ZK51C6RNF\Y_F, ?]367=H3M&M X5L]Q6[
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MZ,W!_W(*V!FWX WZ]?\ 4$L#!!0    ( $$R;E0?#V(3^A   ,#S   5
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MOO K$:J'?R>M155FU6%12I^ 82 K6I$*Z*M1-IHM:JM1FQ]*DD8S0F8>:K-
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MR(=00X*#%WCBZT4JC%)_,,-"14&]!:2FZ/HN./$8 "6Z'=_+O E5^@5 @<=
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M 82"QL8 7WY-ENLD(UX<++^B.-W-8K2DW[M/O%@<-JC1"PR\DDA3;E,P$^_
M%_;SEZ<>63.]BOZO\J#])-W78I4]QJ'7UQIIAS0&ORB6P\X]]B-&\J52]S.V
MF^_B%*TPNTU?A]XJ3D@:^N0N]L4[6=$#%-CBC2QJ#6KZ1GC%_@Z_92H5N@]?
M4$"9QXM7[/(T(02EY+/WSP3G=P5E]8:VHQC;(E3K##(_O0^?\ZQ*ROEQ_@_Q
M%E'T@+@05[LCB))MTV8$B&0.QV_&MQG!:85D^J\FN?17ORU8\B&7$9M_'75:
MGREVFXQ?->?T[^,CQN'P^M]@+J)]47[E1>S2_;A&*+TO:T/(CR=Q!VM$S-(U
MPM,,LWK^Y8:6)<0)FX-:!9FN(VH.BH".;&1'[I8G/*''>UE!A7#G+V]K[DZ.
M"#-7[(>77,.Y#6U -\/E) 2RF-O,O36V+[+9??\N)BG.\B=N:B^<"':;M,NX
MBH3W*E<D:G^W]W1FZ=B8;1&]&><;+ \F%SZC*6QO,24O3K'GI[^&Z7J:D339
M('P?>D]AQ*JP%Z>?R JCT]4:80LJ\G#HIR@W$PE(:#2RJYK<Q2\4L03O'K/M
M-A*_3BYH;#/[@_)SNF.%AU(J"9E);LO8^@M!SUG$;L "2G1ZVBN8L-EZ(=[D
M;Q P(VI^)2P4P7^@*+A-\!<B(DRO+\";LG+)M+J"6+/F[?WFU8\R]K[3IR0)
MOH;']!W)VJG'L$;J?@;'Z4K>;Q8TMFO\+\R5 ?/J5JR8,I._H(>Y&L"G1E5V
MR-'U9OI0$I,PR _N)/Z$*7Z?/;P*XR7]+TJ+Z"N>[MU_4',F381]^E%OA6;/
M5/8^%6<U/3SRYT1X4WK,?*K3$KJQ)_XZ1"]YTMSG,*+G9A(CYM5FRN'"2Q')
M#19<L^CP7P6B94_B./.B.0YC/]RR]Q1V&['ZI-75M?S'CB$%Q^=OVKCU8:8W
M::3RR!VX!S!T7.Y ,=#* I0YX*OQ/R*XP-,N2_KK1_QYY/AU".*103-$@M]8
M\<X]!&?+B KG\&GM*C\(4%64 U HM(2G(NZARA@:P(%'0B9*34(!7;!J[)..
M?O##KE$%/@ %1FO7= B%J+)/:VC!8R7;5^."Y?#.$WCS&1B<L B@Y$GW#S>$
M8D]?C73PU/$X7I<\AWE4WP=?W</BF F@ .CI3HI BIK&(,$+/ 92K<D(" [O
M""UG_]$8PX^U $JU4IC+PC'V@D\"#GBR15*^%]U#,;NI#.)!K2YB]&"",8+%
M11YCXQPL*C6V'I0#LUC2*(9'\=$)$Y01MH(D% IF+:G!967E/@$3@3%,TEK1
M93 +:HTB25J96&#B- (;-6/Y8!86&^?H$=FZ86(R G.(8B?=K+1F !"M>$PW
M:ZT90$<SK-/-HFL&\-&+#76SZ)IA]M&(,'6T^IH!H$3QJ8X67S,5GR$*>G6T
MX%K?>#\#$;>.EEKKB]P8L;R.%F,S;MD3Q?6Z4W5LO\^FR>8IC'-V,%QC;+AZ
M*"<+I2Z%<NQB[S6NPPO/G/G1RWWE7[PJ99V'L5[)IL)B-?&3/U=0%-44/<C8
M:@A[24;TKDE2)@%8T.F4RLL5*]6<SU#^Q*ZZH[%4CP7:9MA?>T12K^:D#1!(
M)34-. V!3-HH']A/'R]JCK(G[ZEN$*?2*@W\MA!>&94NPVD[B^]24B9@#-&
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M"+^P0RF7$_3/2>S37KG6<+4[OMO)<CGTF'BP[QH[]<M'2$L3O5!I$M=,;3>
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MF#H;J&$"BH*:!Z39-75CQ$DN"U"BVVE#LCR7*OT"H(!BH%YX[>R8P]Y7):L
MA4*+'13I*PJS2A,XH$@H+"FGZ3#[*W,C)04H>4HKR4GZRL$D4"4=)G7M:Z^:
M*N!7 \GQPNN:-T%!XI&S9 ]N:I9F/#D+6QN#D2!-REG:6U^=!6E6, &P*TV5
M2@=,T'KH#_6<-IC5S6W*45,I>#"1A;';%#<^]VN6#\J4^GF3,(&$P8,\@Y-9
MO/YT;HS7->45)JQ0V%!B!S<+W)_/"CB-,"Z8\('9SB;SO,U"_9<S@%J<(PX3
M*QB[FN\?-XO87\\*,4DL"4S8'))_]:()9N'\\;RX4!S:!A,V"$=#NQH69G'\
MZ2S83QQH"A,MZ[)OC.HCADVFY^&V4^9D 44-@IP<K<"+X34X![>BJF2,8<C.
MP8-@L%"-873/P13>L^:-843/P<;;OI2.81#/P;+6M5R/82C/R7+6NQB086S/
MP0"B65G(,'+G<&E75STR#-K9W#D%99D,!TB<PX5'KWJ48>#.YI;2MK2581S/
MX>IBK-"686S/X>(B*/&E0NKO[QM T<%_S__ ^7T-0?2:HC@XEC^N0?04)@$B
MX>MW?K)YOR]%]C[U7I,XV>S>YV@=]52ZK[8(ISM*+ O9ROF!][MKE'IA1-Y:
MJPI=SFD>>3G#'B9VLB+-6M#JCO8>?_#7*,BBPF++GV7-W-A\"4*WN[U:WJ)Y
MY<&5;5>LZ 2/F-,D!UV**CVM/OVU%3[](FH%;Q64K[GK](1'E@GFLO_.X,3W
MLPW3,%!PC;;T3 V+3 >TC5"N([!,H 2G9<:OD"8!!L:&M_?&*M4_T)HJL'>;
M+4X*7QS_G5B='O#8F*KP;?F7=;'YJN V2Q'6DXZBUO;J2V>8ZHY4OZ. WH:O
M["<Y-TDZV%./DN?TJY=/:?]CY=:27U3D+V5I][=&XB]H'?J18FT:C2SNB9BD
M.,L+5=TQ(;JB3"*?NK2+@P6.]:\AM=  ;3T?9EZTQN6Z&S"J^\'YP2&OUGQR
MV@ %0*O<0PM-78LG'*B6I5<A:3A@H-=+TH[4:FL9T<)IN R2$2WMW02MN?O7
M^0$G%\G2BQG,5.#QC^O\=G=^8,@Y0WA%A)F<.QP0LLLFS S1X;!H<6=U-HFQ
M(S3-NR[,;+DAY87L^NRLMW 2!&$QT;OX.<&;4K&XN O-V\/.W5UXY=$)^>AQ
MC9"@&%+SB59Q!YNN#I:6L"]R+36/\=N"PE_B4!,VMV>A]+9AZD5Y>:P@5TE8
M[4R6T1!<9>E#DOX/2N=>*'HW6KO[Q7)Y/I9+M=!I7*1YNQLH]7IE616[OI:P
M)0$+)@:CF)S$$,($93 +@;X !JSO+NA_?I,KO4=FJ9K3RK*,"Y0;VI;))9#N
MHAF;(;#*90(B:DVL352KI&ECYO(^QA[AO0XI/H4)AJULL5?Y[FMU>V@ 2]1T
M60\ #Z#GP=B<\.L\WOI+G#P1A%^*7+MMEBY8U6@_C,*R)EC>/<\GD[+88)^#
M%VDEO7"J>MGGARK&$J86M[=/@MLL;3]8]!%%=-#5)Q0C[$7,-1ELJ+)'4E;7
MX05))7>W,2[W^?.YSW<#IJY@.4N\=D5Y#8T(* B7]]@ZI[P9/Y*T@@/.@9^4
MZ@D_!=\TZN AE(6]@<#P$B$G7PEGP[M:OZ724LN$"<PH[-*KDCD<.^ZG) F^
MAA%;ZKLX]>)52.DMQ$OSWS>O?I2QZDC[/K:MMK<,)'1/^?)D[BJ[K597 )9;
MR3SU;+?* >Q9!L0SDR5"*[M9-$*6^Y8_N\_>/Q.<'RJL;*O"]MM^)&MD+[$7
MH(V'?Y?;'DZ:05VGJ]T17ZD!N=TH4,D=EBWMV\TD\J(%Z6U'L6<!I_J(*DFZ
MW@;BRFCNP38C0"2SDH!2331I3ZUH(&-NPGGY]GJP1/XZ3J)DM1/[",6-(2Z"
M. E?T<D8N JY>J)W\]2C'@-!/9E.IMOM6#H=QB+!'(55GTRMS@:Y4DO&J*;?
M;RPP2T4W?->%XG9UT+G6YKK-=Z^I;[,P[8\Z3H6.X*AOP<Y"TN/B447H]'X)
M%!%-'URGRV?=\M@!5_"8R9PD=D"#[A7I)Y5TMU_C0@D4"CU_93\6:@TF3*PZ
M>$=TK="::)V"#=./9.?8%QH%8((T$CNU/@)@HC6LS%:9:IPM1C' -AN@.L>8
M9;M; M+'SN1LM8JN7-/>+N5LU8KN$.E9LIPM9]%Q@W4UF;G[=K$A!N+;U\XB
MCN:H^-29H)X6>2T3.9=(FTND38_B&Q6VFSTW)R<@3-$)6JK?)9?RDDMYR9>Z
MN'0 J#8J<>LL()<\*FT)Z7P>U6AFO1Y1]&!->+;3+N!<BZ[14_J8;38>WLV>
M[Y-XM41X\Y"D:%\KRO;-ADWP+B]!J5/N1=3:8@F4ZH1D%Q5>2R#3GGH8[]C;
M@AM614QK_HTN0 A1AA$+FQN[@TPGBYO'B<\O>,%K 00ZR?6"TQ#(I#NOM_VP
M>":+4RJ+V0Q/*_0V7]7B-S;&M,NOR7*=9,2+@^57"M1N%B-V4-PG7BQF9(U>
M8."5L#>W*1 &_Q)[Q64&!>Q,9[)VCM$FS#941\F;$I*Q(G^YFB^.I.X[JC%.
MJZH>WW_X^&/^;S&+R9I;6Z+JI 1XUYJ82P*8S^4[LMX !$!35F91J%3P6AJ#
M:Y:N$1:#5?VS53G55,DE<NJDJ8,V+X7&7Z]_P]&N8=[7-6ZEG0EOZN=G@H D
MAJ:I10.E6,M:)=:SQ2L./XI1,W*X'_%G$ $LU_,/#*^C@0/%0&L3R/3QVL-6
M KA@TJYMI)68B634.VZ&[7S@=;CVP 3)-(/PQ"E,RLV)1NF5T=F(VA9[HWXW
M<)9BS>5N7'*=C1#NN,"'^[*SA&NN<^UV[FR(<XM5YE_UW7(E@GQ6[>)"-#!M
M@M/*E.F_FM.EO_KMT4>Q1QGV2TRVR ^?0ZJ?\?P6\K96IGR;8.1[A.^7DS0<
M=[+[B(7]9#AN"W$[]UC!OANNOJ46*$";7/S.$9TOGZ)678$2-HOE3P#J]@;C
MW[NX3R_Q(3Q"6!W9=,<>Q4YB]LZ5C$WX;>T]&YEL-DG\F";^[]*]>MK.7LSW
M_EQJ0"FK(2?O V0'-"6@=K0,MR-0HGJ?=O:/\\=U@M.E[KD@:FWL8/A,;Y+K
MBIR?[$7]-(E?$$Y9@*XB J+M$'"@E^UY;ELX4^_"-?:9_XXR!$GW3[Y/J5A=
M);C,@Y">(!H=;=:!0YC.[@IY['V%:[1-2*BHKRKO V1]I/E<)PV!'!F7 %O'
M FRU[O(++U[Q[X/-OXXZK<]A'&ZRC7!B];^/CYC .'/\F[VK RM1,WO.[P32
M[<II:#%A%(>(?)K3,1%[FEE]\Y'UL'\'JF*K<_\Y:0_&N#)\\'0'P\J$8A8(
MGQ9MW1W(*=&\6%$2>ACJCKV!D'>+4 LCTK&UN1(!R,\!J=^H'L(8I0C%^M>R
M3N-8%JW_:"U:^3W&50*\5[D24/L[$#8_V8?T6WT,[M7^QK;"(WN4+M 0H_R&
MMI6;7SV,O3B=X46X6J</&9L4/3W90WQA2GEWZD41"JYV-YZ_KK>5ZT(]QC6V
M-)-LE9&TKXSJ,(JU12V1)'0RCRA-(U2\G3CUR/KP+N Q%$&P@BT' 2HL;I.,
MG[72NOMY9&TYG@Q57ZV]:6I!E?Y<\P_HJOGT#]Y*+^I#.H!!-:GZS>,7V/6$
M?;,ZB[D7!L4FXRM*G4:R0LDD"%@EN#D.8S_<>E$N,&;/DMRL03XQ$.W[:7"G
MH*9+WAW(]KK%Z(\,Q?YN]EQ(P]"GJ%;SU^07#G%W8XNR0"\HSM#G,*)@)C$7
M^9,V0VT'C+8%?7,4>U&Z$PJCEIW->= *&]]]^$<6!F&Z6S"GQ#2A\'@G:ZK1
MP=SI4]GEY2?+15M0%@HQXO!<BXY MM,>MVM$?!QN)6^CJ?L!(XG%&40ARR%I
M15&EF[T+$#T@ITG$ZI9B+[I-\%6"<?*57M(/EQ31%4>CIU6RZ V%_8^%@KQX
M41X%<@@EXIU3[?H:E$JE8.8?+OPVUH#]Y(4QN4\(0606W[RF%(\L)&LVJ=DS
M8W,!J.I^YL2I1^^B7K38GRB$.S%I4W-S.9QKMPC]ZK%R:ER;I:*QO:LTW<CT
M<'EFN!3&NV;&G.CZK.YH,1BN;J_0JBZAZ#204G7E^;_?Q,&MYX<154 H7[31
MJJ2]!YIQ-:NC4/++@G<MYZXY#AA-X, ="\1<GRQ4I,PVK980+6X"'S75A'9C
M H&BK7[73Z\3G@$[3'63/*6W*$6/"%.W* .5I5QOJ.Z5[!"7$UOT'N 20%6I
M![JJE3G(=7].>V.S^K+=(GP?;L+T2/.C%WEXMTP6*,A\]O45/:EBQ'_%MMT
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M2SW8SM8/[.)):NL'APF.LXF6(Q;%,<X=A\ !F) ,=CJJKU?.EJ-LK2F9"-B
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M^[GTZT 4,_L.S506ES.9B:=U$<=L2F5.[B$!6YJNQG8W5GMY@_ !0/GFB5(
M9077;)B!Y ?_DEZP4AC26R''$70,,L?4=#$CX?K1?"-=:[?XMT.4H9:&[OR8
MW85N=0[+GE[&CD;](*HY'-Q-+Y-_P5^Z" )(2RG/J;#%]YGL30_AL)0%N$=[
M_"J-1A:$M9K4.,#5/[#GJ:*>7.S:"71HBC9'G \V7Y^&V=%A#GJ_DCJ'GIQA
MFG]K+[.A"B/$.PP2H,WH )UHU_0V.)F"N3 XZ;(MC3-Z%4/;UF#H%(]V86_-
MWECM\5(=[>?@T>'B3E5=!PXW8*RO.7#C -]-+X4YQ!X.#6'I[.*.D;:B\-U
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MBVM +V>[3R9/ ! J!KTJ)=J$.KKK,-4,[FXNJ+'(^7-_"$IS?R=G'T #[_U
M@P)!.-G?LB(" 0%1_KUM1I?K!102\T$N1*DAQ\H &Z9DYRU[T.9(L\'H&%8
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MQFU2#Q1V0;!*KL!:)2KE+E/N'0',L)A7,WN#$./X^8;JRRL<3W!NF"CXT0Q
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M1\M)$V76F%UBT:QX M^@S8]:+IJZ5'?AFI)O,7'SN[/:6I^3*^KC\T)^^ A
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M;C$\2%\VXWACY$UW=1"K=DFS#*EV,(4189G,BJ>_4S_''"EE=YWQV$VFDNQ
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M,QX"C>191GL$D'XO>[E/D]<P %/;EPS28VZ9,)>!7TJ4CSY>7N8);-D+D4/
M_0:#0#6.<AA2C7.*O*I?$LNO2]M[TW?1ZKHH,A22V/_+U? F6 V( S07K(U1
MA9,'9QOBH1D>:=-AA-7N,+XM"*$:"Y.^\:P'%T7^.<G_D^90F>]H-RN2)RI]
M(@<@3T7.[L6<[-@.A4%.CTWU0\&]"Z='VDXSKG>V)=O;2XYZ#7U0JWE5PX?'
M+V9B_P3A<U]2)D#:8KZ:(3:DGL )DLMJ^N21W?D3)*L98J019-;*C2W+79KX
ME 89H!3)T"\PUY3NB"\0]J4-K1IETQ-#<S2B\/BXLZ]C::+&JB#851F-MVS
M.N'8G=%G7\>J-"WYIO:,Q2)CO=J_3OE7K>C+(L]R#]/U>?2J]PY@S,=>D0,L
M =V&@+J/09F=V'IB?K^-5=5[)BK8K:PWN3.I)F,Q4%2< 8'4HBCEXPJ_E3>/
MA(!1U7WKU=^,<]6(:Z@.B+0A>V!<]B*;(;W&>5*T1$G\/-W_7-.5KY,80? 0
MY"IDT?&(/27L$-)L8#=9Q>LQR4Q#+&K1*;"<Y(DPLV=G:E>33HBE_5A12?U,
M;+P:ZM7TV$+FF:T"AH>P:AM8B"M<1[M5F/(NX#8?J ^Q@)A+S.%817!>66IL
ME2P"KGEY$1@-;F-A7FB4@A>EV.E]RM2UL1HXREU8CA[$A>KY\51/S=..2Q6B
MH8A^(!X*:#%XP@749]I@$J20-Q&#&)7%W0#\J^2440O1*N@+F\Z;K,KDB:I,
M5/#+3C-CV)IUX.OYQ@?(WCU>N,\0W"&^;9,Y->JX*MRW2DC%(5K?P/XM[75[
M%;<DGP09_3^?]J"PYNZ#<K;_Q0:>QO/J-)[)#JXJ3HY3%GKK3%I7&&PP5S?C
MB_@C:WBU:MD 86GA.8@\^LI$T+/ (^($9\]!2RBZ@+\*3X0!-<%&^0Y5<BFG
M:UTM:SJ61P8K[;G$)XE6,L5$P^<SL7_\CK(!Z'*+69GQ,Z*ZXW^X$PNV"64"
M=G#]'F8Y1=,K?QF/A9%7V>48\ER(M D7[XS92/()XYZ1<F2"HY[Q/TJ?93D^
M4V_D#.#M7I8+Q&=!_IJG!25K+\KL(A#Q)Z8,FE1,.&-Q-ZNX4-4P-'->?N2\
MQ/298V%WEF2;I.:7R4^DO@ZU&GDURQT6&[7^0-2/*";$+==?,AYZ=N3>VSM\
M2/8\69]_R40<V8DP5$M.PJ1/=DD4&;7V6/"B(D7\?!5ZSW&2Y:$OLW],A ,
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MP.%(-1Y"T)XLY^K./O[+3X8X>9?P;),1I2GW4"<E3>LE*0WR4E<^-0S9Y 1
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M?7&KO"DA@6T?\TS_-2<(%"P!4Y673=;:9?==L_QO\]\F"D"ILH$<&J7$_8+
M>S_Y&I:FM9:0PJGM<L_W,M\(%784)(Z&LI'?E5M6+4>%&YAX':ZFEG=U1O[E
MP^\^?/A8Q4Z=D3^<??CP ?Y'/)X?\$\:_'?R@7S[Z<.GCRBH "K3=ZC$@3K'
M?C 1,M'XE5"NJ<9W/.,?\DSD[EF_E0QPLV_R[^/I@CZ'<<PU$?0'G !_E6>F
MC[MK#B!FG35->9S+$EI^(>R++>D;1T>G:@H%58.RQT(:(!5EJ1KYZUB/1D9I
M:\$@0D6:2T#697T*BYJ3_T*#(J++]7Y94P2;&AM6)P<  V);05<<9*)04'O,
MUO1$R7'2RK%M8(^1*4E<C+.?B#1FKNI+*)01$91D%=:?(R$NUY=P0Z?@]QGI
MB^ $T8Z,)-'E9\NW,'[V8HN(68-#@,]Z9:40M:%)JR>S6N^GB*D)(A8K*MB[
MJWP JTB.KR%DWM\DZ552/.7K(I(Y:,=C4W*2F)LCB1))]31X:4!2"H8@$C&0
M#'G6&7JD$?OQ\T\T9B\QJ(^+8!/&(?A!(5I7.@G,!)N+P8@8C9<[KXU7>B6F
MS9:89A5JSZ47T>R,_.REO](<X3'DHGCZ19G D=!T XR 4E-$VC;GB"58-2L<
MU0 QIG)D:(!6[\*8WN9T<[2-2X^S"J0)TIX>/_9HM@9BR$["6WL,*_?CHVD.
M<C#9B090XVR4VUH; RRB&;B=4@R'$,Z9=4_V!-S7KE 8[GQ_"6Q!< TNNJO&
M+(M\2HS@?* !W?#50+_!6 0V:;3W%0^,KB)O/2Y?(A+QH-^TG)=P:%@#;G.^
MA#W.JW:#32VL7H;H\J6KYD,6EGQ!,UFY058<=9.=U7?9V?XVLQ4!6<X.W_\'
M"-;/^"*,C5>M^$8#%4F1MN#06K2J.7[V39-</N,T[0::&V1#LQ=;OHFM7!6:
M@M--"<.KV\[_(O(^C$1)\\'(3[6PNR88G\PTL988997C4C\4G*HQETWGG1S)
M=B"U78YK@LPA;-L3W^Z2^)E-:P-8-!">,BK&3A+CH.Y ;H)P.#,<U)0]1O&\
MY./,4M@.[K?56[)Z28J,Z?^/X3O(R$9N#_:+/Z+\;^MF,#5OL7$8.2+I$480
MYV[[K)OB0=TZY<);5KB>^DL@/34S)D6ZI)*[ULB5?*!P<MC/)7@(E#)FQ^#3
M&'7U:5@5LZ>6?%69JZI6G=I+4RTG3919$YSV;_H;M.:NRD53E^HN7%/R[7]2
M+\V^.R-=%;XLQO.=P(+6(T^K;1?!^B5K-;8&\MD!E564:XDYX(#,>Y\*I&X1
MLX\7W:=A[(=;]I?QM4U*6N2)QVY,$U!D@RUI%VU"\''JI.+46@T3?(.^Q$R-
M?@-HU_@9@BW0\;.(X11LP@Q\0_ OB5I3NB3&9_ZH Y- CHQ^"+\:FP>-2<P<
M61387N;/]&L2M2Q'.2@:5)5A\=\EA%#EM?IZEJ,A1YK8)1;1J$M8(<&U0),Y
M&A6KA$Z2:6""X.PYT'N50\Y4[KW;]"2:8D,)=FGY&M\*LM]9#_I<YB\T-1%C
MA(3(5)%&XZ>M;B0^=]OA1B56F)>".)5)P$E(7_,A/3*,"B;-'0N,)JA6J*"8
MV^?SQ$].^F1XJL7WT)Q$29:!J,G-GF<0X\,X0^2S4^-,.?C[G^Q,?#.O^F;6
M;@!\<NL"9X6BNUQS9-1;J+<&" OL'XL@H,$J*05&D<EM,(V_46;D##ZYA/5E
M>D?&P6]#,2>2 NR?![,"&+-M*<B^RESO2=+['2]ANWA/%$#DY5K"!LNI<,!$
MG S;78H*4 ('3($$X'CA-/#1;-L<N<$L&GX1,' D+@@G8A\%1..XG1[(5A<K
M8-^1:9+Q?9]FW7L_'8:M'?XTSL[:$!8CUMF *$*$KTJQK.MW/RK8J>?PTIMM
MD8M@KCUA8-=.8$18H4I0J;]&Y)PD!G<Y*[BNVX2_'=&1LAV;.*-%K<&AMB^'
M37\=1+2(+>VSH>Y&QC8"05*C.%'@GSE.ZMY'1^PHP;-*H2&$$1EQ<M6:11Q6
MQ=9!JP!%1S@2!(KG0"?"P?GW1P#J=N/IUK!T:0N$;EHZ*GS%Z0/>[8]6\73G
M^PT,>R?%; _Q3%IPI)W"PA_IDA2SLE5[1T*NE2'^1B(P[BM M4@2ME8(R1 +
MXF H\'A5VH/E6 Q3+-34UQ8^K!6RX/#U3!??8V3D1I*D4=>><%.99*ERL'!6
MP+IRFA^G7EJD^\M, @?#K?W++>J$\3.*I$QXV#%5'TO4F\#$$>Z+<A#"151U
MF)/DM6E/3TH&T;+NGSZ#BEF]Y8N>=7Y2ZTXVI>J8*4#[&I3ZE.CV)GG1EX*;
M)-K&)"O=8/<2Y+X6=38I^(UY7MOK$V@XG0P(!W)6EVL13;Y,,0UC5*0W3^==
MKF6$.E1A1*H3!'P;Y*9VU)"EI&(I$2Q9!!9@':'FZPCS"@9*\QJXENV78R9;
M$\OEC"U:LJ!:'[T+7^D>,-Y88R,G39!V"R;@1)8Z"_S5RTS,@,F%S_2@ NMQ
M7=%M2GT.6<S^'E&17+S8)&D>_I,[7%(0W_(=;*^<_0Z0K+8C(D.5X8DZ/BDG
MP)$LE"D0.0?, ,CQ]^4TOJ*%:L6(O(/,6D]9M$"9RU?$?(MHK=LJ9\I>\1I[
MY:S<+&=\MYQADW(^UJ5O5PNW+Q+:6;X)I4BW2UE)G'86<BHAM;<4G*X2G#!>
MWR3IFH9YP8:1M> LEMKKKK0G?0/*G*I2>U_U$M8"2,4JK#E9F_&( O'E@=<6
M-1=@(I%D%,).2GJ;8ZQ>)F2/.XOZ ]]OV2I9^.QV8;M0P%O0[#/- ?<N>Q&_
M.?;@RB' P"Q(D6H4 C8^A/++7N2O+6Y)F_P.PN7P@<^MK?2E2=A48:#EM\W;
MONT9?MRD\7'MFS#9:)=)!$]NZD7L^KQ(TC1YHT$52#.RC$^>ACZ\Y_@Q_7(H
M&=QW4JQ)VQ&P4I'&J$1)?)((I-+J+9.ECDWN**WG]K'Z1L]Y'TBV<G=0Z],_
M6C(IR_QR9.HJ,EH55IS)>55%90GIK4Q0E?Z^^I5MM0G<2,'O>\2<C>Q61^:!
M!/?W=XDA% U&BT2)/1"-47.5(@^!_P,RUD,TQLRV9@"^YQ.VF(YXOQRUJ+=L
M29<3U/(Z>I[U, 3V7$*B>O'$%(,R/7F&LZXC*# R,[P5>_$D1A64-VY@Z(1&
MD5,E.-??W&(WS6,]Z]/$/KFB/NYR\L,TZ"=S74#55'O@$DX&'\.4/] J,/4]
MH,'%[DL&KK%2:%[X>?C*TR7&I8N!EHGZBQP*CBD,!N:]2A^HQK.:638=^S6#
M _"_CI*WC*PAZZ;2([QR')LA&U)Q'.$U5[3//],HL.X[;PU9J)W-\I>9^&UV
M;%R[/C2C?EB5)EG9)K-X2"=9A%J,.2=VQO1;P?C6[D/8S-D:>=FTY*]-<9N8
MXJ*&T4[C9 ,8QDEJ%84$ W+9RXU_LAL0("P$%,:H&I%EK*^DC?<] F0(\M9K
M0!KEKE5=GQ;P@SU:'.,%0D]-0&',=*J*Y" P;>[F.UG52CCS=:UKDR4>BI?G
M:?A4Y%AK+4]*/'((PWQ)HH!M'*L5]@ Q@3M@'L+LU[N1X68U@@0H3A1]98Z3
MAJ_*#3M5.;SK]9J"F$I+S"I T@ /:.R'$0^8,%X-L!R4*+!6"#=2']A1B4#[
M:Z(K&CAT86S9-)EJ&WK1 Q5N4B:> O[*T>YGI$;2DARP&#""\YY^T^RM9<,B
ME-_>?7.9TB#,X6_FKDY.$_]^$IQHKT[\(@HW&+/%Q;<O4-PO]\+8KAJN#T'^
MDM%U$4$*KXT0:\+)8XKP:7&W'V!]'B&+8:.Z^ADI.(^151X?:$:]U'\!U#;Z
M2J,$X_V$>WF4^T12YB![%>T2R-&^9\4"<XW #,ZA5^?0/$,!#?]V)>[GFS#S
MO8C'Y=VPGXVKFB:($DY5Q"82I#MS-B(7'"C%0'U*@PP >V1,TDV2XN7+CK7'
M9!;5X'I\K5,<A>,:E;%/4/B47_/E4(JM^629WD,=M6E%X2AV%^S\ J RW299
M.+*"30D@*(@2274*%[))?NIN94[X_*G!U"0HPMY&%#R[HIF?ANCF,@'K7-(E
M"N&3X:B!/B" G0E5V HHD_TBFY772U1!#$0>[U*K"!))T3X<X_BH*5M.5^,(
M47%5>:)6HV(/*:KN);$*#C7+E9=V&X-1@8X#-&:^X-H C?8=>=8>GW$F S0^
M6 \NG/M2MH9J:!:S,U3#ZE+*EP2P!OD"1E'R!@&B32@4IJ\QX@(0\_(%5OG(
M0UV.1<K!R#XB"E$&Q$P1'/+$5T 5&JIE\.2(9TQD$.L LH2P0%!E(9(U\2TM
M!*B%U^SMSW>+(&!M,O''71C34:Y_3I0(<F?R+P0(DV4\=U:B-BYJ3)Q&--KG
M8DQA4"M1DGQ*7_'J-5]5#H8DJ'\=08YC%D9](SN79MK:=RX7IA9,@12:]>QX
MN>$&UNQ7O"*-V()9K G6"_YSO1RQB<++?]ZK.FS?:F60F9::RG_NJJEL$0X\
MS,-GW*F/-,\CW*@+K'F/>Q,J=:!Q$_RKHX GP>(:D:P<I%3X\X3D+V$*%H#4
M,HB[35[%_JS&(-4@9X0/0\0XP#.WB.-0EA0_F6B,B<49)LIKZC[PNV*YAG0Z
M)F.CI7RD"4@.3KQJ=&T9#Q*7EU6H3,&6-6?:A1$;HUP0951RJ2L%(FYOILZI
M0W\5ZS$(!J!]0]B\&CC^+;M_QM7.4PC9+YTW?M;["=8RDC:J:#O!A%-P@53H
M'SL(>"H(D3K:27+>&B9]VXC7R$A6//V=^OC^>C5LI>D7XSY-UF$^(DZ9$[ <
MHWS\+*<-_!XQST8@M7#7?0NTOCN#?T9%P'U>*3=J-.*6/R<Q%NQ(H@B:27>L
MW<*'\E$"[%JP%GO1190D >I9*S;Z2$FF4J3\<@#R!",(SU7.QK EJICF+:HI
MAV MKGA"RL(D!;1/A*5V0T#S6YU7WVH",^I] D++_PZWETDPRO;=- ESPH11
M)D!Z[JRTFX2M,V'!),.NLI2)HJ&/Q::.C1IX?D[Q528E.5ZG\^NP<(Y;HUI]
MMZ$+=8KVSG'+M(>?^7_VU$&XK?]G9PU$.BF7!TOD6A(&L))M(-%<+XHP CXN
MO:WG'U^RAQ,E6PEL_23($E_0/0EF&F)H+U,6\USJY9T5.W5990V*^*(A584,
MQL-WK!NY605;M8Y71>KDN U(<S[R5[(@-7G02Z-=35\'81?PODI[>B8RU2S>
M6,531O]10&["*_O/:D2M\XH405KDKTC-;HZH_%AJR?%C[6>J,5-8SK9".9ZN
MJ+A9GJ+2-EL>N%H-^3-[ALTLS<%\$11^GBWBX)&FKZ%/LU%57R0]3.R1%"U6
M?#'*0PV"CA/%]!U!U=)#)@.Z!-2R$5S",G MY41M64R,S+U\@\2<)>:T9;1"
M(W.O(YC4&;!W!:WHAMU[3&#FP)Q8E W2:[A[53$3KI)[;\2M5(XCL4OE2*6+
M535)0LU&SZX/QCKC385O;P6L%SF8B$5539N.23QX#]0'G*=P'?HB;%7 ,)4U
M-U?)(@C0->I%]UX8W,9,K@]S+QIY+39'!JE!1#%713G11U,.S^2),#@/XW.?
MS\#633KAHHC#O;<8"B!85=47</*KQ8!Q ==(C'SZ:U%/V3UZ=Q#?ZH(L\M4+
M_=E+?P6X? [>.OZY6N3GC.HY)VL1%-8L!]*XFQ-&D#0F;UMD,,9%XUZ:G)M&
M[9!C/<&R^_PFV%+#9(:SK!L!YSM/U54M:5BOG*%FE-]F60$2B4"RYD#6\IP8
M2:"7(Y#)P;*M\=E09SFSB,<:"AZWG,?$.H\"V!/#:\%8%R49U X8F1=<XICR
MH&2%\#0HF+("VJB7K*0RP74_<L;JAF)_3%&Y4K&+&8QK[PC^GN K&.:I$>(Y
M?52[XCT#&]QG)AA7/UFQOV6 ^IS$XR TU%'0NE@?AZ@#3? 1+3-=_Z@1&SR!
M8-U76DMMPU*-RK]YF'O^XL6DUFD.N.)3P:F?(J_-4$ LY04?%_]"V37[ZD6X
M\>&'::/F5Y$A1-A$*.NU(/;+9/,D<$4T0>R8B2(<Z::R'/QJ5'V6PSKD^CF.
M;#NYP>XZB*-0\J^,ID]JX"E ][:*^TW(OGH7CM@#D^-N0WRN"KW-G@DEAX"=
M<_-(X]609; ]NS#4- DV[ DO1 <H>93$S^=LJVQDR#U<E5;S*O (K-Z2U4M2
M9&RTU1OC<+>,Z8K-PEB),38 >]'Y""3'(4@24X*LVJP]9IXSZ55B'$G*A),&
MP 4"Q">I4V:>,_6*^O_)>]?ER'$D7?!58';,SE2916Y79LV9G3[GEZ[9VE$J
M9*'(JIV='V,4B9!8S2"C28:DZ*=?N.-"@ 09%Q($(\O:NC)3(MWA  CX]7-(
M8*MD<9@8PG8(JGTB4)2M-VQ?@#IZ>M<315,%_!15YQU0!I7'2..IB^(*:]GB
MR)FOY,9"(Z%*%^F+P&SZ<Z3S*EM5YP(>@$9.C+,NA2X%[_;6S5?:L<&M0BUY
MYASE;??:=:RL0SL7+U/90J0GCA^_F&7JUA@^ND&&;\L[<]7[!#<8:C2#: ]<
M-UHC*5>??X_1)KH&Y_C6[S',$=%GE\$'1VW'Q(]5ED/R>7^(4P P$VCP.N%Q
M,$Z'ELE,NE)D\/9C<H9<SE"7DWYLXMQ186U5Q;6@+S$<,6GY$*R'*$6K"!*@
M.-VQ)^,.&S_H5C\ZNX';DG3YCP%\Y J[_N#S/<]8W>F^44YW#OZ#3CSM]\:M
M+7_#,4KT-D2NCFIO4W9 X 6TM]8T:**& 1E)?""NXAI^9ZHMG'/JSHI3MK<0
M^[>0I;IREXT! <T1*<'E<Y/G67Z5,1%X8&0X4&C! Z<$N1"-C7ND:,B(8&N&
MJ_VT2>(20:IW)W="JN=RJ[ VK%]0B;U!-H1=<9CFS88@MD8!@W"7J#BLM&(Y
M!5EQ%B!A#O:]<]SKRHE0]?2CFF3>H86^YEE1? ORESA=LO_2DE=+C0I#]0)C
M(&L<!-/;8!2$YR;[AZ(::'[J@9N#T*B0-^',"><N:NQ^E&FQ!G1Z[AF7?LFJ
M+R1W)<*E7YW*O;L :O2EVQ4X:/E,8[7[<R5ITQOK:"M_W[#=<!^OXW*^NEEO
MDFQ'Z5.0!/ENF2UHM WI+1M9_$9AR_4\[9 728 97,Q4L",%\@.-/D>.<$%+
MEJY.-J=RBWW*Y44FV+!2RLOY@%K..1&-U3F*JV_64];8I9&.&$^8W4&O@S(8
MH(Y66.P:80*4W56=#BU,XET.@;1SQ?XZSY?9>R]_5AV#"*@2IN$#W4D+D=C&
MSX<_=S5\J/[]%OS!S,HMLWS6;!I[Q#Z1$%&4G,4[AQFT&9/@A%PF=D1TU0ZB
MR,6!;&QP]_4J(*\XM>)'BH7"Y&_@Y["\?$3YS<Y=DIUH -J8A%EC%IP[<XH%
M#6G\!NZE?HF\@ARIZ(V1KSN0$$8%75,21PK/;1#G"#/TC0:@B8,:^GM<OGY/
ML^>"YLCZ+MULRT*B0(I&ICUU7.#+(8G(NN),WAEKLM5XDQB9@[.1]SFDG+TK
M?7>T^1![%N<!&1*-(P&61.=).%.%Q2G[V9[[--C:/LHU=E5K&8;Y%H]:Y*9#
M^_ >YC+SXBHK,*40 [,]/V?@J#;QK '] QW.JV2;$!BCTSES$Q,><1X2<PK4
M&AM(3\SJXT!1<@:0)09N'$7%1YR!>DENO\W@$!],5+I_9^I!<0W6)X8Y(!<)
M"S)A$I;97?K&!IWEIRK#@@E!+J1BP].O.'@Y< *S7_$Z5YF-? (!)5:( -MZ
MS9;82=H #S-R\U1 / -.K]7Q.D@ND 4RJ\W1ZBS^[%)<N76%F!(V&W&76WSM
MCE..G(IKRTI[K):V36;'V)K/^[$UG^O8FDJ-8;;-=LV!-D%1@1(GR*H\%=6P
MXK:_.]RSI3F<IO5I(R-R:)AYZAJK=!+S:3BHI/28COI3G)(=#?+B9S?.J64>
M .[FTV[]G/4"=Q&$"*<TP<$FXXRSZE);@-I$HPNHWEK')>R>6TI[HTESVJ@8
M06O9@M^A2)ZL*)TY1;@=6K#$D.E.R511)K<@TV]G)).M??C>]7*HS[:4U7)M
MSBBK[9DQU%E*K-AII<2C9*B[%]]0%$#^59*]*R00*;;+FF$-^2!D^XHK(HNX
M^/OE;LG>Z^&T-R@2( F+"D2=URL-*$PMYZ\N$9!U[4'2"C*%,RF:IPL*=9ML
M=UP&15R<!#W<F<P6IZLL7XMVT\_9UFB$)3V.[%!B)U'EB&3/YG)<T!0F=A95
M=SXY3>^B7JHK69%Y2A0S@MS<(3>/([C1JW)"TH,6=Y^%0?+XFJ6T?Z]<I$60
MF+.VTD.,.1EON.W)1L/E3TUYU'6$68&UZO#6'6K,.F3L.8RZV6ZQT&C^"^*J
MN-PKPB0O+$[J4XM@!<463_RT1;%B-TB'B]V?/EY7A7Y::*.Q@E,%U&CL9A:G
MJ!*4N[0<L,*IZO16KT*IU9F,4</D5G)I*ZJ>??4RI:H0"3B-48KD5F![1[\C
MUGD".NA]G-*[DJ[[IO0"'1(#(69BL"DHT D2I^Q$ KC,$$RS#:8Y0&].CKH5
M$$1C_[\ P;>@U3,!,W$0F8M-5\2M'@I4L[P4&1.:[5,4&>, TXNI%1%F$(FR
M[8)@,I# ^&(#S'*R#M(="3Z8FHP-W:D8PSDO10];")<-F4[!(#IY!OH:14ZG
M05Z<WU-F?&<O:?Q/&BV#CTN:LLUYLD*C4R-0HR[I35Z %C4>?!5:[[\S$<.B
MV8,@JBN?*QP5FN,9B*IDRC'U19^]00+>&GTXESD#DG$.SL!PAA9*ZOZ:,(HP
M$91=![('%\I N>F2S)5.I=5M?_GE\[_COP?9= ]&'3;0YJ79SM3AX221NJ]>
M>(\"\)\XWF,#"F+"L4D!7$*XZYJY'K [&>W*-#J, .0YR&&B6!FVQ$S$&L]!
M#+-!PQD+HOO":IMK9NXNYWT=%G2CO$GW6?H"&2G@53H9.&"C><6 ($>$ Y(3
M%L+J#5-4]P#Y35@N:\<0M4(97R&.TPITG>^V)Z;@TN)FP.8!G"*Y\= Y8$!A
MC)2=%HG<U+XM('VMA[,5WW=:G7?R"(U)!86P*&.(J&GE&2YK.)_609)(0(4!
MBE"1'I$$)SOR9-1!\]ZA,< +R7H#4533U_O(B6J5!*+ QIGI,(P48OK%Z*N2
M$$EOTH,W4_];YG]<!6^^+8N2L>_3V<IJ/6B$ST:B3CLB.T.!F@ZW-G5<8S(C
ME_0E3E/N[$W<-J!U(G#E*#U(W!O\T[VLR/MR?XK]93W%7GBG;K-\1>,2>YGA
M(21 1HN[M!=B%#(EEX>5+HCGS-H%Z1C41BA/93E&2'MU!2PUO0FV&ES\?!2\
M9G*R:/27$/9=XM*VG\[,6$PVY/QI3^G,L]A_GRRU,[/&I.(.#&H[,)8[T+D=
M:"N5+M0/_Q;3/,C#UUTO[ I[E7BAUQ$I1B. 5C@5N2586<D'2_UP\9L[\;#*
M%]+DTS++=T_;S28YO<T81R!7U(@D-_7AFX7Y@IC+0RO+2^D3@B2G7M\+4JN\
M=2)KROEW,9 09M$3(VEXM9RD["LPD^B/;8$E.D5K)W1[]>""<I1%^D3SMSBD
M_/1=\% R/-"G3$H;5G??>+WDTKA>U/"(&)^X'H@V0E?%5E.=7-.IQ/25__D_
M_OW++W_]/WSZ0HW_GVA.-%WEXO'N:F;71"IE9494U[05XD,7I;ZGG*L?O/_!
M;1!")L^N3\$3;VX@*;GORA2^TFB;4,C\Y7;;,OBPM7'#DHS>6*B"&T]P%G8B
MY 6U=+-;<O2H<=!1QYD)XW.7TY'9IR,PI\-=\@=4I 4O3/1;2E4N>/I RZ<@
MZ>WWK.B#G"M*214O2DE*2X#;=.<%'5P\Z86KQ&*[F5$F5?I^"GT8"5(_%ZEJ
M&3N'K)C+VDN5[_Q;!N6KB_CE]>0L1#V'FW!ZA!.<O 1FY6B5E#TC;UR.W+$<
MCSFT'2YWCXQ "8X(V1/^>T%7V^0^7O7H^(:4"9+FSBM)G'#J!,B?E6RU[FY(
M?D8V*"&&'"2+&22/<Q'?G!T25Q>+FZ>+L!P&7@B(01FY,_"@7J.5WSJY( MR
M0YZ@SM\Y_D^O$1O?-DXN(^70(2';A]^#FES<;L%E]RU.X_5V+:^/ZY-MPZI5
M.R=/.'TB&%1WX[5+V\Z1C(U*0W<26)HU]+ FK)TI7)L4 XE@[2*AT729AO,"
M.V6!Q3P T=$/ET20(XK>*+@C(K;V]$II"77??7>2*!M >D02=+^7!I+"V$Q6
M4288"=(30KT''$V,I"F'%H>8-GO5I%X62=;!CCQ3":RT32/V3(S8+M"< %2^
M<4,_O*75,-VZ6O"01<.N4?IV.1>U)<+%EOE6583>I>R<1B5X##O^/@XA'^DN
M9?N,?J4IZ#(T A14_IL3LC,Z73$)YP>[EC$D+Y(CAXY*),\Q'#,.1+>Z:00?
MPAD1Q8GCWBI>YREQK9KAE+4>X3NN8@WSU>\!'.<G.W9T $]%%999TCT3<0Q+
M$)M=0N:$CHFU(N^<MD+0<A@%'E0V<U.J* V33XD&!>YG)YXUWV@"BW>RVO0@
M2SXY&H]V]7V%L9]<Z]9?]7Q0Y:*R?YXV.")&]V>84?V<$"1F<F\Y/.M: L(G
M9Q&TI0U,7@*CFT0EQH;1%$%[]N6'YR*,'F.OK4FLUL1YY'P@:9IYUUTRC9AN
M/:A\59IUEW1C95=#@D4*>0JB5T<+9L7-!Z#I@!]MC9T7F&):!C',_C*[^0C6
M@'W#'E_0<INGQ2)+DMLLA_/SY(I1?5B@#K;"D! U-B(&1ZK108Z3'!^^)49(
M8(A$C-'=[%YS5"# ^<_CYRW( H&JOJ:]($MTNAB"&\F>'UHLH\+')MN__O+Y
MI[__C"(Z,NN$[B@S-?HZ)D[H#]_0+UW9[ .+*O:DH*IR749R,;F02-^.#;$<
MB;"G>Z$ZX[YF6?0>)PFV^>ZY*[4^CKR%85RU, QX]A)59^N+8,S[>[O:FZ-,
M0R+MV+UM+*NK13+DK=_/6?I:G[C:@J=928KM\Q]095EF1D.M&:9DN@K#H]5]
MERK#OK433Z6*A&%.^4^&Z*/89O>W-KJOOHU CL1U3T4/LY087A%FZ&D.NZZV
M39I6IF;';:=%#Y-SB-.O;?^,X)^^IF\TR3!7Z2*-%O1EFP10?'(2OG%G&"*J
M.&&.5*YX\5KM,>(/@TIKC3QH'##7K>+A"MS9K9#Z]EW08@/;$^Z"S5%KZ[3O
M"H^MW+-[;H#.,B)B!-3&ZAO3?_RU,#:<'IFK-IZB(!1W%AMM#$W$,/\5NSH.
MDH(HBY[Y3I),1#Q^"VQ<G14NA!.;2PK%#P4E%,]6YOTY':<QNA!.WWGZLMDE
M].B\+_;48:.?715=_TXAWYI&%V_L6WJA-Q_LM(L+^LA$ZM5\;$]\I#@,#("/
MM4K.(7*X1(R7R $3'/&?<MK-9H=B.C9_VNDPX[-[-LS,7;2-@_Y ]PD5)M-U
M%X#;JGI$+]@_I#N]>.WK8,/&%(KKK*;"%,A9-8HFD#8QPY@/P6A/\>H,OVF4
MV5!^8>@WHK@14WOE#*N^X<!2"]\5KV<]!>VU3QVK[O"T"!(4D%V/#\&:_77)
M/KHBP*;8_0KR@T2L)MR\0!O^I5$?HSI_<.&,BLJ 5U.Z[-<QSU^"5/BUF,YT
M38LPCS<\!"83U>\'ZEBA\T+]*:JX@9S/@I\SO=>EK%(!UF4$+5CC OM3)?^/
MT C"J;R&3CPAH3%<QK[ W^/R]6K+K"EF**J8Q8*&25 4\2KFV8D/62JZD6N5
MR7W=IV( O#M**(901;.@(:0:!,]83+/T4RBZHFM-)9TY3T>?(ND[E5,#G(ED
MK47*=.8\BQ72I63#>/?5X^//C)&%@U'[P_>'NWMM2=>;+ _R'4_V&@ D7E&4
M66\CH<0/*$FM\2VTF.).PK&0UH42J9WB\Q7C'*<OW)+Z#F4;D!K0VX8PKN5,
M,"$\;4=4AT!-B#M;87@9E65@W$R2N/0Q('F7Z14N1#.S1@Y<.T?R@8.WOY/M
MWEUH^?0!)M787#LQ3Q]DO4D<#):W9G/PL5:Y<V\TW5*X%&TW:,^ A:#.]8$6
M%<)E$*,)4;)-DMUUG&R9S<ZOE=LLO\S2;8%>KN-OEFZ,&>!&(LY.]('%/*EG
MX$@"SG(4P)FAY;;&%I$+$6RDML 8$>1$!*MS%+<#E>:@-78('L)>! =&+X<,
MYEVB'\:]XZ7?@(V%D*-V"9]C3;[H#4G9FG(R$C;E@0 5PD@: 8M#6HKG*K+9
M"NS+%X=;$BQ,X;GLZ_)"6I4G=IS6GH,(8%AT7J3(F'6:4M&LO [4UT]MJFBW
M 10Z5YID,^BGB\735?;;ER4MCI:FM;LW$/W$J'[Z0DI&UW4'[SXRB!6I^G0_
M(;#3$SNVR6]?")"<\.CM\!&UZ7?WC<@<WXNTD0<L?\73W$]<%970#([K9N:S
M^C5G<H9R&H66@I([,?1&;-\"=CVBJU)OU?:8QVD8;X+D+GV@'^7RG29O]!O3
M95Y/O8',1GJD8DO,AGN*,P1Z@3?AS GG_H-,RGA:Q#7TG0]Y:=K)_KB*Q#0'
M:GK7*CHRQ7VBH]8*8G4ZSDM@(>&<1QR3)'N'FLVZ8B/3TWFXX\1]H]@0Q<>B
MXY J6Y]S.U^YS6H5$WA"1-0E8T>Z!*1S+7CB"AY,W-VW9@=8B&E?UT%Y:MH@
MD"88WF+V%5D#=1[Y"C7Z)&(,SDBVFN9ZN(P./;4WJQ4- =.+IV-#I3)C:!89
M8S(2H(1G(5Q'XKF3@[Z*I<PZQ^IC2+FJU38C7XZ:#IRUQUV&.L><D7K+385@
M5 *U&8)1(T8U>'(2\LP+NQV6\VM%;?-57>L\%1)#(PI*5T.E/A=Y:J'Y2BAQ
M\;./.<%$PC(CLESQ4TO]Z-G(K.-HZ#)GEH5TWP\97#$\6'^]K0*E6-/V0-_Q
M-_W*/AD%5!UJ>(AG)E(BCQ3P7 E02TY=QK5YF2)CP'_M\CP-<L"; & ,F00>
MAWU=C)(HB,,S1V8$"<^@L9O DD</'O9.$?66R_>,_Y!\H^4KFX61TL\LOOYA
M0,M;"BA=YHD-)LN^F(5K=/,A9:EE ED%&@'R34L[$WBBT3QEFLLVAT\?OH]B
M0.Q4O96-9 ?-011#_"*+L9%474Y"6WL;#GX-*8JJP+F GX^W%WBP>GYUQ7X(
M7=N7>1PDPZ2,/&8A"0594B)=9\D%PP@@]NHCF9,K(@D23M'UN3*0"$9$>MZ0
MPMUW)&M.^H$BJ%(:9\ &?<=K1;A4PW;NRNLYS;I:7I]KYUJXBGD+ACT+A&4X
M7U!S^($.*X!9!%R3PN7..0X*9TP,H/.5N@?V#^ G7 5YOH.9<-S>T_DT&.=*
MS8G1W $_-;? S\Z/']=ST 3;/'DF1D3B'&=6*HC.D^=D+/Q.*)7%ACHYK\[1
MFNN<:JHRBD22Y-G'HW3L&5 2:]NA0&N?U(KIA>!V9!WD;$<3]FV\4%<I*D]L
MI]'BXM='64:#;JQ!3!E.FEQ\^K5>I./*HAE2&.G5$T+\2A11F:/FUK094A;#
MDFX3:"10S$&VUN^^0$I[[:4F-JGC/33,Z$?&(56H55E)B\=@!RV23TWY Q)$
MT)CF2'4=D ]WPPG-2.DXO&,%DAD8>6CJPS=CPNP4%.#[O#M\J&,H.?=2#"21
MMJ'V=KI_R%+ 'QG-F5$U1K<+BTL@,<0@+X"=,(-WBV]%R>+WN@)1$_P]=8X?
M:X*,+V"[7D.1N$0]D:U2)"=77MQ@QX:2('8DMV)HH0L]7]VL-TFVHWV3@ 0C
MCA<I@'/9B6M\Y@",SCYVP="9[]V9R-(=+T1%#D2R,/<[^Q8DE[,3TW#9'[VL
M#DOCVAJ!]ZXW@RSF3]P[N#1L_Q%JS4SL+.E_ZY5"6@<)4TX]UZFB0\IB5LVS
M#;;AB>3@S#PC,4S@/E1#_\+%<:4ZX^FP?,^6K]FV"-*(?2E/\4=)*7;P&,1&
M_/++YW]#+ E79_C PQ??!:3-2+*8CBD(B\8J;@W&@44R:R'$<KC[)"S=P@W
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M,N:4M&%#62=A42%%7LLR^I99=/E)L#&LL5UE/S0^16BD+AG]!]X 7AUQ]!I
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M;(,JACE_3N(7O),=GF8BQ^M[&I<%'A/0H629W:5OE-VN)R= R(0XI,O/'VS
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MK21RNY9USS,BRT_<I:*"36<C;M*^8D3438QC<'U/<QIF+VG\3_2A7]*4KF+
M9Q<0#^QOQ3:!J0>;[#[8%'2^NMALV!#!6$*G2<E^=!^O8[YXIUX9^D@P]"#'
M0JK!$#4:;JOB>"#+H1H1$4/"_*MJ4#_T#)K6K9JLO,)"#DB"4X50?\C08?A&
M-&A\I#GZ7X?Y5"15Q%[DOOA1/Y2!I:I#RB!D$N M"HAWY.$09,U,Z.V'%E?/
MTAT!(VZ(X5M3KYWW*JX2,U6K5-ZDKB6<D20"(G:^6JASAH<L(.6O&#)[M6HX
M*UK]M<?&U+ PQZPZN$7D"X<V>JJKYQDU@F';]1K\*ICV3#]!<@P.YY.E#DM
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ML$H@'+&]XJ#RF*G$+4*-5V,MJ]7U'CB#5+]3T98T4<D"YR64.I/K)::S"L!
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M)]3B5VS@%$/?I.;@J7B=J\P&WG91QFOT>/A976NB'3\RYZLGR';&Y.&K($D
M+EA.C'CPY$J9UD0\<5JS7U7,"><.EZ/:)_*%L?,IW4V-#</5R <28>%:*_4?
M1G[SL),;0_@+FO/@L(Q;RPN!W/HLB2.9A_+(WI5FQ7S5A$LOJE.A;PV%D9YB
MC /]G_I(X'.Q@*<7!NS3*-43ON?.2-*JIS!=FRE,TDOBJ@_@*[V,7Y84YD$
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MT,@S$: =*G(<*60%GLI$>:(O:%#VKBZL\FDDR3.0PEXRF"E1"N>BJ!M1W#O
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M!L!;@&E#('P,CA'D_<V1D1BK[9P+;>=8)RJK3=3T("5:$"4>&:O7X/2BF'[
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MYR!:"#D#3G$JI*EDUH1RY,A\>+JZOWJ<7R$2SR"QR(<B3$*RR4*.ON/*"3[
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M).*Z_JC?8$UX-$[)(;2!CD71:W9K$!/N+>\!AFY@PGB!R !,MOE*RQ[L48"
MF'1,LS6:-#F&J!MD_&:6>\)8(' -4XAT42#RK_^;'YOE:P!I9-I+;LHMGN@+
M</U*LY<\V+RRSS+II=(*>D0GZ!@<8S 1C'[>&C4WPP9%>+[Z%OR1Y3(MK]?,
MH]$ 04^@6.4<NIW[P80POA5!R56F,\T!ZNVSV3UO$'V!DR87GS[7F^8YRYL?
M4!CU"7,A/C=Z'#I6,(:4Q?#35JM2D\B1(/,TC-?K;4KOXW5<TFB0O:6($D'5
MU98:9O32#JN/VO4F&F;TAB%6%\%Q2ZSG_2VQGKN[LO%.MV4>IT4<8I#EU+AQ
MQ6U_ES%+%^IZG8OH)RQ&QN,_#NL6IS.=AFOLY27'QNGUF9CI .[DDS%IGZ"^
M +<R^?7SC #.AOLJP (3#R#9*!<.WD5<_/UR!_^]#<(RRX?JZ%F($O^*%_;U
M8GQ@>^&?G.'(S3P=SH 925QCUZ^LZF6&9@'/0L3(+XUY-^[G'5F^QGGTB>.T
ML5V;Y;Q(EAL.4GERZ"GZGN8TS%[2^)_0S/3CDJ9T%9>%+#T!//QM DDFMWFV
M?LSC+.?58.S9QZQ .(53;4&=-6'TB&2N&MEC<P#.'EKAK@D.0-;6P2MJ##_6
M#!E'C$"M*+!90,F$WDBR)*=)(,&E<&IV-'#:YW7[7,11#%WS*F3L'NZ BAXQ
M$;Y=^P0&$\3X\@/>OM>E.@I1N:I)YF40_OTFC=CIA15@MY16":4]5=1KCD\B
M.9%GQNH394?32C##B.M&L7.EP;H36.Q!%+3B0( %5&80R80P+J1B<W9RFG5^
MQJK.[,OJ,!6I'8F .QX 3J5W+'8/#H'PJB!RRTCA6<=R&]E8R.I3B_"SAO2C
M@GWV3G;2\NDTJB-IDH,*9,^@&P,.Q*AX@SX)JF^8$E#D1VGMF/MUNJ^9"&@A
M&,5PO&U$U<"LFA&5%F;TM,;AC&Q >)FY%M-"^P[8OW1;\S++\^P=L+N=IB^$
ME$8%J+P2VQZL*]53Z_3,#*1+5J#M,QN(%$*GDOA C@!%G0E6:S[:D"]NZ0QP
M1B+6D>\W@D&G"!=Y: PZR$/)D_UU#UOQQ%]",.<WY2>^>\3K,+4:AL)ZP[Z4
M->+Z038Z7HO\*OP;3:#-V_="S529'?DB3M5?O D']1SL0Z<(W\7L&<H=&Y<[
M"'F"-6,3;.]+GH42(< %W4#"8/IBK0^U"7;0B[Z%VX?,TP;,@__YC18@V (
M<ZQK.R!YSQ-5*X/CO1A%%:88>'&]I7<IM&N'MNW6^3B>BB>QN0D8YS1D7V51
MHFK!"_-$49(NW=Z'/0F! 7QFI 9YG+'SD89!439'W_Z4YRWW&WV-P\0VX?8G
M/ ]70O8()[/VD7>=_OO?\OD%R(PFU1D%BL<:6]_ZE*=A(V8T[SMVGX7<=Z:-
MU_)KG_.[Y">\P$YM.UJL3TWE/I GG>Q(T7GLUQ_V>KJ++V\9?' U<D$+=N.$
MK^+XSF/E?66/H*6YRG*XEXNG[?,?[+!?9NRY.&]L,@?D/:]VA[OL<E<YS-H.
MN2->]RVH=!L(7R OT(SFJ:JC9*I:7'Q/LV?H&,VCUYLM4W*!>)S$0G?'UU$H
M[D"TSHHC7E,Y&3AX#_1=ZSP3JL>\7^"ZF^@J8Q=RD);7M CS>%/_Q@]^R><1
M=Q&]@3?AFF*$LFB<4;7?^[;%E%NO[K#KM#+WON5S!?2"^V]!*2JU]++71_:A
MA_$F2.Y2,'ANV2');HCE*\UIL"HMVD!_DOZ])%72!R1[@*;;?DQV/.Y1Q[S!
MGJDW:YJ_L#/L:YZ]EZ^BB7==W^QXU/-*F,F@G9]9RZ.>!>!W!].?J@!0EQ[:
M\;A?/T/PDF9,QP]!TV]W,%B>\GUDG^K?>MC"Z.<KW@SLXBV($]!O;K/\*P!*
M#^I+V\-KDEH'B,@4O#2T^L+WO>/[6!$WT3*["!$PK;6ZUGK2'/RV3[<:=,>N
M5\;4S9_.![U?PBJ^A#:(_>8UG_%^W5Y$$?N""YS3><[VQ5M<^T+V/>MYU@$J
M+,OW Y/M,3I.(.-;\*JSJ%6@ZM>^C^.X"$0..4])YGY9,V? >B8?\N*Y7M>Z
MJV*[Y@G\F*:=4\C>Q[Y!"_:A#7IO'\K4]Z0J U15%W-';8O@22(<S[!'9"(S
M3U'&Z!'NF&Y+=T!&4W$6[0L(+E_9JO>/*U9D/ O^-<NB]SA);-+(W_G>V'#Q
MOV9)1/."]V2$,RTO>/7\$],U[7KZ_M<\"U9Y37@JB?2F=)F.^][Q;@A'=-7/
M27\D"9\&\^7U__O++__:8B?KO_3]!54=W_03"7!^H><I/Y=NZYI<L5_9&(2P
M;PL$=I*H].CP_C6>FM2-I9K]*#L/N_LQ(SQF"R'J@FX^2G8IPZ=T'Q?= =)3
MB7J>E(YV M#BXQ54O>(NU9]!%W5"NYW[0]#U/36 I<<['WRVBJC]WN>9^BWX
M0&U) ]G7[']0)M]IM,QDKL?E[@JFG.98*MDXA'M1\_V%0ZUGPPMUN2WB%)"^
M[0KHGG>F(!+W?FO):9TI&YUO>!:GUOK0</!JJ?<0/@_9Z*\!*Y%&-C%/H^0U
M)<OXI&1[7^SZR'[%!ZY_:XU/\U@"GM=:?D-L1,_L#D0O0-?&[7K>MV_)<-LO
M:$2Y5T/4)[]G[9F.![XZO;5JR6[7>Y_R:YS=X@@3S/LQ6%Y16I'U&AV)]60,
MBJ:5#8K$[Z(?ZSSG2>,'&A%'$O.;M:=_",(JWUTS/1D5XL@\Y@]\92*?#6H-
M7+N_E["S77O=]KSW(V[%1A)A8Y/X>8M'5!*DPF&90]P]I_#3(-_I#_$/T'[R
M]:$XG:U:0:,_TC1(REUU#^_9L1UO^A3O"=(0HPLVK@B_*[LWQOJ4SV$O: @N
MA7@52^?XX[;DF$3JF&<*O #Y &]*'-VE5\$F+H.D(5XO:KXOD^$0G&IJ](*"
MHX9=I++!T39(P&%JO;D]#,/SQ"\H^[3CD T4NI+:YL1\PO<^08B_2QMRH'4]
MVQ_W^=T?'")ZBC\P0-2=A=F/G.<5E=A7%?35 RVO.(*X;4F[GO>N<'091NU^
MY4/>FU8M MM 6IJ$I5J /?"0 3B65CS0&DP>C+COPRE^2?'V99="Y06&&N-X
MCV_YL#=]!TG$S?5[7+Y*]#FE6*CNIS*X;T_B.H:"QQ2O*TC:8N?C518U4KKT
MW_G><)75;,U:P>M.J";P@7%MILI@.2:X-P2'*7B>Q54AZYS:-(>V9[U?,;5*
MOJ]Y2TV3_4FO41VND5RD*=-]?\L2=MM5UF.'>G/@>YY7AONJJ@Y(E[N[-&)G
M7+YK2W+H?F-J&XUI60=M,]F)>!+YG54S&MO8K0].)!>+Z3CUK)?#ZDJ.(N#7
M^2$L8H63-7].XA=[!7/7P][5HO4Z+E4>@/3:ARWIQ1V/^Q:$I[<(5[OPM'<Z
M?[O?F(QR9.]_=_,1)MN(1H!U!=Z>;2F\9C=!#CNMD!'( Q6DH;AX+1&E.G2&
MC$ +_0XP "!&T?@X#WIK*G'J1;9#O[6L4$W9A25,C\[P=,=[7CW?6LGQAIG$
MO!#_ MS<54]-D3*QX(C0RTQ6,>D%3.VV@$L^OMT:[3FF+?I.]QO3%<>R3%B/
MG6VMYL]IE":BL]KQB[K\;_O?\QO=PGXY7_9YO?<^[/M&AI'P],+K+7CNN(.3
MU\(^T'?\E1V[[J WIU"#*='+.NLO]8<F$N_7<E4J,Z%3\SGL3:_?#8?$G:^Z
MW:MUM_2Q[WH_];JB!^U8;_O>\GU8! D@B>")S&[6CAB?[4'?456N+(KKT1I5
M-9[P^954>688@^'Y52V72\>SOK<+7GNWQP6&K8_[%J3KJC-ZQLJ$=4A!.O[6
M;"?EVY%:,XQK^<[HF-<P]KM\82>2FH[_TM)48(\CT_*&;[=24+S"_\$"?&-G
M-<;N]902MB#F#[0GK5ZG/@1]3X;-8Z8R_977Z"I($AI=[FZ"\-5\]F WW#%$
M_5X_*KN_@=W:>@OM>\6O7QM5D6\Q4TO*+&VJEO4'INP90^7J:+\8OC7->Q3/
MQJK41):=E.#?J#Z5(V[3PPAZGHS6/G4<N6*>*C0R=@N&8;ZUYV^<0,9[+3H,
M2!G>^P'9&H_ZWL:6!(R6W-2B#;SD !2/GL1]^ST'2""[[PIT#<K =\(E=U9W
M1L;KS_BN6Z8EJ'$(G!6!"O.] +_T'3MH$8W\(BSCM]:#^_"W)^#).=#YUO*H
M;^V6UQ*@4R.*(0L96J'"%HHNMR4'!(.J [M6?]B[GAWQ@''$;GA>0[%X^M[F
M*6E_U*NZMZ^_T_<THGFK:Z"I"/:CY_MN/14-3-=_M<IL[D3B: /6Z]8A/]].
M&['$(O2KW8X=J?Q[7_*-'=H&]MD2&^YZWNNQ=;)RQS0 D<;1+"X3+H3]I66U
M2BA1(T6QRK]Y;DYWK+XOUZ[D^8ZO[)#WO(NF+@SNG.9FMET:ZZ,3TZF[[,RV
M9WU[G0$;AN['<;WYB(N2XCW//S=;6MA@1+UKY#P\I/P:>[!CNY[W7?Q@+ *Z
M?><K9@GA=K3)TOF"UR3%;?I2 =!+;ZI=#>]XUO>9)X[BJWI+B?:@Y9Y7/-9+
M"4?G[N8C1!03Z!VN2]#VS/2S0ZQNH5/>]YB<M(#IMC=;U'XUE3#$]\T&%)1U
M7&K@PD'"IGJ9+6BT#:%;PDO,OF1:=(<FCJ+D^_H]MI,.H@=;[]R3*/GVX&[S
M%)T^S&RZC3_0_=-^$+8_[3W<P",A(JVG70+K@[XU!$B'.+AXJOWIJ1PDU^RV
M3S(TP#$CX&6;!&4&R#Q%*9$Z:/2]8*<U4SKGV[(18!^(I.]OJSV7N[5Z=-\[
MWD]+R#N5I5,[C#4&R46)K2O9#UO;B!STHF^WY/:YH/_8LCUV\[8W=[WUX>EN
MN@?::1\?]J9WPU"/OW2)8W_2HZY^G84<R@O3%V[2Z+K6+*/U(=_?!>9L7AV7
MXFE]W.<-!1H74T?1@5_+G8$HRFV<%]POD@/"-F32-&ZDXTEX5XN,U K9[;H=
M_;_U<>^"0,Q85@9=L0&^9+FHA>I2]O:]Y=M]R7-U#HO:M#[L5>^K^@SH,<E'
M-M> GUI@SD;M.M$@*VL!G8%(^J\9N]&2T<R#4 *J=E:1'?JZ;PAN/ICV#]!X
M8%*JJZW^J/M)WV[+>OSE8EN^PFEV8+BF>MRW-J%RWUJR&A=9DK!O7^6X'0@#
M<"PUGX?$Q?9E6Y3+]VSYFFV+((T@;RU.:4EIJGWZV!:BY: XGH1W? ,9=8+3
MO:[[MC\U%:^&B&'@UR2N*%5O+UH]1&9[W@I13;S+]N$#^RC#G*U1#,["PM*/
M?02>OD^ [6:3X/H&"20(WB;9^UVZRO(U5S<[C+H#7_4MH-2@]<9%;4IWZ\.^
M==/HCRU7G@OPVL,;,6)^<BL!+LEE9LOO5/'+*K^S,RSO@(_WN[H6)V274?BZ
M#O*N'E=[WO&>QR02/N8YYAO"3?K*?@@- S#2T]*M]I3W?6_\?GA"[2CV@Q#V
MVQXJ#U]-E6/YSC;M[D"=Y<CW??L<UIL@SGGGM;I#E"\:6YVN%IY'$?!N'1T;
MO'S/A@F"OF<3<"E7B RM5J'E,>\#KT% LK_(GXGXII'+F4;2*+(G>X)OQ2[Y
M\'R\3UU;.YC]2Z\_[?N($M%L2*5MR8VN/>+[;A4@\LR8@0\(8,P:7LT#*W%.
M).4[7W^UHJ"N4I6I"-W+N;=IB]%KT6[*CEQ[\-O>OZ\F.FUWL*[]>>^BZ!__
M]S3@,&Q@>!>X Q]SNHX!)CG"1T4U#CJJ6[%[>Y'T&,.\83NMW%U$40ZMI_@?
M]W%*O]3CF*T/^@27Y^&26S;)00*Z1TL,MNVYZ2&&7>UI5=<133J=FF_CN@\*
M"0^KL],S!U?C->5_LG]S95RFR,*IRL]:JZD^Z@A\UV+!T<24NE*58EN0;MHC
M0$>\[M.R58,2->5P+D/=SO<T>RYHCNUN[E)FFQ?20\5Q6*N*)W3)'M@PS"FW
MJ?C+JZX4T.@9[B_V%03),F,W6..Z[_2"'T5I @@TW%NS!TNGX]D)*#P5KHIP
MS8##58$6=IA)>U^<ROK(;M:="R,?\CGHRRS=%LM,E%@^YME+'JQ;-E7'LUY%
MB+-%P.RRT)Z;W?:,[RC.J57CJB"6-QJI]G^AU9!SF#!K0&@$OKZ5BK:"[0Y%
MHOL5WV=F7 0O[!1_$;Y[<8BT.Q,[GO>-^0(.>.%4Z; ?+(_YSD;*XY)I"RNH
M%N!*0=UXMJ8H[7W+]]8RG 6W.2:=A[OYBEL2<2B.@/V.AO9W/=;(78&_@^:;
M@'W;4)EHP^^V/>/;D<GQJ/:6FT^AX<\]._F3+#?:9R\SN#$*V-^(G =[)!3>
M^R5-V1E[M][DV1N'?FAFZO0FZ54? 5@PB$31 FP,,4;9X:C $M)=>TN.XU[W
MK<5T81%?#8C'>"!%OQ_"<YCEF^OH-LO7-$]V5]D;G/)M->R=CT\365(ZE, C
MM4W G0=Y!4^T+'G:5 %^!O8\I,WPC-"V91Z4@>^HB_@VYZO3O%C'O._[8C+#
M8@<T=)Z4$F=J+'#9']J^N7IV&AXPGGC))I>]EV#HIL/)U7S8MY==@WH.\GF.
M68H<<U?F(UE=X_M?\]TA0J3%8K95$Z"IX^X_C8+/S7B7LL,W2!ZWSVQ(S,:A
M<%O?/<[W*3@'ON?[4+<&PTV/.?OA%3/I8HS04$;\]?"P^CY*TU0 9&3)O)_%
MX<XU-?;T8\:+I8ZY^8^D[#UAM2>8W5>LL[H3C7E&Q]([G+UO P/U?LW#V.K3
MU!_R&NR+PR0HM__<KH/G%M6_^8C75@WSW^ZN/_^U7NG1A;^U_Q7?VP9T!,C^
M9M8B]U>#1[&S]J/S#9_K@_K-?/6X+?G'"S=''K&OM=2Q><T49Z%U-Q:N!RWO
MFA6_%S%K2<&UB! :5QWLZM3>UWQ#:DA3KQM['MU"C1"^J45<[JIL&@CEMQLW
MSIGZ_OZS5?D>()*4_*NV_&@"=4!,'/KR!. ^ 'J@GF&F_VZ26655]M>2Z2$%
M#XQ\/CR/S/Z^=]^"RA71/BI9@-$$%2CJ_[8[(7H2]1Z*U>$%6O&;+(]Y]U!8
MLQ6O5(;4A= 2#NSEUH>>[[-4%<$W4^"/*:'?][9OUR9^+UT>3?T!GPJA[ %W
M!?I:#JIW0\]K/N+](,C>8@C<W&;Y=;9]+E?;1+J(6Q(R6I_W_3W0)('2.IJR
MCQC.X(MH':=Q@=6U;RJKZP!?WVF4IJ*OUA6_MA+TSA=\7]KV3)G[KJY1^][Q
MO3VM[B%N[J'" $$!MKNP*6R[X70"&:]!]X,+#G1'F0@HH/NH:I;=K+%VQ,*K
MU\?6\YD/L^GN:7_6/QC6UZM>8%B'OCZ!"NI25#YW0X?:G_2Y3EI-_E/\ 0=&
MRXJT/3B%$_5Y?\KL<]W?+ISMFF.ZYFE?4%@;]G,9ZH/" [9V7UI/Y'&'X?MV
M-D+P%VG*QJ4*_ ].3+2_Y_.#P/9I[Y"[ FTL>%$FP ["71$7H/7"OV1H5*F!
M+3[=7M2\EYB+D*@8EH@&VA:UY=$IH*OO-1V;3_F.;M?07\#1&X*/' !D[)A_
M>U[Q^3V9W[M>W,4S1"1* <3=+Z((RMO4<2 B(IU1DX'I^U8E,,S>%0LSGYB&
MEFHHV/M23 Y[S;?#J1]@T^7.3J#-#'?(SO>&KB.J=IKO[4]/Q[&B5>YB".X
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MBZ#O3V/[7"!^?7GS1COZM-J>\^]5M>%U=5SAW6]XA.MG7TJT#;%ZC2G';\R
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M/='<C%&,O"A^\M(I'IK>+<HR>97*S7;.7%8>^2U\Z$W41S@&*7'W##?P,X>
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MI"#']B6A5*RF.0].M D\"4M-N[\JWL#L8R1N3C<B#0_'0'[C'-\I'6B13D
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M; ]"S]4%'LK-G=C,B-XOT::_1T=.8ZF1.9VE&H;8P?!05,KJ,5QA7+0-TJ0
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M@="/5C#<_/V[+\_O9\_7]_??_9___!__\7^]?__NYN[^\=TC^/9NYB?P%=S
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M ZS@SH/H5R](@>*TS_H-,%>\S?CZ30Y$H,/<=4]V6W':O"$&6,$O4;3Z!H,
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M<"'XDMEG?_KXZ;\6@:=Z;"5&LD;;ZU7K,Z#]';6%);D#5)?%Z&U(XVBU!/%
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M.UD<>8?;Q]Q)K,^&2S#TMC8(V?R',V?M+D]9.@4FS-?S-(D3?#Q@N,D7E5_
MNM4HF4\: Q(K0 F"/K[CLOE\"6$2/SU_X=(!OT\?[.\9ODDSNWI;I]XA,("Z
MBL(T7D:%?+9 T09Y]$D(F_>Q>;-L3Q( 0ND]I':Y/&93G.ZCZ(4U]3)-^Q.^
MQ'0S&M'G+@] (I83=SU)VO+90[^#9($9#^:C:X P"[WI 4293_;(XNK_4IZ
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MPUX$J[4Y)D/C@F?./,'UT.ADCNUX\;8X?*L[+(]54&8Q($X/?76.SC>=O#C
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M0W5^?8U;0=\+,I;%F1BKZ? [?/N&6\(8K+[$67ZF9)XF3W"S;2K;ND;5IZK
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M3Z.3V$(.D*RV%L#'H\AZ(UMNJ$%*JG:X!@I3'?,BJ/]N"ZJB&!AF<UL6P"O
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MKW*TE:?H@9FD2C$FPM&3)1-KHY)*VD&*ZBS]M ABZ>,ECR6J%X.%UV-@',^
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M<1G&=+8HMR5WYWS'+I;"2\O/V9"ORS,+\6]C-A]N H!@'%UXH@%<+%?(T1<
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M($DB)I6<'I/[XJ$!9I1,YKB):S<&)JH#W>20QE0XLG")CM =4UYAG+>9Q1.
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M9P+\^REG"IQ=7/4/L>C=Q*(K6\6B3T^&GCD[^_7T9!PZ]MG_ 5!+ P04
M" !!,FY4PNYT3E<"   ;"P  #P   &)D<W@M97@R,U\Q+FAT;<U676^;,!1]
MWZ^XRK2IE4("I*U:8)'Z.4UKJZBKM+T:<P&K8"/;69+]^ET@D1*A;=V:=!$/
M"'-\[O'AV-PHMV4Q?@-1CBRA.T16V +'U]\<?S3PHF'[2(#A$A'%*EDTR J,
M713XH6=Q;ATA$Y0V< ?NNS!5TCI&_,# H^?*AB73F9".5=5JI! 2G1Q%EMO
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M[Q*5C*1<@M\CA!9^W@)(@C@\UDO/N4QQ<<MA'BYC428P)V!IR:E;@$.NQ8R
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M%_Q^@_3N+U?7J [@,!!2L_&5<*1*NUZ%30@(G4LS+//3UYM5)*H;""YF5:8
M?7HX>8/1=X319)<Q6GG_<Q1AB[FJ/-V3U5A]0RY&AJWBN-0(EB4ZNVK:7!D+
M#_!U,DQF8ICIMQ*. N;>7S<F!=Q#GGPB7ND>@Y>[!CGVSMV+(*_9@=<KHV;.
M_C'#NCC!$D<]G$DJ6C C@C\P477+G\BW_KB5-@P.38_MKP\%\Q[;Z??98W.O
M6.?1H[7(=YA^E_&[2'T(P#?0_F<%]T(]"E6W5=K,J;:[ 7/F.;>6L9?H1:2
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MG:*AX3&GFN,$N$^D728AL:?"8'+K/)EQF;"+L\HP4,A"7,=&.1@"CPI!,3V
M:3DE9DDRM/ I]_Q. ;Z%# 5AO: ]B]>(V#7OMX;WX>[P?NV N$#_]4/IVEX
M/,>(QTAN:I2DF#-0 XX!][?(>*KCBGW@#S@-N>!V@DGULF'1%SFB.@YZ-_),
M=&Y_[%*3IW)">:%S\ '&;0*B2.G8*>!VRD,F(;<7X K@"<O1QZ!((:VG._@B
MGD-V4!-^EP@?;3/AV8B*PD5#9 -+$MC'\A'8L5FR'YWE]VN$=W^Y?(_J" X-
M(30;OQ,.56%7J[!. D*GT@RW^<G;Q2H25@4$Y[-**$"?'G9><W2'.!IO,T=+
MZU]D$9:8RYVG>[*<J^^(Q9AAJR@J-))E+IU=UFVFC(4'>*@,G9D(>OJK@*6
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MH5M7<$/!XNN/Z)9XOH1_YV2\26E(-:I(-;$G@V[^?VCTOCJ-$71,Y/?CT7D
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M%CK8=2H;!L=P3$U+8?#3.YNGB3E3P.Z/'\^#Y7. OH+I45D8BQ=X>CO97C>
M3W!/>--=7?T9<!%%Z/1ENWLAE.:L37FOHS_)[5T;W< ]][40+:7T#>7UVM>4
M[X%NC"WB<Z+]GCGM7^V4-/<Q'!$_%-GY-WQ[<C"AH(7,#-9&&47I)0*\ML5.
M."JH8YL24(O.OQ0&'LPJ7K6)N0%\=M?90GYUA)XRHV@P*OR^V74A]VSJ?JAL
M.WG+YVB@O&^BBXHN!<.^X7_1DVRHV+DN1<7.%A2U-E'+2KP0/"2TA%H"#3&T
MK2<QPLE:5QP^#J@0$N>105&WP03FT2N^HK_H0J+_S@# *:$J)'J1.&K)E65,
M&4P4.Q>@=(/]H9OE/Z1--.4]V#\SO=V</R*\76O>0J+^.]:G0L5G(,3DU07H
M@WG<]<.B/\TL4KO$UNRZ\ML5JR,DF1R&,X?7QZK1,7\W5P7D;.>YD<$+;&:V
MP O66X:'&S;GB89GH-I;&=?FU2IS,:19MM(A:\/22ALR)3E3J0Y:-3-02.W@
M[^O0,U#B'U0-PX@KF7ZOD3/4HU_XDDH=A9U/%_*23ZPG[NT)/*SX^F%V^3^8
MY]VNUS^LX<Q#=9,!3UNRKCO&Q==:;U'S9M7WW[%Q%TK;5]+Y ^);4$=1BW9D
M\I"O!VR,VIH6'&_W0L-M?53>X?P-6]:4 :)T_(_%C>+C;=JK@*>>'\%1^<9/
MZC;SH60C$TNM%AH,#C8XEDJC>5+K>U[0KD;E2&'#BU=1*;?"]0]^(&JDKV<E
MBK+;:,*W>\!G)[VQ$E4KTWH#"'7A;\390^9P3;$!3[X[K&G+NVAV;X2R*XSW
M=&&B8D))$Z6PC=+E^FV */S^8GBY/IG#Z9_YK7D4)H,L(_G!2_-$ EXQ;0N4
M;2Y$9HFO\)Z0PO9IK<68;;"S8,6K5DH=!*@LR!&X:%.1VDQ+4^W4;ZJ>NEM#
M,O6!]LSMR> /&NBE*F6QE4QI7$F'2\3WJ2N%<7N'G9TYQ+1M)*8Q;G>_5XHS
MK9*C=NK>%TNC);,2#<MNLT=+&)HQ.\CLU'M;>2.,(@1=4=K]G4JS,E+D XGV
MF44>\*ZK4*4;@"%? M/%AOB\PQI([?X<LSGVHQD+OJ]/;[O$!^I,2@^.W<]C
M.:]WJI#.UW#-(GTI-L8Z=M5G!Q>?F1HD3CPOIWMOO>+.XQUL=0, 3LP?CX.3
M?= (+S[? %RT/B(DQ*=1P>OX]&+\&GW+X)SP(OJVGY\I;6?Y4O8PU&+Q84[.
MYBE_A.Z+[\1O'[RQAM[N-N+[6W;GB7W[M%&Y_8ML/^C*$R(RN]_F8)4-!*%B
MYX^]#9:!YS;6";.5CX(/I%X_M/]S+\M D;!;\@:04&1JF9AS=39XJZ!X*9_2
M7WM4PN5[K811<&O_>-/:Q/PA[\K9U_RUKPK&8MDUCNF;X,,E<>2>E71PWMJU
MR._]C3JZ;7JQKKP(NNBS"_8TNB<:/Y%<W+Y%]MC>=C7DU.@3IF=[)1FJDMZ"
MF2LY4W1H8=\ BC"9I+]./10G(OBQ"W*'\/J\7IP[$9V?=8B^AI?<\\3F.RSY
M^0D7PPEG1_]AT)*HFJR93/3,-'J/K!,87;N7T.'S=EIB3M8K;T72J'2/3[WZ
M\ >(1FJ?LZ^_.*Q7:Q)MG"=#HN-XW1Y")!0D)*1(E-'^*TTN$=2V+P9#QF36
MA):*-+%Z0=44V>IPZ\@-V/>%'7R$.E^;!)FJ7> M@F$8D7),#$E16U*NG:PX
MK8IE-@HZQ?:J<W/<!X(_\8X(@"UNL9#(N8^.S[<_K-\ * VQ-G MLCF60@:?
M#WCG7VBI:*M_;8C(-$FC?B9UQQ;"*W6D HF$L-&_2 ^SO#T R?Q3)S5 .H0%
MH&J2"))_ZZD$,3^LEW'S9@%\T(!J\6D=NMKD[)J*#^1-VKK)",](+\C1V$RY
M6+U"\&7< $89@5D>2*^XSPS<'O934=TSXJ">LJ%\[Z\>_4(0MJ2I-U:6Z>'_
MKHYQ9?N(\+G07GP7^Q1;8PBTAN9X.([P3S.V'+30!'KE=GR?4IQ:%#%;/(=[
MY['#&%A,*+IH3,6NQQU:Y]!\Y'D;QDYE;&<R7P88(3'-SIA>ZEOHJW"OSLUX
M1J)?&7QJR%)G]04 W@%V]/F8MB<99!6^JF;%QIGE2.=9V5&_N&NF%77,YP0!
MK=A?)N(J_%FJJ:H.OR"GY0'NRUJ_O(Y/7.%5M&AYMQYKY>Y@:_^0<4ZQ4>[Y
M<8=K"C?&F8(*>G&D30?]/GMO=K!AR1,1V-<!'Z%),[SW>U4)@YIZ9<)(+<,]
MAEI%A"YC:LKP,^C]G[M=- 59>^3T+8GV7N?O)P<[WLS7.FZSK2NA?Q(!YJP5
M#6XI$2FJ^4=M*E(<]JK%GC684RF5U*-'Q_4R31T:R!F<[^-U&YSQG^(GT-UY
M=>%G@*U/+FB07$>Q2)KM>GUODG'$Q<[SD4]9/ 8$7!?&<S'Q4A\9>2!BK_PB
MPI[D^M#QFF/V.N9>(-@A9UY8_]7!=#\1Y)7$=^R1BL*C.N\"%>J '2/CUTX]
MD#K",\TP%KEUR2CKKM(S)1T[FY<0'0K%=C"#OQ+!]>22[C=JK4%EJ2)++4)D
MLL<[P2<46*/'I)[U*#_%?;_4]7KG"QRH7OEL-_?T93K?B*9%O4J*S: 8K<UD
MY->O'.9(T)+PHASYPZX//FQ#@:"5/&Q<IW*/[W+Z]](AK'B_SR7E0<QHD=WA
MG2/"F%(4QCYL'2(62\*A;CL['$E=.9WM;X''.6.76@[[ IK>A(2P"HY*A9RI
M=E?\N6K#P&N@HHW>H87B1&63\+V..KRM-$SR2SEJC=65I^:AA'A7(G'J$.'9
MUQ4/<Z*_O.L31;*-5B"Q7X\,:XX,,/>$8$W'7FV] 'P#/,/.$BK- ZEY?QW-
M(.?X%/M1RM261$4*@*KXE>]0GV1FY<Y99CR/5)?TYD%[43G6O@^$V-4+1031
M6YF%FZGXB"HZQ@&)^5AP[X->DA\S1.E;!+T7S?$(>37H%=Y+AK?9O+^A$YL"
M&#)>7=V;$2B.)SO7W%M6F!/ID^QXXY:]':9S_<AF>=_Y@;?GV_&OXC1;987-
M@\3=Q*QU@-4ZWKW4 !,]G$5Q'6=UN .V91S_F\JGI W=*]2R7(E%7@X*Y#Z&
M9*1@*W!"A,4^ZR;ICUR=.S_?];:(^RLPM2=0FY-S3")/!(N<?(@-*HV+[[JC
M@4/*2JZXK9F/=J1-_++H!<ISK^$?!JB2;@"@]F+7\JRJ,W\WQD,S"(5=FW_X
MT[LUNVQ?]^VV3QL9:G@>LE!]?)#2MJ'K)?.YJ&@M9)-[&H1@P^(J(-B6>6&3
ML8_]^0AFK5ZMT%Z5_ (SXN,,-DP^FIY>1[5=*^,73S]X]:W2Q6933Z[<=:W2
MZ> AC(+,(LAM[7G2W8N)]ZE;J!KK_0U :%TF2D7G <?*F#41IYDZ->8]1XAA
ME0%X< :U#_W(/ZK85A()KHR;!-M58>V:)&@5I()./<J,),&U;,UVXDNHRJ^V
M^+ 8'(B\[8DCMB-T9K;+TX>F0]CB3_P[R#/3?<E(HE5>$$3RQN#5LK%LDIO7
MP&R:+S1S_=._Z"I=/25O'JPN2B51"TF<&LAB5M>,K/F)& AR3S.@LLG:.J7Q
M>GY2N'E*2+Q>N@42*8G&,L5,MU\H:*>0YZ%_UR-KM,M6&_/&Y?V<,/XV4W8?
M/'M32TAQ4Q\DJ_I*W(_PI<'DMRWEK40]=\=W74'$M8E[B9LB^(65"46%]^:K
M:\^IAF@[L^'"G>NC3SN$G)>CAE/:6:PP.1R!LK]#\;_02%?G!.H%*'NF_0Y:
MJZ^\)S,G(\[\@\\@9RDCX6P@^0,ZAY?<?DC+;T=%L<90L]'64*$IIMF#3G'6
M<KU?G_G4&T<T9Z&_=CHG:#,F:ED7(ZUE),?QI1YE93Y+AS #_F/[=I0. >P'
M_^P%.]:3BMG02A."BC?F^>8]MLP:X(5Y&%)SDH5]]4NDWQ$=-J+)VSOH]A_1
M.8$4WSM<6PUV^BC+>3SZO1P^C4^V*0>HBID_I\>&.3;2>&1/PM[R[Y/_"/NY
MY+AAD)F?#P  A-!T)N(DO]6&H;R+KOP?]2@6/LNFVJ[$/GO?=K[80 AW-G@^
MDJJQMYS..,O+U">Q%=:4I<]DE?T]LE;PE_]'-VN,I0\+T&RVX8).$7P89T2Q
M?T)ERSN12J8S)1.#/IQ'1-VB'0:/O4])^$LJ*J+A04;_VM71&8(8I<.D[@5^
M@G7S#9Q]51A=W!M(WS"[P]W<_DPBW%&?P^2V(K7[79'F^UG+)G#<<Y ?A1%^
MY)TN+FT]8)9L__:=HH5O1C)"YD$F:P$M=YHT%AMV*Q?['&Z)__562\72'$QG
MGD $G^KDX(>8=B;]2H3WVXOQ,;OO%Q!<AF!$3.WL1ISF-C?M$V#6^]E[R8X<
MTPCI!(^I0).AMZ?%Z8P31B;+/]!=WWD@&LAF4N7W&KS5PJVU*DND']UQ.Y2_
M 1!;I+;6OE,LR+@K"2)*L*V QM[GM.^:<SY5O_1A$UI3KJTW-D^(![N\:XK1
M6H0<D=@Z.>.&N#!X.:M29)DA1@1I/X^YH$.,S1J>1R>ZJ;[DJ N7L;Z@:M,*
MN &T>?D,V_4SX,D5I]CRK.IY(1.V$(T4>LB,%K?>I'-VDZN"0"JJ@F1M]U\\
MI2@_#@C_?C83/C+\@E9GWU8<X;(TT!^:6F3]JU5#:7OV!;3>3.]:(VN?339*
M96^OVM]=SG+."#W/8+&Z.*!VT\IK%/%FX6T=.<:)XTB=R:^%[5IJ[O?5P>4(
M*Q9N;U7(HK#_OT($#;[6R+%75)ZWI>AJP^Q!#LC7Q13'.Q)ZGO\Y27\XU(L(
M1JM#"\Q=)[MX_25NDNC% '=:TJ%ZXP!XG1X;>6(SVOC8*M5V2+&GR+12.#"/
M-F8Y YL:NE?4X[2J93%@8EDH^D9[KF,059>-21)>;@^?.-\ ),C%?Y6_H7PO
M)7'IDWLR*W/RWO#P!F!S _#12)KP"4"BLO"0]"WS,O "9_H&,&^>C$PE0V)P
M@'_EBY<OHLH^_V+DD>6Y?ZI1$^IV.3<$>/HCI\/\H"^B"XPO_ PO#?JD0$\R
M7*Y"D3J#8B:0KA9XQZH)0?M83L>9M'I.J<E:U2W8;!A:D9N7\*9.Y!7),3'
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M0A6C>>(+C\=O .OTXLACF=)P[U=>.Z3+X+T(:]3X^_^,)[Z%S9L"NT*F2,5
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M"-:PU(_L<K/X2I5&$3Y=_<(MM@LLGWI)J(%RAFL7<E_%IW%]!IDS(&9E-]V
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MS"V6^%?7U:.'P,-CQW.(:,7+B)3W+T3?6>$,-AT52_[)4_3?\!2^C)1)I?Y
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M;.L_+A+.\B:\8J6A?TXVZ7'4??O"S$N4OP:1:ZML^>209YK2#S)47^\CV*;
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M?1[QZK$[1C;6F%D>]+JSL4.RI=]AQQTF[9Q.0U*54M;4]Z[AE'K]SWNSZD,
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M_;)C=X)W6/T/,8I6FWM%?M%REJD?>7U(*?:Q$%6CB%-K^-=$SQ<)E=_<,.T
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M('@R,^<#9\H.2IL5IUG_,B1_FZ1&0 <N,[#.)%S(>YG\P<+F0-NNJPE3P/E
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M.HAR7.'JYE_>6RTG8L#P]V>U<(QJJ>[0UZC,.H0J+I/]E&$FM.<B?X;3Y(
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MDOQRLN1W4,#ZMQ@I9HZGIFC7L,XDGJI[':[,;V)2G1U5=7R9N<K-=8K.^"*
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M:8C'B^);!IN]IGZ8 ^L[*$6WCQ  N6$WB1@$< 6EWN8?>]LINZ_Y611[I]?
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M%1,N:7>$Y-G6W9H]9\&)]2F:DDLKZ:)<B1;X%!T  1SAKCX0V2L,CD$ %*3
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M'WOR.@8=/I \(S6Z[/#80@ ?7+4>7EX5BT"IBQ8^1\D3.S$E!!"^Z@\\/(,
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M7Z;[^,EMZ4SDN^NCDD-3;<C\<JCU%!N&(FM0?;6LD&CGO^.81*7M?16/3'?
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MRJ@*KN U=4EVX"XOZ U^O])/E1EHL/YO!0RJ/(Q,U[HXQV*#USU'652QHC:
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M;"WPM$[ZI<5";>^F'*#B-GMMD1:#@Z_$%1THAHJ.%_9(QL8Y==+?7Q=U4=K
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M!'[O#F=3\9KL9*RGD,@W<2C%FM)U ]2L\6#V3.K/E/S[GKKB7AXMSTL(HT2
M59&.E2!VL^?2Q1</TE<UT6-[L8?M=[&SL:K>4/OXS4]$-%>&@Z2S&.V-$<S+
MST,(P+WN;A("Z"1(!XWS@O[)Q1$"SSFJEG/;=D%MA,9#3#5MAIK!N]TLDT4F
MOM[ .29=8J^0EF?DXA!Y<J,X])ZSZYU8_Y.I0(2\]CJ!Z"M/;P7^HV#)*OM^
MBOHI5<[PIA-XZ.K\=%2<Q]=6OKAGOW94?]MK1QD#:4[R"W<HH]=!E9\A@%VP
M].L@"8( [F]>Y^9!()?//PK^4?"/ I_H-2VIYK!3-7'XTBZ%_@_AP@AEPOF&
M-74-N(F8(!NNI_U+Y.C+ ]J\EK-)SL]&CVJ/(>,O;*-+:A*FU*%Z5%T5A5);
M-3HTBY/V?36D!)&JQ)ZWKW)+1U90"?;(A9F[$5X8)5L/?26V@1=9D7T2V7CQ
MELY##O3K==5B'Y.DR"KU:H_^^3C;.?/,\M+K._,3,*;O-I5#_R _DCOOH?ZH
M&M:(IE'E (AV4=Q7(RC:;8OXKC"D\?=JA@XNZ]YZX,6R1',@4JR!CK#S9BN-
MW311=!J]WN@I??A/)^+=U&=>&E$S;")Z>BMR?76]9+UKGIN=@N_T2L,$I+&2
MOYAT/9GVI'^\8*E%2K$%J,A06Q02"S0SN#="  \'1[9T SN?'*(ZKHEK@J#)
MZR3++?4N%D=I_63WX$&@@I)Z](V (K<^:Z[K@5%C5K_?'&[S;(3#/0[?%K7F
M\-H+<(\$5I)G].B\) BKB#E<IX-=?$.$9Y9LKT<8F/M<K> W@/@.H@/(37/P
M@?Q?R9EV6:%0MB-X>@[RN$RB:>'-?C/5IS4SB9'KE6ZW=ZSIDA&]2M]$/1DQ
M[4 )=#_"JUS T@@TP\I[\O>1W+H/4\N8[T3WODR167\<9%_#M,/MDZ*1'"BO
M(O+AB>H!?*1:]R.P8-H7[3\E&5R4EA$Q,5FB#G'+888W+PIKE/:0)BHH7UD<
MXXE=CY8D60UXWDY'5,, 5T:Z_*R86REH\E^@B-='RD&IW[00MD[-"VU33<B4
MV1+G$/ZJ*.?45Y\3B8?EEK^C+\"YE''&"P\!:/XB9:Q$MJ'4HF)Y1R:'E^SN
M#@%(JWH/'G0N!]+MY23]@OGBO)]Z%8=OI.8L63581X>H@_:Z"C0<1\NEC>^
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M*K&QJ"'W@,@JRG;\:0V413W?JNC*87M]<Z@*0G/C=5T?0RDIN8=VIC#^+KZ
MODO" $(ZV,M*DH"KJ9<5PB+[SWD*_P]AUTW2 (D"'"HR" &,SPDIG*;CL+-\
M$UGY$59F8KSPNRC+,S,Z&(.:5I"E>MR";R(GG9(>;QZ4MZ]J/^*D^J-UX_VX
M9]<]R0YM3O'*3I!V9B#UG_@J3/A5.M*PU.UB\&;P53Z1?^Q0=2Q]:/+[N^G[
MH9IONA0WQ\1*ZJY3 M3J"R*N='3Z1F ^]LW2MUIV*]D85L+<XRAZ $9^'NN5
M(G7Q%5V&'04MJ=QX1'L>;OO4?2^CEQ.F2.D</O -<A +#\\WU!ER;?QO0@W>
MHA1#4+TNQ";%W';<ZOJDL8I*N.!=KU76J_+?(G$$'\#L%R)7>5BF-@7O**1A
M\0DYHL5S=]8]]WT@@(,>J4J+CLY=O#'-:L^@46$HE;-G?W[> \G#=NGHZU[N
M1#&F>I8WY#Y//%X]R!@GV] 5>_!DF"BEP\H/)URPB6G'*!7YZ/YN-ICG:5^_
M1V?RIU,IJ >'^M1P'4LY?AY&Y=P?@7Y7)2J1-X@PL%MP5:#B/XQ J)OS;>*>
MD6'W_O:$\"4MA@_Q>T394'"HZSC32?$FX/B6J.WAREF/:DA/EX0-N:.S?-09
M-^<[C$]DER?BFAPTGC+<4GL98:3+E#9>!'N%_H?DW0H(@#2YRVU;BCVT.D?)
MS3#F_H)I]?!^ZEV=XL4PV47N16VM6FAF;B_"V*[LLCH":?_C[DFPGN%*1EV+
MB@:&L.2V,/LN["W,;!!3U)(H-B)2R#!FN>8NELCW5M>9B#S^K'0R3LO1:E7.
ML17^OM*WBC2Z$=_%&GGKUW:)VV4\]<^ "UOH$W/PTRXO-9;2$( \#4$WR<(%
M:CT@^!'?(W$A0#YXXN_$*4)_\:D%*UX)@,0OIZ;GTI=!?<FKUR-M,<[GCWV'
M2ACD%&9&M)?#*^V*O.9&O)1/P)(?&$O@/S9+9F?\$=.8_I>-DSAL"86F#QZA
M$WVV9#7=;0?'ZX+D85>RH[R'X@UMB-_JK#4.;0%S<7$8U+8S9,(T^;P F,NB
M8(4D/7&I RJ_S1X<5=]I5:DH0UO3_._(U7'E6,HZ1%HDW;;MQ+G%$$ GDPV.
MT_FGLIO25N,(A]WG85WBU1+V X6I)T=S:RN!#G?#&Z,M"V\%\T7;$\2GHJRB
MJ&V)Z("^A%;=N+- -M^5O%PMP$/EP,WO4M#N-FY**2^@=\FAQ\($;-]:EBNM
M;Y>4%2&%9L\;[_+.N=3 72.N=VH%O'_+4>M0VSGI;"[/OH!LT<LR"J]N]ZG
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MN3XK-3;N(J-B_[#CCQ?O<5-:&D[Q"1]2OXU'.!6X''%=V>Y.2 RB1?S(/-B
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M@>G!@OWPH]F8%G/Z7 1 >5-08?N!NAIF)@V#[I=UU!5E0_L+0*>!P"/5^=P
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M[AW?ONRUH-2<F^9C)-L4CN)O(9,?Q6R2=I*_"&@G9^*GF2N-^-YQE7-T-JE
M2M8[$V</F?.F\X31&>V/@":G([W1J>TH6@.?*BA&Q>GQ_:<R@A_/1/ZLA.2-
M8%]H[*?<0ZK,"E8U-71(2YVY%&B_'G<\[_-?\:?G+9HI#!&D&7-N1?6KDOG(
M%?R\+GTP^].B_7, ?\)J)6DGY&DOEVC:L?"1WI7+;U.ZQ7/.S?W.\O>JW+I
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M9=2U'(&75P KVTZB+>T(]%[JWF.W6BF:AX[>76\HJD2=R:G,?''NG#;6]LG
MYGR4<.7P<[7)#[+DA<?1DT,^]:Z()SGK33E,.9&=K]%9\6)H*#%>Z"5O$PT$
M/;"4?)D'6W7W^^%_BFVXJ]]+/5O/"G(L@L$6N'B.'RQL2^RYR/J: 4BW$+)H
M(Q5T_(4H+[;\%!JGOA$]I3Y]'\4+MS(7\2+04@^/9E4^ NS%VW37G/XSO$4]
M*G<N"MU?([I?X"4W8 JACA =="2P+LC?8@)G?'V]'\9ET /D..8MGE*TV86O
MC1-X? :!9<3^@<S<HLS*8#4=36NN(+^+;<Q;?EC2L5B[12+BR]=[]Q#2HL3/
M.49A8O(&WDLCQ4-TR^!'8PZNY8,K&+B[YOFN6?,+=X^ _[OK+H( ?JQ*F$EM
MH<N:M] _LXCR)?85H!?[$F1-S,$]DK1B,!=]H49+."G]"M 0"-ZBJ=HR0%\"
ME>U/B\U;7X(I>_'SCI>N3TZT7@%H?A1C6PQI+F-Z^3J0J^[]-K'@5LCLGUAZ
MHY$/UAEPM:=NOZB,&RHBP3?Y+"#N X&@HZYY$/4?4%>T=AN,UV>22J"+^(K+
MDZA4(,A5"$9YI*D6<"CQ@<H%0(/Z'YO.BT.HMW]ZA]TS;M&>=4'1BIO1X3PF
M!O4_+6 NRMFEQ&^>FN)"=@R$3[W07QH=TCL;*_]PW7[.TB'2S=Z^MQC/<S="
MX<.T3PSK[=2;&?;O]ATU16!E_#QW0*Q"SM?']"6(BD66#,,1.+0_*CS:Q/UH
M.(NV])37U9O?ES]GO^DN'D?C,I(^:@%&P3QO0I,7!$(RFQB<J2O1>2&8#8:_
M0/)>4[IKT[A0^1QSOB?QX.DR75[8*R X#D:PT78<>T&@U$J]RS9B6HK0#$P<
M^$1%VC52)[,[MMCDSP-L^(!_G^!3+FFOHE9YC)#<'.,UPX2O9R6LZE-[ ;VK
M6J1$QL<.54Z#J7=.O/R@S3Y '\QAIF.[MUP4BH&_%8!K'%*.I9WJQX-0K+!:
M<>74?,NA.30H&:VXXU7O\B1@F<>:1.C"8D5FB9'W,P_M:6\E)MF,@9N<:;)X
MWBAJ.^<5H,8YOSZ2H.73NV;TTFCN,,XW8X,R791<8,A-'#PL].QS5X4XUSW*
M*0\ %0FM8X..^=P+X=7;7!V__9JP"ACIS_O6]HL7@B.R<#+/\LD=SS*\&YD(
M*#F)-5-CM1_E'>ZS)1<BZM9S6VVL/[73TE[_>9D31R3A>_Q"5\E\-:.-+.\/
M8TW50,Q!MJQR9TVW/I<3+M_'+NUTKO:&UD=NN$">I5EC$G?CV)>F#O,E?9+O
MQDS2]\Z3Z'XWC*R)7#6Y(4LT"8@[=$CWJ;0Q_H/Y,XTPKMB!AA@_'@PO(A+6
MW-(@]"_?OA,X!K!Z&\]G4":CXK^#L<DJP/9$)$]7O"0*GS'B^1(YZ:>Z-+UF
M;< X*B4]KIE-W_['LY5TR[BW569M%=DRT1H&67$P8C_1O'$1;*06YQU1Q9<)
M1>@JDOV"V>/PP;<DJQ\%K:4,',@ZB+:U??V",9OXXAU1Q,LJ&4_U38(!R.^S
MEPWB5Y,RBOO]FU":BN++4'2HOG?FU8O7E)%NAT7?R17 B2LQ?>6%<*]RG%G3
M5 &P(X$@K/?.*3\W__M^Y<H2S%*V% ).&FK7,I.^Q';MN)SMF'UG!EQI;"-
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M*>^IL;S[^#%4>9 #W&>')E">&F%K1S,->Q\.I$$YA.=R>VD$:>G*6;O4"R=
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M[M=]U% <\0IB_5C;@\)SF1_-MF 5J/P/]8R(S4E:$T<[=8<,RNRLXAL -@
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M2IF;I?13JDCR6$U[@]]I2O\?/T+K6[3WY[=A2_(UK811/<ZNWFS@K>\>L;P
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MYWMLA1<@%/W"3)%[W0PE'MXJ)HT/O*1: 89Z("F*0G=)M<BY\;093%7G-F(
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MR2K7&$I[/]MM MD;#[=H'I?1WU,UK_:A44A[WPL.P?Q'3HHBACS&).9+7C1
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MB?\*L-3_V=@X8,AV-_C@9$/61UAW%[9Q4\E(Z+K-AD2N)3>Y463()FS4(?H
M=8V25^P59JFI@YY*I%O>'#E8)*^-JG)$PP3Y2QMX7:1CG>(=?[^C4&UKG[*H
MG=YAM]9Q[='58Q-LY--X$GNF6T7J;.V:I$D^=4^7Z,B"Y1M")O870>Z#5KC:
MHWO<T#40]77&:H?W4=;H>LK4?AK>?B=%0<&EV;W*!.4DX3\<?K:;<O06V+#5
M#T7)='J/Y@;W" [R.B$)Z<G]G$S]"30 W[YYJS?["MA0WT^Y::K-4MC<^3"H
MR"S+^_N&%V<_)9IJZI1 ['..,>]>4A7/H^ KX+S\B8DLD2:U-9@JQ6J0U,05
M^ZL3EVLLCJ+ONK>\0K]F0RM/]6^'2(?)SB=^LBLH]@3)PF&K1K9KA?9=K'*4
MRR#NBLR])8'_KRVNC*UGW"O%:94CA0CP@&IK"&1+26$H*0!=.)_O%I*R*><D
MN[Z0P&EA+\R,;?I\(:\KB](BV\O=FATJB%>A/U!UB.=.I#J2X-02M?M[*6!-
MI-#2Z@=9:^#EZL:3=JE^R.=H+'Z<'_S$J)LIFYSV+/[77V,(EO,VU$RS4S5$
MPJH$T>S+%U\!9@=U8C_V1H#"(_3K\4%#ZRHZ.8>V=SHOAU=J%\3N']LC[$OP
M-S1$'-U [S'\7(2I)(QH_&I)V I9]W;6=F&R(0RPP NJL##75P!67TGE5/UB
M0()0\NDZY ]'G%#I0VB'Q;>M(Q)SUY9'G/[X8)> ^9U,5CB8^%]YBR%_>03U
M_5Q-''.8ZL\^9*N%TGW)[@R^Q&A0[6J?\9'8M'E#/)UO5/VWVJI^?\[@Z7*P
MW-^MTK+TFW+[3>SSDU5P8KORD5*Y?4A<M),"XL'@;B%8NYUD<TQ*&3QK5>^K
M1!G+2:NW-)R/X$!\(EQ/B9:A(QQ6:J5Y/&5SJWG#F'II-Z/=\Q"&O[6$,Q[N
MBF;3S_]<<T%UD_T^HY<<A*<D;#IT*&3#[U'A([\I*W6^/SV?40B^O-A.^O85
M@4J4AD#87XUG9&.PW7D3X8(ZFW%CE:6N.E *?YYC^ 5["B7#@"51\X\@A5&Z
M7;FSJ]?M1=X$W?L"M.83WBUB9'V+/E5##PZ%Z;_WX$7WKE"48-50R94P\1<O
MX]PY\YJN\\Z@YRA[^H6^<M%2@HB?)41UO_=(K[.W*G&O%&9RFZ&;%M!KAGG*
MEA@Q8;WA-1\O.X*)YES=$HZ"62XT5:T+!@]GJ;9'9-W>.D,#^E!7M%MEF'WI
M/2[SGIZ'\90R,48#\I:.&CZ\#X;^)]# :,#O,8M#\ZWN%];FN9B*.7Z#7&0I
M%Z,O9[#%,(T@F<UZEU< H=8182:WEW[ESA2WSU( DO0&_JDNP0.RSI+8@:^"
MGTS]M.M1I8&5CWJ)=K@K4@X(/^M=B.J LOY.3-OB? ]<"KM>*RV\E6/+\SC#
ML"U"<.YT0^XF";L59$DY+>EEC,*,QW'XXLB@L'!%U\#*#;K P%3WZ;+GLPJV
M SP&12$68@IM7F1@X']/Q=9QS8-]!49B9 6D<V#D[6AJ!B0^3M /$":[\0(T
MS0H.Z(K[6JJAU?<9T'GE@@/@O\XTDKA/*2NP_]4%.Q=/ 6@K"Q0E K$KBHFB
M5PE!79$$A2!W,:=_26346MN94&]NBA19;<E8H'_^;L_E*LL+(.6/&OVY%F(!
M_KFF^SM$#9IZ\6YQV0_=BZ <7RE?+M;SGDWJZ&T=B*V\IG61'622S&:4] Y'
ME=08_,5W< )N?]#TE!#^Y@2VW1BL,IK]_KV"R56Z(M[LX](A;H\M6&P@B1G>
M\Y@C7JO:BC^I,?R%I)7P448[W\:2R815&L7"XR<$(.2D8#._7SQ.7(RL88_B
M =%]S!*^>9C=',:G:&X*'Z.4Q_]4#C.X\GM";B8;ML_QYA7P05^^<*Q8RMFM
M5@*[M(E>R?D@<7HKEU+31(+YV_P62T&&Z$7'>)5CL?ZJCO[B +:S3K>9I39P
M.(G8WSES%F<UQL]SX]G@Z)'9TF2Z09HFLG<@1:N'UMR,!&D[WB [/M/48BH9
M],TI<[S&C,%CHB>%59</A)-%&?\Q6"4?$/_'O.1)>O*L09Y\6)?!Q(/Q=-;3
M%N&I46S:I NZ/&<E07G,'<L/OKX^0[L+8'RB<B\6T,;6)EVF&%U;1H:75X/^
MK93@6H.1GN6A3VYD3*P)WZ2>][ 7OZY2*AB$0XT&!V:SMBA20=MY^,Y%HC2V
MI.-6QYPI1$EA=WGQZ36CP<Y350</!GF"4NL'I%,[*FA,^>GB!+WR]=%LQ[XQ
M7F;8]ST_+T4PHJI0ESI#_-:7LF3.5_#P@(BF/RU"F27AA;N2M)M#SWI>>&<A
MD"<.QPKQTI!'SOBOE"@#]![=H(%]ANG]_$P^1:S&/PTN=_9<^5::5H[/D 1$
M.*9F9OY__CH_)*6',C?8(Q@>W(3AL?\.)NB7_KUTMT468S<)?*,I)K_;)5RF
M/#1EJOV0EZVF%N0BF*:KCU7F*9"]&KU><.8/L0Y_$-\EEEA;Y1D<XBZ&E$E]
MU"E:QW^/;[*4=*8?%B$H8+]IRRW 4%H8@666RJDU+NFQ[3W;)^SH!*85Y(#H
M/7$&<E6WR$;9RD,H&VC%:TT( " ;U1XOH?YBR+)UHO81T_:"H*CAUSBD)CI2
M0P#I$YGUM1?MGLF.H%\W+G]#<<3?(V];'B591)\)82&9!<?OZ'XS0P&9CR9\
ME?(BTNV@M4U$?I_A.0S6AE%*3_^P_G&^0W[-(F7Q5%JP!'-LZ?Q!)_I,X>1>
M9Y!B0,)NKU3:AP2')0S#E^KBI0-^4%XGTVSNI 7TI.I[-/>-+0&6]++/$L*?
M%]<C->6WU?W3P,/+XXEB?:WN@)UIFR>NH7\0(S4HH:^:'=XQ<ZY\4D+6_8WN
MTY63\QF!*M0VJIV#]JVF_TL?N,-_) \MI"87KWNA[ZIAW^*'M_K.%-I-C>!4
MX"=MC"?$!\TOX34Y7Y7*X $D9<OARG 2,>_(0Y18 2>R$CCO0_X;R"8>B&6&
MG/B(8-:V)L]JVVU$C85O^)O_[C,YC#]\^= ,M=?LY?&*YEBEJF]L^J:POK C
M30!G7-])KDO4A=8#/V=T^P<>*7/+3XA?O8T%SC*9/YAG!/M*$6E4<G-C&]%7
MU&2VDC.>22#50?LP_140Z2.&=1>E7!LZ[C%%N\Y0_\[_EK2!)#N:"TV@1R>G
MU6R:"X5)]&!V*J!>CZ]_RO$@,=-+G:@+6;;*1I@E 0EB6Z5B.597$1V^-T(
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M^M9+ 1["R%Y\K/B8)IW@0(Y4J=8(>8%[X_BQ XZ9"O#IT"69CV"&4M*4UZ@
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M+_;,(KWWPO+KM"V8F88A$=1.2J<I,^=2[%*=.!H!^J$B$K]OW9^1HP_T86D
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MF,+@).N]PA@4#MQS_;H0(3A-H2*OH<M[?FSOPW-E2RCLK^?P4AJR(POSK5(
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M",$A U?(;*D5=?P/6MVC[C Q:*:0[M14UL0!A(Y3 QFIBXA@QVI9],TD8PG
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M2VT)A[OLLB>)8=&GCC:_-YXN7S)_:)?WLD,N69UA0KSI7]PE1N:#*#8(AFE
M_?2-N!^RZ-%.0JGF,9$7OIAB%#RLRS:[VXKZ"B ^%3M^!=2DA'2AEHT5]VXX
M32F!N2K::3QH,(S"./50AJ 04JSJN+U*.9: ZQ]>G-^Q"*>?[Z%?6!..GWJ
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M74(C=3>A$/H,E"?^EF]662$\T'%Y;/Q;J?OIQ/XHVH&799\%Q5_Z0X^4?O9
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M\EX>I_SZKBBV^.C'CWL)25N;@DR 2.K/?I2())P*ZA _RUR'\)]SJLK(3"[
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M_4;L_*_2?U[9?TMN]F&AQ&UKQMGIWO')OWVIY-LJF"OB__>26XJ!1/0[%24
M1DVQ!;.=C%L,0FI-#&GHJ^-&NFTY8&[=2?- @/]K[TJA?CU9=SR Y^L]N;_I
M1;ZAA*>G3&PS(/G2"?_@K7H#STGW>-48;#6C@I5-O:?E\!Z%"_)J2_E-MC^"
M)S^0XS5.5R(A/MU__IX+("F))7O2N\*A+4.\':Q^S+/IV&5Q?B^91XMTW'L2
M=G(VJ"(3$:=^&L^K:R7:5?,#;W.50[:,354@GVK;++MK!VB^[6(0H?!?6=!Z
M [6/'26$GI(/ F0U'B%1X8Y\&IOFX9DH5UPOQV[?7ZFTU%A$BYFY?!$V]4V[
M_N]8N/I_G1'Q/Q"-NJ%P:Z2:JIYO]GVB00^ 8K#*!X4V\XUD EMI.D_RW(7%
M!=%D1\&I0-8WV@C6EV1E8<L/@)UI1C%E,2+:W'R%51X#Y^J+L W)\_NCVZV*
M#]A[>W<K5R/DO2U&\H_I\2?,ZMBB";:WOGS)]:NN_5[_2)U08A3.7LVGN3B)
M?7[!T_A/9&)7<7[AS[(:?2KQ,K- [X7.E9KXO.+@JXW-5]^YHIR8U\* ";(,
MA>B##P TJ<3XU=U<PA/1._-M)MKVV'N%Q'6<@9#4]IS+J493ED':OX] 6ID+
M67S %M#+T^5"V&W46:8''D:VU48D]_EW["O$;XP\ #@4AJ;QK\FS\#NU+\\^
M++-4^U+Y\ODTR63/V9=9T3^N3KN5-[L<[]A;LB)G-?"T9LV.-_3%3?V6TLBP
M9N#@$*U&^+5!O.GEX:Y@7&QIGQRPU+N-7U@TXM8BH.0R:'E03BY5I>)PON*<
M=_6JJ%P_&#WEV;"BF+R$'Z>P0N 2CZC_%T7OTT&GMDG*O3@:U$!EF)/M[*KC
M&DRK$C78NE*1A!Q7NM+7 FR"<KX5T$:Q9#=Q?KTQ%JI&UK-K5@RJ/:H.R#F2
MS,G8K".OW)@!HVOI^]F0';\^@%>P.A:3=F9I#1/Z%J;L!:>:^<_EXGA(CF'N
MVW-=*?5U#H0.!9X,/W<9[Z1X&?ML7*R*Q$AN;="V'#U;\#:K#,:X^=EB^54#
MV]+T1.'/4%--55YI:;([AC7GDJN8(@<5=8SE9DJ9I8!3P_.(7IM/GNL"0N%V
MR<W)9N84S&XV!&:?5"N4Y"WRNHQ/RNQ1GA'=YJX9#(1F!Y[T-Y-<QMK@FVOQ
M!GU'Z";2]D*\R!N@O8^;S37N@8KT/H[@\_%8<L5W,88ILS,Q_;Q(PS]AC )$
MM1&;*NHL19<_5F0/\42H0Q?XXI=]W^#B5A B4OMY8HI<FCNNK9,)\BR^@^6S
M$Z5S(IV^861%O^!(^HF[)1YDM"[E+F%/@7V$&N X2ULSX:#!XM";=F)8$ZK?
M&2J)PA41D3*?7YPYZ2GD@Z<D_9]NH=!H I:?%$PY$IN%B>XGP+/KF/U[VAG;
MD?_E2552.R.E+VUP212"QHBD_U#S_5@4X^Q][BSLJGA8:+Z&1.6%^;2P'^U(
MT'^5/QJV,H'!>?>_+10?8[ /_%9G>.33"-)?ND+H!2$6])6SJ-B,DIWM!6?<
MK_]\)-[%ML5H9* HBY%YO6)(P]@A7;*OIWRD=#T)7U,-9#<!XO305%O:^/3M
M?GXFM?-ZG'7TO_@4069AW<TK:N:5<;=N]SP?O^]K_'>77_Z1PH2E-2K18Y%H
MTM$>JW2K=_=I+CW!"5<=M.J5Z<4N047,CS^YH\50BP&UK/G7SO3=J(,BD]7@
MV.V=$I8-]$!]H$"*J>;?=(F%UPRYUFM9^O]5DN._3Q+V(ZB=]7]D %,F %&R
MX6_'>A!*DC)%A.\;W':ZX^LH\#X]KRW87K^ZS0W ?O4 : HK-)Z*4*-16%)&
MM%T0XK1YKSL!5%3'+FT4&3%6@Z;7@BDGQJT[LJ!?B&*?*@-O<K]+B 0RT;[_
M.S9C/!;2K2%(H9@PI:?0J0A)O7Q63##&O'_+MI1,VI7P65+JA"YP2TB0"U_9
MO4P4I%ZG V]UA[ 4#L@QO\A3E]QL.<^>U8!O32G-SK:$([J>2D_8"@R?\"C%
M1+#RF0;PAO!Z0Y=8/IU6(PX.;F\BYU]_5$9=5=P -S$W3SC" M1BKR63[S*Y
M)5XT4.A+<%+8RYQ>P; MQBK)*14FI_ G6&AKL)LN+\+J%M*#Y"D52AIJ&RHK
M0ID2H^H@>)^'H"GFM==!T2>I?M-Q=8K!/%:X'\IXV=P3>PK[?9_/M]!Z1SP
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M/='4SKZD%R,MSA62,-@\W"8Q[=C#$IMX9I?="[25AH6^5#.Y%;W3R9_9&'5
M)";*!12LN!8<G3O3?KM/C6&^%DF&YK7FR4-P%UHX\#H^]PD\ '"O)E]M&?#O
M0/NM"L[Z%P-%@/)H'P+;#+QI>['=^X^/>OC7BRQ$,!+;'P"89QN1:\65:-4R
M^R9HGCZ6A\)E\I^$FR)RX.9\)%\)2KN=;3F8,_+OS%<8ZV),T O8Q8B1E3<H
M7ZWJTA_QAKD?QO8K5C4%@J<"%]C*\_I]Y>O+!$-]ZXIQV^F:VV2^Q\CVDG^5
M[G/#QL/1.E] /US+NFSTEJZ4\W!F>K*DF$O^Q$)7$VQ.$*FETU8NQM#>-4^D
M-%#W)/4#92OE,>UF\]EF:E_U-BE8@]G*L+(JP-"+[KE_(Q[F)(_<7.;_],Z!
M"4UEFKZD@3U3J<P#$RSP0^\P6OMWP#&8WE'.[_'Z1^ :;(FA]@&0@GW?O")U
M2T<H>M)&.7T+.2Z%TOY(K]6[E&6%;7P5+;X<_4TU/GQ[Z'?VR[\5T/AG:BW4
MQM7?5[:TQ N\N6,*=#!+RLA3^^"%98YX 'Q-W[AW>7/]  @QU5M,O$(.0S>[
MZS--+52NHZOH<WCL'3$5^,I_O')2$R#3:G"W-%5I^)L/W)K(39U-MJ#'OD#L
M#,5S;CNWZ(NP[!;_"1_6N:^Y08'B/*VHYZ^R'ZU/X@?=E8K>GH3]-D6TBOY7
MN]C]:I?7VO#T4MA?LE+G'0^ DR'1Z5LSM$05-;:_9N]G4N]=NW^;AP0U#^S\
M:Y82@?NKV?D? 'I'::Q62AK-?\UGW!C"KC8H=^ZYGPSZ&>;*YAD*(BV46K/8
M%)FP'KFC+'DJ_"]@WMPE.C\ 0# EJ7.KQ=NC.PGY_]#V"NK[P?I?&='<C!O>
M@WN7^_3L_QB0^R\'9NF('&EP=OT:](E4_D-+L=XHSZZ;-<,HILE/6O/R"?^B
M@%DJ_C)IY0[6Y5%;*6'X /A+/FPOX &PD00KOAPAY,TMT/M+=O2O5O\C+D#B
M[YK]N8CXYE\E%%(BN&"_*Z#U+_#E?+_A,VX^VOPV^<_('_^$7 &S'/R3N7^&
M'5C\A3H5]F<<)&CAGV/K3--A!;!2RZ<3A4V+KBC^[5WY)H@IGEP5O^\!T*8$
M_05%_;OF?[W3^]K_T/ZA_4/[A_8/[1_:_^>T/<T!Q1J?\U^X^8A.3+XZD^M/
M"J"WQ]*W%97][6_E-TZQ,+>BO#[&^ODF=7BLUOV-6LT$*:93AR#5U@-@^@>>
M*C""I0I/2=UAC]-*W.H';Y?(28K7-S^(EL4V(94]C:Y.<\Y4O;%$"#XVX <[
M8$\)#N^$/&I_OB2U[KYM/EB?0/=W37Z9DLNF@;\&U:@.WHMI'"DC_:H]4A&\
MEV>&LS:YY!;IQ0S3#C=YG^T*S%_.'CCTOV(QJ2\EOCO>M62G[*PN6KCZ$5C+
MZ23\\D!SG)EEN::^N=J+V#5D-1SP %#4BG$DI;\1Z:\AW1,XYJ 2L4916-1K
M:Q@'UTL=&6[ON9F@)$*-O8;6SP>&L7=JI6B-3*<+188E4^^Q$T-D^XR 57%[
MN9I/*MD9T"XF\2*=V(=>'?MQ;*6:>\R3*G'#S)XU=-98HR694L3@W^<89;71
M-=?[PCEM2=31HO82UF^Q@1.=#X" ?2/CJ ]1%T_GC3SYE2Z/85HY13(&.9?7
M0@\ [(["')[PT"F(T2*>LC6=YS82+=E8517:%K2$)":@E+#M^+'9IW= 4L&5
M8MG0::VQ ^N%J>GWE0E+(J=V?<1^/YD&>!A68*@N9=MM\\NC1=;4%OSG>.AB
M2+/J)?1$UVH^\T.>>7-F!$U$%<_R6AU)#9F@I."W(I?A*Z'\K=N07W6!SYIS
M=L"#$Y+/4UB6:X^7S5(IM)( 9;BC93"M:M,"2%WP<;L)S,J.6<^=)IQ#KZ]A
M1[7ZI$%X>2:%4UG>FEU2T!OHV)P+4?MD&G++"'=/4FN]'\?SQ7M.C/S6PVXZ
M@=EK?3TF]QUWO/49>%[82_;GH/5E@ HO 'A!C@$NG:RX4Z"/[3I'BU8@ZJ2R
M:M9V*.8*Q :Q9"FZ60'AJDVE=G2[LCY-.@>5\6ZY_"^KF+/''45)L@[\:/1*
M.XT8]121W6C"DRQU6TK6_;#?[60<88:P#*@=;<?:<+=SI ]D5H\GI*JFR.G0
MG"_3($>(T7ZGY:>6P5]_(U'J_;-!/4*CH[J?9.@ESOVA:/RT\"?UC!U-&TQS
MX=Z*J ? :^X$&2]G)DC"'-.2/)?*9-'2UV$+O$@96N0GLTC\=RZ%3!8[<OU*
MCE90O*E5W/6NG\7DKL7,3:'+:#9/=>?D;)Y\_21+E; _,8RGO*?7D!;\0A!7
MCB+5T7%)[\4<9/SN!UJ\(0MY5B*XFTH9U$X$W&":)K>%''^'4D38+).3;/6!
MMZOLJXXH7IC0V_W$;-R6&[20&R^B];IX7U6=H%@7V8>7VC*=M#W=1#1A<\MU
MYVWFZ^)(]!C$NP:*GA-1Y]_9=<?0]MT0'SMKQNY<3C2VJ$^,'&DX) 9M/O?(
MIT3- 3T7D!IP6"">IC@1JVF>V#=4#=QV&2C\JBIACZ*H$%-HD@^!!V,)QYPU
M=BC=G8>^;OW2%+,:#I^C]+O^T(DK8623+WN!,X@4+9F8"'% )@"<X9=^EZQ.
M&,J"07*UYKKJ+",&IG@QT#EQ+\0LPS6,QK/X\.AH1ZBGN?/CX40\I)I C8;E
M/ 8@_4534J"[;W[.=N">@=N3GC>^'-*DD(M.NT\B0=EBA]_18R-?U92^=+5:
MQA# Z*6M[<Y)R_U,_T,+;D[RU;.@F(7%X8AV6\VIB[82>E.M_;/D,0@J%^TL
M3!+HU77,(MZ%UL/G^B$M@@^=#">B4_']WRX3(76[!-V+%]YOWJM&@46H J4F
MB7Z\X WUAI<U!, V$K^H_I@9W)>2D%F5^]7!(HXS>N+N7:O77OMOYH'^I%=Q
M??%KCL1[F_M(D%&11N]J?3&&XFWSR6 S(R T,.I?CI:*8+L]L>GSH$W//*;[
M-=NPNE+Z,US:T_]3G/Y_Q<FYXH39-3."XD5K%F, G(&P*/H+TN.,WJB;D*OW
MCQG^KU?KT7QX ##_(YKL']7T?^#\@?,'SO_=. 80VWGJ\#N\A'*"(-BK*ZL9
M++65JY$GSU65.Y[\CCN^:=7 NNH-Y7]\D\MU/369G6AA,L !6%P )2A(FS.W
MC#<(,7?(.'];N=\XHCPL2B$R\J(FD\9'??WJ].\+3:SF5%ZH9>848.= !P5Z
M,:3[H#6$?F(,W?"^4N4Y<HJY"V#-YQJT05<FR@PU"^PK<YBMSA.5=3*LK9>P
MCZ.@KYCDUE&2-;\&MYJ/<T>"B3)5[H]-O:\F\U-Q9[8(I@CVSG=N\GZJAS*Y
MO"L7U/^\BRK+W+:Y"6'G5$!1U&JQ(3'K3:LJ.^ZKZF7P5>4(/Q*QJXS+I>6>
M%^WZ9)WA3/<#L=C.'Y =*!3T\8T@9C;[EXNQ(/8ZP<<D^' EV6NCP.]%6^/F
M<+JAU"?#LPE+H'(&[1CE+Y9N*S0U_7KX3<5+C:X'&Q.[!/"U\WD)F]*,8/[G
M'@\ %P?:0C9_QV*^+C5!R](=>5,+:U/C<I]RH36GU+@#*M24V>6$H)K:F-#S
ML2DF)GXK_?>EXE[<2C-(GLIE^<&<7L)/BQ2EC@@2(6F+V]6"(:>QRT<301,=
M$<V4=:ID1RE/S,WN@=53II'(Y1,L+]]BE1W/IL_E!'N/C$%"-V'^IS9[>\^M
M>#YBN_I(N]=V$5&D^I@CJP)] "F9F)5Q!9>!_6]=:.)965E-AV.L+' BU1_G
M/1?"TOK1Q#&&D$Q5Z>SQA8N1#U@]>_$:AM!-0Q\UU:_C.R\69=A(B=9_\>PQ
M;981?2!W+UCI6&<]3-%?!C1:]"$B.>V"?P,_%;6#G,39LZ'^<H]>/\"-+I_Y
M2=CAP=DP1;2FS^C$'L#H,44TXP]T1@]A0($PN--)4/5BYG,0 E&28M1N@A23
MH3LPL_DJ3H1KU*K"0D<UQZFB-JI?4KJ7NK:'-A>$$Z;UZ\(NPNN=?AJ-XU5V
MN'AWE8,A@NZ3R;XYUN,+0,MRS63$8T"+]T@)R)DG#[:BPZ<00QN+>.]\K.;Z
MU6F@:Y[T>]1-LZ*Y@(8..8XJ4T4NTU8H X"A!8 THRRYPVQ!0Y8!Z',7*]BS
MT"D=*5R)/<HTC3E_@\Z@*P,>57',Y'HKZ9W.L '"/,W"]V=.BQB)&*L]/0I-
M<;AB7:]NKL(9" >I$W22:PX1>B-2NBI9>>0L=!2&%<.;4UW(.CV[>Y $A.O&
MR_'[OQ%UH6 \#\QXGH;UFBFE["@[#I9;F(FS8!613%UC84\='W> ;+T1.'1X
M$-PT[UKT #!C&2"HLB_/C$)<6>#IL_5UW\P"?YX$_JY&.  =R7-+I5*8<5%U
MG'Y\G8T,-UAFC3S+UY7X5!BKTGC&95&NN;&ZBGU1ZRYW&0[._Q@J,'R#_NF>
M/[<8Y)XYJ[, _L;S+*6W3_L;2U#!:Q@N1;_$-QUR;B4@!U I5V-4_$>H!Z97
MJO: B-!H$=O>W@KA%_D!+P8;='2JB.%#/^$;%7AJ,/<=Y[T<M8V[*XB1Q,[4
MV@3;>Z26G*$<+2,MO83MLVF&QM8YX2!W)&)Q8W</W20HG"O8<=CRTX0Z!7=I
ME==D9LDDZ.:KZY-T>!0G31*!R>[O,S/3\V<66G-G6ETMUW[&/\[ EA0[%V;L
M_%,\:Q2&EM-?LVEVX3_2/]+_[Z?_G>T/&PT&'Z<3C)]SU_(@RTS.ZB?V)S _
M/NERN?++_D2R02AYA#_EA]%1.LA=19*PH E?E,W6I'DO.6W0M2]#7/PV/4^V
MS7R##N;VX]*[O6XPY_S)9+P;GW3#A?R8M!CI:]2S BN]]NMHDL+8/#*2Z%%R
M$2'-C/$B9*CDSC"L(4?T6[%DN@\36NQ&8K7/P6([[M[XOL3D0A;ZL82=_<OP
M])*K;X=<P:M0'9'BG'EME^[VZ5)Q+3236ESIIU=\C#ZW/3PCHU+LN[:XFX(9
METP=57)FZ^L[[U,T:'OZ,Z2?"KL%SM\/UST OFZ/W?2*FLBS+$$XV<EZ<BC#
M>4:$,LUT)57%>C_R/TK"E)22%?#J3H&U\>6'<+HN5V(X6A3+Y+ZQH070A]$V
M&TJ]NU97S]B^N$XZ9AD*<,QI"VJ?$UQ+% 8@'QV \92M?\:$DG9>DY^F "NF
M]HR:4_ K><>E#/@#3:Z"4(BW!5HIVO(UM[0J4T+R^B%9\W?-JA'ZE-9UFO&T
MK13&R;Y((/3S8O'T5%ZO-= ^0J+QL-BW<AXCG6MKT3C2S6T$0!=XV[-2!.T1
MB4&V*K+012D[W#;#PDE88!A<BOCL$ZQ_0+;!3\[16ORVH2+POL]-II7CG2\?
MX.?/8!*PG$9!P<_*KSAX' 5FSWI;B/"@J*\VX-5^E>2B'=-QAYWY\UH+4M@8
MV?-/D\GQ6,DHTE:HSO/2#QOGM!3\B$K"^2<[]P;L%>@8!%:KB4&/[!;JVZ&
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M*J+"(S\ETS2O\WF[,W 4) 9S+-"&D#0EDR?OVCT;[XL;D*&E)R/#%"L*+'T
ME*[]<IS:;TP'%.EW]3[.#NT>S*=F6:J4IOUS]N#^(7_('_+OY6'V?P!02P,$
M%     @ 03)N5,$HF@VK30$ 7'H! !$   !I;6<S,S4S,#<X-E\R+FIP9[2Z
M=524T1?W.PA(BY0TJ'1+-XA("T/7$-(Q#D@/K2 B+2 @K70C.71W"D/(  ,,
MW3-T<_G]UOO>^\]=Z[UYGG7^.GN=]7R???;>G[V><__O?AGP5%U931F ]0@
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MK"QRFZG1*C(U5E;BKVH"+MZ_LH 5@+5KFR![XIR%).OUJG*HRMDHJ![0DB3
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MUA>RO^X!-MRT+D$+-N,(;#0SH_=)'UA4.2$D8UYM_QZ ,S%=LCY(6;MTAX4
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M(G]?#VX,1'UO2)2YHV+NV2?5GY91RP':V(CVZ&!MB("_MTO(S!;KJ-,4JZ0
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MA1>9W:;!#:O3 I:5$[DXMG<OC(17MEWJLDFAR42CNE"W8#="L]J,CD^8$"#
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MUE_DS;<XMP*&>M:\_]LLT*^MQA9=T/< XI&LUR,(I,_;.C>%*7(^_!C&]/1
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M2D2-GFS77+X#[EDS[F&F,T$QD+,B]PO"1=&S=9E54;SE#I#3$]CNP37PD9H
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MW^?V]TI(^?I &[/ #+I/_Y>)E?]O)CK?CK3? <2 6![49<.M2W9;IL<KX#M
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MI^=;2O4PXGS'Q@78/J":Q/;3PL8/]C(B3+YL8)W> :B6LQ$U)VA+H80I@*E
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M$&W=!%,Z<[-/9]\S,#ZE'I6;G?+!Z(?*39F.FRF-,BC'4&NPVD9X.4UK(T0
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M&P37GDPN)GP58#%:['7Q>,9ER,(S'+#S^W[[S2;&3.WCFVT> )^\8NMYH,W
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MG^8U14R5L!WE5UQ]!\,:#?4I$\M_&T)S4GAJ8WHP^::W_X!]57<F;Y15IW+
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M):XG\3<440-MOBO-A]HKCU^,DJ#459K*+-*K^TH)SV\?WS\M#>&PG>45VHM
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MP/N^=MN8[]#(>XK=Q;:4\AJ7'!8X]@"(\&+3'#;]%WOW(16^#*3,X(=$TG!
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MD8'3;HRL8AG'-;5FQ=%E#X"^=Z-!.W&9O=-&QO^E)=;D0U7'8_($G2@%K4%
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M%""T!4?F% @E<@#28>LO,J 4PPLC^:94 H4='=J$PTJ9 VV1>[.1^R/3X9S
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MFP5;+(*ZA6XT&V["OD;5+Z:M4(-3?[7<T':.-R1_^*E$SC4RF.]^:5,J,-Z
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ML>R)?7@>]/"7ZVN)8EJ^K?#U<UU6:Z;XUOX>A>I"G..YA7N:TP< OI&$&46
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M;(XG^S"\FIU'-['4O!].\3NR;X_TK ]S@+593F<BV>']BBO>A EH$V^\++I
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M^= #(":W;"<1=;95WQ)7<8])PT[PED,LG./IOH]67,%5WOX_8?_GW[C]N-T
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M(4F+M6COO_RVM[>$.@Y7[U@2I,@FK.O"$\RC]"I78SQP<ODQ3D,]\41VPCE
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MO\-@>6EEF[*"Q<\_X >9('4'O:<-\U1V &E-U-.&'![IY.M.?V*L"6QCD3^
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M45_2YXV[ /I!R@*JKI &ARRM]%<4[F)[YQ-@E5:)U>1/FP0BMQ>\SB+6Q7Z
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M0NC': G?O$_6C)VF.\F)&:I9/N_9A3PHC>ZZZW7EN,X$:4B;2J?MCEKJU57
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M9*&MX\R5%N<W*&&H0IM-@G)QA0,4:]4[3V_>U2UW#HO#6MOQG@U*1:MJ@E-
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M65GO-D<,>]BAX:_?)P<1;TU6?7DM67LENG>L-F?%39][0P\Q1S(<):O9.*^
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MT$BJ),S]K?*R^B\3SW"\/Z*Q7Z'#>YK29ZMUF_A)58(7_VN^S\''N$ !V/2
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MH &!D?Q2MM]-,/)W<S\IVV$<KRE=NM(]3X/)^O#];GK@W\T<%O(*];,5S+Z
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M;KIR-] ^D36\3.YY.=/<H?9.U687%72YKCJ>:N=V=U#J*WI_:2B1&L%9(&I
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M5?V6DX8>>(S2](A^"+2;(7^".XK$]R"Y7/NMEGY)^TF7S</<#P]F;BE4M)!
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MZ7W*I6%0%Q'E4#4I'E7I%*?XB7\O).QFRALAQ6(^,A))J!6IA7@GG<6FMIC
M^Q2#L<\Z[X<'N?IEW1%[X>/E@5AONKPDGCR5BV3:W]16)A&#+ZU?0*#>FG 1
MK:3,*H-FG(&7B1/.,-89D[X0Z]4PZ_W" 7VC;\N)V\NA1GO&!#^5<]B<$Q:>
MV\G)^G*I:0^$YQ:.>!9Q?^<PN[9<YZ=CS\5"8:;]]AN.&21Q\!/K(F^2_[?K
MT2G/LX;\&Z WOKN6SNC@Z.;8:@F>V&SY,#=TO-F[&,U>^\,7%/CC*5_=]TUC
M<+Y2N*!YKB'KQQ[SQPJ&MC.,BX?_+MMV]ZLB.M[%CHN;1\F*QA$/73T58++6
M$_9)+P]QX4U!8T?&8^Q[0AE*_&%Q"SNB3S0\8\HT9"F>_N$8AD+U5*MZ<"F(
MG9O&:N*ST6';V7#B/0ASIB(I40J'%39[W_/#']NF+VK9++=K+CA%<R-F*)-T
MB&B(*QF:*]W1P*WQ#5VP]=M[TX$R_ $W032)VN\ML]B+. 7S.&IE;<+M.#*K
M!/[(F/*9&P+M$WD68_G;3A/P(4#:?_VR/=KOOE<FC(,CGFK"^K26&JO4DATG
M% ))[XUR*GA3V#252 TJK2!SQ:B[JCM2_>;4IA=62Z3G*W7; GJ5PUD\CNS=
M4D>.+7SS>IH_- K/+7A4BLPV-713W/DPL7? [8_?)_6QQ,[K#J7OZU<41!+)
MIBP2EN!P \0P;M!T-AY^[#8)W!4-D*CM%YLP$W: *IV_CZLG:]A#T0#V$TC/
MR#'>H& '+ZET[%UUAD0AO(_(DCFU?#7:5E;SZ.? \W0C$B5Z]\)+UF1P0CXG
MS^!)>#9"X 6$ QKV1_S4->B<5S?$EQ%5TFYJ9V;Q_]'VWO%P?>_>]P@B(@A"
MB!HUC-Z[D.AA]-ZB,T;OPB011(\>G>AEB#H8O?=N=*+WWMMX?+^_W[G/[]SW
M?<[K>5[G/'_MF3UK[=E[KW5=U^=:>ZWW#HNZ ZK]GXEE?P"JI4@)(T7:?<'N
M@[=#\[,F(S3B/%4#_7<>V"&>R/=BX59J;--=KC;8#&YLB6R:XQR8<64F KT;
M=JH1)5T9A2O*]=_M_#43S2@QHHJB+M-WU&9MREJX:J(6EE?#O,K__! #;&*-
M9O9FQ\5"-C(5>)?WYV^KZ,?VE-+2,6M%$E^NB^<5W-D.O- :"0E1-7R6P\0X
MN_W0V;C^)QZU24_PD;JFLF^HU.)]A(=U+SW6^;+)0HFC5WWT./)QGG5Y,8\5
M#LM2(#:6Q'?8XW].=Z3SEZ>P>0&FL,X/X226 5 K1/WT8QE?+2\/'$7ND^O/
M=ATO)VFAF0$L?FX,.YW1?A>5@[]B")][[G6A#5G-?O('G]?*DVT*%S8DBG?F
M<<,HY.95NJ\ ^AG_QLRZDU;%>5%-66@EHSA571;,Y#/+P8M?2;\9?_284WPT
M;,GEI( 44P9?32@7!N:2H&V[# &3]["=@8FK"69Z7,>D!9("5/)I+#0VTB5G
M2VQAZ6%_TK:10HW-!:[+@NVOO@ZP<&U2 DB'E'%,4&ZXL(!!1!&([V:((;,\
M>B)43ZQPK?>NW=E8T$A^)1>H-:DXCO1Q<BN0.GSKC,&_H-_[MGEA]OM%,SK3
M6 Z??1.R6/E. A9T&6UC-BJ:3^^94YL$=',5M%A8DL<J:WE0 ./[I_K%;.W:
M.Z][=?9H_^"?\_O70.NQ$)I-A.]8DPR<WQ'U,33T\^P^Q$$2:2: VPKOXBX9
MX?[R\J1F;94 ?D.[BF3/!2,W:%F)H;H)V2&Q<WT3=O "/.E^3KNH+!.Q^TO)
MT9@,'O:;8H7.210_4ZS0/7!'NVE"UPTGV:&L)G#^HV\AN6F9)75'GQE6V%._
M@B5<$?7J%$':?9-&BY$>2V"$' :>_TPZ>Y#',SB=8F,$$B=',XZ*B([YZ4MG
MRC8L:_24T\<12?8,M<:RXWGU$\6645,,J-B*GQ>4A=MM]'C3B]=/M\!/>]NZ
MCPA95>KT=&QV($2<@J8#T6@'GT/38?9C<750O=_&:U<T_[?Q8^*@7]!N,_U[
M0,G.WW-EO'91PB.W7,M*II,J-[(_CXOPV<7:2*\GI VYQ$8V-;31[P$X_JT/
M.<W-/< /ZW+D?_O:>X,YLJAJY.%UY/^0;7ZLN6&:08VMP>/JT,(OKUR&/BQG
M'#9U]"DIZQ2?^6A5USD3FW]1[-S8ZL.?W)&EPS/W-G2:L5)"1S6R0Y.US?Y%
MW8TO5: 0(;)F.C-!MV%U$J,.=QA: V:VU,?<F_< ^:93 @61\-CE\<?)3D5]
MJY7]%P6O:']@FV91VIR 8Z3!4-+?8.!/2/\V:1'ZK*C/!$[IY=6#@?ZNI^[6
MF+FXA6ZGG^/< Z;#;2R<V?LX%0MFMO5,YVPE;$)V^5<Y"R&M&_FP-V>^]$-K
MTC[@=829;4T/G]0!2N(4_^(AZH^X)5!PX3^Q&?W^0\[>[.H\[!Y0?%90;M80
M,5AVAJK3OOM&BZHJ^Q>I]G-?_;^49R42'0_! R)*YXN9??[R):$B=7+M$TUT
M>C.F@I4K;7+?HVIW&4,)F0C^W9/^AX:C!$"%7Y!CT4<:I7E"3+SV&>0R)6OG
MIUCRS^@G?X*]SS./\.YN19:*<^.S?<OOOJ %>N,[V,-V>0SHTYBA! NL:2R-
MX[F5,G-L=K_>!IV88$UBW$QZY'Y2/2P)-X_W=@_*UV]N(*95!A6('(-J"]>L
MD^=.E<CE*H<KDWV%>_C;GO[Q+MOOFDNSO?/JNF6'X*.^U.7=W8#^0IT8S%#?
MH;N!;L[3;S5!K"%U_V"J_.M>ZL/:2HGKQ]OI%WL2EX5"]!3=I]ZKGQR07:@9
MZ&Y5QS:4S%+)E,RUCPF,SXIM4J=2K,\49\%$85;B%U>1[YDTVR$,"=BKJNH'
M.#RKD'D[U'>AGX6?MQ+R9X 62:ATY6>]UZ?GF7][#V"TU)8%0\06_9-$/)-D
M;Y3=\WLZ@2E%SQ<-9W.[V?.">5(+7JNFMS::!LBU]*5;PC)/W;9Z;9SW4P>_
MDAY\/!SMRF,-=:[X74L0F>+M<ZV1<.&L<P\P,WA(]+N.K0901R!HV_4D'_'9
M.&%EF4%OM,2"R0;;V5G^6I+\*K<BG=Q&$5</W_!1@>Q\P^FIUG8#M+_E(WGJ
M&MCV]FQKTX,#8H;M2T^0^NY39A-B'CI4Y6)$6Z/+QU'1@<J=P'@CGOJPRS(Y
ML3_X=1*("_!D-D(#[Z=8(;]IOVXPJ[*\F)(R'4EA6S07_(HM8?T%9T3*50[P
M'I .1;S[5567^HG<)5@'\R=-RV8>&75!T627QDMWB6D15,=:R1#'OL_^0Y(U
M2<\4*_61L"8X0N&QB/Q9AR)>II<#00AY0=9#5WY:^ZA$<,(\QS=^"+[9P4J'
MB*X^<%OH6"3TDIB%4RES=>ZZSD> '4!UK]Q3LQX<@?O67+>8Y!\HEX&3D)"8
MK6Q-DB2IE_E'TM;'INZ1#@J#\<#I\;CW5= -]R:IC8"-O%>0S:;>+B?L4*5Q
MUE.=V3='W4/[RDZWX9;O$QPO[61S#DZ02_$KO3>W1)%0A0W<^3X#[('VW(^C
M4AN.M]ZC;3YN#D!%W/8"NN/^8DF'4IC=T4A\.&^5GGU\_&T3$</7:.2%MX!?
MJ?')+5Z)4I/M\#V@LOJN@LEOOP9%@1*\LX6([A@?1BF>IPOL)MKMW_Q$43;E
M.*D-T!^3,42E#FF9Q6CA%?A)X5?/?4KWN @*R3=;SND?&UF4;0P&7_B9QC]5
MYE>R39J%.&2.;5GRC=@_4W0=30X\\>N)Y)DM=<A1L-+E4V(4@"/DXWX6)[SV
MX-X3-?<C[I+T<(*\CL9>#1_2TJ))AP&-YL6::\#!']JRDP>73GDS(U7#B*OA
M?UIU2-:8? \NBRC9DUWX!N&%1(PW5;+ZD(U<[#]^L3OJA0\.UC9]1MQ^D77W
MQ'LC964VQSF4MT@@I5PP000>N"%>6[ V[F Y1X](]<<M?A:$X?WJNQEA0([/
M-.S48[LW#1>> \M3@DUM6=1RO\O *9 /44\4H"(-,^/+8FCKR/\P "GLS: H
M>=XN"[\:<'00+9>)Z@&6T[0"N5[[^5=]F(G;D5SEF^MD-?OH$N:M%=6OAK!Y
MR(':%0'SQ9/&'7-?3<-% QF 9*8:5!E6(0=A5SI[F3K(TVFLKS(JH)I2\8+&
M:5=S>?$Q@4325OZ3.*K/YR6?V(%3S$ 'A\G;4X'VI8:JJJF%2AZ.0$66ERG&
M7U]$P+JH4_4G298WE 78[=G.^W\IVGBI>5N <IP[MY=^9-;$%O$?XZ20G%W?
MC.4U(FHU=?<M?G#,XZTN5^ITWXC+I/4=TFV7GX=XZ,_M53'V+3*F?REX83A]
MT\%U*[%QK8TAB>&?<C&@8+^OU)PRIV!)2;_@X>=K*^ 1U=?=/]C%\',UJ8OX
MN^9:?QS\P:.(K_\T$,F ^>S=>;L3_$M"X@4Y:T=6._ ^)ULS@ 1[PVDK70_(
M/0MQ-.7JB=U8OK0]>JB[4K5G7F8?EIZ^Z26$,$("N\^$_\)$B1YYW#U)2$^^
M!QR]@+9Z+1]<$W!("-P#EH'3:U8QKO\@7Z5Y(E#?%(<&[@&7(6OU9$=8'997
M=N)=[!547E)/HKE0#WT"=;'.?,RY+ENC'>Y9I/MJZ+M%-/] O41=Z/"7<123
M1(X[E<B1[+GECVK.=9&;]JL8FDHY[PT**_B&D3%DIOY39TG:P*<A*',;;ZJ-
MV]1"=44=?Y\CVQIG!8004T3^=,#=6SRO<.OU2S5X#3]3)-?XND37:-9(R4#"
M9[_10AB]<SJ'8[<6$]DMC]JEL7;].,=:97WLT(LHHB#TR).DI2QEWL*V>"4%
M>>]/ US$#%I$ZR%.H>"A57>%EECN'Y)D&!Z%H]M:G(IK?1Z/)"YTF_GZ6XIZ
M($O)W2-#R0Y<7_GWT42IFZV.BV9 07;&"B&*^9^F<]_N[BK+>"TW:(:D:F7)
M V?V[T0CF9>RE(0T[2?+RX:+@/D6)KU>&!3^*G-&^GH >Z8(UM.%YK^>8^/+
MG0LW[/\8U'MS?+0!E_@C+9D](UUJFP"?+%KOC"SG9?J"DCW)+G..-<UH6)^I
MV(*T+)F1R0_<%##M^ :+*K&ZS&UQO]_>M!"T$,**@Z4JCX%JHZ<6Y?*[K[Z_
MG*TYZFJR7:\:X!<3T?Q-<J5#_X,S4NAI<]C*3H?QD=6MKXWQV?@]@*_$2K5K
M5B%;W2,B51C:EOHT*:$\C&%4[XS-,W>=>"3O<_]7RQDI>_+OW7MJFY-(+FMD
MOKV)5!G['X-G5%>%"\"R:@@WN.VYP%/B=ZN'/ ^91S[=")O%(3SQ&<"@QY[T
M-Q-]&/66GK)F5DA,B/+(+?L]@/#U*[4V:?D&B\MI2N'?;L^RB>EH(LXH/)XK
MTG51=.^G<!<]TM[1U<,\;@JB2QRZ#K!P^'4/."O3O*7#(1<)G1:_Z\_>F(*>
M]93D+WO-\Q$? :^A'];CJ>.4>F[9%W)OR[N>.L1+2Y^9??D0N+VP(OYAI"<"
MH?.J14X"SA?J+R(PO3<XH>*4?N*OO5I6/?HZ[7A:H;Q=!KM[R':GK,_Y-"%^
MN&>MQXGPH?$_\T7EU7%\YWMIB0;H,?7LE.:1']G;W_4;<W\E;TF_6K:2%"I7
M_G[\8'>UCT8J:,XR[>MX Z2X."FGG5OQZ6S&%;G@G.>!7JM.'R8>XGLWV38P
ML7R,C1%9RI;&;1KV*<MI)<KPU>S[<F# FLS(D'UL:F")HK3)99[N^*G^&\;1
M4R\W>2JE4@JOWF=$:6@E^BBBH9?0X6"OJZ9[ (%4Z$>7?\#JOIUT+)[2&ODY
MW /:M9F*/KT_LL@+45,UX_.OM,Y33M5%*BL_P4"/&:.C9(DE?\DM-AC2<[B?
M!RVRD7?)WU+;JDB_LJ!#C]H6B<P$(*LD)8TD5B#6M@NTUK\@R//$8*=A^!'U
M4&0K DIQF>B*2].!$PDW^!J%-B'K<2OB,QFI3Y&25K5N2>R[:!GIPMPF!NY;
M=4NB"N(OLO)PPLGG_T/YD[Y1\H^?YIBNI^GYC'32K"K\91EN)X-05YG$G6W!
M'R\]7'+]1#PJ07_FBZ?KA9?VLL;/9SC-XDU)-THD![Q"7IAN"<GL&[E75]>.
M:;EE;V>?1L9?&W5EVDS^NAZP!):_59 +NJ1PE+:8\RR<9O+<@^768E^D<347
M3SND(5?:'3,[W[IUF3IFHWY5?^*Q_V&M0@S@3707SY-8"CFC,\K195%QMQ%!
MN+O?@E@TF$=#"_A<]RRV2_3'W!0A6G-]]EW^@3)_"@KKTK]#3G>B[,KDQ5I6
MLWV+A/MQ.,CG6DAG*7H0UELIZ+<G5Z.7%M*#!04+-?V!2H4@$_E[ )I4^T12
M..\>L'(Q0U1,4$!UAYPQH0"D-;XTOE^9&VY(R=36N?(L#VA(B2HB#IC()I39
MG<2M4EA!_R%TNT/4CMQ,0B8(?WXE_ZCLK.T95#BA/?V8;*1IIQ357Y5062 _
M$>.]()&W">Y1_I4=/3IZ)_?),+](:@8:P[AFX<!#S0%"-8"P0EX'@61\%#^7
M?0N+QJ+W1SW./0JZ_7P/V'N(W7H)ZE4WQ@$*:/$ZQ)/; (D59=M*\'@L0Z'V
M+++[I[!RN&"OL #DCH__60CM"<\Q9#[=-B?7-KA0MZ%?I:ZP3(6<C/YIKW#$
M)X(-^ZO;=*:CP9FQ84ACSR^]3AG2W//K-"C,K151H,8BXCQ_>WZG;#.BL=73
MYS.[/Y< &C<=)Y$*Z1ZI)M//SX:/9]4U)LW0NZSY;@G.)G5-Z)[Z*I5D=,[&
MFFB+D4]>40]6N8)?6^7E>D6#4H>0B%="1,S6];8S>7>N$M=$&D'MU:9*OX1"
MK,C/CU0WFXY?3DC\16$;3BH&^TE7A[)^)-984GU[D.0K/8Q@F+..JKF:Z)2D
MBC,ML$'>\/:9QTE:O/6B!.)WB-,A3_5K:$=O1<0+**+BO>CFOPEM-?/"?+%<
M"O[B.?ZK]<G>,J4].+),PI,3*(HV'8B3]6"+.)67P<NS4&*#UFJU?HN?&XI1
M9$D2YQHKCBBCB3T]MX&.^6\\\[H-*8.UUI03(=3YR\'2&<IKA:6^CA!6IAIT
M1L$^@,\/EHYW'O@S=AL/;=0G-RW!%3+HL?8)D8#C MQ5BU2(EIO8Y\/IC V#
M)[!W8$WA323FMWF 69KAVG;?KGY$,3^[O#F*V8F0708Z**;,;;F/IM>;H35F
M^5^'N)W]6IBI?!]G3T;A)D/YI$1W.&S+B#R5"_9&H_*<N26OQ>41B"33;Z1F
M+F^/31<> "MMG34T4ES]0:;G3BN//P_:]LVO;JPK)VS]L2YOD!<OOJON<0_X
M3'#BY]IGI6B-W-*EC_&,F#"W(R-+QF4^Z+G#=%9PC%53&"KMN[ZCVOCP4;!Z
MMF[K#FIX_6K$!L],73S3>S0J@5E(->V2,D"\)Q?>E-2IFV1.4%R&N/N#3?/5
MYYC%4/B.8T]-2M5":/%5M1S-RK6&%K1QH@K[^AOSH_2,GCL]!&U&+0.H]$IL
M4%ZHT4T\?=UZ1)H8Z?(_,1PF[^#P8/#,I>QK!/JM.:LN4T\C/TRPGJ6* V^P
MVY&C&V:?91P=/44C;,')UO9[V?":8(9 :9;-E==?=FWBM?CK("GN\2KT)$=A
M]-:<F'+]AE+7=Y_>5RM^BN>JM$8VFK^.7COV*&#Z\18=\-QKB,]TI_V'OL'"
MVVIM^..^QVO+TK.OXG#3=*S\A\V/1C,G*^^TU0/76WG+'PRYT6!4!#A+,/$9
ML$]SC"?+]]$UL1EY?!3C&\D:[7DW#$J.5/&V3'^[S0;_#MFWIP%5S'7@]E;H
MS_46TOU$BXGPP!.Z^MS]HOM6T1ZET3EX+$*60N]1$D)KJOQBQ?T/]J;"E^[<
MH<P>)TA6\Q"IHC20'WN55$\B(5)]D5AGR[O]VER8K74Z]/V32-=H+B\Z-4X,
M'\?BMX#;=KSQW1*E^>!BM]UY@YE^(Y\8'WJ5#L+P/M*N?N^/,M[I>8S)D.4W
M62'(1<C>W417RDA ,/%/^F0YT0#2(359]/$Q-EZ<>1&-^G$(0]! 72T'KW*7
M>93[!IDVQ6FW&'Y^@L+POIT#&V/<$O"9]I-9>29N!0JS2,FAAE>Z4$.)?M\'
M(5-V#\ F+IV*_HC9D[K.OSQ,<_*I9<(IQ?&Q2XI9RMAN5<W^&>/8PN@V<H_V
M)$EHPM-@A:;H.?01F%JU*D8V^48I)YAZ[X#5[J8^(Y)4C=Y$'(2X^/U6\"QO
M,T'[56GP>A.WGKP#9<8WONQ G;:7@QC?<+LB' 67OY7>>4%_BDF42ARS@Y9Q
M]/$)YJ9M7P7D%#^:8:8EZBV+-QTDQTCSVYY0Y'@.&R\2,=ZOOK%HMS;1=(WG
ME6ICFPPCBD)6O_X=+_'<<#$>Q *V_J6"/?>T(B;=X:=?52)5@!?Q]ES1;'7?
M;.B/XJX?1W$JGF>B-VKW@-=G5RA_-PF"N4B\'JA-WD+[3=:4H9F0%MTZ-1<&
M05<^O?G3)OXZ0H>*MCRCN3E6,/V(%%T_S>DSW=:-4D",;I3URX.<;9(%PZI?
M('HEXDH7GBXR+<SO##("9OM?(L0&C./'U,HFV/=/+R$E9HB9(8HQTA#A\%H,
MH/ES+,JR1=[Y;R74AS%Z\FS96M47VFKS='7TUF@J8<3^]G0V&,?X.3I*SJ.*
M0)%80@*/-R&"Y[=+M=UTHI VJ[''!3;>N!T1.9ASY1UT7NI7'<X\]-' U*R;
M+ RW(05_Q3&X9Y%JK3;CX,*[U4Y9')Y\[JAK/]9Q7:A19L'8?UBVMN&:K&AS
M!K/)A8=(,1D9HJ&HO3>+\/\B2'?"[P&&DP^&7*C/)3:2=Y=J]I M:=T#+K:@
MK9&[.]17QP\%FA11Q)8A48D728SI/F9.MLC?OX;(971-#3[+< M>%"9A?7,U
MQGW_.-6RB)USK&F #MJ,\'V,"1E1WGU4L\>3^^4>8/Q28J"HK.0=J+H^1FFT
MI'A)/FG!JX].O'_MIUMAQ.)D(K?P=0>2KBY2?>P LD>U9G*"7LB)M0[ J[P'
M5.] 3[%"[P&/@BY5S^<=4)^/H']4[@%/Y7EQYWJBAU23%M9W=@F!5;<>.&@6
M<YIOASZI[[.=X:H9RICE]3BLZUR]*>=>2Q;:!8/VZA;OT);O <V9J!>^</U[
M0(:H\>4+B=:272WI-P%W^YFY7DEVR*.9H@,O,CFA#\],KB<$86<\V=-;D)S^
M7.:1)-,=.-HQR%AA^L;^X;:\]6PZ? ,-H(8@'UPD_DL4)OYACCN)3(/9SIUK
MZ<T3Z3L;OUG80W"EXKA]2KVD6:*N/6Y5KEMYF1%!'IN88O#XCU6UV!:#)7_/
MK=B%VU\XGX1KK0$S3Y_];>C9/8#C%):D-N<T!>2_![1=B^<7<U3VR?>Y67VW
MOR7/A[&PR'@U9AX.0EA<"CP%5),Z][QN1*,M!:@2)7K*Q>,REXPI>WSS^0.6
MR3_F[:BF9H*P!<:&;ZRPJCR(>R]G6Y HYC&<]T4D!8!YB."?59?*]'?75+:E
MOJ0P2$1AR J*^O(7Q.=#4I^J6E)UVH)2+QRS[O.BT1/QE07$4R7=*;#*KQ!F
MM/#\2WW9B2I/-S&I$7NKKQ+L?#&QZ/0;#E)>!TD]1^6%N&(:@ Q!P#. N-[.
M3M11DS[UC<T]H'SRL15JAR-A/6(.<;<N(=&3$OY"U9C>]^V_SI%<E8F:>&'Q
M\S-6@^V.EE8U3YN9?4">)I5=0/!<UV]BJ98X/G)+ASH&-2B77EV[\B>]G?7L
M#X/%T?(7LNAD);V.RN%[1='&DP4#:DI:"M?TBZM*A3HVPJ:\'!!/R^GC7O'U
M76TAP^+%F>=3MDRZ\4Q?LMIUNOKGJY=K<Q%C@\FKX1(O]9TVKH)*O)>K.M4B
MQ2:R<O; 8N>C]X#@",+L6KN[/0_EG:,RMHA4G"UMCPN?=FO^]R_^5(QNZGT2
M&#/@ZY4[>D?@7':W[(-V/:F85[G>IT1B)/F;8'G#75#LY!JI%*8=:"A9*?)=
M*E'NN&9.6Y0@;>ZA"VE]8\("%XFQ(:KV$3 H.D>Q@H+M^=4>K&JW]TC/)B$I
M2=(!<_PC0>+RC\^#S>9O3HMDY<:,],U]?/J\+*7V7OZL"9=<+:.CT:!B<+8J
MU[( GW['3A)'(%P/D*G/(\B6QIA^)I;H^)9(S7V9$;T'",M+*K5TB'F,E?3=
M7CN,0P9:>=1\O$YWMAZT.-D08Q*?4_EC_M?5/PS6@BX*^&"B-G4I/S+[WV.%
M/;2@+;+"#+>ADA#GG94(@MF_?S&.DOQ:(XWERH&-3L*7+59@,FF]0&%\HS]N
M3-\K+^\6+W!\V\AQS7Z KS1!_7'(FQ*BRG]=U*1YT[9C%/-/*NMZWT40LH'I
MG]S6S6/C)<7Q0Q[HLNSPZ*\0X+3HCV*?K#Q/4-ND!W]UE"1FO26(G0^G 6$U
M'O,E1I]X\')_5/\ P_9'*S:45?[+>(!)UZFZ@E(^XI5JF(4:5_Q 5MN^&S!5
M7S7^^ECJ1&'VY[4/_D=M"$)+K-1VJGK/6,1P[L8R5C-J,S[]6&D6]2"$=EMC
M6M*/*1_<$-L=D&16-\7:>%K<P$_>]^9J/F4]=[2*V;5HJ++U^T%E";7@QI:.
M(@&F4>RU-##-+A\TK1&I*V F#UE-4$(:2K(DL"P6H=_N5(]L*(93(=_3?"$L
M.*<QF?#% ?%?J^-\[TIT'F#-EZ46<.@MD%]*UDC,\E=)FS=?;:6&>==X$UOG
MJ+%<Z,'JX-=IFM[C10+8(KJ;%UL.P_[R'1NA53@_!TTU@36N3%_N<"5:/[R.
M1PU<QC$,XOM-E.7.Z&Q5PXB+<IN=]W4(005\BJHC=@[LR#T.W,J#6Z<:\NV5
MP"(EF5_:T9"J[?=E+];7L++UY"6D@D*L9"8JI] PHRXX3WM(49I,H1(K.PKW
M@)*\*]B'3R)Y<>_.X=P=C%<,[#A$!UNCI=O"D,8BMJ+*M0_T=1@T^ZO0SP5I
M5)4KJE7%,(<HU5(%PCRK;(?+'YYY*.F;R(><:E,*MCFW&6]\U@&-8\^"/,[*
MZ\&(^1;^6[& XMG1;2'XC=I,+ZF9[]8K3*VS1W430KX?Q[? ?DS  FJ33.3%
M+1Z[UV <7EGNZ<)*+U7[R;4I@I)[<E?/HJ%1Z#U:8\,]P&!2I'!6UFL%*!=K
M'J"5<-B#TBG)&'KB'*CQ+(O>GNQ1[6^-F0+QD1'?BSOE,(OW6VV(B3ODW3,V
M*NE*) ?$XK7N+'/:;?HF6%W36$"IYCM!?:<.ATN$+:Y4:Y<*#EU__AV)],<A
M>(. \AC;[GYJ_.X ^VB.(A[6: .(9_"8.J,_VN;Y9QEUEH6Y"3%&S73CIB@\
MC0C\4AJ-\DOGQW%)S&O!U >TIT5:PN]?^;;UX8B3N>^)Y0_KQ58>7)'QX>>=
M$2-TM>LHM#V4'"MZ<'ZW00[TG/(27F4(/04,,/(*A[S)YBQLFJXVGF%2N6&5
M.<R(' (F/.5I%@MBA/U#SE,+7_KK)A@>4:[MABF0/7TO@2 55+UR.6,,-9I0
M.&Y5XM!&E,7)>3*8"QWXM]S*\KE/5GF2)E?O^[9K:! &(L6(6IJ..7;N 6=M
M]P +[Z*EH2M2UJ9%5&"Y:X/:?N?,\L)\:Y<SPAQ3LKN%.DA=B\W>HJ(V8ID$
MA]Z*16[ <;STQ1;4 ]JX09X)G$"=+[I%Y.PNG.A-3J Q]393Y;&\O0=T@<W:
MA+\16I>UC_[J>:PY$<')TU(@*@01GN[Q><B7J 7LZ/VX.@4?/G4F^V;8$,U=
M16?)TAU_*G\KOO%[QVC@%3&=[3BRY%J,UW[SR!:9!QS)/]6:\%#HS\KE'*\W
M=O-Y.8 A7\FYJ0RX![SBQ58'(:N 9%-TO,E9<TY1,7=/8'V"NW8TUI!8F>_R
M]GCRF\H/D1V6OU5GF3O2XQB^3AUGB(:Q4K9R-5',)O=FD-]%"3YK.()/I*S4
M,B^=77\ZU7E$O*O]:CWUF3)USP\2%F<T5L$[EJ%@B56>+.BD\5VB[?;FC$+;
M*U:[(@?&/VU";"EN!]U%VOSQ A<D)PHN]$+1HOQ<7WG2VY^"</04/B'KDZ!N
M@66\OY;Z?*3Y+A)1G \ND/JNRGA'[_PS?SJ CJ8]([(ULS&P3[628(YPA+"$
M/R9F:Q362F 2;B;T-H/YO"1_-+J4)=(R^G;01E,YS 2NE$)"093A\G #%R\/
M0*@&CS^8*E@ ;2X(H>'E\KH%.J3NV%<?#=IU7/)5/B.>636Q^28\@.;DTF=2
MW!@4IW0U[4V71:F>V.%E>%V!WXU:&+?/IK\B>!U!=S#U(.EZ2ZQ?VIT?6 D0
MZ:?6B*??V<<YCXHHDK8_MY"\^BTY)-X41T\2'^D]689%F!(H^MF'"G^T@3S-
M-VR/]$N1;78*VNL-%,8$#HBJH@B=_GNU^\;G_L<G**C"3"@('J@8)&TRMM&_
M4>*"X@.A" 9$_D+(GMO,/^V?D-%6Z6Z)/:5951O7>M!J^L4$CPB\S==S"M[\
M%4N*(+G3>@8@)P?P"Y<Y_BUS3?*4F[1<V#^?GUO92"!N+$I!C$O5D=(./Z$\
M>L]ZOP^NLN3W,/TNWJ)#5$\PUL#A1+*\MJ1>7^0LADYI?]4K2:%>X\RPJMQM
M8:5@QU 231&-7VNS6FZUQ0_N0*C[C-_EJJBG\TVD)UW%$OD5Y<M7O$E@$5@)
M_XV7> ^PJ;U^6I9O\ZO78>_)DRGZL!ZR+\9/.?'&PL+P%6) 2E*#C(MY10-T
M#E&W:V3B_L-HS<0.>WI!=^BR=P]MMJ0CE6*![W<[9)@6>%S (.$\5Z2$S&%C
M K%^'"\AI?N\IOI1YQ!/5I!,U'NBX3G)V/N- P.1?NB?]U'7IHEN['EBV2.R
M)OG[ >_(NLA(AQ2&X=_U9Z6?GH8_BFPVK<Y2DE&,OV:'3R \3KE@_,M7=8WQ
M(\#S,_J'(%N\]C^P/&1'X\Q0C _"N .*EJ=3_-YOL2)H@I\CN71'PH&_&3]C
MSJ/(_?8)_NO5U9A+/%L9P1VMHE*H6:UY#6=QM]R5 6$;X/HV>V5LT^9P.TK>
M+5_J,M@N)"AJ"I,FW^[&C"_9*>>NJ3UAV7--QV@0C6+[R2QM?1#+X@(9UM%%
M<=#O"='9Z2H<F53":VP+G03:=?H/]IH'@Z2EU4++28K79T2+U[MN2._P^"QR
M>3,O!]<0QP&,PC_4[_PUJW!U9N8[+,"V%Q[ES$Z$OS7?8Y&G1DJFB<1L:4 ,
M^:B)I*$6#KR.LG9'0[P_>(UL&-SSGZ&).'8)K@CNVTQ:*@';0055]6-Z!K/9
MW+Q<B:](9$RQ5:,U L706E[HF^P;E3?6QZ_!2ETGJWT1R/<_Y(GPE:8PJ$VQ
MJL3%K!23/ +9% ;6I(A'K-1ZY9LQK"+DB%,]H.Q5>8LS-M47UGK3K09]1%*(
M[F95Q#._#!-OI.9M-7S&/='**FN^&#FIM;>6+"MI1SSI-"?SI-.;**U!*#=N
M2L#<]:#(IFR. ;%-$BH:IDEG$\OSW/$M68_0<OR)QMCI\M?SZYFIIOF3'(WY
MTYX2QRV[QA='3V$Q=[G+X +B3Q6-[VIV:=S$'DLH5#S;R@&_"JL+A[7QC;Q[
M=C0KVO*#ALJX%QN#T\Q_TMW71@>W+URJ=W3*8&Z^!;>VDR'Z;:'+6+23G)L(
MFG6"Y?F4OL1\\H!A>(LHOZ,GUG&)F4JU1</HP7+$A?+O"&P"M84)R@QWFK48
M\ J=Z)>N=V'C#ZI(B2UE&;BU%*.EVU,7H/[:]..ZG:;AYVKAL!C_A23CR:%K
MD\6S8^'D 35R?1_=,2)9%UXG.KI'>,< NPN*,8XS4-E\EUT95K2B5Z[:,89J
MA0/&^>!^0R$\&$9UWCM*+/^3?!/GBB$N[EU82BD=55:.A>W,:W@3KF7"R>.Q
MDI&P!")E].?);Q<&OGIM35)-B''L7.$7&J4GCG04S/#^GE5TLTN(EJ&_$4Q4
M-"/[XT:W2*RO>(096$"\&F6@_ZTJ+FKJ0_&CB B0B5<Q6 59-Y"DW^(XJK3F
M6T@&TS==9O4J>$V*8<),MC'\RJZ:*!1[?C<GFO0L,,T:PXJ[';L%Y_8M!;_(
MWC(L![I3QR#@L%,AK.BKKU0']PGUE4):JRRM1EA8J.]+-A>P.>P>2/(G."J_
M+(VCL7.6=7"$TAFX-^&?[X#XTRV<36\X8D2J$)V6_=\UI7YC5G]^Z*X2>N-'
M-+5C.95-8P1^8S0W^ G#S^\!C@^IL8[5IE[N+-Z&-$59?_)RE*&SC,:J.07!
MU=AV=;H%56I>BQ6)@M079^^R?5"MZ$32!^N_4=3_<2P!UOM?<736*Q'ALA_*
M2,*S#+I5YPZT/U"4B3>>C8XHB6!G4=^8W@-0G[6A%S/0<.K9E_> TT</(KQQ
M[!9L&M6XU&6@_C<O0I</,?7+AGYX/^XYB5F#(/H1#*P?4%<9N(2&PX(%. .$
M31);N.0,Y.6=1Y3E%^\^B1/=XAH_"O/6.J6B&]Z#K7P5J9=]]4VUK XM4J%
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MR73OL6$&KUNA7,77?0W%'[K&]UXDE21-:DVJZ6$H7D&2IAG<:5C2/Z:7*B#
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MMI8^2J:R&X1R4X&9OM#4HIV^SU68WR@/ *)[X@\O)CPO/L/J:_2<QP:WHW4
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M&VQ*$F@+>LF.DZ!$N8-%/4:G&5IB51V\%8]\@  ]LUC1?\8O;^:9(:=ID'=
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MM*LR'U<^$R=?U61"!I8@B;23U>:7*+FSH5=5*3+FUX _%)+[CVHZ7!:JNM>
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MT9/5&_1?U(X;DUE+!2HP5RQ7'H5%<N<W1U.4.3Q"=1=?=01M=X.)M!T%21"
M#_&=/U"[3W95;CEF+8V$O]K?5K>]I:Y0H/SA)L9<[EBJYBY8F^J*;F%S^^K(
MV]_3-."NAW:U18WC@T,Y>%=F7FDF92N"BITA1(Y"!PU J.Q.HHN9]<?F^0=A
M$B  =_Z]5SIVU6 $@*[*GS2Q<-$O_*$V&B,-J_3@MQWY;S3K50RO857KI,'W
M6>]C(4,I\=VO*67OQ[;L"$EVR2^D2,4FD^1!3$IE#.S4[^E7Y"Y$-J4FHO!-
MQ(82323/]UY9YF6-CAA/MD'F/MU)6^6\R@89KBO&%MH;A2SL!^\'9OBL<TN
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M->\!\<X^D59,XZ\&EJ.-(@,O9N0^')>N/4S6LR3&Y+-"LQ!7E%2P,/#GDD<
M0OR6KYV4%=8=[M2G\EZP*X%H^CK[+?$)[2T$(]>V1HW3C-KZLUI$2N7>%9]%
M@D[GOY%WSI0)"D_"+A2L;=43.16UDI@ /JXF/R!9M=ROAICW -17"BQT$&<Z
M DL#!^CVHX/FG<XM%;U,7:\INU&5_A/Y!I=66CZ?%K 0B8;^ OVQ?/)RB7N"
M>@:Q]$V]NM7BEJ3D$&D_18,XDV=M?).03?G3AJM>T=C[!'D9.@N!'I8CU$RD
MTKV%", PPQ0<#G6[5ZZSH"O5.O E(%UM.VIPI[M!-T0 %B<1 %SI99<=LS-L
M* +0!E';T6G"FF2[E P//QZZ,H8EWZ-R@0]W-<$=&^-M6T1 ! !LF#Q>XD'X
M6]13TE7P4<,Y#U(4>'$R%SG@2!%XF'8,.1Z=%F0:K%\P=V'(T=VV[&9G=H95
M\UN^$@* 5Z") &1*%MS?VTD5&%7XF6>XSA264R![3_R]]U$CE.<&#8:4FK/C
M[HM5%^8ZLU5.CF29^AL+RQWW@!H\X"+C\KS(3[/\S<71@:\JZ4K;49.[] W:
MW_29+T). !62O^Y*XURY)7BVLV'?3>\3 M!QB-P/6P2V2'N,[MBDE[WLP&>8
M?V@()T&*>WOKY2E9&WY,=V4J5G"/8H\ '.Z"0UCN>+BTX &UX,OSMH[D";L+
M0A#:[%8Y(7*@S6+P,-G0[W&04W4V(;V%9_V':-8;R.OV_4S?*-+EMJ,6=[4;
M5 /DK&\@9UWMRA2&%,V)%'T*#N$IT=ZCA6%5 %/NP\) D -W2GS=4V.NMJ_1
M1*DB7%LBNX;*[9_Y8K4C@\2HKNNZZ1XYOG^;3<"WJ5I7)\/7WRJ*1Q-Y''P.
MB0D%/S)2L*F1=#&'>8N##HS7OH,;>V[3[UO3V)9SL_PSB\N M$U_GOI1Q3.2
M<^PC)]O#/N'3+4_*9CX'Y:)B;\GIE=E]SM%-_5!KI60F[_J)M&>FM1^CIO@
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MVC6:J-6V%SSV7"F#\YE83A^[\F3.NY]IY=J2F(N,:)"\88\$2'W>845MTC>
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MW^]+'4. @@#0(P'P+9)Y*GMQ(M;XC(#A+7,&"<B7=&ZDT, RJM.JJ  N+X,
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M ]\6+=C'BU*V6@UJETF'S4WDY+_"ZB\V#=U3DI7FJH%LB']M._HTBP ,*2
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M927&IG&*12-8#^8YBDI/1D+TUSV@KAJ.\;RM\ 4YG+ZM2:7P?:RE-NJS;VL
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MC407J6B&3I/T<%7C$IM2__[2IO)&2^=YZNAF_41AL<V[J<T)<LWF)-9O=.F
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MZG :;P N)EJYA.ID-]/_!U!+ P04    " !!,FY4""J(PAY0  !*9@  $0
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M1,K0R<TGJ,%KN#VH;#UZI?(3[$TMC*-,4^RNA#-52";7?N/E'CCZ'4GB<E
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M*$,HE?NA "?C8Y_X=&=KQM2)VO$"#4/#,KBAQWD%HS9]A,/, P9D%I*YL+
M[+3]Q\:F:RV7KDS\/^$5EI>.W:Y)4]6D<5,58N$E75$IAP([@\6YA^2W$790
MP#37O4JJ)LX$L<1VNZE;X^?/;Y2L.2,ULD+I^P7G:+)" 7_5Z+DZR8^9+/7.
M]JCO_:VDBBP3RKUS=2#=W\O9WX=J95 :)5G9F06Z9#5A7*H1U=W>_?"QOL<!
M?JN?;-O<[S^Q/2QKLR#;("E9_5G6<8_;70H%"+GH)0,#R _+.&RO;JI@\-.<
M1^__=TS8/-41$W@MS_7LW7'W*+^H@J\0<[>#E=ABIVHM+2XX-:[0-(1)91UU
M?[_)]5FX/OHD\#_@1LLC<D::HQ39F2"2M&TM:-KFR68Y1OGU!;'+/@JHA5Z1
M^(Z6,5DYS=.EE=>]KE,II7+6E[^J 3E/UEX%"EC6MEP\N3"!61EFX*>KJC";
M-KT>;/L6:[>/%YWB)18H2:+%S9C'&'P5A,IRXLV])>VX0F\ALS>@RBH.],8,
M77G+)/^:D(XE2A99-S[S3RPB_P"PX]MZS7?X9 R!YC_0<O:[QZ1M>35P>EV-
M")^C^D66<Z27[MAO3TW9E;#NUR$0YIM8$)!]A(T<:,*B]A^HP:+6OA@X/)^X
ML;C\QFE:O@8D&+HK]!]I4 P1KV_0Z!G5";JEC]"Z]]EM@^60IW^<OD<QQ_/?
M,&%].OWHANMF([/\;?HR9QUC9PSC?AH\IY@&%'"9%'F/B]< ,QH$^% +;F5<
MQ;&D^A=X4FD7C7RSFF SE#4W;Z$ 6+9^J Y'L C*FA;:O)%[J %00$C^69+>
MP&L3P1XX45<8%@7@X:M[V+R'>K'RD,5$RX##Y^D/90$*>"8^90%D]J0]YWZZ
MM71D+ _^PNE 7KWU.I\\Q:NK^N2.9TN+_%]P4**;,&DBRE?X$,JIR^=IC3TU
M.'9&7>/;_DQ+MK*[XU+Z4<Z:)YGY>+.1 >)4<H'>ENNS;55,[R]4H78%??YP
M])$M_MY%%[=TC([WP!HHX*$07R8)+2M8I9_<Y3^<+:" S@E'@[.)8I5=(]&5
M@NQQQ/P?E'/L#4YWRSUJWK.M'_-H^U9Z8S;&%,RHKP5!$!LND/K'!\DU_Z7R
M<A"#F["$<L.T[-4M9S1.B7/=+E<&^F>[]0K([UE0ZOA!G:M)Y9XKES;[X,*$
M[RI$D3]J_9>N?!00-J>Y2^7^A1ER<H.TA':NW]H779,$-A4R598M6-)BA=A0
M+F"!I [Y[G'3=6#&_4N]I\*P1.EI,;>4;6#VH6_[-[;[I]5 C=S;]MW\F26:
M,BC@GWSHGZUX/?AZ P/F(X\$#Z^G9;0HEO'J'T,!LK^-6QG!$@?LH"2D"KP8
M!QZQI[U,/"'CM/;O5%T[M[>9OD/G#=T%PIRZ[>3,#"8-UR]IZ"/4[GU*8!SR
M8!PL?2JE&U:A !,CH<U9[FWZRH=(+(+5S\GTN]/%!X'*./2NKF%GX=9D&%K9
M.SA-0>>J;/?>U:"L)G)8&BB_O8-%PZ(,#(?1AR"%)9[T8J&;K;;+),%*Z7K@
MWQF/CW/8[L[R]:Z*W;S;$(B!C_#3LK\]I/?\L_P/R1JXN3U\?VU[_RJV5+*8
M4X>_B516>_1CV]5/M::CD+2-#?4]*?K@]X\E7G)&7*Q=K\5>3>@=QFB*L,=
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M5WS81>@VJW+XH:5>3;6DC;;JLR^RBE,"=\!R-IO0XGQ+3,L$25?;9@ILYIU
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M"0V8H3:*;XL/H(!_E9-@?II4?ES>=@^7*6HTKV7APB<X72ACV\;G-2\R[B+
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M;'M>#=G@:'K$:-EUQ\_NJ_4+HDZZFO3&8AE^=7QBPJ?7GO(4HO+%1(BD 'E
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MB#(.4:Y[K1<BG;J?4!WK? <24(]^<SO*Y:')*3:F;&%JG^*-=/$I&"N?$6"
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M +3N-S0R_SWQ9+A5+CB4^_4?E.RC"92)_^22:/)VO"2$:C#@<FJ$O_MQH&A
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M0_ZXC>$$4L5V$FK)GYRZ/9J]P9]URC^[PM_(/MR-DK<F77W:2H"^T3DFQ<,
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MT=W+QFW:[$+?OQ;P4U6#78"]7^OX#3OM[\]MCX\6[/#;9+-3N;*5>9+XF(5
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MB'L>R[-J/"V0>8F$*[3KVD&CAU!'WXI-?W@+#7=YXY69X_!G#' LM "9BL4
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M]U]:=1 S&R]?6\0BL4Q5UZ@$D(<&3N&EIY\M;];,-/4'I+DQ0$SP+5N>EL4
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M</'&8 G2Q'SHY(;\/>*^_BU;+ P0KM:-XSE8MPLU/F^% :*CKM,Q06-44C!
M>THZQ#"J^C86ZLNK#GVY!0-LXE2($@U60D!#//J@04@XZ$^9V%YY7>F7+R;:
MSDRI8 "\DE#J'=V$3:C!P -4?\OH\4^96<>"%## 3[DX&,"?!WC;;:DHSGK4
M1GJ!KK[Z1^ ETK_+)C4#4ST^=2R#X/?# #UTAJ$\"2:W,, />[C'"7=X,,"?
M\JD?Y$. >U@YH+41>2B+-K;B4!-3+Z0S[@;2UM?[ISSQ!4])&.!#*AT,@&0/
M H?.94::S'L#=XC*VK:A8L"_RQ7\.]BP'1@'P3  \[87#,!TSO)G5!7_C&,M
M=5:BLW[471#=Z1WH-\B_0?X-\F^0?X/\&^3?(/]O"[)<Y&;7>U%,,W>M'HFE
MP?P^">(^D@^C.W1:\!?8C/[+(W"QGD]-0V@KK/!T;@W+1WXF/A0P>'&U>H^T
MOWI+ @- /D<!=>&^6J?" +ZG\+=;*(6JL6TE7  [(>%M?\[Z\J?G:J@SV_N9
M=D!!=_C>WDWPVESF@P$05N$5-+Y[V':)-MEV)@ #W Z;*XKZQ^@/P0 8YZR0
M1Q>H;Z,+%+D-!L#/&IT%[1'F@=8\8 !PTE1F&#)%6R*4=,OD[O[T$<'Q%((!
M@K*)IY?" &-<<C# KQMX)7$4B+Y!EP2Q08!]_]6_H">*@9K>@J(3_N0-R9]=
MG<G!UN"AA(R>P6N-Z4_^\/^MJR52U.7VTG?IZU Q_3\[Q.[V-\YJ?5?\]!NZ
MW]#]ANXW=+^A^PW=;^C^">A$Z32=N+Z'-?%)9"UVBCI.$-U_ZFEVVF577:")
MCY6VS6P&07'+'J73[^!O6]B# 0(.80"E7:@\Z+KQ\#Z2_ Z$ S7EFOT"XEH;
M_?2?_5@P*QBJWPWZX>4<=.']\AJ%KA<&6'>' :8:8(#8U<?2J%N]MBM&T!8<
M%(NL ^ZH;8CZ7=#O<G^7^[O<W^7^+O=_E-N$\?3V$(JE7P<#=-4=@8SA GB[
M+;'-^_1:C*7N*K_@:XD<_X269UC@^^_;@[AE0T?4F:&[7"C495Q@^6[0K5BS
MI$LVR/ Q[^@!Z'%=DESWKDXVB-2#V$/M>X%<T;9?$UN!&O;TSI&[*,XF#'#6
M CK0@0'Z3Z&SXA F_?L$X#E\+JF9@0$4NT!,&VU#O8?5P.0STW)%/2 ,@#H+
MS1F%I,$ QXZ@CBL8H, !!J!J>] E_;<?"S:)W+4A>3S[3TH>OR(2/X?203I_
ME_N[W/_3RL56U E24!0UN0W3@+:/E3H!R4?/G:&GWLOSGUILO;RHK1=B>:A%
M![3)E4(O2&^U88"KIW /VJ =47^;J+HN/[&% <P-@.EGH"UW)YP=X-]&R2+]
MVP3)#''G@_(+" S@#^>+D_E_%W6,^L\I>,&D"S_D=R&D=R2IHFY1$ 88X-X7
MM 7GG0;B?TK4!-E"ISI P#48H._R@&X(M&X#'\%088#W,, #"O!/*8%BOJ#K
M7*P[&  9*IZGJ&<$!PP$_:E_QP4#S"G^*7%LL 2L84X?O?V7Z%[_"091%NCK
MCP5?H:!V&"!Z?TK]!PS0 7<L'Q<J"P-<8X/^-N&AX8)Q+$-U <6 1,EE-O="
MW\  CQ_:SN$^EF?]*;'060_Z#>MO6/_/@I5NLC"+DB$R%*]0]?0H]?@ 6U%4
M<0Q;G64#!L#]XP;O:^ E:8U7'@A2.U]GO7HMYWVSK]/[M_@J'(CRL466 C&D
MK+'BDL[_*W>8+-!W0+\K[G=_^ WK;UC_?X7U3T6=#5!GMOXZ_^=VA-*-0<C/
M:IJ5UV^OE(M1%<DKBT&?5V_D6.76(86TJ@&4PUS&NKSV^7>?:OC/0UN*]]4)
MWE<XY>H^V=7N4X@>#S(4"&Z'6/P$C_J.^FU5*.>CCM;0I=P)ZBTW@19X'J8\
M)'3I3LL]>#2;K!KZQG7S @0)#E:H:G"'*9PYD;F3/DEZNJB>"/3C5*>_L"Q[
M6;[OS3)YRIB%S%S(A#QV[$Q^7KP=FH/[>3"2H#AN@K\G=*7J++#(:Z. 7P#;
M['HN-5YL^9Q,KU@^[S;T:'4=Y[OZNP%]/(V<.\!C8J;":D)BBC?V;G .&D4W
M"@Y5H7B"HIH3(=6DDW33"TTM:;.T-R9[4A6(4=:T-9:IT^.Q:F/_S.YYNCGO
M9Z A$'09WA1S7*\\,'Z5W47! (MMT*E2&9>'YE;])-YR_=ZHT7,!OU#JLC2!
ML;+D5AI0O_ATVW$4-$3J7JS5^C8'!J D58,!:H'WE'3C@\#01Z"*[6?2#KVV
M';M+15$/T\A_'$%%G3V,?8JC")4&/YXO+'CCL]Y/-H $9,]Z8%/JI)N7KNXV
M:FT1 WEY3MQ 8*C @;#**^/[-R%B9N02.QSL [%LE:PJVFQB'NY!V\P6#,TS
M].0\3\YJ, 47EY4;O4+?WE$N,!T?\&P4I.4=<5:+)M(QLW!\$[P^N9;(59<,
M6/"I'4]@1.;W=DJ?*;"_X)I999,O4FFCU65T&\;9:VSKL"BRPKF2)52KFUX3
M9?PH65T9F<,\1+B??E8JW9F&/]6L7. 5)A>,F>48P],AUIH- \C5*);)*=K+
M?Y3)GPK_KC7]XU(]O_\L<((NH"JV^YHFGWE@D?T#RSW:W2-=^G@KJ:ZY(%O3
MV?3REG/50I>QFR+_-- %#U^O*4"J6\FL^OJ*L'-:]GT=]P'=% RPKK _['G]
M^G9D^#2AI.Y;ZZ?[LL3H._6W1:YB^NBW\<1,.LW2VF:"!AY$5K1'N]^R$,^9
MQ<UMNR:2J_5WL#JG_)JCA\=UH45G-U*35NS[XJ$?*\T-" ;8\AKOVD,O4GMM
MT#&X\RQ644ZJ4T6D:ZJGGNVU-CRP :.K^BV1MJQY".U!*-)8DHNZD/0/KNYA
M>5MN5S@SKJOM1NU5FF13H@?+Y-P&& EUB*!JAYD&WAFL\,UAXO#=%\(ZE4OP
M)I8I_ _Z+4;YE\S0.[;]CH:H8-#YNP/]ZT$80"S'\6K(4^2/P\Q*\,:D?\]!
M:WI6E8X+/06*WY%@B6*KOP:__4L;.'%F]%PI%EQ9@:]@@"](*\%0\=AP:S*O
MXQ7H]PD;(RE'4T4NG,JF2QY>ZM)%R5L[-[<\U$>I>V)6)-W.89UR?;6M)W=C
MF2N=6<(YIN;FNUBB3DFG?NAQV<1J@ZJU4Y;? US" 'X2"'@4)/(E]H[L,QM%
M8HXY@QR?L=5UUX$(Z5C[%RO$'[6*E>Y<SUUV?1QN GEG;$(]N;@".42K8PSX
MK7TWO[]5Z,S VXV.TI?R+)UEU#"OR"ZL.6G-)<:9N)7NP'+-E8Z]CK9 !%A_
MZVVC]W@2O7^X+PMV"< (L&;(>OC4J#G^@RNA/)Q4)EV+1[>45*WHJ*6F9667
M1]3%>14M28"7;]A4LW:BZT='W\]-@2>4WTT7RB&*Z_[K_0Q2JZ)N: -5%-'A
MCCT>Z8HK02\HG57.X@HZTQ0K[[RU?\ [IN307XI]='GLV:TO-W/)FP85AP&8
M!/7S%45QQCQV?T#T88 ?7(_P^6C!:0=G_U^XZPX:#& %'V)2W0+L56_GS_'S
M'I:@^G]<I5#%_1?'^0GR6UF*>#/J&>41U\[@X3;\7IF3_=/0_.Y!(W<\\YK3
MH^DCMQ;L.T/7]ZXY2C'D."8"0D2O=4\BSEIUE25K6Y)5W@SSOD#4$X/0[(^L
M+R+GN2N&Q7=D!15IR;%/+_!#0RN\S"V=4).%VX<PJT5]>IQCV.[53=9/ \\/
MD^AYPY.BYCV/XL(73]:($%([2ZD5K>:?T0MH3=KZ-8FCBFI.T6=/UA FTX!F
MA,C%Y%A2B$S!A[K8@JALKA2W4<=K!IJMHUOW//HM38L"U(J6"AE*5CUTJD5W
M1#G8ZIG+$.:JR7&"A^XWU^VWRNQOGPAV];')BK:$9@46:7(]\[ IU$_<55&W
M*/;D:BLOYZK%M3-GIJ9?T3JV=/>-P=C5@&*=[4(H"8KC]<T?./MDFB M=YW4
M/:S %G'REB!ZRB]3*DM.'B!M/!758R,Y:/\,8_4%4_*U&XK-8IU+*Y\J0>P+
MT>[ZEC%%4>SG?W76V-G+#'VHFOVG;CNZP7A^P+I/^BQ9T3^1(75+P9U(>NR!
M)&[]ZB@)"/F&NGIC @.,Q_5&2/;0P "LO&>1$[&ZB?(;M8E(93EF:<R3"8YL
M8A4CXCHD"ND9 ^F_5$_#G3-OM,ZZ,PPSW2C"HQ<=Q( EGR$L4^LSE[K2[5IA
M4;2NB<<A!VPW/C?(+X$$3>!*,X8R")!?ME8",BMV2=8CZB"2Q+$N^9B\.%Z"
M'F(_$%Y86MM6Z!XOR&K.NN_.&)<Y[[TQ8;LXS3WP4Z'H<C>OO-1Y<6TU1/-M
M0R ,(",LW/=5EHQNR5&N9LZB]DTZ3C.EJ5N.3CM)EJ4+WM)CA_@PH0N1CU O
M]TVA_DM^C-);FRYUEX622B%4K>H7(:J#F'OVG+$]V%?=,K0/M&_D)M0;O<1Y
M]29J%IIUBV=%$L_4<OG?@FFOF5XM?U:79/C<8,K8-$AG_9E_[?C R^U4ERF\
M%5>R3&_)HI$D@ZC,X6$2,6C;(3)_,](+8U=G>??K:H^W )A?S>4:K*,]H,?N
M_3&/FYP\5\#6?5;V;+5#C_9LI8;OP.;:BD'17W2WJ#ABW@=Q<Y8*J;1X2K\F
MO(2.KG1+*2SFVCYBTZ7,J*?TF)'>>KNF,20S[3T-A26S2FA@HTTP;T!IP6:+
MTLF :/QR*HZN.XN**H5[N/^H^X[%Q->4S.0#6UGJ_NP_M.Q?&[S_QO0ZS^B@
M<.9X?0H#U-#U%OTM6;$W:EO>/H>,3_M!^;U!T4?P%WB"3P+^[IJA"8X+EVZF
M.^K[NL<*>+NBT8O4A*COWV?Y,T,QKV  MJC,4+I%?MO,?Q__!2'C3#U0/HQ?
M_$W*Q(^?*JPCAS=^+QUO*'QO9[,CV-:[@\*.JR4,ZVNG&78B8C:'[-.^O/7#
MU A/0Y9Q"-]ID/>_N;X6Y**Q>Y?16.-*SC#6NOT)2)S;R+<:I)4'H2_@B(_!
MJXYKPAUVH,CR(733,>49\:I8K7&;"X%>]2A5UJ:!=ES&HDZFL@B;#K@V.8KK
M[D^#BM< @X*WL0)<;-2D!7D'*[BWH+4F/D)==\*BID'?H;Z3YU=6A;^>(9[Q
M +72-U*7U$C8SN*V>E]K#U$Z[!6]P[I'2=]0]ZL!OC$G^)R5Y::<$39@;X)2
MV$!?RC;EV9LK+X=F).<<P#V@%MDJ-DWN-A43L1*03BID877FQTW_^:*$7-HI
M4&?7_2EG^D"1K)F#UQD*H06?FS65Z[M%;&K=9"P:;H387^_SP,M)^ZO(616:
M$Z#*XE?X6%FLS,KW_I(D11Z9$-2Z*?:[YN3\3U'&R2)&;,_X7XD+6W#KS_<F
MW W&-6R#MBEOS8Q<UFT05W4.HVM2Q-3JSW?6"A&)HN=2' ]5H 04[E2=Q-+:
M$0AR'6[]O11B>>:/W%1@CFVMT7!^H8WG'WG3\NC/_-/IGXE2+:L 0 2745^U
MCN-6PES6/>8_Q,TO8%LC1I=W4M\@4Y% >^K*A.WR: :UJY>;R DX,FAZ7N^E
MEBV=O]B-WW&C2A.+T<1K:B**IRK@V%M%/C%M F\/W;!)L@\;/F1'A[%TDN%3
MS:EJI_M#J:)4.,<HJVN[(Q>SF%5[+<M6D/?0+"&\X[.=, ".$S&#]<3AT;5,
MKK'.4\GPZ/"TK]&W:E>'RJDTU'Q[1F)Q$JIA,;6YV[N=NF(/&WRN :=6F96X
M+$NT&9^_'R_V, -&,'@XNB%:8.*TIHWG#,4ACA5B$5MDX0W\/ABYR$"MB>0N
M)5>/3:O#1$W+$T9,PH#1 =6X#T:7W#SW4T!\QR=&I>W%PC]"[YP'?2=43V]+
M@>0:8[*J0=5>[!S%DSF"HK/*I)K@@, LW*]O\*Q5]BK$$@BGQ<Y;]9P_7=Q@
MZ#B7)@HRF)T=\!YWS.M*U*''[F]\U.FE_BKFXKF$\=UQ%'$V1E'7!E6V"'BH
MG5*$I<A7=BA-K![6+&^U0<SUP0^['LOLVO#%RB=!EPX_(<08UKQ2NKC,T(57
M"E&TK"E+RW-PRO#Q[^,T_6&DG\9%<<Y-)P,<2.$4;DMTJNTX 1HAM7_XXS;H
MCR#_<,5AV79IKC*Z;BK(]+CB'77._SZ4NI1\XQ^1S7]G+:8:,$ ,&URNZI#!
M &,SS4DM,5Z<IVJW\F8F1KC)=I3-E,JV.NN^_#'(0EK*AWONFO;V$2IUVZ:)
MMVH# N+=O$[%O_!6/FG*"R-S0^Q"#Z'T!YBI8KVR+SMP@D9I,5YVQ9'&3][-
M\B=QUJTM"W=J3-&',_?:9KU3,5R6U'MQD%'4 $X(2NYQYN0M#6%G8WV+QQ!Q
MX/9+()AG;;/@,@_[3NO 3/@[M$@I1E9N?[$DBD)R)Q+_G:2N80*)(=TK4F1R
M\E9:W@,F"%K^/L&SGH*"0;0J,56CNB7BE'C .3H2,K]IGODD7..7E6Z2&D^V
MG2[^<3, 4>UM-??T,USSX][:A$='3F]B3'[4XNCV"TKXL"@M _;#P/04G*S9
M @P#D(0%, 8VH?<(YWD0OC_8N"8,4!H# ^SEY'JR-(8IC3LQ(!W91,6CR*O8
M!2+L@2YIY\V_>Z2U\,E%\&(<=S\>JFA-XD)?VSS9'X^N/55N".<4OYDS!9X]
MB2I1O"UBBB[<FS02U'#N+<679>OE_5$/'HG.[1%/,*47]3DZ^@4#D+6E2H.%
MEZVO6M#G<U[3YV2QD@2C4H^N?VQ]DR"DGG!"JQPXOBT-GQ+8;-0G'=N"&T6K
M9[2"$NCQ37J'RVM92QM&#6" V3)Z,'+@%0;:<C%7?H[^>QZ%;1WT>A@ 09<4
M0C>*M9]4;),K%8[@6:<X1+X@T,X#0;(PW2BYJI\X8M])U#N3HC0A%@X@IYJD
M@,:QJLO6?#8)R3LND"KY8C^LK1=^/D"=6<'_X1_,&O\^BEB>Q0[MO7-=QM3-
M.?#.[?P1WD)+_5?Y>S=@ $A[VW$;=+*,N4S^M@T&8+9Y@#?)ZL,ANIBRGM%O
MP\"5W7/(-W@72?SUEQCYJ59NP6,"4U!J\FMYYCIO/E8[&"#*JNQ9F?IM4K<G
M2W9ES/-$"?*Z/@LMZ_ZJJ<$#7L?"8<>Z'6/7](YA8%<P0Z:,4 'WC^@>9$@U
MQ)4*7 I=5-*$F-CEBOKBQ"5MH0\-H0-/O[6E J5:JZ8NM4E?R6!Y.@]IR9_8
M\K??E>WKZ'>&W7'(XQRJ3^QZ[C?[N9O4D_IL5*O)R^7E/4/A,.J'BP1BJ%K;
MCAUO7'8"E*6Y^NMGS=.M"(<#XW<M;+JS[\YV6M9+WB&AVKQ![!1X%<7@<'D7
MM:[AC3X!7023JK<X#3DK#W4^7CLC7"[?*=>4D9JA%2WU @-*F)+P"=[R#V77
M*XFYB?1N*A+CC/ 259M)9><,;#-PS0/?!74+T!TE0;3\&,F;HW;('P[;'SFA
M-0UPGDDAV788WG;/4S@;DL2$Z\FMJ_2\EE_D^ F7J?6$:H_="-)IZ3.NCY7U
M4]X8.:G9WL;GO;29U@A4(]:[H44>(\N*E=GQ[[,S"K\3ZO.1".F5_1' N]'F
MT1FT1><_!7E;NG<MZP8RV/Z030/B($2\7&/AV%]][4@LK5M9$25;>[%"@Y_B
M%EH/U\VB'PWOM+C/ILSI!;YP-STT:NO.CT#>3WV&CK=,HK[QS;B8PNHH_X0N
MV-0F5;6VJ''42FT1#P:02^0L_/P$,!9&7D]1/4794[S%E6^>KFD*-HH;HU;E
M6<A*S9J*C43.,83PM'B)]R;E'(9S=#=7OD[99'W;K309QU88XSB-XB1(5[<7
MJ=^C?\YMWG:U-$-L[3H(%4=3AS8E=1:;-/'KB(--#N"-,S.4!O^O7EM&M(RM
MJ._LOO[/G+Y4QU*;,II<E)<5WK=,/M4N'B(7N-/9*!@7D3QY45/!T#)TG?!"
MH'I"A)4H.[I"3?E(_%U.Z]05FNSX%>IA<IU0@$6(EG#6(L6T%G5E2Z^+!9;6
MBL[<\*Z6SK -(TLK%?7<?6@+,,3I\$>X\J'[]XKR=DW&5%]280O&4#F:IFH4
MV2^)%&R#5JS#B&78^?:EX:I!8Z$M#AMHYM<(SV8J\N5?X+$,VA]E>[TH7J"V
MDU?SY:P6$L56?O7/A)Y2+X>@P)4R#/#8]$<$;/#!-:FO_@4I#% '>BS0^7%Z
MX^;9QN[TJ2V*-'WKCR_6^OP>&?I<GDKPJ2NJ"+1(^H@9=QGQ=W0W*QZ$<^^=
MOS8$_-H"&MJ$R[3K4:)_I.">D&W96@@?ZDZ?EK0.NQ2NZ@CUGN36N^CWI:AY
M8;.G;<J6A*DOI&44- H\7@TODG74=)6\5=QC=2THN3HVG)@\JETHN>2<(^^/
M7)_F.?S%77Q/8]\S4^[ M[*=57" EE>:-CO[OE].;6Y@18-G1'B76)+]>H:#
M<[*M:E&QB9,?HPI_<7!MR[.A5\\\#MN^M'WH(8"VBAQ)2=6WCVS-7U*4A2"O
M:^%!=)NSH0 /'!%X(N.M6:BF%7"2S)/6<^*A&7I\0?8MRVB2[++P4FD[=*)S
MQZO?FM&TJ=[MY'.,6<KV5G08&ZF]&\?G&\UI)SPEPF.Y\P,*'I4T9R?E<..G
MKH7LBL:X!O]%O3VY1H-C_MZ+6YT%C ']J"L-G0?M396F_7G%2@;ZQ@$^DB_O
M[L$ Y!U?,D,W!"G^TKJK,)J+>FV 0=VT368($@YYO9."@ ]'NB@ND0GUT9%.
MTW0-W>U7]:2 Y2%SEV=)GVTQ2E\<#G-.*K66C\Z=6EO5.9V;&(]NF9=@ZT:E
MJ>^TYH0U/0S>J#4WI:TG9"0);WD[Z8528UDU54ZWYH',;"C>S-8Q=[YWZ24J
M+IS'VT+P[V:=N3[HL>$=V;%PDUALQ4<A<C=6P5:TW8E/.I*F'.ZJ>[\CN>TV
M:,U:%=-UOUMJ+MTB?*-@8K$X&!8O%, F-?+ANK]P2H%HU")A?9;#PO4CLWE"
MQ4>DIY2=A;Z72 62Y(/DDN15</)L%",_DRR*BTS#\;D#SKR$_LH H"\W.Z1Z
M>6PC4G"Z!3J_V+Z'$T1=Y%:WJ&X8X,X?M AZS-,ST$L'@Z"?5J]780"SV1_J
ME/H1Z6^30"VCVW=D<$7'YO-7ZH!V>B0/Y($IZN+EP&_WV!6O]JGM@SR.6BA2
MLE1?'4E!ONCG&;M5G9RBIP0XB7ZOW+<=0DUR'K?]J^9U1RV/F+7P43 %N LO
M%>TN!L6]PISO2[/,*":T]9>%+X@&QH<&="X&7[D=N-]/2U'_E)/=F[=F4%;P
M&R]YV]88.=^.AB+3_ES _N=FDE=M3>'\KW*M Y=RX88N.[F!+,%?TP34300I
M\4,M3L4'">4_K*_H!H-#1OI-374>7Q2(!U^- 0AF,@$P0%X>#$ PE)DZ]YA]
MZE'I4;18-(OAXL#1&8D@_=8>R,O 9'U$R3J_+&OS5C=G_5L&^21YW=.?F7']
M.RXM5Z3L$TLR%[+D_70I54V8&O<Q[I/4F;[6?X5H_-_FQ2>*K>YVT_ZO2ZYJ
M-\J3E]-H7EY6YH09::HRT,\^#(JJEC5\:*+2&JO:NL\./L7IDT87J?Q;!T/T
M877]X^[4L\-&@>[9>8-I2^/Z$?[L>N&[RU\\)2C_3TWE[]8'SB"G;6BL!R#M
MQHBA% I("M#R"0@/*GX=-G*Q<7K%)]U.YC2:*_03%5O50_N!;Y*ZNLEOK6.1
MXK4$J9$[D:-@S\_FF<M407W:&Y7*VMB'6)UWI'U)@#91$2L7*S?D5 N[EV#'
M5:Q _2%5#:=EDHW#H_*#6E8=4Q(EG;>>]Y^(QI "<-(6KB,3V@RMM+JM;X(A
M_O9^LKT^30XI#\JQVA/&-4G[''SOZWR.XU7KA:/3Q7A^0;Z4X^;GKZ?1_<!T
MI90TC!:A"&Z/\]T3(A;]7!?JR1_9=W\=7YR'2-C7CGR1^<M"4:78*8)-V44:
M36SD^)O)5ZSB /%6#!SG?UTQHRG=)SAQ5M7QC>?&IT*X*G3WKLH[2'.9.T$,
MQ%^9;U?*EFBN7/<985OP85(4_3Q_>/\Y(W]E3FOY!:-E)",V^1/\&T.6N4N!
M? 2IT#X8X&M99_HEZ43;&2L07'2AKZ6M%99X\C-TR>=CI00.NKN]:^8OC<S"
M>7-G@I@J#7UM7=K'3<3"-2];\^E_W!#4&&LVEE$[)WN1"O(IFRO1!I+Q1P0D
M%&RY!<PZN].(3! M[O6>CW)%1QW*#3%:*FJ.'=YS=+')HI<94"@ 3!P;A"O\
MQRJ0HWJ*YU>US%^Y7:LKZ'3&M!JS(NO<&RL][<;1FX".0"0L3];J7]?V,O>1
M6OQ1H]-$2:W):.=S@_D+E)MK#$TRF2)I/W1VDP -H@K35ZE H8H'ZQP>OU5;
MX0?\,WDY;"QUH^CW(901_N3Y)@9C_F-C"/G_=,BI0ME"L^L;NP5YD 7.4+H]
M;J+JXE[VUMBSQK]=Y:1Y@9+SPP?03U4C8N9AEB^T.Z\KXH N<?'V&^^6$S[V
M$X'_F4M@<7"&IUOBFI9TY;%?4:W$J*,4+<:X8B]*+VK?(EZ[,"]UR"%^ZR.6
MO(^D?NI.VY)SE9:!)6WB]&S(O!L_XQOW2UX_<6]Q'$.X8\7]_$(YW66B&2UC
M!-\+6LCFEN#32K@C<ILY8#*SBIY?),?</74GU=29LJF*TC2<'.TK$8E$^VXD
MFGH=V-O7I11DN'A PY@1KT_S.GC 3V(YHAG@<9WW&9<33C0^8*MJ,\AU*JM;
MH!Y:Y(@$,4M5/A,,0@XU/"0P2O[6&)%,J&<-2)6/A<( 0":1&1_&<85%7>V5
MQ9SN;+ \PJYE-+>)M5T[$8EYS4Q#]MSHENY!O-H%Z9TI0P>Y]\>Q9_<T@5_B
M$7BB$=^Z)**B-=FE[$X2'S*N=MV+3G<Q]]H?3*:65Y=+$DAYO9X7KEN3!5B,
MR\1K'*^[Y4:3AW+0GQP]+8R4I+C$28 !7N@' ?> .: U8]"FJ,]L9M&\^1NM
M[^\M")L\\OVMF!!]ITAE_&>CU?Y-PV4T-/I-O(]W>TI;Q'-BFT6%4+ YD35Y
M12>@-$%71--5/N#WD9LLC@>PMA89"!_Q_E_')%5-5RJO;0J=V+A>H$MLFQ:A
M*"Q];%6EHCK[B:JBHH[[2DN[^89-_"4UZ[E$NZIX S^*MD<PXYKD<6[D%QT3
MB@A_.@P%<20?BG_QO8J][-6^UM*-[7Z=!7]\)*;MZ\ )>V2*EX^3?:-2[H<+
M?,N/T4X66 ZIK1+ULG>7BRF3Y03P3DWVK\VX]"D3Z;)@]5M.<)CAYM9YL*#F
M-['GL=ZHD%_?YR=O"W+L=$[W\AE/K2P9AKNWASC'_)[$F#VEILJC"AW]\S"3
M8Y!TJ:)VPZRGG=-=#1Y%#<^&5[;!D3A2SK^MR>04',SP"GR?=;EY2FV@,$'T
MAO8%"OK8BQXY7M7\W$CC9<) XC-WNS0O[G<^I/\?1'=!_G&0CLUTQ._LJ#+Y
MSN-CO08A7_,,%8+M+O$MWNY,"V]A:[(!Y?FJ0%R5[L^.$4-E,I+A\.E"JU*_
MCUPN3R<&/&*:OBI6!SB$KYGB; N^JIFX$J!3!->%#>BRI)2:BKS[Z(_P%7!C
M:43T1*^*7=(.WC=98VC$2'Z&$UP ,4H;SLZU6QB]WMRH3*0I,[1TA[I%LOG8
MMWT0X$$N-<\J9W/HY((^JY\NM?84N/YRBKD<WD.M1_9N8&O-IT7XLCB_V6;#
M2UNN;>;2BDD>VEOU>6,[?21.Q3BN_==F.CB?GRG[P#TOTNGQ\Z%,T^11V=$*
M]H.4E:W&SX<VT?<-QU0=UXT?'>9N@]IY2W.<*TEI#_KZQANO^]4 7E[[\UC.
M3HV[719A0+0O6C.I9EBY&6\U#1,H2B<#482(ME['WJD$]9"03S3+9L]9W%N%
MJS5F(08=C0R!*\@,0K@IWNBLN1QJM+*</4[>JG<Z+ZCY.EA7++&U9&OG,9_P
MW"7'WJ:ETCGT-CH=[X9""#E*4KO VJMO$C?"*WN:-G@,>5\BS(Z-&PM(7I&^
ML<!-HTOO7,&OKHRQD+A96M*K<C-W77O&<X(\*QB7RMA4=-O4[DT^B3EY=+\=
M_6H8^Z7MI@N?P^A;'2.(!;G>6>'\[0D,H#C-S^=18J;N[T[(T+WA$+ZM$GYS
M.!>ZY_A\8\PQ0EQQW!/'RWP(G%\7[[ KEU5D9=AM5P]>B< <X^!913 7?)E$
MS"<SQ=Y7?%6DB5T\*5Z3IFKIW^R0 @.@VBTD%G,% ]<=%U&-<A^;!D"5(2_3
MU.,J9=Q^[#HO76YR%Y'0UK2 KW;2GP4%.J'QNFX-W<S.;! 73>(?_'*"\*I%
MA1Q=H3%M>"=L2%0/+CY0^&2'F>+^.%C4M8NZ?<6_V2*82;I!2N0:) D6;0TP
MS5W06Y8U#W^-X, R8NMP@_1BM\Y.6]\&7'UOY>,O,9G9$HVW+#"4+8J%1$:M
M2ADIAFYO@:Y-+':X^08N$S\O]YI=T_>3?W3ND5'R+%Y^TH^ G?[*\>&A#-O,
M?LGL/CYK_>IKR'$QJT9_?#\M<(TD%8.]N%J$:<^;?O9*0$1SS)J!?:^F"'N9
ML !454?F,%T!IQ"'ZEQGWPX_PW5/'R=2YS%/TP7775.YW?9FU$BI)_]XJ2,,
M0'A0A_"Q:9+]SJK--C;PK=CVKR7WM!<]K@6"I$(%KJ8:4]5ARX0*0+/&I00S
MC).G/FY,ISV"U7R:<^*J8 3H1P$C:#U(40]T=KX/82DUNZZL@([,'BM)_+C4
M3/ #\D?=8LYFNFXL>+0],Z^]'NMG'T7'Y)ZJ8NG;0];:SCTKV<DY*Y+V_12#
MIM?!(M!8>>QD*TGG/Q:].(N=>5F^LL,84B2?<6O:JQ50T 5>M1*#[ILNIG<Z
M@U FQZI'45Q=.IP)>D/) SU*9#^6""PA;5(&K@$ZC<(=KNY52##.9C**;[6[
MKK5*4JXQ#]A"L$9"8G<>?OFXD7'2B73>7S>M6[T7(%0_ZREPO"Y4PC]Z=Q$C
M"B6*GIP$YBB?8Y*R\S(6K<FZ Y_2WE4>8U+0[FGXO7BB3:Q,'ED3LF8EWAXK
MDF>6%)B(DU9C\2XNZ<MUU4#)-Y=(A_1U:SZU(%\&CE'46QNUU@3A^B2S4M7-
MZJ4W8G)?-],2]U=QE+O5ZEH%FR?7RL]&,O+DB1+3[N^71&K<C00TT-N"I/C]
MAPY.^!DK/25JIGL2+"UGQA+?SZ6#P6VT<P?:>'<5M[/XN)TPP"O4Y\7=Y=(6
M^5OQ]VRL#O0V-,&V;B\)@(-I<4<J*C3LJN%1J!I+9JTXD_2EF^<G;^M4HKD0
MJGW[^C::+S:1HG/GOM2RS>_/Q$]*.HKTOZ0-7Z7A_\:STV+>?+IQD@@J_.+\
M>DY31Y=W:3O^^> WSC0)XH+NAPX+D>RIY(]G>A%N1>VY6HO!8TC:7Y0XO\4&
MZ/@>6,0G])+03+(W$7NH3E2O9RTW1GQCNP,7O2PB2K'G@0%0]B$.F?(;I,_A
ME'?SF,JBZ\4OPV)TX*OG][.I9@OH,996Q];>Q!:8YJ$XE X4%;]V,ZP>SMAF
M\3(Y:W^>."7UAE^);*RO'Z,+<)B\*LZU$IJC3P0$Z&8[^ 'UI;INLQB;N/R*
M]: K(RMLS+@LY%7<"3N+U9<+'T;YSVE/(RV+RZB21D#(!^I*W<^E^0ZQZ=GJ
M?+H< > 1\[2"];+7NIYO:\L;(J4CQ%Y\[7AY\DT\YNG#-T+NR\T:#BN\Q-I[
M]6".MB<,J8^MT0Y\=V++JMLJK]<\A^S1P;/^H1UG\E\Y/("OO%I/WK(KZ,F2
M)KI21HK^@@&T\:A>DG+WC\K5+-\J*R8HC!MH5@\>(M5]_%JRI:?-@\+ZX7+4
M?:E@QT*X6,C+GO[R(3GSR:NNB5=>OL")YHMUDRKIM6-U!<M^)R_^G,4F ]='
M:6^G/8*XBI:)DV-QS0S7WHULD-8:%&NYT?7=-5[&!>,Q(\5CNU5.Y-B'4<N4
M\ >%UC<8#DEG-=?^Z\M/J3V5UZ73.78,F1@=NXW;][BXJ/:>N6<WR@5MH&JC
M)EHQG#)DR5XW); $? (&9:RA9X5N\JN6F*]0CYF,%4.HBD2=[ =*;Y@#0OF9
M>3!22%)=<V_3!#PZ5Q G^7FR-?5T1RG>\R6':6AV8&P@((3'B'D]4Y[2QM=[
M[8=TVYO?^C69/5^URT\0Z\37=Y'P_,,ER?0! ;2,Q#]#SSPF(]IJ<[F<R%H
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MA]YI;O%5Q?.#GD-U][91TPK02_*6YJ5=+#QL'!"E-%=>(/I\,KX4G.XR(V$
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M\A5=[?-TQKS":!9C2__$!9!H1\;R)AB\L5J[J[C6?K>&R5R[[WGFHE8W\CO
MIP1P#UX.>YF7OHI[PBLOQQ$<0XXBF1GK-J1842I\+I *;1:12L=:W,&D.ZAG
MG%NO<WH"$$21K;THM7]'X%ZDRS\\:2&,82;MN4HWG!KX]:1U)9I_Q%8+]3QQ
M)(^+HKXJ?/U#%/E!QRO$!;N5DQ!LZ]JSXMKF"?"E]>SP31R'7A?"7"TK$5_\
M.^VO RFU5U->7/_Z?/-]$;8/U!<9*/1/)_"T-3'-2P4<IY8&!R0/15R!^1BN
M^WZ"?Q^O1@M!Q>*N#^54+;@=]SIB+"I#5ZI27'N)D5N8B1K0#=2DK>',K;A&
M'(I<A3@CG< L9G6PNFH+(D*/*B%RH4%&($ ,J7.FYSH.'W<Z5/4-M,*18A^>
MQ$Y:*94#_.21O$"K%-U9;MP7I> \YF*HC<8^LNT)>&4SM/WI;ZS&K^#&B NB
MP-@ 0/KY]U-)RYI:TV2;S+,+RR!;H160^P)&]-@/;CMT0=:JVY7:IE4R]CC=
M?%9,JN^T9)0U?IY(8A95L*"^1N4C[M5/MM(I(>F:-0PI;V1)5![-]WY_FRW7
MRK@N_-+>>%VX-C3 7LX,"WLM]^$?>1:*&(YQYV-Y I4:PYZ%I61_)[<$A2F.
MWMY%!'U=$(;EJ'T2O<F<C\;7E5X?^LE[A4(K Y:J2O7I:OK4@3:2ZQN0O; P
M/;5'=.U8."UUZRP? B>"RL3E4HTT?HZ:XE55NL_G0JC9+J5X"$OCMTN#9S-E
M^=$?CQW=F>+RF!RP%OM]Z5T*H$9@AP-:/A1^/71/LXDD,W%+6][DE'/++/,[
M$;8>-7Y(A7S/]8_;"=1Q\)\()A,^7R--"R&'P3A.49O'8VO;_Q)6H!*4EK=_
M]*YE-.\X^G(Y4R?2>NL4CX;SR6,Q]1)M)XMU>"@-.,;Y1QREIH;'Y[S;ELS<
MRSD6]'KLL$[5";4KR;O-?U]#UEIE9)1@*Z"^-N\2?Z9,X]&6F*7JJ@YTZF_X
M,XM6]="_R*(/@_86QQ)O+K+,OS;U;W 1>P)0PE2&#XVA_SKZ)N[?.33_.X6\
MC6V6KCN3LGF&H?YL\P?G]&%\A^D=+IRK>XQBZ;IM]'QY00H77I[K1?_#;G[U
MF1(C]=FBEAF3%1^$NJB""O=#Y0#C>'CX:-^44N! -2Q@@7IG*)@[(DOOI:LF
MF:K'64R$RP>90JLV>MCZAF*C6H.+JB3FR;?V# \QB_TF8[ (R67Z=6\/NU_F
M2#3!JIUE1,V+\FBR=?%:9R5L*U(!ZJ%R.0HI3&$#?(GCG,3\$G ]+77CQ/V;
MM7U93F<R_T\I@Z_ZPK$6.Z@W#YF> 'JSS*L<F* 6%.<O9ZCXWL*4E'\/BYL.
M>I6#-/:>Y'?4O!38[:Z;6&E]G\/^W/W"6W#PM!SZS9SHF>"WJ#S:U4=,>/F?
MR[?Z(ZU4O0NY8(_HP')=W=YBW0X;QOCIJG"-#J!%YL8%,KSOI##Z7FL=G*9&
M&F$-5Q"*/MU"!_S.6GO>Y#^X?TX"[A81_UF?G$QI&'A!PT9:'F'O<40SAZJ5
M'O:5L/5(6V/)\"QP4]VFNA,^- //VB7TJ80?2*;3SF.>9B\,>Z0T21=ZKN-)
M]-6)V&08F;EBSQ//]VX!>U(PAQV'C#Q0TW"N@.,6:G;HN9BO7/2L1KAAZKK;
M99+W/(4/A7U'9P>TXCG"^A9O+-(V3:HY<7F-$DOGB[E]VY=#)D>_#I1&BP&7
ME_/S_*CD'S JA35N+E=/0)B*G23:773("5()^D,+E0#.7:^+V:(!*OE?TO1>
M'BZN['ON"-^U5H'^PG5]*%"LS$I7%WFIE>RJF9T737@_K,"*)7?7B%XTRCM0
MLLPYZ4PCT>M# :>O:IZ&E!EK%Y!643#]R6RX&D,J0'7W1"IZ#%_N52&UJA"A
M&OE<V ]CP_WX,B_MI"A%T9I)<S?<:SV!E@M>'C]CZ!MXY?]1]I.>\NNIDQ0C
ML/4HSKVN,<CJT4T.AK$IBO%;0H;K3CL,!\P[&%T<YFY"VC'#BU$,W6K-T[7)
MI!Y!E^$_'LH7^IGG=AJH,R4JY/^<&(3Q9_6X<W&T2'CG6]E:+JLNLE$[45>-
M8M-G-.:;@6.*#=?2P#L]3<?SH^G&=[J^ENYMYC[G67M53X!G=\LSR.*UI?>B
M$TYU/4(_AXE'?-GE'E"T+B^N^L!!)Y&4R4'W%N4+>KNW/\;WM*R-FH.I>TH;
M1[=M_(P>;HU;17XN9].$<AY ;0]'6K=J!;GCL:,MNXL9"S'#3TMIJ!1\HYHR
M JWJ(*9)?X9LOJE19G'RQC9T;&:-MCJT'/5_:5>*2LW\#=?",;W\0[K:YU4G
MKF>"UD0<Z_M>Q3,JU8 !19U)VS8%%%X[%)@_/NHS#@L>,/Z2*:OG0=R?771>
M06YMMW_51!=:=IC;$K"XV,\<9T)=\D(6K7%4(JXL*[2-HJ$5Q9D"_4O@"J7:
M4F1QCE;HA-?/0QEM"% NYU>EXB23Y[^<=2KX*IY;B[@'S_]1\F;,%3T!5D:.
M3%ML'\9XN&B2UM.M99&Y)?=,RGC^A1L:OD6L+;\O*U9A'] <$Z+1WA8*E5NE
M];2?-!Q)-4ZVPX#QF+],3X&M@13](^DF"+YD$;[;D%"^_2Q\-T.-\8OGZ?S3
MU<6RKRW2J5<?7O!.O:B#14!D_KG^6T/L9TBRJTLUT/<7?^BX@^?K,:?B5JI*
M)KZ_$6=R,]&8 8Y\@D^R\.B6\()N8H ]=;A&:)TJ&?.=Y0F=E"3;02;.).N2
MVPJLOF(40V/]*[$\0C;V_DA]X'<#?N-\.4"BF Q,)#=EH1<$^CN9JG+_=YS#
M__LR- [;-R2<'W&T3&"0$NWHT@ DZ9E&$O?SH17_W[=#_I%;OQOD3[L3$_W8
MT%8W]8MY&C5:LKK!Q&1QG-5CGJJ%7IK3,._# .KV?/ZSC0;U3/\K>2^Q[F\+
M@.FJ[<XSZ!ZM4,VD$_D%Y/.7&8[<^%50&5%7*><!<;I-GY#8[I9QDX@'FQBL
ME&?M"KYAGC0"B8(K.PR0N0*N.I#[:LBKJCU="/3\S0\M[KP!:J. 2@R+E=3/
M[!/:M#2HX)1USXB![QA[\#R+$66,<#FT9(Q-4\J5[%* BK8/"THS:PVD_;9-
M;O,L/8?I)44#!4> #'H[O,XH2324,94%CSJ<1ML5PY22'7WW/WLTRJ(D]"F3
MFHN1)Z#'':6Y&/OVX-C(GSC1W<4CZ@E]"]PHDK80W'@]_2_;'\:++#>^\09_
MO]CX/2+ZEU=5=)I&ZR$YDJ\3>AUYAQ_UE!'_F+I^MP"\S,^Y;NK6F3:?\AES
M-_$E.A:8K7*WT9IV<$2<Y0QSVDY(O?9C(Y8]:8T.*[76#4I/1H-AKK"S=P_A
MQ3OD4M H.<+K=G-6_\.G_5EGH@SVP*DOJAPY:,N"W=F)X8 E#O,)!ZQO7%OD
MF2]Q7N#IWBXL!I) 9^"[R30!?D+EPX 2DH\ 7("HYF=P#A=)08A8VYC(W)BM
M^'T8EI!9GQ!CA5KO=S7(!=%+UIS8?SGMGA6!=A>\RZ'.)5*V$8A\'/;>^3#T
MWQ1"Z/X=_?+M_ZN-Q\PMXF,=BC-^ ;(X^^KC45G?BY<@3'KJP#X[WY?CL+KP
MT4DJ;;+OW#E]$;N_OQ$,J-?^[X]0>=&^>LC8X]!K[TI=I=_;I8=H&WSM8=&^
M_CXJIGN)<TJS?OJ(RUE,>F\Q..RXW&LDSVD74W[?LM"%C3%Y!HA=8*W;;%VE
MMT?I?!8IQ__C4<6WXD6>+08R:BVB%6/$#7[E@&V>4K#$)O3>L2% PE]&'LF:
M<\ >[?$$Z&QRR5T#^>(/<?R9[R!DS*WXY7(^^%X&*5VS.O)6KZ8F8/=+O ZK
M-N<;[^K? -?^2C&V[)R(RJI1JV6<JLKX;1U;9]&;ORIJ?JNUZ0-W5%6LB,GO
M^U*A>][)O'\"-M3@Y>RQ >Q;+<,22;RWLU92U,/LD1RN72*:[?D@Y.RK00R!
M/'+*^0 ^;7* G33/H7I%R_-":UVSQ*BMRWRAVI0"G;QTONC^\FVV@5OCIA+6
M9AP*6H:3Y:QU;R$=ZY=W)-UY<0*STA>8J#)/PQ!=_3JH18G89;&CN_5=$BC-
M_XT/-[J9!_Y<O^[^;L[A\V@+[1.!M#(PHZ:@;E#BFB35H)E$DJG!+R#MHGTX
MLB@G(I(-1^4D/[AP70'/P9V3=*\'C3(7$!+O3C[FTZ-Y^+KB&R__,0%RF6DJ
M*CH?.YZC\V=Q-R/^ZF49E+<#+N+\T(K8TX7M(Z@[DI/-)GD#A #X/;,J4J)5
MVAM';51(LH0!L]89Q;SXE,P!?3KZ*N&[AC%?W?8*-T&%V8TJ'=UUN +=]672
M1!?0)!JM\YQ.?M?R[QL*7_".1\()%]BGAAGTW!/:KFQ=Q$9T<L(__W_:1/H^
MN+X4L2LBUE?H% \D7275]F-W^+C!A/\(LUYP:H(%KW-_DO>?IFU@Y$/C^)^"
M5),L%*@&7MM/H[(J.[;9:>-\$S[)?>"R 22E6W[-;$>L<)(8G+B.\V C7&[>
MVCIZF?+S!\8.CA^W$'H[0//BV^XR1R6<']OIF.&T[Y'O# ]V( Y*O*".E=D
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M,7_2O[E$H=(<+2Q6(S4;5&%Q;=E&I0/I7:V+YMA*&UHLP]ZAZ*?]J?\\4M^
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M/V^B;LJ6Y">R)\\]Q61IZ^T)>]#_T<=>4X4I@W[6NX3YWYZRB[>OGKK,81-
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M>8&,V6"Y7MNJDC?NYV1;6SK0:CQJ__?7?5M""]T>3D=?,G7##&R-\.9XBWS
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M5N_+Z8G)O\3$# CH&3XK2^J@6'VFL.J)C>^E/SIO!)%['5OC,:ICSZ+9G+]
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M>9?CCUEQ2SO.I]IZ"QG<BN(T^O9*I%^,=?_*[ G00O67/=,^X'HZ'X@$ZI9
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M1Y@DK%:*TN8L@;0SWL5=TK+8\0G9THE,UG:KH@<@1LZ4<L@GIJFMGP",'D^
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MIA?:/M$G:5=\J<?Z";9SB%&%8IL@ZHV;]GLGM8TH")AM&O-H\T@9<S6NS!\
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M3@WHV:!O0\N;DE_O/S<K>D[L\X!=]WM[<W\+OTN53J7&KF"J88I5@A!RQ%5
M+5H1&1C&\UKFT#RIRX^BC D:B=?]:D=#.YIS@@G5&@T;"QBRNN7G8>TQ-< Q
M:-G10<D*\ND"+S&T(<6\W@U;!;V*W)X9CX!1 L56=>KADUS.;-DVPXN'KU1R
M),=2^>/MZ.OU=A.O4K+-262J%:2"2LWD/"(@-UU*U_13LQSX&K]DM/@>2SQ5
M09E\&/N_Y)TKK\$1F4.!%WK#WN&$HC'O/P8(\>N5%WU\<LKS9,?S*D1U4F#W
M 4#LY$/*M3>.11\NX0+]*"KA?:U?.J;&:W!BC"1VO'@ /.'9>P#4K]_(#S\
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MS.$L<]'H]/?9WN]&2*UV4]X?F]^F\A"&S,C=9K6L''6L;1U^4\8$E(U/ULN
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M1LW-+] &:5&O)2XR,47H!N:0=I_"1F(=YL(E=LU2-_OTLW3$@D,KYH9=O=.
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M$A:%]%3N' M&T0,T2-;["]WPESFF=KEG9.'PF1IX\JFRCW<,K5_\D[ZXVS<
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M-*J6YH8>.2#!V[[2JY0' /.-_@, ]O=,"Z%.VQ?'IE>.TR@O4J+&Z,2R0ES
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MH!+(,-[3(4+0C(G=0V&P5TB_KJ;2%_V/<;]XL_ 989K_2UG12$"?L!EVFAI
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MHYX\EV]E6JMLO=3!2^Z0 ^)=!$M"X#!=8),T #]YZH9DZQ6#!H-)VRWWX=O
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M/W4,M9G*BQ4MJ=@VJ-%TQ^<F^<PE,XG;G5UDEU(^/>NKN3CW]RMLMP8K_G3
M;J>!"%[I53 W)]5[Z7OK^UH$0'EB'XQBJ+S_,^Z<_](NS!3(-;#^NZ;OD4(!
MNZTW*U4_JJG%ZN2W]#*M:#/_-QD6*P TT#411A[*=6.\HEY/X=396&'B.);/
MY"D^\!).=Y5.V87Z)-57U5PQ4UEUE)<Z]_GQ29?:A7M@BTB3S<B2]L$Y^\Z*
M(2'5+UD^#4/3+,2O[=(S0[B%;KS]=-!'M[PR.BD@A<QS$I8'!!0H]K33W9AW
M"_^8Y)#2TKR(-,G'44I09O6.5M.QR.E<V=3@6"364736!"EF4^G91S6W8NDO
MZJR41-!4EXYZ0_^?76XG]W^%A<H0TQ7:=#;V_IQR4J?S+Y5.G)<+*B.+$5B4
M-^++;9$S/^!=;61L\C[[V<Z1B8!:[H5\:^OEX]F<B.8PBX3,5HF/R$E!%+0(
MU.9^=6"_5/<2!]6RCBUUW@:3YE6LPJ##V!)*U+BKO.*\+/$MTN*R ();N. 1
MA:DRYTPB(?P1*4G6L5D51Z@/?T+.CR>'6<ODF\/0BTGM(GVE8ENDCB EJ6$[
MIOY-Z./6X!A_NP%R40_GJ?8Z3$:ZV[(09JW@4[4R6M@WA@_"%)QF(>7],4F&
MIJ(>4W[-4I\HR?O2'$\$"Y-'OQ8D&#M$4?W/=]BD)#\U7$NT>66L$)A4=49V
MF/- O_.GHPJ@ZI,G=$#2[=#VP_RW"U5<WRN((PN9@N2?S4NB\\D-B1VU,%:U
M^;  ,$]IB?X"-6ZC=%YOZ@_ZXZ.,.T 8>9(_0>VOX>X$GY(=Y&,>A=XY58F:
MDE93@/LJ8YCWMLT_C[?$O,AD/50MMJ.%EU2*K(7?;OJ:7NX#L"_0\-(L [MS
M;\A 1V],X2#[%T4YW&8ZID.4O4[^O9L$A7/D\?TWQ1=V?.-%1):^9_P5L2W[
M<6?0BQ],1[%#YM#,,0JT+KL'9E>N^9#];&UD:/,G#NR)\[ID])J%+)RSK&!_
M^-T:56+[T2#80FCXV\?RG]A[;N=:4Y-IBUM)E M2HZX?#QF_RO1Y.+)6/2UJ
MV2L2:[OF' -__1\37=6Y:"J0.BV4MP.C&W7CCL]NEU#D2#*O,CJ:O\G?G4\&
MC)O0L#*W=$'5!#;!'1G'N%Z\D77XQAPTMFT5,"FZ.AV'TL1TYSJY&X!VF%2?
M;WT.P[ERLFO)+]N^+.Q<?-QFYL;0!R+X)9PCF>#QIG5.;*C7,V=RG,=VSO-*
M+4RS:6RE:AS^AYN5 S,S^XTZ4$ />NZ%$BM2ZHRB!<L[6T&*%K%HXBP1M7/H
MW33_8U:LX7-I00U/+I*+]U*63H)GO[L#\ I])4)%1H43..K\=)9!T;G1+Z<)
MM/Q-R+8U+MS<-ANP@9;$Y<'Q&0!L.+2;4V02I?/4>!9DI&>7XC&3:M6$K%TP
M=*G<PNI9NUJITWO#V^[X>.$=K2JGVGLU]VSH5;908/S^;^IS>!C*NR45;G-&
M^RG)"W?_=&).[0'H-\,/[#@4HRM6QJ_AD=Z@C0/8JI&D,EH]GJUY[[SE0P^]
MSB&^P%HL0M$;HS*()XG>3YB<M<^N/V(/'I!;^+B-&)L.LS!T?0P[+%E+P(%'
M/F1UE3&/V0'7%5LHQ;]H+MF^ Y#REK/_JHM7B= $O<SR>A3-SYQ>1B5&S3G)
M.-@80&M7O9W!:+.G%Z5XIE!3,SO9#XV,R>JY+DVH&)DT;KKX7%!!5U 'Y,H8
MQ*:032;W?'VYV2VQ'S*QYU"<;?#7!>^6LZ W_@[@"_>+ AF]-;[G'"_BEP8,
MKK0;FEI !-/??__94.YME,-VOD6,VV4\KQF5$IG9[X0*E^0YZ CC8M:PVI@"
MGOPQ9/A!9N@K<.CJ_-+ZRFW,U/M!WFU0#-5%DG+3A19#?O/)AWE#4"LE.60P
MGX;  ?M@U797 =Y^2>?/>@@YBU^5?M9.P* (TGE*LQHZ;[)OTHCK6Z6N/NHR
M+TL[VWRHT!R5_J/*]C)^;N&E35DNDEL&3]1*OK5;T<4'+1O!8U9YB K^PY.G
M!XL]&%EWQ_I88\JCLCV@ND+R=$ZIU-;[OJ_,'!FN@;QG(6V+U-I[R4Q/+T81
M>_\7>V\9%-?WK0UV H0$A^!.()"@">X:+ 1W&@L2:)PT[A(@N$-P=QJG<0@.
M(5@##73C[NXZ_-Z:J?K?_WOO^]9,S9>IN1_VAU759YUSGKWW6L\Z>_5:G.<A
M$:SG%,#+@'[56X,HX5WT0!(4D0]-G:/P&B^TE:'][W_XZS%%).53UAC/D*6=
M?DHDM.<H48D*7:];%_'K:V[2!>.]XSY,XWVBEZ%=)44-C$H9!EZ9>UMF4@M:
MSW4UC,\KD<\-"'>>OK[T&(/):;-?6>B.[PO3.Y:\W3^N"@!AQ>U@D8N#!U:A
M<K]WA_'NQ"?T@([@KZ4SR+DJ.;N*?>BGM;/K&L<L1WU*O"&.KE=FGRR"L36&
M',*X?G5''&^//1!-NAT:C)]GO6C/*C) +AHLUH&L4;'(ANS1^2DK "(^"=?.
MF!DOZE>I^"2G3";L\IH]0W-.371,%CLV$(2 [SI9=O-6BKB]O'K[P\/Y#@8(
M0Z#QD*T[23(M>DZ?,I$_F(*IMPV?06B>NPBM>6W=G^?;F&_OPJ3(6<(C8#R@
M\$]WDV?_M#:Q(?H4.YM%W*MQ$IO8:BW]YJB7V_ F RW,1P VB%RTUK1R9YI/
MFZ K$N3Z_9M\0Y2X^N*V <>_G@W^A'./8H RB:%33I$2MN<SII%+)QQ?HF"4
MYB[$HO> TJ@NBR+E"J#$"H4!49PZ&(SY)0(P0^2QMBEP]]X7"NE89GCHFN5
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M!#&&$@P_7%1F1C>D7<0#. 4(;0)+-A:>P>QX('3.0L.^!J#<%N>7'(NF:/2
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MN"BX9K1+9$AM3MB!M8H:@^$O4E=TED-?Z*X9EW:H6;;@OR72&E*KFHS-[+I
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M5G-Z?<W"E,*\7GPECP!K3/NJT"]&6U?(6M^4=*?-7;6%+;X'LOAN\L2@_.:
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M"LL;#F&5)[ CI=VDOU8+:Z'@.5,FVEDTGZXX/Y^ 8;]=8 )*._S='=5BP//
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M?LB-MA9=OB\)?_#M](W=?@0<-3P"=M > ?&^]T$T_RJX!Q%ZZE[B[G\Q.GW
MO(M6?@0$/<&IPG&7]@C8>_<?)):_[_(0HXV^5B9/N!\9K7GXWK$] F[\?=>>
MGO&K[+\*AE^EJ>'>W;?J)'>/@(!' /W$(V#YZ<DF,1\!C$]088C]!^D4X]U%
M[0$-XE?'YAW)-776T^3Z/F0;7?,] F94_U70_J4J6Y_E\##YY*G$ECK^=]"*
ME-^&_#>R_XWL?R/[7R/[;WI$,W+#6,IOCOZ)6"N)QOUAW+>^A'TX2*IO;NP#
MAZAI$DQ;RAO6B++8<6&:MY5!/ 8D:FYF)!/#M):A=%+^=2?HM!%3TC.*A'?B
MJSW4[(&*4NVC\@W6MP&X+]3R/XD!7'UXI&2/SMKIKY1S)6P=J@R0\A=IKHZ)
MIT2+%&U-/"W+N!@&EN1H\VW[/>H[?&;7\?0$'TBLL&)P -09PWR*8UY2>6ZR
M"A-UN[NDA[:8[KD:%L'&\OPC*#AYL4KW>.7D8N'VP;4X02LB?'N"$7^^$/0A
M<[)0F$![WDT/B<#?'2<?W+H?NBQNILJ,<'<]HG_N.?OBS<WX&]/LP>'_!WMO
M&11GU&6--L&")P0-FJ#!W:$#! \>W%V:QMTE0((&#TYP=W=OW"4T3N/N-/[Q
M3M6]=V;NW#OO5,WWYZOYL?\\N[IKG77Z/+U6/[OW_G!];!0X,CJ^_B2?B;,;
MM\O[1-G>FH)#>[U7KI1#$<-_OX"(NI?"12S>R?*Q^8PG(W._K,[JJ\G]GQ;?
MA(5YBM-CNB3I]CD:E;(2 SG7K&LQ^XZ!)Y>_WX;M=?[;6DK^E]I/OI__>6F
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MY '<6[6XYTUM? :4++?8<D:U[A"7)I[2A:1H40NH^)[&#FZ+C&3DTKH&':.
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M&[[*VHSP-9T]EFE!C:1L/!TK* [_9-(T[58V&E]6%S,/=XH*G<>G"_66\=M
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MN =%\9>3=*:T-Q6Z"[#[F)Y#?]-1J22>"@Z(\R*_'B>-ZNC1#]9W6V-6GZ-
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M)C4<C!(,_,[**3KGYGG\"%V&O89KW(1<H\H$,0E)LKM$X/T@7HF,%_$%U]I
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M<)-3_.DOQ.T<*]_!I<Y?4?KMO?MV\,MRW'TWIGOOYIJ\)[CF(ZHZ/XX/HD<
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MMF.1S6&8_E?#&;NK/8!I'L5JM8VDSO6)<$EIYH898:3!EKU_&4I7_.DS[\7
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MY[.Q.U:MN%.F'< &L/=Q4?\'E@E$X+TZ:#%J?5]BZ5$LL:M@"?Z6A<]%=6,
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M7Q \XO%0-")H_R^Z U/RSX#P87 PTQB6UD6:(S D<3#=3,;+F:LD2+6/O08
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MVI^R_/=ZEO_R+_][8-S__B]02P$"% ,4    " !!,FY4L]W &V05!0 BTC@
M$0              @ $     8F1S>"TR,#(Q,3(S,2YH=&U02P$"% ,4
M" !!,FY4M!RMFP4>   E9@$ $0              @ &3%04 8F1S>"TR,#(Q
M,3(S,2YX<V102P$"% ,4    " !!,FY4'P]B$_H0  # \P  %0
M    @ '',P4 8F1S>"TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ 03)N
M5)A(LLX.3P  ,\<% !4              ( !]$0% &)D<W@M,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( $$R;E3N99KF-P8! -^""P 5
M  "  364!0!B9'-X+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    " !!,FY4
MQ#3R>>QT  !V"@D %0              @ &?F@8 8F1S>"TR,#(Q,3(S,5]P
M<F4N>&UL4$L! A0#%     @ 03)N5/"DOOR9#P  L(8  !$
M ( !O@\' &)D<W@M97@Q,%\Q,S(N:'1M4$L! A0#%     @ 03)N5,+N=$Y7
M @  &PL   \              ( !AA\' &)D<W@M97@R,U\Q+FAT;5!+ 0(4
M Q0    ( $$R;E3NM_8<,0@  &U$   /              "  0HB!P!B9'-X
M+65X,S%?,2YH=&U02P$"% ,4    " !!,FY4"P)G2$ (  !\1   #P
M        @ %H*@< 8F1S>"UE>#,Q7S(N:'1M4$L! A0#%     @ 03)N5&D@
MG3'K!   X24   \              ( !U3(' &)D<W@M97@S,E\Q+FAT;5!+
M 0(4 Q0    ( $$R;E29M[3_\P0  .TE   /              "  >TW!P!B
M9'-X+65X,S)?,BYH=&U02P$"% ,4    " !!,FY4$_;*[!]>  #J:P  $0
M            @ $-/0< :6UG,S,U,S W.#9?,"YJ<&=02P$"% ,4    " !!
M,FY4<5:/"4-[ 0!LU $ $0              @ %;FP< :6UG,S,U,S W.#9?
M,2YJ<&=02P$"% ,4    " !!,FY4P2B:#:M- 0!<>@$ $0
M@ '-%@D :6UG,S,U,S W.#9?,BYJ<&=02P$"% ,4    " !!,FY4QIF^% M$
M  "M3@  $0              @ &G9 H :6UG,S,U,S W.#9?,RYJ<&=02P$"
M% ,4    " !!,FY4%Y=L1BRR   @VP  $0              @ 'AJ H :6UG
M,S,U,S W.#9?-"YJ<&=02P$"% ,4    " !!,FY4^\T1J<=G  !/=@  $0
M            @ $\6PL :6UG,S,U,S W.#9?-2YJ<&=02P$"% ,4    " !!
M,FY4""J(PAY0  !*9@  $0              @ $RPPL :6UG,S,U,S W.#9?
M-BYJ<&=02P$"% ,4    " !!,FY4WZV[6:YE @!!P@( $0
M@ %_$PP :6UG,S,U,S W.#9?-RYJ<&=02P4&     !0 % #R!   7'D.

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
